<SEC-DOCUMENT>0001437749-19-005272.txt : 20190319
<SEC-HEADER>0001437749-19-005272.hdr.sgml : 20190319
<ACCEPTANCE-DATETIME>20190319165805
ACCESSION NUMBER:		0001437749-19-005272
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190319
DATE AS OF CHANGE:		20190319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DiaMedica Therapeutics Inc.
		CENTRAL INDEX KEY:			0001401040
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36291
		FILM NUMBER:		19692088

	BUSINESS ADDRESS:	
		STREET 1:		2 CARLSON PARKWAY
		STREET 2:		SUITE 260
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55447
		BUSINESS PHONE:		(763) 496-5454

	MAIL ADDRESS:	
		STREET 1:		2 CARLSON PARKWAY
		STREET 2:		SUITE 260
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55447

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DiaMedica Inc.
		DATE OF NAME CHANGE:	20070525
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dmtp20181231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<html>
<head>
	<title>dmtp20181231_10k.htm</title>


	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2019 12:28:43 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" docsect="2" id="52201" sectdesc="Cover Page">&nbsp;</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>UNITED STATES</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>FORM 10-K</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Mark one)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9746;&nbsp;&nbsp;<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>For the fiscal year ended December 31, 2018</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>or</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744;&nbsp;&nbsp;<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">For the transition period from ________________ to __________________.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Commission file number: 001-36291</b></p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>DIAMEDICA THERAPEUTICS INC.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Canada</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(State or other jurisdiction of incorporation or organization)</p>
			</td>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Not Applicable</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(I.R.S. Employer Identification No.)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">&nbsp;</td>
			<td style="vertical-align:top;width:50%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>2 Carlson Parkway, Suite 260</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Minneapolis, Minnesota</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Address of principal executive offices)</p>
			</td>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>55447</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Zip Code)</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Registrant&rsquo;s telephone number, including area code:<b> (763) 496-5454</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Title of each class</p>
			</td>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Name of each exchange on which registered</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Voting Common Shares, no par value per share</b></p>
			</td>
			<td style="vertical-align:top;width:50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>The Nasdaq Capital Market</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>The Nasdaq Stock Market LLC</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Securities registered pursuant to Section 12(g) of the Act: <b>None</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES &#9744;&nbsp;NO &#9746;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES &#9744;&nbsp;NO &#9746;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES &#9744;&nbsp;NO &#9746;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES &#9746; NO&nbsp;&#9744;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&sect;229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. &#9746;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:25%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Large accelerated filer&nbsp;&#9744;</p>
			</td>
			<td style="vertical-align:top;width:16.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Accelerated filer&nbsp;&#9744;</p>
			</td>
			<td style="vertical-align:top;width:33.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Non-accelerated filer&nbsp;&#9744;</p>
			</td>
			<td style="vertical-align:top;width:25%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Smaller reporting company &#9746;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:25%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Emerging growth company &#9746;</p>
			</td>
			<td style="vertical-align:top;width:16.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:33.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:25%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9746;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Act). YES &#9744;&nbsp;NO &#9746;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">The aggregate market value of the registrant&rsquo;s voting common shares held by non-affiliates, computed by reference to the closing sales price at which the voting common shares was last sold as of June 30, 2018 (the last business day of the registrant&rsquo;s most recently completed second fiscal quarter) as reported by TSX Venture Exchange on that date was $59.8 million.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">As of March 14, 2019, there were 11,956,874 voting common shares outstanding.</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 18pt;">Part III of this Annual Report on Form 10-K incorporates by reference information (to the extent specific sections are referred to herein) from the registrant&rsquo;s Proxy Statement for its 2019 Annual General and Special Meeting of Shareholders to be held May 22, 2019.</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="3" id="52202" sectdesc="Table of Contents">&nbsp;</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DIAMEDICA THERAPEUTICS INC.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>ANNUAL REPORT ON FORM 10-K</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>FISCAL YEAR ENDED DECEMBER 31, 2018</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>TABLE OF CONTENTS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td colspan="2" style="width: 8%;">&nbsp;</td>
			<td style="width: 5%; text-align: right; border-bottom: thin solid rgb(0, 0, 0);"><b>Page</b></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" rowspan="1" style="width: 8%;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</td>
			<td style="width: 5%; text-align: right;">1</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="width: 8%;">&nbsp;</td>
			<td style="width: 5%; text-align: right;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="width: 8%;">INDUSTRY AND MARKET DATA</td>
			<td style="width: 5%; text-align: right;">2</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">&nbsp;</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">PART I</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%; text-align: right;">3</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">&nbsp;</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">Item 1.</td>
			<td style="width: 87%;">Business</td>
			<td style="width: 5%; text-align: right;">3</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">Item 1A.</td>
			<td style="width: 87%;">Risk Factors</td>
			<td style="width: 5%; text-align: right;">28</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">Item 1B.</td>
			<td style="width: 87%;">Unresolved Staff Comments</td>
			<td style="width: 5%; text-align: right;">62</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">Item 2.</td>
			<td style="width: 87%;">Properties</td>
			<td style="width: 5%; text-align: right;">62</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">Item 3.</td>
			<td style="width: 87%;">Legal Proceedings</td>
			<td style="width: 5%; text-align: right;">62</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">Item 4.</td>
			<td style="width: 87%;">Mine Safety Disclosures</td>
			<td style="width: 5%; text-align: right;">63</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">&nbsp;</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">PART II</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%; text-align: right;">64</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">&nbsp;</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">Item 5.</td>
			<td style="width: 87%;">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</td>
			<td style="width: 5%; text-align: right;">64</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">Item 6.</td>
			<td style="width: 87%;">Selected Financial Data</td>
			<td style="width: 5%; text-align: right;">66</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">Item 7.</td>
			<td style="width: 87%;">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</td>
			<td style="width: 5%; text-align: right;">67</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">Item 7A.</td>
			<td style="width: 87%;">Quantitative and Qualitative Disclosures About Market Risk&nbsp;</td>
			<td style="width: 5%; text-align: right;">76</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">Item 8.</td>
			<td style="width: 87%;">Financial Statements and Supplementary Data</td>
			<td style="width: 5%; text-align: right;">77</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">Item 9.</td>
			<td style="width: 87%;">Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</td>
			<td style="width: 5%; text-align: right;">101</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">Item 9A.</td>
			<td style="width: 87%;">Controls and Procedures</td>
			<td style="width: 5%; text-align: right;">101</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">Item 9B.&nbsp;</td>
			<td style="width: 87%;">Other Information</td>
			<td style="width: 5%; text-align: right;">101</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">&nbsp;</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">PART III&nbsp;</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%; text-align: right;">103</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">&nbsp;</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">Item 10.</td>
			<td style="width: 87%;">Directors, Executive Officers and Corporate Governance&nbsp;</td>
			<td style="width: 5%; text-align: right;">103</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">Item 11.</td>
			<td style="width: 87%;">Executive Compensation</td>
			<td style="width: 5%; text-align: right;">103</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">Item 12.</td>
			<td style="width: 87%;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</td>
			<td style="width: 5%; text-align: right;">104</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">Item 13.</td>
			<td style="width: 87%;">Certain Relationships and Related Transactions, and Director Independence&nbsp;</td>
			<td style="width: 5%; text-align: right;">105</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">Item 14.</td>
			<td style="width: 87%;">Principal Accounting Fees and Services</td>
			<td style="width: 5%; text-align: right;">105</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">&nbsp;</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">PART IV</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%; text-align: right;">106</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">&nbsp;</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">Item 15.&nbsp;</td>
			<td style="width: 87%;">Exhibits, Financial Statement Schedules</td>
			<td style="width: 5%; text-align: right;">106</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 8%;">Item 16.</td>
			<td style="width: 87%;">Form 10-K Summary</td>
			<td style="width: 5%; text-align: right;">111</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 8%;">&nbsp;</td>
			<td style="width: 87%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" rowspan="1" style="width: 8%;">SIGNATURES</td>
			<td style="width: 5%; text-align: right;">112</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:Infinity%;margin-top:0pt;text-align:center;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">i</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<div contenteditable="false" docsect="12" id="52203" sectdesc="Other">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>This annual report on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections. For more information, see &ldquo;Cautionary Note Regarding Forward-Looking Statements.&rdquo;</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>As used in this report, references to &ldquo;DiaMedica,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; or &ldquo;us,&rdquo; unless the context otherwise requires, refer to DiaMedica Therapeutics Inc. and its subsidiaries, all of which are consolidated in DiaMedica&rsquo;s consolidated financial statements. References in this report to &ldquo;common shares&rdquo; means our voting common shares, no par value per share.</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks and trade names in this report are referred to without the &reg; and &trade; symbols, but such references should not be construed as any indicator that the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies&rsquo; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">ii</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Statements in this annual report on Form 10-K that are not descriptions of historical facts are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that are based on management&rsquo;s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and share price. We have attempted to identify forward-looking statements by terminology including &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo; &ldquo;predicts,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; the negative of these terms or other comparable terminology, and the use of future dates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The forward-looking statements in this report include, among other things, statements about:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our plans to develop, obtain regulatory approval for and commercialize our DM199 product candidate for the treatment of acute ischemic stroke and chronic kidney disease and our expectations regarding the benefits of our DM199 product candidate;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to conduct successful clinical testing of our DM199 product candidate for acute ischemic stroke and chronic kidney disease;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to obtain required regulatory approvals of our DM199 product candidate for acute ischemic stroke and chronic kidney disease;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the perceived benefits of our DM199 product candidate over existing treatment options for acute ischemic stroke and chronic kidney disease;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the potential size of the markets for our DM199 product candidate and our ability to serve those markets;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the rate and degree of market acceptance, both in the United States and internationally, of our DM199 product candidate for acute ischemic stroke and chronic kidney disease;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to partner with and generate revenue from biopharmaceutical and pharmaceutical partners to develop, obtain regulatory approval for and commercialize our DM199 product candidate for acute ischemic stroke and chronic kidney disease;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the success, cost and timing of planned clinical trials, as well as our reliance on collaboration with third parties to conduct our clinical trials;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our commercialization, marketing and manufacturing capabilities and strategy;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expectations regarding federal, state, and foreign regulatory requirements and developments, such as potential FDA regulation of our DM199 product candidate for acute ischemic stroke and chronic kidney disease;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expectations regarding competition and our ability to obtain data exclusivity for our DM199 product candidate for acute ischemic stroke and chronic kidney disease;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to obtain funding for our operations, including funding necessary to complete planned clinical trials and obtain regulatory approvals for our DM199 product candidate for acute ischemic stroke and chronic kidney disease;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our DM199 product candidate;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the requirements of being a U.S. public reporting company; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our anticipated use of the net proceeds from our recent initial public offering.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under <i>&ldquo;Part I. Item 1A. Risk Factors</i> in this report. Moreover, we operate in a very competitive and rapidly-changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, including the securities laws of the United States, we do not intend to update any forward-looking statements to conform these statements to actual results or to changes in our expectations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>INDUSTRY AND MARKET DATA</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In addition to the industry, market and competitive position data referenced in this report from our own internal estimates and research, some market data and other statistical information included in this report are based in part upon information obtained from third-party industry publications, research, surveys and studies, none of which we commissioned. Third-party industry publications, research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are responsible for all of the disclosure in this report and while we believe that each of the publications, research, surveys and studies included in this report are prepared by reputable sources, we have not independently verified market and industry data from third-party sources. In addition, while we believe our internal company research and estimates are reliable, such research and estimates have not been verified by independent sources. Assumptions and estimates of our and our industry&rsquo;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &ldquo;<i>Part I. Item 1A. Risk Factors</i>.&rdquo; These and other factors could cause our future performance to differ materially from our assumptions and estimates. See &ldquo;<i>Cautionary Note Regarding Forward-Looking Statements</i>.&rdquo;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>PART I</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 1.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Business</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Overview</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are a clinical stage biopharmaceutical company primarily focused on the development of novel recombinant (synthetic) proteins. Our goal is to use our patented and licensed technologies to establish our company as a leader in the development and commercialization of novel recombinant proteins to treat kidney and neurological diseases. Our primary focus is on chronic kidney disease (&ldquo;CKD&rdquo;) and acute ischemic stroke (&ldquo;AIS&rdquo;). We plan to advance our lead drug candidate, DM199, through clinical trials, as appropriate, to create shareholder value by establishing its clinical and commercial potential as a therapy for CKD and AIS.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">DM199 is a recombinant form of human tissue kallikrein-1 (&ldquo;KLK1&rdquo;). KLK1 is a serine protease (protein) produced in the pancreas, kidneys and salivary glands, which plays a critical role in the regulation of local blood flow and vasodilation (the widening of blood vessels which decreases blood pressure) in the body, as well as an important role in inflammation and oxidative stress (an imbalance between potentially damaging reactive oxygen species, or free radicals, and antioxidants in your body). We believe DM199 has the potential to treat a variety of diseases where healthy functioning requires sufficient activity of KLK1 and its system, the kallikrein-kinin system (&ldquo;KKS&rdquo;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our current product candidates in preclinical and clinical development are as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div><img src="chart01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">KLK1 is involved in multiple biochemical processes. The most well-characterized activity of KLK1 is its enzymatic cleavage of low molecular weight kininogen (&ldquo;LMWK&rdquo;) to produce bradykinin (&ldquo;BK&rdquo;)-like peptides, collectively known as kinins, which activate BK receptors (BK1R, BK2R). Activation of BK receptors by kinins sets in motion metabolic pathways that can improve blood flow (through vasodilation), dampen inflammation, and protect tissues and end-organs from ischemic damage. Scientific literature, including publications in <i>Circulation Research</i>, <i>Immunopharmacology</i> and <i>Kidney International</i>, suggests that lower endogenous KLK1 levels in patients are associated with diseases related to vascular disorders, such as kidney diseases, stroke and hypertension. We believe DM199 could replenish KLK1 levels to properly activate the BK system that protects the kidney and brain from damage. By providing this additional supply of KLK1, DM199 treatment could improve blood flow to damaged end-organs, such as kidneys and brain, supporting the structural integrity and normal functioning.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DM199 (KLK1): Increasing Blood Flow in Brain and Kidneys</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div><img src="image01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe DM199 may provide new treatment options with significant benefits over the current standards of care by offering potentially fewer side effects and a therapeutic treatment option to a greater number of patients. There are no approved therapies in the United States or the European Union, of which we are aware, to address low KLK1 levels. We are positioning DM199 for worldwide use. We have conducted and are conducting clinical trials in Europe and Australia to support regulatory filings in the United States, Europe and around the world; with an initial focus on the United States. In December 2018, the FDA accepted our Investigational New Drug application (&ldquo;IND&rdquo;) for the initiation of a Phase Ib clinical trial of DM199 in patients with moderate or severe CKD caused by Type I or Type II diabetes and in February 2019, we initiated dosing patients in this study. The results from this Phase Ib study will assist us in the design of upcoming Phase II studies in patients suffering from rare diseases and CKD. The DM199 drug levels from this Phase Ib study will also help determine the optimal dose levels for testing in the Phase II studies.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Lower KLK1 levels are associated with initial stroke events and are also a predictor of stroke recurrence after an initial stroke. As shown in the graph below, the red line represents patients in the lowest KLK1 quartile who are at the highest risk for recurrence of stroke. (2,478 stroke patients and event free survival over 5&nbsp;years).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div style="text-align: center;"><img src="graph01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">For patients suffering from kidney disease, studies have shown that KLK1 excretion, or levels of KLK1 in the urine, significantly decreased in patients with mild kidney disease and was further reduced in patients with severe renal failure requiring dialysis as compared to healthy subjects, as illustrated in the graph below.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Low KLK1 Levels Associated With Kidney Disease</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div style="text-align: center;"><img src="chart02.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Our Strategy</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our goal is to become a leader in the discovery, development, and commercialization of recombinant proteins for the treatment of severe and life-threatening diseases. We seek to identify and select, for development and partnership, recombinant proteins with novel mechanisms that have biological properties with broad applicability. Once we have selected a class of recombinant proteins, we apply their biological properties to clinical settings with unmet needs, and we evaluate opportunities based on estimated development timelines and costs, regulatory pathway, and commercial opportunities. After identifying suitable molecules for clinical development, we intend to mitigate development risk by maintaining a diversified and broad clinical pipeline, analyzing data to determine the potential of each program and entering into development collaborations with industry-leading companies.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Currently, our strategy includes the following key components:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">DM199 for CKD - advance Phase Ib and Phase II studies</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">DM199 for AIS - complete our ongoing Phase II study</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">DM199 for other vascular diseases - initiate Phase II studies, with sufficient resources</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Leverage our technologies to expand our development pipeline</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Use our expertise to identify and manufacture other novel recombinant proteins</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Targeted Indications and Markets for DM199</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Chronic Kidney Disease</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">CKD is characterized by a progressive decline in overall kidney function as measured by glomerular filtration rate (&ldquo;GFR&rdquo;) (a test used to check how well the kidneys are filtering excess fluid and waste products out of your blood), and albuminuria (the amount of albumin protein excreted in your urine). When&nbsp;GFR gets too low, patients develop end stage renal disease (&ldquo;ESRD&rdquo;) and require dialysis or a kidney transplant to survive. Among multiple underlying causes, CKD often begins with an increase in blood glucose, which leads to the thickening of the glomerular membrane, known as fibrosis. As the kidney function becomes impaired, GFR decreases and abnormal amounts of protein are released into the urine collecting tubules of the kidney through damaged capillary pores. Additionally, increased blood glucose leads to increased blood pressure, reactive oxygen species, advanced glycation end product formation (harmful compounds that are formed when protein or fat combine with sugar in the bloodstream) and inflammation. As this continues, structural components of the kidney (the nephron) begin to collapse, resulting in cell ischemia and cell death. As the renal damage continues, a progressive thickening of the basement membrane is seen along with continued pathological changes in the cell and inflammation. Early stages of CKD are characterized as microalbuminuria (small amounts of protein leak into the urine). Late stages are characterized as macroalbuminuria (large amount of protein in the urine). The rate of decline depends on the type of diabetes, genetic predisposition, glycemic controls, and blood pressure. At the final stages of CKD, the kidneys fail completely and dialysis or a kidney transplant is needed.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">CKD is a widespread health problem that generates significant economic burden throughout the world, including:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">30 million Americans and 120 million Chinese suffer from this debilitating and potentially life-threatening condition according to the National Kidney Foundation.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The primary causes of CKD are diabetes (Type 2 and Type 1) and hypertension. The Medical Clinics of North America estimates that over 40% of those with Type 2 diabetes and 20% of those with Type 1 diabetes will eventually develop CKD, making it one of the more common risks for diabetics.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Patients with CKD are at greater risk for hypertension and heart disease.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Currently, there is no cure for CKD and treatment involves management of the disease. Blood pressure medications, such as angiotensin converting enzyme inhibitors (&ldquo;ACEi&rdquo;) or angiotensin receptor blockers (&ldquo;ARB&rdquo;), are often prescribed to control hypertension, and hopefully, slow the progression of CKD. Nevertheless, according to the National Kidney Foundation, many patients continue to show declining kidney function, with the overall population having a lifetime risk of 3.6% of developing ESRD, where dialysis or a kidney transplant are needed. We believe DM199 offers a potentially novel approach for the treatment CKD since KLK1 protein plays a vital role in normal kidney function, and BK and BK receptors are critical for kidney health and integrity. Since patients with moderate to severe CKD often excrete abnormally low levels of KLK1 in their urine, we believe that DM199 may prevent or reduce further kidney damage by replenishing KLK1 levels and restoring the protective BK system.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Acute Ischemic Stroke</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stroke is characterized by the rapidly developing loss of brain function due to disturbance in the blood. As a result, the affected area of the brain becomes inactive and eventually dies. Strokes can be classified into two major categories: AIS and hemorrhagic stroke. AIS is characterized by interruption of the blood supply by a blood clot (ischemia), while a hemorrhagic stroke results from rupture, or bleeding, of a blood vessel or an abnormal vascular structure. According to the U.S. Center for Disease Control and Prevention (&ldquo;CDC&rdquo;), about 87% of strokes are ischemic in nature with the remainder classified as hemorrhagic. According to the CDC, worldwide, stroke is an important cause of adult disability and the second leading cause of death in developed countries. Risk factors for stroke include advanced age, hypertension (high blood pressure), previous stroke or transient ischemic attack (&ldquo;TIA&rdquo;), diabetes, high cholesterol, cigarette smoking and atrial fibrillation. According to the World Health Organization, each year approximately 15 million people worldwide suffer a stroke, of which 5.5 million will die and 5.0 million will be permanently disabled. According to the CDC:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Every year in the United States, approximately 795,000 people experience a new or recurrent stroke each year (ischemic or hemorrhagic). Approximately 610,000 of these are first events and 185,000 are recurrent stroke events.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stroke caused approximately one of every 20 deaths in the United States. On average, someone in the United States has a stroke every 40 seconds, and someone dies from a stroke every four minutes.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stroke costs the United States $34 billion annually, including the cost of health care services, medications and lost productivity.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">At the site of a blood flow blockage in the brain, there exist two major ischemic zones - the core ischemic zone with nearly complete loss of blood flow, and the surrounding ischemic penumbra having partially reduced blood flow. Within minutes, the significant lack of blood flow in the core (<i>i.e.</i>,&nbsp;glucose and oxygen deprivation) rapidly depletes energy stores and triggers the loss of ion gradients, ultimately leading to neuronal cell death. The ischemic penumbra zone, however, may remain viable for several hours via collateral arteries that branch from the main occluded artery in the core zone. Unfortunately, the penumbra is at great risk of delayed tissue damage due to inflammation and cell death, or apoptosis. As time goes on, a lack of blood flow in the ischemic zone (infarct) leads to fluid buildup (edema) and swelling which creates intracranial pressure. This pressure on the brain leads to tissue compression resulting in additional ischemia. Additional events in AIS include vascular damage to the blood vessel lining or endothelium, loss of structural integrity of brain tissue and blood vessels, and inflammation. A stroke can lead to permanent damage with memory loss, speech problems, reading and comprehension difficulties, physical disabilities, and emotional/behavioral problems. The long-term costs of stroke are substantial, with many patients requiring extended hospitalization, extended physical therapy or rehabilitation, and/or long-term institutional or family care. However, provided the extended window of viability in the penumbra, next generation stroke therapies are being developed to protect valuable brain tissue during the hours to a week after a stroke.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Acute Ischemic Stroke Treatment Options</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><img src="chart03.jpg">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe that stroke represents an area of significant unmet medical need, and a KLK1 treatment (such as DM199) could provide a treatment option and a significant patient benefit with its proposed therapeutic window of up to 24 hours after the first sign of symptoms. Currently, the only pharmacological intervention for AIS is the use of tissue plasminogen activator (&ldquo;tPA&rdquo;), which must be given within 4.5 hours of symptom onset. Mechanical thrombectomy, in which the clot is removed using catheter-based tools, is also available to some patients. Despite the availability of these treatments, many patients are not eligible due to the location of the clot, the elapsed time after the stroke occurred, or safety considerations. Thus, we believe DM199 offers significant advantages over the current treatment options and fills an unmet need for patients who cannot receive tPA. Additionally, DM199 may also offer a complimentary follow-on treatment for patients who initially receive tPA or mechanical thrombectomy treatments. Based on the number of strokes each year (approximately 1.7 million in the United States, Europe and Japan and 15 million worldwide) and the $8,500 estimated cost per patient for the current standard of care, tPA, we believe the annual market opportunity for DM199 could be significant.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DM199 Acute Ischem</b><b>ic Stroke: Proposed Mechanism</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div style="text-align: center;"><img src="image02.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">KLK1 in China (marketed under the brand name Kailikang&reg;) is widely used for the treatment of AIS, making therapy available to hundreds of thousands of patients who currently have no options. Kailikang&reg; is a human urine-extracted KLKl protein. We believe that the proprietary DM199 protein could result in an improved efficacy with optimized pharmacokinetics (drug level exposure) and avoid the side effects of risk of endotoxins, impurities and antibody formation in comparison to Kailikang&reg; that is isolated from human urine. We also believe that DM199 addresses potential supply constraints that makes Kailikang&reg; difficult and expensive to produce given the limited source of human urine. We believe these factors make the recombinant protein DM199 a product candidate that is better positioned for regulatory approval worldwide than a urine-derived protein since we believe it can meet the rigorous required manufacturing standards.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Potential Treatments with DM199</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Chronic Kidney Disease</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We also believe DM199 has the potential to offer therapeutic benefits for CKD patients. The KLK1 protein plays a vital role in normal kidney function, and BK and BK receptors are critical for kidney health and integrity. Patients with moderate to severe CKD often excrete abnormally low levels of KLK1 in their urine, leading to the hypothesis that this KLK1 deficit contributes to disease progression. We believe that DM199 may replenish KLK1 levels and activate the BK system that protects the kidney from damage. In fact, DM199 treatment in an animal model of Type 1 diabetes delayed the onset of the disease, attenuated the degree of insulitis (inflammation in the insulin producing islet cells of the pancreas) and improved pancreatic beta cell mass in a dose-dependent manner by increasing T-regs. By providing additional KLK1, DM199 has the following potentially beneficial actions:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Improve blood flow to the kidney by restoring proper regulation of blood flow through veins arteries and especially capillaries (vasoregulation);</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Support the structural integrity of the kidney by reducing scar tissue formation (fibrosis), oxidative stress, and inflammation; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Activate mechanisms that upregulate T-regs, improve insulin sensitization, glucose uptake and glycogen synthesis, and lower blood pressure.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Further supporting the hypothesis that an intact KKS is critical for normal kidney function, a series of observational studies published in Immunopharmacology showed the amount of KLK1 released into the urine appears to be inversely correlated with the severity of disease in patients with CKD. Urinary KLK1 excretion was decreased in patients with both mild (not requiring dialysis) and severe (kidney failure/hemodialysis) renal disease compared to controls. The severity of the disease was negatively correlated with KLK1 excretion. Decreases in urinary KLK1 activity was seen especially when the reduction was associated with decreased glomerular filtration rate. We believe DM199 may potentially have advantages over ACEi because it restores already depleted KLK1 levels.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">DM199 treatment is intended to directly replenish KLK1 levels, normalizing kidney function. Current treatment options, especially ACEi drugs, only partially restore kidney function and are associated with high-risk side effects. Importantly, it is becoming increasingly clear that part of the beneficial effect of ACEi drugs involves preventing the normal breakdown of BK leading to substantial increases in BK levels throughout the body. While higher BK levels benefit the kidney, ACEi drugs can generate excessive BK where is it not needed, potentially leading to side effects such as persistent cough, angioedema (swelling of skin and tissue) and hyperkalemia (abnormally high potassium levels that can lead to cardiac arrest and sudden death). We believe DM199 treatment could allow KLK1 to follow its normal physiological processes and release BK when and where it is needed, avoiding these side effects. Importantly, we believe successful treatment with ACEi in kidney disease requires a fully functional kallikrein kinin system, KLK1 and bradykinin systems, potentially making ACEi drugs less effective in patients with a pre-existing KLK1 deficit.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">KLK1 derived from the pancreas of a pig, or porcine KLK1, is currently used to treat CKD in China and Japan. Porcine KLK1 is also used to treat hypertension and retinopathy in Japan, China and Korea. Based on IQVIA data and our estimates, we estimate millions of patients have been treated with porcine KLK1 for CKD, retinopathy and other vascular diseases in Asia. Over 20 clinical papers have been published in the Chinese literature supporting the therapeutic activity in CKD patients of porcine KLK1 given alone or in combination with an ARB or an ACEi. These unblinded studies involve treatment durations ranging from a few weeks up to six months and report improvement in kidney disease based on decreased urinary albumin excretion rates and other clinical endpoints of kidney disease.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div style="text-align: center;"><img src="chart04.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">There is a significant need for new and alternative treatment strategies for CKD and we believe that the combined results of these studies, which are consistent with our proposed mechanism of action for and preclinical studies of DM199, provide a good rationale for formal clinical development of DM199. We intend to seek approval for use of DM199 as a novel and ground-breaking therapy for CKD. We believe DM199 could potentially complement the use of ACEi or ARBs to improve kidney functions without increasing the risk for hyperkalemia, chronic cough, angioedema or other related side effects. Less than 30% of patients with CKD are believed to be on optimal dose of ACEi or ARB due in part to risk of hyperkalemia which can lead to cardiac arrest and sudden death. We believe DM199, through the activation of the BK system, may complement the renin-angiotensin system, primarily targeted by ACEi and ARBs. Activation of the BK system may improve the function of the diseased renal system by improving vasodilation and insulin sensitization, as well as blocking fibrosis, inflammation, thrombosis and oxidative stress. A significant potential advantage of DM199 over ACEi/ARB treatments is that hyperkalemia may be less likely with DM199. We anticipate that DM199 will boost KLK1 levels to release physiological levels of BK when and where needed, generating beneficial nitric oxide and prostacyclin while increasing regulatory T cells (T-regs or TREGS) to reduce inflammation.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DM199 (Recombinant KLK1), ACEi, ARB and Plasma Kallikrein Proposed Mechanism of Actions</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div style="text-align: center;"><img src="chart05.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Acute Ischemic Stroke</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe treatment of AIS with DM199 could have both immediate and long-term benefits for patients that could significantly improve outcomes following AIS. Immediate actions include activation of the KKS to release nitric oxide and improve microcirculation in ischemic tissue along with improvements in the balance between blood flow and brain activity (neurovascular coupling). Long-term (days following the stroke) actions include the restoration of the blood brain barrier through increases in T regulatory cells (&ldquo;T-regs&rdquo; &ndash; a subpopulation of T cells that modulate the immune system and prevent autoimmune disease) and inhibition of apoptotic cell death.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In China, a human urine-extracted KLKl protein (Kailikang&reg;) is approved and marketed by Techpool Bio-Pharma Inc., a company controlled by Shanghai Pharmaceuticals Holding Co. Ltd. We believe Kailikang&reg; has been approved for the treatment of AIS in China with a treatment window of up to 48&nbsp;hours post-stroke. Based on IQVIA data, other publications and internal estimates, we believe over 500,000 stroke patients have been treated with Kailikang&reg; for acute ischemic stroke in Asia. More than 50 published clinical studies, covering over 4,000 stroke patients, have demonstrated a beneficial effect of Kailikang&reg; treatment in AIS. According to a publication in the <i>China Journal of Neurology</i>, in a double-blinded, placebo-controlled trial of 446 patients treated with either KLK1 or a placebo administered up to 48 hours after a stroke showed significantly better scores on the European Stroke Scale and Activities of Daily Living at three weeks post-treatment and after three months using the Barthel Index.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">11</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div style="text-align: center;"><img src="chart06.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Furthermore, a comprehensive meta-analysis covering 24 clinical studies involving 2,433 patients published in the <i>Journal of Evidenced Based Medicine</i> concluded that human urinary KLK1 appears to ameliorate neurological deficits for patients with AIS and improves long-term outcomes, though a few treated patients suffered from transient hypotension.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As DM199 is a recombinant form of human KLK1, we believe it has the potential to preserve &ldquo;at risk&rdquo; brain tissue by increasing cerebral blood flow, establishing better collateral circulation, decreasing inflammation, reducing cell death, or apoptosis, and facilitating improved blood flow to at-risk ischemic penumbra brain tissue. We believe DM199 offers the potential for an improved recombinant product for worldwide use. We are developing DM199 to treat AIS patients with therapy beyond the current window of 3 to 4.5 hours for tPA to up to 24 hours after the first sign of symptoms, thereby filling a large unmet need of patients who cannot receive tPA under the currently available treatment window of tPA. We believe this could potentially make therapy available to the millions of patients worldwide who currently have limited options.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Other Potential Programs</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are also currently developing a diagnostic tool, DMDx, to measure KLK1 levels. Several published studies indicate KLK1 insufficiency is associated with multiple disease states including hypertension, CKD and AIS. Levels of endogenous KLK1 in both urine and plasma are inversely correlated with disease severity. Importantly, the decrease in urinary protein occurs in a disease state (e.g. CKD), where a primary hallmark is increased secretion of many other proteins. In this way, we believe KLK1 is a potentially unique diagnostic tool for such diseases.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe DM199 may also offer a potentially novel treatment for vascular dementia patients. Vascular dementia is caused by chronic impaired blood supply within the brain, often associated with TIA or prior stroke. According to the Alzheimer&rsquo;s Society, one third of all stroke survivors could develop dementia within five years. According to the U.S. National Institute of Neurological Disorders and Stroke, there are over 6 million stroke survivors in the United States alone. In a clinical study, KLK1 isolated from human urine demonstrated the ability to improve cognitive function in vascular dementia patients and increase cerebral blood flow. We have drafted a protocol synopsis for a Phase II study in vascular dementia. Our decision to commence this study will be dependent upon our cash resources.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Our Competition and Current Treatments for Chronic Kidney Disease and Acute Ischemic Stroke</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The biopharmaceutical industry is highly competitive and characterized by rapidly advancing technologies that focus on rapid development of proprietary drugs. We believe that our product candidates, development capabilities, experience and scientific knowledge provide us with competitive advantages. However, we face significant potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources than we do, and experience in obtaining U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) and other regulatory approvals of treatments and commercializing those treatments. Accordingly, our competitors may be more successful than us in obtaining approval for competitive products and achieving widespread market acceptance. Our competitors&rsquo; treatments may be more effectively marketed and sold than any products we may commercialize, thus limiting our market share and resulting in a longer period before we can recover the expenses of developing and commercializing our product candidates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These activities may lead to consolidated efforts that allow for more rapid development of competitive product candidates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We also compete for staff, development and clinical resources. These competitors may impair our ability to recruit or retain qualified scientific and management personnel, our ability to work with specific advisors, clinical contract organizations, due to conflicts of interest or capacity constraints, and may also delay recruitment of clinical study sites and study volunteers, impeding progress in our development programs.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We expect any products that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, price and the availability of reimbursement from government or other third-party payers. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are viewed as safer, more effective or less expensive than any products that we may develop.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Chronic Kidney Disease</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In the United States, we are aware of only one currently approved treatment for CKD. That treatment is an ACEi (marketed under the brand name Captopril&reg;) which is approved for the treatment of patients with CKD caused by Type 1 diabetes. There are several pharmaceutical products for the treatment of CKD currently in clinical development, some of which include:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Mineralcorticortisteroid receptor agonist (Bayer HealthCare Pharmaceuticals LLC)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">CCR2 receptor antagonists (ChemoCentryx, Inc., Bristol-Myers Squibb Company)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Oxidative stress, cyclo-oxygenase 2 inhibitors (Reata Pharmaceuticals, Inc.)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Glycosylation inhibitors (Glycadia, Inc. aka Glycadia Pharmaceuticals)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Endothelin A receptor antagonists (AbbVie Inc.)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cyclin nucleotide phosphodiesterase inhibitor (Pfizer Inc.)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Aldosterone receptor antagonists (Mitsubishi Tanabe Pharma Corporation)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Nitric oxide enzyme inhibitor (GenKyoTex SA)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Nitric oxide (Cyclerion/Ironwood Pharmaceuticals, Inc.)</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">13</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Current treatment strategies for CKD include the strict control of high blood pressure and high blood sugar. The ACEi drug Captopril is approved for use in patients with CKD due to Type 1 diabetes and both ACEi and ARBs are widely prescribed to slow the progression of CKD. However, according to the National Kidney Foundation, 3.6% of the U.S. population over their lifetime will develop ESRD requiring dialysis or kidney transplantation. Furthermore, the treatment with ACEi and ARBs has been linked to hyperkalemia (elevated blood potassium levels), which increases the risk for abnormal heart rhythms and sudden death. In fact, two clinical trials investigating the use of ACEi and ARB combination therapy in kidney disease were stopped prematurely because participants developed hyperkalemia. The added complication of hyperkalemia results in patients receiving suboptimal dosing or patients being untreated because they cannot tolerate the treatment. Additional side effects with ACEi treatment are angioedema (swelling of skin tissue) and persistent cough.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">DM199 treatment is intended to directly replenish KLK1 levels, normalizing kidney function. Current treatment options, especially ACEi drugs, only partially restore kidney function and the association with high-risk side effects. ACEi drugs can generate excessive BK where is it not needed, potentially leading to related side effects such as cough and angioedema (swelling of skin and tissue). We believe DM199 treatment would potentially allow KLK1 to follow its normal physiological processes and release BK when and where it is needed, avoiding these side effects. Importantly, successful treatment with ACEi in kidney disease requires a fully functional KLK1 system, potentially making ACEi drugs less effective in patients with a pre-existing KLK1 deficit.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Acute Ischemic Stroke</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Currently, there is one approved pharmaceutical treatment for acute ischemic stroke. That treatment is tPA (marketed under the brand name Activase&reg;), and its therapeutic window is limited to 3 to 4.5&nbsp;hours after the AIS. There are, however, a number of companies that are actively pursuing a variety of approaches to develop pharmaceutical products for the treatment of AIS including, among others:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stem cells (Athersys, Inc.)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cerebral edema (Biogen Inc.)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Anti-inflammatory and clot dissolving (Biogen Inc.)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cell protection and anti-inflammation (ZZ Biotech LLC)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Inhibits platelet aggregation (Acticor Biotech SAS)</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe that there is a large unmet therapeutic need for AIS treatments that can be administered beyond the 3 to 4.5-hour time window of tPA. With this large unmet therapeutic need, there is significant competition to develop new therapeutic options. New therapeutic options in development include tissue protection focused therapies (deliverable from hours to days after the stroke) that preserve and protect brain cells beyond the tPA therapeutic window. Currently, the most advanced treatments involve the mechanical removal of blood clots in brain arteries through sophisticated catheter-based approaches. According to published research, use of mechanical thrombectomy is growing and the window of time after a stroke where the procedure can be used is widening. These therapies are especially targeted toward preserving viable cells in the ischemic penumbra hours after a stroke. The goal is to provide treatment options for the vast majority of AIS patients who do not receive hospital care early enough to qualify for tPA therapy. We believe there is a very significant market opportunity for a drug that has a therapeutic window beyond that of tPA and is able to obtain regulatory approval.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In January 2019, we announced the publication of a paper titled &ldquo;<u>Human Tissue Kallikrein In The Treatment Of Acute Ischemic Stroke</u><i>&rdquo;</i> in the peer reviewed journal, <i>Therapeutic Advances in Neurological Disorders (&ldquo;TAND&rdquo;)</i>. The paper reviews the scientific literature covering the biochemical role of KLK1 and presents the mechanistic rationale for using KLK1 as an additional pharmacological treatment for AIS. In addition to the biochemical mechanism of KLK1, the review highlights supporting results from human genetics and preclinical animal models of brain ischemia. It also reviews published clinical results for treatment of AIS by a form of KLK1 that is isolated from human urine. This form has been approved for post-infarct treatment of AIS in China and data has been published on clinical trials involving over 4,000 patients. The paper offers a series of testable therapeutic hypotheses for demonstrating the long-term beneficial effect of KLK1 treatment in AIS patients and the reasons for this action.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">14</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>DM199 Clinical Studies</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have completed five clinical trials with DM199 in over 120 volunteers, including multiple Phase I single dose ascending and multiple dose ascending studies in healthy volunteers and patients with Type 2 diabetes. Chronic dosing studies over 16 to 28 days were also conducted in healthy volunteers and patients with Type 2 diabetes. (see Table 1 below). As is generally the case for early phase clinical trials, the primary endpoints for all studies were safety, tolerability, and pharmacokinetics. The Phase II (Part D) study also investigated a series of secondary endpoints that included blood glucose concentration, insulin levels, glucose tolerance testing and a variety of experimental biomarkers of evaluating the potential efficacy of DM199 in treating Type 2 diabetes patients.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Table 1 DM199 Trial Design Overview</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px; width: 17.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Trial</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 15.6%; border-top: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Participants (N)</p>
			</td>
			<td style="vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px; width: 21.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Design</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 20.5%; border-top: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Doses (&micro;g/kg)</p>
			</td>
			<td style="vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: 1px; width: 7.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Route</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 16.7%; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Length</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 17.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Phase-I Part A</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:15.6%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Healthy (32)</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 21.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Single ascending dose</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:20.5%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">5, 15, 30, 50</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 7.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">SC</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 16.7%; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">1 week</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 17.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Phase-I Part B</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:15.6%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Type 2 diabetes (10)</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 21.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Single ascending dose</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:20.5%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">0.3, 1.5, 15</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 7.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">SC</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 16.7%; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">1 week</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 17.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Phase-I Part C</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:15.6%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Healthy (18)</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 21.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Multiple ascending dose</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:20.5%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">3, 15, 25</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 7.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">SC</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 16.7%; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6 doses over 16 days</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 17.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Phase-IIA Part D</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:15.6%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Type 2 diabetes (36)</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 21.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Blinded multiple dose</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:20.5%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Placebo, 3, 15</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 7.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">SC</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 16.7%; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">10 doses over 28 days</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 17.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Phase I Bridging</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:15.6%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Healthy (36)</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 21.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Single ascending dose</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:20.5%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">0.25, 0.50, 0.75</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">1.0</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">3.0</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 7.7%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">IV</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">IV</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">SC</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 16.7%; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">1 week</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In combination, these studies showed that DM199 was well tolerated and demonstrated clear physiological activity. After subcutaneous (&ldquo;SC&rdquo;) injection (under the skin), DM199 exhibited a favorable pharmacokinetic profile with extended half-life (<i>i.e.</i>,&nbsp;the time required to reduce concentration of the drug in the body by one-half), supporting potential dosing intervals of up to one week. The dose-limiting tolerability issue in healthy volunteers was orthostatic hypotension (a condition in which blood pressure falls significantly when a person stands) observed largely at the 50&nbsp;&micro;g/kg dose level, which is much greater than those anticipated to be efficacious in patients. In each trial, observed treatment emergent side-effects were mild to moderate in severity and resolved. The most common treatment-emergent side effects included headache, dizziness, nausea and injection site pain, the majority of which were observed in the highest dose group of the Phase I-Part A trial.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Two of our clinical studies have focused on patients with Type 2 diabetes. The first study enrolled 10&nbsp;Type 2 diabetic patients. The patients were dosed with either DM199, at three single ascending dose levels or placebo. DM199 was well-tolerated at all three dose levels by the diabetic patients with no dose limiting side effects. The second study in patients with Type 2 diabetes enrolled 36 patients treated with one of two SC dose levels of DM199 or placebo over 28 days. This study achieved its primary endpoints and demonstrated that DM199 was well-tolerated. The secondary endpoints for this study, however, were not met. The secondary efficacy endpoints were confounded due to what we believe were significant execution errors caused by protocol deviations occurring at the clinical trial site that were unable to be reconciled. See &ldquo;<i>Part I. Item 1. Business&mdash;Legal Proceedings</i>&rdquo; for more information on this study.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In February 2018, we initiated treatment on the first patient in our Phase II REMEDY trial assessing the safety, tolerability and markers of therapeutic efficacy of DM199 in patients suffering from AIS. Our REMEDY trial is expected to enroll up to 100 patients to evaluate DM199 in patients with AIS. The study drug (DM199 or placebo) will be administered as an intravenous (&ldquo;IV&rdquo;) infusion within 24&nbsp;hours of stroke symptom onset, followed by SC injections later that day and once every 3 days for 21 days. The study is designed to measure safety and tolerability along with multiple tests designed to investigate DM199&rsquo;s therapeutic potential including plasma-based biomarkers and standard functional stroke measures assessed at 90 days post-stroke. Standard functional stroke measurements include the Modified Rankin Scale, National Institutes of Health Stroke Scale, the Barthel Index and C-reactive protein, a measure of inflammation.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In February 2019, we began enrolling patients in a Phase Ib clinical study evaluating DM199 in CKD patients, This study is being conducted at 3 sites in the U.S. and all sites are actively enrolling patients. The open label clinical trial is evaluating three dose levels of DM199, administered by a single subcutaneous (&ldquo;SC&rdquo;) dose, in 32 patients with moderate or severe CKD. Primary endpoints include safety, tolerability pharmacokinetics, change in KLK1 levels, albumin to creatine ratios and kidney biomarkers measured over a 12-day period. This study is intended to assist in identifying dose levels for use in subsequent Phase II trials.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In 2017, we completed and published in the <i>International Journal of Clinical Trials</i> the results from a Phase lb study with DM199 designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. Specifically, this study compared multiple doses levels of DM199, administered via IV and SC routes to identify a dose and delivery route that most closely compared to or improves upon the pharmacokinetic and pharmacodynamics profile of the approved urinary KLK1 in China. We found that a dose of DM199 administered via IV infusion mimicked the drug profile of IV-administered urinary derived KLK1 (Kailikang&reg;). We believe that this study also identified a dose of DM199, administered via SC injection, which had a superior pharmacokinetic profile and that maintained more normal KLK1 levels throughout day. Below are results from our clinical trial showing the pharmacokinetic profile of subcutaneously administered DM199 observed in study subjects as compared to what we believe is normal range in healthy subjects.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div style="text-align: center;"><img src="chart07.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Potential DM199 Commercial Advantages</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Several researchers have studied the structural and functional properties of KLK1. This deep body of knowledge has revealed the potential clinical benefits of KLK1 treatments. Today, forms of KLK1 derived from human urine and porcine pancreas are sold in Japan, China and Korea to treat acute ischemic stroke, chronic kidney disease, retinopathy, hypertension and related diseases. We are not aware of any synthetic version of KLK1 with regulatory approval for human use in any country, nor are we aware of any synthetic version in development besides our drug candidate DM199 (recombinant human KLK1). We believe at least five companies have attempted to create a synthetic version of KLK1.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">16</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The growing understanding of KLK1&rsquo;s role in human health and its use in Asia as an approved therapeutic highlight two important potential commercial advantages for DM199:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679; </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>KLK1 treatment is sold in Japan, China and Korea</b>. Research has shown that patients with low levels of KLK1 are associated with a variety of diseases related to vascular dysfunction, such as chronic kidney disease, acute ischemic strokes, retinopathy and hypertension. Clinical trial data with human urine and porcine KLK1 has demonstrated statistically significant clinical benefits of treating a variety of patients with KLK1 compared to placebo. These efficacy results are further substantiated by established markets in Japan, China and Korea for pharmaceutical sales of KLK1 derived from human urine and porcine pancreas.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679; </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>KLK1 treatment has had limited side effects and has been well tolerated in studies to date</b>. KLK1 is naturally produced by the human body; and therefore, the body&rsquo;s own control mechanisms act to limit potential side effects. The only notable side effect observed in our clinical trials was orthostatic hypotension, or sudden drop in blood pressure, which was only seen at doses significantly higher than our anticipated therapeutic dose levels. Routine clinical use of KLK1 treatment in Asia has been well-tolerated by patients. In 2017, we completed a clinical trial comparing the pharmacokinetic profile of DM199 to Kailikang&reg; for acute ischemic stroke, which showed DM199, when administered in intravenous form, to have a profile similar to Kailikang&reg;. Further, when DM199 was administered subcutaneously, DM199 demonstrated a superior, longer acting, pharmacokinetic profile to Kailikang&reg;.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have conducted numerous internal and third-party analyses to demonstrate that DM199 is structurally and functionally equivalent to KLK1 derived from human urine. The amino acid structure of DM199 is identical to the human urine form, and the enzymatic and pharmacokinetic profiles are substantially similar to both human urinary and porcine derived KLK1. The physiological effects of DM199 on blood pressure, from our completed studies, mirror that of human urinary and porcine-derived forms of KLK1. We believe that the results of this work suggest that the therapeutic action of DM199 will be the same or better than that of the forms marketed in Asia. In addition, we believe that there are also significant formulation, manufacturing, regulatory and other advantages for our synthetic human KLK1 drug candidate DM199:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679; </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Potency and Impurity Considerations</b>. KLK1 derived from human urine or porcine pancreas may contain impurities, endotoxins, and chemical byproducts due to the inherent variability of the isolation and purification process. We believe that this creates the risk of inconsistencies in potency and impurities from one production run to the next. However, we expect to produce a consistent formulation of KLK1 that is free of endotoxins and other impurities, which we believe will provide therapeutic benefits.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679; </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Cost and Scalability</b>. Large quantities of human urine and porcine pancreas must be obtained to derive a small amount of KLK1. This creates potential procurement, cost and logistical challenges to source the necessary raw organic material, particularly for human urine sourced KLK1. Once sourced, the raw organic material is processed using chemicals and costly capital equipment and produces a significant amount of byproduct waste. Our novel recombinant manufacturing process utilizes widely available raw materials and can be readily scaled for commercial production. Accordingly, we believe our manufacturing process has significant cost and scalability advantages.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679; </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Regulatory</b>. We are not aware of any attempts by manufacturers of the urine or porcine based KLK1 products to pursue regulatory approvals in the United States. We believe that this is related to challenges presented by using inconsistent and potentially hazardous biomaterials, such as human urine and porcine pancreas, and their resulting ability to produce a consistent drug product. Our novel recombinant manufacturing process utilizes widely available raw materials which we believe provides a significant regulatory advantage, particularly in regions such as the United States, Europe and Canada, where safety standards are high. In addition, we believe that DM199 could qualify for 12 years of data exclusivity under the Biologics Price Competition and Innovation Act of 2009, which was enacted as part of the ACA.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">17</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Regulatory Approval</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Securing regulatory approval for the manufacture and sale of human therapeutic products in the United States, Europe, Canada and other commercial territories is a long and costly process that is controlled by that particular territory&rsquo;s national regulatory agency. The national regulatory agency in the United States is the FDA, in Europe it is EMA, and in Canada it is Health Canada. Other national regulatory agencies have similar regulatory approval processes, but each national regulatory agency has its own approval processes. Approval in the United States, Europe or Canada does not assure approval by other national regulatory agencies, although often test results from one country may be used in applications for regulatory approval in another country.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Prior to obtaining regulatory approval to market a drug product, every national regulatory agency has a variety of statutes and regulations which govern the principal development activities. These laws require controlled research and testing of products, governmental review, and approval of a submission containing preclinical and clinical data establishing the safety and efficacy of the product for each use sought, approval of manufacturing facilities including adherence to good manufacturing practices (&ldquo;GMP&rdquo;) during production and storage, and control of marketing activities, including advertising, labeling and pricing approval.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">None of our product candidates have been completely developed or tested; and, therefore, we are not yet in a position to seek regulatory approval in any territory to market any of our product candidates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The clinical testing, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export, and marketing, among other things, of our product candidates are subject to extensive regulation by governmental authorities in the United States and other countries. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process, approval process, or after approval may subject us to a variety of administrative or judicial sanctions, including refusal by the applicable regulatory authority to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>U.S. Approval Process</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In the United States, the FDA, a federal government agency, is responsible for the drug approval process. The FDA&rsquo;s mission is to ensure that all medications on the market are safe and effective. The FDA&rsquo;s approval process examines potential drugs; and only those that meet strict requirements are approved.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The U.S. food and drug regulations require licensing of manufacturing facilities, carefully controlled research and testing of products, governmental review and approval of test results prior to marketing of therapeutic products, and adherence to GMP, as defined by each licensing jurisdiction, during production.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">18</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The drug approval process begins with the discovery of a potential drug. Pharmaceutical companies then test the drug extensively. A description of the different stages in the drug approval process in the United States follows.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Stage 1: Preclinical Research</i></b>. After an experimental drug is discovered, research is conducted to help determine its potential for treating or curing an illness. This is called preclinical research. Animal and/or bench studies are conducted to determine if there are any harmful effects of the drug and to help understand how the drug works. Information from these experiments is submitted to the FDA in an IND. The FDA reviews the information in the IND and decides if the drug is safe to study in humans.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Stage 2: Clinical Research</i></b>. In Stage 2, the experimental drug is studied in humans. The studies are known as clinical trials. Clinical trials are carefully designed and controlled experiments in which the experimental drug is administered to patients to test its safety and to determine the effectiveness of an experimental drug. The four general phases of clinical research are described below.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Phase I Clinical Studies</i>. Phase I clinical studies are generally conducted with healthy volunteers who are not taking other medicines; patients with the illness that the drug is intended to treat are not tested at this stage. Ultimately, Phase I studies demonstrate how an experimental drug affects the body of a healthy individual. Phase I consists of a series of small studies consisting of &ldquo;tens&rdquo; of volunteers. Tests are done on each volunteer throughout the study to see how the person&rsquo;s body processes, responds to, and is affected by the drug. Low doses and high doses of the drug are usually studied, resulting in the determination of the safe dosage range in volunteers by the end of Phase I. This information will determine whether the drug proceeds to Phase II.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Phase II Clinical Studies</i>. Phase II clinical studies are conducted in order to determine how an experimental drug affects people who have the disease to be treated. Phase II usually consists of a limited number of studies that help determine the drug&rsquo;s short-term safety, side effects, and general effectiveness. The studies in Phase II often are controlled investigations involving comparison between the experimental drug and a placebo, or between the experimental drug and an existing drug. Information gathered in Phase II studies will determine whether the drug proceeds to Phase III.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Phase III Clinical Studies</i>. Phase III clinical studies are expanded controlled and uncontrolled trials that are used to more fully investigate the safety and effectiveness of the drug. These trials differ from Phase II trials because a larger number of patients are studied (sometimes in the thousands) and because the studies are usually of longer duration. As well, Phase Ill studies can include patients who have more than one illness and are taking medications in addition to the experimental drug used in the study. Therefore, the patients in Phase III studies more closely reflect the general population. The information from Phase III forms the basis for most of the drug&rsquo;s initial labeling, which will guide physicians on how to use the drug.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Phase IV Clinical Studies</i>. Phase IV clinical studies are conducted after a drug is approved. Companies often conduct Phase IV studies to more fully understand how their drug compares to other drugs. Also, the FDA may require additional studies after the drug is approved. FDA-required Phase IV studies often investigate the drug in specific types of patients that may not have been included in the Phase III studies and can involve very large numbers of patients to further assess the drug&rsquo;s safety.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Stage 3: FDA Review for Approval</i></b>. Following Phase III, the pharmaceutical company prepares reports of all studies conducted on the drug and a complete dossier on the manufacturing of the product and submits the reports to the FDA in a New Drug Application (&ldquo;NDA&rdquo;). The FDA reviews the information in the NDA to determine if the drug is safe and effective for its intended use. Occasionally, the FDA will ask experts for their opinion of the drug. If the FDA determines that the drug is safe and effective, the drug will be approved.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">19</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Stage 4: Marketing</i></b>. After the FDA has approved the experimental drug, the pharmaceutical company can make it available to physicians and their patients. A company also may continue to conduct research to discover new uses for the drug. Each time a new use for a drug is discovered, the drug once again is subject to the entire FDA approval process before it can be marketed for that purpose.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Any pharmaceutical products for which FDA approvals are obtained are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, promoting pharmaceutical products for uses or in patient populations that are not described in the pharmaceutical product&rsquo;s approved labeling (known as &ldquo;off-label use&rdquo;), industry-sponsored scientific and educational activities and promotional activities involving the internet. Failure to comply with FDA requirements can have negative consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The FDA also may require post-marketing testing, known as Phase IV testing, risk evaluation and mitigation strategies and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe that DM199 could qualify for 12 years of data exclusivity under the Biologics Price Competition and Innovation Act of 2009 (the &ldquo;BPCIA&rdquo;), which was enacted as part of the ACA. Under the BPCIA, an application for a biosimilar product (&ldquo;BLA&rdquo;) cannot be submitted to the FDA until four years, or if approved by the FDA, until 12 years, after the original brand product identified as the reference product is approved under a BLA. The BPCIA provides an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &ldquo;interchangeable&rdquo; based on its similarity to an existing brand product. The new law is complex and is only beginning to be interpreted and implemented by the FDA.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>European Approval Process</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The EMA is roughly parallel to the U.S. FDA in terms of the drug approval process and the strict requirements for approval. The EMA was set up in 1995 in an attempt to harmonize, but not replace, the work of existing national medicine regulatory bodies in individual European countries. As with the FDA, the EMA drug review and approval process follows different stages from preclinical testing through clinical testing in Phase I, II, and III. There are some differences between the FDA and EMA review process, specifically the review process in individual European countries. Such differences may allow certain drug products to be tested in patients at an earlier stage of development.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Other Healthcare Laws and Compliance Requirements</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services and other divisions of the U.S. government, including, the Department of Health and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. For example, if a drug product is reimbursed by Medicare, Medicaid, or other federal or state healthcare programs, our company, including our sales, marketing and scientific/educational grant programs, must comply with the federal False Claims Act, as amended, the federal Anti-Kickback Statute, as amended, and similar state laws. If a drug product is reimbursed by Medicare or Medicaid, pricing and rebate programs must comply with, as applicable, the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 (&ldquo;OBRA&rdquo;), and the Medicare Prescription Drug Improvement and Modernization Act of 2003. Among other things, OBRA requires drug manufacturers to pay rebates on prescription drugs to state Medicaid programs and empowers states to negotiate rebates on pharmaceutical prices, which may result in prices for our future products that will likely be lower than the prices we might otherwise obtain. Additionally, the ACA substantially changes the way healthcare is financed by both governmental and private insurers. There may continue to be additional proposals relating to the reform of the U.S. healthcare system, in the future, some of which could further limit coverage and reimbursement of drug products. If drug products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements may apply.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">20</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Pharmaceutical Coverage, Pricing and Reimbursement</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and adequate reimbursement from third-party payers, including government health administrative authorities, managed care providers, private health insurers and other organizations. In the United States, private health insurers and other third-party payers often provide reimbursement for products and services based on the level at which the government (through the Medicare or Medicaid programs) provides reimbursement for such treatments. Third-party payers are increasingly examining the medical necessity and cost-effectiveness of medical products and services in addition to their safety and efficacy; and, accordingly, significant uncertainty exists as to the coverage and reimbursement status of newly approved therapeutics. In particular, in the United States, the European Union and other potentially significant markets for our product candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. As a result, coverage and adequate third party reimbursement may not be available for our products to enable us to realize an appropriate return on our investment in research and product development.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The market for our product candidates for which we may receive regulatory approval will depend significantly on access to third-party payers&rsquo; drug formularies or lists of medications for which third-party payers provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payers may refuse to include a particular branded drug in their formularies or may otherwise restrict patient access to a branded drug when a less costly generic equivalent or another alternative is available. In addition, because each third-party payer individually approves coverage and reimbursement levels, obtaining coverage and adequate reimbursement is a time-consuming and costly process. We would be required to provide scientific and clinical support for the use of any product candidate to each third-party payer separately with no assurance that approval would be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our product candidates. This process could delay the market acceptance of any of our product candidates for which we may receive approval and could have a negative effect on our future revenues and operating results. We cannot be certain that our product candidates will be considered cost-effective. If we are unable to obtain coverage and adequate payment levels for our product candidates from third-party payers, physicians may limit how much or under what circumstances they will prescribe or administer them and patients may decline to purchase them. This in turn could affect our ability to successfully commercialize our products and impact our profitability, results of operations, financial condition, and future success.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">21</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Research and Development</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have devoted substantially all of our efforts to research and development (&ldquo;R&amp;D&rdquo;) which therefore comprises the largest component of our operating costs. Our primary focus over the past approximately eight years has been our lead product candidate, DM199, which is currently in clinical development for AIS and CKD.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We expect our R&amp;D expenses will continue to increase in the future as we advance our initial product candidate through clinical trials in AIS and CKD and seek to expand our product candidate portfolio. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming and we consider the active management and development of our clinical pipeline to be integral to our long-term success. The actual probability of success for each product candidate, clinical indication and preclinical program may be affected by a variety of factors including, among other things, the safety and efficacy data for product candidates, amounts invested in the program, competition and competitive developments, manufacturing capability and commercial viability.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Research and development expenses include:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expenses incurred under contract research agreements and other agreements with third parties;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expenses incurred under agreements with clinical trial sites that conduct research and development activities on our behalf;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">employee and consultant-related expenses, which include salaries, benefits, travel and share-based compensation;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">laboratory and vendor expenses related to the execution of clinical trials and non-clinical studies;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the cost of acquiring, developing, manufacturing, and distributing clinical trial materials; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance, and other supply costs.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Research and development costs are expensed as incurred. Costs for certain development activities such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We expect that it will be several years, if ever, before we have any product candidates ready for commercialization.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Manufacturing</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of DM199 nor do we have plans to develop our own manufacturing operations in the foreseeable future. We rely on Catalent Pharma Solutions, LLC (&ldquo;Catalent&rdquo;) for all of our required raw materials, active pharmaceutical ingredients and finished DM199 product candidate for our clinical trials. We have licensed certain gene expression technology and we contract with Catalent for the manufacture of DM199. The royalty term is indefinite but may be canceled by us on 90 days&rsquo; prior written notice. The license may not be terminated by Catalent unless we fail to make required milestone and royalty payments. We currently employ internal resources and third-party consultants to manage our manufacturing relationship with Catalent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">22</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Sales and Marketing</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have not yet defined our sales, marketing or product distribution strategy for our initial product candidate, or any future product candidates, because it is still early in the clinical development stage. We currently expect to partner with a large pharmaceutical company for sales execution. However, our future commercial strategy may include the use of distributors, a contract sales force or the establishment of our own commercial and specialty sales force, as well as similar strategies for regions and territories outside the United States.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Intellectual Property</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We view patents and other means of intellectual property protection including trade secrets as an important component of our core business. We focus on translating our innovations into intangible property protecting our proprietary technology from infringement by competitors. To that end, patents are reviewed frequently and continue to be sought in relation to those components or concepts of our preclinical and clinical products to provide protection. Our strategy, where possible, is to file patent applications to protect our product candidates, as well as methods of manufacturing, administering and using a product candidate. Prior art searches of both patent and scientific databases are performed to evaluate novelty, inventiveness and freedom-to-operate. We require all employees, consultants, and parties to sign a collaborative research agreement and to execute confidentiality agreements upon the commencement of employment, consulting relationships, or a collaboration with us. These agreements require that all confidential information developed or made known during the course of the engagement with us is to be kept confidential. We also maintain agreements with our scientific staff and all parties contracted in a scientific capacity affirming that all inventions resulting from work performed for us, using our property, or relating to our business and conceived or completed during the period covered by the agreement are the exclusive property of our company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our patent portfolio includes patents and pending applications that are owned by us, which include claims for composition of matter and methods of use. For our DM199 program, this includes two patent families that are directed to composition of matter, and methods of use.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The DM199 patents protect composition of matter including compositions of glycoforms, formulations, methods of administration and a variety of therapeutic approaches pertaining to current and potential future indications. We currently have additional patent applications for DM199. Additionally, for the manufacture of DM199, we have licensed an expression system and cell line with proven GMP and regulatory support and are contracting with a contract manufacturing organization (&ldquo;CMO&rdquo;) with proven GMP experience in manufacturing of recombinant proteins for clinical trials.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of DM199. We intend to rely on Catalent for the manufacture of DM199. We have licensed certain gene expression technology and we contract with Catalent for the manufacture of DM199. Under the terms of this license, certain milestone and royalty payments may become due and are dependent upon, among other factors, performing clinical trials, obtaining regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain. The royalty term is indefinite but may be canceled by us on 90 days&rsquo; prior written notice. The license may not be terminated by Catalent unless we fail to make required milestone and royalty payments.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our DM199 patent portfolio includes granted U.S. patents, a granted European patent, one pending U.S. patent application and a worldwide pending application filed under the Patent Cooperation Treaty (&ldquo;PCT&rdquo;). Granted or pending claims offer various forms of protection for DM199 including claims to compositions of matter, pharmaceutical compositions, specific formulations and dosing levels, and methods for treating a variety of diseases, including stroke, chronic kidney disease, and related disorders. These U.S. patents and applications, and their foreign equivalents, are described in more detail below.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">23</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Issued patents held by us cover the DM199 composition of matter based on an optimized combination of closely-related isoforms that differ in the extent of glycosylation (process by which sugars are chemically attached to proteins). Issued claims in this patent family cover the most pharmacologically active variants of DM199 and methods of using the same for treating ischemic conditions and these patents are due to expire in 2033. A second patent family includes an issued U.S. patent with claims directed to methods of treating subjects by administering a SC formulation of DM199 or related recombinant kallikrein-1 polypeptides. The PCT patent application is directed to a range of dose levels and dosing regimens of DM199 that are potentially useful for treating a wide range of diseases including, e.g. pulmonary arterial hypertension, cardiac ischemia, chronic kidney disease, diabetes, stroke, and vascular dementia.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Methods and reagents required for commercial scale manufacture of DM199 are subject to a series of patents issued to our manufacturing partner. As noted above, we exclusively license these patents from our manufacturing partner for the production of DM199 or any human KLK1 protein. We believe that our proprietary technology along with trade secrets will provide substantial protection from third-party competitors. We believe DM199 cannot be reversed engineered for a copycat version to be made. In addition, DiaMedica has specialized knowledge of the manufacturing process.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe that the most relevant granted patents with composition of matter or method of use claims covering DM199 are listed below, along with their projected expiration dates exclusive of any patent term extension.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 25%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Patent Number</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 41%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Title</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Geography</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Expiration</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:25%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Issued patents</i></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 41%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:25%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">US 9,364,521</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 41%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Composition of Matter &ndash; Human Tissue Kallikrein 1 Glycosylation Isoforms</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">US</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2033</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:25%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 41%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:25%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">EP 2 854 841</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 41%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Composition of Matter &ndash; Human Tissue Kallikrein 1 Glycosylation Isoforms</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Europe</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2033</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:25%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 41%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:25%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">US 9,616,015</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 41%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Formulations for Human Tissue Kallikrein-1 for Parenteral Delivery and Related Methods</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">US</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2033</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:25%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 41%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:25%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Pending applications</i></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 41%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:25%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">PCT/US2018/021749</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 41%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Dosage Forms of Tissue Kallikrein 1</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">US/Worldwide</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2038</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>License Agreement</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In September 2018, we entered into a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. (&ldquo;Ahon Pharma&rdquo;), which grants Ahon Pharma exclusive rights to develop and commercialize DM199 for acute ischemic stroke in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Under the terms of the agreement, we received an upfront payment of $500,000 on signing and are entitled to receive an additional payment of $4.5 million upon regulatory clearance to initiate a clinical trial in China. We also have the potential to receive up to an additional $27.5 million in development and sales related milestones and up to approximately 10% royalties on net sales of DM199 in the licensed territories. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territories will be the sole responsibility of Ahon Pharma. This agreement may be terminated at any time by Ahon Pharma by providing 120 days written notice. Fosun Pharma, through its partnership with SK Group, a South Korea based company is an investor in DiaMedica through its equity investment in 2016.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">24</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Employees</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of December 31, 2018, we had 9 full-time employees. We have never had a work stoppage and none of our employees are covered by collective bargaining agreements. We believe our employee relations are good.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Executive Officers</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table sets forth information as of December 31, 2018 regarding each of our current executive officers:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Name</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 8%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Age</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 53%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Positions</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Rick Pauls</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">47</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">President and Chief Executive Officer, Director</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Scott Kellen</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">53</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer and Secretary</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Todd Verdoorn, Ph.D.</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">57</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Scientific Officer</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 35%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Harry Alcorn, Pharm.D.</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">62</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 53%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Medical Officer</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The present principal occupations and recent employment history of each of our executive officers are set forth below.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Rick Pauls</i> was appointed our President and Chief Executive Officer in January 2010. Mr. Pauls has served as a member of our Board of Directors since April 2005 and the Chairman of the Board from April 2008 to July 2014. Prior to joining DiaMedica, Mr. Pauls was the Co-Founder and Managing Director of CentreStone Ventures Inc., a life sciences venture capital fund, from February 2002 until January 2010. Mr.&nbsp;Pauls was an analyst for Centara Corporation, another early stage venture capital fund, from January 2000 until January 2002. From June 1997 until November 1999, Mr. Pauls worked for General Motors Acceptation Corporation specializing in asset-backed securitization and structured finance. Mr. Pauls previously served as an independent member of the board of directors of LED Medical Diagnostics, Inc. Mr.&nbsp;Pauls received his Bachelor of Arts in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe that Mr. Pauls&rsquo; experience in the biopharmaceutical industry as an executive and investor and his extensive knowledge of all aspects of our company, business, industry, and day-to-day operations as a result of his role as our President and Chief Executive Officer enable him to make valuable contributions to our Board of Directors. In addition, as a result of his role as President and Chief Executive Officer, Mr.&nbsp;Pauls provides unique insight into our future strategies, opportunities and challenges, and serves as the unifying element between the leadership and strategic direction provided by our Board of Directors and the implementation of our business strategies by management.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Scott Kellen</i> was appointed our Chief Financial Officer and Secretary in April 2018. Prior to joining DiaMedica, Mr. Kellen served as Vice President and Chief Financial Officer of Sun BioPharma, Inc., a publicly-traded clinical stage drug development company, from October 2015 until April 2018. From February 2010 to September 2015, Mr. Kellen served as Chief Financial Officer and Secretary of Kips Bay Medical, Inc., a publicly-traded medical device company, and became Chief Operating Officer of Kips Bay in March 2012. From November 2007 to May 2009, Mr. Kellen served as Finance Director of Transoma Medical, Inc. From 2005 to October 2007, Mr. Kellen served as Corporate Controller of ev3 Inc. From March 2003 to April 2005, Mr. Kellen served as Senior Manager, Audit and Advisory Services of Deloitte &amp; Touche, LLP. Altogether, Mr. Kellen has spent more than 25 years in the life sciences industry, focusing on publicly traded early stage and growth companies. Mr. Kellen has a Bachelor of Science degree in Business Administration from the University of South Dakota and is a Certified Public Accountant (inactive).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">25</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Todd Verdoorn, Ph.D.</i> was appointed our Chief Scientific Officer in May 2016. From January 2016 to April 2016, Dr. Verdoorn served as our Vice President, Neuroscience. Prior to joining DiaMedica, Dr.&nbsp;Verdoorn served as Chief Scientist at Intuitive Quantitation, LLC, a company that provides strategic and tactical leadership for companies creating new treatments, from May 2013 to December 2016. From September 2011 to May 2013, Dr. Verdoorn served as Vice President, Neurobiology at NeuroTherapeutics Pharma, Inc., a company that develops and markets therapeutics. From January 2008 to August 2011, Dr. Verdoorn served as Chief Scientist for Orasi Medical, Inc., a medical device company. From June 2007 to January 2008, Dr.&nbsp;Verdoorn served as Chief Scientific Officer for Smart Bioscience SAS, a company that discovers and develops small-molecule therapeutics. Prior to joining Smart Bioscience, Dr. Verdoorn served as Chief Scientific Officer at Algos Preclinical Services, Inc., a research and consulting company, from January 2003 to June 2007. Dr. Verdoorn has more than 26&nbsp;years of experience working with both public and private companies to develop new treatments for neurological diseases, including five years working with Bristol-Myers Squibb&rsquo;s stroke group. Dr.&nbsp;Verdoorn has a Bachelor of Arts degree in Chemistry from Central College and he earned his Ph.D. in Neurobiology from the University of North Carolina, conducting his post-doctoral research at the Max Planck Institute with Nobel Laureate Dr. Bert Sakmann and served as Associate Professor of Pharmacology at Vanderbilt University School of Medicine.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Harry Alcorn Jr. Pharm.D.</i> was appointed our Chief Medical Officer in August 2018. Prior to joining DiaMedica, Dr. Alcorn served as Chief Scientific Officer at DaVita Clinical Research (&ldquo;DCR&rdquo;), a company that provides clinical research services for Pharmaceutical and Biotech companies, from October 1997 to June 2018. While at DCR, Dr. Alcorn was responsible for clinical research operations, including the formation and management of the early clinical and late phase research services. Dr.&nbsp;Alcorn also founded the U.S. Renal Network, the first network of Phase I renal research sites in the United States. Dr. Alcorn developed DCR&rsquo;s site management organization for clinical trials. Dr.&nbsp;Alcorn also served as an Executive Director, a Pharmacist and an Investigator at DCR. During this time, from Jan 2013 to December 2014, he also served on the Board of Directors for the Association of Clinical Pharmacology Units, an association of Phase I clinical trial sites. Dr. Alcorn has over 30 years of clinical research experience working with Biotech and Pharmaceutical companies, both public and private, in conducting research in renal, hepatic and cardiovascular disease. Dr. Alcorn has written and consulted on the development of several protocols and has served as Principal Investigator or Sub Investigator in numerous studies and, for several of these studies, presented study design and results to the FDA. Currently he holds clinical faculty appointments with the University of Minnesota, Creighton University, University of Nebraska Medical Center, Virginia Commonwealth and the University of Colorado, Denver. Dr. Alcorn graduated from Creighton University with a Bachelor of Pharmacy and went on to earn his Doctor of Pharmacy degree from University of Nebraska Medical Center.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Enforceability of Civil Liabilities Against Foreign Persons</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are organized under and governed by the federal laws of Canada, and, accordingly, are governed by the applicable laws of Canada. There is doubt as to the enforceability, in original actions in Canadian courts, of liabilities based upon the U.S. federal securities laws or the securities laws or &ldquo;blue sky&rdquo; laws of any state within the United States and as to the enforceability in Canadian courts of judgments of U.S. courts obtained in actions based upon the civil liability provisions of the U.S. federal securities laws or any such state securities laws or blue sky laws. Accordingly, it may not be possible to enforce judgments obtained in the United States against us.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">26</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Available Information</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are a corporation organized under Canada Business Corporations Act (&ldquo;CBCA&rdquo;). Our company was initially incorporated under the name Diabex Inc. pursuant to The Corporations Act (Manitoba) by articles of incorporation dated January 21, 2000. Our articles were amended (i) on February 26, 2001 to change our corporate name to DiaMedica Inc., (ii) on April 11, 2016 to continue the Company from The Corporations Act (Manitoba) to the CBCA, (iii)&nbsp;on December 28, 2016 to change our corporate name to DiaMedica Therapeutics Inc., (iv) on September 24, 2018 to permit us to hold shareholder meetings in the United States and to permit our directors, between annual meetings of our shareholders, to appoint one or more additional directors to serve until the next annual meeting of shareholders; provided, however, that the number of additional directors shall not at any time exceed one-third of the number of directors who held office at the expiration of the last meeting of shareholders, and (v) on November 15, 2018 to effect a 1-for-20 consolidation of our common shares.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our registered office is located at 301-1665 Ellis Street, Kelowna, British Columbia, V1Y 2B3 and our principal executive office is located at our wholly owned subsidiary, DiaMedica USA Inc., located at 2&nbsp;Carlson Parkway, Suite 260, Minneapolis, Minnesota, USA 55447. Our telephone number is 763-496-5454. Our internet website address is http://www.diamedica.com. Information contained on our website does not constitute part of this report.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We make available, free of charge and through our Internet web site, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to any such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnishes it to, the Securities and Exchange Commission (&ldquo;SEC&rdquo;). Reports filed with the SEC may be viewed at www.sec.gov.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Implications of Being an Emerging Growth Company</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As a company with less than $1.07 billion of revenue during our last fiscal year, we are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (&ldquo;JOBS Act&rdquo;), and we may remain an emerging growth company for up to five years from December 31, 2018. However, if certain events occur prior to the end of such five-year period, including if we become a large accelerated filer, our annual gross revenue exceeds $1.07 billion, or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other public companies that are not emerging growth companies. In particular, in this report, we have provided only two years of audited financial statements and have not included certain other information that would be required if we were not an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold equity interests. However, we have irrevocably elected not to avail ourselves of the extended transition period for complying with new or revised accounting standards, and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">27</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 1A.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risk Factors</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following are the most significant factors known to us that could materially adversely affect our business, operating results or financial condition.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Risks Related to Our Financial Position and Need for Additional Capital</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We have incurred substantial losses since our inception and expect to continue to incur future substantial losses and may never become profitable.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are a clinical stage biopharmaceutical company focused on the development of novel recombinant proteins. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to prove effective, gain regulatory approval or become commercially viable. We do not have any products approved by regulatory authorities and have not generated any revenues from product sales to date, and do not expect to generate any sales revenue for several years. We have incurred significant research, development and other expenses related to our ongoing operations and expect to continue to incur such expenses. As a result, we have not been profitable and have incurred significant operating losses in every reporting period since our inception. For the year ended December 31, 2018 and 2017, we incurred a net loss of $5.7 million and $4.3 million, respectively. As of December 31, 2018, we had an accumulated deficit of $46.0 million. We expect to continue to incur substantial operating losses until such time as any future product sales, royalty payments, licensing fees, and/or milestone payments are sufficient to generate revenues to fund our continuing operations. We expect our operating losses to increase in the near term as we continue the research, development and clinical trials of, and seek regulatory approval for, our product candidates. In addition, we expect our operating expenses to increase in 2019 compared to 2018 as a result of our recently obtained Nasdaq-listed U.S. public reporting company status. We are unable to predict the extent of any future losses or when we will become profitable, if ever. Even if we do achieve profitability, we may not be able to sustain or increase profitability on an ongoing basis.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We currently have no sales revenue and do not expect any sales revenue for several years. Accordingly, we will need additional funding to continue our research and development activities and other operations, which may not be available to us on acceptable terms, or at all.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our future operations will be dependent upon our ability to develop our product candidates, obtain research grant funding, obtain required regulatory approvals, generate product sales, negotiate collaboration or license agreements or other strategic alternatives, and/or secure additional funds. Despite our recent initial public offering, we expect we will need substantial additional capital to further our research and development (&ldquo;R&amp;D&rdquo;) activities, planned clinical trials, regulatory activities and otherwise develop our product candidate, DM199, or any future product candidates to a point where they may be commercially sold. While we are striving to achieve these plans, there is no assurance these and other strategies will be achieved or that additional financing will be obtained on favorable terms or at all. We expect our current cash, which includes the net proceeds of our recent initial public offering, to be sufficient to allow us to complete our current Phase II Remedy trial in patients with acute ischemic stroke and our current Phase Ib study in patients with chronic kidney disease and a Phase II study in patients with chronic kidney disease and to otherwise fund our planned operations through 2020. However, the amount and timing of future funding requirements will depend on many factors, including the timing and results of our ongoing development efforts, the potential expansion of our current development programs, potential new development programs and related general and administrative (&ldquo;G&amp;A&rdquo;) support. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time. We may elect to raise additional funds even before we need them if market conditions for raising additional capital are favorable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">28</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Since our inception, we have financed our operations from public and private sales of equity, the exercise of warrants and stock options, interest income on funds available for investment, and government grants and tax credit, and we expect to continue this practice for the foreseeable future. We do not have any existing credit facilities under which we could borrow funds. We may seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if our clinical data is not positive or economic and market conditions deteriorate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Although we have previously been successful in obtaining financing through our equity securities offerings, there can be no assurance that we will be able to do so in the future. To the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted. Debt financing, if available, may involve agreements that include conversion discounts or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, or strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. It is possible that financing will not be available or, if available, may not be on favorable terms. The availability of financing will be affected by the results of our clinical studies and other scientific and clinical research; our ability to attain regulatory approvals; market acceptance of our product candidates; the state of the capital markets generally with particular reference to pharmaceutical, biotechnology, and medical companies; the status of strategic alliance agreements; and other relevant commercial considerations. If adequate funding is not available, we may be required to implement cost reduction strategies; delay, reduce, or eliminate one or more of our product development programs; relinquish significant rights to product candidates or obtain funds on less favorable terms than we would otherwise accept; and/or divest assets or cease operations through a merger, sale, or liquidation of our company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We are exposed to the financial risk related to the fluctuation of foreign exchange rates and the degrees of volatility of those rates.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We may be adversely affected by foreign currency fluctuations. To date, we have been primarily funded through issuances of equity and proceeds from the exercise of warrants and stock options, which are denominated both in Canadian and U.S. dollars. Currently, the majority of our expenditures are in U.S. dollars, however, significant costs are also incurred in Canadian dollars, British pounds, and Australian dollars; and, therefore, we are subject to foreign currency fluctuations which may, from time to time, impact our financial position and results of operations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Risks Related to our Business and our Industry</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We are an early stage company with no approved products and no revenue from commercialization of our products.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are at an early stage of development of our product candidate, DM199, for the treatment of AIS and CKD. We have not completed the development of any product candidate and, accordingly, have not begun to commercialize, any product candidate or generate any sales revenues from any product candidate. DM199 requires significant additional clinical testing and investment prior to seeking marketing approval. A commitment of substantial resources by ourselves and potential partners to continue to conduct clinical trials for DM199 will be required to meet applicable regulatory standards, obtain required regulatory approvals, and successfully commercialize this product candidate. DM199 is not expected to be commercially available for several years, if at all.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">29</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Our prospects depend on the success of our product candidate, DM199, which is at an early stage of development, and we may not generate sales revenue for several years, if at all, from this product candidate or any future product candidates.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are highly dependent on the success of DM199 and we may not be able to successfully obtain regulatory or marketing approval for, or successfully commercialize, this product candidate. To date, we have expended significant time, resources and effort on the development of DM199, including conducting preclinical and clinical trials, for the treatment of acute ischemic stroke and chronic kidney disease. Although we intend to study the use of DM199 to treat multiple diseases, we have no other product candidates in our current clinical development pipeline. Our ability to generate sales revenues and to achieve commercial success in the near term will initially depend almost entirely on our ability to successfully develop, obtain regulatory approval for and then successfully commercialize DM199. Prior to commercialization of any potential product, significant additional investments will be necessary to complete the development of DM199 or any future product candidates. Preclinical and clinical trial work must be completed before DM199 or any future product candidate could be ready for use within the markets that we have identified. We may fail to develop any products, to obtain regulatory approvals, to enter clinical trials, or to commercialize any products. Competitors may develop alternative products and methodologies to diagnose and treat the disease indications we are pursuing, thus reducing our competitive advantages. We do not know whether any of our product development efforts will prove to be effective, meet applicable regulatory standards, obtain the requisite regulatory approvals, be capable of being manufactured at a reasonable cost, or successfully marketed. The product candidate we are currently developing is not expected to be commercially viable for several years. In addition, our product candidate may cause undesirable side effects. Results of early preclinical research may not be indicative of the results that will be obtained in later stages of preclinical or clinical research. If regulatory authorities do not approve our product candidate or any future product candidates or if we fail to maintain regulatory compliance, we would have limited ability to commercialize our product candidate or any future product candidates, and our business and results of operations would be harmed. If we do succeed in developing viable products from our product candidates, we will face many potential obstacles such as the need to develop or obtain manufacturing, marketing, and distribution capabilities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We rely and will continue to rely on third parties to plan, conduct, and monitor our preclinical and clinical trials, and their failure to perform as required could cause substantial harm to our business.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We rely and will continue to rely on third parties to conduct a significant portion of our preclinical and clinical development activities. Preclinical activities include in vivo studies providing access to specific disease models, pharmacology and toxicology studies, and assay development. Clinical development activities include trial design, regulatory submissions, clinical patient recruitment, clinical trial monitoring, clinical data management and analysis, safety monitoring, and project management. If there is any dispute or disruption in our relationship with third parties, or if they are unable to provide quality services in a timely manner and at a feasible cost, our active development programs may face delays. Further, if any of these third parties fails to perform as we expect or if their work fails to meet regulatory requirements, our testing could be delayed, cancelled, or rendered ineffective.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">30</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We rely on a contract manufacturer over whom we have limited control. If we are subject to quality, cost, or delivery issues with the preclinical and clinical grade materials supplied by this or future contract manufacturers, our business operations could suffer significant harm.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We rely on a contract manufacturing organization (&ldquo;CMO&rdquo;) to manufacture our product candidate, DM199, for our preclinical studies and clinical trials. We rely on this CMO for manufacturing, filling, packaging, storing, and shipping of drug product in compliance with current good manufacturing practices (&ldquo;GMP&rdquo;) regulations applicable to our product candidate. The U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) ensures the quality of drug products by carefully monitoring drug manufacturers&rsquo; compliance with &ldquo;GMP&rdquo; regulations. The &ldquo;GMP&rdquo; regulations for drugs contain minimum requirements for the methods, facilities, and controls used in manufacturing, processing, and packing of a drug product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">There can be no assurances that this CMO will be able to meet our timetable and requirements. If we are unable to arrange for alternative third-party manufacturing sources on commercially reasonable terms or in a timely manner, we may be delayed in the development of DM199 and any future product candidates. Further, CMOs must operate in compliance with GMP regulations and failure to do so could result in, among other things, the disruption of product supplies. Our dependence upon this CMO and any future third parties for the manufacture of our product candidates may adversely affect our ability to develop our product candidates on a timely and competitive basis and, if we are able to commercialize our product candidates, may adversely affect our profit margins.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we would incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct preclinical studies in animals and extensive clinical trials in humans to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive and difficult to design and implement, can take many years to complete, and has uncertain outcomes. The outcome of preclinical studies and early clinical trials may not predict the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. We do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any of our product candidates in any jurisdiction. A product candidate may fail for safety or efficacy reasons at any stage of the testing process. A major risk we face is the possibility that neither our current or future product candidates will successfully gain market approval from the FDA or other regulatory authorities, resulting in us being unable to derive any commercial revenue from them after investing significant amounts of capital in multiple stages of preclinical and clinical testing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>If we experience delays in clinical testing, we will be delayed in commercializing our product candidates, and our business may be substantially harmed.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We cannot predict whether any clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Our product development costs will increase if we experience delays in clinical testing. Significant clinical trial delays could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before us, which would impair our ability to successfully commercialize our product candidates and may harm our financial condition, results of operations and prospects. The commencement and completion of clinical trials for our product candidates may be delayed for a number of reasons, including delays related, but not limited, to:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure by regulatory authorities to grant permission to proceed or placing the clinical trial on hold;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">31</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">patients failing to enroll or remain in our trials at the rate we expect;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">suspension or termination of clinical trials by regulators for many reasons, including concerns about patient safety or failure of our contract manufacturers to comply with GMP requirements;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any changes to our manufacturing process that may be necessary or desired;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delays or failure to obtain clinical supply from contract manufacturers of our product candidates necessary to conduct clinical trials;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">product candidates demonstrating a lack of safety or efficacy during clinical trials;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">patients choosing an alternative treatment for the indications for which we are developing any of our product candidates or participating in competing clinical trials;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">patients failing to complete clinical trials due to dissatisfaction with the treatment, side effects, or other reasons;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">reports of clinical testing on similar technologies and products raising safety and/or efficacy concerns;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">competing clinical trials and scheduling conflicts with participating clinicians;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">clinical investigators not performing our clinical trials on their anticipated schedule, dropping out of a trial, or employing methods not consistent with the clinical trial protocol, regulatory requirements or other third parties not performing data collection and analysis in a timely or accurate manner;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure of our contract research organizations (&ldquo;CROs&rdquo;) to satisfy their contractual duties or meet expected deadlines;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">inspections of clinical trial sites by regulatory authorities, Institutional Review Boards (&ldquo;IRBs&rdquo;) or ethics committees finding regulatory violations that require us to undertake corrective action, resulting in suspension or termination of one or more sites or the imposition of a clinical hold on the entire study;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">one or more IRBs or ethics committees rejecting, suspending or terminating the study at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial; or</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure to reach agreement on acceptable terms with prospective clinical trial sites.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our product development costs will increase if we experience delays in testing or approval or if we need to perform more or larger clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend study protocols to reflect these changes. Amendments may require us to resubmit our study protocols to regulatory authorities or IRBs or ethics committees for re-examination, which may impact the cost, timing or successful completion of that trial. Delays or increased product development costs may have a material adverse effect on our business, financial condition, and prospects.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">32</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><i>&nbsp;</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our current product candidate and the activities associated with its development and commercialization, including design, research, testing, manufacture, safety, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, advertising, promotion, sale, distribution, import, export, and reporting of safety and other post-market information, are subject to comprehensive regulation by the FDA, the European Medicines Agency (&ldquo;EMA&rdquo;) and other foreign regulatory agencies. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-parties to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&rsquo;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA, EMA or other regulatory authorities may determine that our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. As a result, any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In addition, changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We are in litigation with Pharmaceutical Research Associates Group B.V., a contract research organization, seeking to compel them to comply with the terms of a clinical trial research agreement and their failure to perform as required could adversely affect our ability to obtain regulatory approval for DM199.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In March 2013, we entered into a clinical research agreement with Pharmaceutical Research Associates Group B.V. (&ldquo;PRA Netherlands&rdquo;) to perform a double-blinded, placebo-controlled, single-dose and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and proof of concept of DM199 in healthy subjects and in patients with Type 2 diabetes mellitus. In one arm of this study, we enrolled 36 patients with Type 2 diabetes who were treated with two SC dose levels of DM199 over a 28-day period. This study achieved its primary endpoint and demonstrated that DM199 was well tolerated. The secondary endpoints for this study, however, were not met. We believe there were significant execution errors in Part D of the study that were caused by protocol deviations occurring at the clinical trial site that were unable to be reconciled. We believe these included dosing errors and sample mix-ups. These errors undermined our ability to interpret the secondary endpoints. To date, we have been unable to obtain the complete study records from PRA Netherlands for the arm of the study which included 36 patients with Type 2 diabetes and was intended to measure primary endpoints (safety, tolerability) and secondary endpoints (blood glucose concentration, insulin levels, glucose tolerance test and a variety of experimental biomarkers). Without these records and given our inability to reconcile the protocol deviations, we have been unable to generate a final study report. Due in part to these confounded secondary endpoints, we are not currently continuing the clinical study of DM199 for Type 2 diabetes. We have initiated litigation with PRA Netherlands to compel them to comply with the terms of the clinical research agreement, including providing full study records, and to recover damages. Litigation distracts the attention of our management from our business, is expensive and the outcome is uncertain.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">33</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We may not be able to obtain FDA acceptance of INDs to commence clinical trials in the United States on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed in a timely manner, or at all.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Prior to commencing clinical trials in the United States for our current or any future product candidates, we will likely be required to have an accepted IND for each product candidate and for each targeted indication. During the fourth quarter of 2018, we filed and the FDA accepted an IND for a Phase Ib clinical trial of DM199 in patients with moderate or severe CKD caused by Type I or Type II diabetes. We have not filed any other INDs to initiate a clinical trial for DM199 in the United States. A submission of an IND may not result in the FDA allowing further clinical trials to begin and, once begun, issues may arise that will require us to suspend or terminate such clinical trials. Additionally, even if relevant regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, these regulatory authorities may change their requirements in the future. Failure to submit or have effective INDs and commence clinical programs will significantly limit our opportunity to generate revenue.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>If we have difficulty enrolling patients in clinical trials, the completion of the trials may be delayed or not completed at all.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As DM199 and any future product candidates advance from preclinical testing to clinical testing, and then through progressively larger and more complex clinical trials, we will need to enroll an increasing number of patients that meet our eligibility criteria. There is significant competition for recruiting patients in clinical trials, and we may be unable to enroll the patients we need to complete clinical trials on a timely basis or at all. The factors that affect our ability to enroll patients are largely uncontrollable and include, but are not limited to, the following:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">size and nature of the patient population;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">eligibility and exclusion criteria for the trial;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">design of the study protocol;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">competition with other companies for clinical sites or patients;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the perceived risks and benefits of the product candidate under study;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the patient referral practices of physicians; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the number, availability, location, and accessibility of clinical trial sites.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We may not be able to reproduce the results of previously conducted clinical studies and/or comparisons to other forms of KLK1, including Kailikang&reg;, thereby displacing other forms of KLK1, including Kailikang&reg;.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">While there have been numerous studies demonstrating the efficacy of Kailikang&reg;, we rely on the scientific and clinical knowledge and experience of other biotechnology and pharmaceutical companies and organizations in conducting those clinical studies. No assurance can be given that in our clinical trials involving DM199 we will be able to reproduce results of previously conducted studies or displace other forms of KLK1 in the market.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">34</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Negative results from clinical trials or studies of others and adverse safety events involving the targets of our product candidates may have an adverse impact on our future commercialization efforts.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">From time to time, studies or clinical trials on various aspects of biopharmaceutical products are conducted by academic researchers, competitors, or others. The results of these studies or trials, when published, may have a significant effect on the market for the biopharmaceutical product that is the subject of the study. The publication of negative results of studies or clinical trials or adverse safety events related to our product candidates, or the therapeutic areas in which our product candidates compete, could adversely affect our share price and our ability to finance future development of our product candidates, and our business and financial results could be materially and adversely affected.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive, or the trials are not well designed.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Clinical trials must be conducted in accordance with the FDA&rsquo;s current Good Clinical Practices requirements, or cGCPs, or analogous requirements of applicable foreign regulatory authorities. Clinical trials are subject to oversight by the FDA, other foreign governmental agencies, and IRBs or ethics committees at the study sites where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates produced in accordance with applicable current Good Manufacturing Practices. Clinical trials may be suspended by us or by the FDA, other foreign regulatory authorities, or by an IRB or ethic committee with respect to a particular clinical trial site, for various reasons, including:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or study protocols;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">deficiencies in the clinical trial operations or trial sites;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">unforeseen adverse side effects or the emergence of undue risks to study subjects;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">deficiencies in the trial design necessary to demonstrate efficacy;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the product candidate may not appear to offer benefits over current therapies; or</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the quality or stability of the product candidate may fall below acceptable standards.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The design and implementation of clinical trials is a complex process. As a Company, we have limited experience designing and implementing clinical trials, and failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory approval on the basis of the trial results, as well as lead to increased or unexpected costs. We may not successfully or cost-effectively design and implement clinical trials that achieve our desired clinical endpoints efficiently, or at all. A clinical trial that is not well designed may delay or even prevent initiation of the trial, can lead to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the study results, or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement from third party payers. Additionally, a trial that is not well-designed could be inefficient or more expensive than it otherwise would have been, or we may incorrectly estimate the costs to implement the clinical trial, which could lead to a shortfall in funding.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">35</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Regulatory approval processes are lengthy, expensive, and inherently unpredictable. Our inability to obtain regulatory approval for our product candidates would substantially harm our business.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our shareholders and other investors should be aware of the risks, problems, delays, expenses, and difficulties which we may encounter in light of the extensive regulatory environment within which our business is carried out. Numerous statutes and regulations govern the preclinical and clinical development, manufacture and sale, and post-marketing responsibilities for non-therapeutic and human therapeutic products in the United States, European Union, Canada, Australia and other countries that are the intended markets for our current and future product candidates. Such legislation and regulation governs the approval of manufacturing facilities, the testing procedures, and controlled research that must be carried out, and the preclinical and clinical data that must be collected prior to marketing approval. Our R&amp;D efforts, as well as any future clinical trials, and the manufacturing and marketing of any products we may develop, will be subject to and restricted by such extensive regulation.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The process of obtaining necessary regulatory approvals is lengthy, expensive, and uncertain. We may fail to obtain the necessary approvals to commence or continue clinical testing or to manufacture or market our potential products in reasonable time frames, if at all. In addition, governmental authorities in the United States or other countries may enact regulatory reforms or restrictions on the development of new therapies that could adversely affect the regulatory environment in which we operate or the development of any products we may develop.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Completing clinical testing and obtaining required approvals is expected to take several years and to require the expenditure of substantial resources. There can be no assurance that clinical trials will be completed successfully within any specified period of time, if at all. Furthermore, clinical trials may be delayed or suspended at any time by us or by the various regulatory authorities if it is determined at any time that the subjects or patients are being exposed to unacceptable risks.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Any failure or delay in obtaining regulatory approvals would adversely affect our ability to utilize our technology and would therefore adversely affect our operations. Furthermore, no assurance can be given that our current or future product candidates will prove to be safe and effective in clinical trials or that they will receive the requisite regulatory approval. Moreover, any regulatory approval of a drug which is eventually obtained may be granted with specific limitations on the indicated uses for which that drug may be marketed. Furthermore, product approvals may be withdrawn if problems occur following initial marketing or if compliance with regulatory standards is not maintained.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The FDA and other federal and state agencies, including the U.S. Department of Justice (&ldquo;DOJ&rdquo;), closely regulate compliance with all requirements governing prescription drug products, including requirements pertaining to marketing and promotion of drugs in accordance with the provisions of the approved labeling and manufacturing of products in accordance with GMP requirements. The FDA and DOJ impose stringent restrictions on manufacturers&rsquo; communications regarding off-label use and if we do not market our products for their approved indications, we may be subject to enforcement action for off-label marketing. Violations of such requirements may lead to investigations alleging violations of the Food, Drug and Cosmetic Act and other statutes, including the False Claims Act and other federal and state health care fraud and abuse laws as well as state consumer protection laws.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">36</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our failure to comply with all regulatory requirements, and later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, may yield various results, including:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">litigation involving patients taking our products;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">restrictions on such products, manufacturers or manufacturing processes;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">restrictions on the labeling or marketing of a product;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">restrictions on product distribution or use;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">requirements to conduct post-marketing studies or clinical trials;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">warning or untitled letters;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">withdrawal of the products from the market;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">refusal to approve pending applications or supplements to approved applications that we submit;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">recall of products;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">fines, restitution or disgorgement of profits or revenues;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">suspension or withdrawal of marketing approvals;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">damage to relationships with any potential collaborators;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">unfavorable press coverage and damage to our reputation;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">refusal to permit the import or export of our products;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">product seizure; or</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">injunctions or the imposition of civil or criminal penalties.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Non-compliance by us or any future collaborator with regulatory requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Non-compliance with European Union requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, also can result in significant financial penalties. Similarly, failure to comply with the European Union&rsquo;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We may not achieve our publicly announced milestones according to schedule, or at all.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">From time to time, we may announce the timing of certain events we expect to occur, such as the anticipated timing of results from our clinical trials. These statements are forward-looking and are based on the best estimates of management at the time relating to the occurrence of such events. However, the actual timing of such events may differ significantly from what has been publicly disclosed. The timing of events such as the initiation or completion of a clinical trial, filing of an application to obtain regulatory approval, or an announcement of additional clinical trials for a product candidate may ultimately vary from what is publicly disclosed. These variations in timing may occur as a result of different events, including the nature of the results obtained during a clinical trial or during a research phase, problems with a CMO or CRO or any other event having the effect of delaying the publicly announced timeline. We undertake no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as otherwise required by law. Any variation in the timing of previously announced milestones could have a material adverse effect on our business plan, financial condition or operating results, and the trading price of our common shares.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">37</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Future development collaborations may be important to us. If we are unable to enter into or maintain these collaborations, or if these collaborations are not successful, our business could be adversely affected.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We may in the future determine to seek to collaborate with pharmaceutical and biotechnology companies for development or commercialization of our current or future product candidates. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for any collaboration will depend, among other things, upon our assessment of the collaborator&rsquo;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&rsquo;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential development schedule or reduce the scope of research activities, or increase our expenditures and undertake discovery, nonclinical or clinical development activities at our own expense. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development activities, we may not be able to continue or further develop our current or future product candidates and our business may be materially and adversely affected.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Future collaborations we may enter into may involve the following risks:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">collaborators may not perform their obligations as expected;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">changes in the collaborators&rsquo; strategic focus or available funding, or external factors, such as an acquisition, may divert resources or create competing priorities;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">collaborators may delay discovery, nonclinical or clinical development, provide insufficient funding for product development of targets selected by us, stop or abandon discovery, nonclinical or clinical development for a product candidate, or repeat or conduct new discovery, and nonclinical and clinical development for a product candidate;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed than our products;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the development of our product candidates;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the discovery, preclinical or clinical development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">collaborators may not properly maintain or defend our intellectual property rights or intellectual property rights licensed to us or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">38</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Additionally, subject to its contractual obligations to us, if a collaborator is involved in a business combination, the collaborator might deemphasize or terminate the development of any of our product candidates. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">If our collaborations do not result in the successful development of products or product candidates, product candidates could be delayed and we may need additional resources to develop product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this report also apply to the activities of our collaborators.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We recently entered into a license and collaboration agreement with Ahon Pharma which allows the licensee to have exclusive rights to develop and commercialize DM199 for AIS in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. in exchange for an upfront cash payment, potential future milestone payments and sales royalties. As a result, we are dependent upon this licensee for such development and commercialization and are not guaranteed of receipt of the potential future milestone payments and sales royalties.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We recently entered into a license and collaboration agreement with Ahon Pharma, a subsidiary of Fosun Pharma, which grants Ahon Pharma exclusive rights to develop and commercialize DM199 for AIS in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Under the terms of the agreement, we received an upfront payment of $500,000 on signing and are entitled to receive an additional payment of $4.5 million upon regulatory clearance to initiate a clinical trial in China. We also have the potential to receive an additional $27.5 million in development and sales related milestones and up to approximately 10% royalties on net sales of DM199 in the licensed territories. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territories will be the sole responsibility of Ahon Pharma. As a result, we are dependent upon Ahon Pharma for such development and commercialization. There can be no assurance that we will receive the potential future milestone payments and sales royalties. This agreement may be terminated at any time by Ahon Pharma by providing 120 days written notice.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>The successful commercialization of our current or future product candidates, if approved, will depend on achieving market acceptance and we may not be able to gain sufficient acceptance to generate significant revenue.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Even if our product candidates are successfully developed and receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payers such as private insurers or governments and other funding parties, and the medical community. The degree of market acceptance for any products we develop will depend on a number of factors, including:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">demonstration of the clinical efficacy and safety;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the prevalence and severity of any adverse side effects;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">limitations or warnings contained in the product&rsquo;s approved labeling;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">cost-effectiveness and availability of acceptable pricing;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">competitive product profile versus alternative treatment methods and the superiority of alternative treatment or therapeutics;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the effectiveness of marketing and distribution methods and support for the products; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">coverage and reimbursement policies of government and third-party payers to the extent that our products could receive regulatory approval but not be approved for coverage by or receive adequate reimbursement from government and quasi-government agencies or other third-party payers.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">39</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Disease indications may be small subsets of a disease that could be parsed into smaller and smaller indications as different subsets of diseases are defined. This increasingly fine characterization of diseases could have negative consequences; including creating an approved indication that is so small as not to have a viable market for us. If future technology allows characterization of a disease in a way that is different from the characterization used for large pivotal studies, it may make those studies invalid or reduce their usefulness, and may require repeating all or a portion of the studies. Future technology may supply better prognostic ability which could reduce the portion of patients projected to need a new therapy. Even after being cleared by regulatory authorities, a product may later be shown to be unsafe or not to have its purported effect, thereby preventing its widespread use or requiring withdrawal from the market.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>If we fail to obtain coverage and adequate reimbursement for our products, our revenue-generating ability will be diminished and there is no assurance that the anticipated market for our products will be sustained.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe that there may be many different applications for products successfully derived from our technologies and that the anticipated market for products under development will continue to expand. However, due to competition from existing or new products and the yet-to-be established commercial viability of our products, no assurance can be given that these beliefs will prove to be correct. Physicians, patients, formularies, payers or the medical community in general may not accept or utilize any products that we may develop. Other drugs may be approved during our clinical testing which could change the accepted treatments for the disease targeted and make our product candidates obsolete.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our ability to commercialize our future products, if any, successfully will depend, in part, on the extent to which coverage and adequate reimbursement for such products and related treatments will be available from governmental health payer programs at the federal and state levels, including Medicare and Medicaid, private health insurers, managed care plans and other organizations. No assurance can be given that third-party coverage and adequate reimbursement will be available that will allow us to maintain price levels sufficient for the realization of an appropriate return on our investment in product development. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and private health insurers, managed care plans and other organizations is critical to new product acceptance. There is no uniform coverage and reimbursement policy among third-party payers in the United States; however, private third-party payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Additionally, coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. Even if we obtain coverage for our product candidates, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. In addition, healthcare reform and controls on healthcare spending may limit the price we charge for any products and the amounts thereof that we can sell. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outside of the United States, the successful commercialization of our products will depend largely on obtaining and maintaining government coverage, because in many countries patients are unlikely to use prescription drugs that are not covered by their government healthcare programs. Negotiating coverage and reimbursement with governmental authorities can delay commercialization by 12&nbsp;months or more. Coverage and reimbursement policies may adversely affect our ability to sell our products on a profitable basis. In many international markets, governments control the prices of prescription pharmaceuticals, including through the implementation of reference pricing, price cuts, rebates, revenue-related taxes and profit control, and we expect prices of prescription pharmaceuticals to decline over the life of the product or as volumes increase.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">40</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We will not be able to successfully commercialize our current or future product candidates without establishing sales and marketing capabilities internally or through collaborators.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We currently have no sales and marketing staff. We may not be able to find suitable sales and marketing staff and collaborators for our product candidates. We have no prior experience in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any collaborators may not be adequate or successful or could terminate or materially reduce the effort they direct to our products. The development of a marketing and sales capability will require significant expenditures, management resources and time. The cost of establishing such a sales force may exceed any potential product revenue, or our marketing and sales efforts may be unsuccessful. If we are unable to develop an internal marketing and sales capability in a timely fashion, or at all, or if we are unable to enter into a marketing and sales arrangement with a third party on acceptable terms, we may be unable to successfully develop and seek regulatory approval for our product candidates and/or effectively market and sell approved products, if any.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We face competition from other biotechnology and pharmaceutical companies and our financial condition and operations will suffer if we fail to effectively compete.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Technological competition is intense in the industry in which we operate. Competition comes from pharmaceutical companies, biotechnology companies, and universities, as well as companies that offer non-pharmaceutical solutions in the markets we may attempt to address with our products. Many of our competitors have substantially greater financial and technical resources; more extensive R&amp;D capabilities; and greater marketing, distribution, production, and human resources than we do. Moreover, competitors may develop products more quickly than us and may obtain regulatory approval for such products more rapidly than we do. Products and processes which are more effective than those that we intend to develop may be developed by our competitors. R&amp;D by others may render our product candidates non-competitive or obsolete.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Our product candidates may face competition sooner than expected.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe that DM199 could qualify for 12 years of data exclusivity in the United States under the Biologics Price Competition and Innovation Act of 2009 (&ldquo;BPCIA&rdquo;), which was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &ldquo;ACA&rdquo;). Under the BPCIA, an application for a biosimilar product, or BLA, cannot be submitted to the FDA until four years, or if approved by the FDA, until 12 years, after the original brand product identified as the reference product is approved under a BLA. The BPCIA provides an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &ldquo;interchangeable&rdquo; based on its similarity to an existing brand product. The new law is complex and is only beginning to be interpreted and implemented by the FDA. While it is uncertain when any such processes may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for any of our product candidates that are biologics. There is also a risk that the U.S. Congress could repeal or amend the BPCIA to shorten this exclusivity period, potentially creating the opportunity for biosimilar competition sooner than anticipated after the expiration of our patent protection. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference product in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">41</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Even if, as we expect, our current or future product candidates are considered to be reference products eligible for 12 years of exclusivity under the BPCIA, another company could market competing products if the FDA approves a full BLA for such product containing the sponsor&rsquo;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the products. Moreover, an amendment or repeal of the BPCIA could result in a shorter exclusivity period for our product candidates, which could have a material adverse effect on our business.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Our relationships with customers and third-party payers will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, program exclusion, contractual damages, reputational harm and diminished profits and future earnings.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Healthcare providers, physicians and third-party payers will likely play a primary role in the recommendation and prescription of any product candidates for which we receive marketing approval. Our future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute the products for which we receive marketing approval. Currently, restrictions under applicable federal and state healthcare laws and regulations include the following:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. This statute may apply to our marketing practices, educational programs, pricing policies and relationships with healthcare providers. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal False Claims Act imposes civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. The government also may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal Health Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;), as amended by the Health Information Technology for Economic and Clinical Health Act, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal transparency requirements under the ACA, require manufacturers of covered drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and investment interests;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">42</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&ldquo;PDMA&rdquo;) and its implementation regulations, as well as the Drug Supply Chain Security Act (&ldquo;DSCSA&rdquo;), which regulates the distribution of and tracing of prescription drugs and prescription drug samples at the federal level, and sets minimum standards for the regulation of drug distributors by the states. The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove counterfeit and other illegitimate products from the market; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the U.S. Foreign Corrupt Practices Act of 1977, as amended (&ldquo;FCPA&rdquo;), the U.S. domestic bribery statute contained in 18 U.S.C. &sect;201, the U.S. Travel Act.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The risk of our being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. We are unable to predict what additional federal or state legislation or regulatory initiatives may be enacted in the future regarding our business or the healthcare industry in general, or what effect such legislation or regulations may have on us. Federal or state governments may impose additional restrictions or adopt interpretations of existing laws that could have a material adverse effect on us.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Laws, restrictions, and other regulatory measures are also imposed by anti-kickback, fraud and abuse, and other healthcare laws and regulations in international jurisdictions and in those jurisdictions we face the same issues as in the United State regarding exposure to criminal sanctions, civil penalties, program exclusion, contractual damages, reputational harm, and diminished profits and future earnings.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">43</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We heavily rely on the capabilities and experience of our key executives and scientists and the loss of any of them could affect our ability to develop our products.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We depend on our management personnel. We also depend on our scientific and clinical collaborators and advisors, all of whom have outside commitments that may limit their availability to us. In addition, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled scientific, managerial, medical, clinical, and regulatory personnel, particularly as we expand our activities and seek regulatory approvals for clinical trials. We enter into agreements with scientific and clinical collaborators and advisors, key opinion leaders, and academic partners in the ordinary course of our business. We also enter into agreements with physicians and institutions who will recruit patients into our clinical trials on our behalf in the ordinary course of our business. Notwithstanding these arrangements, we face significant competition for these types of personnel from other companies, research and academic institutions, government entities and other organizations. We cannot predict our success in hiring or retaining the personnel we require for continued growth. The loss of the services of any of our executive officers or other key personnel could potentially harm our business, operating results, or financial condition.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We will likely need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As we advance DM199 and any future product candidates through preclinical testing and clinical studies, and develop our current or future product candidates, we will need to increase our product development, scientific, regulatory and compliance and administrative headcount to manage these programs. In addition, to meet our obligations as a public company, we will need to increase our general and administrative capabilities. Our management, personnel and systems currently in place may not be adequate to support this future growth. Our need to effectively manage our operations, growth and various projects requires that we:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">successfully attract and recruit new employees with the expertise and experience we will require;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">manage our clinical programs effectively, which we anticipate being conducted at numerous clinical sites;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">develop a marketing, distribution and sales infrastructure if we seek to market our products directly; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">continue to improve our operational, manufacturing, quality assurance, financial and management controls, reporting systems and procedures.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">If we are unable to successfully manage this growth and increased complexity of operations, our business may be adversely affected.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing and reporting standards we have established, comply with federal and state health-care fraud and abuse laws and regulations, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a substantial impact on our business and results of operations, including the imposition of substantial fines or other sanctions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">44</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We may expand our business through the acquisition of companies or businesses or by entering into collaborations or by in-licensing product candidates, each of which could disrupt our business and harm our financial condition.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have in the past and may in the future seek to expand our pipeline and capabilities by acquiring one or more companies or businesses, entering into collaborations, or in-licensing one or more product candidates. Acquisitions, collaborations and in-licenses involve numerous risks, including, but not limited to:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">substantial cash expenditures;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">technology development risks;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">potentially dilutive issuances of equity securities;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">difficulties in assimilating the operations of the acquired companies;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">potential disputes regarding contingent consideration;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">diverting our management&rsquo;s attention away from other business concerns;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">entering markets in which we have limited or no direct experience; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">potential loss of our key employees or key employees of the acquired companies or businesses.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We cannot provide assurance that any acquisition, collaboration, or in-license will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired company or business or in-licensed product candidate. In addition, our future success would depend in part on our ability to manage the growth associated with some of these acquisitions, collaborations and in-licenses. We cannot provide assurance that we would be able to successfully combine our business with that of acquired businesses, manage a collaboration or integrate in-licensed product candidates. Furthermore, the development or expansion of our business may require a substantial capital investment by us.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Our current or future product candidates may cause undesirable side effects or have other properties that could prevent their regulatory approval, limit the commercial scope of their approved uses, or result in significant negative consequences following any marketing approval.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of our trials could reveal unacceptable side effects or unexpected characteristics. In such an event, we could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by any such products, a number of potentially significant negative consequences could result, including:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may suspend marketing of, or withdraw or recall, such product;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory authorities may withdraw approvals of such product;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">45</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory authorities may require additional warnings on the label or otherwise seek to limit the scope of the approved uses reflected in the label of such product;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA may require the use of or modification of a Risk Evaluation and Mitigation Strategy (&ldquo;REMS&rdquo;) or a comparable foreign regulatory authority may require the establishment or modification of a similar strategy that may, for instance, restrict distribution of our products and impose other implementation requirements on us;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory authorities may require that we conduct post-marketing studies;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we could be sued and held liable for harm caused to patients; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our reputation may suffer.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate or otherwise materially harm the commercial prospects for the product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We face the risk of product liability claims, which could exceed our insurance coverage and produce recalls, each of which could deplete our cash resources.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are exposed to the risk of product liability claims alleging that use of our product candidates caused an injury or harm. These claims can arise at any point in the development, testing, manufacture, marketing, or sale of our product candidates and may be made directly by patients involved in clinical trials of our product candidates, by consumers or healthcare providers, or by individuals, organizations, or companies selling our products. Product liability claims can be expensive to defend, even if the product or product candidate did not actually cause the alleged injury or harm.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Insurance covering product liability claims becomes increasingly expensive as a product candidate moves through the development pipeline to commercialization. To protect against potential product liability risks, we have AUD$20 million per occurrence and AUD$20 million aggregate clinical trial insurance for the REMEDY Phase II clinical trial in Australia and US$5.0 million product liability insurance coverage. However, there can be no assurance that such insurance coverage is or will continue to be adequate or available to us at a cost acceptable to us or at all. We may choose or find it necessary under our collaboration agreements to increase our insurance coverage in the future. We may not be able to secure greater or broader product liability insurance coverage on acceptable terms or at reasonable costs when needed. Any liability for damages resulting from a product liability claim could exceed the amount of our coverage, require us to pay a substantial monetary award from our own cash resources and have a material adverse effect on our business, financial condition, and results of operations. Moreover, a product recall, if required, could generate substantial negative publicity about our products and business, inhibit or prevent commercialization of other products and product candidates, or negatively impact existing or future collaborations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>If we are unable to maintain product liability insurance required by our third parties, the corresponding agreements would be subject to termination, which could have a material adverse impact on our operations.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Some of our license, clinical trials and other agreements with third parties require, and in the future may require, us to maintain product liability insurance. If we cannot maintain acceptable amounts of coverage on commercially reasonable terms in accordance with the terms set forth in these agreements, the corresponding agreements would be subject to termination, which could have a material adverse impact on our operations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A risk of product liability claims, and related negative publicity, is inherent in the development of human therapeutics and other products. Product liability insurance is expensive, its availability is limited, and it may not be offered on terms acceptable to us, or at all. The commercialization of our potential products could be inhibited or prevented by an inability to maintain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims. A product liability claim against us or the withdrawal of a product from the market could have a material adverse effect upon us and our financial condition.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">46</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>A variety of risks are associated with operating our business internationally which could materially adversely affect our business.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We conduct certain R&amp;D operations in Australia. In addition, we may conduct certain future clinical trials and plan to seek regulatory approval of our product candidates outside of the United States. Accordingly, we are subject to risks related to operating in foreign countries, including:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">different regulatory requirements for drug approvals in foreign countries;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">different standards of care in various countries that could complicate the evaluation of our product candidates;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">different United States and foreign drug import and export rules;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">reduced protection for intellectual property rights in certain countries;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">unexpected changes in tariffs, trade barriers, and regulatory requirements;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">compliance with the Foreign Corrupt Practices Act and other anti-corruption and anti-bribery laws;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">foreign taxes, including withholding of payroll taxes;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">potential liability resulting from development work conducted by foreign partners;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">business interruptions resulting from natural disasters or geopolitical actions, including war and terrorism, or systems failure including cybersecurity breaches; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">compliance with evolving and expansive international data privacy laws, such as the European Union General Data Protection Regulation.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Future legislation in the United States, Europe or other countries, and/or regulations and policies adopted by the FDA, the EMA or comparable regulatory authorities, may increase the time and cost required for us or our collaborator to conduct and complete clinical trials of our current or future product candidates.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The FDA and the EMA have each established regulations to govern the product development and approval process, as have other foreign regulatory authorities. The policies of the FDA, the EMA and other regulatory authorities may change. For example, in December 2016, the 21st Century Cures Act (&ldquo;Cures Act&rdquo;) was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation, but not all of its provisions have yet been implemented. Additionally, in August 2017, the FDA issued final guidance setting forth its current thinking with respect to development programs and clinical trial designs for antibacterial drugs to treat serious bacterial diseases in patients with an unmet medical need. We cannot predict what if any effect the Cures Act or any existing or future guidance from the FDA or other regulatory authorities will have on the development of our product candidates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">47</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Recently enacted and future legislation may increase the difficulty and cost for us and our collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Among policy makers and payers in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. For example, the ACA, which was enacted in the United States in March 2010, includes measures to change health care delivery, decrease the number of individuals without insurance, ensure access to certain basic health care services, and contain the rising cost of care. This healthcare reform movement, including the enactment of the ACA, has significantly changed health care financing by both governmental and private insurers in the United States. With respect to pharmaceutical manufacturers, the ACA increased the number of individuals with access to health care coverage, including prescription drug coverage, but it simultaneously imposed, among other things, increased liability for rebates and discounts owed to certain entities and government health care programs, new fees for the manufacture or importation of certain branded drugs, and new transparency reporting requirements under the Physician Payments Sunshine Act.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the current administration to repeal or replace certain aspects of the ACA. Since January 2017, two U.S. Presidential Executive Orders have been signed and other directives designed to delay the implementation of any certain provisions of the ACA or otherwise remove some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &ldquo;individual mandate.&rdquo; Additionally, on January 22, 2018, the U.S. President signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018, or the &ldquo;BBA,&rdquo; among other things, amends the ACA, effective January 1, 2019, to increase from 50&nbsp;percent to 70&nbsp;percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &ldquo;donut hole.&rdquo;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In addition to the ACA, other federal health reform measures have been proposed and adopted in the United States. For example, legislation has been enacted to reduce the level of reimbursement paid to providers under the Medicare program over time, as well as phase in alternative payment models for provider services under the Medicare program with the goal of incentivizing the attainment of pre-defined quality measures. As these measures are not fully in effect, and since the U.S. Congress could intervene to prevent their full implementation, it is unclear how payment reductions or the introduction of the quality payment program will impact overall physician reimbursement under the Medicare program. It is also unclear if changes in Medicare payments to providers would impact such providers&rsquo; willingness to prescribe and administer our products, if approved. Further, there has been heightened governmental scrutiny over the manner in which companies set prices for their marketed products. For example, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and patient programs, and reform government program reimbursement methodologies for drug products.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">48</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we may receive for any product, if approved. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our current or future product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&rsquo;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We conduct certain research and development operations through our Australian wholly-owned subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development incentive payment allowed by Australian regulations, our business and results of operations could suffer.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In July 2016, we formed a wholly-owned Australian subsidiary, DiaMedica Australia Pty Ltd., to conduct various clinical activities for our product and development candidate in Australia. Due to the geographical distance and lack of employees currently in Australia, as well as our lack of experience operating in Australia, we may not be able to efficiently or successfully monitor, develop and commercialize our lead product candidate in Australia, including conducting clinical trials. Furthermore, we have no assurance that the results of any clinical trials that we conduct for our product candidate in Australia will be accepted by the FDA or foreign regulatory authorities for development and commercialization approvals.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In addition, current Australian tax regulations provide for a refundable R&amp;D incentive payment equal to 43.5% of qualified expenditures. We received incentive payments of approximately AUD$&nbsp;306,000 and AUD$&nbsp;777,000 during 2017 and 2018, respectively, for research expenditures made during 2016 and 2017. If our subsidiary loses its ability to operate in Australia, or if we are ineligible or unable to receive the R&amp;D incentive payment, or the Australian government significantly reduces or eliminates the incentive program, our business and results of operation may be adversely affected.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Risks Related to Intellectual Property</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>If we are unable to adequately protect and enforce our intellectual property, our competitors may take advantage of our development efforts or acquired technology and compromise our prospects of marketing and selling our key product candidates.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe that patents and other proprietary rights are key to our business. Our policy is to file patent applications to protect technology, inventions, and improvements that may be important to the development of our business. We also rely upon trade secrets, know-how, continuing technological innovations, and licensing opportunities to develop and maintain our competitive position. We plan to enforce our issued patents and our rights to proprietary information and technology. We review third-party patents and patent applications, both to refine our own patent strategy and to identify useful licensing opportunities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">49</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our success depends, in part, on our ability to secure and protect our intellectual property rights and to operate without infringing on the proprietary rights of others or having third parties circumvent the rights owned or licensed by us. We have a number of patents, patent applications and rights to patents related to our compounds, product candidates and technology, but we cannot be certain that they will be enforceable or provide adequate protection or that pending patent applications will result in issued patents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">To the extent that development, manufacturing, and testing of our product candidates is performed by third party contractors, such work is performed pursuant to fee for service contracts. Under the contracts, all intellectual property, technology know-how, and trade secrets arising under such agreements are our exclusive property and must be kept confidential by the contractors. It is not possible for us to be certain that we have obtained from the contractors all necessary rights to such technologies. Disputes may arise as to the scope of the contract or possible breach of contract. No assurance can be given that our contracts would be enforceable or would be upheld by a court.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The patent positions of pharmaceutical and biotechnology firms, ourselves included, are uncertain and involve complex questions of law and fact for which important legal issues remain unresolved. Therefore, it is not clear whether our pending patent applications will result in the issuance of patents or whether we will develop additional proprietary products which are patentable. Part of our strategy is based on our ability to secure a patent position to protect our technology. There is no assurance that we will be successful in this approach and failure to secure patent protection may have a material adverse effect upon us and our financial condition. Also, we may fail in our attempt to commercialize products using currently patented or licensed technology without having to license additional patents. Moreover, it is not clear whether the patents issued or to be issued will provide us with any competitive advantages or if any such patents will be the target of challenges by third parties, whether the patents of others will interfere with our ability to market our products, or whether third parties will circumvent our patents by means of alternate processes. Furthermore, it is possible for others to develop products which have the same effect as our product candidates or technologies on an independent basis or to design around technologies patented by us. Patent applications relating to or affecting our business may have been filed by pharmaceutical or biotechnology companies or academic institutions. Such applications may conflict with our technologies or patent applications and such conflict could reduce the scope of patent protection which we could otherwise obtain or even lead to the rejection of our patent applications. There is no assurance that we can enter into licensing arrangements on commercially reasonable terms, or develop or obtain alternative technology in respect of, patents issued to third parties that incidentally cover our products or production technologies. Any inability to secure licenses or alternative technology could result in delays in the introduction of some of our product candidates or even lead to us being prevented from pursuing the development, manufacture, or sale of certain products. Moreover, we could potentially incur substantial legal costs in defending legal actions which allege patent infringement, or by initiating patent infringement suits against others. It is not possible for us to be certain that we are the creator of inventions covered by pending patent applications or that we were the first to invent or file patent applications for any such inventions. While we have used commercially reasonable efforts to obtain assignments of intellectual property from all individuals who may have created materials on our behalf (including with respect to inventions covered by our patent and pending patent applications), it is not possible for us to be certain that we have obtained all necessary rights to such materials. No assurance can be given that our patents, if issued, would be upheld by a court, or that a competitor&rsquo;s technology or product would be found to infringe on our patents. Moreover, much of our technology know-how that is not patentable may constitute trade secrets. Therefore, we require our employees, consultants, advisors, and collaborators to enter into confidentiality agreements either as stand-alone agreements or as part of their consulting contracts. However, no assurance can be given that such agreements will provide meaningful protection of our trade secrets, know-how, or other proprietary information in the event of any unauthorized use or disclosure of confidential information. Also, while we have used commercially reasonable efforts to obtain executed copies of such agreements from all employees, consultants, advisors and collaborators, no assurance can be given that executed copies of all such agreements have been obtained.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">50</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We may require additional third-party licenses to effectively develop and manufacture our key products and are currently unable to predict the availability or cost of such licenses.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A substantial number of patents have already been issued to other biotechnology and pharmaceutical companies. To the extent that valid third-party patent rights cover our product candidates, we or our strategic collaborators would be required to seek licenses from the holders of these patents in order to manufacture, use, or sell these product candidates, and payments under them would reduce our profits from these product candidates. We are currently unable to predict the extent to which we may wish or be required to acquire rights under such patents, the availability and cost of acquiring such rights, and whether a license to such patents will be available on acceptable terms, or at all. There may be patents in the United States or in foreign countries or patents issued in the future that are unavailable to license on acceptable terms. Our inability to obtain such licenses may hinder or eliminate our ability to develop, manufacture and market our product candidates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Changes in patent law and its interpretation could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property rights, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves technological and legal complexity, and obtaining and enforcing biopharmaceutical patents is costly, time consuming, and inherently uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors&rsquo; or collaborators&rsquo; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the U.S. Patent and Trademark Office (&ldquo;USPTO&rdquo;), the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&rsquo; or collaborators&rsquo; ability to obtain new patents or to enforce existing patents and patents we and our licensors or collaborators may obtain in the future. Changes in either the patent laws or interpretation of the patent laws in the United States or other countries could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates or (ii)&nbsp;invent any of the inventions claimed in our or our licensor&rsquo;s patents or patent applications.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">51</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors&rsquo; or collaborators&rsquo; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the U.S. Patent and Trademark Office, and similar legislative, judicial, and administrative bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&rsquo; or collaborators&rsquo; ability to obtain new patents or to enforce existing patents and patents we and our licensors or collaborators may obtain in the future.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Litigation regarding patents, patent applications, and other proprietary rights may be expensive, time consuming and cause delays in the development and manufacturing of our key product candidates.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Third parties may claim that we are using their proprietary information without authorization. Third parties may also have or obtain patents and may claim that technologies licensed to or used by us infringe their patents. If we are required to defend patent infringement actions brought by third parties, or if we sue to protect our own patent rights or otherwise to protect our proprietary information and to prevent its disclosure, we may be required to pay substantial litigation costs and managerial attention may be diverted from business operations even if the outcome is in our favor. In addition, any legal action that seeks damages or an injunction to stop us from carrying on our commercial activities relating to the affected technologies could subject us to monetary liability (including treble damages and attorneys&rsquo; fees if we are found to have willfully infringed) and require us or any third-party licensors to obtain a license to continue to use the affected technologies. We cannot predict whether we would prevail in any of these types of actions or that any required license would be available on commercially acceptable terms or at all. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Competitors may infringe our patents or other intellectual property. If we were to initiate legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Moreover, similar challenges may be made by third parties outside the context of litigation, e.g., via administrative proceedings such as post grant or inter partes review in the United States or via oppositions or other similar proceedings in other countries/regions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">52</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation, validity or enforceability, interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation or such other proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common shares.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are a party to a license agreement relating to an expression system and cell line for use in the production of DM199 or any human KLK1, and we may need to obtain additional licenses from others to advance our R&amp;D activities or allow the commercialization of DM199 or any other product candidates we may identify and pursue. Future license agreements may impose, various development, diligence, commercialization, and other obligations on us. If any of our in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties main gain access to technologies that are material to our business, and we may be required to cease our development and commercialization of DM199 or other product candidates that we may identify or to seek alternative manufacturing methods. However, suitable alternatives may not be available or the development of suitable alternatives may result in a significant delay in our commercialization of DM199. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including, but not limited to:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the sublicensing of patent and other rights under our collaborative development relationships;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the priority of invention of patented technology.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">53</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Because we rely on third parties to develop our products, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees, and consultants prior to beginning research or disclosing proprietary information. These agreements typically restrict the ability of our collaborators, advisors, employees, and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. We also conduct joint R&amp;D programs which may require us to share trade secrets under the terms of R&amp;D collaboration or similar agreements. However, we cannot be certain that such agreements have been entered into with all relevant parties. Moreover, despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development, or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. Trade secrets can be difficult to protect. If the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating any trade secrets. A competitor&rsquo;s discovery of our trade secrets may impair our competitive position and could have a material adverse effect on our business and financial condition.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">54</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&rsquo;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We may not be able to protect our intellectual property rights throughout the world.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">55</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Risks Related to Our Common Shares</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Our common share price has been volatile and may continue to be volatile.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our common shares trade on The Nasdaq Capital Market under the trading symbol &ldquo;DMAC.&rdquo; A number of factors could influence the volatility in the trading price of our common shares, including changes in the economy or in the financial markets, industry related developments, and the impact of material events and changes in our operations. Our quarterly losses may vary because of expenses we incur related to future research including the timing of costs for manufacturing and initiating and completing preclinical and clinical trials. Each of these factors could lead to increased volatility in the market price of our common shares. In addition, the market prices of the securities of our competitors may also lead to fluctuations in the trading price of our common shares.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We do not have a very active trading market for our common shares and one may never develop.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our common shares trade on The Nasdaq Capital Market under the trading symbol &ldquo;DMAC.&rdquo; We do not have a very active trading market for our common shares and one may never develop. Although we anticipate a more active trading market for our common shares will develop in the future, we can give no assurance that this will occur or that an active trading market will be sustained. If an active market for our common shares does not develop, it may be difficult for you to sell shares at a favorable price or at all.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Our recent share consolidation may not increase the market price for our common shares on a sustained basis.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On November 15, 2018, we implemented a share consolidation of our common shares, which was previously approved by our shareholders, pursuant to which each 20 common shares outstanding on the record date for the share consolidation was combined into one common share. We cannot predict whether the share consolidation will increase the market price for our common shares on a sustained basis. The history of similar share consolidations for companies in similar circumstances is varied, and we cannot predict whether:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the share consolidation will result in a sustained price per share that will attract brokers and investors who do not trade in lower priced stocks;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the share consolidation will result in a price per share that will increase our ability to attract and retain employees and other service providers;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the market price per share will remain at a level in excess of the minimum bid price as required for continued listing on The Nasdaq Capital Market; or</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">even if the share consolidation does increase the market price of our common shares on a sustained basis, we will otherwise meet the requirements of The Nasdaq Capital Market and be able to maintain our listing.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">56</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We have never paid dividends and do not expect to do so in the foreseeable future.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have not declared or paid any cash dividends on our common shares to date. The payment of dividends in the future will be dependent on our earnings and financial condition and on such other factors as our Board of Directors considers appropriate. Unless and until we pay dividends, shareholders may not receive a return on their shares. There is no present intention by our Board of Directors to pay dividends on our common shares. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, appreciation, if any, in the market price of our common shares will be your sole source of gain for the foreseeable future.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We may issue additional common shares resulting in share ownership dilution.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Future dilution may occur due to additional future equity financing events by us. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted. In addition, if outstanding options, warrants, or deferred share units are exercised or otherwise converted into our common shares, our shareholders will experience additional dilution.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>It may be difficult for non-Canadian shareholders or other investors to obtain and enforce judgments against us because of our Canadian incorporation and presence.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are a corporation existing under the federal laws of Canada. Two of our directors and several of the experts we utilize are residents of Canada, and all or a substantial portion of their assets, and a portion of our assets, are located outside the United States. Consequently, it may be difficult for holders of our securities who reside in the United States to effect service within the United States upon those directors and the experts who are not residents of the United States. It may also be difficult for holders of our securities who reside in the United States to realize in the United States upon judgments of courts of the United States predicated upon our civil liability and the civil liability of our directors, officers, and experts under the United States federal securities laws. Our shareholders and other investors should not assume that Canadian courts (i)&nbsp;would enforce judgments of United States courts obtained in actions against us or such directors, officers, or experts predicated upon the civil liability provisions of the United States federal securities laws or the securities or &ldquo;blue sky&rdquo; laws of any state or jurisdiction of the United States, or (ii) would enforce, in original actions, liabilities against us or such directors, officers, or experts predicated upon the United States federal securities laws or any securities or &ldquo;blue sky&rdquo; laws of any state or jurisdiction of the United States. In addition, the protections afforded by Canadian securities laws may not be available to our shareholders or other investors in the United States.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>If there are substantial sales of our common shares or the perception that such sales could occur, the market price of our common shares could decline.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Sales of substantial numbers of our common shares or the perception that such sales could occur, especially after the expiration of the 180-day period lock-up period to which our directors, officers and their affiliated entities ae subject, could cause a decline in the market price of our common shares. Any sales by existing shareholders or holders who exercise their warrants or stock options may have an adverse effect on our ability to raise capital and may adversely affect the market price of our common shares.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">57</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We could be subject to securities class action litigation, which is expensive and could divert management attention.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In the past, securities class action litigation has often been brought against a company following a decline or increase in the market price of its securities or certain significant business transactions. We may become involved in this type of litigation in the future. If we face such litigation, it could result in substantial costs and a diversion of management&rsquo;s attention and our resources, which could harm our business.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>If securities or industry analysts do not publish research or reports about our business, or publish negative reports about our business, the market stock of our common shares and trading volume could decline.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The trading market for our common shares in the United States will depend in part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our shares or change their opinion of our shares, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause the market price of our common shares or trading volume to decline.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We are an &ldquo;emerging growth company,&rdquo; and the reduced disclosure requirements applicable to emerging growth companies may make our common shares less attractive to our shareholders and other investors.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012. We may remain an emerging growth company until December 31, 2023, the last day of the fiscal year following the fifth anniversary of our first sale of common shares pursuant to a registration statement under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) or until such earlier time as we have more than $1.07 billion in annual revenue, the market value of our common shares held by non-affiliates is more than $700 million or we issue more than $1 billion of non-convertible debt over a three-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (&ldquo;Section 404&rdquo;) not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Our shareholders and other investors may find our common shares less attractive as a result of our reliance on these exemptions. If some of our shareholders or other investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and the trading price of our common shares may be more volatile.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In addition, Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised financial accounting standards. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we have determined to opt out of such extended transition period and, as a result, we will comply with new or revised financial accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised financial accounting standards is irrevocable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">58</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our shareholders and other investors may find our common shares less attractive as a result of our reliance on these exemptions. If some of our shareholders or other investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and the trading price of our common shares may be more volatile.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>As a result of our recent initial public offering and listing on The Nasdaq Capital Market, we expect to incur increased costs as a result of operating as a Nasdaq-listed U.S. public reporting company, and we anticipate that our management will be required to devote substantial time to new compliance initiatives.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As a Nasdaq-listed U.S. public reporting company, we anticipate that we will incur, particularly after we are no longer an &ldquo;emerging growth company,&rdquo; significant legal, accounting and other expenses that we did not incur as a company with shares solely listed on the TSX Venture Exchange. In addition, the Sarbanes-Oxley Act of 2002 (&ldquo;Sarbanes-Oxley&rdquo;) and rules subsequently implemented by the SEC and Nasdaq impose various requirements on U.S. public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with U.S. public company reporting and Sarbanes-Oxley requirements and we may have to hire additional accounting, finance, and other personnel to assist us with our efforts to comply with these requirements.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We have no operating experience as a Nasdaq-listed publicly traded company in the United States.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have no operating experience as a Nasdaq-listed publicly traded company in the United States. Although the individuals who now constitute our management team have experience managing a Nasdaq-listed publicly-traded company, there is no assurance that the past experience of our management team will be sufficient to operate the Company as a publicly traded company in the United States, including timely compliance with the disclosure requirements of the SEC. We are required to develop and implement internal control systems and procedures in order to satisfy the periodic and current reporting requirements under applicable SEC regulations and comply with the Nasdaq listing standards. These requirements will place significant strain on our management team, infrastructure and other resources. In addition, our management team may not be able to successfully or efficiently manage the Company as a U.S. public reporting company that is subject to significant regulatory oversight and reporting obligations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Our inability to comply with Nasdaq&rsquo;s continued listing requirements could result in our common shares being delisted, which could affect the market price and liquidity of our common shares and reduce our ability to raise capital.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are required to meet certain qualitative and financial tests to maintain the listing of our common shares on The Nasdaq Capital Market. If we do not maintain compliance with Nasdaq&rsquo;s continued listing requirements within specified periods and subject to permitted extensions, our common shares may be recommended for delisting (subject to any appeal we would file). No assurance can be provided that we will comply with these continued listing requirements. If our common shares were delisted, it could be more difficult to buy or sell our common shares and to obtain accurate quotations, and the price of our common shares could suffer a material decline. Delisting would also impair our ability to raise additional capital.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">59</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Our shareholder rights plan may delay or prevent an acquisition of us that shareholders may consider favorable or may prevent efforts by our shareholders to change our directors or our management, which could decrease the value of your common shares.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our shareholders approved the adoption of a shareholder rights plan agreement on December 21, 2017. The shareholder rights plan is designed to provide adequate time for our Board of Directors and shareholders to assess an unsolicited takeover bid for our company, to provide our Board of Directors with sufficient time to explore and develop alternatives for maximizing shareholder value if a takeover bid is made, and to provide shareholders with an equal opportunity to participate in a takeover bid and receive full and fair value for their common shares. The shareholder rights plan is set to expire at the close of our annual meeting of shareholders in 2020. The rights will become exercisable only when a person, including any party related to it, acquires or attempts to acquire 20% or more of our outstanding common shares without complying with the &ldquo;permitted bid&rdquo; provisions of the plan or without approval of our Board of Directors. Should such an acquisition occur or be announced, each right would, upon exercise, entitle a rights holder, other than the acquiring person and related persons, to purchase common shares at a 50% discount to the market price at the time. Under the plan, a &ldquo;permitted bid&rdquo; is a bid made to all holders of our common shares and which is open for acceptance for not less than 60 days. If at the end of 60 days at least 50% of the outstanding common shares, other than those owned by the offeror and certain related parties have been tendered, the offeror may take up and pay for the common shares but must extend the bid for a further 10 days to allow other shareholders to tender.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">While we believe our rights plan enables our Board of Directors to help ensure that our shareholders are not deprived of the opportunity to realize the full and fair value of their investments, the rights plan may inhibit a change in control of our company by a third party in a transaction not approved by our Board of Directors. If a change in control is inhibited or delayed in this manner, it may adversely affect the market price of our common shares.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Any failure to maintain an effective system of internal controls may result in material misstatements of our consolidated financial statements or cause us to fail to meet our reporting obligations or fail to prevent fraud; and in that case, our shareholders or other investors could lose confidence in our financial reporting, which would harm our business and could negatively impact the price of our common shares.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. If we fail to maintain an effective system of internal controls, we might not be able to report our financial results accurately or prevent fraud; and in that case, our shareholders or other investors could lose confidence in our financial reporting, which would harm our business and could negatively impact the price of our common shares. As a result of our limited administrative staffing levels, internal controls which rely on segregation of duties in many cases are not possible. Due to resource constraints and the present stage of our development, we do not have sufficient size and scale to warrant the hiring of additional staff to address this potential weakness at this time. To help mitigate the impact of this, we are highly reliant on the performance of compensating procedures and senior management&rsquo;s review and approval. Even if we conclude that our internal control over financial reporting provides reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles in the United States, because of its inherent limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm our results of operations or cause us to fail to meet our future reporting obligations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">If we fail to timely achieve and maintain the adequacy of our internal control over financial reporting, we may not be able to produce reliable financial reports or help prevent fraud. Our failure to achieve and maintain effective internal control over financial reporting could prevent us from complying with our reporting obligations on a timely basis, which could result in the loss of shareholder or other investor confidence in the reliability of our consolidated financial statements, harm our business and negatively impact the trading price of our common shares.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">60</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pursuant to Section 404 of the Sarbanes-Oxley Act, we will be required to furnish a report by our management on our internal control over financial reporting beginning with our annual report on Form 10-K next year, and after we are no longer an emerging growth company, we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will have to engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. There is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Canadian laws differ from the laws in effect in the United States and may afford less protection to holders of our securities.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are a Canadian corporation and are subject to the CBCA and applicable Canadian securities laws as a Canadian reporting issuer, which laws may differ from those governing a company formed under the laws of a United States jurisdiction. The provisions under the CBCA and other relevant laws may affect the rights of shareholders differently than those of a company governed by the laws of a United States jurisdiction, and may, together with our articles and by-laws, have the effect of delaying, deferring or discouraging another party from acquiring control of our company by means of a tender offer, a proxy contest or otherwise, or may affect the price an acquiring party would be willing to offer in such an instance.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>We may be classified as a &ldquo;passive foreign investment company,&rdquo; which may have adverse U.S. federal income tax consequences for U.S. shareholders.</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Generally, for any taxable year in which 75% or more of our gross income is passive income, or at least 50% of the average quarterly value of our assets (which may be determined in part by the market value of our common shares, which is subject to change) are held for the production of, or produce, passive income, we would be characterized as a passive foreign investment company (&ldquo;PFIC&rdquo;) for U.S. federal income tax purposes. Based on the price of our common shares and the composition of our gross assets (i) we believe that we were a PFIC for the taxable year ended December 31, 2016, and (ii) we do not believe that we were a PFIC for the taxable years ended December 31, 2018 and 2017. Our status as a PFIC is a fact-intensive determination made on an annual basis, and we cannot provide any assurance regarding our PFIC status for the taxable year ending December 31, 2019 or for future taxable years.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">If we are a PFIC for any year during a non-corporate U.S. shareholder&rsquo;s holding period of our common shares, then such non-corporate U.S. shareholder generally will be required to treat any gain realized upon a disposition of our common shares, or any so-called &ldquo;excess distribution&rdquo; received on our common shares, as ordinary income, rather than as capital gain, and the preferential tax rate applicable to dividends received on our common shares would not be available. Interest charges would also be added to the taxes on gains and distributions realized by all U.S. holders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">61</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A U.S. shareholder may avoid these adverse tax consequences by making a timely and effective &ldquo;qualified electing fund&rdquo; election (&ldquo;QEF election&rdquo;). A U.S. shareholder who makes a QEF election generally must report, on a current basis, its share of our ordinary earnings and net capital gains, whether or not we distribute any amounts to our shareholders. The QEF election is available only if the company characterized as a PFIC provides a U.S. shareholder with certain information regarding its earnings and capital gains as required under applicable U.S. Treasury regulations. In the event we become a PFIC, we intend to provide all information and documentation that a U.S. shareholder making a QEF election is required to obtain for U.S. federal income tax purposes (e.g., the U.S. shareholder&rsquo;s pro rata share of ordinary income and net capital gain, and a &ldquo;PFIC Annual Information Statement&rdquo; as described in applicable U.S. Treasury regulations).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A U.S. shareholder may also mitigate the adverse tax consequences by timely making a mark-to-market election. A U.S. shareholder who makes the mark-to-market election generally must include as ordinary income each year the increase in the fair market value of the common shares and deduct from gross income the decrease in the value of such shares during each of its taxable years. A mark-to-market election may be made and maintained only if our common shares are regularly traded on a qualified exchange, including Nasdaq. Whether our common shares are regularly traded on a qualified exchange is an annual determination based on facts that, in part, are beyond our control. Accordingly, a U.S. shareholder might not be eligible to make a mark-to-market election to mitigate the adverse tax consequences if we are characterized as a PFIC.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Each U.S. shareholder should consult their own tax advisors with respect to the possibility of making these elections and the U.S. federal income tax consequences of the acquisition, ownership and disposition of our common shares. In addition, our PFIC status may deter certain U.S. investors from purchasing our common shares, which could have an adverse impact on the market price of our common shares.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 1B.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Unresolved Staff Comments</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">This Item 1B is inapplicable to us as a smaller reporting company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 2.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Properties</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our principal executive offices, together with our research and development operations, are at the office of our wholly owned subsidiary, DiaMedica USA Inc., located at 2 Carlson Parkway, Suite 260, Minneapolis, Minnesota, USA 55447. We lease these premises, which consist of approximately 3,800&nbsp;square feet, pursuant to a lease that expires in August 2022. We believe that our facilities are adequate for our current needs and that suitable additional space will be available as and when needed on acceptable terms.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 3.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Legal Proceedings</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In March 2013, we entered into a clinical research agreement with PRA Netherlands to perform a double-blinded, placebo-controlled, single-dose and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and proof of concept of DM199 in healthy subjects and in patients with Type 2 diabetes mellitus. In one arm of this study, we enrolled 36 patients with Type 2 diabetes who were treated with two SC dose levels of DM199 over a 28-day period. This study achieved its primary endpoint and demonstrated that DM199 was well-tolerated. The secondary endpoints for this study, however, were not met. The secondary efficacy endpoints were confounded due to what we believe were significant execution errors caused by protocol deviations occurring at the clinical trial site that were unable to be reconciled. To date, we have been unable to obtain the complete study records from PRA Netherlands and generate a final study report. On November 14, 2017, we initiated litigation with PRA Netherlands in the United States District Court, Southern District of New York, to compel them to comply with the terms of the clinical research agreement, including providing full study records and to recover damages. After PRA Netherlands objected to the venue, on August 24, 2018, we re-filed our complaint against both PRA Netherlands and its U.S. subsidiary, PRA Health Sciences, Inc. (&ldquo;PRA USA&rdquo; and collectively with PRA Netherlands, &ldquo;PRA&rdquo;), in the United States District Court, District of Delaware. PRA again objected to the venue, we intend to re-file our complaint against PRA in the United States District Court, District of Minnesota. The complaint alleges, among other things, that PRA failed to conduct the study in accordance with the study protocol and with generally accepted standards for conducting such clinical trials and that PRA further refused to provide us with all data, records and documentation, and/or access thereto, related to the study in accordance with the clinical trial study agreement. The complaint seeks to compel PRA to comply with the terms of the clinical trial study agreement, including providing full study records and to recover damages. On November 19, 2018, PRA Netherlands and PRA USA filed motions to dismiss the lawsuit. We subsequently requested, and PRA Netherlands and PRA USA agreed, that we be permitted to file a motion seeking to transfer the Delaware action to the United States District Court, District of Minnesota. On February 20, 2019, we filed this motion to transfer venue.<b> </b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">62</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">From time to time, we may be subject to other various ongoing or threatened legal actions and proceedings, including those that arise in the ordinary course of business, which may include employment matters and breach of contract disputes. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. Other than the PRA matter noted above, we are not currently engaged in or aware of any threatened legal actions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 4.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Mine Safety Disclosures</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Not applicable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">63</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>PART II</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 5.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Market Information</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our common shares are listed on The Nasdaq Capital Market under the trading symbol &ldquo;DMAC&rdquo; and have been so listed since December 7, 2018, the date of our initial public offering in the United States. Our common shares previously traded in Canada on the TSX Venture Exchange under the trading symbol &ldquo;DMA&rdquo; through January 18, 2019. We voluntarily delisted our common shares from the TSX Venture Exchange since we believe that the financial and administrative costs associated with maintaining a dual listing are not justified. Prior to our initial public offering, our common shares traded over-the-counter in the United States on the OTCQB marketplace under the trading symbol &ldquo;DMCAD&rdquo; from November 15, 2018 to December 7, 2018 and before November 15, 2018, under the trading symbol &ldquo;DMCAF.&rdquo;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Number of Record Holders</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of March 14, 2019, we had 50 holders of record of our common shares. This does not include persons whose common shares are in nominee or &ldquo;street name&rdquo; accounts through brokers or other nominees.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Dividend Policy</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have never declared or paid cash dividends on our common shares, and currently do not have any plans to do so in the foreseeable future. We expect to retain our future earnings, if any, for use in the operation and expansion of our business. Moreover, we may in the future become subject to contractual restrictions on, or prohibitions against, the payment of dividends. Subject to the foregoing, the payment of cash dividends in the future, if any, will be at the discretion of our Board of Directors and will depend upon such factors as earnings levels, capital requirements, our overall financial condition and any other factors deemed relevant by our Board of Directors. As a result, you will likely need to sell your common shares to realize a return on your investment, and you may not be able to sell your shares at or above the price you paid for them.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Use of Proceeds</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On December 11, 2018, the SEC declared effective our registration statement on Form S-1 (File No. 333- 228313), as amended, filed in connection with our initial public offering. Pursuant to the registration statement, we issued and sold an aggregate of 4,100,000 common shares in the initial public offering at a price to the public of $4.00 per share. As a result of the offering, we received gross proceeds of approximately $16.4 million, resulting in net proceeds to us of approximately $14.7 million, after deduction of underwriters&rsquo; discounts and commissions and offering expenses. None of the expenses associated with the initial public offering were paid to directors, officers, persons owning ten percent or more of any class of equity securities, or to their associates, or to our affiliates. Craig-Hallum Capital Group LLC acted as the sole managing underwriter for the offering.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We intend to use the net proceeds from the offering to fund clinical development of DM199, to conduct research activities and for working capital and general corporate purposes. We expect the net proceeds of the offering to be sufficient to allow us to complete our current Phase II Remedy trial in patients with acute ischemic stroke and our current Phase Ib trial in patients with chronic kidney disease and a Phase II study in patients with chronic kidney disease. We do not expect the net proceeds of the offering to be sufficient to fund, and we expect to require additional funding to complete, the development of DM199 through regulatory approval and commercialization, which we may seek through public or private equity or debt financings or through collaborations with other biotechnology companies or other sources. The expected use of the net proceeds from our initial public offering represents our intentions based upon our current plans and business conditions. As of the date of this report, we cannot predict with any certainty all of the particular uses for the net proceeds or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures and the extent of product development and commercialization may vary significantly depending on numerous factors, including the status, results and timing of our planned clinical trials, as well as any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from the offering.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">64</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pending their use as described above, we plan to invest the net proceeds in short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or guaranteed obligations of the U.S. government.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">There has been no material change in the planned use of proceeds from our initial public offering from that described in the final prospectus, dated December 6, 2018, filed with the SEC on December 10, 2018 pursuant to Rule 424(b)(4) under the Securities Act.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Purchases of Equity Securities by the Company</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We did not purchase any common shares or other equity securities of our company during the fourth quarter ended December 31, 2018.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Recent Sales of Unregistered Equity Securities</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As referred above under &ldquo;Use of Proceeds,&rdquo; upon the closing of our initial public offering on December 11, 2018, as additional underwriting compensation and in exchange for cash consideration of $50, we granted the underwriter a warrant to purchase 205,000 common shares (equal to 5.0% of the common shares sold in the initial public offering) at an exercise price of $4.80 per share (equal to 120% of the initial public offering price per common share in the initial public offering), subject to customary anti-dilution provisions. The warrant is exercisable for a term of five years. The warrant includes a cashless exercise provision entitling the underwriter to surrender a portion of the underlying common shares that has a value equal to the aggregate exercise price in lieu of paying cash upon exercise. The warrant was issued to the underwriter in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act since the issuance did not involve a public offering, the recipient took the securities for investment and not resale, and we took appropriate measures to restrict transfer. We did not pay underwriter discounts or commissions in connection with the issuance of the warrant to the underwriter.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We did not sell any other unregistered equity securities of our company during the fourth quarter ended December 31, 2018.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">65</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 6.</b>&nbsp;</td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Selected Financial Data</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following tables present, as of the dates and for the periods indicated, our selected historical financial data as indicated therein. The consolidated statements of operations data for the years ended December 31, 2018 and 2017 and the consolidated balance sheet data as of December 31, 2018 and 2017 are derived from our audited financial statements that are included elsewhere in this annual report on Form&nbsp;10-K. The consolidated statements of operations data for the year ended December 31, 2016 and the consolidated balance sheet data as of December 31, 2016 are derived from our audited financial statements that are not included in this annual report on Form&nbsp;10-K. Our historical results are not indicative of the results to be expected in the future.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">You should read this information together with our financial statements and the related notes, as well as the section entitled &ldquo;<i>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</i>&rdquo; included elsewhere in this report.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Fiscal Year Ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(in thousands, except share and per share data)</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Consolidated Statements of Operations Data:</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating revenues:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">License revenue</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,522</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,206</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,739</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,313</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total operating expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,261</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,519</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B3" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6,761</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,519</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other (income) expense</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Governmental assistance &ndash; research incentives</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,214</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(244</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Other (income) expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Change in fair value of warrant liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total other (income) expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,107</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(259</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss before income tax</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,564</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,260</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">80</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss and comprehensive loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,734</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,260</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss per share, basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.74</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.72</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average number of shares outstanding:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,743,520</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,935,790</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2017</p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Consolidated Balance Sheet:</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,823</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,353</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Working capital</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,676</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">491</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,339</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,802</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,296</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,003</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total shareholders&rsquo; equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,025</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">799</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">66</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Item 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations is based upon accounting principles generally accepted in the United States of America and discusses the financial condition and results of operations for DiaMedica Therapeutics Inc. and subsidiaries for the years ended December 31, 2018 and 2017.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">This discussion should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this report. The following discussion contains forward-looking statements that involve numerous risks and uncertainties. Our actual results could differ materially from the forward-looking statements as a result of these risks and uncertainties. See &ldquo;<i>Cautionary Note Regarding Forward-Looking Statements</i>&rdquo; for additional cautionary information.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Overview</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We are a clinical stage biopharmaceutical company primarily focused on the development of novel recombinant proteins. Our goal is to use our patented and licensed technologies to establish our company as a leader in the development and commercialization of therapeutic treatments for novel recombinant proteins to treat kidney and neurological diseases. Our current primary focus is on AIS and CKD. We plan to advance DM199, our lead drug candidate, through required clinical trials to create shareholder value by establishing its clinical and commercial potential as a therapy for AIS and CKD.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In February 2018, we initiated treatment on the first patient in our Phase II REMEDY trial assessing the safety, tolerability and markers of therapeutic efficacy of DM199 in patients suffering from AIS. Our REMEDY trial is expected to enroll up to 100 patients to evaluate DM199 in patients with AIS. In December 2018, the FDA accepted our Investigational New Drug application for the initiation of a Phase Ib clinical trial of DM199 in patients with moderate or severe CKD caused by Type I or Type II diabetes and in February 2019, we initiated dosing patients in this study. The results from this Phase Ib study will assist us in the design of upcoming Phase II studies in patients suffering from rare diseases and CKD. The DM199 drug levels from this Phase Ib study will also help determine the optimal dose levels for testing in the Phase II studies.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In September 2018, we entered into a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. (&ldquo;Ahon Pharma&rdquo;), which grants Ahon Pharma exclusive rights to develop and commercialize DM199 for acute ischemic stroke in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Under the terms of the agreement, we received an upfront payment of $500,000 on signing and are entitled to receive an additional payment of $4.5 million upon regulatory clearance to initiate a clinical trial in China. We also have the potential to receive up to an additional $27.5 million in development and sales related milestones and up to approximately 10% royalties on net sales of DM199 in the licensed territories. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territories will be the sole responsibility of Ahon Pharma. This agreement may be terminated at any time by Ahon Pharma by providing 120 days written notice. Fosun Pharma, through its partnership with SK Group, a South Korea based company is an investor in DiaMedica through its equity investment in 2016.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have not generated any revenues from product sales. Since our inception, we have financed our operations from public and private sales of equity, the exercise of warrants and stock options, interest income on funds available for investment, and government grants and tax credits. We have incurred losses in each year since our inception. Our net losses were $5.7 million and $4.3 million for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, we had an accumulated deficit of $46.0 million. Substantially all of our operating losses resulted from expenses incurred in connection with product candidate development programs, our R&amp;D activities and G&amp;A support costs associated with our operations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">67</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. In the near term, we anticipate that our expenses will increase as we:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">advance the ongoing clinical development of DM199;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">maintain, expand and protect our intellectual property portfolio; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide G&amp;A support for our operations.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In addition, we expect our operating expenses to increase in 2019 compared to 2018 as a result of our recently obtained Nasdaq-listed U.S. public reporting company status.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In December 2018, we completed an initial public offering of our common shares in the United States, by issuing 4,100,000 common shares at an offering price of $4.00 per share, for net proceeds to us of approximately $14.7 million, after deducting underwriting discounts and commissions and offering expenses.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">While we expect our rate of future negative cash flow per month to vary due to the timing of expenses incurred, we expect our current cash, which includes the net proceeds of our initial public offering, to be sufficient to allow us to complete our current ongoing Phase II Remedy trial in patients with AIS and our current Phase Ib trial in patients with CKD and a Phase II study in patients with CKD and to otherwise fund our planned operations through the end of 2020.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Financial Overview</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Revenues</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Since our inception, we have incurred losses while advancing the R&amp;D of our therapeutic product candidates. We have not generated any revenues from product sales and do not expect to do so for a number of years. We may never generate sales revenues from our current DM199 product candidate as we may never succeed in obtaining regulatory approval or commercial sale of this product candidate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In September 2018, we entered into a license and collaboration agreement with Ahon Pharma under the terms of which we granted exclusive rights to develop and commercialize DM199 for acute ischemic stroke in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Under the terms of the agreement, we received a non-refundable upfront payment of $500,000, due upon signing the agreement, and we are entitled to an additional non-refundable payment of $4.5 million upon regulatory clearance to initiate a clinical trial in China. We also have the potential to receive up to an additional $27.5 million in development and sales related milestones and up to approximately 10% royalties on net sales of DM199 in the licensed territories. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territories will be the sole responsibility of Ahon Pharma. This agreement may be terminated at any time by Ahon Pharma by providing 120 days written notice.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Research and Development Expenses</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">R&amp;D expenses consist primarily of fees paid to external service providers such as contract research organizations and contract manufacturing organizations related to clinical trials, contractual obligations for clinical development, clinical sites, laboratory testing, preclinical trials, development of DM199 and the related manufacturing processes, salaries, benefits, share-based compensation and other personnel costs. We incurred $4.5 million and $3.2 million in R&amp;D expenses for the years ended December 31, 2018 and 2017, respectively. Over the past approximately eight years, our R&amp;D efforts have been primarily focused on developing DM199.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">68</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">At this time, due to the risks inherent in the clinical development process and the early stage of our product development programs, we are unable to estimate with any certainty the costs we will incur in the continued development of DM199 or any of our preclinical development programs. We expect that our R&amp;D expenses may increase if we are successful in advancing DM199, or any of our preclinical programs, into advanced stages of clinical development. The process of conducting clinical trials necessary to obtain regulatory approval and manufacturing scale-up to support expanded development and potential future commercialization is costly and time consuming. Any failure by us or delay in completing clinical trials, manufacturing scale-up or in obtaining regulatory approvals could lead to increased R&amp;D expenses and, in turn, have a material adverse effect on our results of operations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>General and Administrative Expenses</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">G&amp;A expenses consist primarily of salaries and related benefits, including share-based compensation related to our executive, finance, business development and support functions. Other G&amp;A expenses include rent and utilities, travel expenses and professional fees for auditing, tax and legal services. We expect that G&amp;A expenses will increase in the future as we expand our operating activities. In addition, G&amp;A expenses are expected to reflect increased costs associated with our listing on The Nasdaq Capital Market and U.S. public reporting company status, which commenced in December 2018. We incurred one-time costs of approximately $360,000 in 2018, associated with the Nasdaq listing process and related legal and accounting fees.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Other (Income) Expense</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Other (income) expense consists primarily of governmental assistance &ndash; research incentives, change in the fair value of our warrants that are accounted for as derivative liabilities, interest income, and foreign currency exchange gains and losses.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Critical Accounting Policies and Estimates</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Management&rsquo;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">While our significant accounting policies are more fully described in Note 3 to our consolidated financial statements included elsewhere in this report, we believe the following discussion addresses our most critical accounting policies, which are those that are most important to the portrayal of our financial condition and results of operations and require our most difficult, subjective and complex judgments.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Revenue Recognition</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We followed Accounting Standards Codification (&ldquo;ASC&rdquo;) 606, &ldquo;<i>Revenue from Contracts with Customers</i>&rdquo; in accounting for our license and collaboration agreement with Ahon Pharma. Accordingly, the Company recognizes revenue upon transfer of control of the product to our customer in an amount that reflects the consideration we expect to receive in exchange.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">69</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We intend to enter into arrangements for the research and development and/or manufacture of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including (i) intellectual property rights or licenses, (ii) R&amp;D services or (iii) manufacturing services. The underlying terms of these arrangements generally would provide for consideration to DiaMedica in the form of nonrefundable, up-front license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We intend to utilize the sales and usage-based royalty exception in arrangements that result from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Share-based Compensation</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We account for all share-based compensation awards using a fair value method. The cost of employee and non-employee services received in exchange for awards of equity instruments is measured and recognized based on the estimated grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The fair value of share-based awards is estimated using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our common share price, as well as assumptions regarding a number of complex and subjective variables. Risk-free interest rates are based upon Canadian Government bond rates appropriate for the expected term of each award. Expected volatility rates are based on the historical volatility equal to the expected life of the option. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by us for the years ended December 31, 2018 and 2017:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Common share fair value</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">$8.84 - $9.33</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">$5.20 - $8.40</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2.1 &ndash; 2.2%</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">1.1%</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected option life</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.8 &ndash; 5.0</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.5</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected common share price volatility</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">123.5 &ndash; 135.7%</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">84.7 &ndash; 156.8%</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>&nbsp;</i></p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">70</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Recently Adopted Accounting Pronouncements</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In May 2014, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued a new accounting standard that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard and clarifying standards require an entity to recognize revenue when control of promised goods or services is transferred to the customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted this new standard as of January 1, 2018, but the adoption as of this date had no impact on our financial statements as we had no revenue until the third quarter of 2018.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In February 2016, the FASB issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2016-02, <i>Leases</i>. The guidance in ASU 2016-02 supersedes the lease recognition requirements in the Accounting Standards Codification Topic 840, Leases. ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. The new standard requires the immediate recognition of all excess tax benefits and deficiencies in the income statement and requires classification of excess tax benefits as an operating activity as opposed to a financing activity in the statements of cash flows. This standard became effective for us on January 1, 2019.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The FASB has subsequently issued the following amendments to ASU 2016-02, which have the same effective date and transition date of January 1, 2019, and which we collectively refer to as the new leasing standards:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU No. 2018-01, <i>Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</i>, which permits an entity to elect an optional transition practical expedient to not evaluate under Topic 842 land easements that exist or expired prior to adoption of Topic 842 and that were not previously accounted for as leases under the prior standard, ASC 840, Leases.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU No. 2018-10, <i>Codification Improvements to Topic 842, Leases</i>, which amends certain narrow aspects of the guidance issued in ASU 2016-02.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU No. 2018-11, <i>Leases (Topic 842): Targeted Improvements</i>, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption as well as an additional practical expedient for lessors to not separate non-lease components from the associated lease component.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU No. 2018-20, <i>Narrow-Scope Improvements for Lessors</i>, which contains certain narrow scope improvements to the guidance issued in ASU 2016-02.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We adopted the new leasing standards on January 1, 2019, using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019; and consequently, financial information will not be updated and the disclosures required under Topic 842 will not be provided for dates and periods prior to January 1, 2019. We have reviewed our existing lease contracts and the impact of the new leasing standards on our consolidated results of operations, financial position and disclosures. Upon adoption of the new leasing standards, we expect to recognize a lease liability and related right-of-use asset on our consolidated balance sheet of approximately $200,000. The impact of adoption of the new leasing standards will have not have a material impact to our consolidated statements of operations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">71</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In June 2018, the FASB issued ASU No. 2018-07, &ldquo;<i>Improvements to Nonemployee Share-Based Payment Accounting</i>,&quot; to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. This ASU is effective for public entities for fiscal years beginning after December 15, 2018, with early adoption permitted. Prior to the adoption of this ASU, stock-based compensation awarded to non-employees was subject to revaluation over its vesting terms. Subsequent to the adoption of this ASU, non-employee share-based payment awards are measured on the date of grant, similar to share-based payment awards granted to employees. We do not expect that the adoption of this ASU will impact our financial position or our consolidated statements of operations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Results of Operations</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Comparison of the Years Ended December 31, 2018 and 2017</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table summarizes our results of operations for the years ended December 31, 2018 and 2017 (in thousands):</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Year Ended</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">License revenue</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,522</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,206</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,739</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,313</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other (income) expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,107</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(259</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>License Revenue</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">License revenue for 2018 was comprised of the initial $500,000 license payment we were entitled to receive upon signing of the September 27, 2018 license and collaboration agreement with Ahon Pharma.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Research and Development Expenses</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">R&amp;D expenses were $4.5 million for the year ended December 31, 2018 compared to $3.2 million for the year ended December 31, 2017, an increase of $1.3 million. The increase was primarily due to the additional preclinical testing and related costs required to support an application for an investigational new drug application in the United States, higher study costs for the REMEDY Phase 2 stroke study as compared with the DM199 bridging study which was substantially completed in 2017, and increased personnel and non-cash stock-based compensation costs.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>General and Administrative Expenses</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">G&amp;A expenses were $2.7 million for the year ended December 31, 2018 compared to $1.3 million for the year ended December 31, 2017. General and administrative costs increased due to one-time costs incurred associated with our planned public offering in the United States, primarily the Nasdaq listing process and related legal and accounting fees. Higher salaries, fees and short-term benefits due to the addition of staff and higher share-based compensation also contributed to the increase during 2018.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">72</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Other (Income) Expense</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Other income, net, was $1.1 million for the year ended December 31, 2018 compared to $259,000 for 2017. The increase resulted primarily from the recognition of the R&amp;D incentive from the Australian Government paid for qualifying research work performed by DiaMedica Australia. This increase was partially offset by increased foreign currency transaction losses.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Liquidity and Capital Resources</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table summarizes our liquidity and capital resources as of December 31, 2018 and 2017 and for each of years ended December 31, 2018 and 2017, and is intended to supplement the more detailed discussion that follows (in thousands):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Liquidity and Capital Resources</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,823</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,353</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,339</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,802</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,296</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,003</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total shareholders&rsquo; equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,025</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">799</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Working capital</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,676</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">491</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Year Ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash Flow Data</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash flow provided by (used in):</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Operating activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,696</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,900</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Investing activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(50</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Financing activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,216</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,539</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net increase (decrease) in cash</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,470</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(383</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Working Capital</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We had cash of $16.8 million, current liabilities of $1.3 million and working capital of $15.5 million as of December 31, 2018, compared $1.4 million in cash, $1.0 million in current liabilities and $491,000 in working capital as of December 31, 2017. The increases in cash and working capital are due to our December 2018 initial public offering in the United States and March 2018 private placement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Cash Flows</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Operating Activities</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Net cash used in operating activities for the year ended December 31, 2018 was $5.7 million compared to $3.9 million for the year ended December 31, 2017. This increase relates primarily to an increase in the net loss, in addition to the effects of the changes in operating assets and liabilities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Investing Activities</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Investing activities consist primarily of purchases of property and equipment. Net cash used in investing activities was $50,000 for the year ended December 31, 2018 compared to $22,000 for the year ended December 31, 2017. This increase relates primarily to the expansion of our office space and staff.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">73</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Financing Activities</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financing activities consist primarily of net proceeds from the sale of common shares and warrants and proceeds from the exercise of stock options and warrants. Net cash provided by financing activities was $21.2&nbsp;million for the year ended December 31, 2018 compared to $3.5 million for the year ended December 31, 2017. Cash flows from financing activities for 2018 included net proceeds from our December 2018 initial public offering and private placements of our common shares and warrants to purchase common shares in March 2018.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In December 2018, we completed an initial public offering of our common shares in the United States by issuing 4,100,000 common shares at an offering price of $4.00 per share, resulting in net proceeds to us of approximately $14.7 million, after deducting underwriting discounts and commissions and offering expenses.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On March 29, 2018, we completed, in two tranches, a brokered and non-brokered private placement of 1,322,965 units at a price of $4.90 per unit for aggregate gross proceeds of approximately $6.3 million. Each unit consisted of one common share and one-half of one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share at a price of $7.00 at any time prior to expiration on March 19, 2020 and March 29, 2020 for tranche 1 and tranche 2, respectively. The warrants are subject to early expiration under certain conditions. In connection with the offering, we paid an aggregate cash fee of approximately $384,000 to brokers and issued an aggregate of 80,510 compensation options. Each compensation option entitles the holder to purchase one common share at $4.90, the offering price, for a period of two years from the closing of the offering, subject to acceleration on the same terms as the warrants issued to the investors.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On December 18, 2017, we completed a non-brokered private placement of 181,220 units at a price of $5.20 per unit for aggregate gross proceeds of approximately $944,000. Each unit consisted of one common share and one-half of one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share at a price of $7.00 at any time prior to expiration on December 19, 2019, subject to early expiration under certain conditions. On April 17, 2017, we completed a non-brokered private placement of 526,316 units at a price of $3.80 per unit for aggregate proceeds of approximately $2,000,000. Each unit consists of one common share and one-half common share purchase warrant. Each whole warrant entitles the holder to purchase one common share at a price of $4.60 at any time prior to expiration on April 17, 2019. The warrant expiration date can be accelerated at our option in the event that the volume-weighted average trading price of our common shares exceeds $6.00 per common share for any 10 consecutive trading days.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Capital Requirements</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Since our inception, we have incurred losses while advancing the R&amp;D of our product candidates. We have not generated any revenues from product sales and do not expect to do so for a number of years. We do not know when, or if, we will generate any sales revenue from our DM199 product candidate or any future product candidates. We do not expect to generate any revenue from sales of product candidates unless and until we obtain regulatory approval. We expect to continue to incur substantial operating losses until such time as any future product sales, royalty payments, licensing fees, and/or milestone payments are sufficient to generate revenues to fund our continuing operations. We expect our operating losses to increase in the near term as we continue the research, development and clinical trials of, and seek regulatory approval for, our DM199 product candidate. In addition, we expect our operating expenses to increase in 2019 compared to 2018 as a result of our recently obtained Nasdaq-listed U.S. public reporting company status. In the long-term, subject to obtaining regulatory approval of our DM199 product candidate or any other future product candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">74</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accordingly, despite our recent initial public offering, we expect we will need substantial additional capital to further our R&amp;D activities, planned clinical trials, regulatory activities and otherwise develop our product candidate, DM199, or any future product candidates, to a point where they may be commercially sold. While we are striving to achieve these plans, there is no assurance these and other strategies will be achieved or that additional funding will be obtained on favorable terms or at all. While our rate of future negative cash flow per month will vary due to the timing of expenses incurred, we expect our current cash, which includes the net proceeds of our recent initial public offering, to be sufficient to allow us to complete our current ongoing Phase II Remedy trial in patients with AIS and our current Phase Ib trial in patients with CKD and a Phase II study in patients with CKD and to otherwise fund our planned operations through 2020. However, the amount and timing of future funding requirements will depend on many factors, including the timing and results of our ongoing development efforts, the potential expansion of our current development programs, potential new development programs and related G&amp;A support. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time. We may elect to raise additional funds even before we need them if market conditions for raising additional capital are favorable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Since our inception, we have financed our operations from public and private sales of equity, the exercise of warrants and stock options, interest income on funds available for investment, and government grants and tax credits, and we expect to continue this practice for the foreseeable future. We do not have any existing credit facilities under which we could borrow funds. We may seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if our clinical data is not positive or economic and market conditions deteriorate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">To the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted. Debt financing, if available, may involve agreements that include conversion discounts or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, or strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. The availability of financing will be affected by our clinical data and other results of scientific and clinical research; the ability to attain regulatory approvals; market acceptance of our product candidates; the state of the capital markets generally with particular reference to pharmaceutical, biotechnology, and medical companies; the status of strategic alliance agreements; and other relevant commercial considerations. If adequate funding is not available, we may be required to implement cost reduction strategies; delay, reduce, or eliminate one or more of our product development programs; relinquish significant rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us; and/or divest assets or cease operations through a merger, sale, or liquidation of our company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Commitments and Contingencies</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In the normal course of business, we incur obligations to make future payments as we execute our business plan. As of December 31, 2018, we had outstanding commitments, including R&amp;D contracts and other commitments, that are known and committed of approximately $1.9 million over the next 12&nbsp;months and approximately $600,000 in the following 12 months. These contracts relate to preclinical, clinical, and development activities, including the clinical research organization conducting the Phase II clinical trial for DM199 related to AIS. These commitments are subject to significant change and the ultimate amounts due may be materially different as these obligations are affected by, among other factors, the number and pace of patients enrolled, the number of clinical study sites, amount of time to complete study enrollments and the time required to finalize the analysis and reporting of study results. These commitments are generally cancelable upon 30 days&rsquo; notice, with our obligation then limited to costs incurred up to that date. As of December 31, 2018, we had future operating lease commitments totaling approximately $240,000 over the remainder of the lease, of which $62,000 is due over the next 12 months.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">75</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have entered into a license agreement with Catalent Pharma Solutions, LLC (&ldquo;Catalent&rdquo;) whereby we have licensed certain gene expression technology and we contract with Catalent for the manufacture of DM199. Under the terms of this license, certain milestone and royalty payments may become due under this agreement and are dependent upon, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain. As of December 31, 2018, two milestones remain which include $185,000 due upon the initiation of dosing in our first Phase III trial and $185,000 upon our first regulatory approval for commercial sale. Following the launch of our first product, we will also incur a royalty of less than 1% on net sales. The royalty term is indefinite but may be canceled by us on 90 days&rsquo; prior written notice. The license may not be terminated by Catalent unless we fail to make required milestone and royalty payments.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During 2018 and 2017, we did not have any off-balance sheet arrangements (as defined by applicable SEC regulations) that are reasonably likely to have a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Internal Control Over Financial Reporting</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pursuant to Section 404(a) of the Sarbanes-Oxley Act, commencing with our annual report on Form 10-K next year, our management will be required to report on the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a U.S. public reporting company under the Exchange Act, we may need to upgrade our systems, including information technology, implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Item 7A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quantitative and Qualitative Disclosures About Market Risk</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">This Item 7A is inapplicable to DiaMedica as a smaller reporting company and has been omitted pursuant to Item 305(e) of SEC Regulation S-K.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">76</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Item 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Supplementary Data</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="margin: 0pt; width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Page</u></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Report of Independent Registered Public Accounting Firm</p>
			</td>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">78</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Consolidated Balance Sheets as of December 31, 2018 and 2017</p>
			</td>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">79</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: -18pt;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2018 and 2017</p>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">80</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left; text-indent: -18pt;">Consolidated Statements of Shareholders&rsquo; Equity for the years ended December 31, 2018 and 2017</p>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">81</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Consolidated Statements of Cash Flows for the years ended December 31, 2018 and 2017</p>
			</td>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">82</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notes to Consolidated Financial Statements</p>
			</td>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">83</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">77</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">To the Board of Directors and Shareholders of</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">DiaMedica Therapeutics Inc.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Opinion on the Financial Statements</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have audited the accompanying consolidated balance sheets of DiaMedica Therapeutics Inc. and Subsidiaries (the &ldquo;Company&rdquo;) as of December 31, 2018 and 2017, and the related consolidated statements of operations and comprehensive loss, shareholders&rsquo; equity (deficit), and cash flows for each of the years then ended, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Basis for Opinion</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">These financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board of the United States of America (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Baker Tilly Virchow Krause, LLP</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have served as the Company&rsquo;s auditors since 2016.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Minneapolis, MN</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">March 19, 2019</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">78</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="4" id="52204" sectdesc="Balance Sheet">&nbsp;</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Consolidated Balance Sheets</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands, except share amounts)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div data-td-statement-type="balance-sheet" data-td-taggable-table="" data-td-v2v-id="1552825356737">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>ASSETS</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current assets:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Cash</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,823</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,353</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Amounts receivable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">780</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Prepaid expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">369</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">61</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Total current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,972</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,494</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Deposit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">271</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">271</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Property and equipment, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Total non-current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">367</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">308</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B3" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,339</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,802</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Accounts payable and accrued liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,291</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">919</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Capital lease obligation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Warrant liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">84</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Total current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,296</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,003</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long term liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Capital lease obligation, non-current</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Total long term liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Commitments and contingencies (Note 9)</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shareholders&rsquo; equity:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt; text-indent: -9pt;">Common shares, no par value; unlimited authorized; 11,956,874 and 6,370,661 shares issued and outstanding, as of December 31, 2018 and 2017, respectively</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Additional paid-in capital</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62,993</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,033</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Accumulated deficit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(45,968</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(40,234</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Total shareholders&rsquo; equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,025</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">799</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities and shareholders&rsquo; equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,339</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,802</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">See accompanying notes to consolidated financial statements.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">79</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="5" id="52205" sectdesc="Income Statement">&nbsp;</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Consolidated Statements of Operations and Comprehensive Loss</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands, except share and per share amounts)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div data-td-statement-type="income" data-td-taggable-table="" data-td-v2v-id="1552825370764">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Year Ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating revenues:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">License revenues</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">500</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,522</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,206</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,739</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,313</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Total operating expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,261</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,519</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6,761</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,519</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other (income) expense:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Governmental assistance &ndash; research incentives</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,214</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(244</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Other (income) expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(6</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Change in fair value of warrant liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Total other income</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,107</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(259</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B2" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B2" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.B3" style="padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.B3" style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".trail.B3" style="padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss before income tax expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,654</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,260</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">80</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss and comprehensive loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,734</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,260</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted net loss per share</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.74</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.72</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding &ndash; basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,743,520</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,935,790</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">See accompanying notes to consolidated financial statements.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">80</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="7" id="52206" sectdesc="Stockholders' Equity">&nbsp;</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Consolidated Statements of Shareholders&rsquo; Equity</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands, except share amounts)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div data-td-statement-type="stockholders-equity" data-td-taggable-table="" data-td-v2v-id="1552825377557">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Common</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Shares</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Additional </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Paid-In </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Capital</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accumulated Deficit</b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Total Shareholders&rsquo; Equity</b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Balances at December 31, 2016</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,526,046</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,085</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(35,974</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,111</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt; text-indent: -9pt;">Issuance of common shares and warrants, net of offering costs of $292</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">707,536</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,917</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,917</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt; text-indent: -9pt;">Exercise of common share purchase warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">134,079</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">615</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">615</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt; text-indent: -9pt;">Exercise of common stock option</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Share-based compensation expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">409</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">409</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,260</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,260</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Balances at December 31, 2017</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,370,661</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,033</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(40,234</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">799</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt; text-indent: -9pt;">Issuance of common shares and warrants, net of offering costs of $529</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,322,965</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,840</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,840</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt; text-indent: -9pt;">Issuance of common shares, net of offering costs of $1,674</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,100,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,726</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,726</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt; text-indent: -9pt;">Exercise of common share purchase warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">146,294</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">731</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">731</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Exercise of common stock option</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,954</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">43</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">43</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Share-based compensation expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">620</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">620</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,734</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,734</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Balances at December 31, 2018</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,956,874</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,993</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(45,968</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,025</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">81</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" docsect="8" id="52207" sectdesc="Cash Flows">&nbsp;</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Consolidated Statements of Cash Flows</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(In thousands, except share amounts)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div data-td-statement-type="cash-flows" data-td-taggable-table="" data-td-v2v-id="1552825417437">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Year Ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash flows from operating activities</b>:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,734</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,260</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Share-based compensation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">620</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">409</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Change in fair value of warrant liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(9</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Changes in operating assets and liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Amounts receivable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(700</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(27</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Prepaid expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(308</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Deposits</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(271</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Accounts payable and accrued liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">372</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">248</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 36pt;">Net cash used in operating activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,696</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,900</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash flows from investing activities</b>:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Purchase of property and equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(50</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(22</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Net cash used in financing activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(50</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash flows from financing activities</b>:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Proceeds from issuance of common shares, net of offering costs</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,726</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,917</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Proceeds from issuance of common shares and warrants, net offering costs</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,840</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Proceeds from the exercise of common share purchase warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">607</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">615</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Proceeds from exercise of stock options</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">43</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 27pt;">Net cash provided by financing activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,216</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,539</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net increase (decrease) in cash</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,470</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(383</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash at beginning of year</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,353</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,736</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash at end of year</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,823</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,353</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Supplemental disclosure of </b><b>c</b><b>ash</b><b> flow information</b>:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Cash paid for interest</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Supplemental disclosure of non-cash transactions</b>:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Reclassification of warrant liability upon warrant exercise</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">123</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Assets acquired under capital lease</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">See accompanying notes to consolidated financial statements.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">82</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>DiaMedica Therapeutics Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Notes to Consolidated Financial Statements</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="52208" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825429475">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>1.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Business</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">DiaMedica Therapeutics Inc. and its wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. (collectively &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;DiaMedica&rdquo; and the &ldquo;Company&rdquo;), exist for the primary purpose of advancing the clinical and commercial development of a proprietary recombinant KLK1 protein for the treatment of kidney and neurological diseases with our primary focus on chronic kidney disease and acute ischemic stroke. Our parent company is governed under the Canada Business Corporations Act and, commencing on December 4, 2018, our common shares are publicly traded on The Nasdaq Capital Market under the symbol &ldquo;DMAC.&rdquo; The Company&rsquo;s shares were previously traded on the TSX Venture Exchange in Canada and on the OTCQB in the United States.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Effective November 15, 2018, we implemented a 1-for-20 consolidation of our common shares. No fractional shares were issued in connection with the share consolidation. Instead, the Company rounded to the nearest whole number the number of shares shareholders would be entitled to receive in connection with the consolidation. The share consolidation was approved by our shareholders as of November 6, 2018 and was implemented to increase the market price per common share to a level that qualified for listing on The Nasdaq Capital Market. Proportional adjustments were also made to common shares reserved for issuance under the Company&rsquo;s equity-based compensation plans and outstanding stock options, deferred share units and warrants. All references to share and per share amounts included in these consolidated financial statements have been retroactively restated to reflect the share consolidation.</p>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="52209" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825437655">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>2.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risks and Uncertainties</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">DiaMedica is subject to many risks and uncertainties. We are in the clinical stage of development of our initial product candidate, DM199, for the treatment of chronic kidney disease and acute ischemic stroke. The Company has not completed the development of any product candidate and, accordingly, has not begun to commercialize any product candidate or generate any revenues from the sale of any product candidate. DM199 requires significant additional clinical testing and investment prior to seeking marketing approval and is not expected to be commercially available for several years, if at all. The Company&rsquo;s future success is dependent upon the success of its development efforts, its ability to demonstrate clinical progress for its DM199 product candidate in the United States or other markets, its ability to obtain required governmental approvals of its product candidate and ultimately its ability to license or market and sell its DM199 product candidate, and its ability to obtain additional financing to fund these efforts.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of December 31, 2018, we have incurred losses of $46.0 million since our inception in 2000. For the year ended December 31, 2018, we incurred a net loss of $5.7&nbsp;million and negative cash flows from operating activities of $5.7&nbsp;million. We expect to continue to incur operating losses until such time as any future product sales, royalty payments, licensing fees, and/or milestone payments are sufficient to generate revenue to fund our continuing operations. Further, we expect our operating losses to increase in the near term as we continue the research, development and clinical trials of, and to seek regulatory approval for, our product candidate. In addition, we expect our operating expenses to increase in 2019 compared to 2018 as a result of our recently obtained Nasdaq-listed U.S. public reporting company status. As of December 31, 2018, DiaMedica had cash of $16.8 million, working capital of $16.7 million and shareholders&rsquo; equity of $17.0 million. Our principal sources of cash have included net proceeds from the issuance of equity securities, including most recently an initial public offering of our common shares in the United States in December 2018. See Note 8 titled &ldquo;Shareholders&rsquo; Equity&rdquo; for additional information. Although the Company has previously been successful in obtaining financing through equity securities offerings, there is no assurance that we will be able to do so in the future. This is particularly true if our clinical data is not positive or economic and market conditions deteriorate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">83</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Despite our recent initial public offering in the United States, we expect that we will need substantial additional capital to further our research and development activities, complete the required clinical trials, regulatory activities and otherwise develop our product candidate, DM199, or any future product candidates, to a point where they may be commercially sold. We expect our current cash, which includes the net proceeds of our recent initial public offering, to be sufficient to allow us to complete our currently ongoing Phase II Remedy trial in patients with AIS, our Phase Ib trial in patients with CKD and a planned Phase II study in patients with CKD caused by rare diseases and to otherwise fund our planned operations through 2020. However, the amount and timing of our future funding requirements will depend on many factors, including the timing and results of ongoing development efforts, the potential expansion of current development programs, potential new development programs and related general and administrative support. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time.</p>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="52210" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825450488">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>3.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Summary of Significant Accounting Policies </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Basis of consolidation</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying consolidated financial statements include the assets, liabilities and expenses of DiaMedica Therapeutics Inc., and our wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. All significant intercompany transactions and balances have been eliminated in consolidation.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Functional currency</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The United States dollar is our functional currency as it represents the economic effects of the underlying transactions, events and conditions and various other factors including the currency of historical and future expenditures and the currency in which funds from financing activities are mostly generated by the Company. A change in the functional currency occurs only when there is a material change in the underlying transactions, events and condition. A change in functional currency could result in material differences in the amounts recorded in the consolidated statement of loss and comprehensive loss for foreign exchange gains and losses. All amounts in the accompanying consolidated financial statements are in U.S. dollars unless otherwise indicated.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Use of estimates</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Concentration of credit risk</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand and savings accounts at commercial banks. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">84</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Fair value of financial instruments </i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Carrying amounts of certain of the Company&rsquo;s financial instruments, including amounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. Certain of the Company&rsquo;s common share purchase warrants are required to be reported at fair value. The fair value of common share purchase warrants is disclosed in Note 10 titled &ldquo;Warrant Liability.&rdquo;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Fair value measurements</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Fair value is defined as the exit price, or amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&rsquo;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The hierarchy is broken down into three levels defined as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level 1&mdash;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level 2&mdash;Quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or model-derived valuations for which all significant inputs are observable, either directly or indirectly.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level 3&mdash;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our cash is comprised of bank deposits in demand and savings accounts. As of December 31, 2018, the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Common share warrant liability</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The common share warrants that were issued in connection with the February 2016 private placements of common shares were classified as a liability in the consolidated balance sheets, as the common share warrants had an exercise price stated in Canadian dollars, which is different than our functional currency, and thus these warrants qualified as derivative instruments. The fair value of these common share warrants was re-measured at each financial reporting period and immediately before exercise, with any changes in fair value being recognized as a component of other income (expense) in our consolidated statements of operations. These warrants were exercised in February 2018, see Note 8 titled &ldquo;Warrant Liability.&rdquo;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Long-lived assets</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Property and equipment are stated at purchased cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three to ten years for office equipment and four years for computer equipment. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheets and the resulting gain or loss is reflected in the consolidated statements of operations. Repairs and maintenance are expensed as incurred.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">85</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Long-lived assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset or related group of assets may not be recoverable. If the expected future undiscounted cash flows are less than the carrying amount of the asset, an impairment loss is recognized at that time. Measurement of impairment may be based upon appraisal, market value of similar assets or discounted cash flows.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Revenue recognition</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We followed ASC 606, &ldquo;Revenue from Contracts with Customers&rdquo; in accounting for our License and Collaboration agreement with Ahon Pharmaceutical Co Ltd. Accordingly, the Company recognizes revenue upon transfer of control of the product to our customer in an amount that reflects the consideration we expect to receive in exchange.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We intend to enter into arrangements for the research and development (R&amp;D) and/or manufacture of products and product candidates. Such arrangements may require us to deliver various rights, services and/or goods, including (i) intellectual property rights or licenses, (ii) R&amp;D services or (iii) manufacturing services. The underlying terms of these arrangements generally would provide for consideration to DiaMedica in the form of nonrefundable, up-front license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In arrangements involving more than one performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is not available.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. We intend to utilize the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Research and development costs</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Research and development costs include expenses incurred in the conduct of human clinical trials, for third-party service providers performing various testing and accumulating data related to non-clinical studies&#894; sponsored research agreements&#894; developing the manufacturing process necessary to produce sufficient amounts of the DM199 compound for use in our non-clinical studies and human clinical trials&#894; consulting resources with specialized expertise related to execution of our development plan for our DM199 product candidate&#894; and personnel costs, including salaries, benefits and share-based compensation.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">86</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (&ldquo;CROs&rdquo;). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual work performed at each clinical trial site and by each CRO.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Patent costs</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Costs associated with prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, resulting in probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in research and development costs and were $156,000 and $160,000 for the years ended December 31, 2018 and 2017, respectively.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Share-based compensation</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The cost of employee and non-employee services received in exchange for awards of equity instruments is measured and recognized based on the estimated grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The fair value of share-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our share price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon Canadian Government bond rates appropriate for the expected term of each award. Expected volatility rates are based on the on historical volatility equal to the expected life of the option. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Income taxes</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of December 31, 2018 and 2017. See Note 13, &ldquo;Income Taxes&rdquo; for additional information. The Company&rsquo;s policy is to classify interest and penalties related to income taxes as income tax expense in the Consolidated Statements of Operations and Comprehensive Loss.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">87</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Government assistance</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Government assistance relating to research and development performed by DiaMedica Australia Pty Ltd. is recorded as a component of Other (income) expense. Government assistance was initially recognized when reasonable assurance existed that the Company complied with the conditions attached to the incentive program and that the incentive payments would be received. In subsequent periods, the government assistance was recognized when the related expenditures were incurred. During 2018, we recognized $621,000 and $593,000 for research activities performed in 2018 and 2017, respectively. During 2017, we recognized $244,000 for research activities performed in 2016.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Net loss per share</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table summarizes our calculation of net loss per common share for the periods (in thousands, except share and per share data):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825450483">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Year Ended</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,734</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,260</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding&mdash;basic and diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,743,520</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,935,790</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted net loss per share</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.74</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.72</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</table>
</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825450484">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Year Ended</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">639,359</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">480,035</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under common share purchase warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">807,563</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">216,213</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under deferred unit plan</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,183</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">21,183</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,468,105</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">717,431</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Recently adopted accounting pronouncements</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In May 2014, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued a new accounting standard that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard and clarifying standards require an entity to recognize revenue when control of promised goods or services is transferred to the customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted this new standard as of January 1, 2018, but the adoption as of this date had no impact on our financial statements, as we had no revenue until the third quarter of 2018. We followed ASC 606, &ldquo;Revenue from Contracts with Customers&rdquo; in accounting for our License and Collaboration agreement with Ahon Pharmaceutical Co Ltd. (Note 11).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">88</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Recently issued accounting pronouncements</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In February 2016, the FASB issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2016-02, <i>Leases</i>. The guidance in ASU 2016-02 supersedes the lease recognition requirements in the Accounting Standards Codification Topic 840, Leases. ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. The new standard requires the immediate recognition of all excess tax benefits and deficiencies in the income statement and requires classification of excess tax benefits as an operating activity as opposed to a financing activity in the statements of cash flows. This standard became effective for us on January 1, 2019.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The FASB has subsequently issued the following amendments to ASU 2016-02, which have the same effective date and transition date of January 1, 2019, and which we collectively refer to as the new leasing standards:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU No. 2018-01, <i>Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</i>, which permits an entity to elect an optional transition practical expedient to not evaluate under Topic 842 land easements that existed or expired prior to adoption of Topic 842 and that were not previously accounted for as leases under the prior standard, ASC 840, Leases.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU No. 2018-10, <i>Codification Improvements to Topic 842, Leases</i>, which amends certain narrow aspects of the guidance issued in ASU 2016-02.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU No. 2018-11, <i>Leases (Topic 842): Targeted Improvements</i>, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption as well as an additional practical expedient for lessors to not separate non-lease components from the associated lease component.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU No. 2018-20, <i>Narrow-Scope Improvements for Lessors</i>, which contains certain narrow scope improvements to the guidance issued in ASU 2016-02.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We adopted the new leasing standards on January 1, 2019, using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019; and, consequently, financial information will not be updated and the disclosures required under Topic 842 will not be provided for dates and periods prior to January 1, 2019. We have reviewed our existing lease contracts and the impact of the new leasing standards on our consolidated results of operations, financial position and disclosures. Upon adoption of the new leasing standards, we expect to recognize a lease liability and related right-of-use asset on our consolidated balance sheet of approximately $200,000. The impact of adoption of the new leasing standards will not have a material impact on our consolidated statements of operations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In June 2018, the FASB issued ASU No. 2018-07, &ldquo;<i>Improvements to Nonemployee Share-Based Payment Accounting</i>,&quot; to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. This ASU is effective for public entities for fiscal years beginning after December 15, 2018, with early adoption permitted. Prior to the adoption of this ASU, stock-based compensation awarded to non-employees was subject to revaluation over its vesting terms. Subsequent to the adoption of this ASU, non-employee share-based payment awards are measured on the date of grant, similar to share-based payment awards granted to employees. We do not expect that the adoption of this ASU will impact our financial position or our consolidated statements of operations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">89</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="52211" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825466534">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>4.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Amounts Receivable</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Amounts receivable consisted of the following (in thousands):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825466533">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31,</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31, </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development incentives</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">622</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales-based taxes receivable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">134</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">80</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total amounts receivable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">780</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">80</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="52212" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825476731">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>5.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Deposit</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Deposit consisted of the following (in thousands):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825476730">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31,</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31, </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Advances to vendor</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">271</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">271</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total deposit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">271</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">271</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have advanced funds to a vendor engaged to support the performance of the REMEDY Phase 2 clinical trial. The funds advanced will be held, interest free, by this vendor until the completion of the trial and applied to final trial invoices or refunded. This deposit is classified as non-current as the trial is not expected to be completed during 2019.</p>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="52213" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825489118">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>6.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Property and Equipment</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Property and equipment consisted of the following (in thousands):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825489117">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31,</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31,</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Furniture and equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">71</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">120</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(24</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(26</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Property and equipment, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">96</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">37</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Depreciation expense for the years ended December 31, 2018 and 2017 was $15,000 and $4,000, respectively. During 2018, we disposed of $17,000 of equipment, which was fully depreciated.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">90</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="52214" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825502037">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>7.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Accounts Payable and Accrued Liabilities</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accounts payable and accrued liabilities consisted of the following (in thousands):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825502037">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31,</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31, </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Trade and other payables</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">483</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">513</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued compensation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">417</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">355</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical study costs</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">292</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued research and other professional fees</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued taxes and other liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">34</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total accrued liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,291</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">919</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="52215" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825515856">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>8.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Warrant Liability</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In February 2016, the Company completed, in two tranches, a non-brokered private placement of 234,375 units with each unit consisting of one common share and one half of one common share purchase warrant. The Company issued 117,188 warrants. Each warrant entitled the holder to purchase one common share at a price of $5.00 Canadian dollars at any time prior to expiry on February 18 or 25, 2018 for Tranche 1 and Tranche 2, respectively.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As the warrant exercise price was stated in Canadian dollars and the Company&rsquo;s functional currency is the U.S. dollar, the warrants were deemed to be derivative instruments, with their estimated fair value classified as a liability on the Company&rsquo;s consolidated balance sheet. The initial estimated fair value of the warrants was recorded as a warrant liability with subsequent changes in the estimated fair value recognized in the consolidated statements of operations and comprehensive loss. The Company allocated $281,000 of the net proceeds to the warrant liability and the balance of the proceeds to the common shares. The initial fair value of the warrants was determined using a Black-Scholes pricing model with the following assumptions: expected volatilities of 191.8 &ndash; 225.0%, risk-free interest rates of 0.43 &ndash; 0.49%, and expected life of 2 years.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In connection with the offering, the Company issued an aggregate of 10,915 compensation warrants. Each compensation warrant entitled the holder to purchase one common share at $5.00 Canadian dollars for a period of 2 years from the date of issuance. The Company estimated the value of these warrants at $24,000, which was included in the issuance costs. The initial fair value of the warrants was determined using a Black-Scholes valuation model with the following assumptions: expected volatilities of 191.8 &ndash; 225.0%, risk-free interest rates of 0.43&nbsp;&ndash; 0.49%, and expected life of 2 years.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During February 2018, 121,256 common shares were issued on the exercise of warrants for gross proceeds of approximately $483,000 and the remaining 4,346 warrants expired.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The fair value of the Company&rsquo;s common share purchase warrant liability was calculated using a Black-Scholes valuation model and is classified as Level 3 in the fair value hierarchy. The fair values at the time of exercise of the warrants were estimated using the following valuation assumptions: expected volatilities of 16.7%, risk-free interest rates of 1.8%, and expected life of 0.01-0.03 years.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">91</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following is a rollforward of the fair value of the warrants (in thousands):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825515855">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Warrant Liability</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Ending balance December 31, 2017</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">84</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercises</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(123</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Ending balance December 31, 2018</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="52216" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825528494">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>9.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Commitments and Contingencies</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Clinical trials and product development</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In the normal course of business, the Company incurs obligations to make future payments as it executes its business plan. These contracts relate to preclinical, clinical and development activities, including the clinical research organization conducting our Phase II clinical trial for acute ischemic stroke. These commitments are subject to significant change and the ultimate amounts due may be materially different as these obligations are affected by, among other factors, the number and pace of patients enrolled, the number of clinical study sites, amount of time to complete study enrollments and the time required to finalize the analysis and reporting of study results. Clinical research agreements are generally cancelable upon 30 days&rsquo; notice, with the Company&rsquo;s obligation then limited to costs incurred up to that date. Cancelation terms for product development contracts vary and are generally dependent upon timelines for sourcing research materials and reserving laboratory time. As of December 31, 2018, the Company estimates that its outstanding commitments including research and development contracts are approximately $1.9 million over the next 12 months and approximately $600,000 in the following 12 months.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On September 11, 2017, the Company announced the initiation of REMEDY, a 60-patient Phase II clinical trial evaluating DM199 in patients with acute ischemic stroke. The study drug (DM199 or placebo) will be administered as an intravenous infusion within 24 hours of stroke symptom onset, followed by subcutaneous (under the skin) injections later that day and once every 3 days for 21 days. The study is designed to measure safety and tolerability along with multiple tests designed to investigate DM199&rsquo;s therapeutic potential including plasma-based biomarkers and standard functional stroke measures assessed at 90 days post-stroke (Modified Rankin Scale, National Institutes of Health Stroke Scale, Barthel Index, and C-reactive protein, a measure of inflammation).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On February 14, 2019, the Company announced the first enrollment in its Phase Ib dose ranging study in patients with moderate or severe CKD caused by Type I or Type II diabetes. The results from this Phase Ib study will assist us in the design of upcoming Phase II studies in patients suffering from rare diseases and CKD. The DM199 drug levels from this Phase Ib study will be used to determine the optimal dose levels for testing in the Phase II studies.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Additional clinical trials will be subsequently required if the results of the Phase II are positive. However, at this time, we are unable to reasonably estimate the total costs of future trials. Such costs are contingent on and subject to change depending on the results of current and future clinical trials as well as developments in the regulatory requirements. Clinical trial costs are expensed as incurred.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Technology license</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company has entered into a license agreement with Catalent Pharma Solutions, LLC (&ldquo;Catalent&rdquo;) whereby we have licensed certain gene expression technology and we contract with Catalent for the manufacture of DM199. Under the terms of this license, certain milestone and royalty payments may become due under this agreement and are dependent upon, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain. As of December 31, 2018, two milestones remain which include $185,000 due upon the initiation of dosing in our first Phase III trial and $185,000 upon our first regulatory approval for commercial sale. Following the launch of our first product, we will also incur a royalty of less than 1% on net sales. The royalty term is indefinite but may be canceled by us on 90 days&rsquo; prior written notice. The license may not be terminated by Catalent unless we fail to make required milestone and royalty payments. There were no amounts due or payable under this agreement during 2018 and 2017.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">92</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Indemnification of directors and officers</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company, as permitted under laws of the Canada and in accordance with the Company&rsquo;s by-laws and indemnification agreements, will indemnify and advance expenses to its directors and officers to the fullest extent permitted by law and may choose to indemnify other employees or agents from time to time. The Company has secured insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to the Company. As of December 31, 2018, there was no pending litigation or proceeding involving any director or officer of the Company as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. Insofar as indemnification for liabilities arising under the United States Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) may be permitted to directors, officers and controlling persons of the Company, the Company has been advised that, in the opinion of the United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;), such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company had not recorded any liabilities for these obligations as of December 31, 2018 or 2017.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Future minimum lease payments</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company leases certain office space under a non-cancelable operating lease. On May 3, 2017, the Company amended the lease agreement to extend its lease term by 42 months, for an expiration date of August 31, 2022, and increase its leased space. Rent is expensed on a straight-line basis.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Future minimum lease payments under this operating lease are as follows (in thousands):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825528493">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">66</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">244</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="52217" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825547959">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>10.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Shareholders&rsquo; Equity</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Authorized capital stock</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company has authorized share capital of an unlimited number of common voting shares and the shares do not have a stated par value.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company&#39;s annual general meeting and any extraordinary general meeting.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">93</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Shareholders rights plan</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company adopted a shareholder rights plan agreement (the &ldquo;Rights Plan&rdquo;). The Rights Plan is designed to provide adequate time for the Board of Directors and the shareholders to assess an unsolicited takeover bid for the Company, to provide the Board of Directors with sufficient time to explore and develop alternatives for maximizing shareholder value if a takeover bid is made, and to provide shareholders with an equal opportunity to participate in a takeover bid and receive full and fair value for their common shares. The Rights Plan was renewed at the Company&rsquo;s annual meeting of shareholders in December 2017 and is set to expire at the close of the Company&rsquo;s annual meeting of shareholders in 2020.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The rights issued under the Rights Plan will initially attach to and trade with the common shares and no separate certificates will be issued unless an event triggering these rights occurs. The rights will become exercisable only when a person, including any related person or entity, acquires or attempts to acquire 20% or more of the outstanding common shares without complying with the &ldquo;Permitted Bid&rdquo; provisions of the Rights Plan or without approval of the Board of Directors. Should such an acquisition occur or be announced, each right would, upon exercise, entitle a rights holder, other than the acquiring person and related persons, to purchase common shares at a 50% discount to the market price at the time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Under the Plan, a Permitted Bid is a bid made to all holders of the common shares and which is open for acceptance for not less than 60 days. If at the end of 60 days at least 50% of the outstanding common shares, other than those owned by the offeror and certain related parties have been tendered, the offeror may take up and pay for the common shares but must extend the bid for a further 10 days to allow other shareholders to tender.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The issuance of common shares upon the exercise of the rights is subject to receipt of certain regulatory approvals.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Public offering during 2018</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On December 11, 2018, the Company issued and sold an aggregate of 4,100,000 common shares in an initial public offering at a price to the public of $4.00 per share. As a result of the offering, the Company received gross proceeds of $16.4 million, which resulted in net proceeds to the Company of approximately $14.7 million, after deducting underwriting discounts and commissions and offering expenses. None of the expenses associated with the initial public offering were paid to directors, officers, persons owning ten percent or more of any class of equity securities, or to their associates, or to our affiliates. On December 11, 2018, as additional underwriting compensation and in exchange for cash consideration of $50, the Company granted the underwriter a warrant to purchase 205,000 common shares (equal to 5.0% of the common shares sold in the initial public offering) at an exercise price of $4.80 per share (equal to 120% of the initial public offering price per common share in the initial public offering), subject to customary anti-dilution provisions. The warrant is exercisable for a term of five years. The warrant includes a cashless exercise provision entitling the underwriter to surrender a portion of the underlying common shares that has a value equal to the aggregate exercise price in lieu of paying cash upon exercise.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Private placements during 2018</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On March 29, 2018, the Company completed, in two tranches, a brokered and non-brokered private placement of 1,322,965 units at a price of $4.90 per unit for aggregate gross proceeds of approximately $6.3&nbsp;million. Each unit consisted of one common share and one half of one common share purchase warrant. The Company issued 661,482 warrants. Each warrant entitles the holder to purchase one common share at a price of $7.00 at any time prior to expiry on March 19, 2020 and March 29, 2020 for Tranche 1 and Tranche 2, respectively. The warrants are subject to early expiry under certain conditions. The warrant expiry date can be accelerated at the option of the Company, in the event that the volume- weighted average trading price of the Company&rsquo;s common shares exceeds $12.00 per common share for any 21 consecutive trading days. In connection with this offering, the Company paid aggregate finder&rsquo;s fees of approximately $384,000 and issued an aggregate of 80,510 compensation warrants. Each compensation warrant entitles the holder to purchase one common share at $4.90 for a period of 2 years from the closing of this offering, subject to acceleration on the same terms as the common share purchase warrants.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">94</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During the year ended December 31, 2018, 128,594 common shares were issued on the exercise of warrants for gross proceeds of $607,000 and 16,954 common shares were issued on the exercise of options for gross proceeds of $43,000.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Private placements during 2017</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On December 18, 2017, the Company completed a non-brokered private placement of 181,220 units at a price of $5.20 per unit for aggregate gross proceeds of approximately $944,000, or $934,000 net of issuance costs. Each unit consisted of one common share and one half of one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share at a price of $7.00 at any time prior to expiry on December 19, 2019. Warrants are subject to early expiry, at the option of the Company, if on any date the volume-weighted average closing trading price of the common shares on any recognized stock exchange equals or exceeds $12.00 for a period of 21 consecutive trading days.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On April 17, 2017, the Company completed a non-brokered private placement of 526,316 units at a price of $3.80 per unit for aggregate gross proceeds of approximately $2,000,000, or $1,983,000 net of issuance costs. Each unit consisted of one common share and one half of one common share purchase warrant. Each whole warrant entitles the holder to purchase one common share at a price of $4.60 at any time prior to expiry on April 17, 2019. The warrants were subject to early expiry, at the option of the Company, if on any date the volume-weighted average closing trading price of the common shares on any recognized Canadian stock exchange equaled or exceeded $6.00 for a period of 10 consecutive trading days, which occurred in October 2017. The Company exercised its call option and 131,578 shares were issued for the warrants exercised and the remaining warrants were cancelled.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During the year ended December 31, 2017, 134,079 common shares were issued on the exercise of warrants for gross proceeds of $615,000 and 3,000 common shares were issued on the exercise of options for gross proceeds of $7,000.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Shares reserved</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825547958">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31, 2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options outstanding</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">639,359</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred share units outstanding</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,183</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shares available for grant under the Option Plan</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">123,376</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under common share purchase warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">807,563</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,591,479</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="52218" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825562767">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>11.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>License and Collaboration Agreement with Related Party</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On September 27, 2018, the Company entered into a license and collaboration agreement (the &ldquo;License Agreement&rdquo;) with Ahon Pharmaceutical Co Ltd. (&ldquo;Ahon Pharma&rdquo;), which grants Ahon Pharma exclusive rights to develop and commercialize DM199 for acute ischemic stroke in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Under the terms of the agreement, the Company is entitled to receive a non-refundable upfront payment of $500,000 due upon signing the License Agreement and an additional non-refundable payment of $4.5 million upon regulatory clearance to initiate a clinical trial in China. The Company also has the potential to receive up to an additional $27.5 million in development and sales related milestones and up to approximately 10% royalties on net sales of DM199 in the licensed territories. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territories will be the sole responsibility of Ahon Pharma. The License Agreement may be terminated at any time by Ahon Pharma by providing 120 days written notice.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">95</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company received the $500,000 upfront license fee and recorded it as revenue during the year ended December 31, 2018. The $4.5&nbsp;million payment and the up to $27.5 million in additional development and sales related milestones were determined to be at-risk substantive performance milestones and were not recordable as revenue as they were determined to be fully constrained using the most likely amount method. Revenue will be recognized for these milestones when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Under the terms of the License Agreement, the Company is obligated to pay, and Ahon Pharma may withhold, approximately 10% of any license fee as income tax due in China. The Company will record this withholding as income tax at the time it records the related license fee revenue. Accordingly, with respect to the $500,000 license fee, the Company recorded this withholding as income tax at the time it recorded this license fee revenue.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Ahon Pharma is a subsidiary of Shanghai Fosun Pharmaceutical (Group) co. Ltd. (&ldquo;Fosun Pharma&rdquo;) which, through its partnership with SK Group, a South Korea based company, is an investor in DiaMedica, holding approximately 8.4% of our common shares as of December 31, 2018. This investment was made in 2016.</p>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="52219" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825577425">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>12.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Share-Based Compensation</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Deferred share unit plan</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The DiaMedica Therapeutics Inc. Amended and Restated Deferred Share Unit Plan (&ldquo;DSU Plan&rdquo;) promotes greater alignment of long-term interests between non-executive directors and executive officers of the Company and its shareholders through the issuance of deferred share units (&ldquo;DSUs&rdquo;). Since the value of DSUs increases or decreases with the market price of the common shares, DSUs reflect a philosophy of aligning the interests of directors and executive officers by tying compensation to share price performance. For the year ended December 31, 2018 and 2017, there were no DSUs or common shares underlying DSUs issued. The Company has reserved for issuance up to 100,000 common shares under the DSU Plan and 21,183 DSUs were outstanding at December 31, 2018 and 2017.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Stock option plan</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The DiaMedica Therapeutics Inc. Stock Option Plan Amended and Restated November 6, 2018 (the &ldquo;Option Plan&rdquo;) allows the Board of Directors from time to time, in its sole discretion, and in accordance with the requirements of the Nasdaq Stock Market, to grant the Company&rsquo;s directors, officers, employees and certain consultants (as such terms are used in the Option Plan) non-transferable options to purchase common shares. The shareholders approved the adoption of the Option Plan on September 22, 2011, which was then amended and restated on October 23, 2015, December 21, 2017 and November 6, 2018. The number of common shares reserved for issuance under the Option Plan at any time is equal to the lesser of: 783,918 (subject to adjustment) and 10% of the issued common shares at the relevant time and the aggregate number of common shares reserved for issuance under any other compensation or incentive mechanism or plan (including deferred share unit plans or employee stock option plans, if any), shall not exceed 10% of our issued shares at the relevant time. In addition, the maximum number of common shares that may be issued under the Option Plan upon the exercise of incentive stock options within the meaning of Section 422 of the United States Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;) is 283,918 shares (subject to adjustment).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">96</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of December 31, 2018, options to purchase 639,359 common shares were outstanding. Options granted vest at various rates and have terms of up to 10 years. As the TSX Venture Exchange was the principal trading market for the Company&rsquo;s common shares, all options previously granted under the Option Plan have been priced in Canadian dollars.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The aggregate number of common shares reserved for issuance under the Option Plan and the DSU Plan as of December 31, 2018 was 783,918.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Share-based compensation expense for each of the periods presented is as follows (in thousands):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825577418">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31,</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31, </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">170</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">60</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">450</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">349</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total share-based compensation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">620</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">409</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We recognize share-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A summary of option activity is as follows (in thousands except share and per share amounts):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825577419">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Shares</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Underlying</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Options</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Weighted</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Average Exercise</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Price Per Share</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>(CAD$)</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Aggregate</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Intrinsic Value</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>(CAD$)</b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at December 31, 2016</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">427,850</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.68</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">187</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Granted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">127,635</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.11</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Exercised</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.00</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Expired/cancelled</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(72,450</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13.29</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeited</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at December 31, 2017</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">480,035</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.45</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">674</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Granted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">196,800</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11.08</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Exercised</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16,954</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.29</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Expired/cancelled</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeited</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(20,522</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.99</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at December 31, 2018</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">639,359</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7.87</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">97</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A summary of the status of our unvested shares during the year ended and as of December 31, 2018 is as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825577420">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Shares Under</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Option</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Weighted Average Grant Date Fair Value Per Share</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>(CAD$)</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2017</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">216,793</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.69</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Granted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">196,800</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.30</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Vested</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(150,739</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.48</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeitures</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(20,522</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7.27</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2018</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">242,332</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7.45</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Information about stock options outstanding, vested and expected to vest as of December 31, 2018, is as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825577422">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td colspan="10" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11011100000%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Outstanding, Vested and Expected to Vest</b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td id=".lead.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td colspan="6" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 110111%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Options Vested and Exercisable</b></b></p>
			</td>
			<td id=".trail.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td colspan="3" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 163%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Per Share Exercise</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Price</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Shares</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Weighted </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Average </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Remaining</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Contractual </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Life (Years)</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Weighted </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Average </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Exercise Price </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>(CAD$)</b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Options </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Exercisable</b></b></p>
			</td>
			<td id=".trail.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td id=".lead.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Weighted</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Average </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Remaining </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Contractual </b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Life (Years)</b></b></p>
			</td>
			<td id=".trail.D6" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$2.00</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;">-</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">$2.60</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.8</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.00</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,000</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.8</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$2.80</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;">-</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">$3.20</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">125,400</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.9</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.00</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">125,400</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.9</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$3.40</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;">-</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">$5.20</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">130,405</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.0</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.12</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">91,239</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.0</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$5.40</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;">-</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">$10.20</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">98,063</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.5</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.39</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,563</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.5</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$10.40</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;">-</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">$34.00</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">235,491</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8.2</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13.86</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">79,825</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.6" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5.9</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">639,359</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7.8</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.4" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7.87</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.5" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">397,027</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.6" style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7.1</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The cumulative grant date fair value of employee options vested during the years ended December 31, 2018 and 2017 was $508,000 and $213,000, respectively. Total proceeds received for options exercised during the years ended December 31, 2018 and 2017 were $43,000 and $7,000, respectively.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of December 31, 2018 and 2017, total compensation expense related to unvested employee stock options not yet recognized was $1.4 million and $551,000, respectively, which is expected to be allocated to expenses over a weighted-average period of 2.01 and 1.97 years, respectively.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The aggregate intrinsic value of stock options exercised during the years ended December 31, 2018 and 2017 was $104,000 and 12,000, respectively.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by the Company for the years ended December 31, 2018 and 2017:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825577423">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td colspan="3" id=".amt.D2" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 53%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
			<td colspan="3" id=".amt.D3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 53%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Common share fair value</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">$8.84</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$9.33</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">$5.20</td>
			<td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$8.40</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;2.1</td>
			<td id=".amt.2" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&ndash;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.2%</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;</td>
			<td id=".amt.3" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">1.1%</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;</td>
			<td id=".amt.2" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;</td>
			<td id=".amt.3" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected option life</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;4.8</td>
			<td id=".amt.2" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&ndash;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.0</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;</td>
			<td id=".amt.3" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.5</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;123.5</td>
			<td id=".amt.2" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&ndash;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">135.7%</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&nbsp;84.7</td>
			<td id=".amt.3" style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&ndash;</td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">156.8%</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">98</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><i>Nonemployee share-based compensation</i></b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We account for stock options granted to nonemployees in accordance with FASB ASC 505. In connection with stock options granted to nonemployees, we recorded $205,000 and $308,000 for nonemployee share-based compensation during the years ended December 31, 2018 and 2017, respectively.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">These amounts were based upon the fair values of the vested portion of the grants. Amounts expensed during the remaining vesting period will be determined based on the fair value at the time of vesting.</p>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="52220" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825588326">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>13.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Employee Benefit Plan</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We maintain an employee 401(k) retirement savings plan (the &ldquo;401(k) Plan&rdquo;). The 401(k) Plan provides eligible employees with an opportunity to make tax-deferred contributions into a long-term investment and savings program. All employees over the age of 21 may elect to participate in the 401(k) Plan beginning on their hire date. The 401(k) Plan allows eligible employees to contribute a portion of their annual compensation, subject only to maximum limits required by law. We contribute an amount equal to 4% of each employees&rsquo; compensation under the safe harbor provisions provided by the Internal Revenue Service rules governing 401(k) plans. Employee and employer safe harbor contributions vest immediately.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have recorded contribution expenses of $45,000 and $33,000 for the years ended December&nbsp;31, 2018 and 2017, respectively.</p>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="52221" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1552825601762">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>14.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Income Taxes</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company has incurred net operating losses since inception. The Company has not reflected the benefit of net operating loss carryforwards in the accompanying financial statements and has established a full valuation allowance against its deferred tax assets.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as operating losses and tax credit carryforwards.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The significant components of our deferred tax assets and liabilities are as follows (in thousands):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825601758">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets (liabilities):</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Non-capital losses carried forward</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,280</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,233</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Research and development expenditures</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">887</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">887</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Share issue costs</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">529</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">117</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Patents and other</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">293</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">319</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Accruals</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(97</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Property and equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Total deferred tax asset, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,886</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,552</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Valuation allowance</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(10,886</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,552</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax asset</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that the deferred tax assets arising from the above-mentioned future tax benefits are currently not likely to be realized and, accordingly, we have provided a full valuation allowance.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">99</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The reconciliation of the Canadian statutory income tax rate applied to the net loss for the year to the income tax expense is as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825601759">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Year Ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Statutory income tax rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27.0</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27.0</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax recovery based on statutory rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,119</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,160</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Share-based compensation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">243</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">110</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gain on revaluation of warrant liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(450</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Australian research and development incentive</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">103</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">314</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">172</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">204</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in unrecognized temporary differences</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,131</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">534</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(80</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Net operating losses and tax credit carryforwards as of December 31, 2018, are as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1552825601760">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Amount</b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>(In thousands)</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Expiration Years</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-capital income tax losses, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32,002</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Beginning 2026</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development expense carry forwards</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,284</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Indefinitely</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tax credits</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">525</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&nbsp;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Beginning 2020</p>
			</td>
		</tr>

</table>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company is subject to taxation in the Canada, the United States and Australia. Tax returns, since the inception of DiaMedica Therapeutics Inc. are subject to examinations by Canadian tax authorities and may change upon examination. Tax returns of DiaMedica USA, Inc., since its inception in 2012 and thereafter, are subject to examination by the U.S. federal and state tax authorities. Tax returns of DiaMedica Therapeutics Australia Pty Ltd., since its inception in 2016 and thereafter, are subject to examination by the Australian tax authorities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">100</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>
</div>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div contenteditable="false" docsect="10" id="52222" sectdesc="MD&amp;A to end of document">&nbsp;</div>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 9.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">None.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 9A.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Controls and Procedures</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the United States Securities Exchange Act of 1934, as amended (&ldquo;Exchange Act&rdquo;)) that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC&rsquo;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of its Chief Executive Officer and its Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of such period to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&rsquo;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Management&rsquo;s Report on Internal Control over Financial Reporting</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">This annual report on Form 10-K does not include a report of management&rsquo;s assessment regarding internal control over financial reporting or an attestation report of our registered independent public accounting firm due to a transition period established by rules of the SEC for newly public companies.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Changes in Internal Control over Financial Reporting</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">There was no change in our internal control over financial reporting that occurred during the fourth quarter ended December 31, 2018 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 9B.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Other Information</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>DiaMedica Therapeutics Inc. 2018 Short-Term Incentive Payouts</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On March 14, 2019, the Compensation Committee (the &ldquo;Compensation Committee&rdquo;) of the Board of Directors of DiaMedica Therapeutics Inc. approved payouts under DiaMedica&rsquo;s 2018 Short-Term Incentive (&ldquo;STI&rdquo;) program for our executive officers.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In addition to base compensation, we provide our named executive officers the opportunity to earn short-term incentive (STI) compensation based on the achievement of certain annual corporate and individual related performance goals. Our STI program directly aligns the interests of our executive officers and shareholders by providing an incentive for the achievement of key corporate and individual performance objectives that are critical to the success of our company and linking a significant portion of each executive&rsquo;s annual compensation to the achievement of such objectives.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Under the 2018 STI program, each executive officer named in our most recent Summary Compensation Table (&ldquo;named executive officer&rdquo;) had a target incentive percentage that was a percentage of his base salary:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 96%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt auto 0pt 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 49%; border-bottom: thin solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Name</b></p>
			</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 49%; border-bottom: thin solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Percentage of Salary Base</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 49%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Rick Pauls</p>
			</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 49%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">50%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 49%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Scott Kellen</p>
			</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 49%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">30%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 49%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Todd Verdoorn</p>
			</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 49%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">30%</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2018 STI payouts were based on the achievement of two pre-established corporate performance objectives that related to regulatory and clinical milestones and three to five pre-established individual performance objectives. Mr. Paul&rsquo;s individual performance objectives for fiscal 2018 related to raising additional financing, building the executive team and obtaining a U.S. Nasdaq listing. Mr. Kellen&rsquo;s individual performance objectives for fiscal 2018 related to raising additional financing, financial accounting objectives and obtaining a U.S. Nasdaq listing. Mr. Verdoorn&rsquo;s individual performance objectives for fiscal 2018 related to research and development objectives.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The table below sets forth the overall achievement percentage by each named executive officer of their performance objectives and their respective 2018 STI payout:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" class="finTable" style="width: 96%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin: 0pt auto 0pt 0pt;">

		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 58%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Name</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Achievement Percentage</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2018 STI Payout</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Rick Pauls</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">95.0%</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">$</td>
			<td id=".amt.3" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">163,875</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Scott Kellen</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">97.5%</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".amt.3" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">70,200</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Todd Verdoorn</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">50.0%</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".amt.3" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">36,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">102</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>PART III</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 10.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Directors, Executive Officers and Corporate Governance</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Directors</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The information in the &ldquo;Voting Proposal One &ndash; Election of Directors&rdquo; section of our definitive proxy statement to be filed with the SEC with respect to our next annual general meeting of shareholders, which involves the election of directors, is incorporated in this annual report on Form 10-K by reference.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Executive Officers</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Information concerning our executive officers is included in this annual report on Form 10-K under Item 1 of Part I under &ldquo;Executive Officers.&rdquo;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Section 16(a) Beneficial Ownership Reporting Compliance</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The information in the &ldquo;Stock Ownership&mdash;Section 16(a) Beneficial Ownership Reporting Compliance&rdquo; section of our definitive proxy statement to be filed with the SEC with respect to our next annual general meeting of shareholders, which involves the election of directors, is incorporated in this annual report on Form 10-K by reference.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Code of Ethics</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have adopted a code of business conduct and ethics applicable to all of our directors, officers and employees, in accordance with Section 406 of the Sarbanes-Oxley Act, the rules of the SEC promulgated thereunder, and the Nasdaq Listing Rules. In the event that any changes are made or any waivers from the provisions of the code of business conduct and ethics are made, these events would be disclosed on our website or in a report on Form 8-K within four business days of such event. The code of business conduct and ethics is posted on our website at www.diamedica.com. Copies of the code of business conduct and ethics will be provided free of charge upon written request directed to Investor Relations, DiaMedica Therapeutics Inc., 2 Carlson Parkway, Suite 260, Minneapolis, Minnesota 55447.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Changes to Nomination Procedures</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During the fourth quarter of fiscal 2018, we made no material changes to the procedures by which shareholders may recommend nominees to the Company&rsquo;s Board of Directors.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Audit Committee Matters</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The information in the &ldquo;Corporate Governance&mdash;Audit Committee&rdquo; section of our definitive proxy statement to be filed with the SEC with respect to our next annual general meeting of shareholders, which involves the election of directors, is incorporated in this annual report on Form 10-K by reference.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 11.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Executive Compensation</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The information in the &ldquo;Director Compensation&rdquo; and &ldquo;Executive Compensation&rdquo; sections of our definitive proxy statement to be filed with the SEC with respect to our next annual general meeting of shareholders, which involves the election of directors, is incorporated in this annual report on Form 10-K by reference.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">103</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 54pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 12.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Stock Ownership</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The information in the &ldquo;Stock Ownership&mdash;Security Ownership of Certain Beneficial Owners&rdquo; and &ldquo;Stock Ownership&mdash;Security Ownership of Management&rdquo; sections of our definitive proxy statement to be filed with the SEC with respect to our next annual general meeting of shareholders, which involves the election of directors, is incorporated in this annual report on Form 10-K by reference.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Securities Authorized for Issuance under Equity Compensation Plans</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table summarizes outstanding options and other awards under our equity compensation plans as of December 31, 2018. Our equity compensation plans as of December 31, 2018 were the DiaMedica Therapeutics Inc. Stock Option Plan Amended and Restated November 6, 2018 and the DiaMedica Therapeutics Inc. Amended and Restated Deferred Share Unit Plan.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>(a)</b></b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>(b)</b></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>(c)</b></b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 37%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Plan Category</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Number of Securities </b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>to be Issued Upon </b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Exercise of </b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Outstanding Options, </b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Warrants and Rights</b></b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Weighted-Average </b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Exercise Price of </b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Outstanding</b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Options, Warrants </b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>and Rights</b></b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Number of Securities </b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Remaining Available for</b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Future Issuance Under </b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Equity Compensation </b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>Plans (excluding </b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>securities reflected in </b></b></b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b><b>column (a))</b></b></b></p>
			</td>
			<td id=".trail.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Equity compensation plans approved by security holders</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">660,542<sup>(1)</sup></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">$</td>
			<td id=".amt.3" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">7.87<sup>(2)</sup></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".amt.4" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">123,376<sup>(3)</sup></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Equity compensation plans not approved by security holders</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.2" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td id=".amt.3" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; padding-bottom: 1px;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td id=".amt.4" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Total</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">660,542<sup>(1)</sup></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">$</td>
			<td id=".amt.3" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">7.87</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&nbsp;</td>
			<td id=".amt.4" style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">123,376<sup>(3)</sup></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Amount includes 639,359 common shares issuable upon the exercise of stock options outstanding as of December 31, 2018 under the DiaMedica Therapeutics Inc. Stock Option Plan Amended and Restated November 6, 2018 and 21,183 common shares issuable under the DiaMedica Therapeutics Inc. Amended and Restated Deferred Share Unit Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Not included in the weighted-average exercise price calculation are 21,183 DSU awards.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3)</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Amount includes 123,376 shares remaining available at December 31, 2018 for future issuance under DiaMedica Therapeutics Inc. Stock Option Plan Amended and Restated November 6, 2018 and the DiaMedica Therapeutics Inc. Amended and Restated Deferred Share Unit Plan. Of these shares, a maximum of 78,817 common shares are available at December 31, 2018 for future issuance under the Deferred Share Unit Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">104</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 13.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Certain Relationships and Related Transactions, and Director Independence</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The information in the &ldquo;Related Person Relationships and Transactions&rdquo; and &ldquo;Corporate Governance&mdash;Director Independence&rdquo; sections of our definitive proxy statement to be filed with the SEC with respect to our next annual general meeting of shareholders, which involves the election of directors, is incorporated in this annual report on Form 10-K by reference.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 14.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Principal Accounting Fees and Services</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The information in the &ldquo;Voting Proposal Four&mdash;Appointment of Baker Tilly Virchow Krause, LLP as our Independent Registered Public Accounting Firm and Authorization of the Board of Directors to Fix the Auditors&rsquo; Remuneration&mdash;Audit, Audit-Related, Tax and Other Fees&rdquo; and &ldquo;Voting Proposal Four&mdash;Appointment of Baker Tilly Virchow Krause, LLP as our Independent Registered Public Accounting Firm and Authorization of the Board of Directors to Fix the Auditors&rsquo; Remuneration&mdash;&mdash;Audit Committee Pre-Approval Policies and Procedures&rdquo; sections of our definitive proxy statement to be filed with the SEC with respect to our next annual general meeting of shareholders, which involves the election of directors, is incorporated in this annual report on Form 10-K by reference.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">105</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%; margin: 0pt;">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>PART IV</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 15.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Exhibits, Financial Statement Schedules</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Financial Statements</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our consolidated financial statements are included in <i>&ldquo;Part III, Item 8. Financial Statements and Supplementary Data.&rdquo;</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Financial Statement Schedules</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">All financial statement schedules are omitted because they are inapplicable since we are a smaller reporting company.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Exhibits</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The exhibits being filed or furnished with this report are listed below, along with an indication as to each management contract or compensatory plan or arrangement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A copy of any exhibits listed or referred to herein will be furnished at a reasonable cost to any person who is a shareholder upon receipt from any such person of a written request for any such exhibit. Such request should be sent to: Mr. Scott Kellen, Chief Financial Officer and Corporate Secretary, DiaMedica Therapeutics Inc., 2 Carlson Parkway, Suite 260, Minneapolis, Minnesota 55447, Attn: Shareholder Information.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 8%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item No.</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Method of Filing</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">1.1</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918021894/ex_131385.htm" style="-sec-extract:exhibit;">Underwriting Agreement dated December 6, 2018 between Craig-Hallum Capital Group LLC and DiaMedica Therapeutics Inc.</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 1.1 to DiaMedica&rsquo;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on December 11, 2018<br>
			(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">3.1</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128093.htm" style="-sec-extract:exhibit;">Certificate of Continuance of DiaMedica Therapeutics Inc. dated April 11, 2016</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 3.1 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">3.2</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128094.htm" style="-sec-extract:exhibit;">Certificate of Amendment of DiaMedica Therapeutics Inc. dated December 28, 2016</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 3.2 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">3.3</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128095.htm" style="-sec-extract:exhibit;">Certificate of Amendment of DiaMedica Therapeutics Inc. dated September 24, 2018 </a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 3.3 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">106</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 8%; border-bottom: thin solid rgb(0, 0, 0);"><b>Item No.</b></td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; border-bottom: thin solid rgb(0, 0, 0);"><b>Item</b></td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; border-bottom: thin solid rgb(0, 0, 0); text-align: center;"><b>Method of Filing</b></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">3.4</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918021086/ex_129907.htm" style="-sec-extract:exhibit;">Certificate of Amendment of DiaMedica Therapeutics Inc. dated November 15, 2018</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 3.4 to DiaMedica&rsquo;s Registration Statement on Form S-1/A as filed with the Securities and Exchange Commission on November 19, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">3.5</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128096.htm" style="-sec-extract:exhibit;">By-Law No. 1 and 2 of DiaMedica Therapeutics Inc. as amended and restated on September 30, 2018</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 3.5 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">4.1</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128097.htm" style="-sec-extract:exhibit;">Investment Agreement between Hermeda Industrial Co., Ltd. and DiaMedica Inc. dated July 16, 2016 </a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 4.1 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">4.2</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128098.htm" style="-sec-extract:exhibit;">Shareholder Rights Plan Agreement dated December 21, 2017 by and between DiaMedica Therapeutics Inc. and Computershare Investor Services Inc.</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 4.2 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">4.9</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128105.htm" style="-sec-extract:exhibit;">Form of Investor Warrant issued in connection with the March 2018 private placement</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 4.9 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">4.10</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128106.htm" style="-sec-extract:exhibit;">Form of Broker Warrant issued in connection with the March 2018 private placement</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 4.10 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">4.11</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128107.htm" style="-sec-extract:exhibit;">Form of Investor Warrant issued in connection with the December 2017 private placement</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 4.11 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">107</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 8%; border-bottom: thin solid rgb(0, 0, 0);"><b>Item No.</b></td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; border-bottom: thin solid rgb(0, 0, 0);"><b>Item</b></td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; border-bottom: thin solid rgb(0, 0, 0); text-align: center;"><b>Method of Filing</b></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">4.12</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918021894/ex_131397.htm" style="-sec-extract:exhibit;">Warrant dated December 11, 2018 issued by DiaMedica Therapeutics Inc. to Craig-Hallum Capital Group LLC&nbsp;</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.1 to DiaMedica&rsquo;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on December 11, 2018<br>
			(File No. 001-36291)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">4.13</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918021086/ex_129908.htm" style="-sec-extract:exhibit;">Specimen Certificate representing common shares of DiaMedica Therapeutics Inc.</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 4.13 to DiaMedica&rsquo;s Registration Statement on Form S-1/A as filed with the Securities and Exchange Commission on November 19, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.1#</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128111.htm" style="-sec-extract:exhibit;">DiaMedica Therapeutics Inc. Stock Option Plan Amended and Restated November 6, 2018</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.1 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.2#</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128109.htm" style="-sec-extract:exhibit;">Form of Option Agreement under the DiaMedica Therapeutics Inc. Stock Option Plan Amended and Restated December 21, 2017</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.2 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.3#</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128690.htm" style="-sec-extract:exhibit;">Form of Option Agreement under the DiaMedica Therapeutics Inc. Stock Option Plan Amended and Restated November 6, 2018</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.3 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.4#</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128110.htm" style="-sec-extract:exhibit;">DiaMedica Therapeutics Inc. Amended and Restated Deferred Share Unit Plan</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.4 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.5#</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128112.htm" style="-sec-extract:exhibit;">Form of Indemnification Agreement</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.5 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">108</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 8%; border-bottom: thin solid rgb(0, 0, 0);"><b>Item No.</b></td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; border-bottom: thin solid rgb(0, 0, 0);"><b>Item</b></td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; border-bottom: thin solid rgb(0, 0, 0); text-align: center;"><b>Method of Filing</b></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.6#</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128113.htm" style="-sec-extract:exhibit;">Employment Agreement by and between DiaMedica Therapeutics Inc. and Rick Pauls</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.6 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.7#</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_137868.htm" style="-sec-extract:exhibit;">Employment Agreement by and between DiaMedica Therapeutics Inc. and Scott Kellen</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Filed herewith</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.8#</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128114.htm" style="-sec-extract:exhibit;">Employment Agreement by and between DiaMedica Therapeutics Inc. and Todd Verdoorn, Ph.D.</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.7 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.9#</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_137869.htm" style="-sec-extract:exhibit;">Employment Agreement by and between DiaMedica Therapeutics Inc. and Harry Alcorn, Ph.D.</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.10</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128115.htm" style="-sec-extract:exhibit;">Two Carlson Parkway Office Lease between One Two Holdings LLC and DiaMedica USA Inc. dated September 18, 2015</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.8 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.11</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128116.htm" style="-sec-extract:exhibit;">Supplemental to Lease Agreement between One Two Holdings LLC and DiaMedica USA Inc. dated December 16, 2015</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.9 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.12</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128117.htm" style="-sec-extract:exhibit;">First Amendment to Lease between One Two Holdings LLC and DiaMedica USA Inc. dated May 3, 2017</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.10 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.13</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128118.htm" style="-sec-extract:exhibit;">Second Amendment to Lease between One Two Holdings LLC and DiaMedica USA Inc. dated September 5, 2017</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.11 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">109</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 8%; border-bottom: thin solid rgb(0, 0, 0);"><b>Item No.</b></td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; border-bottom: thin solid rgb(0, 0, 0);"><b>Item</b></td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; border-bottom: thin solid rgb(0, 0, 0); text-align: center;"><b>Method of Filing</b></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.14<sup>(1)</sup></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128119.htm" style="-sec-extract:exhibit;">GPEx<sup>&reg; </sup>- Derived Cell Line Sale Agreement between DiaMedica Therapeutics Inc. and Catalent Pharma Solutions, LLC dated February 2, 2012<sup>&nbsp;</sup></a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.12 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.15</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128120.htm" style="-sec-extract:exhibit;">First Amendment to GPEx<sup>&reg; </sup>Development and Manufacturing Agreement between DiaMedica Therapeutics Inc. and Catalent Pharma Solutions, LLC dated April 10, 2017</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.13 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.16<sup>(1)</sup></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128121.htm" style="-sec-extract:exhibit;">License and Collaboration Agreement between DiaMedica Therapeutics Inc. and Ahon Pharmaceutical Co., Ltd. dated September 27, 2018</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.14 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10.17<sup>(1)</sup></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/1401040/000143774918020300/ex_128122.htm" style="-sec-extract:exhibit;">Supply Agreement between DiaMedica Therapeutics Inc. and Ahon Pharmaceutical Co., Ltd. dated September 27, 2018</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Incorporated by reference to Exhibit 10.15 to DiaMedica&rsquo;s Registration Statement on Form S-1 as filed with the Securities and Exchange Commission on November 9, 2018 (File No. 333-228313)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">21.1</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_137957.htm" style="-sec-extract:exhibit;">Subsidiaries of DiaMedica Therapeutics Inc.</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">23.1</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_137958.htm" style="-sec-extract:exhibit;">Consent of Baker Tilly Virchow Krause, LLP</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">31.1</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_137959.htm" style="-sec-extract:exhibit;">Certification of President and Chief Executive Officer Pursuant to SEC Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">31.2</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_137960.htm" style="-sec-extract:exhibit;">Certification of Chief Financial Officer Pursuant to SEC Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">32.1</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_137961.htm" style="-sec-extract:exhibit;">Certification of President and Chief Executive Officer Pursuant to Rule 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Furnished herewith</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">32.2</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_137962.htm" style="-sec-extract:exhibit;">Certification of Chief Financial Officer Pursuant to Rule 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Furnished herewith</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">110</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 8%; border-bottom: thin solid rgb(0, 0, 0);"><b>Item No.</b></td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; border-bottom: thin solid rgb(0, 0, 0);"><b>Item</b></td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; border-bottom: thin solid rgb(0, 0, 0); text-align: center;"><b>Method of Filing</b></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">101</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following materials from DiaMedica Therapeutics Inc.&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2018, formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Income (Loss), (iv) the Consolidated Statements of Equity, (v) the Consolidated Statements of Cash Flows, and (vi)&nbsp;Notes to Consolidated Financial Statements</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Filed herewith</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">#</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Indicates a management contract or compensatory plan or arrangement.</p>
			</td>
		</tr>

</table>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup>(1)</sup></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Portions of this exhibit have been redacted and are subject to an order granting confidential treatment under Rule 406 of the United States Securities Act of 1933, as amended (File No. 333-228313, CF #36833). The redacted material was filed separately with the Securities and Exchange Commission.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 63pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Item 16.</b></td>
			<td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Form 10-K Summary</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">None.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">111</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>SIGNATURES</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin-top: 0; margin-bottom: 0;"><b>DIAMEDICA THERAPEUTICS INC.</b></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;">Date: March 19, 2019</p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>Rick Pauls</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;">Rick Pauls</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;">President and Chief Executive Officer</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:Infinity%;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 38%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Name</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Title</b></p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Rick Pauls</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">President, Chief Executive Officer and Director</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">March 19, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">Rick Pauls</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">(principal executive officer)</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Scott Kellen</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer and Secretary</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">March 19, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">Scott Kellen</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">(principal financial and accounting officer)</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Richard Pilnik</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chairman of the Board</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">March 19, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">Richard Pilnik</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Michael Giuffre, M.D.</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Director</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">March 19, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">Michael Giuffre, M.D.</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ James Parsons</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Director</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">March 19, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">James Parsons</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Zhenyu Xiao, Ph.D.</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Director</p>
			</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">March 19, 2019</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38%;">Zhenyu Xiao, Ph.D.</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 43%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">112</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>ex_137868.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<html>
<head>
	<title>ex_137868.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2019 9:56:02 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.7</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>EMPLOYMENT AGREEMENT</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">This Employment Agreement (&ldquo;<u>Agreement</u>&rdquo;) is effective as of September 12, 2018 (&ldquo;<u>Effective Date</u>&rdquo;), by and between DiaMedica USA, Inc. a Delaware corporation (the &ldquo;<u>Company</u>&rdquo;), and Scott Kellen, an individual (&ldquo;<u>Executive</u>&rdquo;). The Company and Executive are sometimes referred to as the &ldquo;<u>Parties</u>&rdquo; or &ldquo;<u>Party</u>&rdquo; in this Agreement, and the Company may designate the parent company of the Company or a subsidiary to be the employer of the Executive.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In consideration of the mutual promises, covenants and agreements contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>1.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>EMPLOYMENT AND DUTIES.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Job Title and Responsibilities</u>. The Company hereby employs Executive, and Executive hereby agrees to be employed, as Chief Financial Officer (together with such other position or positions consistent with Executive&rsquo;s title as the Company&rsquo;s Chief Executive Officer may specify from time to time), reporting to the Company&rsquo;s Chief Executive Officer and will have such duties and responsibilities commensurate with such title. The Parties understand, acknowledge and agree that Executive may also serve in similar positions with the parent company of the Company or any subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Full-Time Best Efforts</u>. Executive agrees to devote Executive&rsquo;s full professional time and attention to the business of the Company (and its subsidiaries, affiliates, or related entities) and the performance of Executive&rsquo;s obligations under this Agreement, and will at all times faithfully, industriously and to the best of Executive&rsquo;s ability, experience and talent, perform all of Executive&rsquo;s obligations hereunder. Executive shall not, at any time during Executive&rsquo;s employment by the Company, directly or indirectly, act as a partner, officer, director, consultant or Executive, or provide services in any other capacity to any other business enterprise that conflicts with the Company&rsquo;s business or Executive&rsquo;s duty of loyalty to the Company. Executive shall seek the written consent of the Company prior to accepting any outside board positions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Duty of Loyalty</u>. Executive acknowledges that during Executive&rsquo;s employment with the Company, Executive has participated in and will participate in relationships with existing and prospective clients, customers, partners, suppliers, service providers and vendors of the Company that are essential elements of the Company&rsquo;s goodwill. The parties acknowledge that Executive owes the Company a fiduciary duty to conduct all affairs of the Company in accordance with all applicable laws and the highest standards of good faith, trust, confidence and candor, and to endeavor, to the best of Executive&rsquo;s ability, to promote the best interests of the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conflict of Interest</u>. Executive agrees that while employed by the Company, and except with the advance written consent of the Board, Executive will not enter into, on behalf of the Company, or cause the Company or any of its affiliates to enter into, directly or indirectly, any transactions with any business organization in which Executive or any member of Executive&rsquo;s immediate family may be interested as a shareholder, partner, member, trustee, director, officer, employee, consultant, lender or guarantor or otherwise; <u>provided</u>, <u>however</u>, that nothing in this Agreement shall restrict transactions between the Company and any company whose stock is listed on a national securities exchange or actively traded in the over-the-counter market and over which Executive does not have the ability to control or significantly influence policy decisions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>2.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>COMPENSATION. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Base Pay</u>. The Company agrees to pay Executive gross annual compensation of $240,000 (&ldquo;<u>Base Salary</u>&rdquo;), less usual and customary withholdings, which shall be payable in arrears in accordance with the Company&rsquo;s customary payroll practices. The Base Salary will be subject to normal periodic review, and such review will consider Executive&rsquo;s contributions to the Company and the Company&rsquo;s overall performance.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Bonus and Incentive Compensation</u>. Executive shall be eligible for discretionary bonus and incentive based compensation approved by the Board of Directors of the Company (or a committee thereof) (the &ldquo;<u>Board</u>&rdquo;) from time to time at its sole discretion as to eligibility and timing of payments.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Equity Award</u>. Subject to approval by the Board (or a committee thereof), Executive shall be eligible to receive equity-based compensation awards from time to time as determined by the Board pursuant to the DiaMedica Therapeutics Inc. Stock Option Plan, or any successor plan thereto (such plan, the &ldquo;<u>Plan</u>&rdquo;). The type of equity award(s), grant timing and vesting terms will be in the sole discretion of the Board (or a committee thereof).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Benefits</u>. During Executive&rsquo;s employment, Executive will be eligible to participate in the Company&rsquo;s benefit programs, as governed by the terms of the official plan documents. Executive acknowledges that the Company may amend or terminate any of its benefit plans or programs at any time and for any reason. Executive will be eligible for paid time off or PTO per year, in accordance with the Company&rsquo;s policies in effect from time to time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Clawback</u>. Executive agrees that any incentive or other compensation or benefits provided by the Company under this Agreement or otherwise&nbsp;will be subject to recoupment or clawback by the Company under any applicable clawback or recoupment policy of the Company as may be in effect from time to time or as required by applicable law, regulation or stock exchange listing requirement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>3.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>CONFIDENTIAL INFORMATION.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Disclosure, Non-Use and Definition of Confidential Information</u>. Executive understands that during Executive&rsquo;s employment relationship with the Company, the Company intends to provide Executive with information, including Confidential Information (as defined herein), without which Executive would not be able to perform Executive&rsquo;s duties to the Company. Executive agrees, at all times during the term of Executive&rsquo;s employment relationship and thereafter, to hold in strictest confidence, and not to use or disclose, except for the benefit of the Company to the extent necessary to perform Executive&rsquo;s obligations to the Company, any Confidential Information that Executive obtains, accesses or creates during the term of the relationship, whether or not during working hours, until such Confidential Information becomes publicly and widely known and made generally available through no wrongful act of Executive or of others under confidentiality obligations as to the information involved. Executive understands that &ldquo;<u>Confidential Information</u>&rdquo; means information and physical material not generally known or available outside the Company and information and physical material entrusted to the Company by third parties under an obligation of non-disclosure or non-use or both. &ldquo;<u>Confidential Information</u>&rdquo; includes, without limitation, inventions, technical data, trade secrets, know-how, clinical data, regulatory information and strategies, marketing ideas or plans, research, product or service ideas or plans, business strategies, investments, investment opportunities, potential investments, market studies, industry studies, historical financial data, financial information and results, budgets, identity of customers, forecasts (financial or otherwise), possible or pending transactions, customer lists and domain names, price lists, and pricing methodologies. Any information that Executive knows or should reasonably know is Confidential Information, or that Employer treats as Confidential Information, will be presumed to be Confidential Information.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exceptions</u>. At all times, both during Executive&rsquo;s employment and after its termination, Executive will keep and hold all such Confidential Information in strict confidence and trust. Executive will not use or disclose any Confidential Information without the prior written consent of the Company, except as may be necessary to perform Executive&rsquo;s duties as an Executive of the Company for the benefit of the Company. Executive may disclose information that Executive is required to disclose by valid order of a government agency or court of competent jurisdiction, <u>provided</u> that Executive will:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notify the Company in writing immediately upon learning that such an order may be sought or issued,</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooperate with the Company as reasonably requested if the Company seeks to contest such order or to place protective restrictions on the disclosure pursuant to such order, and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comply with any protective restrictions in such order and disclose only the information specified in the order.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp; &nbsp; &nbsp;&nbsp;<u>Return of Confidential Information</u>. Upon termination of employment with the Company, Executive will promptly deliver to the Company all documents and materials of any nature pertaining to Executive&rsquo;s work with the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Copyright Information</u>. Executive agrees not to infringe the copyrights of the Company, its customers or third parties (including, without limitation, Executive&rsquo;s previous employers, customers, etc.) by unauthorized or unlawful copying, modifying or distributing of copyrighted material, including plans, drawings, reports, financial analyses, market studies, computer software and the like.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>4.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>COVENANT NOT TO COMPETE. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Competition Covenant.</u> Executive agrees that during the Restricted Period (as defined below), without the prior written consent of the Company, Executive shall not, directly or indirectly within the Territory (as defined below): (i) personally, by agency, as an Executive, independent contractor, consultant, officer, director, manager, agent, associate, investor (other than as a passive investor holding less than five percent (5%) of the outstanding equity of an entity), or by any other artifice or device, engage in any Competitive Business (as defined below), (ii) assist others, including but not limited to Executives of the Company, to engage in any Competitive Business, or (iii) own, purchase, finance or organize a Competitive Business.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<u>Competitive Business</u>&rdquo; means (i) any person, entity or organization which is engaged in, consulting regarding or engaged in the development, production, marketing or selling of any pharmaceutical-based product, process, technology, invention or service which resembles, competes with or is intended to resemble or compete with a product, process, technology, device, invention or service under or being considered for research or development or being promoted, marketed, sold or serviced by the Company or any subsidiary; or (ii) any other line of business that the Company or any subsidiary, is actively preparing to pursue at any time during the term of Executive&rsquo;s employment with the Company and in which Executive is involved.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<u>Territory</u>&rdquo; means the United States of America or locations where the Company is directly or indirectly developing or selling products or services.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<u>Restricted Period</u>&rdquo; means the period of Executive&rsquo;s employment with the Company and for a period of twelve (12) months following the termination of Executive&rsquo;s employment.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>5.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>NON-SOLICITATION AND NON-INTERFERENCE COVENANTS. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Solicitation of Employees and Others</u>. During the Restricted Period, (i)&nbsp;Executive shall not, directly or indirectly, solicit, recruit, or induce, or attempt to solicit, recruit or induce any employee, consultant, independent contractor, vendor, supplier, or agent to terminate or otherwise adversely affect his or her employment or other business relationship (or prospective employment or business relationship) with the Company, and (ii) Executive shall not, directly or indirectly, solicit, recruit, or induce, or attempt to solicit, recruit or induce any employee to work for Executive or any other person or entity, other than the Company or its affiliates or related entities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Solicitation of Customers</u>. During the Restricted Period, Executive shall not, directly or indirectly, solicit, recruit, or induce any Customer (as defined below) for the purpose of (i)&nbsp;providing any goods or services related to a Competitive Business, or (ii) interfering with or otherwise adversely affecting the contracts or relationships, or prospective contracts or relationships, between the Company (including any related or affiliated entities) and such Customers. &ldquo;<u>Customer</u>&rdquo; means a person or entity with which Executive had contact or about whom Executive gained information while an employee of the Company, and to which the Company was selling or providing products or services, was in active negotiations for the sale of its products or services, or was otherwise doing business as of the date of the cessation of Executive&rsquo;s employment with the Company or for whom the Company had otherwise done business within the twelve (12) month period immediately preceding the cessation of Executive&rsquo;s employment with the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>6.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>ACKNOWLEDGEMENTS. </b>Executive acknowledges and agrees that:<b> </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The geographic and duration restrictions contained in Sections 4 and 5 of this Agreement are fair, reasonable, and necessary to protect the Company&rsquo;s legitimate business interests and trade secrets, given the geographic scope of the Company&rsquo;s business operations, the competitive nature of the Company&rsquo;s business, and the nature of Executive&rsquo;s position with the Company;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive&rsquo;s employment creates a relationship of confidence and trust between Executive and the Company with respect to the Confidential Information, and Executive will have access to Confidential Information (including but not limited to trade secrets) that would be valuable or useful to the Company&rsquo;s competitors;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&rsquo;s Confidential Information is a valuable asset of the Company, and any violation of the restrictions set forth in this Agreement would cause substantial injury to the Company;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The restrictions contained in this Agreement will not unreasonably impair or infringe upon Executive&rsquo;s right to work or earn a living after Executive&rsquo;s employment with the Company ends; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is a contract for the protection of trade secrets under applicable law and is intended to protect the Confidential Information (including trade secrets) identified above.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>7.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>&ldquo;BLUE PENCIL&rdquo; AND SEVERABILITY PROVISION. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">If a court of competent jurisdiction declares any provision of this Agreement invalid, void, voidable, or unenforceable, the court shall reform such provision(s) to render the provision(s) enforceable, but only to the extent absolutely necessary to render the provision(s) enforceable and only in view of the parties&rsquo; express desire that the Company be protected to the greatest possible extent under applicable law from improper competition and the misuse or disclosure of trade secrets and Confidential Information. To the extent such a provision (or portion thereof) may not be reformed so as to make it enforceable, it may be severed and the remaining provisions shall remain fully enforceable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>8.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>INVENTIONS. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Inventions Retained and Licensed</u>. Executive acknowledges and agrees that Executive has no rights in any Inventions (as that term is defined below) other than inventions and information created, discovered or developed by Executive, whether or not patentable or registrable under patent, copyright or similar statutes, made or conceived or reduced to practice or learned by Executive, either alone or with others before Executive&rsquo;s employment with the Company, which list of inventions Executive has provided the Company in writing on or prior to the Effective Date (&ldquo;<u>Prior Inventions</u>&rdquo;). Executive shall not incorporate, or permit to be incorporated, any Prior Invention owned by Executive or in which he has an interest in a Company product, process or machine without the Company&rsquo;s prior written consent. Notwithstanding the foregoing, if, in the course of Executive&rsquo;s employment with the Company, Executive directly or indirectly incorporates into a Company product, process or machine a Prior Invention owned by Executive or in which Executive has an interest, the Company is hereby granted and shall have a non-exclusive, royalty-free, irrevocable, perpetual, world-wide license to make, have made, modify, use, create derivative works from and sell such Prior Invention as part of or in connection with such product, process or machine.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignment of Inventions</u>. Executive shall promptly make full, written disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and hereby irrevocably transfers and assigns, and agrees to transfer and assign, to the Company, or its designee, all Executive&rsquo;s right, title and interest in and to any and all inventions, original works of authorship, developments, concepts, improvements, designs, discoveries, ideas, trademarks (and all associated goodwill), mask works, or trade secrets, whether or not they may be patented or registered under copyright or similar laws, which Executive may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during Executive&rsquo;s employment by the Company (the &ldquo;<u>Inventions</u>&rdquo;). Executive further acknowledges that all original works of authorship which are made by Executive (solely or jointly with others) within the scope of and during the period of Executive&rsquo;s employment with the Company and which may be protected by copyright are &ldquo;<u>Works Made For Hire</u>&rdquo; as that term is defined by the United States Copyright Act. Executive understands and agrees that the decision whether to commercialize or market any Invention developed by Executive solely or jointly with others is within the Company&rsquo;s sole discretion and the Company&rsquo;s sole benefit and that no royalty will be due to Executive as a result of the Company&rsquo;s efforts to commercialize or market any such invention.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Executive recognizes that Inventions relating to Executive&rsquo;s activities while working for the Company and conceived or made by Executive, whether alone or with others, within one (1) year after cessation of Executive&rsquo;s employment, may have been conceived in significant part while employed by the Company. Accordingly, Executive acknowledges and agrees that such Inventions shall be presumed to have been conceived during Executive&rsquo;s employment with the Company and are to be, and hereby are, assigned to the Company unless and until Executive has established the contrary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The requirements of this Section 8B do not apply to any intellectual property for which no equipment, supplies, facility or trade secret information of the Company was used, and which was developed entirely on the Executive&rsquo;s own time, and (i) which does not relate (x) directly to the Company&rsquo;s business or (y) to the Company&rsquo;s actual or demonstrably anticipated research and development or (ii) which does not result from any work the Executive performed for the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Maintenance of Records</u>. Executive agrees to keep and maintain adequate and current written records of all Inventions made by Executive (solely or jointly with others) during Executive&rsquo;s employment with the Company. The records will be in the form of notes, sketches, drawings and any other format that may be specified by the Company. The records will be available to and remain the sole property of the Company at all times.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Patent, Trademark and Copyright Registrations</u>. Executive agrees to assist the Company, or its designee, at the Company&rsquo;s expense, in every proper way to secure the Company&rsquo;s rights in the Inventions and any copyrights, patents, trademarks, service marks, mask works, or any other intellectual property rights in any and all countries relating thereto, including, but not limited to, the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments the Company reasonably deems necessary in order to apply for and obtain such rights and in order to assign and convey to the Company, its successors, assigns, and nominees the sole and exclusive rights, title, and interest in and to such inventions, and any copyrights, patents, trademarks, service marks, mask works, or any other intellectual property rights relating thereto. Executive further agrees that Executive&rsquo;s obligation to execute or cause to be executed, when it is in Executive&rsquo;s power to do so, any such instrument or paper shall continue after termination or expiration of this Agreement or the cessation of Executive&rsquo;s employment with the Company. If the Company is unable because of Executive&rsquo;s mental or physical incapacity or for any other reason, after reasonably diligent efforts, to secure Executive&rsquo;s signature to apply for or to pursue any application for any United States or foreign patents, trademarks or copyright registrations covering inventions or original works of authorship assigned to the Company as above, then Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Executive&rsquo;s agent and attorney-in-fact to act for and in Executive&rsquo;s behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent, trademarks or copyright registrations thereon with the same legal force and effect as if executed by Executive; this power of attorney shall be a durable power of attorney which shall come into existence upon Executive&rsquo;s mental or physical incapacity.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>9.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>SURVIVAL AND REMEDIES. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Executive&rsquo;s obligations of nondisclosure, non-solicitation, non-interference, and non-competition under this Agreement shall survive the cessation of Executive&rsquo;s employment with the Company and shall remain enforceable. In addition, Executive acknowledges that upon a breach or threatened breach of any obligation of nondisclosure, non-solicitation, non-interference, or non-competition of this Agreement, the Company may suffer irreparable harm and damage for which money alone cannot fully compensate the Company. Executive therefore agrees that upon such breach or threat of imminent breach of any such obligation, the Company shall be entitled to seek a temporary restraining order, preliminary injunction, permanent injunction or other injunctive relief, without posting any bond or other security, barring Executive from violating any such provision. This Section 9 shall not be construed as an election of any remedy, or as a waiver of any right available to the Company under this Agreement or the law, including the right to seek damages from Executive for a breach of any provision of this Agreement and the right to require Executive to account for and pay over to the Company all profits or other benefits derived or received by Executive as the result of such a breach, nor shall this Section 9 be construed to limit the rights or remedies available under state law for any violation of any provision of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>10.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>TERMINATION.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination By Either Party</u>. Either Party may terminate the Executive&rsquo;s at-will employment at any time with or without notice, and with or without cause. Except as provided in this Section 10, upon termination of employment, Executive shall only be entitled to Executive&rsquo;s accrued but unpaid Base Salary, any earned but unpaid bonus for the year prior to the date of termination, and other benefits earned under any Company-provided plans, policies and arrangements for the period preceding the effective date of the termination of employment. With respect to any earned but unpaid bonus for the year prior to the date of termination, the terms of which bonus plan require Executive to be an employee of the Company as of the date of payment, no payment will be made to Executive (or if applicable, the Executive&rsquo;s beneficiary) if Executive&rsquo;s employment with the Company terminates voluntarily by Executive, other than for Good Reason pursuant to Section 10C, or if Executive&rsquo;s employment with the Company is terminated by the Company for Cause, but will be paid if Executive&rsquo;s employment with the Company terminates due to Executive&rsquo;s death or disability.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination Without Cause</u>. If the Company terminates Executive&rsquo;s employment without Cause (defined below), Executive shall be entitled to receive, in addition to the amounts due under Section 10A, as continuing severance pay at a rate equal to Executive&rsquo;s Base Salary, as then in effect, for nine (9) months from the date of termination of employment, plus a lump-sum payment equal to a pro rata portion of Executive&rsquo;s target annual bonus for the year in which the date of termination occurs (based on the date of termination), in each case, less all required tax withholdings and other applicable deductions, payable in accordance with the Company&rsquo;s standard payroll procedures, commencing on the effective date of a Separation Agreement and Release of claims against the Company and after the end of any applicable rescission or revocation period, and provided that Executive has not revoked or rescinded (or attempted to revoke or rescind) any claims under such Release, in substantially the form of <u>Exhibit A</u> attached hereto, the timely execution and performance by Executive of which is specifically a condition to Executive&rsquo;s receipt of any of the payments and benefits provided under this Section 10B; <u>provided</u> that (1)&nbsp;such Separation Agreement and Release shall be executed and be fully effective within sixty (60) days of the Executive&rsquo;s termination of employment; (2) the first payment shall include any amounts that would have been paid to Executive if payment had commenced on the date of termination of employment; and (3) Executive shall not be required to execute a release of any claims arising from the Company&rsquo;s failure to comply with its obligations under Section 10A. Subject to Executive&rsquo;s execution and non-revocation of the Separation Agreement and Release, if Executive timely and effectively elects continuation coverage under the Company&rsquo;s group health plan pursuant to COBRA or similar state law, the Company will pay or reimburse the premiums for such coverage of Executive (and Executive&rsquo;s dependents, as applicable) at the same rate it pays for active employees for a period for nine (9) months from the date of termination of employment; <u>provided</u> that the Company&rsquo;s obligation to make such payments shall immediately expire if Executive ceases to be eligible for continuation coverage under COBRA or similar state law or otherwise terminates such coverage. Notwithstanding the foregoing, any of the foregoing payments due under this Section 10B shall commence within seventy (70) days of Executive&rsquo;s termination of employment, <u>provided</u> that if such seventy (70)-day period spans two (2) calendar years, payments shall commence in the latter calendar year. In addition to the foregoing and subject to Executive&rsquo;s timely execution of a Separation Agreement and Release that has been executed and not revoked within any applicable rescission period that has expired within sixty (60) days of the Executive&rsquo;s termination of employment, Executive shall be entitled to the immediate vesting of all outstanding equity awards then held by Executive.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination Upon a Change in Control</u>. If the Company or any successor in interest to the Company terminates Executive&rsquo;s employment without Cause in connection with or within twelve (12) months after a Change in Control (defined below) or if Executive terminates Executive&rsquo;s employment for Good Reason (defined below) within twelve (12) months after a Change in Control, Executive shall be entitled to receive, in addition to the amounts due under Section 10A, a lump-sum payment equal to twelve (12) months of Executive&rsquo;s Base Salary, as then in effect or as in effect immediately prior to a material reduction of Executive&rsquo;s Base Salary which was the reason Executive resigned for Good Reason, plus a lump-sum payment equal to a pro rata portion of Executive&rsquo;s target annual bonus for the year in which the date of termination occurs (based on the date of termination), in each case, less all tax withholdings and other applicable deductions the Company reasonably determines are required to be made, payable on the first regular payroll date after the effective date of a Separation Agreement and Release that has been executed and not revoked within any applicable rescission period that has expired within sixty (60) days of the Executive&rsquo;s termination of employment, in substantially the form of <u>Exhibit A</u> attached hereto, the execution and performance by Executive of which is specifically a condition to Executive&rsquo;s receipt of any of the payments and benefits provided under this Section 10C; <u>provided</u> that Executive shall not be required to execute a release of any claims arising from the Company&rsquo;s failure to comply with its obligations under Section 10A. Subject to Executive&rsquo;s execution and non-revocation of the Separation Agreement and Release, if Executive timely and effectively elects continuation coverage under the Company&rsquo;s group health plan pursuant to COBRA or similar state law, the Company will pay or reimburse the premiums for such coverage of Executive (and Executive&rsquo;s dependents, as applicable) at the same rate it pays for active employees for a period for twelve (12) months from the date of termination of employment; <u>provided</u> that the Company&rsquo;s obligation to make such payments shall immediately expire if Executive ceases to be eligible for continuation coverage under COBRA or similar state law or otherwise terminates such coverage. Notwithstanding the previous provisions of this Section 10C, any payments due under this Section 10C shall commence within seventy (70) days of Executive&rsquo;s termination of employment, <u>provided</u> that if such seventy (70)-day period spans two calendar years, payments shall commence in the latter calendar year. In addition to the foregoing and subject to Executive&rsquo;s timely execution of a Separation Agreement and Release that has been executed and not revoked within any applicable rescission period that has expired within sixty (60) days of the Executive&rsquo;s termination of employment, Executive shall be entitled to the immediate vesting of all outstanding equity awards then held by Executive. The payments and benefits described in this Section 10C are in lieu of, and not in addition to, the payments and benefits described in Section 10B, it being understood by Executive that he shall be paid and receive only one set of severance payments and benefits.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Notwithstanding any other provisions of this Agreement, if any &ldquo;payments&rdquo; (including, without limitation, any benefits or transfers of property or the acceleration of the vesting of any benefits) in the nature of compensation under any arrangement that is considered contingent on a &ldquo;change in control&rdquo; for purposes of Section 280G of the Internal Revenue Code of 1986, as amended (the &ldquo;<u>Code</u>&rdquo;), together with any other payments that Executive has the right to receive from the Company or any corporation that is a member of an &ldquo;affiliated group&rdquo; (as defined in Section 1504(a) of the Code without regard to Section 1504(b) of the Code) of which the Company is a member, would constitute a &ldquo;parachute payment&rdquo; (as defined in Section 280G(b)(2) of the Code), such &ldquo;payments&rdquo; may, at Executive&rsquo;s sole election, be reduced to the largest amount as will result in no portion of such &ldquo;payments&rdquo; being subject to the excise tax imposed by Section 4999 of the Code. Any reduction of the payments shall be made in the following order: (1) options with an exercise price above the fair market value of the stock, provided the options give rise to a payment; (2) pro rata among amounts that constitute deferred compensation under Code Section 409A; and (3) reduction of any remaining payments in the manner determined at the discretion of Executive.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the change in control shall perform the foregoing calculations. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The accounting firm shall provide its calculations to the Company and Executive within sixty (60) calendar days after the date on which Executive&rsquo;s right to a payment is triggered and the payment will be paid to Executive within seventy-four (74) calendar days of the date on which Executive&rsquo;s right to a payment is triggered. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination for Cause, Death or Disability, or Resignation</u>. If Executive&rsquo;s employment with the Company terminates voluntarily by Executive, other than for Good Reason pursuant to Section 10C above, or if Executive&rsquo;s employment with the Company is terminated by the Company for Cause or due to Executive&rsquo;s death or disability, then payments of compensation by the Company to Executive hereunder will terminate immediately, except that Executive (or the Executive&rsquo;s beneficiary if Executive&rsquo;s termination is on account of death) will be entitled to the amounts due under Section 10A.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<u>Cause</u>.&rdquo; For all purposes under this Agreement, &ldquo;<u>Cause</u>&rdquo; is defined as (a) gross negligence or willful failure to perform Executive&rsquo;s duties and responsibilities to the Company; (b) commission of any act of fraud, theft, embezzlement, financial dishonesty or any other willful misconduct that has caused or is reasonably expected to result in injury to the Company; (c)&nbsp;conviction of, or pleading guilty or <i>nolo contendere</i> to, any felony or a lesser crime involving dishonesty or moral turpitude; (d) material breach by Executive of any of Executive&rsquo;s obligations under this Agreement or any written agreement or covenant with the Company, including the policies adopted from time to time by the Company applicable to all Executives, that has not been cured within thirty (30) days of notice of such breach or (e) the Company terminates the employment of Executive in connection with a liquidation, dissolution or winding down of the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<u>Good Reason</u>.&rdquo; For all purposes under this Agreement, &ldquo;<u>Good Reason</u>&rdquo; is defined as Executive&rsquo;s resignation within thirty (30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without Executive&rsquo;s express written consent: (a) a material reduction of Executive&rsquo;s duties, authority, reporting level, or responsibilities, relative to Executive&rsquo;s duties, authority, reporting level, or responsibilities in effect immediately prior to such Change in Control; (b) a material reduction in Executive&rsquo;s base compensation; or (c) the Company&rsquo;s requiring of Executive to change the principal location at which Executive is to perform Executive&rsquo;s services by more than fifty (50) miles. Executive will not resign for Good Reason without first providing the Company with written notice within thirty (30) days of the initial occurrence of the event that Executive believes constitutes &ldquo;<u>Good Reason</u>&rdquo; specifically identifying the acts or omissions constituting the grounds for Good Reason and providing Company a reasonable cure period of not less than thirty (30) days following the date of such notice and during which such condition has not been cured.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<u>Change in Control</u>.&rdquo; For all purposes under this Agreement, a &ldquo;<u>Change in Control</u>&rdquo; will mean the occurrence of any of the following:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 90pt;">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the acquisition, other than from the Company or Parent (as defined below), by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (&ldquo;<u>Exchange Act</u>&rdquo;)) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of either the then outstanding common shares, no par value (&ldquo;<u>Common Shares</u>&rdquo;), of DiaMedica Therapeutics Inc., a company organized under the laws of Canada (&ldquo;<u>Parent</u>&rdquo;), or the combined voting power of the then outstanding voting securities of Parent entitled to vote generally in the election of directors, but excluding, for this purpose, any such acquisition by Parent or any of its subsidiaries, or any employee benefit plan (or related trust) of Parent or its subsidiaries, or any entity with respect to which, following such acquisition, more than fifty percent (50%) of, respectively, the then outstanding equity of such entity and the combined voting power of the then outstanding voting equity of such entity entitled to vote generally in the election of all or substantially all of the members of such entity&rsquo;s governing body is then beneficially owned, directly or indirectly, by the individuals and entities who were the beneficial owners, respectively, of the Common Shares and voting securities of Parent immediately prior to such acquisition in substantially the same proportion as their ownership, immediately prior to such acquisition, of the then outstanding Common Shares or the combined voting power of the then outstanding voting securities of Parent entitled to vote generally in the election of directors, as the case may be; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">11</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 90pt;">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the consummation of a reorganization, merger or consolidation of Parent, in each case, with respect to which all or substantially all of the individuals and entities who were the respective beneficial owners of the Common Shares and voting securities of Parent immediately prior to such reorganization, merger or consolidation do not, following such reorganization, merger or consolidation, beneficially own, directly or indirectly, more than fifty percent (50%) of, respectively, the then outstanding Common Shares and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such reorganization, merger or consolidation; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 90pt;">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the sale or other disposition of all or substantially all of the assets of Parent; provided the occurrence under (a), (b) or (c), constitutes a &ldquo;change in the ownership or effective control of a corporation, or a change in the ownership of a substantial portions of the assets of a corporation&rdquo; under Section 409A of the Code.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Other Benefits</u>. In the event of a termination of Executive&rsquo;s employment with the Company, the provisions of this Section 10 are Executive&rsquo;s exclusive right to severance benefits and are in lieu of participation in any other severance policy or plan to which Executive might otherwise be entitled.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">G.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination from any Offices Held</u>. Upon Executive&rsquo;s termination of employment with the Company, Executive agrees that and any and all offices held with Parent or any subsidiary, including the Company, if applicable, shall be automatically terminated. Executive agrees to cooperate with the Company and execute any documents reasonably required by the Company or competent authorities to effect this provision.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">H.&nbsp;&nbsp;&nbsp;&nbsp;<u>Return of Company Property</u>. All devices, records, reports, data, notes, compilations, lists, proposals, correspondence, specifications, equipment, drawings, blueprints, manuals, planners, calendars, schedules, discs, financial plans and information, or other recorded matter, whether in hard copy, electronic media or otherwise (including all copies or reproductions made or maintained, whether on the Company&rsquo;s premises or otherwise), pertaining to Executive&rsquo;s work for the Company, or relating to the Company or the Company&rsquo;s Confidential Information, whether created or developed by Executive alone or jointly during Executive&rsquo;s employment with the Company, are the exclusive property of the Company. Executive shall surrender the same (as well as any other property of the Company) to the Company upon its request or promptly upon the cessation of employment.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>11.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>NO CONFLICTING AGREEMENTS OR IMPROPER USE OF THIRD-PARTY INFORMATION. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">During Executive&rsquo;s employment with the Company, Executive shall not improperly use or disclose any Confidential information or trade secrets of any former employer or other person or entity, and Executive shall not bring on to the premises of the Company any unpublished document or Confidential information belonging to any such former employer, person or entity, unless consented to in writing by the former employer, person or entity. Executive represents that he has not improperly used or disclosed any Confidential information or trade secrets of any other person or entity during the application process or while employed or affiliated with the Company. Executive also acknowledges and agrees that he is not subject to any contract, agreement, or understanding that would prevent Executive from performing Executive&rsquo;s duties for the Company or otherwise complying with this Agreement. To the extent Executive violates this provision, or Executive&rsquo;s employment with the Company constitutes a breach or threatened breach of any contract, agreement, or obligation to any third party, Executive shall indemnify and hold the Company harmless from all damages, expenses, costs (including reasonable attorneys&rsquo; fees) and liabilities incurred in connection with, or resulting from, any such violation or threatened violation.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>12.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>GENERAL PROVISIONS.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law; Consent To Personal Jurisdiction</u>. The laws of the State of Minnesota shall govern the Executive&rsquo;s employment and this Agreement without regard to conflict of laws principles. Executive and the Company each hereby consents to the personal jurisdiction of the state courts located in Hennepin County, State of Minnesota, and the federal district court sitting in Hennepin County, State of Minnesota, if that court otherwise possesses jurisdiction over the matter, for any legal proceeding concerning Executive&rsquo;s employment or termination of employment, or arising from or related to this Agreement or any other agreement executed between Executive and the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement</u>. This Agreement, together with the Exhibits hereto, sets forth this entire Agreement between the Company (and any of its related or affiliated entities, officers, agents, owners or representatives) and Executive relating to the subject matter herein, and supersedes any and all prior discussions and agreements, whether written or oral, on the subject matter hereof, including without limitation that certain offer letter agreement dated as of January 2, 2018. To the extent that this Agreement may conflict with the terms of another written agreement between Executive and the Company, the terms of this Agreement will control.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Modification</u>. No modification of or amendment to this Agreement will be effective unless in writing and signed by Executive and an authorized representative of the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver</u>. The Company&rsquo;s failure to enforce any provision of this Agreement shall not act as a waiver of its ability to enforce that provision or any other provision. The Company&rsquo;s failure to enforce any breach of this Agreement shall not act as a waiver of that breach or any future breach. No waiver of any of the Company&rsquo;s rights under this Agreement will be effective unless in writing. Any such written waiver shall not be deemed a continuing waiver unless specifically stated, and shall operate only as to the specific term or condition waived and shall not constitute a waiver of such term or condition for the future or as to any act other than that specifically waived.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">13</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. This Agreement shall be assignable to, and shall inure to the benefit of and bind, the Company&rsquo;s, affiliates, subsidiaries, successors and assigns. Executive shall not have the right to assign Executive&rsquo;s rights or obligations under this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Construction</u>. The language used in this Agreement will be deemed to be language chosen by Executive and the Company to express their mutual intent, and no rules of strict construction will be applied against either Party.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">G.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts</u>. This Agreement may be executed in any number of counterparts, each of which shall be enforceable, and all of which together shall constitute one agreement. Signatures of the parties that are transmitted in person or by facsimile or e-mail shall be accepted as originals.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">H.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Further Assurances</u>. Executive agrees to execute any proper oath or verify any document required to carry out the terms of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Title and Headings</u>. The titles, captions and headings of this Agreement are included for ease of reference only and will be disregarded in interpreting or construing this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">J.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. All notices and communications that are required or permitted to be given under this Agreement shall be in writing and shall be sufficient in all respects if given and delivered in person, by electronic mail, by facsimile, by overnight courier, or by certified mail, postage prepaid, return receipt requested, to the receiving Party at such Party&rsquo;s address shown in the signature blocks below or to such other address as such Party may have given to the other by notice pursuant to this Section. Notice shall be deemed given (i) on the date of delivery in the case of personal delivery, electronic mail or facsimile, or (ii) on the delivery or refusal date as specified on the return receipt in the case of certified mail or on the tracking report in the case of overnight courier.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">K.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Code Section 409A</u>. The amounts payable under this Agreement are intended to be exempt from the requirements of Section 409A of the Code (&ldquo;<u>Section 409A</u>&rdquo;). For purposes of Section 409A, any right to a series of installment payments is to be treated as a right to a series of separate payments. Any payments due under this Agreement on account of a termination of employment shall only be payable if the termination constitutes a &ldquo;separation from service&rdquo; within the meaning of Section 409A. To the extent that any such payments are determined to be deferred compensation subject to Section 409A, (i) the terms of this Agreement shall be interpreted to avoid incurring any penalties under Section 409A, and (ii) any payments due to a &ldquo;specified Executive&rdquo; of a publicly-traded company upon a separation from service shall be delayed until the first day of the seventh month following such separation from service. Notwithstanding the foregoing, in no event shall the Company be responsible for any taxes or penalties due under Section 409A.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>13.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>EXECUTIVE&rsquo;S ACKNOWLEDGMENTS. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Executive acknowledges that he is executing this Agreement voluntarily and without duress or undue influence by the Company or anyone else and that Executive has carefully read this Agreement and fully understands the terms, consequences, and binding effect of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i>[Remainder of page intentionally left blank]</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">14</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed this Employment Agreement as of the date first written above.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td colspan="2" rowspan="1" style="width: 7%;" valign="top" width="50%"><b>EXECUTIVE</b></td>
			<td style="width: 15%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" rowspan="1" style="width: 8%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><b>DIAMEDICA USA, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 7%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 15%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 8%;" valign="bottom" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 7%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td align="left" nowrap="nowrap" style="width: 8%;" valign="bottom" width="35%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td align="left" nowrap="nowrap" style="width: 8%;" valign="bottom" width="35%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" rowspan="1" style="width: 7%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="50%">/s/ Scott Kellen</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td align="left" nowrap="nowrap" style="width: 8%;" valign="bottom" width="35%">Print Name:</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="12%">Rick Pauls&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" rowspan="1" style="width: 7%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;">Scott Kellen</p>
			</td>
			<td style="width: 15%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 8%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="width: 7%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 8%;" valign="top" width="35%">Signature:</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="12%">/s/ Rick Pauls</td>
		</tr>
		<tr>
			<td style="width: 7%;" valign="top" width="50%">Date:</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;">9/14/2018</p>
			</td>
			<td style="width: 15%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 8%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;">Title:</p>
			</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;">President &amp; CEO</p>
			</td>
		</tr>
		<tr>
			<td style="width: 7%;" valign="top" width="50%">Address:</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="50%">2 Carlson Parkway, Suite 260</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 8%;" valign="top" width="35%">Date:</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="12%">9/14/2018</td>
		</tr>
		<tr>
			<td colspan="2" rowspan="1" style="width: 7%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="50%">Minneapolis, MN 55447</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 8%;" valign="top" width="35%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 8%;" valign="top" width="35%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="12%">&nbsp;</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>EXHIBIT A</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>FORM OF SEPARATION AGREEMENT AND RELEASE</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">This Separation Agreement (&ldquo;<u>Agreement</u>&rdquo;) and the Release, which is attached and incorporated by reference as <u>Exhibit A</u> (&ldquo;<u>Release</u>&rdquo;), are made by and between Scott Kellen (&ldquo;<u>Executive</u>&rdquo;), and DiaMedica USA, Inc., its affiliates, related or predecessor corporations, parent, subsidiaries, successors and assigns (&ldquo;<u>Employer</u>&rdquo;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Employer and Executive (collectively, &ldquo;<u>Parties</u>&rdquo;) wish to end their employment relationship in an honorable, dignified and orderly fashion. Toward that end, the Parties have agreed to separate according to the following terms.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">IN CONSIDERATION OF THIS AGREEMENT, THE PARTIES AGREE AS FOLLOWS:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination</u>. Executive&rsquo;s employment shall end on a date and time Employer shall determine (&ldquo;<u>Termination Date</u>&rdquo;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Consideration</u>. Employer shall, (1) after receipt of a fully executed Agreement and Release; (2) after expiration of all applicable rescission periods; and (3) provided Executive complies with Executive&rsquo;s obligations under this Agreement, provide Executive with separation benefits (&ldquo;<u>Consideration</u>&rdquo;) in compliance with Executive&rsquo;s Employment Agreement attached as <u>Exhibit B</u>:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination of Benefits</u>. Except as otherwise provided by this Agreement, Executive&rsquo;s participation in Employer&rsquo;s employee benefits, bonus, and all other compensation or commission plans, will terminate on the Termination Date, unless otherwise provided by law, or benefit plan. Executive shall receive no compensation or benefits under such plans, except as specifically provided in Section 2 of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Execution of Agreement and Release of all Claims</u>. Executive agrees to fully execute this Agreement, and the Release attached as <u>Exhibit A</u>, releasing any and all actual or potential claims which may have arisen at any time during Executive&rsquo;s employment with or termination from employment with Employer. Executive&rsquo;s failure to execute this Agreement and/or Release, or any attempt to rescind this Agreement or that Release, shall terminate this Agreement, and the Parties&rsquo; respective rights and obligations under this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Satisfactory Performance and Cooperation During Transition</u>. Executive shall fully cooperate with Employer in responding to questions, providing assistance and information, and defending against claims of any type, and will otherwise assist Employer as Employer may request through Executive&rsquo;s Termination Date (&ldquo;<u>Transition Period</u>&rdquo;). More specifically:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the Transition Period, Executive shall reasonably cooperate with Employer as it meets and otherwise communicates/works, with Employer&rsquo;s employees, customers, strategic relationships, consultants, and vendors on the transition of Executive&rsquo;s duties to other individuals. Executive shall be available, upon reasonable notice, during business hours to respond to Employer&rsquo;s questions and electronic communications. Employer shall reimburse Executive for Executive&rsquo;s reasonable out-of-pocket expenses (such reimbursement shall not include compensation for any such time or Executive&rsquo;s attorney&rsquo;s fees) incurred in accordance with this Section upon submission of receipts to Employer for such expenses.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">16</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive shall not, absent Employer&rsquo;s specific approval, initiate any form of communication with Employer&rsquo;s employees, customers or strategic partners regarding Employer, Employer&rsquo;s products or employees, and shall communicate with such persons in the above capacity only in conjunction with person(s) who Employer has designated to participate in such communications.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Stipulation of No Charges</u>. Executive affirmatively represents that Executive has not filed nor caused to be filed any charges, claims, complaints, or actions against Employer before any federal, state, or local administrative agency, court, or other forum. Except as expressly provided in this Agreement or required by law, Executive acknowledges and agrees that Executive has been paid all wages, bonuses, compensation, benefits and other amounts that are due, with the exception of any vested right under the terms of a written ERISA-qualified benefit plan. Executive waives any right to any form of recovery or compensation from any legal action, excluding any action claiming this Agreement and Release violate the Age Discrimination in Employment Act (&ldquo;<u>ADEA</u>&rdquo;) and/or the Older Workers Benefit Protection Act (&ldquo;<u>OWBPA</u>&rdquo;), filed or threatened to be filed by Executive or on Executive&rsquo;s behalf based on Executive&rsquo;s employment, terms of employment, or separation from, Employer. Executive understands that any Consideration paid to Executive pursuant to this Agreement may be deducted from any monetary award Executive may receive as a result of a successful ADEA and/or OWBPA claim or challenge to this Agreement and Release. This does not preclude Executive from eligibility for unemployment benefits, and does not preclude or obstruct Executive&rsquo;s right to file a Charge with the Equal Employment Opportunity Commission (&ldquo;<u>EEOC</u>&rdquo;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Return of Property</u>. Executive shall return, on or before the Termination Date, all Employer property in Executive&rsquo;s possession or control, including but not limited to any drawings, orders, files, documents, notes, computers, laptop computers, fax machines, cell phones, smart devices, access cards, fobs, keys, reports, manuals, records, product samples, correspondence and/or other documents or materials related to Employer&rsquo;s business that Executive has compiled, generated or received while working for Employer, including all electronically stored information, copies, samples, computer data, disks, or records of such materials. Executive must return to Employer, and Executive shall not retain, any Employer property as previously defined in this section.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.&nbsp;&nbsp;&nbsp;&nbsp;<u>Agreement Not to Seek Future Employment</u>. Executive agrees that Executive will never knowingly seek nor accept employment or a consulting/independent contractor relationship with Employer, nor any other entity owned by Employer, either directly or through a consulting firm.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">17</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">9.&nbsp; &nbsp; &nbsp;&nbsp;<u>Withholding for Amounts Owed to Employer</u>. Execution of this Agreement shall constitute Executive&rsquo;s authorization for Employer to make deductions from Executive&rsquo;s Consideration, for Executive&rsquo;s indebtedness to Employer, or to repay Employer for unaccrued vacation or other Paid Time Off already taken, Executive purchases, wage or benefit overpayment, or other Employer claims against Executive, to the extent permitted by applicable law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Disparagement</u>. Executive agrees that, unless it is in the context of an EEOC or other civil rights or other government enforcement agency investigation or proceeding, Executive will make no critical, disparaging or defamatory comments regarding Employer or any Released Party, as defined in the Release, in any respect or make any comments concerning the conduct or events which precipitated Executive&rsquo;s separation. Furthermore, Executive agrees not to assist or encourage in any way any individual or group of individuals to bring or pursue a lawsuit, charge, complaint, or grievance, or make any other demands against Employer or any Released Party. This provision does not prohibit Executive from participating in an EEOC or other civil rights or other government enforcement agency charge, investigation or proceeding, or from providing testimony or documents pursuant to a lawful subpoena or as otherwise required by law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Employment Agreement and Protection of Confidential Information.</u> Executive agrees to comply with the provisions of and the restrictions set forth in Executive&rsquo;s Employment Agreement (Exhibit B), including without limitation the obligation not to use or disclose Confidential Information (as defined in the Employment Agreement).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Confidentiality</u>. It is the intent of Employer and Executive that the terms of this Agreement be treated as Confidential Information (as defined in the Employment Agreement), except to the extent this Agreement is required to be disclosed under applicable federal securities laws, as determined by Employer. Executive warrants that Executive has not and agrees that Executive will not in the future disclose the terms of this Agreement, or the terms of the Consideration to be paid by Employer to Executive as part of this Agreement, to any person other than Executive&rsquo;s attorney, tax advisor, spouse, or representatives of any state or federal regulatory agency, who shall be bound by the same prohibitions against disclosure as bind Executive, and Executive shall be responsible for advising those individuals or agencies of this confidentiality provision. Executive shall not provide or allow to be provided to any person this Agreement, or any copies thereof, nor shall Executive now or in the future disclose the terms of this Agreement to any person, with the sole exception of communications with Executive&rsquo;s spouse, attorney and tax advisor, unless otherwise ordered to do so by a court or agency of competent jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Invalidity</u>. In case any one or more of the provisions of this Agreement or Release shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained in this Agreement and Release will not in any way be affected or impaired thereby.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Admissions</u>. The Parties expressly deny any and all liability or wrongdoing and agree that nothing in this Agreement or the Release shall be deemed to represent any concession or admission of such liability or wrongdoing or any waiver of any defense.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">18</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. The laws of the State of Minnesota shall govern this Agreement without regard to conflict of laws principles. The Parties each hereby consent to the personal jurisdiction of the state courts located in Hennepin County, State of Minnesota, and the federal district court sitting in Hennepin County, State of Minnesota, if that court otherwise possesses jurisdiction over the matter, for any legal proceeding concerning or related to this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Voluntary and Knowing Action</u>. Executive acknowledges that Executive has had sufficient opportunity to review the terms of this Agreement and attached Release, and that Executive has voluntarily and knowingly entered into this Agreement. Employer shall not be obligated to provide any Consideration to Executive pursuant to this Agreement in the event Executive elects to rescind/revoke the Release. The Release becomes final and binding on the Parties upon expiration of the rescission/revocation period, provided Executive has not exercised Executive&rsquo;s option to rescind/revoke the Release. Any attempt by Executive to rescind any part of the Release obligates Executive to immediately return all Consideration under this Agreement to counsel for Employer.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Legal Counsel and Fees</u>. Except as otherwise provided in this Agreement and the Release, the Parties agree to bear their own costs and attorneys&rsquo; fees, if any. Executive acknowledges that Employer, by this Agreement, has advised him that Executive may consult with an attorney of Executive&rsquo;s choice prior to executing this Agreement and the Release. Executive acknowledges that Executive has had the opportunity to be represented by legal counsel during the negotiation and execution of this Agreement and the Release, and that Executive understands Executive will be fully bound by this Agreement and the Release.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Modification</u>. This Agreement may be modified or amended only by a writing signed by both Employer and Executive.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. This Agreement is binding on and inures to the benefit of the Parties&rsquo; respective successors and assigns.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. All notices and communications that are required or permitted to be given under this Agreement shall be in writing and shall be sufficient in all respects if given and delivered in person, by electronic mail, by facsimile, by overnight courier, or by certified mail, postage prepaid, return receipt requested, to the receiving Party at such Party&rsquo;s address below or to such other address as such Party may have given to the other by notice pursuant to this Section. Notice shall be deemed given (i) on the date of delivery in the case of personal delivery, electronic mail or facsimile, or (ii) on the delivery or refusal date as specified on the return receipt in the case of certified mail or on the tracking report in the case of overnight courier.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">19</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">If to Employer:</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%;">DIAMEDICA USA, INC.</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%;">Attention: Chief Executive Officer</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%;">Two Carlson Parkway, Suite 260</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%;">Minneapolis, MN 55447</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%;">&nbsp;</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">With a copy to:&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%;">Amy E. Culbert</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%;">Fox Rothschild LLP</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%;">Campbell Mithun Tower - Suite 2000</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%;">222 South Ninth Street</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%;">Minneapolis, MN 55402-3338</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%;">&nbsp;</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">If to Executive:</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Scott Kellen</p>
			</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 15%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Waivers</u>. No failure or delay by either Party in exercising any right or remedy under this Agreement will waive any provision of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>. This Agreement may be executed simultaneously in counterparts, each of which shall be an original, but all of which shall constitute but one and the same agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement</u>. Except for any continuing, post-employment, obligations under <u>Exhibit B</u>, or employment related Employer policy, or as otherwise provided in this Agreement, this Agreement, the attached Release, and <u>Exhibit B</u> are the entire Agreement between Employer and Executive relating to Executive&rsquo;s employment and separation. Executive understands that this Agreement and the Release cannot be changed unless it is done in writing and signed by both Employer and Executive.&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i>[Remainder of page intentionally left blank]</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">20</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 53.8%;"><b>EXECUTIVE</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 53.8%;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 53.8%;">Scott Kellen</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:53.8%;margin-right:0pt;margin-top:0pt;text-align:justify;">Dated: ___________, 20____</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:53.8%;"><b>DIAMEDICA USA, INC.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:53.8%;">By:&nbsp;<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:53.8%;">Its:&nbsp;<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:53.8%;margin-right:0pt;margin-top:0pt;text-align:justify;">Dated: ___________, 20____</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:53.8%;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">21</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;"><b>EXHIBIT A</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>RELEASE</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">I.</p>
			</td>
			<td>
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;"><u>Definitions</u>. I, Scott Kellen, intend all words used in this release (&ldquo;<u>Release</u>&rdquo;) to have their plain meanings in ordinary English. Technical legal words are not needed to describe what I mean. Specific terms I use in this Release have the following meanings:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">A.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&ldquo;<u>I</u>,&rdquo; &ldquo;<u>Me</u>,&rdquo; and &ldquo;<u>My</u>&rdquo; individually and collectively mean Scott Kellen and anyone who has or obtains or asserts any legal rights or claims through Me or on My behalf.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">B.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&ldquo;<u>Employer</u>&rdquo; as used in this Release, shall at all times mean DiaMedica USA, Inc. and any affiliates, related or predecessor corporations, parent corporations or subsidiaries, successors and assigns.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">C.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&ldquo;<u>Released Party</u>&rdquo; or &ldquo;<u>Released Parties</u>&rdquo; as used in this Release, shall at all times mean DiaMedica USA, Inc. and its affiliates, related or predecessor corporations, parent corporations, subsidiaries, successors and assigns, present or former officers, directors, shareholders, agents, employees, representatives and attorneys, whether in their individual or official capacities, and its affiliates, related or predecessor corporations, parent corporations or subsidiaries, successors and assigns, present or former officers, directors, shareholders, agents, employees, representatives and attorneys, whether in their individual or official capacities, benefit plans and plan administrators, and insurers, insurers&rsquo; counsel, whether in their individual or official capacities, and the current and former trustees or administrators of any pension, 401(k), or other benefit plan applicable to the employees or former employees of Employer, in their official and individual capacities.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">D.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&ldquo;<u>My Claims</u>&rdquo; mean any and all of the actual or potential claims of any kind whatsoever I may have had, or currently may have against Employer or any Released Party, whether known or unknown, that are in any way related to My employment with or separation from employment with Employer, including, but not limited to any claims for: invasion of privacy; breach of written or oral, express or implied, contract; fraud; misrepresentation; violation of the Age&nbsp;Discrimination in Employment Act of 1967 (&ldquo;<u>ADEA</u>&rdquo;), 29&nbsp;U.S.C. &sect;&nbsp;626, as amended; the Genetic Information Nondiscrimination Act of 2008 (&ldquo;<u>GINA</u>&rdquo;), 42&nbsp;U.S.C. &sect;&nbsp;2000, <u>et</u>&nbsp;<u>seq.</u>, the Older&nbsp;Workers Benefit Protection Act of 1990 (&ldquo;<u>OWBPA</u>&rdquo;), 29&nbsp;U.S.C. &sect;&nbsp;626(f), Title VII of the Civil&nbsp;Rights Act of 1964 (&ldquo;<u>Title&nbsp;VII</u>&rdquo;), 42&nbsp;U.S.C. &sect;&nbsp;2000e, <u>et</u> <u>seq.</u>, the Americans with Disabilities Act (&ldquo;<u>ADA</u>&rdquo;), 29&nbsp;U.S.C. &sect;&nbsp;2101, <u>et</u>&nbsp;<u>seq.</u>, and as amended (&ldquo;<u>ADAAA</u>&rdquo;), the Executive Retirement Income Security Act of 1974 (&ldquo;<u>ERISA</u>&rdquo;), as amended, 29&nbsp;U.S.C. &sect;&nbsp;1001, <u>et</u>&nbsp;<u>seq.</u>, Equal Pay Act (&ldquo;<u>EPA</u>&rdquo;), 29&nbsp;U.S.C. &sect;&nbsp;206(d), the Worker Adjustment and Retraining Notification Act (&ldquo;<u>WARN</u>&rdquo;), 29 U.S.C. &sect;&nbsp;2101, <u>et</u> <u>seq.</u>, the Family and Medical Leave Act (&ldquo;<u>FMLA</u>&rdquo;), 29 U.S.C. &sect;&nbsp;2601, <u>et</u> <u>seq.</u>; National Labor Relations Act, 29 U.S.C. &sect;&nbsp;141, <u>et</u> <u>seq.</u>, the False Claims Act, 31&nbsp;U.S.C. &sect;&nbsp;3729, <u>et</u> <u>seq.</u>, Anti-Kickback Statute, 42 U.S.C. &sect;&nbsp;1320a, <u>et</u> <u>seq.</u>, the Minnesota Human Rights Act, Minn. Stat. &sect;&nbsp;363A.01, <u>et</u>&nbsp;<u>seq.</u>, Minn. Stat. &sect;&nbsp;181, <u>et</u>&nbsp;<u>seq.</u>, the Minnesota Whistleblower Act, Minn. Stat. &sect;&nbsp;181.931, <u>et</u>&nbsp;<u>seq.</u>, or any and all other Minnesota, and other state human rights or fair employment practices statutes, administrative regulations, or local ordinances, and any other Minnesota or other federal, state, local or foreign statute, law, rule, regulation, ordinance or order, all as amended. This includes, but is not limited to, claims for violation of any civil rights laws based on protected class status; claims for assault, battery, defamation, intentional or negligent infliction of emotional distress, breach of the covenant of good faith and fair dealing; promissory estoppel; negligence; negligent hiring; retention or supervision; retaliation; constructive discharge; violation of whistleblower protection laws; unjust enrichment; violation of public policy; and, all other claims for unlawful employment practices, and all other common law or statutory claims.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 80%;">&nbsp;</td>
			<td style="width: 20%; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 80%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 80%;">&nbsp;</td>
			<td style="width: 20%;">EXECUTIVE INITIALS</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Ex. A-1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">II.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><u>Agreement to Release My Claims</u>. Except as stated in Section V of this Release, I agree to release all My Claims and waive any rights to My Claims. I also agree to withdraw any and all of My charges and lawsuits against Employer; <i>except that</i> I may, but am not required to, withdraw or dismiss, or attempt to withdraw or dismiss, any charges that I may have pending against Employer with the Employment Opportunity Commission (&ldquo;<u>EEOC</u>&rdquo;) or other civil rights enforcement agency. In exchange for My agreement to release My Claims, I am receiving satisfactory Consideration from Employer to which I am not otherwise entitled by law, contract, or under any Employer policy. The Consideration I am receiving is a full and fair consideration for the release of all My Claims. Employer does not owe Me anything in addition to what I will be receiving according to the Separation&nbsp;Agreement which I have signed.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">III.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><u>Unknown Claims</u>. In waiving and releasing any and all actual, potential, or threatened claims against Employer, whether or not now known to me, I understand that this means that if I later discover facts different from or in addition to those facts currently known by me, or believed by me to be true, the waivers and releases of this Release will remain effective in all respects &ndash; despite such different or additional facts and my later discovery of such facts, even if I would not have agreed to the Separation Agreement and this Release if I had prior knowledge of such facts.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">IV.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><u>Confirmation of No Claims, Etc</u>. I am not aware of any other facts, evidence, allegations, claims, liabilities, or demands relating to alleged or potential violations of law that may give rise to any claim or liability on the part of any Released Party under the Securities Exchange Act of 1934, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the False Claims Act, the Anti-kickback Statute. I understand that nothing in this Release interferes with My right to file a complaint, charge or report with any law enforcement agency, with the Securities and Exchange Commission (&ldquo;<u>SEC</u>&rdquo;) or other regulatory body, or to participate in any manner in an SEC or other governmental investigation or proceeding under any such law, statute or regulation, or to require notification or prior approval by Employer of any such a complaint, charge or report.&nbsp; I understand and agree, however, that I waive My right to recover any whistleblower award under the Securities Exchange Act of 1934, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or other individual relief in any administrative or legal action whether brought by the SEC or other governmental or law enforcement agency, Me, or any other party, unless and to the extent that such waiver is contrary to law.&nbsp; I agree that the Released Parties reserve any and all defenses which they might have against any such allegations or claims brought by Me or on My behalf. I understand that Employer is relying on My representations in this Release and related Separation Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 80%;">&nbsp;</td>
			<td style="width: 20%; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 80%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 80%;">&nbsp;</td>
			<td style="width: 20%;">EXECUTIVE INITIALS</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Ex. A-2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">V.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><u>Exclusions from Release</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">A.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">The term &ldquo;Claims&rdquo; does not include My rights, if any, to claim the following: unemployment insurance benefits; workers compensation benefits; claims for My vested post-termination benefits under any 401(k) or similar retirement benefit plan; My rights to group medical or group dental insurance coverage pursuant to section 4980B of the Internal Revenue Code of 1986, as amended (&ldquo;<u>COBRA</u>&rdquo;); My rights to enforce the terms of this Release; or My rights to assert claims that are based on events occurring after this Release becomes effective.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">B.</p>
			</td>
			<td>
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify; font-size: 10pt;">Nothing in this Release interferes with My right to file or maintain a charge with the Equal Employment Opportunity Commission or other local civil rights enforcement agency or participate in any manner in an EEOC or other such agency investigation or proceeding. I, however, understand that I am waiving My right to recover individual relief including, but not limited to, back pay, front pay, reinstatement, attorneys&rsquo; fees, and/or punitive damages, in any administrative or legal action whether brought by the EEOC or other civil rights enforcement agency, Me, or any other party.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">C.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Nothing in this Release interferes with My right to challenge the knowing and voluntary nature of this Release under the ADEA and/or OWBPA.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">D.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">I agree that Employer reserves any and all defenses, which it has or might have against any claims brought by Me. This includes, but is not limited to, Employer&rsquo;s right to seek available costs and attorneys&rsquo; fees as allowed by law, and to have any monetary award granted to Me, if any, reduced by the amount of money that I received in consideration for this Release.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 80%;">&nbsp;</td>
			<td style="width: 20%; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 80%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 80%;">&nbsp;</td>
			<td style="width: 20%;">EXECUTIVE INITIALS</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Ex. A-3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">VI.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><u>Older Workers Benefit Protection Act</u>. The Older Workers Benefit Protection Act applies to individuals age 40 and older and sets forth certain criteria for such individuals to waive their rights under the Age Discrimination in Employment Act in connection with an exit incentive program or other employment termination program. I understand and have been advised that, if applicable, the above release of My Claims is subject to the terms of the OWBPA. The OWBPA provides that a covered individual cannot waive a right or claim under the ADEA unless the waiver is knowing and voluntary. If I am a covered individual, I acknowledge that I have been advised of this law, and I agree that I am signing this Release voluntarily, and with full knowledge of its consequences. I understand that Employer is giving Me twenty-one (21) days from the date I received a copy of this Release to decide whether I want to sign it. I acknowledge that I have been advised to use this time to consult with an attorney about the effect of this Release. If I sign this Release before the end of the twenty-one (21) day period it will be My personal, voluntary decision to do so, and will be done with full knowledge of My legal rights. I agree that material and/or immaterial changes to the Separation Agreement or this Release will not restart the running of this consideration period. I also acknowledge that the Separation Agreement, this Release and any other attachments or exhibits have each been written in a way that I understand.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">VII.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><u>Right to Rescind and/or Revoke</u>. I understand that insofar as this Release relates to my rights under the Age Discrimination in Employment Act, it shall not become effective or enforceable until seven (7) days after I sign it. I also have the right to rescind (or revoke) this Release insofar as it extends to potential claims under the ADEA by written notice to Employer within seven (7) calendar days following my signing this Release, and within fifteen (15) calendar days as to waiver of claims under the Minnesota Human Rights Act (the &ldquo;<u>Rescission Period</u>&rdquo;). Any such rescission (or revocation) must be in writing and hand-delivered to Employer or, if sent by mail, postmarked within the applicable time period, sent by certified mail, return receipt requested, and addressed as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">A.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">post-marked within the seven (7) day Rescission Period or, if applicable, fifteen (15) day Rescission Period;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">B.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">properly addressed to DiaMedica USA, Inc., Attention: Chief Executive Officer, Two Carlson Parkway, Suite 260, Minneapolis, MN 55447; and</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">C.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">sent by certified mail, return receipt requested.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">I understand that the Consideration I am receiving for settling and releasing my Claims is contingent upon my agreement to be bound by the terms of this Release. Accordingly, if I decide to revoke this Release as provided herein, I understand that I am not entitled to the Consideration offered in the Separation Agreement. I further understand that if I attempt to revoke my release of ADEA, MHRA or any other claims, I must immediately return to the Employer any Consideration that I may have received under my Separation Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">VIII.</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>I Understand the Terms of this Release</u>. I have had the opportunity to read this Release carefully and understand all its terms. I have had the opportunity to review this Release with My own attorney. In agreeing to sign this Release, I have not relied on any oral statements or explanations made by Employer, including its employees or attorneys. I understand and agree that this Release and the attached Agreement contain all the agreements between Employer and Me. We have no other written or oral agreements.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 53.8%;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:53.8%;">Scott Kellen</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:53.8%;">Dated: ____________, 20____</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 80%;">&nbsp;</td>
			<td style="width: 20%; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 80%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 80%;">&nbsp;</td>
			<td style="width: 20%;">EXECUTIVE INITIALS</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Ex. A-4</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>3
<FILENAME>ex_137869.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<html>
<head>
	<title>ex_137869.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2019 9:07:55 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.9</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>EMPLOYMENT AGREEMENT</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">This Employment Agreement (&ldquo;<u>Agreement</u>&rdquo;) is effective as of September 12, 2018 (&ldquo;<u>Effective Date</u>&rdquo;), by and between DiaMedica USA, Inc. a Delaware corporation (the &ldquo;<u>Company</u>&rdquo;), and Harry Alcorn, an individual (&ldquo;<u>Executive</u>&rdquo;). The Company and Executive are sometimes referred to as the &ldquo;<u>Parties</u>&rdquo; or &ldquo;<u>Party</u>&rdquo; in this Agreement, and the Company may designate the parent company of the Company or a subsidiary to be the employer of the Executive.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In consideration of the mutual promises, covenants and agreements contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>1.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>EMPLOYMENT AND DUTIES.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Job Title and Responsibilities</u>. The Company hereby employs Executive, and Executive hereby agrees to be employed, as Chief Medical Officer (together with such other position or positions consistent with Executive&rsquo;s title as the Company&rsquo;s Chief Executive Officer may specify from time to time), reporting to the Company&rsquo;s Chief Executive Officer and will have such duties and responsibilities commensurate with such title. The Parties understand, acknowledge and agree that Executive may also serve in similar positions with the parent company of the Company or any subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Full-Time Best Efforts</u>. Executive agrees to devote Executive&rsquo;s full professional time and attention to the business of the Company (and its subsidiaries, affiliates, or related entities) and the performance of Executive&rsquo;s obligations under this Agreement, and will at all times faithfully, industriously and to the best of Executive&rsquo;s ability, experience and talent, perform all of Executive&rsquo;s obligations hereunder. Executive shall not, at any time during Executive&rsquo;s employment by the Company, directly or indirectly, act as a partner, officer, director, consultant or Executive, or provide services in any other capacity to any other business enterprise that conflicts with the Company&rsquo;s business or Executive&rsquo;s duty of loyalty to the Company. Executive shall seek the written consent of the Company prior to accepting any outside board positions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Duty of Loyalty</u>. Executive acknowledges that during Executive&rsquo;s employment with the Company, Executive has participated in and will participate in relationships with existing and prospective clients, customers, partners, suppliers, service providers and vendors of the Company that are essential elements of the Company&rsquo;s goodwill. The parties acknowledge that Executive owes the Company a fiduciary duty to conduct all affairs of the Company in accordance with all applicable laws and the highest standards of good faith, trust, confidence and candor, and to endeavor, to the best of Executive&rsquo;s ability, to promote the best interests of the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conflict of Interest</u>. Executive agrees that while employed by the Company, and except with the advance written consent of the Board, Executive will not enter into, on behalf of the Company, or cause the Company or any of its affiliates to enter into, directly or indirectly, any transactions with any business organization in which Executive or any member of Executive&rsquo;s immediate family may be interested as a shareholder, partner, member, trustee, director, officer, employee, consultant, lender or guarantor or otherwise; <u>provided</u>, <u>however</u>, that nothing in this Agreement shall restrict transactions between the Company and any company whose stock is listed on a national securities exchange or actively traded in the over-the-counter market and over which Executive does not have the ability to control or significantly influence policy decisions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>2.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>COMPENSATION. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Base Pay</u>. The Company agrees to pay Executive gross annual compensation of $240,000 (&ldquo;<u>Base Salary</u>&rdquo;), less usual and customary withholdings, which shall be payable in arrears in accordance with the Company&rsquo;s customary payroll practices. The Base Salary will be subject to normal periodic review, and such review will consider Executive&rsquo;s contributions to the Company and the Company&rsquo;s overall performance.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Bonus and Incentive Compensation</u>. Executive shall be eligible for discretionary bonus and incentive based compensation approved by the Board of Directors of the Company (or a committee thereof) (the &ldquo;<u>Board</u>&rdquo;) from time to time at its sole discretion as to eligibility and timing of payments.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Equity Award</u>. Subject to approval by the Board (or a committee thereof), Executive shall be eligible to receive equity-based compensation awards from time to time as determined by the Board pursuant to the DiaMedica Therapeutics Inc. Stock Option Plan, or any successor plan thereto (such plan, the &ldquo;<u>Plan</u>&rdquo;). The type of equity award(s), grant timing and vesting terms will be in the sole discretion of the Board (or a committee thereof).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Benefits</u>. During Executive&rsquo;s employment, Executive will be eligible to participate in the Company&rsquo;s benefit programs, as governed by the terms of the official plan documents. Executive acknowledges that the Company may amend or terminate any of its benefit plans or programs at any time and for any reason. Executive will be eligible for paid time off or PTO per year, in accordance with the Company&rsquo;s policies in effect from time to time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Clawback</u>. Executive agrees that any incentive or other compensation or benefits provided by the Company under this Agreement or otherwise&nbsp;will be subject to recoupment or clawback by the Company under any applicable clawback or recoupment policy of the Company as may be in effect from time to time or as required by applicable law, regulation or stock exchange listing requirement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>3.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>CONFIDENTIAL INFORMATION.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Disclosure, Non-Use and Definition of Confidential Information</u>. Executive understands that during Executive&rsquo;s employment relationship with the Company, the Company intends to provide Executive with information, including Confidential Information (as defined herein), without which Executive would not be able to perform Executive&rsquo;s duties to the Company. Executive agrees, at all times during the term of Executive&rsquo;s employment relationship and thereafter, to hold in strictest confidence, and not to use or disclose, except for the benefit of the Company to the extent necessary to perform Executive&rsquo;s obligations to the Company, any Confidential Information that Executive obtains, accesses or creates during the term of the relationship, whether or not during working hours, until such Confidential Information becomes publicly and widely known and made generally available through no wrongful act of Executive or of others under confidentiality obligations as to the information involved. Executive understands that &ldquo;<u>Confidential Information</u>&rdquo; means information and physical material not generally known or available outside the Company and information and physical material entrusted to the Company by third parties under an obligation of non-disclosure or non-use or both. &ldquo;<u>Confidential Information</u>&rdquo; includes, without limitation, inventions, technical data, trade secrets, know-how, clinical data, regulatory information and strategies, marketing ideas or plans, research, product or service ideas or plans, business strategies, investments, investment opportunities, potential investments, market studies, industry studies, historical financial data, financial information and results, budgets, identity of customers, forecasts (financial or otherwise), possible or pending transactions, customer lists and domain names, price lists, and pricing methodologies. Any information that Executive knows or should reasonably know is Confidential Information, or that Employer treats as Confidential Information, will be presumed to be Confidential Information.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exceptions</u>. At all times, both during Executive&rsquo;s employment and after its termination, Executive will keep and hold all such Confidential Information in strict confidence and trust. Executive will not use or disclose any Confidential Information without the prior written consent of the Company, except as may be necessary to perform Executive&rsquo;s duties as an Executive of the Company for the benefit of the Company. Executive may disclose information that Executive is required to disclose by valid order of a government agency or court of competent jurisdiction, <u>provided</u> that Executive will:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notify the Company in writing immediately upon learning that such an order may be sought or issued,</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooperate with the Company as reasonably requested if the Company seeks to contest such order or to place protective restrictions on the disclosure pursuant to such order, and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Comply with any protective restrictions in such order and disclose only the information specified in the order.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Return of Confidential Information</u>. Upon termination of employment with the Company, Executive will promptly deliver to the Company all documents and materials of any nature pertaining to Executive&rsquo;s work with the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Copyright Information</u>. Executive agrees not to infringe the copyrights of the Company, its customers or third parties (including, without limitation, Executive&rsquo;s previous employers, customers, etc.) by unauthorized or unlawful copying, modifying or distributing of copyrighted material, including plans, drawings, reports, financial analyses, market studies, computer software and the like.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>4.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>COVENANT NOT TO COMPETE. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Competition Covenant.</u> Executive agrees that during the Restricted Period (as defined below), without the prior written consent of the Company, Executive shall not, directly or indirectly within the Territory (as defined below): (i) personally, by agency, as an Executive, independent contractor, consultant, officer, director, manager, agent, associate, investor (other than as a passive investor holding less than five percent (5%) of the outstanding equity of an entity), or by any other artifice or device, engage in any Competitive Business (as defined below), (ii) assist others, including but not limited to Executives of the Company, to engage in any Competitive Business, or (iii) own, purchase, finance or organize a Competitive Business.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp; &nbsp; &nbsp; &nbsp;<u>Definitions</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<u>Competitive Business</u>&rdquo; means (i) any person, entity or organization which is engaged in, consulting regarding or engaged in the development, production, marketing or selling of any pharmaceutical-based product, process, technology, invention or service which resembles, competes with or is intended to resemble or compete with a product, process, technology, device, invention or service under or being considered for research or development or being promoted, marketed, sold or serviced by the Company or any subsidiary; or (ii) any other line of business that the Company or any subsidiary, is actively preparing to pursue at any time during the term of Executive&rsquo;s employment with the Company and in which Executive is involved.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<u>Territory</u>&rdquo; means the United States of America or locations where the Company is directly or indirectly developing or selling products or services.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<u>Restricted Period</u>&rdquo; means the period of Executive&rsquo;s employment with the Company and for a period of twelve (12) months following the termination of Executive&rsquo;s employment.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>5.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>NON-SOLICITATION AND NON-INTERFERENCE COVENANTS. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Solicitation of Employees and Others</u>. During the Restricted Period, (i)&nbsp;Executive shall not, directly or indirectly, solicit, recruit, or induce, or attempt to solicit, recruit or induce any employee, consultant, independent contractor, vendor, supplier, or agent to terminate or otherwise adversely affect his or her employment or other business relationship (or prospective employment or business relationship) with the Company, and (ii) Executive shall not, directly or indirectly, solicit, recruit, or induce, or attempt to solicit, recruit or induce any employee to work for Executive or any other person or entity, other than the Company or its affiliates or related entities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Solicitation of Customers</u>. During the Restricted Period, Executive shall not, directly or indirectly, solicit, recruit, or induce any Customer (as defined below) for the purpose of (i)&nbsp;providing any goods or services related to a Competitive Business, or (ii) interfering with or otherwise adversely affecting the contracts or relationships, or prospective contracts or relationships, between the Company (including any related or affiliated entities) and such Customers. &ldquo;<u>Customer</u>&rdquo; means a person or entity with which Executive had contact or about whom Executive gained information while an employee of the Company, and to which the Company was selling or providing products or services, was in active negotiations for the sale of its products or services, or was otherwise doing business as of the date of the cessation of Executive&rsquo;s employment with the Company or for whom the Company had otherwise done business within the twelve (12) month period immediately preceding the cessation of Executive&rsquo;s employment with the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>6.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>ACKNOWLEDGEMENTS. </b>Executive acknowledges and agrees that:<b> </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The geographic and duration restrictions contained in Sections 4 and 5 of this Agreement are fair, reasonable, and necessary to protect the Company&rsquo;s legitimate business interests and trade secrets, given the geographic scope of the Company&rsquo;s business operations, the competitive nature of the Company&rsquo;s business, and the nature of Executive&rsquo;s position with the Company;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive&rsquo;s employment creates a relationship of confidence and trust between Executive and the Company with respect to the Confidential Information, and Executive will have access to Confidential Information (including but not limited to trade secrets) that would be valuable or useful to the Company&rsquo;s competitors;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&rsquo;s Confidential Information is a valuable asset of the Company, and any violation of the restrictions set forth in this Agreement would cause substantial injury to the Company;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The restrictions contained in this Agreement will not unreasonably impair or infringe upon Executive&rsquo;s right to work or earn a living after Executive&rsquo;s employment with the Company ends; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is a contract for the protection of trade secrets under applicable law and is intended to protect the Confidential Information (including trade secrets) identified above.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>7.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>&ldquo;BLUE PENCIL&rdquo; AND SEVERABILITY PROVISION. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">If a court of competent jurisdiction declares any provision of this Agreement invalid, void, voidable, or unenforceable, the court shall reform such provision(s) to render the provision(s) enforceable, but only to the extent absolutely necessary to render the provision(s) enforceable and only in view of the parties&rsquo; express desire that the Company be protected to the greatest possible extent under applicable law from improper competition and the misuse or disclosure of trade secrets and Confidential Information. To the extent such a provision (or portion thereof) may not be reformed so as to make it enforceable, it may be severed and the remaining provisions shall remain fully enforceable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>8.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>INVENTIONS. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Inventions Retained and Licensed</u>. Executive acknowledges and agrees that Executive has no rights in any Inventions (as that term is defined below) other than inventions and information created, discovered or developed by Executive, whether or not patentable or registrable under patent, copyright or similar statutes, made or conceived or reduced to practice or learned by Executive, either alone or with others before Executive&rsquo;s employment with the Company, which list of inventions Executive has provided the Company in writing on or prior to the Effective Date (&ldquo;<u>Prior Inventions</u>&rdquo;). Executive shall not incorporate, or permit to be incorporated, any Prior Invention owned by Executive or in which he has an interest in a Company product, process or machine without the Company&rsquo;s prior written consent. Notwithstanding the foregoing, if, in the course of Executive&rsquo;s employment with the Company, Executive directly or indirectly incorporates into a Company product, process or machine a Prior Invention owned by Executive or in which Executive has an interest, the Company is hereby granted and shall have a non-exclusive, royalty-free, irrevocable, perpetual, world-wide license to make, have made, modify, use, create derivative works from and sell such Prior Invention as part of or in connection with such product, process or machine.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignment of Inventions</u>. Executive shall promptly make full, written disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and hereby irrevocably transfers and assigns, and agrees to transfer and assign, to the Company, or its designee, all Executive&rsquo;s right, title and interest in and to any and all inventions, original works of authorship, developments, concepts, improvements, designs, discoveries, ideas, trademarks (and all associated goodwill), mask works, or trade secrets, whether or not they may be patented or registered under copyright or similar laws, which Executive may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during Executive&rsquo;s employment by the Company (the &ldquo;<u>Inventions</u>&rdquo;). Executive further acknowledges that all original works of authorship which are made by Executive (solely or jointly with others) within the scope of and during the period of Executive&rsquo;s employment with the Company and which may be protected by copyright are &ldquo;<u>Works Made For Hire</u>&rdquo; as that term is defined by the United States Copyright Act. Executive understands and agrees that the decision whether to commercialize or market any Invention developed by Executive solely or jointly with others is within the Company&rsquo;s sole discretion and the Company&rsquo;s sole benefit and that no royalty will be due to Executive as a result of the Company&rsquo;s efforts to commercialize or market any such invention.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Executive recognizes that Inventions relating to Executive&rsquo;s activities while working for the Company and conceived or made by Executive, whether alone or with others, within one (1) year after cessation of Executive&rsquo;s employment, may have been conceived in significant part while employed by the Company. Accordingly, Executive acknowledges and agrees that such Inventions shall be presumed to have been conceived during Executive&rsquo;s employment with the Company and are to be, and hereby are, assigned to the Company unless and until Executive has established the contrary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The requirements of this Section 8B do not apply to any intellectual property for which no equipment, supplies, facility or trade secret information of the Company was used, and which was developed entirely on the Executive&rsquo;s own time, and (i) which does not relate (x) directly to the Company&rsquo;s business or (y) to the Company&rsquo;s actual or demonstrably anticipated research and development or (ii) which does not result from any work the Executive performed for the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Maintenance of Records</u>. Executive agrees to keep and maintain adequate and current written records of all Inventions made by Executive (solely or jointly with others) during Executive&rsquo;s employment with the Company. The records will be in the form of notes, sketches, drawings and any other format that may be specified by the Company. The records will be available to and remain the sole property of the Company at all times.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Patent, Trademark and Copyright Registrations</u>. Executive agrees to assist the Company, or its designee, at the Company&rsquo;s expense, in every proper way to secure the Company&rsquo;s rights in the Inventions and any copyrights, patents, trademarks, service marks, mask works, or any other intellectual property rights in any and all countries relating thereto, including, but not limited to, the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments and all other instruments the Company reasonably deems necessary in order to apply for and obtain such rights and in order to assign and convey to the Company, its successors, assigns, and nominees the sole and exclusive rights, title, and interest in and to such inventions, and any copyrights, patents, trademarks, service marks, mask works, or any other intellectual property rights relating thereto. Executive further agrees that Executive&rsquo;s obligation to execute or cause to be executed, when it is in Executive&rsquo;s power to do so, any such instrument or paper shall continue after termination or expiration of this Agreement or the cessation of Executive&rsquo;s employment with the Company. If the Company is unable because of Executive&rsquo;s mental or physical incapacity or for any other reason, after reasonably diligent efforts, to secure Executive&rsquo;s signature to apply for or to pursue any application for any United States or foreign patents, trademarks or copyright registrations covering inventions or original works of authorship assigned to the Company as above, then Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Executive&rsquo;s agent and attorney-in-fact to act for and in Executive&rsquo;s behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent, trademarks or copyright registrations thereon with the same legal force and effect as if executed by Executive; this power of attorney shall be a durable power of attorney which shall come into existence upon Executive&rsquo;s mental or physical incapacity.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>9.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>SURVIVAL AND REMEDIES. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Executive&rsquo;s obligations of nondisclosure, non-solicitation, non-interference, and non-competition under this Agreement shall survive the cessation of Executive&rsquo;s employment with the Company and shall remain enforceable. In addition, Executive acknowledges that upon a breach or threatened breach of any obligation of nondisclosure, non-solicitation, non-interference, or non-competition of this Agreement, the Company may suffer irreparable harm and damage for which money alone cannot fully compensate the Company. Executive therefore agrees that upon such breach or threat of imminent breach of any such obligation, the Company shall be entitled to seek a temporary restraining order, preliminary injunction, permanent injunction or other injunctive relief, without posting any bond or other security, barring Executive from violating any such provision. This Section 9 shall not be construed as an election of any remedy, or as a waiver of any right available to the Company under this Agreement or the law, including the right to seek damages from Executive for a breach of any provision of this Agreement and the right to require Executive to account for and pay over to the Company all profits or other benefits derived or received by Executive as the result of such a breach, nor shall this Section 9 be construed to limit the rights or remedies available under state law for any violation of any provision of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>10.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>TERMINATION.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination By Either Party</u>. Either Party may terminate the Executive&rsquo;s at-will employment at any time with or without notice, and with or without cause. Except as provided in this Section 10, upon termination of employment, Executive shall only be entitled to Executive&rsquo;s accrued but unpaid Base Salary, any earned but unpaid bonus for the year prior to the date of termination, and other benefits earned under any Company-provided plans, policies and arrangements for the period preceding the effective date of the termination of employment. With respect to any earned but unpaid bonus for the year prior to the date of termination, the terms of which bonus plan require Executive to be an employee of the Company as of the date of payment, no payment will be made to Executive (or if applicable, the Executive&rsquo;s beneficiary) if Executive&rsquo;s employment with the Company terminates voluntarily by Executive, other than for Good Reason pursuant to Section 10C, or if Executive&rsquo;s employment with the Company is terminated by the Company for Cause, but will be paid if Executive&rsquo;s employment with the Company terminates due to Executive&rsquo;s death or disability.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination Without Cause</u>. If the Company terminates Executive&rsquo;s employment without Cause (defined below), Executive shall be entitled to receive, in addition to the amounts due under Section 10A, as continuing severance pay at a rate equal to Executive&rsquo;s Base Salary, as then in effect, for nine (9) months from the date of termination of employment, plus a lump-sum payment equal to a pro rata portion of Executive&rsquo;s target annual bonus for the year in which the date of termination occurs (based on the date of termination), in each case, less all required tax withholdings and other applicable deductions, payable in accordance with the Company&rsquo;s standard payroll procedures, commencing on the effective date of a Separation Agreement and Release of claims against the Company and after the end of any applicable rescission or revocation period, and provided that Executive has not revoked or rescinded (or attempted to revoke or rescind) any claims under such Release, in substantially the form of <u>Exhibit A</u> attached hereto, the timely execution and performance by Executive of which is specifically a condition to Executive&rsquo;s receipt of any of the payments and benefits provided under this Section 10B; <u>provided</u> that (1)&nbsp;such Separation Agreement and Release shall be executed and be fully effective within sixty (60) days of the Executive&rsquo;s termination of employment; (2) the first payment shall include any amounts that would have been paid to Executive if payment had commenced on the date of termination of employment; and (3) Executive shall not be required to execute a release of any claims arising from the Company&rsquo;s failure to comply with its obligations under Section 10A. Subject to Executive&rsquo;s execution and non-revocation of the Separation Agreement and Release, if Executive timely and effectively elects continuation coverage under the Company&rsquo;s group health plan pursuant to COBRA or similar state law, the Company will pay or reimburse the premiums for such coverage of Executive (and Executive&rsquo;s dependents, as applicable) at the same rate it pays for active employees for a period for nine (9) months from the date of termination of employment; <u>provided</u> that the Company&rsquo;s obligation to make such payments shall immediately expire if Executive ceases to be eligible for continuation coverage under COBRA or similar state law or otherwise terminates such coverage. Notwithstanding the foregoing, any of the foregoing payments due under this Section 10B shall commence within seventy (70) days of Executive&rsquo;s termination of employment, <u>provided</u> that if such seventy (70)-day period spans two (2) calendar years, payments shall commence in the latter calendar year. In addition to the foregoing and subject to Executive&rsquo;s timely execution of a Separation Agreement and Release that has been executed and not revoked within any applicable rescission period that has expired within sixty (60) days of the Executive&rsquo;s termination of employment, Executive shall be entitled to the immediate vesting of all outstanding equity awards then held by Executive.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination Upon a Change in Control</u>. If the Company or any successor in interest to the Company terminates Executive&rsquo;s employment without Cause in connection with or within twelve (12) months after a Change in Control (defined below) or if Executive terminates Executive&rsquo;s employment for Good Reason (defined below) within twelve (12) months after a Change in Control, Executive shall be entitled to receive, in addition to the amounts due under Section 10A, a lump-sum payment equal to twelve (12) months of Executive&rsquo;s Base Salary, as then in effect or as in effect immediately prior to a material reduction of Executive&rsquo;s Base Salary which was the reason Executive resigned for Good Reason, plus a lump-sum payment equal to a pro rata portion of Executive&rsquo;s target annual bonus for the year in which the date of termination occurs (based on the date of termination), in each case, less all tax withholdings and other applicable deductions the Company reasonably determines are required to be made, payable on the first regular payroll date after the effective date of a Separation Agreement and Release that has been executed and not revoked within any applicable rescission period that has expired within sixty (60) days of the Executive&rsquo;s termination of employment, in substantially the form of <u>Exhibit A</u> attached hereto, the execution and performance by Executive of which is specifically a condition to Executive&rsquo;s receipt of any of the payments and benefits provided under this Section 10C; <u>provided</u> that Executive shall not be required to execute a release of any claims arising from the Company&rsquo;s failure to comply with its obligations under Section 10A. Subject to Executive&rsquo;s execution and non-revocation of the Separation Agreement and Release, if Executive timely and effectively elects continuation coverage under the Company&rsquo;s group health plan pursuant to COBRA or similar state law, the Company will pay or reimburse the premiums for such coverage of Executive (and Executive&rsquo;s dependents, as applicable) at the same rate it pays for active employees for a period for twelve (12) months from the date of termination of employment; <u>provided</u> that the Company&rsquo;s obligation to make such payments shall immediately expire if Executive ceases to be eligible for continuation coverage under COBRA or similar state law or otherwise terminates such coverage. Notwithstanding the previous provisions of this Section 10C, any payments due under this Section 10C shall commence within seventy (70) days of Executive&rsquo;s termination of employment, <u>provided</u> that if such seventy (70)-day period spans two calendar years, payments shall commence in the latter calendar year. In addition to the foregoing and subject to Executive&rsquo;s timely execution of a Separation Agreement and Release that has been executed and not revoked within any applicable rescission period that has expired within sixty (60) days of the Executive&rsquo;s termination of employment, Executive shall be entitled to the immediate vesting of all outstanding equity awards then held by Executive. The payments and benefits described in this Section 10C are in lieu of, and not in addition to, the payments and benefits described in Section 10B, it being understood by Executive that he shall be paid and receive only one set of severance payments and benefits.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Notwithstanding any other provisions of this Agreement, if any &ldquo;payments&rdquo; (including, without limitation, any benefits or transfers of property or the acceleration of the vesting of any benefits) in the nature of compensation under any arrangement that is considered contingent on a &ldquo;change in control&rdquo; for purposes of Section 280G of the Internal Revenue Code of 1986, as amended (the &ldquo;<u>Code</u>&rdquo;), together with any other payments that Executive has the right to receive from the Company or any corporation that is a member of an &ldquo;affiliated group&rdquo; (as defined in Section 1504(a) of the Code without regard to Section 1504(b) of the Code) of which the Company is a member, would constitute a &ldquo;parachute payment&rdquo; (as defined in Section 280G(b)(2) of the Code), such &ldquo;payments&rdquo; may, at Executive&rsquo;s sole election, be reduced to the largest amount as will result in no portion of such &ldquo;payments&rdquo; being subject to the excise tax imposed by Section 4999 of the Code. Any reduction of the payments shall be made in the following order: (1) options with an exercise price above the fair market value of the stock, provided the options give rise to a payment; (2) pro rata among amounts that constitute deferred compensation under Code Section 409A; and (3) reduction of any remaining payments in the manner determined at the discretion of Executive.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the change in control shall perform the foregoing calculations. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The accounting firm shall provide its calculations to the Company and Executive within sixty (60) calendar days after the date on which Executive&rsquo;s right to a payment is triggered and the payment will be paid to Executive within seventy-four (74) calendar days of the date on which Executive&rsquo;s right to a payment is triggered. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination for Cause, Death or Disability, or Resignation</u>. If Executive&rsquo;s employment with the Company terminates voluntarily by Executive, other than for Good Reason pursuant to Section 10C above, or if Executive&rsquo;s employment with the Company is terminated by the Company for Cause or due to Executive&rsquo;s death or disability, then payments of compensation by the Company to Executive hereunder will terminate immediately, except that Executive (or the Executive&rsquo;s beneficiary if Executive&rsquo;s termination is on account of death) will be entitled to the amounts due under Section 10A.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<u>Cause</u>.&rdquo; For all purposes under this Agreement, &ldquo;<u>Cause</u>&rdquo; is defined as (a) gross negligence or willful failure to perform Executive&rsquo;s duties and responsibilities to the Company; (b) commission of any act of fraud, theft, embezzlement, financial dishonesty or any other willful misconduct that has caused or is reasonably expected to result in injury to the Company; (c)&nbsp;conviction of, or pleading guilty or <i>nolo contendere</i> to, any felony or a lesser crime involving dishonesty or moral turpitude; (d) material breach by Executive of any of Executive&rsquo;s obligations under this Agreement or any written agreement or covenant with the Company, including the policies adopted from time to time by the Company applicable to all Executives, that has not been cured within thirty (30) days of notice of such breach or (e) the Company terminates the employment of Executive in connection with a liquidation, dissolution or winding down of the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<u>Good Reason</u>.&rdquo; For all purposes under this Agreement, &ldquo;<u>Good Reason</u>&rdquo; is defined as Executive&rsquo;s resignation within thirty (30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without Executive&rsquo;s express written consent: (a) a material reduction of Executive&rsquo;s duties, authority, reporting level, or responsibilities, relative to Executive&rsquo;s duties, authority, reporting level, or responsibilities in effect immediately prior to such Change in Control; (b) a material reduction in Executive&rsquo;s base compensation; or (c) the Company&rsquo;s requiring of Executive to change the principal location at which Executive is to perform Executive&rsquo;s services by more than fifty (50) miles. Executive will not resign for Good Reason without first providing the Company with written notice within thirty (30) days of the initial occurrence of the event that Executive believes constitutes &ldquo;<u>Good Reason</u>&rdquo; specifically identifying the acts or omissions constituting the grounds for Good Reason and providing Company a reasonable cure period of not less than thirty (30) days following the date of such notice and during which such condition has not been cured.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<u>Change in Control</u>.&rdquo; For all purposes under this Agreement, a &ldquo;<u>Change in Control</u>&rdquo; will mean the occurrence of any of the following:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 90pt;">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the acquisition, other than from the Company or Parent (as defined below), by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (&ldquo;<u>Exchange Act</u>&rdquo;)) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of either the then outstanding common shares, no par value (&ldquo;<u>Common Shares</u>&rdquo;), of DiaMedica Therapeutics Inc., a company organized under the laws of Canada (&ldquo;<u>Parent</u>&rdquo;), or the combined voting power of the then outstanding voting securities of Parent entitled to vote generally in the election of directors, but excluding, for this purpose, any such acquisition by Parent or any of its subsidiaries, or any employee benefit plan (or related trust) of Parent or its subsidiaries, or any entity with respect to which, following such acquisition, more than fifty percent (50%) of, respectively, the then outstanding equity of such entity and the combined voting power of the then outstanding voting equity of such entity entitled to vote generally in the election of all or substantially all of the members of such entity&rsquo;s governing body is then beneficially owned, directly or indirectly, by the individuals and entities who were the beneficial owners, respectively, of the Common Shares and voting securities of Parent immediately prior to such acquisition in substantially the same proportion as their ownership, immediately prior to such acquisition, of the then outstanding Common Shares or the combined voting power of the then outstanding voting securities of Parent entitled to vote generally in the election of directors, as the case may be; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">11</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 90pt;">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the consummation of a reorganization, merger or consolidation of Parent, in each case, with respect to which all or substantially all of the individuals and entities who were the respective beneficial owners of the Common Shares and voting securities of Parent immediately prior to such reorganization, merger or consolidation do not, following such reorganization, merger or consolidation, beneficially own, directly or indirectly, more than fifty percent (50%) of, respectively, the then outstanding Common Shares and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such reorganization, merger or consolidation; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 90pt;">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the sale or other disposition of all or substantially all of the assets of Parent; provided the occurrence under (a), (b) or (c), constitutes a &ldquo;change in the ownership or effective control of a corporation, or a change in the ownership of a substantial portions of the assets of a corporation&rdquo; under Section 409A of the Code.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Other Benefits</u>. In the event of a termination of Executive&rsquo;s employment with the Company, the provisions of this Section 10 are Executive&rsquo;s exclusive right to severance benefits and are in lieu of participation in any other severance policy or plan to which Executive might otherwise be entitled.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">G.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination from any Offices Held</u>. Upon Executive&rsquo;s termination of employment with the Company, Executive agrees that and any and all offices held with Parent or any subsidiary, including the Company, if applicable, shall be automatically terminated. Executive agrees to cooperate with the Company and execute any documents reasonably required by the Company or competent authorities to effect this provision.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">H.&nbsp;&nbsp; &nbsp;<u>Return of Company Property</u>. All devices, records, reports, data, notes, compilations, lists, proposals, correspondence, specifications, equipment, drawings, blueprints, manuals, planners, calendars, schedules, discs, financial plans and information, or other recorded matter, whether in hard copy, electronic media or otherwise (including all copies or reproductions made or maintained, whether on the Company&rsquo;s premises or otherwise), pertaining to Executive&rsquo;s work for the Company, or relating to the Company or the Company&rsquo;s Confidential Information, whether created or developed by Executive alone or jointly during Executive&rsquo;s employment with the Company, are the exclusive property of the Company. Executive shall surrender the same (as well as any other property of the Company) to the Company upon its request or promptly upon the cessation of employment.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>11.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>NO CONFLICTING AGREEMENTS OR IMPROPER USE OF THIRD-PARTY INFORMATION. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">During Executive&rsquo;s employment with the Company, Executive shall not improperly use or disclose any Confidential information or trade secrets of any former employer or other person or entity, and Executive shall not bring on to the premises of the Company any unpublished document or Confidential information belonging to any such former employer, person or entity, unless consented to in writing by the former employer, person or entity. Executive represents that he has not improperly used or disclosed any Confidential information or trade secrets of any other person or entity during the application process or while employed or affiliated with the Company. Executive also acknowledges and agrees that he is not subject to any contract, agreement, or understanding that would prevent Executive from performing Executive&rsquo;s duties for the Company or otherwise complying with this Agreement. To the extent Executive violates this provision, or Executive&rsquo;s employment with the Company constitutes a breach or threatened breach of any contract, agreement, or obligation to any third party, Executive shall indemnify and hold the Company harmless from all damages, expenses, costs (including reasonable attorneys&rsquo; fees) and liabilities incurred in connection with, or resulting from, any such violation or threatened violation.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>12.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>GENERAL PROVISIONS.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law; Consent To Personal Jurisdiction</u>. The laws of the State of Minnesota shall govern the Executive&rsquo;s employment and this Agreement without regard to conflict of laws principles. Executive and the Company each hereby consents to the personal jurisdiction of the state courts located in Hennepin County, State of Minnesota, and the federal district court sitting in Hennepin County, State of Minnesota, if that court otherwise possesses jurisdiction over the matter, for any legal proceeding concerning Executive&rsquo;s employment or termination of employment, or arising from or related to this Agreement or any other agreement executed between Executive and the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement</u>. This Agreement, together with the Exhibits hereto, sets forth this entire Agreement between the Company (and any of its related or affiliated entities, officers, agents, owners or representatives) and Executive relating to the subject matter herein, and supersedes any and all prior discussions and agreements, whether written or oral, on the subject matter hereof, including without limitation that certain offer letter agreement dated as of January 2, 2018. To the extent that this Agreement may conflict with the terms of another written agreement between Executive and the Company, the terms of this Agreement will control.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Modification</u>. No modification of or amendment to this Agreement will be effective unless in writing and signed by Executive and an authorized representative of the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver</u>. The Company&rsquo;s failure to enforce any provision of this Agreement shall not act as a waiver of its ability to enforce that provision or any other provision. The Company&rsquo;s failure to enforce any breach of this Agreement shall not act as a waiver of that breach or any future breach. No waiver of any of the Company&rsquo;s rights under this Agreement will be effective unless in writing. Any such written waiver shall not be deemed a continuing waiver unless specifically stated, and shall operate only as to the specific term or condition waived and shall not constitute a waiver of such term or condition for the future or as to any act other than that specifically waived.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">13</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. This Agreement shall be assignable to, and shall inure to the benefit of and bind, the Company&rsquo;s, affiliates, subsidiaries, successors and assigns. Executive shall not have the right to assign Executive&rsquo;s rights or obligations under this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Construction</u>. The language used in this Agreement will be deemed to be language chosen by Executive and the Company to express their mutual intent, and no rules of strict construction will be applied against either Party.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">G.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts</u>. This Agreement may be executed in any number of counterparts, each of which shall be enforceable, and all of which together shall constitute one agreement. Signatures of the parties that are transmitted in person or by facsimile or e-mail shall be accepted as originals.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">H.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Further Assurances</u>. Executive agrees to execute any proper oath or verify any document required to carry out the terms of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Title and Headings</u>. The titles, captions and headings of this Agreement are included for ease of reference only and will be disregarded in interpreting or construing this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">J.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. All notices and communications that are required or permitted to be given under this Agreement shall be in writing and shall be sufficient in all respects if given and delivered in person, by electronic mail, by facsimile, by overnight courier, or by certified mail, postage prepaid, return receipt requested, to the receiving Party at such Party&rsquo;s address shown in the signature blocks below or to such other address as such Party may have given to the other by notice pursuant to this Section. Notice shall be deemed given (i) on the date of delivery in the case of personal delivery, electronic mail or facsimile, or (ii) on the delivery or refusal date as specified on the return receipt in the case of certified mail or on the tracking report in the case of overnight courier.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">K.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Code Section 409A</u>. The amounts payable under this Agreement are intended to be exempt from the requirements of Section 409A of the Code (&ldquo;<u>Section 409A</u>&rdquo;). For purposes of Section 409A, any right to a series of installment payments is to be treated as a right to a series of separate payments. Any payments due under this Agreement on account of a termination of employment shall only be payable if the termination constitutes a &ldquo;separation from service&rdquo; within the meaning of Section 409A. To the extent that any such payments are determined to be deferred compensation subject to Section 409A, (i) the terms of this Agreement shall be interpreted to avoid incurring any penalties under Section 409A, and (ii) any payments due to a &ldquo;specified Executive&rdquo; of a publicly-traded company upon a separation from service shall be delayed until the first day of the seventh month following such separation from service. Notwithstanding the foregoing, in no event shall the Company be responsible for any taxes or penalties due under Section 409A.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>13.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="text-transform:uppercase;font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>EXECUTIVE&rsquo;S ACKNOWLEDGMENTS. </b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Executive acknowledges that he is executing this Agreement voluntarily and without duress or undue influence by the Company or anyone else and that Executive has carefully read this Agreement and fully understands the terms, consequences, and binding effect of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i>[Remainder of page intentionally left blank]</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">14</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed this Employment Agreement as of the date first written above.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td colspan="2" rowspan="1" style="width: 7%;" valign="top" width="50%"><b>EXECUTIVE</b></td>
			<td style="width: 15%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" rowspan="1" style="width: 8%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><b>DIAMEDICA USA, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 7%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 15%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 8%;" valign="bottom" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 7%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="50%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 15%;" valign="top" width="3%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 8%;" valign="top" width="35%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="12%">
			<p style="margin-top: 0; margin-bottom: 0;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 7%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 8%;" valign="top" width="35%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" rowspan="1" style="width: 7%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="50%">/s/ Harry Alcorn Jr.</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 8%;" valign="top" width="35%">Print Name:</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="12%">Rick Pauls&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" rowspan="1" style="width: 7%;" valign="top" width="50%">Harry Alcorn Jr.</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 8%;" valign="top" width="35%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 8%;" valign="top" width="35%">Signature:</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="12%">/s/ Rick Pauls</td>
		</tr>
		<tr>
			<td style="width: 7%;" valign="top" width="50%">Date:</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="50%">9/14/2018</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 8%;" valign="top" width="35%">Title:</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="12%">President &amp; CEO</td>
		</tr>
		<tr>
			<td style="width: 7%;" valign="top" width="50%">Address:</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="50%">2 Carlson Parkway, Suite 260</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 8%;" valign="top" width="35%">Date:</td>
			<td style="width: 35%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="12%">9/14/2018</td>
		</tr>
		<tr>
			<td colspan="2" rowspan="1" style="width: 7%; border-bottom: thin solid rgb(0, 0, 0);" valign="top" width="50%">Minneapolis, MN 55447</td>
			<td style="width: 15%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 8%;" valign="top" width="35%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="12%">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>EXHIBIT A</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>FORM OF SEPARATION AGREEMENT AND RELEASE</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">This Separation Agreement (&ldquo;<u>Agreement</u>&rdquo;) and the Release, which is attached and incorporated by reference as <u>Exhibit A</u> (&ldquo;<u>Release</u>&rdquo;), are made by and between Harry Alcorn (&ldquo;<u>Executive</u>&rdquo;), and DiaMedica USA, Inc., its affiliates, related or predecessor corporations, parent, subsidiaries, successors and assigns (&ldquo;<u>Employer</u>&rdquo;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Employer and Executive (collectively, &ldquo;<u>Parties</u>&rdquo;) wish to end their employment relationship in an honorable, dignified and orderly fashion. Toward that end, the Parties have agreed to separate according to the following terms.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">IN CONSIDERATION OF THIS AGREEMENT, THE PARTIES AGREE AS FOLLOWS:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">1.&nbsp; &nbsp; &nbsp;&nbsp;<u>Termination</u>. Executive&rsquo;s employment shall end on a date and time Employer shall determine (&ldquo;<u>Termination Date</u>&rdquo;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.&nbsp; &nbsp; &nbsp;<u>Consideration</u>. Employer shall, (1) after receipt of a fully executed Agreement and Release; (2) after expiration of all applicable rescission periods; and (3) provided Executive complies with Executive&rsquo;s obligations under this Agreement, provide Executive with separation benefits (&ldquo;<u>Consideration</u>&rdquo;) in compliance with Executive&rsquo;s Employment Agreement attached as <u>Exhibit B</u>:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">3.&nbsp; &nbsp; &nbsp;&nbsp;<u>Termination of Benefits</u>. Except as otherwise provided by this Agreement, Executive&rsquo;s participation in Employer&rsquo;s employee benefits, bonus, and all other compensation or commission plans, will terminate on the Termination Date, unless otherwise provided by law, or benefit plan. Executive shall receive no compensation or benefits under such plans, except as specifically provided in Section 2 of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">4.&nbsp; &nbsp; &nbsp;&nbsp;<u>Execution of Agreement and Release of all Claims</u>. Executive agrees to fully execute this Agreement, and the Release attached as <u>Exhibit A</u>, releasing any and all actual or potential claims which may have arisen at any time during Executive&rsquo;s employment with or termination from employment with Employer. Executive&rsquo;s failure to execute this Agreement and/or Release, or any attempt to rescind this Agreement or that Release, shall terminate this Agreement, and the Parties&rsquo; respective rights and obligations under this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">5.&nbsp; &nbsp; &nbsp;<u>Satisfactory Performance and Cooperation During Transition</u>. Executive shall fully cooperate with Employer in responding to questions, providing assistance and information, and defending against claims of any type, and will otherwise assist Employer as Employer may request through Executive&rsquo;s Termination Date (&ldquo;<u>Transition Period</u>&rdquo;). More specifically:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">a.&nbsp; &nbsp; &nbsp; During the Transition Period, Executive shall reasonably cooperate with Employer as it meets and otherwise communicates/works, with Employer&rsquo;s employees, customers, strategic relationships, consultants, and vendors on the transition of Executive&rsquo;s duties to other individuals. Executive shall be available, upon reasonable notice, during business hours to respond to Employer&rsquo;s questions and electronic communications. Employer shall reimburse Executive for Executive&rsquo;s reasonable out-of-pocket expenses (such reimbursement shall not include compensation for any such time or Executive&rsquo;s attorney&rsquo;s fees) incurred in accordance with this Section upon submission of receipts to Employer for such expenses.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">16</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 63pt;">b.&nbsp; &nbsp; &nbsp;Executive shall not, absent Employer&rsquo;s specific approval, initiate any form of communication with Employer&rsquo;s employees, customers or strategic partners regarding Employer, Employer&rsquo;s products or employees, and shall communicate with such persons in the above capacity only in conjunction with person(s) who Employer has designated to participate in such communications.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">6.&nbsp; &nbsp; &nbsp;&nbsp;<u>Stipulation of No Charges</u>. Executive affirmatively represents that Executive has not filed nor caused to be filed any charges, claims, complaints, or actions against Employer before any federal, state, or local administrative agency, court, or other forum. Except as expressly provided in this Agreement or required by law, Executive acknowledges and agrees that Executive has been paid all wages, bonuses, compensation, benefits and other amounts that are due, with the exception of any vested right under the terms of a written ERISA-qualified benefit plan. Executive waives any right to any form of recovery or compensation from any legal action, excluding any action claiming this Agreement and Release violate the Age Discrimination in Employment Act (&ldquo;<u>ADEA</u>&rdquo;) and/or the Older Workers Benefit Protection Act (&ldquo;<u>OWBPA</u>&rdquo;), filed or threatened to be filed by Executive or on Executive&rsquo;s behalf based on Executive&rsquo;s employment, terms of employment, or separation from, Employer. Executive understands that any Consideration paid to Executive pursuant to this Agreement may be deducted from any monetary award Executive may receive as a result of a successful ADEA and/or OWBPA claim or challenge to this Agreement and Release. This does not preclude Executive from eligibility for unemployment benefits, and does not preclude or obstruct Executive&rsquo;s right to file a Charge with the Equal Employment Opportunity Commission (&ldquo;<u>EEOC</u>&rdquo;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.&nbsp; &nbsp; &nbsp;&nbsp;<u>Return of Property</u>. Executive shall return, on or before the Termination Date, all Employer property in Executive&rsquo;s possession or control, including but not limited to any drawings, orders, files, documents, notes, computers, laptop computers, fax machines, cell phones, smart devices, access cards, fobs, keys, reports, manuals, records, product samples, correspondence and/or other documents or materials related to Employer&rsquo;s business that Executive has compiled, generated or received while working for Employer, including all electronically stored information, copies, samples, computer data, disks, or records of such materials. Executive must return to Employer, and Executive shall not retain, any Employer property as previously defined in this section.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.&nbsp; &nbsp; &nbsp;<u>Agreement Not to Seek Future Employment</u>. Executive agrees that Executive will never knowingly seek nor accept employment or a consulting/independent contractor relationship with Employer, nor any other entity owned by Employer, either directly or through a consulting firm.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">17</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">9.&nbsp; &nbsp; &nbsp;&nbsp;<u>Withholding for Amounts Owed to Employer</u>. Execution of this Agreement shall constitute Executive&rsquo;s authorization for Employer to make deductions from Executive&rsquo;s Consideration, for Executive&rsquo;s indebtedness to Employer, or to repay Employer for unaccrued vacation or other Paid Time Off already taken, Executive purchases, wage or benefit overpayment, or other Employer claims against Executive, to the extent permitted by applicable law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Disparagement</u>. Executive agrees that, unless it is in the context of an EEOC or other civil rights or other government enforcement agency investigation or proceeding, Executive will make no critical, disparaging or defamatory comments regarding Employer or any Released Party, as defined in the Release, in any respect or make any comments concerning the conduct or events which precipitated Executive&rsquo;s separation. Furthermore, Executive agrees not to assist or encourage in any way any individual or group of individuals to bring or pursue a lawsuit, charge, complaint, or grievance, or make any other demands against Employer or any Released Party. This provision does not prohibit Executive from participating in an EEOC or other civil rights or other government enforcement agency charge, investigation or proceeding, or from providing testimony or documents pursuant to a lawful subpoena or as otherwise required by law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Employment Agreement and Protection of Confidential Information.</u> Executive agrees to comply with the provisions of and the restrictions set forth in Executive&rsquo;s Employment Agreement (Exhibit B), including without limitation the obligation not to use or disclose Confidential Information (as defined in the Employment Agreement).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Confidentiality</u>. It is the intent of Employer and Executive that the terms of this Agreement be treated as Confidential Information (as defined in the Employment Agreement), except to the extent this Agreement is required to be disclosed under applicable federal securities laws, as determined by Employer. Executive warrants that Executive has not and agrees that Executive will not in the future disclose the terms of this Agreement, or the terms of the Consideration to be paid by Employer to Executive as part of this Agreement, to any person other than Executive&rsquo;s attorney, tax advisor, spouse, or representatives of any state or federal regulatory agency, who shall be bound by the same prohibitions against disclosure as bind Executive, and Executive shall be responsible for advising those individuals or agencies of this confidentiality provision. Executive shall not provide or allow to be provided to any person this Agreement, or any copies thereof, nor shall Executive now or in the future disclose the terms of this Agreement to any person, with the sole exception of communications with Executive&rsquo;s spouse, attorney and tax advisor, unless otherwise ordered to do so by a court or agency of competent jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Invalidity</u>. In case any one or more of the provisions of this Agreement or Release shall be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained in this Agreement and Release will not in any way be affected or impaired thereby.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Admissions</u>. The Parties expressly deny any and all liability or wrongdoing and agree that nothing in this Agreement or the Release shall be deemed to represent any concession or admission of such liability or wrongdoing or any waiver of any defense.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">18</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. The laws of the State of Minnesota shall govern this Agreement without regard to conflict of laws principles. The Parties each hereby consent to the personal jurisdiction of the state courts located in Hennepin County, State of Minnesota, and the federal district court sitting in Hennepin County, State of Minnesota, if that court otherwise possesses jurisdiction over the matter, for any legal proceeding concerning or related to this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Voluntary and Knowing Action</u>. Executive acknowledges that Executive has had sufficient opportunity to review the terms of this Agreement and attached Release, and that Executive has voluntarily and knowingly entered into this Agreement. Employer shall not be obligated to provide any Consideration to Executive pursuant to this Agreement in the event Executive elects to rescind/revoke the Release. The Release becomes final and binding on the Parties upon expiration of the rescission/revocation period, provided Executive has not exercised Executive&rsquo;s option to rescind/revoke the Release. Any attempt by Executive to rescind any part of the Release obligates Executive to immediately return all Consideration under this Agreement to counsel for Employer.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Legal Counsel and Fees</u>. Except as otherwise provided in this Agreement and the Release, the Parties agree to bear their own costs and attorneys&rsquo; fees, if any. Executive acknowledges that Employer, by this Agreement, has advised him that Executive may consult with an attorney of Executive&rsquo;s choice prior to executing this Agreement and the Release. Executive acknowledges that Executive has had the opportunity to be represented by legal counsel during the negotiation and execution of this Agreement and the Release, and that Executive understands Executive will be fully bound by this Agreement and the Release.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Modification</u>. This Agreement may be modified or amended only by a writing signed by both Employer and Executive.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. This Agreement is binding on and inures to the benefit of the Parties&rsquo; respective successors and assigns.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. All notices and communications that are required or permitted to be given under this Agreement shall be in writing and shall be sufficient in all respects if given and delivered in person, by electronic mail, by facsimile, by overnight courier, or by certified mail, postage prepaid, return receipt requested, to the receiving Party at such Party&rsquo;s address below or to such other address as such Party may have given to the other by notice pursuant to this Section. Notice shall be deemed given (i) on the date of delivery in the case of personal delivery, electronic mail or facsimile, or (ii) on the delivery or refusal date as specified on the return receipt in the case of certified mail or on the tracking report in the case of overnight courier.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">19</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">If to Employer:</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%;">DIAMEDICA USA, INC.</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%;">Attention: Chief Executive Officer</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%;">Two Carlson Parkway, Suite 260</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%;">Minneapolis, MN 55447</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%;">&nbsp;</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">With a copy to:&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%;">Amy E. Culbert</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%;">Fox Rothschild LLP</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%;">Campbell Mithun Tower - Suite 2000</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%;">222 South Ninth Street</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%;">Minneapolis, MN 55402-3338</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%;">&nbsp;</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">If to Executive:&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%;">Harry Alcorn</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 20%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 30%; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 40%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Waivers</u>. No failure or delay by either Party in exercising any right or remedy under this Agreement will waive any provision of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>. This Agreement may be executed simultaneously in counterparts, each of which shall be an original, but all of which shall constitute but one and the same agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">23.&nbsp; &nbsp; &nbsp;<u>Entire Agreement</u>. Except for any continuing, post-employment, obligations under <u>Exhibit B</u>, or employment related Employer policy, or as otherwise provided in this Agreement, this Agreement, the attached Release, and <u>Exhibit B</u> are the entire Agreement between Employer and Executive relating to Executive&rsquo;s employment and separation. Executive understands that this Agreement and the Release cannot be changed unless it is done in writing and signed by both Employer and Executive.&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i>[Remainder of page intentionally left blank]</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">20</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 53.8%;"><b>EXECUTIVE</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 53.8%;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 53.8%;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 53.8%;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 53.8%;">Harry Alcorn</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:53.8%;margin-right:0pt;margin-top:0pt;text-align:justify;">Dated: ___________, 20____</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:53.8%;"><b>DIAMEDICA USA, INC.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:53.8%;">By:&nbsp;<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:53.8%;">Its:&nbsp;<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:53.8%;margin-right:0pt;margin-top:0pt;text-align:justify;">Dated: ___________, 20____</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:53.8%;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">21</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;"><b>EXHIBIT A</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>RELEASE</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">I.<b> </b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Definitions</u>. I, Harry Alcorn, intend all words used in this release (&ldquo;<u>Release</u>&rdquo;) to have their plain meanings in ordinary English. Technical legal words are not needed to describe what I mean. Specific terms I use in this Release have the following meanings:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">A.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&ldquo;<u>I</u>,&rdquo; &ldquo;<u>Me</u>,&rdquo; and &ldquo;<u>My</u>&rdquo; individually and collectively mean Harry Alcorn and anyone who has or obtains or asserts any legal rights or claims through Me or on My behalf.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">B.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&ldquo;<u>Employer</u>&rdquo; as used in this Release, shall at all times mean DiaMedica USA, Inc. and any affiliates, related or predecessor corporations, parent corporations or subsidiaries, successors and assigns.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">C.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&ldquo;<u>Released Party</u>&rdquo; or &ldquo;<u>Released Parties</u>&rdquo; as used in this Release, shall at all times mean DiaMedica USA, Inc. and its affiliates, related or predecessor corporations, parent corporations, subsidiaries, successors and assigns, present or former officers, directors, shareholders, agents, employees, representatives and attorneys, whether in their individual or official capacities, and its affiliates, related or predecessor corporations, parent corporations or subsidiaries, successors and assigns, present or former officers, directors, shareholders, agents, employees, representatives and attorneys, whether in their individual or official capacities, benefit plans and plan administrators, and insurers, insurers&rsquo; counsel, whether in their individual or official capacities, and the current and former trustees or administrators of any pension, 401(k), or other benefit plan applicable to the employees or former employees of Employer, in their official and individual capacities.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">D.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&ldquo;<u>My Claims</u>&rdquo; mean any and all of the actual or potential claims of any kind whatsoever I may have had, or currently may have against Employer or any Released Party, whether known or unknown, that are in any way related to My employment with or separation from employment with Employer, including, but not limited to any claims for: invasion of privacy; breach of written or oral, express or implied, contract; fraud; misrepresentation; violation of the Age&nbsp;Discrimination in Employment Act of 1967 (&ldquo;<u>ADEA</u>&rdquo;), 29&nbsp;U.S.C. &sect;&nbsp;626, as amended; the Genetic Information Nondiscrimination Act of 2008 (&ldquo;<u>GINA</u>&rdquo;), 42&nbsp;U.S.C. &sect;&nbsp;2000, <u>et</u>&nbsp;<u>seq.</u>, the Older&nbsp;Workers Benefit Protection Act of 1990 (&ldquo;<u>OWBPA</u>&rdquo;), 29&nbsp;U.S.C. &sect;&nbsp;626(f), Title VII of the Civil&nbsp;Rights Act of 1964 (&ldquo;<u>Title&nbsp;VII</u>&rdquo;), 42&nbsp;U.S.C. &sect;&nbsp;2000e, <u>et</u> <u>seq.</u>, the Americans with Disabilities Act (&ldquo;<u>ADA</u>&rdquo;), 29&nbsp;U.S.C. &sect;&nbsp;2101, <u>et</u>&nbsp;<u>seq.</u>, and as amended (&ldquo;<u>ADAAA</u>&rdquo;), the Executive Retirement Income Security Act of 1974 (&ldquo;<u>ERISA</u>&rdquo;), as amended, 29&nbsp;U.S.C. &sect;&nbsp;1001, <u>et</u>&nbsp;<u>seq.</u>, Equal Pay Act (&ldquo;<u>EPA</u>&rdquo;), 29&nbsp;U.S.C. &sect;&nbsp;206(d), the Worker Adjustment and Retraining Notification Act (&ldquo;<u>WARN</u>&rdquo;), 29 U.S.C. &sect;&nbsp;2101, <u>et</u> <u>seq.</u>, the Family and Medical Leave Act (&ldquo;<u>FMLA</u>&rdquo;), 29 U.S.C. &sect;&nbsp;2601, <u>et</u> <u>seq.</u>; National Labor Relations Act, 29 U.S.C. &sect;&nbsp;141, <u>et</u> <u>seq.</u>, the False Claims Act, 31&nbsp;U.S.C. &sect;&nbsp;3729, <u>et</u> <u>seq.</u>, Anti-Kickback Statute, 42 U.S.C. &sect;&nbsp;1320a, <u>et</u> <u>seq.</u>, the Minnesota Human Rights Act, Minn. Stat. &sect;&nbsp;363A.01, <u>et</u>&nbsp;<u>seq.</u>, Minn. Stat. &sect;&nbsp;181, <u>et</u>&nbsp;<u>seq.</u>, the Minnesota Whistleblower Act, Minn. Stat. &sect;&nbsp;181.931, <u>et</u>&nbsp;<u>seq.</u>, or any and all other Minnesota, and other state human rights or fair employment practices statutes, administrative regulations, or local ordinances, and any other Minnesota or other federal, state, local or foreign statute, law, rule, regulation, ordinance or order, all as amended. This includes, but is not limited to, claims for violation of any civil rights laws based on protected class status; claims for assault, battery, defamation, intentional or negligent infliction of emotional distress, breach of the covenant of good faith and fair dealing; promissory estoppel; negligence; negligent hiring; retention or supervision; retaliation; constructive discharge; violation of whistleblower protection laws; unjust enrichment; violation of public policy; and, all other claims for unlawful employment practices, and all other common law or statutory claims.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="margin: 0pt; width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">EXECUTIVE INITIALS</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Ex. A-1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">II.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><u>Agreement to Release My Claims</u>. Except as stated in Section V of this Release, I agree to release all My Claims and waive any rights to My Claims. I also agree to withdraw any and all of My charges and lawsuits against Employer; <i>except that</i> I may, but am not required to, withdraw or dismiss, or attempt to withdraw or dismiss, any charges that I may have pending against Employer with the Employment Opportunity Commission (&ldquo;<u>EEOC</u>&rdquo;) or other civil rights enforcement agency. In exchange for My agreement to release My Claims, I am receiving satisfactory Consideration from Employer to which I am not otherwise entitled by law, contract, or under any Employer policy. The Consideration I am receiving is a full and fair consideration for the release of all My Claims. Employer does not owe Me anything in addition to what I will be receiving according to the Separation&nbsp;Agreement which I have signed.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">III.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><u>Unknown Claims</u>. In waiving and releasing any and all actual, potential, or threatened claims against Employer, whether or not now known to me, I understand that this means that if I later discover facts different from or in addition to those facts currently known by me, or believed by me to be true, the waivers and releases of this Release will remain effective in all respects &ndash; despite such different or additional facts and my later discovery of such facts, even if I would not have agreed to the Separation Agreement and this Release if I had prior knowledge of such facts.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">IV.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><u>Confirmation of No Claims, Etc</u>. I am not aware of any other facts, evidence, allegations, claims, liabilities, or demands relating to alleged or potential violations of law that may give rise to any claim or liability on the part of any Released Party under the Securities Exchange Act of 1934, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the False Claims Act, the Anti-kickback Statute. I understand that nothing in this Release interferes with My right to file a complaint, charge or report with any law enforcement agency, with the Securities and Exchange Commission (&ldquo;<u>SEC</u>&rdquo;) or other regulatory body, or to participate in any manner in an SEC or other governmental investigation or proceeding under any such law, statute or regulation, or to require notification or prior approval by Employer of any such a complaint, charge or report.&nbsp; I understand and agree, however, that I waive My right to recover any whistleblower award under the Securities Exchange Act of 1934, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or other individual relief in any administrative or legal action whether brought by the SEC or other governmental or law enforcement agency, Me, or any other party, unless and to the extent that such waiver is contrary to law.&nbsp; I agree that the Released Parties reserve any and all defenses which they might have against any such allegations or claims brought by Me or on My behalf. I understand that Employer is relying on My representations in this Release and related Separation Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="margin: 0pt; width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">EXECUTIVE INITIALS</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Ex. A-2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">V.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><u>Exclusions from Release</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">A.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">The term &ldquo;Claims&rdquo; does not include My rights, if any, to claim the following: unemployment insurance benefits; workers compensation benefits; claims for My vested post-termination benefits under any 401(k) or similar retirement benefit plan; My rights to group medical or group dental insurance coverage pursuant to section 4980B of the Internal Revenue Code of 1986, as amended (&ldquo;<u>COBRA</u>&rdquo;); My rights to enforce the terms of this Release; or My rights to assert claims that are based on events occurring after this Release becomes effective.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">B.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Nothing in this Release interferes with My right to file or maintain a charge with the Equal Employment Opportunity Commission or other local civil rights enforcement agency or participate in any manner in an EEOC or other such agency investigation or proceeding. I, however, understand that I am waiving My right to recover individual relief including, but not limited to, back pay, front pay, reinstatement, attorneys&rsquo; fees, and/or punitive damages, in any administrative or legal action whether brought by the EEOC or other civil rights enforcement agency, Me, or any other party.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">C.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Nothing in this Release interferes with My right to challenge the knowing and voluntary nature of this Release under the ADEA and/or OWBPA.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">D.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">I agree that Employer reserves any and all defenses, which it has or might have against any claims brought by Me. This includes, but is not limited to, Employer&rsquo;s right to seek available costs and attorneys&rsquo; fees as allowed by law, and to have any monetary award granted to Me, if any, reduced by the amount of money that I received in consideration for this Release.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="margin: 0pt; width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">EXECUTIVE INITIALS</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Ex. A-3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">VI.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><u>Older Workers Benefit Protection Act</u>. The Older Workers Benefit Protection Act applies to individuals age 40 and older and sets forth certain criteria for such individuals to waive their rights under the Age Discrimination in Employment Act in connection with an exit incentive program or other employment termination program. I understand and have been advised that, if applicable, the above release of My Claims is subject to the terms of the OWBPA. The OWBPA provides that a covered individual cannot waive a right or claim under the ADEA unless the waiver is knowing and voluntary. If I am a covered individual, I acknowledge that I have been advised of this law, and I agree that I am signing this Release voluntarily, and with full knowledge of its consequences. I understand that Employer is giving Me twenty-one (21) days from the date I received a copy of this Release to decide whether I want to sign it. I acknowledge that I have been advised to use this time to consult with an attorney about the effect of this Release. If I sign this Release before the end of the twenty-one (21) day period it will be My personal, voluntary decision to do so, and will be done with full knowledge of My legal rights. I agree that material and/or immaterial changes to the Separation Agreement or this Release will not restart the running of this consideration period. I also acknowledge that the Separation Agreement, this Release and any other attachments or exhibits have each been written in a way that I understand.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">VII.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><u>Right to Rescind and/or Revoke</u>. I understand that insofar as this Release relates to my rights under the Age Discrimination in Employment Act, it shall not become effective or enforceable until seven (7) days after I sign it. I also have the right to rescind (or revoke) this Release insofar as it extends to potential claims under the ADEA by written notice to Employer within seven (7) calendar days following my signing this Release, and within fifteen (15) calendar days as to waiver of claims under the Minnesota Human Rights Act (the &ldquo;<u>Rescission Period</u>&rdquo;). Any such rescission (or revocation) must be in writing and hand-delivered to Employer or, if sent by mail, postmarked within the applicable time period, sent by certified mail, return receipt requested, and addressed as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">A.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">post-marked within the seven (7) day Rescission Period or, if applicable, fifteen (15) day Rescission Period;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">B.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">properly addressed to DiaMedica USA, Inc., Attention: Chief Executive Officer, Two Carlson Parkway, Suite 260, Minneapolis, MN 55447; and</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">C.</p>
			</td>
			<td>
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">sent by certified mail, return receipt requested.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">I understand that the Consideration I am receiving for settling and releasing my Claims is contingent upon my agreement to be bound by the terms of this Release. Accordingly, if I decide to revoke this Release as provided herein, I understand that I am not entitled to the Consideration offered in the Separation Agreement. I further understand that if I attempt to revoke my release of ADEA, MHRA or any other claims, I must immediately return to the Employer any Consideration that I may have received under my Separation Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">VIII.</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>I Understand the Terms of this Release</u>. I have had the opportunity to read this Release carefully and understand all its terms. I have had the opportunity to review this Release with My own attorney. In agreeing to sign this Release, I have not relied on any oral statements or explanations made by Employer, including its employees or attorneys. I understand and agree that this Release and the attached Agreement contain all the agreements between Employer and Me. We have no other written or oral agreements.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 53.8%;"><u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:53.8%;">Harry Alcorn</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:53.8%;">Dated: ____________, 20____</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="margin: 0pt; width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">EXECUTIVE INITIALS</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;">Ex. A-4</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ex_137957.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html>
<head>
	<title>ex_137957.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2019 3:09:15 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 21.1</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SUBSIDIARIES OF THE REGISTRANT</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="margin-left:0.1%;width:99.9%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: thin 1px 1px; width: 5.5%;">&nbsp;</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 53.2%; border-top: thin solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><b>Entity Name</b></p>
			</td>
			<td style="vertical-align: top; border-color: rgb(0, 0, 0); border-style: solid; border-width: thin 1px 1px; width: 41.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Country of Incorporatio</b>n</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: thin solid rgb(0, 0, 0); width: 5%; border-left: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); padding: 0px 0px 0px 3px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">1.</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:53.2%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">DiaMedica USA Inc.</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 41.2%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Delaware, USA</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 5.5%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); padding: 0px 0px 0px 3px;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt;">2.</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:53.2%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">DiaMedica Australia Pty Ltd.</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 41.2%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Australian</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex_137958.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
<head>
	<title>ex_137958.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2019 3:08:59 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 23.1</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We consent to the incorporation by reference in the Registration Statement on Form S-8 (File Nos. 333-228821) of DiaMedica Therapeutics Inc. and Subsidiaries of our report dated March 19, 2019, relating to the consolidated financial statements of DiaMedica Therapeutics Inc. and Subsidiaries, which appears on page 74 of this annual report on Form 10-K for the fiscal year ended December 31, 2018.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Baker Tilly Virchow Krause, LLP</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Minneapolis, Minnesota</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">March 19, 2019</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex_137959.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
	<title>ex_137959.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2019 3:08:21 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 31.1</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CERTIFICATION PURSUANT TO SECTION 302(A) OF THE<br>
SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">I, Rick Pauls, certify that:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.&nbsp; &nbsp; &nbsp; I have reviewed this annual report on Form 10-K of DiaMedica Therapeutics Inc.;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2.&nbsp; &nbsp; &nbsp; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.&nbsp; &nbsp; &nbsp; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.&nbsp; &nbsp; &nbsp; The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">5.&nbsp; &nbsp; &nbsp; The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: March 19, 2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 52.2%; text-align: left;"><u>/s/ Rick Pauls</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;">Rick Pauls</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;">President and Chief Executive Officer</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;">(principal executive officer)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex_137960.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
	<title>ex_137960.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2019 3:07:41 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 31.2</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CERTIFICATION PURSUANT TO SECTION 302(A) OF THE<br>
SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">I, Scott Kellen, certify that:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.&nbsp; &nbsp; &nbsp; I have reviewed this annual report on Form 10-K of DiaMedica Therapeutics Inc.;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2.&nbsp; &nbsp; &nbsp; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.&nbsp; &nbsp; &nbsp; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.&nbsp; &nbsp; &nbsp; The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">5.&nbsp; &nbsp; &nbsp; The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: March 19, 2019&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 52.2%; text-align: left;"><u>/s/ Scott Kellen</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;">Scott Kellen</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;">Chief Financial Officer and Corporate Secretary</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;">(principal financial officer)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex_137961.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
	<title>ex_137961.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2019 3:07:12 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 32.1</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CERTIFICATION PURSUANT TO SECTION 302(A) OF THE<br>
SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In connection with the Annual Report of DiaMedica Therapeutics Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ending December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Rick Pauls, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:36pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:36pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;"><u>/s/ Rick Pauls&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;">Rick Pauls</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;">President and Chief Executive Officer</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;">(principal executive officer)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Minneapolis, Minnesota</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">March 19, 2019</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex_137962.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
<head>
	<title>ex_137962.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2019 3:06:28 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 32.2</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CERTIFICATION PURSUANT TO SECTION 302(A) OF THE<br>
SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In connection with the Annual Report of DiaMedica Therapeutics Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ending December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Scott Kellen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:36pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:36pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;"><u>/s/ Scott Kellen&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;">Scott Kellen</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;">Chief Financial Officer and Corporate Secretary</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.2%;margin-right:0pt;margin-top:0pt;text-align:left;">(principal financial officer)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Minneapolis, Minnesota</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">March 19, 2019</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>dmac-20181231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:27PM UTC 2019-03-19--><xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dmac="http://www.diamedica.com/20181231" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="dmac-20181231.xsd" xlink:type="simple"/>
  <dei:AmendmentFlag contextRef="d_2018-01-01_2018-12-31" id="c-19">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2018-01-01_2018-12-31" id="c-4">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2018-01-01_2018-12-31" id="c-18">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2018-01-01_2018-12-31" id="c-17">2018</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2018-01-01_2018-12-31" id="c-16">2018-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2018-01-01_2018-12-31" id="c-15">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2018-01-01_2018-12-31" id="c-2">0001401040</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2019-03-14" decimals="INF" id="c-12" unitRef="xbrli-shares">11956874</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2018-01-01_2018-12-31" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="d_2018-01-01_2018-12-31" id="c-9">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod contextRef="d_2018-01-01_2018-12-31" id="c-10">true</dei:EntityExTransitionPeriod>
  <dei:EntityFilerCategory contextRef="d_2018-01-01_2018-12-31" id="c-5">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="i_2018-06-30" decimals="-5" id="c-13" unitRef="iso4217-usd">59800000</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="d_2018-01-01_2018-12-31" id="c-1">DiaMedica Therapeutics Inc.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="d_2018-01-01_2018-12-31" id="c-14">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="d_2018-01-01_2018-12-31" id="c-11">true</dei:EntitySmallBusiness>
  <dei:EntityVoluntaryFilers contextRef="d_2018-01-01_2018-12-31" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2018-01-01_2018-12-31" id="c-8">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2018-01-01_2018-12-31" id="c-3">dmac</dei:TradingSymbol>
  <dmac:AccruedClinicalStudyCostsCurrent contextRef="i_2018-12-31" decimals="-3" id="c44756777" unitRef="iso4217-usd">292000</dmac:AccruedClinicalStudyCostsCurrent>
  <dmac:AccruedClinicalStudyCostsCurrent contextRef="i_2017-12-31" id="c44756778" unitRef="iso4217-usd" xs:nil="true"/>
  <dmac:AccruedResearchAndProfessionalFeesCurrent contextRef="i_2018-12-31" decimals="-3" id="c44756779" unitRef="iso4217-usd">65000</dmac:AccruedResearchAndProfessionalFeesCurrent>
  <dmac:AccruedResearchAndProfessionalFeesCurrent contextRef="i_2017-12-31" decimals="-3" id="c44756780" unitRef="iso4217-usd">45000</dmac:AccruedResearchAndProfessionalFeesCurrent>
  <dmac:AccruedTaxesAndOtherLiabilitiesCurrent contextRef="i_2018-12-31" decimals="-3" id="c44756781" unitRef="iso4217-usd">34000</dmac:AccruedTaxesAndOtherLiabilitiesCurrent>
  <dmac:AccruedTaxesAndOtherLiabilitiesCurrent contextRef="i_2017-12-31" decimals="-3" id="c44756782" unitRef="iso4217-usd">6000</dmac:AccruedTaxesAndOtherLiabilitiesCurrent>
  <dmac:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c44756482" unitRef="iso4217-usd">615000</dmac:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised>
  <dmac:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c44756483" unitRef="iso4217-usd" xs:nil="true"/>
  <dmac:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756484" unitRef="iso4217-usd">615000</dmac:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised>
  <dmac:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c44756518" unitRef="iso4217-usd">731000</dmac:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised>
  <dmac:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c44756519" unitRef="iso4217-usd" xs:nil="true"/>
  <dmac:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756520" unitRef="iso4217-usd">731000</dmac:AdjustmentsToAdditionalPaidInCapitalWarrantsExercised>
  <dmac:AdvancesToVendor contextRef="i_2018-12-31" decimals="-3" id="c44756752" unitRef="iso4217-usd">271000</dmac:AdvancesToVendor>
  <dmac:AdvancesToVendor contextRef="i_2017-12-31" decimals="-3" id="c44756753" unitRef="iso4217-usd">271000</dmac:AdvancesToVendor>
  <dmac:ClassOfWarrantOrRightIssuedDuringPeriod contextRef="d_2018-03-29_2018-03-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756901" unitRef="xbrli-shares">661482</dmac:ClassOfWarrantOrRightIssuedDuringPeriod>
  <dmac:ClassOfWarrantOrRightIssuedDuringPeriod contextRef="d_2018-03-29_2018-03-29_ClassOfWarrantOrRightAxis-CompensationWarrantsMember" decimals="INF" id="c44756909" unitRef="xbrli-shares">80510</dmac:ClassOfWarrantOrRightIssuedDuringPeriod>
  <dmac:ClassOfWarrantOrRightWarrantsExpiredDuringPeriod contextRef="d_2018-02-01_2018-02-28_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" decimals="INF" id="c44756816" unitRef="xbrli-shares">4346</dmac:ClassOfWarrantOrRightWarrantsExpiredDuringPeriod>
  <dmac:ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants contextRef="i_2018-12-11_ClassOfWarrantOrRightAxis-WarrantsIssuedWithIPOMember" decimals="INF" id="c44756891" unitRef="xbrli-pure">1.2</dmac:ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants>
  <dmac:CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone contextRef="i_2018-09-27_RelatedPartyTransactionAxis-LicenseAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis-AhonPharmaMember" decimals="INF" id="c44756955" unitRef="iso4217-usd">27500000</dmac:CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone>
  <dmac:CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance contextRef="i_2018-09-27_RelatedPartyTransactionAxis-LicenseAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis-AhonPharmaMember" decimals="INF" id="c44756954" unitRef="iso4217-usd">4500000</dmac:CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance>
  <dmac:CollaborationAgreementPaymentOfLicenseFee contextRef="d_2018-01-01_2018-12-31_RelatedPartyTransactionAxis-LicenseAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis-AhonPharmaMember" decimals="INF" id="c44756959" unitRef="iso4217-usd">500000</dmac:CollaborationAgreementPaymentOfLicenseFee>
  <dmac:CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones contextRef="i_2018-09-27_RelatedPartyTransactionAxis-LicenseAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis-AhonPharmaMember" decimals="3" id="c44756956" unitRef="xbrli-pure">0.1</dmac:CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones>
  <dmac:CommonStockReservedForFutureIssuanceTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-29">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;639,359&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred share units outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,183&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Shares available for grant under the Option Plan&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;123,376&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common shares issuable under common share purchase warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;807,563&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,591,479&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</dmac:CommonStockReservedForFutureIssuanceTableTextBlock>
  <dmac:DeferredTaxAssetsPropertyPatentsAndOther contextRef="i_2018-12-31" decimals="-3" id="c44757155" unitRef="iso4217-usd">293000</dmac:DeferredTaxAssetsPropertyPatentsAndOther>
  <dmac:DeferredTaxAssetsPropertyPatentsAndOther contextRef="i_2017-12-31" decimals="-3" id="c44757156" unitRef="iso4217-usd">319000</dmac:DeferredTaxAssetsPropertyPatentsAndOther>
  <dmac:DeferredTaxAssetsPropertyShareIssueCosts contextRef="i_2018-12-31" decimals="-3" id="c44757153" unitRef="iso4217-usd">529000</dmac:DeferredTaxAssetsPropertyShareIssueCosts>
  <dmac:DeferredTaxAssetsPropertyShareIssueCosts contextRef="i_2017-12-31" decimals="-3" id="c44757154" unitRef="iso4217-usd">117000</dmac:DeferredTaxAssetsPropertyShareIssueCosts>
  <dmac:EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44757179" unitRef="iso4217-usd">1131000</dmac:EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount>
  <dmac:EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44757180" unitRef="iso4217-usd">534000</dmac:EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount>
  <dmac:EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44757169" unitRef="iso4217-usd">-1119000</dmac:EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount>
  <dmac:EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44757170" unitRef="iso4217-usd">-1160000</dmac:EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount>
  <dmac:EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44757173" unitRef="iso4217-usd">450000</dmac:EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount>
  <dmac:EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44757174" unitRef="iso4217-usd">2000</dmac:EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount>
  <dmac:FunctionalCurrencyPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c44756620">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Functional currency&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The United States dollar is our functional currency as it represents the economic effects of the underlying transactions, events and conditions and various other factors including the currency of historical and future expenditures and the currency in which funds from financing activities are mostly generated by the Company. A change in the functional currency occurs only when there is a material change in the underlying transactions, events and condition. A change in functional currency could result in material differences in the amounts recorded in the consolidated statement of loss and comprehensive loss for foreign exchange gains and losses. All amounts in the accompanying consolidated financial statements are in U.S. dollars unless otherwise indicated.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</dmac:FunctionalCurrencyPolicyTextBlock>
  <dmac:GovernmentAssistancePolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c44756644">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Government assistance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Government assistance relating to research and development performed by DiaMedica Australia Pty Ltd. is recorded as a component of Other (income) expense. Government assistance was initially recognized when reasonable assurance existed that the Company complied with the conditions attached to the incentive program and that the incentive payments would be received. In subsequent periods, the government assistance was recognized when the related expenditures were incurred. During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; we recognized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$621,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$593,000&lt;/div&gt; for research activities performed in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively. During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; we recognized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$244,000&lt;/div&gt; for research activities performed in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</dmac:GovernmentAssistancePolicyTextBlock>
  <dmac:IncomeFromGovernmentalAssistance contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756451" unitRef="iso4217-usd">1214000</dmac:IncomeFromGovernmentalAssistance>
  <dmac:IncomeFromGovernmentalAssistance contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756452" unitRef="iso4217-usd">244000</dmac:IncomeFromGovernmentalAssistance>
  <dmac:MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale contextRef="i_2018-12-31_OtherCommitmentsAxis-TechnologyLicenseMember" decimals="INF" id="c44756846" unitRef="iso4217-usd">185000</dmac:MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale>
  <dmac:MilestonePaymentDueUponInitiationOfPhaseIIITrial contextRef="i_2018-12-31_OtherCommitmentsAxis-TechnologyLicenseMember" decimals="INF" id="c44756844" unitRef="iso4217-usd">185000</dmac:MilestonePaymentDueUponInitiationOfPhaseIIITrial>
  <dmac:PatentCostsPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c44756638">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patent costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Costs associated with prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, resulting in probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in research and development costs and were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$156,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$160,000&lt;/div&gt; for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</dmac:PatentCostsPolicyTextBlock>
  <dmac:PatentExpense contextRef="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="INF" id="c44756654" unitRef="iso4217-usd">156000</dmac:PatentExpense>
  <dmac:PatentExpense contextRef="d_2017-01-01_2017-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="INF" id="c44756655" unitRef="iso4217-usd">160000</dmac:PatentExpense>
  <dmac:PaymentForFindersFee contextRef="d_2018-03-29_2018-03-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756908" unitRef="iso4217-usd">384000</dmac:PaymentForFindersFee>
  <dmac:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756566" unitRef="iso4217-usd">5840000</dmac:ProceedsFromIssuanceOfCommonStockAndWarrants>
  <dmac:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="d_2017-01-01_2017-12-31" id="c44756567" unitRef="iso4217-usd" xs:nil="true"/>
  <dmac:ProceedsFromIssuanceOfCommonStockNet contextRef="d_2018-12-11_2018-12-11_SubsidiarySaleOfStockAxis-IPOMember" decimals="INF" id="c44756884" unitRef="iso4217-usd">14700000</dmac:ProceedsFromIssuanceOfCommonStockNet>
  <dmac:ProceedsFromIssuanceOfUnits contextRef="d_2018-03-29_2018-03-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756897" unitRef="iso4217-usd">6300000</dmac:ProceedsFromIssuanceOfUnits>
  <dmac:ProceedsFromIssuanceOfUnits contextRef="d_2017-12-18_2017-12-18_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756920" unitRef="iso4217-usd">944000</dmac:ProceedsFromIssuanceOfUnits>
  <dmac:ProceedsFromIssuanceOfUnits contextRef="d_2017-04-17_2017-04-17_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756931" unitRef="iso4217-usd">2000000</dmac:ProceedsFromIssuanceOfUnits>
  <dmac:ProceedsFromIssuanceOfUnitsNet contextRef="d_2017-12-18_2017-12-18_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756921" unitRef="iso4217-usd">934000</dmac:ProceedsFromIssuanceOfUnitsNet>
  <dmac:ProceedsFromIssuanceOfUnitsNet contextRef="d_2017-04-17_2017-04-17_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756932" unitRef="iso4217-usd">1983000</dmac:ProceedsFromIssuanceOfUnitsNet>
  <dmac:RelcassificationOfWarrantLiabilityUponWarrantExercise contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756584" unitRef="iso4217-usd">123000</dmac:RelcassificationOfWarrantLiabilityUponWarrantExercise>
  <dmac:RelcassificationOfWarrantLiabilityUponWarrantExercise contextRef="d_2017-01-01_2017-12-31" id="c44756585" unitRef="iso4217-usd" xs:nil="true"/>
  <dmac:ResearchAndDevelopmentIncentiveReceivable contextRef="i_2018-12-31" decimals="-3" id="c44756740" unitRef="iso4217-usd">622000</dmac:ResearchAndDevelopmentIncentiveReceivable>
  <dmac:ResearchAndDevelopmentIncentiveReceivable contextRef="i_2017-12-31" id="c44756741" unitRef="iso4217-usd" xs:nil="true"/>
  <dmac:ResearchGrantRecognizedResearchActivitiesPerformed2016 contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c44756667" unitRef="iso4217-usd">244000</dmac:ResearchGrantRecognizedResearchActivitiesPerformed2016>
  <dmac:ResearchGrantRecognizedResearchActivitiesPerformed2017 contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756663" unitRef="iso4217-usd">593000</dmac:ResearchGrantRecognizedResearchActivitiesPerformed2017>
  <dmac:ResearchGrantRecognizedResearchActivitiesPerformed2018 contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756662" unitRef="iso4217-usd">621000</dmac:ResearchGrantRecognizedResearchActivitiesPerformed2018>
  <dmac:RightsExercisablePercentOfDiscountToMarketPrice contextRef="i_2018-12-31" decimals="INF" id="c44756874" unitRef="xbrli-pure">0.5</dmac:RightsExercisablePercentOfDiscountToMarketPrice>
  <dmac:RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual contextRef="i_2018-12-31" decimals="INF" id="c44756873" unitRef="xbrli-pure">0.2</dmac:RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual>
  <dmac:RisksAndUncertaintiesTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139648">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Risks and Uncertainties&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;DiaMedica is subject to many risks and uncertainties. We are in the clinical stage of development of our initial product candidate, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199,&lt;/div&gt; for the treatment of chronic kidney disease and acute ischemic stroke. The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; completed the development of any product candidate and, accordingly, has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; begun to commercialize any product candidate or generate any revenues from the sale of any product candidate. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&lt;/div&gt; requires significant additional clinical testing and investment prior to seeking marketing approval and is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expected to be commercially available for several years, if at all. The Company&amp;#x2019;s future success is dependent upon the success of its development efforts, its ability to demonstrate clinical progress for its &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&lt;/div&gt; product candidate in the United States or other markets, its ability to obtain required governmental approvals of its product candidate and ultimately its ability to license or market and sell its &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&lt;/div&gt; product candidate, and its ability to obtain additional financing to fund these efforts.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;we have incurred losses of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$46.0&lt;/div&gt; million since our inception in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2000.&lt;/div&gt; For the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;we incurred a net loss of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.7&lt;/div&gt;&amp;nbsp;million and negative cash flows from operating activities of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.7&lt;/div&gt;&amp;nbsp;million. We expect to continue to incur operating losses until such time as any future product sales, royalty payments, licensing fees, and/or milestone payments are sufficient to generate revenue to fund our continuing operations. Further, we expect our operating losses to increase in the near term as we continue the research, development and clinical trials of, and to seek regulatory approval for, our product candidate. In addition, we expect our operating expenses to increase in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019&lt;/div&gt; compared to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; as a result of our recently obtained Nasdaq-listed U.S. public reporting company status. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;DiaMedica had cash of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$16.8&lt;/div&gt; million, working capital of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$16.7&lt;/div&gt; million and shareholders&amp;#x2019; equity of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$17.0&lt;/div&gt; million. Our principal sources of cash have included net proceeds from the issuance of equity securities, including most recently an initial public offering of our common shares in the United States in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2018. &lt;/div&gt;See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt; titled &amp;#x201c;Shareholders&amp;#x2019; Equity&amp;#x201d; for additional information. Although the Company has previously been successful in obtaining financing through equity securities offerings, there is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; assurance that we will be able to do so in the future. This is particularly true if our clinical data is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; positive or economic and market conditions deteriorate.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Despite our recent initial public offering in the United States, we expect that we will need substantial additional capital to further our research and development activities, complete the required clinical trials, regulatory activities and otherwise develop our product candidate, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199,&lt;/div&gt; or any future product candidates, to a point where they &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be commercially sold. We expect our current cash, which includes the net proceeds of our recent initial public offering, to be sufficient to allow us to complete our currently ongoing Phase II Remedy trial in patients with AIS, our Phase Ib trial in patients with CKD and a planned Phase II study in patients with CKD caused by rare diseases and to otherwise fund our planned operations through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2020.&lt;/div&gt; However, the amount and timing of our future funding requirements will depend on many factors, including the timing and results of ongoing development efforts, the potential expansion of current development programs, potential new development programs and related general and administrative support. We &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;require significant additional funds earlier than we currently expect and there is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; assurance that we will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; need or seek additional funding prior to such time.&lt;/div&gt;&lt;/div&gt;</dmac:RisksAndUncertaintiesTextBlock>
  <dmac:SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions contextRef="i_2018-12-31_PlanNameAxis-OptionPlanMember" decimals="INF" id="c44756976" unitRef="xbrli-shares">783918</dmac:SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions>
  <dmac:SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares contextRef="i_2018-12-31_PlanNameAxis-OptionPlanMember" decimals="INF" id="c44756982" unitRef="xbrli-shares">283918</dmac:SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares>
  <dmac:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c44756473" unitRef="xbrli-shares">707536</dmac:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants>
  <dmac:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c44756501" unitRef="xbrli-shares">1322965</dmac:StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants>
  <dmac:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c44756474" unitRef="iso4217-usd">2917000</dmac:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
  <dmac:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c44756475" unitRef="iso4217-usd" xs:nil="true"/>
  <dmac:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756476" unitRef="iso4217-usd">2917000</dmac:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
  <dmac:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c44756502" unitRef="iso4217-usd">5840000</dmac:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
  <dmac:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c44756503" unitRef="iso4217-usd" xs:nil="true"/>
  <dmac:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756504" unitRef="iso4217-usd">5840000</dmac:StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants>
  <dmac:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants contextRef="d_2018-02-01_2018-02-28_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" decimals="INF" id="c44756814" unitRef="xbrli-shares">121256</dmac:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants>
  <dmac:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756913" unitRef="xbrli-shares">128594</dmac:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants>
  <dmac:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants contextRef="d_2017-01-01_2017-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756940" unitRef="xbrli-shares">131578</dmac:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants>
  <dmac:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c44756941" unitRef="xbrli-shares">134079</dmac:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants>
  <dmac:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c44756481" unitRef="xbrli-shares">134079</dmac:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants>
  <dmac:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c44756517" unitRef="xbrli-shares">146294</dmac:StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants>
  <dmac:UnitsIssuedDuringPeriodUnitsNewIssues contextRef="d_2016-02-01_2016-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756787" unitRef="xbrli-shares">234375</dmac:UnitsIssuedDuringPeriodUnitsNewIssues>
  <dmac:UnitsIssuedDuringPeriodUnitsNewIssues contextRef="d_2018-03-29_2018-03-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756895" unitRef="xbrli-shares">1322965</dmac:UnitsIssuedDuringPeriodUnitsNewIssues>
  <dmac:UnitsIssuedDuringPeriodUnitsNewIssues contextRef="d_2017-12-18_2017-12-18_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756918" unitRef="xbrli-shares">181220</dmac:UnitsIssuedDuringPeriodUnitsNewIssues>
  <dmac:UnitsIssuedDuringPeriodUnitsNewIssues contextRef="d_2017-04-17_2017-04-17_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756929" unitRef="xbrli-shares">526316</dmac:UnitsIssuedDuringPeriodUnitsNewIssues>
  <dmac:UnitsIssuedPricePerUnit contextRef="d_2017-12-18_2017-12-18_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756919" unitRef="iso4217-usd-per-xbrli-shares">5.20</dmac:UnitsIssuedPricePerUnit>
  <dmac:UnitsIssuedPricePerUnit contextRef="d_2017-04-17_2017-04-17_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756930" unitRef="iso4217-usd-per-xbrli-shares">3.80</dmac:UnitsIssuedPricePerUnit>
  <dmac:UnitsNumberOfCommonSharePurchaseWarrantPerUnit contextRef="i_2016-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756789" unitRef="xbrli-shares">0.5</dmac:UnitsNumberOfCommonSharePurchaseWarrantPerUnit>
  <dmac:UnitsNumberOfCommonSharePurchaseWarrantPerUnit contextRef="i_2018-03-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756899" unitRef="xbrli-shares">0.5</dmac:UnitsNumberOfCommonSharePurchaseWarrantPerUnit>
  <dmac:UnitsNumberOfCommonSharePurchaseWarrantPerUnit contextRef="i_2017-12-18_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756923" unitRef="xbrli-shares">0.5</dmac:UnitsNumberOfCommonSharePurchaseWarrantPerUnit>
  <dmac:UnitsNumberOfCommonSharePurchaseWarrantPerUnit contextRef="i_2017-04-17_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756934" unitRef="xbrli-shares">0.5</dmac:UnitsNumberOfCommonSharePurchaseWarrantPerUnit>
  <dmac:UnitsNumberOfCommonSharesPerUnit contextRef="i_2016-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756788" unitRef="xbrli-shares">1</dmac:UnitsNumberOfCommonSharesPerUnit>
  <dmac:UnitsNumberOfCommonSharesPerUnit contextRef="i_2018-03-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756898" unitRef="xbrli-shares">1</dmac:UnitsNumberOfCommonSharesPerUnit>
  <dmac:UnitsNumberOfCommonSharesPerUnit contextRef="i_2017-12-18_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756922" unitRef="xbrli-shares">1</dmac:UnitsNumberOfCommonSharesPerUnit>
  <dmac:UnitsNumberOfCommonSharesPerUnit contextRef="i_2017-04-17_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756933" unitRef="xbrli-shares">1</dmac:UnitsNumberOfCommonSharesPerUnit>
  <dmac:WarrantLiabilitiesTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139660">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2016, &lt;/div&gt;the Company completed, in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; tranches, a non-brokered private placement of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;234,375&lt;/div&gt; units with each unit consisting of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; half of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share purchase warrant. The Company issued &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;117,188&lt;/div&gt; warrants. Each warrant entitled the holder to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.00&lt;/div&gt; Canadian dollars at any time prior to expiry on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 18 &lt;/div&gt;or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; for Tranche &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; and Tranche &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,&lt;/div&gt; respectively.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;As the warrant exercise price was stated in Canadian dollars and the Company&amp;#x2019;s functional currency is the U.S. dollar, the warrants were deemed to be derivative instruments, with their estimated fair value classified as a liability on the Company&amp;#x2019;s consolidated balance sheet. The initial estimated fair value of the warrants was recorded as a warrant liability with subsequent changes in the estimated fair value recognized in the consolidated statements of operations and comprehensive loss. The Company allocated &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$281,000&lt;/div&gt; of the net proceeds to the warrant liability and the balance of the proceeds to the common shares. The initial fair value of the warrants was determined using a Black-Scholes pricing model with the following assumptions: expected volatilities of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;191.8&lt;/div&gt; &amp;#x2013; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;225.0%,&lt;/div&gt; risk-free interest rates of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.43&lt;/div&gt; &amp;#x2013; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.49%,&lt;/div&gt; and expected life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; years.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;In connection with the offering, the Company issued an aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,915&lt;/div&gt; compensation warrants. Each compensation warrant entitled the holder to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.00&lt;/div&gt; Canadian dollars for a period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; years from the date of issuance. The Company estimated the value of these warrants at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$24,000,&lt;/div&gt; which was included in the issuance costs. The initial fair value of the warrants was determined using a Black-Scholes valuation model with the following assumptions: expected volatilities of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;191.8&lt;/div&gt; &amp;#x2013; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;225.0%,&lt;/div&gt; risk-free interest rates of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.43&lt;/div&gt;&amp;nbsp;&amp;#x2013; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.49%,&lt;/div&gt; and expected life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; years.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2018, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;121,256&lt;/div&gt; common shares were issued on the exercise of warrants for gross proceeds of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$483,000&lt;/div&gt; and the remaining &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,346&lt;/div&gt; warrants expired.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The fair value of the Company&amp;#x2019;s common share purchase warrant liability was calculated using a Black-Scholes valuation model and is classified as Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; in the fair value hierarchy. The fair values at the time of exercise of the warrants were estimated using the following valuation assumptions: expected volatilities of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16.7%,&lt;/div&gt; risk-free interest rates of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.8%,&lt;/div&gt; and expected life of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.01&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.03&lt;/div&gt; years.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The following is a rollforward of the fair value of the warrants (in thousands):&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Ending balance December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;84&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in fair value&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercises&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(123&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Ending balance December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</dmac:WarrantLiabilitiesTextBlock>
  <dmac:WarrantsAndRightsExercisesInPeriod contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756824" unitRef="iso4217-usd">123000</dmac:WarrantsAndRightsExercisesInPeriod>
  <dmac:WarrantsAndRightsOutstandingExpirationStockPriceTrigger contextRef="i_2018-03-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756906" unitRef="iso4217-usd-per-xbrli-shares">12</dmac:WarrantsAndRightsOutstandingExpirationStockPriceTrigger>
  <dmac:WarrantsAndRightsOutstandingExpirationStockPriceTrigger contextRef="i_2017-12-18_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756927" unitRef="iso4217-usd-per-xbrli-shares">12</dmac:WarrantsAndRightsOutstandingExpirationStockPriceTrigger>
  <dmac:WarrantsAndRightsOutstandingExpirationStockPriceTrigger contextRef="i_2017-04-17_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756938" unitRef="iso4217-usd-per-xbrli-shares">6</dmac:WarrantsAndRightsOutstandingExpirationStockPriceTrigger>
  <dmac:WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants contextRef="i_2018-12-11_ClassOfWarrantOrRightAxis-WarrantsIssuedWithIPOMember" decimals="INF" id="c44756889" unitRef="xbrli-pure">0.05</dmac:WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants>
  <dmac:WarrantsAndRightsThresholdConsecutiveTradingDays contextRef="d_2017-12-18_2017-12-18_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756928" unitRef="xbrli-pure">21</dmac:WarrantsAndRightsThresholdConsecutiveTradingDays>
  <dmac:WarrantsAndRightsThresholdConsecutiveTradingDays contextRef="d_2017-04-17_2017-04-17_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756939" unitRef="xbrli-pure">10</dmac:WarrantsAndRightsThresholdConsecutiveTradingDays>
  <dmac:WarrantsIssuedCashConsideration contextRef="d_2018-12-11_2018-12-11_ClassOfWarrantOrRightAxis-WarrantsIssuedWithIPOMember" decimals="INF" id="c44756887" unitRef="iso4217-usd">50000</dmac:WarrantsIssuedCashConsideration>
  <dmac:WorkingCapital contextRef="i_2018-12-31" decimals="-5" id="c44756608" unitRef="iso4217-usd">16700000</dmac:WorkingCapital>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="i_2018-12-31" decimals="-3" id="c44756783" unitRef="iso4217-usd">1291000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="i_2017-12-31" decimals="-3" id="c44756784" unitRef="iso4217-usd">919000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139658">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Accounts Payable and Accrued Liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Accounts payable and accrued liabilities consisted of the following (in thousands):&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Trade and other payables&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;483&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;513&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;417&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;355&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued clinical study costs&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;292&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued research and other professional fees&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;65&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;45&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued taxes and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;"&gt;Total accrued liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,291&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;919&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AccountsPayableTradeCurrent contextRef="i_2018-12-31" decimals="-3" id="c44756773" unitRef="iso4217-usd">483000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent contextRef="i_2017-12-31" decimals="-3" id="c44756774" unitRef="iso4217-usd">513000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2018-12-31" decimals="-3" id="c44756746" unitRef="iso4217-usd">780000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2017-12-31" decimals="-3" id="c44756747" unitRef="iso4217-usd">80000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2018-12-31" decimals="-3" id="c44756768" unitRef="iso4217-usd">24000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2017-12-31" decimals="-3" id="c44756769" unitRef="iso4217-usd">26000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2018-12-31" decimals="-3" id="c44756430" unitRef="iso4217-usd">62993000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2017-12-31" decimals="-3" id="c44756431" unitRef="iso4217-usd">41033000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756480" unitRef="iso4217-usd">292000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="d_2018-01-01_2018-12-31_SubsidiarySaleOfStockAxis-StockAndWarrantsIssuance1Member" decimals="-3" id="c44756508" unitRef="iso4217-usd">529000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="d_2018-01-01_2018-12-31_SubsidiarySaleOfStockAxis-StockIssuanceMember" decimals="-3" id="c44756516" unitRef="iso4217-usd">1674000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-NonemployeeStockOptionsMember" decimals="INF" id="c44757003" unitRef="iso4217-usd">205000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-NonemployeeStockOptionsMember" decimals="INF" id="c44757004" unitRef="iso4217-usd">308000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c44757007" unitRef="iso4217-usd">170000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c44757008" unitRef="iso4217-usd">60000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c44757009" unitRef="iso4217-usd">450000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c44757010" unitRef="iso4217-usd">349000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44757011" unitRef="iso4217-usd">620000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44757012" unitRef="iso4217-usd">409000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember" decimals="INF" id="c44756731" unitRef="xbrli-shares">639359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember" decimals="INF" id="c44756732" unitRef="xbrli-shares">480035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-CommonStockPurchaseWarrantsMember" decimals="INF" id="c44756733" unitRef="xbrli-shares">807563</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-CommonStockPurchaseWarrantsMember" decimals="INF" id="c44756734" unitRef="xbrli-shares">216213</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-DeferredShareUnitsMember" decimals="INF" id="c44756735" unitRef="xbrli-shares">21183</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-DeferredShareUnitsMember" decimals="INF" id="c44756736" unitRef="xbrli-shares">21183</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756737" unitRef="xbrli-shares">1468105</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c44756738" unitRef="xbrli-shares">717431</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2018-12-31" decimals="-3" id="c44756399" unitRef="iso4217-usd">18339000</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2017-12-31" decimals="-3" id="c44756400" unitRef="iso4217-usd">1802000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2018-12-31" decimals="-3" id="c44756391" unitRef="iso4217-usd">17972000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2017-12-31" decimals="-3" id="c44756392" unitRef="iso4217-usd">1494000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsNoncurrent contextRef="i_2018-12-31" decimals="-3" id="c44756397" unitRef="iso4217-usd">367000</us-gaap:AssetsNoncurrent>
  <us-gaap:AssetsNoncurrent contextRef="i_2017-12-31" decimals="-3" id="c44756398" unitRef="iso4217-usd">308000</us-gaap:AssetsNoncurrent>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139647">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Business&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;DiaMedica Therapeutics Inc. and its wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. (collectively &amp;#x201c;we,&amp;#x201d; &amp;#x201c;us,&amp;#x201d; &amp;#x201c;our,&amp;#x201d; &amp;#x201c;DiaMedica&amp;#x201d; and the &amp;#x201c;Company&amp;#x201d;), exist for the primary purpose of advancing the clinical and commercial development of a proprietary recombinant &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;KLK1&lt;/div&gt; protein for the treatment of kidney and neurological diseases with our primary focus on chronic kidney disease and acute ischemic stroke. Our parent company is governed under the Canada Business Corporations Act and, commencing on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 4, 2018, &lt;/div&gt;our common shares are publicly traded on The Nasdaq Capital Market under the symbol &amp;#x201c;DMAC.&amp;#x201d; The Company&amp;#x2019;s shares were previously traded on the TSX Venture Exchange in Canada and on the OTCQB in the United States.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Effective &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 15, 2018, &lt;/div&gt;we implemented a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;-for-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt; consolidation of our common shares. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; fractional shares were issued in connection with the share consolidation. Instead, the Company rounded to the nearest whole number the number of shares shareholders would be entitled to receive in connection with the consolidation. The share consolidation was approved by our shareholders as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 6, 2018 &lt;/div&gt;and was implemented to increase the market price per common share to a level that qualified for listing on The Nasdaq Capital Market. Proportional adjustments were also made to common shares reserved for issuance under the Company&amp;#x2019;s equity-based compensation plans and outstanding stock options, deferred share units and warrants. All references to share and per share amounts included in these consolidated financial statements have been retroactively restated to reflect the share consolidation.&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="i_2018-12-31" decimals="-3" id="c44756405" unitRef="iso4217-usd">5000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="i_2017-12-31" id="c44756406" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="i_2018-12-31" decimals="-3" id="c44756412" unitRef="iso4217-usd">18000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="i_2017-12-31" id="c44756413" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:Cash contextRef="i_2018-12-31" decimals="-3" id="c44756607" unitRef="iso4217-usd">16823000</us-gaap:Cash>
  <us-gaap:Cash contextRef="i_2017-12-31" decimals="-3" id="c44756576" unitRef="iso4217-usd">1353000</us-gaap:Cash>
  <us-gaap:Cash contextRef="i_2016-12-31" decimals="-3" id="c44756577" unitRef="iso4217-usd">1736000</us-gaap:Cash>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756574" unitRef="iso4217-usd">15470000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756575" unitRef="iso4217-usd">-383000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756793" unitRef="iso4217-cad-per-xbrli-shares">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" decimals="INF" id="c44756806" unitRef="iso4217-cad-per-xbrli-shares">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2018-12-11_ClassOfWarrantOrRightAxis-WarrantsIssuedWithIPOMember" decimals="INF" id="c44756890" unitRef="iso4217-usd-per-xbrli-shares">4.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2018-03-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756903" unitRef="iso4217-usd-per-xbrli-shares">7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2018-03-29_ClassOfWarrantOrRightAxis-CompensationWarrantsMember" decimals="INF" id="c44756911" unitRef="iso4217-usd-per-xbrli-shares">4.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2017-12-18_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756926" unitRef="iso4217-usd-per-xbrli-shares">7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2017-04-17_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756937" unitRef="iso4217-usd-per-xbrli-shares">4.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756792" unitRef="xbrli-shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" decimals="INF" id="c44756805" unitRef="xbrli-shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2018-03-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756902" unitRef="xbrli-shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2018-03-29_ClassOfWarrantOrRightAxis-CompensationWarrantsMember" decimals="INF" id="c44756910" unitRef="xbrli-shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2017-12-18_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756925" unitRef="xbrli-shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2017-04-17_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756936" unitRef="xbrli-shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2018-12-11_ClassOfWarrantOrRightAxis-WarrantsIssuedWithIPOMember" decimals="INF" id="c44756888" unitRef="xbrli-shares">205000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756791" unitRef="xbrli-shares">117188</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" decimals="INF" id="c44756804" unitRef="xbrli-shares">10915</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2018-12-31" id="c44756417" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2017-12-31" id="c44756418" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139662">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Commitments and Contingencies&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Clinical trials and product development&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;In the normal course of business, the Company incurs obligations to make future payments as it executes its business plan. These contracts relate to preclinical, clinical and development activities, including the clinical research organization conducting our Phase II clinical trial for acute ischemic stroke. These commitments are subject to significant change and the ultimate amounts due &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be materially different as these obligations are affected by, among other factors, the number and pace of patients enrolled, the number of clinical study sites, amount of time to complete study enrollments and the time required to finalize the analysis and reporting of study results. Clinical research agreements are generally cancelable upon &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30&lt;/div&gt; days&amp;#x2019; notice, with the Company&amp;#x2019;s obligation then limited to costs incurred up to that date. Cancelation terms for product development contracts vary and are generally dependent upon timelines for sourcing research materials and reserving laboratory time. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;the Company estimates that its outstanding commitments including research and development contracts are approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.9&lt;/div&gt; million over the next &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months and approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$600,000&lt;/div&gt; in the following &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 11, 2017, &lt;/div&gt;the Company announced the initiation of REMEDY, a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt;-patient Phase II clinical trial evaluating &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&lt;/div&gt; in patients with acute ischemic stroke. The study drug (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&lt;/div&gt; or placebo) will be administered as an intravenous infusion within &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24&lt;/div&gt; hours of stroke symptom onset, followed by subcutaneous (under the skin) injections later that day and once every &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; days for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21&lt;/div&gt; days. The study is designed to measure safety and tolerability along with multiple tests designed to investigate &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&amp;#x2019;s&lt;/div&gt; therapeutic potential including plasma-based biomarkers and standard functional stroke measures assessed at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;90&lt;/div&gt; days post-stroke (Modified Rankin Scale, National Institutes of Health Stroke Scale, Barthel Index, and C-reactive protein, a measure of inflammation).&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 14, 2019, &lt;/div&gt;the Company announced the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; enrollment in its Phase Ib dose ranging study in patients with moderate or severe CKD caused by Type I or Type II diabetes. The results from this Phase Ib study will assist us in the design of upcoming Phase II studies in patients suffering from rare diseases and CKD. The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&lt;/div&gt; drug levels from this Phase Ib study will be used to determine the optimal dose levels for testing in the Phase II studies.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Additional clinical trials will be subsequently required if the results of the Phase II are positive. However, at this time, we are unable to reasonably estimate the total costs of future trials. Such costs are contingent on and subject to change depending on the results of current and future clinical trials as well as developments in the regulatory requirements. Clinical trial costs are expensed as incurred.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Technology license&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The Company has entered into a license agreement with Catalent Pharma Solutions, LLC (&amp;#x201c;Catalent&amp;#x201d;) whereby we have licensed certain gene expression technology and we contract with Catalent for the manufacture of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199.&lt;/div&gt; Under the terms of this license, certain milestone and royalty payments &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;become due under this agreement and are dependent upon, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; milestones remain which include &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$185,000&lt;/div&gt; due upon the initiation of dosing in our &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; Phase III trial and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$185,000&lt;/div&gt; upon our &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; regulatory approval for commercial sale. Following the launch of our &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; product, we will also incur a royalty of less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1%&lt;/div&gt; on net sales. The royalty term is indefinite but &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be canceled by us on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;90&lt;/div&gt; days&amp;#x2019; prior written notice. The license &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be terminated by Catalent unless we fail to make required milestone and royalty payments. There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; amounts due or payable under this agreement during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Indemnification of directors and officers&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The Company, as permitted under laws of the Canada and in accordance with the Company&amp;#x2019;s by-laws and indemnification agreements, will indemnify and advance expenses to its directors and officers to the fullest extent permitted by law and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;choose to indemnify other employees or agents from time to time. The Company has secured insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to the Company. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;there was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; pending litigation or proceeding involving any director or officer of the Company as to which indemnification is required or permitted, and we are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; aware of any threatened litigation or proceeding that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;result in a claim for indemnification. Insofar as indemnification for liabilities arising under the United States Securities Act of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1933,&lt;/div&gt; as amended (the &amp;#x201c;Securities Act&amp;#x201d;) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be permitted to directors, officers and controlling persons of the Company, the Company has been advised that, in the opinion of the United States Securities and Exchange Commission (the &amp;#x201c;SEC&amp;#x201d;), such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; recorded any liabilities for these obligations as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Future minimum lease payments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The Company leases certain office space under a non-cancelable operating lease. On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 3, 2017, &lt;/div&gt;the Company amended the lease agreement to extend its lease term by &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;42&lt;/div&gt; months, for an expiration date of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 31, 2022, &lt;/div&gt;and increase its leased space. Rent is expensed on a straight-line basis.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Future minimum lease payments under this operating lease are as follows (in thousands):&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;64&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;66&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;68&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;46&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Total&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;244&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2012-12-31_PlanNameAxis-The2012DSUPlanMember" decimals="INF" id="c44756972" unitRef="xbrli-shares">100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2018-12-31_PlanNameAxis-The2012DSUPlanMember" decimals="INF" id="c44756973" unitRef="xbrli-shares">21183</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2018-12-31_PlanNameAxis-The2012DSUPlanAndOptionPlanMember" decimals="INF" id="c44756985" unitRef="xbrli-shares">783918</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2017-12-31_PlanNameAxis-The2012DSUPlanMember" decimals="INF" id="c44756974" unitRef="xbrli-shares">21183</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2018-12-31_StatementEquityComponentsAxis-StockOptionsOutstandingMember" decimals="INF" id="c44756946" unitRef="xbrli-shares">639359</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2018-12-31_StatementEquityComponentsAxis-DeferredShareUnitsMember" decimals="INF" id="c44756947" unitRef="xbrli-shares">21183</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2018-12-31_StatementEquityComponentsAxis-DiamedicaStockOptionPlanMember" decimals="INF" id="c44756948" unitRef="xbrli-shares">123376</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2018-12-31_StatementEquityComponentsAxis-WarrantMember" decimals="INF" id="c44756949" unitRef="xbrli-shares">807563</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="i_2018-12-31" decimals="INF" id="c44756950" unitRef="xbrli-shares">1591479</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockNoParValue contextRef="i_2018-12-31" decimals="-3" id="c44756422" unitRef="iso4217-usd-per-xbrli-shares">0</us-gaap:CommonStockNoParValue>
  <us-gaap:CommonStockNoParValue contextRef="i_2017-12-31" decimals="-3" id="c44756423" unitRef="iso4217-usd-per-xbrli-shares">0</us-gaap:CommonStockNoParValue>
  <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="d_2018-01-01_2018-12-31" id="c44756424">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
  <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="d_2017-01-01_2017-12-31" id="c44756425">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
  <us-gaap:CommonStockSharesIssued contextRef="i_2018-12-31" decimals="INF" id="c44756426" unitRef="xbrli-shares">11956874</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2017-12-31" decimals="INF" id="c44756427" unitRef="xbrli-shares">6370661</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2018-12-31" decimals="INF" id="c44756428" unitRef="xbrli-shares">11956874</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2017-12-31" decimals="INF" id="c44756429" unitRef="xbrli-shares">6370661</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2018-12-31" id="c44756420" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommonStockValue contextRef="i_2017-12-31" id="c44756421" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139673">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Employee Benefit Plan&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We maintain an employee &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;401&lt;/div&gt;(k) retirement savings plan (the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x201c;401&lt;/div&gt;(k) Plan&amp;#x201d;). The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;401&lt;/div&gt;(k) Plan provides eligible employees with an opportunity to make tax-deferred contributions into a long-term investment and savings program. All employees over the age of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;elect to participate in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;401&lt;/div&gt;(k) Plan beginning on their hire date. The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;401&lt;/div&gt;(k) Plan allows eligible employees to contribute a portion of their annual compensation, subject only to maximum limits required by law. We contribute an amount equal to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4%&lt;/div&gt; of each employees&amp;#x2019; compensation under the safe harbor provisions provided by the Internal Revenue Service rules governing &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;401&lt;/div&gt;(k) plans. Employee and employer safe harbor contributions vest immediately.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We have recorded contribution expenses of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$45,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$33,000&lt;/div&gt; for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c44756640">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The cost of employee and non-employee services received in exchange for awards of equity instruments is measured and recognized based on the estimated grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The fair value of share-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our share price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon Canadian Government bond rates appropriate for the expected term of each award. Expected volatility rates are based on the on historical volatility equal to the expected life of the option. The assumed dividend yield is zero, as we do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect to declare any dividends in the foreseeable future. The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2018-01-01_2018-12-31" id="c44756624">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Concentration of credit risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand and savings accounts at commercial banks. At times, such deposits &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be in excess of insured limits. The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; experienced any losses on its deposits of cash.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c44756618">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of consolidation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The accompanying consolidated financial statements include the assets, liabilities and expenses of DiaMedica Therapeutics Inc., and our wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. All significant intercompany transactions and balances have been eliminated in consolidation.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:ContractualObligation contextRef="i_2018-12-31_OtherCommitmentsAxis-TechnologyLicenseMember" decimals="INF" id="c44756852" unitRef="iso4217-usd">0</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligation contextRef="i_2018-12-31_OtherCommitmentsAxis-IndemnificationAgreementsMember" decimals="INF" id="c44756859" unitRef="iso4217-usd">0</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligation contextRef="i_2017-12-31_OtherCommitmentsAxis-TechnologyLicenseMember" decimals="INF" id="c44756853" unitRef="iso4217-usd">0</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligation contextRef="i_2017-12-31_OtherCommitmentsAxis-IndemnificationAgreementsMember" decimals="INF" id="c44756860" unitRef="iso4217-usd">0</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="i_2018-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember" decimals="INF" id="c44756828" unitRef="iso4217-usd">1900000</us-gaap:ContractualObligationDueInNextTwelveMonths>
  <us-gaap:ContractualObligationDueInSecondYear contextRef="i_2018-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember" decimals="INF" id="c44756830" unitRef="iso4217-usd">600000</us-gaap:ContractualObligationDueInSecondYear>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-24">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Advances to vendor&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;271&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;271&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;"&gt;Total deposit&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;271&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;271&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="i_2018-12-31" decimals="-3" id="c44757151" unitRef="iso4217-usd">887000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="i_2017-12-31" decimals="-3" id="c44757152" unitRef="iso4217-usd">887000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="i_2018-12-31" id="c44757165" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="i_2017-12-31" id="c44757166" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsNet contextRef="i_2018-12-31" decimals="-3" id="c44757161" unitRef="iso4217-usd">10886000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet contextRef="i_2017-12-31" decimals="-3" id="c44757162" unitRef="iso4217-usd">8552000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="i_2018-12-31" decimals="-3" id="c44757149" unitRef="iso4217-usd">9280000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="i_2017-12-31" decimals="-3" id="c44757150" unitRef="iso4217-usd">7233000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2018-12-31" decimals="-3" id="c44757163" unitRef="iso4217-usd">10886000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2017-12-31" decimals="-3" id="c44757164" unitRef="iso4217-usd">8552000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilitiesDeferredExpense contextRef="i_2018-12-31" decimals="-3" id="c44757157" unitRef="iso4217-usd">97000</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
  <us-gaap:DeferredTaxLiabilitiesDeferredExpense contextRef="i_2017-12-31" id="c44757158" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="i_2018-12-31" decimals="-3" id="c44757159" unitRef="iso4217-usd">6000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="i_2017-12-31" decimals="-3" id="c44757160" unitRef="iso4217-usd">4000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44757137" unitRef="iso4217-usd">45000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c44757138" unitRef="iso4217-usd">33000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="d_2018-01-01_2018-12-31" decimals="2" id="c44757135" unitRef="xbrli-pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DepositsAssetsNoncurrent contextRef="i_2018-12-31" decimals="-3" id="c44756754" unitRef="iso4217-usd">271000</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:DepositsAssetsNoncurrent contextRef="i_2017-12-31" decimals="-3" id="c44756755" unitRef="iso4217-usd">271000</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:Depreciation contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756758" unitRef="iso4217-usd">15000</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c44756759" unitRef="iso4217-usd">4000</us-gaap:Depreciation>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="i_2018-12-31" id="c44756407" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="i_2017-12-31" decimals="-3" id="c44756408" unitRef="iso4217-usd">84000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativesPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c44756630">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Common share warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The common share warrants that were issued in connection with the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2016 &lt;/div&gt;private placements of common shares were classified as a liability in the consolidated balance sheets, as the common share warrants had an exercise price stated in Canadian dollars, which is different than our functional currency, and thus these warrants qualified as derivative instruments. The fair value of these common share warrants was re-measured at each financial reporting period and immediately before exercise, with any changes in fair value being recognized as a component of other income (expense) in our consolidated statements of operations. These warrants were exercised in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2018, &lt;/div&gt;see Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt; titled &amp;#x201c;Warrant Liability.&amp;#x201d;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139667">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Share-Based Compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Deferred share unit plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The DiaMedica Therapeutics Inc. Amended and Restated Deferred Share Unit Plan (&amp;#x201c;DSU Plan&amp;#x201d;) promotes greater alignment of long-term interests between non-executive directors and executive officers of the Company and its shareholders through the issuance of deferred share units (&amp;#x201c;DSUs&amp;#x201d;). Since the value of DSUs increases or decreases with the market price of the common shares, DSUs reflect a philosophy of aligning the interests of directors and executive officers by tying compensation to share price performance. For the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; there were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; DSUs or common shares underlying DSUs issued. The Company has reserved for issuance up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100,000&lt;/div&gt; common shares under the DSU Plan and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,183&lt;/div&gt; DSUs were outstanding at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock option plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The DiaMedica Therapeutics Inc. Stock Option Plan Amended and Restated &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 6, 2018 (&lt;/div&gt;the &amp;#x201c;Option Plan&amp;#x201d;) allows the Board of Directors from time to time, in its sole discretion, and in accordance with the requirements of the Nasdaq Stock Market, to grant the Company&amp;#x2019;s directors, officers, employees and certain consultants (as such terms are used in the Option Plan) non-transferable options to purchase common shares. The shareholders approved the adoption of the Option Plan on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 22, 2011, &lt;/div&gt;which was then amended and restated on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 23, 2015, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 21, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 6, 2018. &lt;/div&gt;The number of common shares reserved for issuance under the Option Plan at any time is equal to the lesser of: &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;783,918&lt;/div&gt; (subject to adjustment) and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10%&lt;/div&gt; of the issued common shares at the relevant time and the aggregate number of common shares reserved for issuance under any other compensation or incentive mechanism or plan (including deferred share unit plans or employee stock option plans, if any), shall &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; exceed &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10%&lt;/div&gt; of our issued shares at the relevant time. In addition, the maximum number of common shares that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be issued under the Option Plan upon the exercise of incentive stock options within the meaning of Section &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;422&lt;/div&gt; of the United States Internal Revenue Code of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1986,&lt;/div&gt; as amended (the &amp;#x201c;Code&amp;#x201d;) is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;283,918&lt;/div&gt; shares (subject to adjustment).&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;options to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;639,359&lt;/div&gt; common shares were outstanding. Options granted vest at various rates and have terms of up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt; years. As the TSX Venture Exchange was the principal trading market for the Company&amp;#x2019;s common shares, all options previously granted under the Option Plan have been priced in Canadian dollars.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The aggregate number of common shares reserved for issuance under the Option Plan and the DSU Plan as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;783,918.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Share-based compensation expense for each of the periods presented is as follows (in thousands):&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;170&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;450&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;349&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total share-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;620&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;409&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We recognize share-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;A summary of option activity is as follows (in thousands except share and per share amounts):&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Underlying&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average Exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Price Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(CAD$)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Intrinsic Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(CAD$)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balances at December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;427,850&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.68&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;187&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;127,635&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.11&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.00&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Expired/cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(72,450&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.29&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balances at December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;480,035&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.45&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;674&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;196,800&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.08&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16,954&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.29&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Expired/cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(20,522&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.99&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balances at December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;639,359&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.87&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;A summary of the status of our unvested shares during the year ended and as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;is as follows:&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shares Under&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Option&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(CAD$)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unvested at December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;216,793&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.69&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;196,800&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.30&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Vested&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(150,739&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.48&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Forfeitures&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(20,522&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.27&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unvested at December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;242,332&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.45&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Information about stock options outstanding, vested and expected to vest as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;is as follows:&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11011100000%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Outstanding, Vested and Expected to Vest&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 110111%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Options Vested and Exercisable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="3" rowspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 163%; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Per Share Exercise&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Contractual &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Life (Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise Price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(CAD$)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercisable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Remaining &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Contractual &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Life (Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$2.00&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.60&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.8&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.00&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.8&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$2.80&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.20&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125,400&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.9&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.00&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125,400&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.9&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$3.40&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.20&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;130,405&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.12&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;91,239&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$5.40&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10.20&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;98,063&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.5&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.39&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50,563&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.5&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$10.40&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$34.00&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;235,491&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.2&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.86&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;79,825&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.9&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;639,359&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.8&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.87&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;397,027&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.1&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The cumulative grant date fair value of employee options vested during the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$508,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$213,000,&lt;/div&gt; respectively. Total proceeds received for options exercised during the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$43,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7,000,&lt;/div&gt; respectively.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; total compensation expense related to unvested employee stock options &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; yet recognized was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.4&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$551,000,&lt;/div&gt; respectively, which is expected to be allocated to expenses over a weighted-average period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.01&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.97&lt;/div&gt; years, respectively.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The aggregate intrinsic value of stock options exercised during the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$104,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,000,&lt;/div&gt; respectively.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by the Company for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 53%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 53%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;Common share fair value&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8.84&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$9.33&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.20&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8.40&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;2.1&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.2%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.1%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected option life&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;4.8&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected stock price volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;123.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;135.7%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;84.7&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;156.8%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Nonemployee share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We account for stock options granted to nonemployees in accordance with FASB ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;505.&lt;/div&gt; In connection with stock options granted to nonemployees, we recorded &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$205,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$308,000&lt;/div&gt; for nonemployee share-based compensation during the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;These amounts were based upon the fair values of the vested portion of the grants. Amounts expensed during the remaining vesting period will be determined based on the fair value at the time of vesting.&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756465" unitRef="iso4217-usd-per-xbrli-shares">-0.74</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c44756466" unitRef="iso4217-usd-per-xbrli-shares">-0.72</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c44756646">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The following table summarizes our calculation of net loss per common share for the periods (in thousands, except share and per share data):&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,734&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,260&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average shares outstanding&amp;#x2014;basic and diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,743,520&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,935,790&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Basic and diluted net loss per share&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.74&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.72&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The following outstanding potential common shares were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; included in the diluted net loss per share calculations as their effects were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; dilutive:&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Employee and non-employee stock options&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;639,359&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;480,035&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common shares issuable under common share purchase warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;807,563&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;216,213&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common shares issuable under deferred unit plan&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,183&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,183&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2018-01-01_2018-12-31" decimals="2" id="c44757167" unitRef="xbrli-pure">0.27</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2017-01-01_2017-12-31" decimals="2" id="c44757168" unitRef="xbrli-pure">0.27</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2018-12-31" decimals="-3" id="c44756775" unitRef="iso4217-usd">417000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2017-12-31" decimals="-3" id="c44756776" unitRef="iso4217-usd">355000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2018-01-01_2018-12-31" id="c44756996">P2Y3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2017-01-01_2017-12-31" id="c44756997">P1Y354D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="i_2018-12-31" decimals="INF" id="c44756994" unitRef="iso4217-usd">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="i_2017-12-31" decimals="INF" id="c44756995" unitRef="iso4217-usd">551000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756823" unitRef="iso4217-usd">39000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756456" unitRef="iso4217-usd">-9000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c44756628">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fair value measurements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Fair value is defined as the exit price, or amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&amp;#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The hierarchy is broken down into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; levels defined as follows:&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"&gt; &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 27pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&amp;#x2014;Unadjusted&lt;/div&gt; quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"&gt; &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 27pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&amp;#x2014;Quoted&lt;/div&gt; prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; active or model-derived valuations for which all significant inputs are observable, either directly or indirectly.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"&gt; &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 27pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&amp;#x2014;Prices&lt;/div&gt; or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Our cash is comprised of bank deposits in demand and savings accounts. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:FairValueOfAssetsAcquired contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756586" unitRef="iso4217-usd">24000</us-gaap:FairValueOfAssetsAcquired>
  <us-gaap:FairValueOfAssetsAcquired contextRef="d_2017-01-01_2017-12-31" id="c44756587" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2018-01-01_2018-12-31" id="c44756626">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fair value of financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Carrying amounts of certain of the Company&amp;#x2019;s financial instruments, including amounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. Certain of the Company&amp;#x2019;s common share purchase warrants are required to be reported at fair value. The fair value of common share purchase warrants is disclosed in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt; titled &amp;#x201c;Warrant Liability.&amp;#x201d;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756444" unitRef="iso4217-usd">2739000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756445" unitRef="iso4217-usd">1313000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c44756632">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Long-lived assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Property and equipment are stated at purchased cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; years for office equipment and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;four&lt;/div&gt; years for computer equipment. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheets and the resulting gain or loss is reflected in the consolidated statements of operations. Repairs and maintenance are expensed as incurred.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Long-lived assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset or related group of assets &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be recoverable. If the expected future undiscounted cash flows are less than the carrying amount of the asset, an impairment loss is recognized at that time. Measurement of impairment &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be based upon appraisal, market value of similar assets or discounted cash flows.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756459" unitRef="iso4217-usd">-5654000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756460" unitRef="iso4217-usd">-4260000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139674">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The Company has incurred net operating losses since inception. The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; reflected the benefit of net operating loss carryforwards in the accompanying financial statements and has established a full valuation allowance against its deferred tax assets.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as operating losses and tax credit carryforwards.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The significant components of our deferred tax assets and liabilities are as follows (in thousands):&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax assets (liabilities):&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Non-capital losses carried forward&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,280&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,233&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Research and development expenditures&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;887&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;887&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Share issue costs&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;529&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;117&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Patents and other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;293&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;319&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Accruals&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(97&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Property and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;"&gt;Total deferred tax asset, net&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,886&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,552&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(10,886&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8,552&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax asset&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that the deferred tax assets arising from the above-mentioned future tax benefits are currently &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; likely to be realized and, accordingly, we have provided a full valuation allowance.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The reconciliation of the Canadian statutory income tax rate applied to the net loss for the year to the income tax expense is as follows:&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Statutory income tax rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Income tax recovery based on statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,119&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,160&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Share-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;243&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;110&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gain on revaluation of warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(450&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Australian research and development incentive&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;103&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;314&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;172&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in unrecognized temporary differences&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,131&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;534&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Income tax expense&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(80&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Net operating losses and tax credit carryforwards as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;are as follows:&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(In thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Expiration Years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Non-capital income tax losses, net&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,002&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Beginning 2026&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development expense carry forwards&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,284&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Indefinitely&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Tax credits&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;525&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Beginning 2020&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The Company is subject to taxation in the Canada, the United States and Australia. Tax returns, since the inception of DiaMedica Therapeutics Inc. are subject to examinations by Canadian tax authorities and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;change upon examination. Tax returns of DiaMedica USA, Inc., since its inception in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2012&lt;/div&gt; and thereafter, are subject to examination by the U.S. federal and state tax authorities. Tax returns of DiaMedica Therapeutics Australia Pty Ltd., since its inception in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and thereafter, are subject to examination by the Australian tax authorities.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756461" unitRef="iso4217-usd">80000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2017-01-01_2017-12-31" id="c44756462" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c44756642">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt; See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,&lt;/div&gt; &amp;#x201c;Income Taxes&amp;#x201d; for additional information. The Company&amp;#x2019;s policy is to classify interest and penalties related to income taxes as income tax expense in the Consolidated Statements of Operations and Comprehensive Loss.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44757175" unitRef="iso4217-usd">103000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44757176" unitRef="iso4217-usd">314000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44757171" unitRef="iso4217-usd">243000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44757172" unitRef="iso4217-usd">110000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44757177" unitRef="iso4217-usd">172000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44757178" unitRef="iso4217-usd">204000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
  <us-gaap:IncomeTaxesReceivable contextRef="i_2018-12-31" decimals="-3" id="c44756742" unitRef="iso4217-usd">134000</us-gaap:IncomeTaxesReceivable>
  <us-gaap:IncomeTaxesReceivable contextRef="i_2017-12-31" id="c44756743" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756554" unitRef="iso4217-usd">372000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756555" unitRef="iso4217-usd">248000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756548" unitRef="iso4217-usd">700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756549" unitRef="iso4217-usd">27000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="d_2018-01-01_2018-12-31" id="c44756552" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756553" unitRef="iso4217-usd">271000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756550" unitRef="iso4217-usd">308000</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756551" unitRef="iso4217-usd">-6000</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:InterestPaidNet contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756581" unitRef="iso4217-usd">11000</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756582" unitRef="iso4217-usd">57000</us-gaap:InterestPaidNet>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-28">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;64&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;66&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;68&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;46&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Total&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;244&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="i_2018-12-31" decimals="-3" id="c44756867" unitRef="iso4217-usd">244000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="i_2018-12-31" decimals="-3" id="c44756863" unitRef="iso4217-usd">64000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="i_2018-12-31" decimals="-3" id="c44756866" unitRef="iso4217-usd">46000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="i_2018-12-31" decimals="-3" id="c44756865" unitRef="iso4217-usd">68000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="i_2018-12-31" decimals="-3" id="c44756864" unitRef="iso4217-usd">66000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="i_2017-05-03_LeaseArrangementTypeAxis-OfficeSpaceMember" id="c44756862">P3Y180D</us-gaap:LesseeOperatingLeaseTermOfContract>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2018-12-31" decimals="-3" id="c44756436" unitRef="iso4217-usd">18339000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2017-12-31" decimals="-3" id="c44756437" unitRef="iso4217-usd">1802000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2018-12-31" decimals="-3" id="c44756409" unitRef="iso4217-usd">1296000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2017-12-31" decimals="-3" id="c44756410" unitRef="iso4217-usd">1003000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent contextRef="i_2018-12-31" decimals="-3" id="c44756414" unitRef="iso4217-usd">18000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent contextRef="i_2017-12-31" id="c44756415" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139652">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Amounts Receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Amounts receivable consisted of the following (in thousands):&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development incentives&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;622&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Sales-based taxes receivable&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;134&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;80&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;"&gt;Total amounts receivable&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;780&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;80&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
  <us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="i_2018-12-31_LegalEntityAxis-SKGroupMember_OwnershipAxis-DiaMedicaMember" decimals="3" id="c44756966" unitRef="xbrli-pure">0.084</us-gaap:MinorityInterestOwnershipPercentageByParent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756572" unitRef="iso4217-usd">21216000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756573" unitRef="iso4217-usd">3539000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756561" unitRef="iso4217-usd">-50000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756562" unitRef="iso4217-usd">-22000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756604" unitRef="iso4217-usd">-5696000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756557" unitRef="iso4217-usd">-3900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756603" unitRef="iso4217-usd">-5734000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" id="c44756494" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c44756495" unitRef="iso4217-usd">-4260000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756496" unitRef="iso4217-usd">-4260000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" id="c44756530" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetIncomeLoss contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c44756531" unitRef="iso4217-usd">-5734000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c44756649">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recently adopted accounting pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2014, &lt;/div&gt;the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued a new accounting standard that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard and clarifying standards require an entity to recognize revenue when control of promised goods or services is transferred to the customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted this new standard as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2018, &lt;/div&gt;but the adoption as of this date had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; impact on our financial statements, as we had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; revenue until the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018.&lt;/div&gt; We followed ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;606,&lt;/div&gt; &amp;#x201c;Revenue from Contracts with Customers&amp;#x201d; in accounting for our License and Collaboration agreement with Ahon Pharmaceutical Co Ltd. (Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;).&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recently issued accounting pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2016, &lt;/div&gt;the FASB issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Leases&lt;/div&gt;. The guidance in ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&lt;/div&gt; supersedes the lease recognition requirements in the Accounting Standards Codification Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;840,&lt;/div&gt; Leases. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&lt;/div&gt; requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. The new standard requires the immediate recognition of all excess tax benefits and deficiencies in the income statement and requires classification of excess tax benefits as an operating activity as opposed to a financing activity in the statements of cash flows. This standard became effective for us on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The FASB has subsequently issued the following amendments to ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; which have the same effective date and transition date of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019, &lt;/div&gt;and which we collectively refer to as the new leasing standards:&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"&gt; &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 18pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;01,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;): Land Easement Practical Expedient for Transition to Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;&lt;/div&gt;, which permits an entity to elect an optional transition practical expedient to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; evaluate under Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt; land easements that existed or expired prior to adoption of Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt; and that were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; previously accounted for as leases under the prior standard, ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;840,&lt;/div&gt; Leases.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"&gt; &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 18pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Codification Improvements to Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842,&lt;/div&gt; Leases&lt;/div&gt;, which amends certain narrow aspects of the guidance issued in ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"&gt; &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 18pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;): Targeted Improvements&lt;/div&gt;, which allows for a transition approach to initially apply ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&lt;/div&gt; at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption as well as an additional practical expedient for lessors to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; separate non-lease components from the associated lease component.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"&gt; &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 18pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Narrow-Scope Improvements for Lessors&lt;/div&gt;, which contains certain narrow scope improvements to the guidance issued in ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We adopted the new leasing standards on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019, &lt;/div&gt;using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019; &lt;/div&gt;and, consequently, financial information will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be updated and the disclosures required under Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt; will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be provided for dates and periods prior to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019. &lt;/div&gt;We have reviewed our existing lease contracts and the impact of the new leasing standards on our consolidated results of operations, financial position and disclosures. Upon adoption of the new leasing standards, we expect to recognize a lease liability and related right-of-use asset on our consolidated balance sheet of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$200,000.&lt;/div&gt; The impact of adoption of the new leasing standards will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a material impact on our consolidated statements of operations.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2018, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;07,&lt;/div&gt; &amp;#x201c;&lt;div style="display: inline; font-style: italic;"&gt;Improvements to Nonemployee Share-Based Payment Accounting&lt;/div&gt;," to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. This ASU is effective for public entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018, &lt;/div&gt;with early adoption permitted. Prior to the adoption of this ASU, stock-based compensation awarded to non-employees was subject to revaluation over its vesting terms. Subsequent to the adoption of this ASU, non-employee share-based payment awards are measured on the date of grant, similar to share-based payment awards granted to employees. We do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect that the adoption of this ASU will impact our financial position or our consolidated statements of operations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NonoperatingIncomeExpense contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756457" unitRef="iso4217-usd">1107000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756458" unitRef="iso4217-usd">259000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OpenTaxYear contextRef="d_2018-01-01_2018-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" id="c44757145">2012 2013 2014 2015 2016 2017 2018</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear contextRef="d_2018-01-01_2018-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_IncomeTaxAuthorityNameAxis-AustralianTaxationOfficeMember" id="c44757147">2016 2017 2018</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear contextRef="d_2018-01-01_2018-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" id="c44757146">2012 2013 2014 2015 2016 2017 2018</us-gaap:OpenTaxYear>
  <us-gaap:OperatingExpenses contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756446" unitRef="iso4217-usd">7261000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756447" unitRef="iso4217-usd">4519000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756448" unitRef="iso4217-usd">-6761000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756449" unitRef="iso4217-usd">-4519000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeaseLiability contextRef="i_2019-01-01_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c44756724" unitRef="iso4217-usd">200000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseRightOfUseAsset contextRef="i_2019-01-01_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c44756718" unitRef="iso4217-usd">200000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OtherAssetsDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139654">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Deposit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Deposit consisted of the following (in thousands):&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Advances to vendor&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;271&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;271&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;"&gt;Total deposit&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;271&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;271&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We have advanced funds to a vendor engaged to support the performance of the REMEDY Phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; clinical trial. The funds advanced will be held, interest free, by this vendor until the completion of the trial and applied to final trial invoices or refunded. This deposit is classified as non-current as the trial is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expected to be completed during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756453" unitRef="iso4217-usd">-68000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756454" unitRef="iso4217-usd">6000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherReceivables contextRef="i_2018-12-31" decimals="-3" id="c44756744" unitRef="iso4217-usd">24000</us-gaap:OtherReceivables>
  <us-gaap:OtherReceivables contextRef="i_2017-12-31" decimals="-3" id="c44756745" unitRef="iso4217-usd">80000</us-gaap:OtherReceivables>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756559" unitRef="iso4217-usd">50000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756560" unitRef="iso4217-usd">22000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PrepaidExpenseCurrent contextRef="i_2018-12-31" decimals="-3" id="c44756389" unitRef="iso4217-usd">369000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="i_2017-12-31" decimals="-3" id="c44756390" unitRef="iso4217-usd">61000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2018-12-11_2018-12-11_SubsidiarySaleOfStockAxis-IPOMember" decimals="INF" id="c44756883" unitRef="iso4217-usd">16400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756564" unitRef="iso4217-usd">14726000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756565" unitRef="iso4217-usd">2917000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756916" unitRef="iso4217-usd">43000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c44756944" unitRef="iso4217-usd">7000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2016-02-01_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" decimals="INF" id="c44756798" unitRef="iso4217-usd">281000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2018-02-01_2018-02-28_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" decimals="INF" id="c44756815" unitRef="iso4217-usd">483000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756914" unitRef="iso4217-usd">607000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c44756942" unitRef="iso4217-usd">615000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139656">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Property and equipment consisted of the following (in thousands):&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Furniture and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;49&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Computer equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;71&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;120&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(24&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(26&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;"&gt;Property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;96&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;37&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Depreciation expense for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$15,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4,000,&lt;/div&gt; respectively. During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; we disposed of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$17,000&lt;/div&gt; of equipment, which was fully depreciated.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756761" unitRef="iso4217-usd">17000</us-gaap:PropertyPlantAndEquipmentDisposals>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2018-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" decimals="-3" id="c44756762" unitRef="iso4217-usd">49000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" decimals="-3" id="c44756763" unitRef="iso4217-usd">40000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2018-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" decimals="-3" id="c44756764" unitRef="iso4217-usd">71000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" decimals="-3" id="c44756765" unitRef="iso4217-usd">23000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2018-12-31" decimals="-3" id="c44756766" unitRef="iso4217-usd">120000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31" decimals="-3" id="c44756767" unitRef="iso4217-usd">63000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2018-12-31" decimals="-3" id="c44756770" unitRef="iso4217-usd">96000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2017-12-31" decimals="-3" id="c44756771" unitRef="iso4217-usd">37000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-25">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Furniture and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;49&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Computer equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;71&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;120&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(24&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(26&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;"&gt;Property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;96&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;37&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2018-01-01_2018-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MinimumMember" id="c44756635">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2018-01-01_2018-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MaximumMember" id="c44756637">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2018-01-01_2018-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" id="c44756639">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139666">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;License and Collaboration Agreement with Related Party&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 27, 2018, &lt;/div&gt;the Company entered into a license and collaboration agreement (the &amp;#x201c;License Agreement&amp;#x201d;) with Ahon Pharmaceutical Co Ltd. (&amp;#x201c;Ahon Pharma&amp;#x201d;), which grants Ahon Pharma exclusive rights to develop and commercialize &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&lt;/div&gt; for acute ischemic stroke in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Under the terms of the agreement, the Company is entitled to receive a non-refundable upfront payment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$500,000&lt;/div&gt; due upon signing the License Agreement and an additional non-refundable payment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.5&lt;/div&gt; million upon regulatory clearance to initiate a clinical trial in China. The Company also has the potential to receive up to an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$27.5&lt;/div&gt; million in development and sales related milestones and up to approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10%&lt;/div&gt; royalties on net sales of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&lt;/div&gt; in the licensed territories. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territories will be the sole responsibility of Ahon Pharma. The License Agreement &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be terminated at any time by Ahon Pharma by providing &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;120&lt;/div&gt; days written notice.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The Company received the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$500,000&lt;/div&gt; upfront license fee and recorded it as revenue during the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018. &lt;/div&gt;The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.5&lt;/div&gt;&amp;nbsp;million payment and the up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$27.5&lt;/div&gt; million in additional development and sales related milestones were determined to be at-risk substantive performance milestones and were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; recordable as revenue as they were determined to be fully constrained using the most likely amount method. Revenue will be recognized for these milestones when it is probable that a significant reversal of the cumulative revenue recognized will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; occur. Under the terms of the License Agreement, the Company is obligated to pay, and Ahon Pharma &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;withhold, approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10%&lt;/div&gt; of any license fee as income tax due in China. The Company will record this withholding as income tax at the time it records the related license fee revenue. Accordingly, with respect to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$500,000&lt;/div&gt; license fee, the Company recorded this withholding as income tax at the time it recorded this license fee revenue.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Ahon Pharma is a subsidiary of Shanghai Fosun Pharmaceutical (Group) co. Ltd. (&amp;#x201c;Fosun Pharma&amp;#x201d;) which, through its partnership with SK Group, a South Korea based company, is an investor in DiaMedica, holding approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.4%&lt;/div&gt; of our common shares as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018. &lt;/div&gt;This investment was made in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756442" unitRef="iso4217-usd">4522000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756443" unitRef="iso4217-usd">3206000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2018-01-01_2018-12-31" id="c44756636">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and development costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Research and development costs include expenses incurred in the conduct of human clinical trials, for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party service providers performing various testing and accumulating data related to non-clinical studies&amp;#x37e; sponsored research agreements&amp;#x37e; developing the manufacturing process necessary to produce sufficient amounts of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&lt;/div&gt; compound for use in our non-clinical studies and human clinical trials&amp;#x37e; consulting resources with specialized expertise related to execution of our development plan for our &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&lt;/div&gt; product candidate&amp;#x37e; and personnel costs, including salaries, benefits and share-based compensation.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (&amp;#x201c;CROs&amp;#x201d;). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual work performed at each clinical trial site and by each CRO.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2018-12-31" decimals="-3" id="c44756601" unitRef="iso4217-usd">-45968000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2017-12-31" decimals="-3" id="c44756433" unitRef="iso4217-usd">-40234000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756439" unitRef="iso4217-usd">500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="d_2017-01-01_2017-12-31" id="c44756440" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:RevenueFromRelatedParties contextRef="d_2018-09-27_2018-09-27_RelatedPartyTransactionAxis-LicenseAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis-AhonPharmaMember" decimals="INF" id="c44756953" unitRef="iso4217-usd">500000</us-gaap:RevenueFromRelatedParties>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2018-01-01_2018-12-31" id="c44756634">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We followed ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;606,&lt;/div&gt; &amp;#x201c;Revenue from Contracts with Customers&amp;#x201d; in accounting for our License and Collaboration agreement with Ahon Pharmaceutical Co Ltd. Accordingly, the Company recognizes revenue upon transfer of control of the product to our customer in an amount that reflects the consideration we expect to receive in exchange.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We intend to enter into arrangements for the research and development (R&amp;amp;D) and/or manufacture of products and product candidates. Such arrangements &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;require us to deliver various rights, services and/or goods, including (i) intellectual property rights or licenses, (ii) R&amp;amp;D services or (iii) manufacturing services. The underlying terms of these arrangements generally would provide for consideration to DiaMedica in the form of nonrefundable, up-front license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;In arrangements involving more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; available.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; occur. We intend to utilize the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-23">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development incentives&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;622&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Sales-based taxes receivable&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;134&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;80&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;"&gt;Total amounts receivable&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;780&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;80&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-26">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Trade and other payables&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;483&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;513&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;417&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;355&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued clinical study costs&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;292&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued research and other professional fees&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;65&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;45&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued taxes and other liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;"&gt;Total accrued liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,291&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;919&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Employee and non-employee stock options&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;639,359&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;480,035&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common shares issuable under common share purchase warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;807,563&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;216,213&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common shares issuable under deferred unit plan&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,183&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,183&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,468,105&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;717,431&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-35">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax assets (liabilities):&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Non-capital losses carried forward&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,280&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,233&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Research and development expenditures&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;887&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;887&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Share issue costs&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;529&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;117&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Patents and other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;293&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;319&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Accruals&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(97&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Property and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;"&gt;Total deferred tax asset, net&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,886&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,552&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(10,886&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(8,552&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax asset&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,734&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,260&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average shares outstanding&amp;#x2014;basic and diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,743,520&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,935,790&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Basic and diluted net loss per share&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.74&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.72&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-36">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Statutory income tax rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Income tax recovery based on statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,119&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,160&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Share-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;243&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;110&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gain on revaluation of warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(450&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Australian research and development incentive&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;103&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;314&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;172&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in unrecognized temporary differences&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,131&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;534&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Income tax expense&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(80&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;170&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;450&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;349&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total share-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;620&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;409&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-32">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shares Under&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Option&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(CAD$)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unvested at December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;216,793&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.69&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;196,800&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.30&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Vested&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(150,739&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.48&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Forfeitures&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(20,522&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.27&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unvested at December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;242,332&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.45&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-33">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11011100000%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Outstanding, Vested and Expected to Vest&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 110111%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Options Vested and Exercisable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td colspan="3" rowspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 163%; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Per Share Exercise&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Price&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Contractual &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Life (Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise Price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(CAD$)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercisable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Remaining &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Contractual &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Life (Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$2.00&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.60&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.8&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.00&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.8&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$2.80&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.20&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125,400&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.9&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.00&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125,400&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.9&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$3.40&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.20&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;130,405&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.12&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;91,239&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$5.40&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10.20&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;98,063&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.5&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.39&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50,563&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.5&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$10.40&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$34.00&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;235,491&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.2&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.86&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;79,825&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.9&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 3%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 16%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;639,359&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.8&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.87&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;397,027&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.1&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-31">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Underlying&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average Exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Price Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(CAD$)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Intrinsic Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(CAD$)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balances at December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;427,850&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.68&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;187&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;127,635&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.11&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.00&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Expired/cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(72,450&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.29&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balances at December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;480,035&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.45&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;674&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;196,800&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.08&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Exercised&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16,954&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.29&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Expired/cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(20,522&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.99&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balances at December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;639,359&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.87&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-34">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 53%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 53%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;Common share fair value&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8.84&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$9.33&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.20&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8.40&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;2.1&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.2%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.1%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected option life&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;4.8&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected stock price volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;123.5&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;135.7%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;84.7&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2013;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;156.8%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-27">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Ending balance December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;84&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in fair value&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercises&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(123&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Ending balance December 31, 2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756541" unitRef="iso4217-usd">620000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756542" unitRef="iso4217-usd">409000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="i_2018-12-31_RangeAxis-MinimumMember" decimals="INF" id="c44757098" unitRef="iso4217-usd-per-xbrli-shares">8.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="i_2018-12-31_RangeAxis-MaximumMember" decimals="INF" id="c44757100" unitRef="iso4217-usd-per-xbrli-shares">9.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="i_2017-12-31_RangeAxis-MinimumMember" decimals="INF" id="c44757101" unitRef="iso4217-usd-per-xbrli-shares">5.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="i_2017-12-31_RangeAxis-MaximumMember" decimals="INF" id="c44757103" unitRef="iso4217-usd-per-xbrli-shares">8.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2018-01-01_2018-12-31" decimals="3" id="c44757111" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2017-01-01_2017-12-31" decimals="3" id="c44757114" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2018-01-01_2018-12-31_RangeAxis-MinimumMember" decimals="3" id="c44757122" unitRef="xbrli-pure">1.235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2018-01-01_2018-12-31_RangeAxis-MaximumMember" decimals="3" id="c44757124" unitRef="xbrli-pure">1.357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2017-01-01_2017-12-31_RangeAxis-MinimumMember" decimals="3" id="c44757125" unitRef="xbrli-pure">0.847</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember" decimals="3" id="c44757127" unitRef="xbrli-pure">1.568</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2018-01-01_2018-12-31_RangeAxis-MinimumMember" decimals="3" id="c44757104" unitRef="xbrli-pure">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2018-01-01_2018-12-31_RangeAxis-MaximumMember" decimals="3" id="c44757106" unitRef="xbrli-pure">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2017-01-01_2017-12-31" decimals="3" id="c44757108" unitRef="xbrli-pure">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756999" unitRef="iso4217-usd">104000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c44757000" unitRef="iso4217-usd">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757022" unitRef="xbrli-shares">72450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c44757037" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c44757025" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757040" unitRef="xbrli-shares">20522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757016" unitRef="xbrli-shares">127635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757031" unitRef="xbrli-shares">196800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44757048" unitRef="xbrli-shares">196800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44757049" unitRef="iso4217-cad-per-xbrli-shares">9.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757015" unitRef="iso4217-cad">187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757030" unitRef="iso4217-cad">674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c44757045" unitRef="iso4217-cad" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2018-12-31_PlanNameAxis-OptionPlanMember" decimals="INF" id="c44756983" unitRef="xbrli-shares">639359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757013" unitRef="xbrli-shares">427850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757028" unitRef="xbrli-shares">480035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757043" unitRef="xbrli-shares">639359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757014" unitRef="iso4217-cad-per-xbrli-shares">7.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757029" unitRef="iso4217-cad-per-xbrli-shares">6.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757044" unitRef="iso4217-cad-per-xbrli-shares">7.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-OptionPlanMember" decimals="1" id="c44756979" unitRef="xbrli-pure">0.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-The2012DSUPlanMember" decimals="INF" id="c44756970" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="d_2017-01-01_2017-12-31_PlanNameAxis-The2012DSUPlanMember" decimals="INF" id="c44756971" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757020" unitRef="iso4217-cad-per-xbrli-shares">3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757035" unitRef="iso4217-cad-per-xbrli-shares">3.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757023" unitRef="iso4217-cad-per-xbrli-shares">13.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c44757038" unitRef="iso4217-cad-per-xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c44757026" unitRef="iso4217-cad-per-xbrli-shares" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757041" unitRef="iso4217-cad-per-xbrli-shares">8.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757017" unitRef="iso4217-cad-per-xbrli-shares">6.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757032" unitRef="iso4217-cad-per-xbrli-shares">11.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" decimals="INF" id="c44757056" unitRef="iso4217-cad-per-xbrli-shares">2</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" decimals="INF" id="c44757063" unitRef="iso4217-cad-per-xbrli-shares">2.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" decimals="INF" id="c44757070" unitRef="iso4217-cad-per-xbrli-shares">3.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" decimals="INF" id="c44757077" unitRef="iso4217-cad-per-xbrli-shares">5.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" decimals="INF" id="c44757084" unitRef="iso4217-cad-per-xbrli-shares">10.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" decimals="INF" id="c44757061" unitRef="xbrli-shares">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" decimals="INF" id="c44757068" unitRef="xbrli-shares">125400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" decimals="INF" id="c44757075" unitRef="xbrli-shares">91239</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" decimals="INF" id="c44757082" unitRef="xbrli-shares">50563</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" decimals="INF" id="c44757089" unitRef="xbrli-shares">79825</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="i_2018-12-31" decimals="INF" id="c44757096" unitRef="xbrli-shares">397027</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" decimals="INF" id="c44757058" unitRef="xbrli-shares">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" decimals="INF" id="c44757065" unitRef="xbrli-shares">125400</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" decimals="INF" id="c44757072" unitRef="xbrli-shares">130405</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" decimals="INF" id="c44757079" unitRef="xbrli-shares">98063</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" decimals="INF" id="c44757086" unitRef="xbrli-shares">235491</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="i_2018-12-31" decimals="INF" id="c44757093" unitRef="xbrli-shares">639359</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" decimals="INF" id="c44757057" unitRef="iso4217-cad-per-xbrli-shares">2.60</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" decimals="INF" id="c44757064" unitRef="iso4217-cad-per-xbrli-shares">3.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" decimals="INF" id="c44757071" unitRef="iso4217-cad-per-xbrli-shares">5.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" decimals="INF" id="c44757078" unitRef="iso4217-cad-per-xbrli-shares">10.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" decimals="INF" id="c44757085" unitRef="iso4217-cad-per-xbrli-shares">34</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-OptionPlanMember" id="c44756984">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2018-01-01_2018-12-31_RangeAxis-MinimumMember" id="c44757116">P4Y292D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2018-01-01_2018-12-31_RangeAxis-MaximumMember" id="c44757118">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2017-01-01_2017-12-31" id="c44757120">P4Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2017-12-31" decimals="INF" id="c44757046" unitRef="xbrli-shares">216793</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2018-12-31" decimals="INF" id="c44757054" unitRef="xbrli-shares">242332</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44757052" unitRef="xbrli-shares">20522</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44757053" unitRef="iso4217-cad-per-xbrli-shares">7.27</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="i_2017-12-31" decimals="INF" id="c44757047" unitRef="iso4217-cad-per-xbrli-shares">3.69</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="i_2018-12-31" decimals="INF" id="c44757055" unitRef="iso4217-cad-per-xbrli-shares">7.45</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756987" unitRef="iso4217-usd">508000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c44756988" unitRef="iso4217-usd">213000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44757050" unitRef="xbrli-shares">150739</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44757051" unitRef="iso4217-cad-per-xbrli-shares">4.48</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" id="c44757062">P6Y292D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" id="c44757069">P6Y328D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" id="c44757076">P8Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" id="c44757083">P8Y182D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" id="c44757090">P5Y328D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31" id="c44757097">P7Y36D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" decimals="INF" id="c44757060" unitRef="iso4217-cad-per-xbrli-shares">2</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" decimals="INF" id="c44757067" unitRef="iso4217-cad-per-xbrli-shares">3</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" decimals="INF" id="c44757074" unitRef="iso4217-cad-per-xbrli-shares">5.12</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" decimals="INF" id="c44757081" unitRef="iso4217-cad-per-xbrli-shares">6.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" decimals="INF" id="c44757088" unitRef="iso4217-cad-per-xbrli-shares">13.86</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="i_2018-12-31" decimals="INF" id="c44757095" unitRef="iso4217-cad-per-xbrli-shares">7.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" id="c44757059">P6Y292D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" id="c44757066">P6Y328D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" id="c44757073">P8Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" id="c44757080">P8Y182D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" id="c44757087">P8Y73D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2018-01-01_2018-12-31" id="c44757094">P7Y292D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2018-12-11_SubsidiarySaleOfStockAxis-IPOMember" decimals="INF" id="c44756882" unitRef="iso4217-usd-per-xbrli-shares">4</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2018-03-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c44756896" unitRef="iso4217-usd-per-xbrli-shares">4.90</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesOutstanding contextRef="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c44756469" unitRef="xbrli-shares">5526046</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c44756497" unitRef="xbrli-shares">6370661</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c44756533" unitRef="xbrli-shares">11956874</us-gaap:SharesOutstanding>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139649">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of consolidation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The accompanying consolidated financial statements include the assets, liabilities and expenses of DiaMedica Therapeutics Inc., and our wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. All significant intercompany transactions and balances have been eliminated in consolidation.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Functional currency&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The United States dollar is our functional currency as it represents the economic effects of the underlying transactions, events and conditions and various other factors including the currency of historical and future expenditures and the currency in which funds from financing activities are mostly generated by the Company. A change in the functional currency occurs only when there is a material change in the underlying transactions, events and condition. A change in functional currency could result in material differences in the amounts recorded in the consolidated statement of loss and comprehensive loss for foreign exchange gains and losses. All amounts in the accompanying consolidated financial statements are in U.S. dollars unless otherwise indicated.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Concentration of credit risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand and savings accounts at commercial banks. At times, such deposits &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be in excess of insured limits. The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; experienced any losses on its deposits of cash.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fair value of financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Carrying amounts of certain of the Company&amp;#x2019;s financial instruments, including amounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. Certain of the Company&amp;#x2019;s common share purchase warrants are required to be reported at fair value. The fair value of common share purchase warrants is disclosed in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt; titled &amp;#x201c;Warrant Liability.&amp;#x201d;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fair value measurements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Fair value is defined as the exit price, or amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&amp;#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The hierarchy is broken down into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; levels defined as follows:&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 27pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&amp;#x2014;Unadjusted&lt;/div&gt; quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 27pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&amp;#x2014;Quoted&lt;/div&gt; prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; active or model-derived valuations for which all significant inputs are observable, either directly or indirectly.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 27pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&amp;#x2014;Prices&lt;/div&gt; or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Our cash is comprised of bank deposits in demand and savings accounts. As of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Common share warrant liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The common share warrants that were issued in connection with the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2016 &lt;/div&gt;private placements of common shares were classified as a liability in the consolidated balance sheets, as the common share warrants had an exercise price stated in Canadian dollars, which is different than our functional currency, and thus these warrants qualified as derivative instruments. The fair value of these common share warrants was re-measured at each financial reporting period and immediately before exercise, with any changes in fair value being recognized as a component of other income (expense) in our consolidated statements of operations. These warrants were exercised in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2018, &lt;/div&gt;see Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt; titled &amp;#x201c;Warrant Liability.&amp;#x201d;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Long-lived assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Property and equipment are stated at purchased cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; years for office equipment and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;four&lt;/div&gt; years for computer equipment. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheets and the resulting gain or loss is reflected in the consolidated statements of operations. Repairs and maintenance are expensed as incurred.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Long-lived assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset or related group of assets &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be recoverable. If the expected future undiscounted cash flows are less than the carrying amount of the asset, an impairment loss is recognized at that time. Measurement of impairment &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be based upon appraisal, market value of similar assets or discounted cash flows.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Revenue recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We followed ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;606,&lt;/div&gt; &amp;#x201c;Revenue from Contracts with Customers&amp;#x201d; in accounting for our License and Collaboration agreement with Ahon Pharmaceutical Co Ltd. Accordingly, the Company recognizes revenue upon transfer of control of the product to our customer in an amount that reflects the consideration we expect to receive in exchange.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We intend to enter into arrangements for the research and development (R&amp;amp;D) and/or manufacture of products and product candidates. Such arrangements &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;require us to deliver various rights, services and/or goods, including (i) intellectual property rights or licenses, (ii) R&amp;amp;D services or (iii) manufacturing services. The underlying terms of these arrangements generally would provide for consideration to DiaMedica in the form of nonrefundable, up-front license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;In arrangements involving more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; available.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; occur. We intend to utilize the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and development costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Research and development costs include expenses incurred in the conduct of human clinical trials, for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party service providers performing various testing and accumulating data related to non-clinical studies&amp;#x37e; sponsored research agreements&amp;#x37e; developing the manufacturing process necessary to produce sufficient amounts of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&lt;/div&gt; compound for use in our non-clinical studies and human clinical trials&amp;#x37e; consulting resources with specialized expertise related to execution of our development plan for our &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;DM199&lt;/div&gt; product candidate&amp;#x37e; and personnel costs, including salaries, benefits and share-based compensation.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (&amp;#x201c;CROs&amp;#x201d;). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual work performed at each clinical trial site and by each CRO.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patent costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Costs associated with prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, resulting in probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in research and development costs and were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$156,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$160,000&lt;/div&gt; for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The cost of employee and non-employee services received in exchange for awards of equity instruments is measured and recognized based on the estimated grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The fair value of share-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our share price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon Canadian Government bond rates appropriate for the expected term of each award. Expected volatility rates are based on the on historical volatility equal to the expected life of the option. The assumed dividend yield is zero, as we do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect to declare any dividends in the foreseeable future. The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt; See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,&lt;/div&gt; &amp;#x201c;Income Taxes&amp;#x201d; for additional information. The Company&amp;#x2019;s policy is to classify interest and penalties related to income taxes as income tax expense in the Consolidated Statements of Operations and Comprehensive Loss.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Government assistance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Government assistance relating to research and development performed by DiaMedica Australia Pty Ltd. is recorded as a component of Other (income) expense. Government assistance was initially recognized when reasonable assurance existed that the Company complied with the conditions attached to the incentive program and that the incentive payments would be received. In subsequent periods, the government assistance was recognized when the related expenditures were incurred. During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; we recognized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$621,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$593,000&lt;/div&gt; for research activities performed in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; respectively. During &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; we recognized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$244,000&lt;/div&gt; for research activities performed in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The following table summarizes our calculation of net loss per common share for the periods (in thousands, except share and per share data):&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,734&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,260&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average shares outstanding&amp;#x2014;basic and diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,743,520&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,935,790&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Basic and diluted net loss per share&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.74&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.72&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The following outstanding potential common shares were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; included in the diluted net loss per share calculations as their effects were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; dilutive:&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Employee and non-employee stock options&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;639,359&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;480,035&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common shares issuable under common share purchase warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;807,563&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;216,213&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common shares issuable under deferred unit plan&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,183&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,183&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,468,105&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;717,431&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recently adopted accounting pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2014, &lt;/div&gt;the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued a new accounting standard that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard and clarifying standards require an entity to recognize revenue when control of promised goods or services is transferred to the customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted this new standard as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2018, &lt;/div&gt;but the adoption as of this date had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; impact on our financial statements, as we had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; revenue until the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018.&lt;/div&gt; We followed ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;606,&lt;/div&gt; &amp;#x201c;Revenue from Contracts with Customers&amp;#x201d; in accounting for our License and Collaboration agreement with Ahon Pharmaceutical Co Ltd. (Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;).&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recently issued accounting pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2016, &lt;/div&gt;the FASB issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Leases&lt;/div&gt;. The guidance in ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&lt;/div&gt; supersedes the lease recognition requirements in the Accounting Standards Codification Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;840,&lt;/div&gt; Leases. ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&lt;/div&gt; requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. The new standard requires the immediate recognition of all excess tax benefits and deficiencies in the income statement and requires classification of excess tax benefits as an operating activity as opposed to a financing activity in the statements of cash flows. This standard became effective for us on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The FASB has subsequently issued the following amendments to ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; which have the same effective date and transition date of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019, &lt;/div&gt;and which we collectively refer to as the new leasing standards:&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 18pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;01,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;): Land Easement Practical Expedient for Transition to Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;&lt;/div&gt;, which permits an entity to elect an optional transition practical expedient to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; evaluate under Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt; land easements that existed or expired prior to adoption of Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt; and that were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; previously accounted for as leases under the prior standard, ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;840,&lt;/div&gt; Leases.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 18pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Codification Improvements to Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842,&lt;/div&gt; Leases&lt;/div&gt;, which amends certain narrow aspects of the guidance issued in ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 18pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;): Targeted Improvements&lt;/div&gt;, which allows for a transition approach to initially apply ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02&lt;/div&gt; at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption as well as an additional practical expedient for lessors to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; separate non-lease components from the associated lease component.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 18pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x25cf;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Narrow-Scope Improvements for Lessors&lt;/div&gt;, which contains certain narrow scope improvements to the guidance issued in ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;We adopted the new leasing standards on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019, &lt;/div&gt;using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019; &lt;/div&gt;and, consequently, financial information will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be updated and the disclosures required under Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt; will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be provided for dates and periods prior to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 1, 2019. &lt;/div&gt;We have reviewed our existing lease contracts and the impact of the new leasing standards on our consolidated results of operations, financial position and disclosures. Upon adoption of the new leasing standards, we expect to recognize a lease liability and related right-of-use asset on our consolidated balance sheet of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$200,000.&lt;/div&gt; The impact of adoption of the new leasing standards will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a material impact on our consolidated statements of operations.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 2018, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;07,&lt;/div&gt; &amp;#x201c;&lt;div style="display: inline; font-style: italic;"&gt;Improvements to Nonemployee Share-Based Payment Accounting&lt;/div&gt;," to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. This ASU is effective for public entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 15, 2018, &lt;/div&gt;with early adoption permitted. Prior to the adoption of this ASU, stock-based compensation awarded to non-employees was subject to revaluation over its vesting terms. Subsequent to the adoption of this ASU, non-employee share-based payment awards are measured on the date of grant, similar to share-based payment awards granted to employees. We do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect that the adoption of this ASU will impact our financial position or our consolidated statements of operations.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c44756490" unitRef="iso4217-usd">409000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c44756491" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756492" unitRef="iso4217-usd">409000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c44756526" unitRef="iso4217-usd">620000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c44756527" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756528" unitRef="iso4217-usd">620000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2018-12-11_2018-12-11_SubsidiarySaleOfStockAxis-IPOMember" decimals="INF" id="c44756881" unitRef="xbrli-shares">4100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c44756509" unitRef="xbrli-shares">4100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756915" unitRef="xbrli-shares">16954</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c44756943" unitRef="xbrli-shares">3000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c44756485" unitRef="xbrli-shares">3000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c44756521" unitRef="xbrli-shares">16954</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757019" unitRef="xbrli-shares">3000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c44757034" unitRef="xbrli-shares">16954</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c44756510" unitRef="iso4217-usd">14726000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c44756511" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756512" unitRef="iso4217-usd">14726000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c44756486" unitRef="iso4217-usd">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c44756487" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2017-01-01_2017-12-31" decimals="-3" id="c44756488" unitRef="iso4217-usd">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c44756522" unitRef="iso4217-usd">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" id="c44756523" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2018-01-01_2018-12-31" decimals="-3" id="c44756524" unitRef="iso4217-usd">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31" decimals="-3" id="c44756609" unitRef="iso4217-usd">17025000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c44756470" unitRef="iso4217-usd">37085000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c44756471" unitRef="iso4217-usd">-35974000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31" decimals="-3" id="c44756472" unitRef="iso4217-usd">1111000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c44756498" unitRef="iso4217-usd">41033000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c44756499" unitRef="iso4217-usd">-40234000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31" decimals="-3" id="c44756500" unitRef="iso4217-usd">799000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="-3" id="c44756534" unitRef="iso4217-usd">62993000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="-3" id="c44756535" unitRef="iso4217-usd">-45968000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2018-01-01_2018-12-31" id="s1139664">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt"&gt;  &lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;td style="width: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shareholders&amp;#x2019; Equity&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Authorized capital stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The Company has authorized share capital of an unlimited number of common voting shares and the shares do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have a stated par value.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; vote per share at the Company's annual general meeting and any extraordinary general meeting.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Shareholders rights plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The Company adopted a shareholder rights plan agreement (the &amp;#x201c;Rights Plan&amp;#x201d;). The Rights Plan is designed to provide adequate time for the Board of Directors and the shareholders to assess an unsolicited takeover bid for the Company, to provide the Board of Directors with sufficient time to explore and develop alternatives for maximizing shareholder value if a takeover bid is made, and to provide shareholders with an equal opportunity to participate in a takeover bid and receive full and fair value for their common shares. The Rights Plan was renewed at the Company&amp;#x2019;s annual meeting of shareholders in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2017 &lt;/div&gt;and is set to expire at the close of the Company&amp;#x2019;s annual meeting of shareholders in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2020.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The rights issued under the Rights Plan will initially attach to and trade with the common shares and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; separate certificates will be issued unless an event triggering these rights occurs. The rights will become exercisable only when a person, including any related person or entity, acquires or attempts to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20%&lt;/div&gt; or more of the outstanding common shares without complying with the &amp;#x201c;Permitted Bid&amp;#x201d; provisions of the Rights Plan or without approval of the Board of Directors. Should such an acquisition occur or be announced, each right would, upon exercise, entitle a rights holder, other than the acquiring person and related persons, to purchase common shares at a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt; discount to the market price at the time.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Under the Plan, a Permitted Bid is a bid made to all holders of the common shares and which is open for acceptance for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt; days. If at the end of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt; days at least &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt; of the outstanding common shares, other than those owned by the offeror and certain related parties have been tendered, the offeror &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;take up and pay for the common shares but must extend the bid for a further &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt; days to allow other shareholders to tender.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The issuance of common shares upon the exercise of the rights is subject to receipt of certain regulatory approvals.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Public offering during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 11, 2018, &lt;/div&gt;the Company issued and sold an aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,100,000&lt;/div&gt; common shares in an initial public offering at a price to the public of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.00&lt;/div&gt; per share. As a result of the offering, the Company received gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$16.4&lt;/div&gt; million, which resulted in net proceeds to the Company of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$14.7&lt;/div&gt; million, after deducting underwriting discounts and commissions and offering expenses. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;None&lt;/div&gt; of the expenses associated with the initial public offering were paid to directors, officers, persons owning &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; percent or more of any class of equity securities, or to their associates, or to our affiliates. On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 11, 2018, &lt;/div&gt;as additional underwriting compensation and in exchange for cash consideration of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$50,&lt;/div&gt; the Company granted the underwriter a warrant to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;205,000&lt;/div&gt; common shares (equal to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.0%&lt;/div&gt; of the common shares sold in the initial public offering) at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.80&lt;/div&gt; per share (equal to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;120%&lt;/div&gt; of the initial public offering price per common share in the initial public offering), subject to customary anti-dilution provisions. The warrant is exercisable for a term of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years. The warrant includes a cashless exercise provision entitling the underwriter to surrender a portion of the underlying common shares that has a value equal to the aggregate exercise price in lieu of paying cash upon exercise.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Private placements during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 29, 2018, &lt;/div&gt;the Company completed, in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; tranches, a brokered and non-brokered private placement of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,322,965&lt;/div&gt; units at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.90&lt;/div&gt; per unit for aggregate gross proceeds of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6.3&lt;/div&gt;&amp;nbsp;million. Each unit consisted of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; half of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share purchase warrant. The Company issued &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;661,482&lt;/div&gt; warrants. Each warrant entitles the holder to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7.00&lt;/div&gt; at any time prior to expiry on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 19, 2020 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 29, 2020 &lt;/div&gt;for Tranche &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; and Tranche &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,&lt;/div&gt; respectively. The warrants are subject to early expiry under certain conditions. The warrant expiry date can be accelerated at the option of the Company, in the event that the volume- weighted average trading price of the Company&amp;#x2019;s common shares exceeds &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12.00&lt;/div&gt; per common share for any &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21&lt;/div&gt; consecutive trading days. In connection with this offering, the Company paid aggregate finder&amp;#x2019;s fees of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$384,000&lt;/div&gt; and issued an aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;80,510&lt;/div&gt; compensation warrants. Each compensation warrant entitles the holder to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.90&lt;/div&gt; for a period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; years from the closing of this offering, subject to acceleration on the same terms as the common share purchase warrants.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;During the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2018, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;128,594&lt;/div&gt; common shares were issued on the exercise of warrants for gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$607,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,954&lt;/div&gt; common shares were issued on the exercise of options for gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$43,000.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Private placements during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 18, 2017, &lt;/div&gt;the Company completed a non-brokered private placement of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;181,220&lt;/div&gt; units at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.20&lt;/div&gt; per unit for aggregate gross proceeds of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$944,000,&lt;/div&gt; or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$934,000&lt;/div&gt; net of issuance costs. Each unit consisted of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; half of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share purchase warrant. Each whole warrant entitles the holder to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7.00&lt;/div&gt; at any time prior to expiry on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 19, 2019. &lt;/div&gt;Warrants are subject to early expiry, at the option of the Company, if on any date the volume-weighted average closing trading price of the common shares on any recognized stock exchange equals or exceeds &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12.00&lt;/div&gt; for a period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21&lt;/div&gt; consecutive trading days.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 17, 2017, &lt;/div&gt;the Company completed a non-brokered private placement of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;526,316&lt;/div&gt; units at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.80&lt;/div&gt; per unit for aggregate gross proceeds of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,000,000,&lt;/div&gt; or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,983,000&lt;/div&gt; net of issuance costs. Each unit consisted of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; half of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share purchase warrant. Each whole warrant entitles the holder to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.60&lt;/div&gt; at any time prior to expiry on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 17, 2019. &lt;/div&gt;The warrants were subject to early expiry, at the option of the Company, if on any date the volume-weighted average closing trading price of the common shares on any recognized Canadian stock exchange equaled or exceeded &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6.00&lt;/div&gt; for a period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt; consecutive trading days, which occurred in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 2017. &lt;/div&gt;The Company exercised its call option and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;131,578&lt;/div&gt; shares were issued for the warrants exercised and the remaining warrants were cancelled.&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;During the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;134,079&lt;/div&gt; common shares were issued on the exercise of warrants for gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$615,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,000&lt;/div&gt; common shares were issued on the exercise of options for gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$7,000.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Shares reserved&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;639,359&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred share units outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,183&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Shares available for grant under the Option Plan&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;123,376&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common shares issuable under common share purchase warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;807,563&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,591,479&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="d_2018-11-15_2018-11-15_StatementEquityComponentsAxis-ReverseStockSplitMember" decimals="INF" id="c44756591" unitRef="xbrli-pure">20</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="d_2018-01-01_2018-12-31" id="c-37">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(In thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Expiration Years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Non-capital income tax losses, net&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,002&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Beginning 2026&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development expense carry forwards&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,284&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Indefinitely&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Tax credits&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;525&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;Beginning 2020&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="i_2018-12-31_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember" decimals="-3" id="c44757183" unitRef="iso4217-usd">32002000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="i_2018-12-31_TaxCreditCarryforwardAxis-ResearchMember" decimals="-3" id="c44757185" unitRef="iso4217-usd">3284000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="i_2018-12-31_TaxCreditCarryforwardAxis-TaxCreditsMember" decimals="-3" id="c44757187" unitRef="iso4217-usd">525000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="d_2018-01-01_2018-12-31_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember" id="c44757184">2026-01-01</us-gaap:TaxCreditCarryforwardExpirationDate>
  <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="d_2018-01-01_2018-12-31_TaxCreditCarryforwardAxis-TaxCreditsMember" id="c44757188">2020-01-01</us-gaap:TaxCreditCarryforwardExpirationDate>
  <us-gaap:UseOfEstimates contextRef="d_2018-01-01_2018-12-31" id="c44756622">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" decimals="INF" id="c44756808" unitRef="iso4217-usd">24000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="i_2017-12-31" decimals="-3" id="c44756822" unitRef="iso4217-usd">84000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="i_2018-12-31" id="c44756825" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MinimumMember" decimals="INF" id="c44756799" unitRef="xbrli-pure">1.918</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MaximumMember" decimals="INF" id="c44756800" unitRef="xbrli-pure">2.25</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember" decimals="INF" id="c44756801" unitRef="xbrli-pure">0.0043</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MaximumMember" decimals="INF" id="c44756802" unitRef="xbrli-pure">0.0049</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" decimals="INF" id="c44756803" unitRef="xbrli-pure">2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MinimumMember" decimals="INF" id="c44756809" unitRef="xbrli-pure">1.918</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MaximumMember" decimals="INF" id="c44756810" unitRef="xbrli-pure">2.25</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember" decimals="INF" id="c44756811" unitRef="xbrli-pure">0.0043</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MaximumMember" decimals="INF" id="c44756812" unitRef="xbrli-pure">0.0049</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" decimals="INF" id="c44756813" unitRef="xbrli-pure">2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2018-02-28_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" decimals="INF" id="c44756818" unitRef="xbrli-pure">0.167</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2018-02-28_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" decimals="INF" id="c44756819" unitRef="xbrli-pure">0.018</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2018-02-28_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember" decimals="INF" id="c44756820" unitRef="xbrli-pure">0.01</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="i_2018-02-28_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember" decimals="INF" id="c44756821" unitRef="xbrli-pure">0.03</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" id="c44756807">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2018-12-11_ClassOfWarrantOrRightAxis-WarrantsIssuedWithIPOMember" id="c44756892">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="i_2018-03-29_ClassOfWarrantOrRightAxis-CompensationWarrantsMember" id="c44756912">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="d_2018-01-01_2018-12-31" decimals="INF" id="c44756467" unitRef="xbrli-shares">7743520</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c44756468" unitRef="xbrli-shares">5935790</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-cad-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:CAD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-cad">
    <xbrli:measure>iso4217:CAD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="d_2016-02-01_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-01</xbrli:startDate>
      <xbrli:endDate>2016-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-02-01_2016-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-01</xbrli:startDate>
      <xbrli:endDate>2016-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-CommonStockPurchaseWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-DeferredShareUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-NonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:NonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_PlanNameAxis-The2012DSUPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2012DSUPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-17_2017-04-17_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-17</xbrli:startDate>
      <xbrli:endDate>2017-04-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-17_2017-04-17_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-17</xbrli:startDate>
      <xbrli:endDate>2017-04-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-12-18_2017-12-18_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-18</xbrli:startDate>
      <xbrli:endDate>2017-12-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-12-18_2017-12-18_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-18</xbrli:startDate>
      <xbrli:endDate>2017-12-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-CommonStockPurchaseWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-DeferredShareUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeAndNonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:EmployeeAndNonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_AwardTypeAxis-NonemployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dmac:NonemployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember_IncomeTaxAuthorityNameAxis-AustralianTaxationOfficeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_PlanNameAxis-OptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:OptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_PlanNameAxis-The2012DSUPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2012DSUPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_RelatedPartyTransactionAxis-LicenseAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis-AhonPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dmac:LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dmac:AhonPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange5Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_SubsidiarySaleOfStockAxis-StockAndWarrantsIssuance1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:StockAndWarrantsIssuance1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_SubsidiarySaleOfStockAxis-StockIssuanceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dmac:StockIssuanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dmac:NoncapitalIncomeTaxLossesNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_TaxCreditCarryforwardAxis-TaxCreditsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dmac:TaxCreditsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-02-01_2018-02-28_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-02-01</xbrli:startDate>
      <xbrli:endDate>2018-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-03-29_2018-03-29_ClassOfWarrantOrRightAxis-CompensationWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-29</xbrli:startDate>
      <xbrli:endDate>2018-03-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-03-29_2018-03-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-29</xbrli:startDate>
      <xbrli:endDate>2018-03-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-03-29_2018-03-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-29</xbrli:startDate>
      <xbrli:endDate>2018-03-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-09-27_2018-09-27_RelatedPartyTransactionAxis-LicenseAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis-AhonPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dmac:LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dmac:AhonPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-09-27</xbrli:startDate>
      <xbrli:endDate>2018-09-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-11-15_2018-11-15_StatementEquityComponentsAxis-ReverseStockSplitMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dmac:ReverseStockSplitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-11-15</xbrli:startDate>
      <xbrli:endDate>2018-11-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-12-11_2018-12-11_ClassOfWarrantOrRightAxis-WarrantsIssuedWithIPOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedWithIPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-11</xbrli:startDate>
      <xbrli:endDate>2018-12-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-12-11_2018-12-11_SubsidiarySaleOfStockAxis-IPOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-12-11</xbrli:startDate>
      <xbrli:endDate>2018-12-11</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2012-12-31_PlanNameAxis-The2012DSUPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2012DSUPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-17_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-04-17_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-04-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-05-03_LeaseArrangementTypeAxis-OfficeSpaceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">dmac:OfficeSpaceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-05-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-18_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-18_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_OtherCommitmentsAxis-IndemnificationAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dmac:IndemnificationAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_OtherCommitmentsAxis-TechnologyLicenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dmac:TechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PlanNameAxis-The2012DSUPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2012DSUPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-02-28_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-02-28_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-02-28_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-02-28_ClassOfWarrantOrRightAxis-CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-29_ClassOfWarrantOrRightAxis-CompensationWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:CompensationWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-29_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-29_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-09-27_RelatedPartyTransactionAxis-LicenseAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis-AhonPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">dmac:LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">dmac:AhonPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-09-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-11_ClassOfWarrantOrRightAxis-WarrantsIssuedWithIPOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dmac:WarrantsIssuedWithIPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-11_SubsidiarySaleOfStockAxis-IPOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-11</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_LegalEntityAxis-SKGroupMember_OwnershipAxis-DiaMedicaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dmac:SKGroupMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">dmac:DiaMedicaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_OtherCommitmentsAxis-IndemnificationAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dmac:IndemnificationAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_OtherCommitmentsAxis-ResearchAndDevelopmentContractsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dmac:ResearchAndDevelopmentContractsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_OtherCommitmentsAxis-TechnologyLicenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">dmac:TechnologyLicenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_PlanNameAxis-OptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:OptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_PlanNameAxis-The2012DSUPlanAndOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2012DSUPlanAndOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_PlanNameAxis-The2012DSUPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dmac:The2012DSUPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">dmac:ExercisePriceRange5Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-DeferredShareUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dmac:DeferredShareUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-DiamedicaStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dmac:DiamedicaStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-StockOptionsOutstandingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">dmac:StockOptionsOutstandingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_TaxCreditCarryforwardAxis-NoncapitalIncomeTaxLossesNetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dmac:NoncapitalIncomeTaxLossesNetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_TaxCreditCarryforwardAxis-ResearchMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-31_TaxCreditCarryforwardAxis-TaxCreditsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">dmac:TaxCreditsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-01-01_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-14">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001401040</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>dmac-20181231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:27PM UTC 2019-03-19--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dmac="http://www.diamedica.com/20181231" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.diamedica.com/20181231">
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dmac-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dmac-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dmac-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dmac-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.diamedica.com/20181231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations-and-comprehensive-loss" roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-shareholders-equity" roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-shareholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-shareholders-equity-parentheticals" roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-business" roleURI="http://www.diamedica.com/20181231/role/statement-note-1-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 1 - Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-risks-and-uncertainties" roleURI="http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 2 - Risks and Uncertainties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies" roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 3 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-amounts-receivable" roleURI="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 4 - Amounts Receivable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-deposit" roleURI="http://www.diamedica.com/20181231/role/statement-note-5-deposit">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 5 - Deposit</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-property-and-equipment" roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 6 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accounts-payable-and-accrued-liabilities" roleURI="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 7 - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-warrant-liability" roleURI="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 8 - Warrant Liability</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments-and-contingencies" roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 9 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-shareholders-equity" roleURI="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 10 - Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-license-and-collaboration-agreement-with-related-party" roleURI="http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 11 - License and Collaboration Agreement With Related Party</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation" roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 12 - Share-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-employee-benefit-plan" roleURI="http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 13 - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes" roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 14 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.diamedica.com/20181231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-tables" roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-amounts-receivable-tables" roleURI="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 4 - Amounts Receivable (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-deposit-tables" roleURI="http://www.diamedica.com/20181231/role/statement-note-5-deposit-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 5 - Deposit (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-property-and-equipment-tables" roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 6 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accounts-payable-and-accrued-liabilities-tables" roleURI="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 7 - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-warrant-liability-tables" roleURI="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 8 - Warrant Liability (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments-and-contingencies-tables" roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 9 - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-shareholders-equity-tables" roleURI="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 10 - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation-tables" roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 12 - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes-tables" roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 14 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-business-details-textual" roleURI="http://www.diamedica.com/20181231/role/statement-note-1-business-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 1 - Business (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-risks-and-uncertainties-details-textual" roleURI="http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-amounts-receivable-amounts-receivable-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-amounts-receivable-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 4 - Amounts Receivable - Amounts Receivable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-deposit-deposits-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-5-deposit-deposits-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 5 - Deposit - Deposits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-property-and-equipment-details-textual" roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 6 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-property-and-equipment-property-and-equipment-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 6 - Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 7 - Accounts Payable and Accrued Liabilities - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-warrant-liability-details-textual" roleURI="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 8 - Warrant Liability (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-warrant-liability-rollforward-of-fair-value-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-rollforward-of-fair-value-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 8 - Warrant Liability - Rollforward of Fair Value (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments-and-contingencies-details-textual" roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 9 - Commitments and Contingencies - Future Minimum Lease Payment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-shareholders-equity-details-textual" roleURI="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note 10 - Shareholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-shareholders-equity-shares-reserved-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-shares-reserved-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 10 - Shareholders' Equity - Shares Reserved (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-license-and-collaboration-agreement-with-related-party-details-textual" roleURI="http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 11 - License and Collaboration Agreement With Related Party (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation-details-textual" roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 12 - Share-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation-stock-option-activity-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note 12 - Share-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation-unvested-shares-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-unvested-shares-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note 12 - Share-based Compensation - Unvested Shares (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation-stock-options-outstanding-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note 12 - Share-based Compensation - Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-sharebased-compensation-stock-option-assumptions-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-option-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">054 - Disclosure - Note 12 - Share-based Compensation - Stock Option Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-employee-benefit-plan-details-textual" roleURI="http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">055 - Disclosure - Note 13 - Employee Benefit Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes-details-textual" roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">056 - Disclosure - Note 14 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">057 - Disclosure - Note 14 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">058 - Disclosure - Note 14 - Income Taxes - Reconciliation of Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes-net-operating-losses-details" roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-net-operating-losses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">059 - Disclosure - Note 14 - Income Taxes - Net Operating Losses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="dmac_AccruedClinicalStudyCostsCurrent" name="AccruedClinicalStudyCostsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_AccruedResearchAndProfessionalFeesCurrent" name="AccruedResearchAndProfessionalFeesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" name="AccruedTaxesAndOtherLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised" name="AdjustmentsToAdditionalPaidInCapitalWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_AdvancesToVendor" name="AdvancesToVendor" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_AhonPharmaMember" name="AhonPharmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" name="ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants" name="ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone" name="CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance" name="CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_CollaborationAgreementPaymentOfLicenseFee" name="CollaborationAgreementPaymentOfLicenseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones" name="CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_CommonStockPurchaseWarrantsMember" name="CommonStockPurchaseWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" name="CommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" name="CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_CompensationWarrantsMember" name="CompensationWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_DeferredShareUnitsMember" name="DeferredShareUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_DeferredTaxAssetsPropertyPatentsAndOther" name="DeferredTaxAssetsPropertyPatentsAndOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_DeferredTaxAssetsPropertyShareIssueCosts" name="DeferredTaxAssetsPropertyShareIssueCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_DiaMedicaMember" name="DiaMedicaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_DiamedicaStockOptionPlanMember" name="DiamedicaStockOptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" name="EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" name="EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount" name="EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_EmployeeAndNonemployeeStockOptionsMember" name="EmployeeAndNonemployeeStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange1Member" name="ExercisePriceRange1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange2Member" name="ExercisePriceRange2Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange3Member" name="ExercisePriceRange3Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange4Member" name="ExercisePriceRange4Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ExercisePriceRange5Member" name="ExercisePriceRange5Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_FunctionalCurrencyPolicyTextBlock" name="FunctionalCurrencyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_GovernmentAssistancePolicyTextBlock" name="GovernmentAssistancePolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_IncomeFromGovernmentalAssistance" name="IncomeFromGovernmentalAssistance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_IndemnificationAgreementsMember" name="IndemnificationAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale" name="MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial" name="MilestonePaymentDueUponInitiationOfPhaseIIITrial" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_NoncapitalIncomeTaxLossesNetMember" name="NoncapitalIncomeTaxLossesNetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NonemployeeStockOptionsMember" name="NonemployeeStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_OfficeSpaceMember" name="OfficeSpaceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_OptionPlanMember" name="OptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_PatentExpense" name="PatentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_PaymentForFindersFee" name="PaymentForFindersFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ProceedsFromIssuanceOfUnits" name="ProceedsFromIssuanceOfUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ProceedsFromIssuanceOfUnitsNet" name="ProceedsFromIssuanceOfUnitsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise" name="RelcassificationOfWarrantLiabilityUponWarrantExercise" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ResearchAndDevelopmentContractsMember" name="ResearchAndDevelopmentContractsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ResearchAndDevelopmentIncentiveReceivable" name="ResearchAndDevelopmentIncentiveReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016" name="ResearchGrantRecognizedResearchActivitiesPerformed2016" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017" name="ResearchGrantRecognizedResearchActivitiesPerformed2017" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018" name="ResearchGrantRecognizedResearchActivitiesPerformed2018" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_ReverseStockSplitMember" name="ReverseStockSplitMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_RightsExercisablePercentOfDiscountToMarketPrice" name="RightsExercisablePercentOfDiscountToMarketPrice" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual" name="RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="dmac_RisksAndUncertaintiesTextBlock" name="RisksAndUncertaintiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_SKGroupMember" name="SKGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions" name="SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares" name="SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_StockAndWarrantsIssuance1Member" name="StockAndWarrantsIssuance1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" name="StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" name="StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_StockIssuanceMember" name="StockIssuanceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" name="StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_StockOptionsOutstandingMember" name="StockOptionsOutstandingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_TaxCreditsMember" name="TaxCreditsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_TechnologyLicenseMember" name="TechnologyLicenseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_The2012DSUPlanAndOptionPlanMember" name="The2012DSUPlanAndOptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_The2012DSUPlanMember" name="The2012DSUPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_UnitsIssuedDuringPeriodUnitsNewIssues" name="UnitsIssuedDuringPeriodUnitsNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_UnitsIssuedPricePerUnit" name="UnitsIssuedPricePerUnit" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit" name="UnitsNumberOfCommonSharePurchaseWarrantPerUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="dmac_UnitsNumberOfCommonSharesPerUnit" name="UnitsNumberOfCommonSharesPerUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="dmac_WarrantLiabilitiesTextBlock" name="WarrantLiabilitiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_WarrantsAndRightsExercisesInPeriod" name="WarrantsAndRightsExercisesInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger" name="WarrantsAndRightsOutstandingExpirationStockPriceTrigger" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants" name="WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="dmac_WarrantsAndRightsThresholdConsecutiveTradingDays" name="WarrantsAndRightsThresholdConsecutiveTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_WarrantsIssuedCashConsideration" name="WarrantsIssuedCashConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_WarrantsIssuedInPrivatePlacementMember" name="WarrantsIssuedInPrivatePlacementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_WarrantsIssuedWithIPOMember" name="WarrantsIssuedWithIPOMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dmac_WorkingCapital" name="WorkingCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" name="statement-statement-note-10-shareholders-equity-shares-reserved-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-10-shareholders-equity-tables" name="statement-statement-note-10-shareholders-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" name="statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" name="statement-statement-note-12-sharebased-compensation-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-12-sharebased-compensation-stock-option-assumptions-details" name="statement-statement-note-12-sharebased-compensation-stock-option-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" name="statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-12-sharebased-compensation-tables" name="statement-statement-note-12-sharebased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-12-sharebased-compensation-unvested-shares-details" name="statement-statement-note-12-sharebased-compensation-unvested-shares-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-14-income-taxes-net-operating-losses-details" name="statement-statement-note-14-income-taxes-net-operating-losses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" name="statement-statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-14-income-taxes-tables" name="statement-statement-note-14-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" name="statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" name="statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" name="statement-statement-note-3-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-4-amounts-receivable-amounts-receivable-details" name="statement-statement-note-4-amounts-receivable-amounts-receivable-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-4-amounts-receivable-tables" name="statement-statement-note-4-amounts-receivable-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-5-deposit-deposits-details" name="statement-statement-note-5-deposit-deposits-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-5-deposit-tables" name="statement-statement-note-5-deposit-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-6-property-and-equipment-property-and-equipment-details" name="statement-statement-note-6-property-and-equipment-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-6-property-and-equipment-tables" name="statement-statement-note-6-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" name="statement-statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-tables" name="statement-statement-note-7-accounts-payable-and-accrued-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-8-warrant-liability-rollforward-of-fair-value-details" name="statement-statement-note-8-warrant-liability-rollforward-of-fair-value-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-8-warrant-liability-tables" name="statement-statement-note-8-warrant-liability-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" name="statement-statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-note-9-commitments-and-contingencies-tables" name="statement-statement-note-9-commitments-and-contingencies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dmac_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>dmac-20181231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:28PM UTC 2019-03-19--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:href="dmac-20181231.xsd#statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-amounts-receivable-details" xlink:href="dmac-20181231.xsd#statement-note-4-amounts-receivable-amounts-receivable-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-amounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchAndDevelopmentIncentiveReceivable" xlink:label="dmac_ResearchAndDevelopmentIncentiveReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_OtherReceivables" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_IncomeTaxesReceivable" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="dmac_ResearchAndDevelopmentIncentiveReceivable" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-5-deposit-deposits-details" xlink:href="dmac-20181231.xsd#statement-note-5-deposit-deposits-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-5-deposit-deposits-details" xlink:type="extended">
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AdvancesToVendor" xlink:label="dmac_AdvancesToVendor" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="dmac_AdvancesToVendor" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-property-and-equipment-details" xlink:href="dmac-20181231.xsd#statement-note-6-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:href="dmac-20181231.xsd#statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AccruedClinicalStudyCostsCurrent" xlink:label="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="dmac-20181231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="dmac-20181231.xsd#dmac_IncomeFromGovernmentalAssistance" xlink:label="dmac_IncomeFromGovernmentalAssistance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="dmac_IncomeFromGovernmentalAssistance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-cash-flows" xlink:href="dmac-20181231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets" xlink:href="dmac-20181231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:label="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:label="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>dmac-20181231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:27PM UTC 2019-03-19--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities" xlink:href="dmac-20181231.xsd#statement-note-7-accounts-payable-and-accrued-liabilities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-5-deposit" xlink:href="dmac-20181231.xsd#statement-note-5-deposit" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-5-deposit" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable" xlink:href="dmac-20181231.xsd#statement-note-4-amounts-receivable" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-document-and-entity-information" xlink:href="dmac-20181231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="dmac-20181231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNoParValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" xlink:href="dmac-20181231.xsd#statement-consolidated-statements-of-shareholders-equity-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockAndWarrantsIssuance1Member" xlink:label="dmac_StockAndWarrantsIssuance1Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockIssuanceMember" xlink:label="dmac_StockIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dmac_StockAndWarrantsIssuance1Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dmac_StockIssuanceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-1-business" xlink:href="dmac-20181231.xsd#statement-note-1-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-1-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ReverseStockSplitMember" xlink:label="dmac_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="dmac_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties" xlink:href="dmac-20181231.xsd#statement-note-2-risks-and-uncertainties" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_RisksAndUncertaintiesTextBlock" xlink:label="dmac_RisksAndUncertaintiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dmac_RisksAndUncertaintiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:href="dmac-20181231.xsd#statement-note-3-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment" xlink:href="dmac-20181231.xsd#statement-note-6-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability" xlink:href="dmac-20181231.xsd#statement-note-8-warrant-liability" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:label="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantLiabilitiesTextBlock" xlink:label="dmac_WarrantLiabilitiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedInPrivatePlacementMember" xlink:label="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dmac_WarrantLiabilitiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies" xlink:href="dmac-20181231.xsd#statement-note-9-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_IndemnificationAgreementsMember" xlink:label="dmac_IndemnificationAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_OfficeSpaceMember" xlink:label="dmac_OfficeSpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchAndDevelopmentContractsMember" xlink:label="dmac_ResearchAndDevelopmentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_TechnologyLicenseMember" xlink:label="dmac_TechnologyLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="dmac_ResearchAndDevelopmentContractsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="dmac_TechnologyLicenseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="dmac_IndemnificationAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="dmac_OfficeSpaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity" xlink:href="dmac-20181231.xsd#statement-note-10-shareholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CompensationWarrantsMember" xlink:label="dmac_CompensationWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedInPrivatePlacementMember" xlink:label="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedWithIPOMember" xlink:label="dmac_WarrantsIssuedWithIPOMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dmac_WarrantsIssuedWithIPOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dmac_CompensationWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party" xlink:href="dmac-20181231.xsd#statement-note-11-license-and-collaboration-agreement-with-related-party" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AhonPharmaMember" xlink:label="dmac_AhonPharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DiaMedicaMember" xlink:label="dmac_DiaMedicaMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_LicenseAgreementMember" xlink:label="dmac_LicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_SKGroupMember" xlink:label="dmac_SKGroupMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dmac_LicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dmac_AhonPharmaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="dmac_SKGroupMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dmac_DiaMedicaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_OptionPlanMember" xlink:label="dmac_OptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_The2012DSUPlanAndOptionPlanMember" xlink:label="dmac_The2012DSUPlanAndOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2012DSUPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_OptionPlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2012DSUPlanAndOptionPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_NonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan" xlink:href="dmac-20181231.xsd#statement-note-13-employee-benefit-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-significant-accounting-policies-policies" xlink:href="dmac-20181231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_FunctionalCurrencyPolicyTextBlock" xlink:label="dmac_FunctionalCurrencyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_GovernmentAssistancePolicyTextBlock" xlink:label="dmac_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_PatentCostsPolicyTextBlock" xlink:label="dmac_PatentCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dmac_FunctionalCurrencyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dmac_PatentCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dmac_GovernmentAssistancePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:href="dmac-20181231.xsd#statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-tables" xlink:href="dmac-20181231.xsd#statement-note-4-amounts-receivable-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-5-deposit-tables" xlink:href="dmac-20181231.xsd#statement-note-5-deposit-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-5-deposit-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-tables" xlink:href="dmac-20181231.xsd#statement-note-6-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-tables" xlink:href="dmac-20181231.xsd#statement-note-7-accounts-payable-and-accrued-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-tables" xlink:href="dmac-20181231.xsd#statement-note-8-warrant-liability-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-tables" xlink:href="dmac-20181231.xsd#statement-note-9-commitments-and-contingencies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-tables" xlink:href="dmac-20181231.xsd#statement-note-10-shareholders-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-tables" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-tables" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-1-business-details-textual" xlink:href="dmac-20181231.xsd#statement-note-1-business-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-1-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ReverseStockSplitMember" xlink:label="dmac_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="dmac_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties-details-textual" xlink:href="dmac-20181231.xsd#statement-note-2-risks-and-uncertainties-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WorkingCapital" xlink:label="dmac_WorkingCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WorkingCapital" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="dmac-20181231.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_PatentExpense" xlink:label="dmac_PatentExpense" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016" xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017" xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018" xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_PatentExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-details-textual" xlink:href="dmac-20181231.xsd#statement-note-6-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-details-textual" xlink:href="dmac-20181231.xsd#statement-note-8-warrant-liability-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" xlink:label="dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:label="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsIssuedDuringPeriodUnitsNewIssues" xlink:label="dmac_UnitsIssuedDuringPeriodUnitsNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit" xlink:label="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsNumberOfCommonSharesPerUnit" xlink:label="dmac_UnitsNumberOfCommonSharesPerUnit" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedInPrivatePlacementMember" xlink:label="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsIssuedDuringPeriodUnitsNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsNumberOfCommonSharesPerUnit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-details-textual" xlink:href="dmac-20181231.xsd#statement-note-9-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_IndemnificationAgreementsMember" xlink:label="dmac_IndemnificationAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale" xlink:label="dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial" xlink:label="dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_OfficeSpaceMember" xlink:label="dmac_OfficeSpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchAndDevelopmentContractsMember" xlink:label="dmac_ResearchAndDevelopmentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_TechnologyLicenseMember" xlink:label="dmac_TechnologyLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="dmac_ResearchAndDevelopmentContractsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="dmac_TechnologyLicenseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="dmac_IndemnificationAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="dmac_OfficeSpaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-details-textual" xlink:href="dmac-20181231.xsd#statement-note-10-shareholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="dmac_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants" xlink:label="dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CompensationWarrantsMember" xlink:label="dmac_CompensationWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_PaymentForFindersFee" xlink:label="dmac_PaymentForFindersFee" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfUnits" xlink:label="dmac_ProceedsFromIssuanceOfUnits" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfUnitsNet" xlink:label="dmac_ProceedsFromIssuanceOfUnitsNet" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_RightsExercisablePercentOfDiscountToMarketPrice" xlink:label="dmac_RightsExercisablePercentOfDiscountToMarketPrice" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual" xlink:label="dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsIssuedDuringPeriodUnitsNewIssues" xlink:label="dmac_UnitsIssuedDuringPeriodUnitsNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsIssuedPricePerUnit" xlink:label="dmac_UnitsIssuedPricePerUnit" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit" xlink:label="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsNumberOfCommonSharesPerUnit" xlink:label="dmac_UnitsNumberOfCommonSharesPerUnit" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger" xlink:label="dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants" xlink:label="dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsAndRightsThresholdConsecutiveTradingDays" xlink:label="dmac_WarrantsAndRightsThresholdConsecutiveTradingDays" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedCashConsideration" xlink:label="dmac_WarrantsIssuedCashConsideration" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedInPrivatePlacementMember" xlink:label="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedWithIPOMember" xlink:label="dmac_WarrantsIssuedWithIPOMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dmac_WarrantsIssuedWithIPOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dmac_CompensationWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_RightsExercisablePercentOfDiscountToMarketPrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WarrantsIssuedCashConsideration" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsIssuedDuringPeriodUnitsNewIssues" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ProceedsFromIssuanceOfUnits" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsNumberOfCommonSharesPerUnit" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_PaymentForFindersFee" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsIssuedPricePerUnit" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ProceedsFromIssuanceOfUnitsNet" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WarrantsAndRightsThresholdConsecutiveTradingDays" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party-details-textual" xlink:href="dmac-20181231.xsd#statement-note-11-license-and-collaboration-agreement-with-related-party-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AhonPharmaMember" xlink:label="dmac_AhonPharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone" xlink:label="dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance" xlink:label="dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CollaborationAgreementPaymentOfLicenseFee" xlink:label="dmac_CollaborationAgreementPaymentOfLicenseFee" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones" xlink:label="dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DiaMedicaMember" xlink:label="dmac_DiaMedicaMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_LicenseAgreementMember" xlink:label="dmac_LicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_SKGroupMember" xlink:label="dmac_SKGroupMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="dmac_LicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="dmac_AhonPharmaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="dmac_SKGroupMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="dmac_DiaMedicaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_CollaborationAgreementPaymentOfLicenseFee" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-details-textual" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_OptionPlanMember" xlink:label="dmac_OptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions" xlink:label="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares" xlink:label="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_The2012DSUPlanAndOptionPlanMember" xlink:label="dmac_The2012DSUPlanAndOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2012DSUPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_OptionPlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dmac_The2012DSUPlanAndOptionPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_NonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan-details-textual" xlink:href="dmac-20181231.xsd#statement-note-13-employee-benefit-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-details-textual" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:href="dmac-20181231.xsd#statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-option-assumptions-details" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-stock-option-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-option-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-shareholders-equity" xlink:href="dmac-20181231.xsd#statement-consolidated-statements-of-shareholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised" xlink:label="dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-amounts-receivable-details" xlink:href="dmac-20181231.xsd#statement-note-4-amounts-receivable-amounts-receivable-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-amounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchAndDevelopmentIncentiveReceivable" xlink:label="dmac_ResearchAndDevelopmentIncentiveReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ResearchAndDevelopmentIncentiveReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxesReceivable" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivables" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-5-deposit-deposits-details" xlink:href="dmac-20181231.xsd#statement-note-5-deposit-deposits-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-5-deposit-deposits-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AdvancesToVendor" xlink:label="dmac_AdvancesToVendor" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AdvancesToVendor" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-property-and-equipment-details" xlink:href="dmac-20181231.xsd#statement-note-6-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:href="dmac-20181231.xsd#statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AccruedClinicalStudyCostsCurrent" xlink:label="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableTradeCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-rollforward-of-fair-value-details" xlink:href="dmac-20181231.xsd#statement-note-8-warrant-liability-rollforward-of-fair-value-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-rollforward-of-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsAndRightsExercisesInPeriod" xlink:label="dmac_WarrantsAndRightsExercisesInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WarrantsAndRightsExercisesInPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-shares-reserved-details" xlink:href="dmac-20181231.xsd#statement-note-10-shareholders-equity-shares-reserved-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-shares-reserved-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DiamedicaStockOptionPlanMember" xlink:label="dmac_DiamedicaStockOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="dmac_StockOptionsOutstandingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="dmac_DiamedicaStockOptionPlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-unvested-shares-details" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-unvested-shares-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-unvested-shares-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-net-operating-losses-details" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes-net-operating-losses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-net-operating-losses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoncapitalIncomeTaxLossesNetMember" xlink:label="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_TaxCreditsMember" xlink:label="dmac_TaxCreditsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="dmac_TaxCreditsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="dmac-20181231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_IncomeFromGovernmentalAssistance" xlink:label="dmac_IncomeFromGovernmentalAssistance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="dmac_IncomeFromGovernmentalAssistance" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-cash-flows" xlink:href="dmac-20181231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise" xlink:label="dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange3Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange4Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="dmac_ExercisePriceRange5Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:href="dmac-20181231.xsd#statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:href="dmac-20181231.xsd#statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CommonStockPurchaseWarrantsMember" xlink:label="dmac_CommonStockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_CommonStockPurchaseWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets" xlink:href="dmac-20181231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:label="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:label="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>dmac-20181231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:27PM UTC 2019-03-19--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DocumentAndEntityInformation" xlink:label="dmac_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="dmac_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DocumentAndEntityInformation" xlink:to="dmac_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherReceivables-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_OtherReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherReceivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="dmac_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="dmac_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common share fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-significant-accounting-policies-policies" xlink:label="dmac_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-significant-accounting-policies-policies" xlink:to="dmac_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:to="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" xlink:label="dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod</link:label>
    <link:label xlink:label="dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Expired During Period</link:label>
    <link:label xlink:label="dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights expired during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" xlink:to="dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-4-amounts-receivable-tables" xlink:label="dmac_statement-statement-note-4-amounts-receivable-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-4-amounts-receivable-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Amounts Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-4-amounts-receivable-tables" xlink:to="dmac_statement-statement-note-4-amounts-receivable-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-5-deposit-tables" xlink:label="dmac_statement-statement-note-5-deposit-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-5-deposit-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Deposit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-5-deposit-tables" xlink:to="dmac_statement-statement-note-5-deposit-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued taxes and other liabilities</link:label>
    <link:label xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of accrued taxes and other liabilities classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:to="dmac_AccruedTaxesAndOtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-6-property-and-equipment-tables" xlink:label="dmac_statement-statement-note-6-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-6-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-6-property-and-equipment-tables" xlink:to="dmac_statement-statement-note-6-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AccruedClinicalStudyCostsCurrent" xlink:label="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="dmac_AccruedClinicalStudyCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued clinical study costs</link:label>
    <link:label xlink:label="dmac_AccruedClinicalStudyCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of accrued clinical study costs classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AccruedClinicalStudyCostsCurrent" xlink:to="dmac_AccruedClinicalStudyCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-tables" xlink:label="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-tables" xlink:to="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchAndDevelopmentIncentiveReceivable" xlink:label="dmac_ResearchAndDevelopmentIncentiveReceivable" xlink:type="locator"/>
    <link:label xlink:label="dmac_ResearchAndDevelopmentIncentiveReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development incentives</link:label>
    <link:label xlink:label="dmac_ResearchAndDevelopmentIncentiveReceivable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of research and development incentives receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ResearchAndDevelopmentIncentiveReceivable" xlink:to="dmac_ResearchAndDevelopmentIncentiveReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-8-warrant-liability-tables" xlink:label="dmac_statement-statement-note-8-warrant-liability-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-8-warrant-liability-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Warrant Liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-8-warrant-liability-tables" xlink:to="dmac_statement-statement-note-8-warrant-liability-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long term liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale" xlink:label="dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale" xlink:type="locator"/>
    <link:label xlink:label="dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale</link:label>
    <link:label xlink:label="dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, Due Upon First Regulatory Approval for Commercial Sale</link:label>
    <link:label xlink:label="dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of milestone payment due upon first regulatory approval for commercial sale.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale" xlink:to="dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-9-commitments-and-contingencies-tables" xlink:label="dmac_statement-statement-note-9-commitments-and-contingencies-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-9-commitments-and-contingencies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-9-commitments-and-contingencies-tables" xlink:to="dmac_statement-statement-note-9-commitments-and-contingencies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial" xlink:label="dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial" xlink:type="locator"/>
    <link:label xlink:label="dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial</link:label>
    <link:label xlink:label="dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, Due Upon Initiation of Phase III Trial</link:label>
    <link:label xlink:label="dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of milestone payment due upon initiation of Phase III trial</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial" xlink:to="dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-10-shareholders-equity-tables" xlink:label="dmac_statement-statement-note-10-shareholders-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-10-shareholders-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Shareholders' Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-10-shareholders-equity-tables" xlink:to="dmac_statement-statement-note-10-shareholders-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-12-sharebased-compensation-tables" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-12-sharebased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Share-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-tables" xlink:to="dmac_statement-statement-note-12-sharebased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsAndRightsExercisesInPeriod" xlink:label="dmac_WarrantsAndRightsExercisesInPeriod" xlink:type="locator"/>
    <link:label xlink:label="dmac_WarrantsAndRightsExercisesInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_WarrantsAndRightsExercisesInPeriod</link:label>
    <link:label xlink:label="dmac_WarrantsAndRightsExercisesInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercises</link:label>
    <link:label xlink:label="dmac_WarrantsAndRightsExercisesInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of warrant exercises during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_WarrantsAndRightsExercisesInPeriod" xlink:to="dmac_WarrantsAndRightsExercisesInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants" xlink:label="dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants</link:label>
    <link:label xlink:label="dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrants or Rights, Percent of IPO Price Per Share of Exercise Price of Warrants</link:label>
    <link:label xlink:label="dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent amount of exercise price of warrants measured against the IPO price per share of stock issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants" xlink:to="dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-14-income-taxes-tables" xlink:label="dmac_statement-statement-note-14-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-14-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-14-income-taxes-tables" xlink:to="dmac_statement-statement-note-14-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants" xlink:label="dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants" xlink:type="locator"/>
    <link:label xlink:label="dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants</link:label>
    <link:label xlink:label="dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Percent of Outstanding Common Stock Outstanding Called by Warrants</link:label>
    <link:label xlink:label="dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of outstanding common stock outstanding called by warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants" xlink:to="dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:to="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedCashConsideration" xlink:label="dmac_WarrantsIssuedCashConsideration" xlink:type="locator"/>
    <link:label xlink:label="dmac_WarrantsIssuedCashConsideration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_WarrantsIssuedCashConsideration</link:label>
    <link:label xlink:label="dmac_WarrantsIssuedCashConsideration-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Issued, Cash Consideration</link:label>
    <link:label xlink:label="dmac_WarrantsIssuedCashConsideration-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of cash consideration given for warrants issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_WarrantsIssuedCashConsideration" xlink:to="dmac_WarrantsIssuedCashConsideration-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:to="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_OfficeSpaceMember" xlink:label="dmac_OfficeSpaceMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_OfficeSpaceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Space [Member]</link:label>
    <link:label xlink:label="dmac_OfficeSpaceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to office space.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_OfficeSpaceMember" xlink:to="dmac_OfficeSpaceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-4-amounts-receivable-amounts-receivable-details" xlink:label="dmac_statement-statement-note-4-amounts-receivable-amounts-receivable-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-4-amounts-receivable-amounts-receivable-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Amounts Receivable - Amounts Receivable (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-4-amounts-receivable-amounts-receivable-details" xlink:to="dmac_statement-statement-note-4-amounts-receivable-amounts-receivable-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone" xlink:label="dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone" xlink:type="locator"/>
    <link:label xlink:label="dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone</link:label>
    <link:label xlink:label="dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Payment Upon Development and Sales Milestone</link:label>
    <link:label xlink:label="dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of additional payment receivable upon development and sales milestone in collaboration agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone" xlink:to="dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-5-deposit-deposits-details" xlink:label="dmac_statement-statement-note-5-deposit-deposits-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-5-deposit-deposits-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Deposit - Deposits (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-5-deposit-deposits-details" xlink:to="dmac_statement-statement-note-5-deposit-deposits-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance" xlink:label="dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance" xlink:type="locator"/>
    <link:label xlink:label="dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance</link:label>
    <link:label xlink:label="dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Non-refundable Payment Payable Upon Regulatory Clearance</link:label>
    <link:label xlink:label="dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-refundable payment receivable payable upon regulatory clearance in a collaboration agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance" xlink:to="dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-6-property-and-equipment-property-and-equipment-details" xlink:label="dmac_statement-statement-note-6-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-6-property-and-equipment-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Property and Equipment - Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-6-property-and-equipment-property-and-equipment-details" xlink:to="dmac_statement-statement-note-6-property-and-equipment-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:label="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Accounts Payable and Accrued Liabilities - Accounts Payable and Accrued Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:to="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedWithIPOMember" xlink:label="dmac_WarrantsIssuedWithIPOMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_WarrantsIssuedWithIPOMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued With IPO [Member]</link:label>
    <link:label xlink:label="dmac_WarrantsIssuedWithIPOMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to warrants issued with IPO.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_WarrantsIssuedWithIPOMember" xlink:to="dmac_WarrantsIssuedWithIPOMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected option life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-8-warrant-liability-rollforward-of-fair-value-details" xlink:label="dmac_statement-statement-note-8-warrant-liability-rollforward-of-fair-value-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-8-warrant-liability-rollforward-of-fair-value-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Warrant Liability - Rollforward of Fair Value (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-8-warrant-liability-rollforward-of-fair-value-details" xlink:to="dmac_statement-statement-note-8-warrant-liability-rollforward-of-fair-value-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_LicenseAgreementMember" xlink:label="dmac_LicenseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_LicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label xlink:label="dmac_LicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_LicenseAgreementMember" xlink:to="dmac_LicenseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:label="dmac_statement-statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Commitments and Contingencies - Future Minimum Lease Payment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:to="dmac_statement-statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" xlink:label="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Shareholders' Equity - Shares Reserved (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" xlink:to="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CollaborationAgreementPaymentOfLicenseFee" xlink:label="dmac_CollaborationAgreementPaymentOfLicenseFee" xlink:type="locator"/>
    <link:label xlink:label="dmac_CollaborationAgreementPaymentOfLicenseFee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_CollaborationAgreementPaymentOfLicenseFee</link:label>
    <link:label xlink:label="dmac_CollaborationAgreementPaymentOfLicenseFee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Payment of License Fee</link:label>
    <link:label xlink:label="dmac_CollaborationAgreementPaymentOfLicenseFee-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of payment received from license fees in a collaboration agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CollaborationAgreementPaymentOfLicenseFee" xlink:to="dmac_CollaborationAgreementPaymentOfLicenseFee-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:to="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones" xlink:label="dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones" xlink:type="locator"/>
    <link:label xlink:label="dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones</link:label>
    <link:label xlink:label="dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Percent of Royalties Upon Development and Sales Milestones</link:label>
    <link:label xlink:label="dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent of royalties upon development and sales milestones in a collaboration agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones" xlink:to="dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Share-based Compensation - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:to="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions" xlink:label="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions" xlink:type="locator"/>
    <link:label xlink:label="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions</link:label>
    <link:label xlink:label="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Options</link:label>
    <link:label xlink:label="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The highest quantity of options that can be issued under the plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions" xlink:to="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-12-sharebased-compensation-unvested-shares-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-unvested-shares-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-12-sharebased-compensation-unvested-shares-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Share-based Compensation - Unvested Shares (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-unvested-shares-details" xlink:to="dmac_statement-statement-note-12-sharebased-compensation-unvested-shares-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AhonPharmaMember" xlink:label="dmac_AhonPharmaMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_AhonPharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ahon Pharma [Member]</link:label>
    <link:label xlink:label="dmac_AhonPharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to Ahon Pharma.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AhonPharmaMember" xlink:to="dmac_AhonPharmaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Share-based Compensation - Stock Options Outstanding (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:to="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DiaMedicaMember" xlink:label="dmac_DiaMedicaMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_DiaMedicaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DiaMedica [Member]</link:label>
    <link:label xlink:label="dmac_DiaMedicaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to DiamMedica.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DiaMedicaMember" xlink:to="dmac_DiaMedicaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-12-sharebased-compensation-stock-option-assumptions-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-option-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-option-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Share-based Compensation - Stock Option Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-stock-option-assumptions-details" xlink:to="dmac_statement-statement-note-12-sharebased-compensation-stock-option-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_SKGroupMember" xlink:label="dmac_SKGroupMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_SKGroupMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SK Group [Member]</link:label>
    <link:label xlink:label="dmac_SKGroupMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the SK Group.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_SKGroupMember" xlink:to="dmac_SKGroupMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="dmac_statement-statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="dmac_statement-statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:label="dmac_statement-statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Income Taxes - Reconciliation of Income Tax Rate (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:to="dmac_statement-statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-14-income-taxes-net-operating-losses-details" xlink:label="dmac_statement-statement-note-14-income-taxes-net-operating-losses-details" xlink:type="locator"/>
    <link:label xlink:label="dmac_statement-statement-note-14-income-taxes-net-operating-losses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Income Taxes - Net Operating Losses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_statement-statement-note-14-income-taxes-net-operating-losses-details" xlink:to="dmac_statement-statement-note-14-income-taxes-net-operating-losses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise" xlink:label="dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise" xlink:type="locator"/>
    <link:label xlink:label="dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liability upon warrant exercise</link:label>
    <link:label xlink:label="dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of reclassification of warrant liability upon warrant exercise.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise" xlink:to="dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatements" xlink:label="dmac_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="dmac_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NotesToFinancialStatements" xlink:to="dmac_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares" xlink:label="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares</link:label>
    <link:label xlink:label="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares</link:label>
    <link:label xlink:label="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The highest number of shares that can be issued under the plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares" xlink:to="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="dmac_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="dmac_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalLeaseObligationsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average grant-date fair value (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested, weighted average grant-date fair value (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeitures, weighted average grant-date fair value (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, weighted average grant-date fair value (in CAD per share)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, weighted average grant-date fair value (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeitures (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, weighted average exercise price (in CAD per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balances, weighted average exercise price (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited, weighted average exercise price (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired / cancelled, weighted average exercise price (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average exercise price (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, weighted average exercise price (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="dmac_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="dmac_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_ClassOfWarrantOrRightIssuedDuringPeriod</link:label>
    <link:label xlink:label="dmac_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued During Period</link:label>
    <link:label xlink:label="dmac_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="dmac_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ReverseStockSplitMember" xlink:label="dmac_ReverseStockSplitMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Stock Split [Member]</link:label>
    <link:label xlink:label="dmac_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The conversion of a reverse stock split where there is a reduction in the shares outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ReverseStockSplitMember" xlink:to="dmac_ReverseStockSplitMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired/cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfAssetsAcquired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets acquired under capital lease</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableTradeCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RevenueFromRelatedParties</link:label>
    <link:label xlink:label="us-gaap_RevenueFromRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Cash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label xlink:label="us-gaap_Cash-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Ending Balance</link:label>
    <link:label xlink:label="us-gaap_Cash-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash at beginning of year</link:label>
    <link:label xlink:label="us-gaap_Cash-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash at end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseArrangementTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDepositOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidExpense</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityExTransitionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of common stock option (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of common stock option</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares, net of offering costs of $1,674 (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares, net of offering costs of $1,674</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedTermMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseLiability</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised" xlink:label="dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of common share purchase warrants</link:label>
    <link:label xlink:label="dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in additional paid in capital (APIC) resulting from the exercise of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised" xlink:to="dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_IncomeFromGovernmentalAssistance" xlink:label="dmac_IncomeFromGovernmentalAssistance" xlink:type="locator"/>
    <link:label xlink:label="dmac_IncomeFromGovernmentalAssistance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_IncomeFromGovernmentalAssistance</link:label>
    <link:label xlink:label="dmac_IncomeFromGovernmentalAssistance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Governmental assistance &#8211; research incentives</link:label>
    <link:label xlink:label="dmac_IncomeFromGovernmentalAssistance-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of income generated from governmental assistance including, but not limited to, research incentives and grants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_IncomeFromGovernmentalAssistance" xlink:to="dmac_IncomeFromGovernmentalAssistance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockAndWarrantsIssuance1Member" xlink:label="dmac_StockAndWarrantsIssuance1Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_StockAndWarrantsIssuance1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock and Warrants Issuance 1 [Member]</link:label>
    <link:label xlink:label="dmac_StockAndWarrantsIssuance1Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to an issuance of common stock and warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_StockAndWarrantsIssuance1Member" xlink:to="dmac_StockAndWarrantsIssuance1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:type="locator"/>
    <link:label xlink:label="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of common share purchase warrants (in shares)</link:label>
    <link:label xlink:label="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise of Common Stock Warrants</link:label>
    <link:label xlink:label="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares issued during the period due to the exercise of common stock warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:to="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares and warrants, net of offering costs (in shares)</link:label>
    <link:label xlink:label="dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of common stock shares and warrants issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:to="dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares and warrants, net of offering costs</link:label>
    <link:label xlink:label="dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of common stock and warrants for issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:to="dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositsAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposit</link:label>
    <link:label xlink:label="us-gaap_DepositsAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deposit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseRightOfUseAsset</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common shares and warrants, net offering costs</link:label>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash inflow from the issuance of common stock and warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsIssuedPricePerUnit" xlink:label="dmac_UnitsIssuedPricePerUnit" xlink:type="locator"/>
    <link:label xlink:label="dmac_UnitsIssuedPricePerUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_UnitsIssuedPricePerUnit</link:label>
    <link:label xlink:label="dmac_UnitsIssuedPricePerUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Units Issued, Price Per Unit</link:label>
    <link:label xlink:label="dmac_UnitsIssuedPricePerUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The per unit price of units issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_UnitsIssuedPricePerUnit" xlink:to="dmac_UnitsIssuedPricePerUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsIssuedDuringPeriodUnitsNewIssues" xlink:label="dmac_UnitsIssuedDuringPeriodUnitsNewIssues" xlink:type="locator"/>
    <link:label xlink:label="dmac_UnitsIssuedDuringPeriodUnitsNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_UnitsIssuedDuringPeriodUnitsNewIssues</link:label>
    <link:label xlink:label="dmac_UnitsIssuedDuringPeriodUnitsNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Units Issued During Period, Units, New Issues</link:label>
    <link:label xlink:label="dmac_UnitsIssuedDuringPeriodUnitsNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new units issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_UnitsIssuedDuringPeriodUnitsNewIssues" xlink:to="dmac_UnitsIssuedDuringPeriodUnitsNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WorkingCapital" xlink:label="dmac_WorkingCapital" xlink:type="locator"/>
    <link:label xlink:label="dmac_WorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_WorkingCapital</link:label>
    <link:label xlink:label="dmac_WorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:label xlink:label="dmac_WorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of working capital.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_WorkingCapital" xlink:to="dmac_WorkingCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_RisksAndUncertaintiesTextBlock" xlink:label="dmac_RisksAndUncertaintiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_RisksAndUncertaintiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Text Block]</link:label>
    <link:label xlink:label="dmac_RisksAndUncertaintiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A complete disclosure of the risks and uncertainties the company may face.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_RisksAndUncertaintiesTextBlock" xlink:to="dmac_RisksAndUncertaintiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_PatentCostsPolicyTextBlock" xlink:label="dmac_PatentCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_PatentCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent Costs [Policy Text Block]</link:label>
    <link:label xlink:label="dmac_PatentCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for patent costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_PatentCostsPolicyTextBlock" xlink:to="dmac_PatentCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_FunctionalCurrencyPolicyTextBlock" xlink:label="dmac_FunctionalCurrencyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_FunctionalCurrencyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Functional Currency [Policy Text Block]</link:label>
    <link:label xlink:label="dmac_FunctionalCurrencyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for functional currency in use by the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_FunctionalCurrencyPolicyTextBlock" xlink:to="dmac_FunctionalCurrencyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfUnits" xlink:label="dmac_ProceedsFromIssuanceOfUnits" xlink:type="locator"/>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_ProceedsFromIssuanceOfUnits</link:label>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Units</link:label>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfUnits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow associated with the issuance of units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ProceedsFromIssuanceOfUnits" xlink:to="dmac_ProceedsFromIssuanceOfUnits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CommonStockPurchaseWarrantsMember" xlink:label="dmac_CommonStockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_CommonStockPurchaseWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Purchase Warrants [Member]</link:label>
    <link:label xlink:label="dmac_CommonStockPurchaseWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to common stock purchase warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CommonStockPurchaseWarrantsMember" xlink:to="dmac_CommonStockPurchaseWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee and Non-employee Stock Options [Member]</link:label>
    <link:label xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to employee and non-employee stock option awards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_PatentExpense" xlink:label="dmac_PatentExpense" xlink:type="locator"/>
    <link:label xlink:label="dmac_PatentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_PatentExpense</link:label>
    <link:label xlink:label="dmac_PatentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent Expense</link:label>
    <link:label xlink:label="dmac_PatentExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of expense associated with gaining and maintaining certain patents.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_PatentExpense" xlink:to="dmac_PatentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_GovernmentAssistancePolicyTextBlock" xlink:label="dmac_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_GovernmentAssistancePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance [Policy Text Block]</link:label>
    <link:label xlink:label="dmac_GovernmentAssistancePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for government assistance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_GovernmentAssistancePolicyTextBlock" xlink:to="dmac_GovernmentAssistancePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AdvancesToVendor" xlink:label="dmac_AdvancesToVendor" xlink:type="locator"/>
    <link:label xlink:label="dmac_AdvancesToVendor-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advances to vendor</link:label>
    <link:label xlink:label="dmac_AdvancesToVendor-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of advances to vendor held as an asset by the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AdvancesToVendor" xlink:to="dmac_AdvancesToVendor-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_DeferredShareUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Share Units [Member]</link:label>
    <link:label xlink:label="dmac_DeferredShareUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to deferred share units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DeferredShareUnitsMember" xlink:to="dmac_DeferredShareUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit" xlink:label="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit" xlink:type="locator"/>
    <link:label xlink:label="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit</link:label>
    <link:label xlink:label="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Units, Number of Common Share Purchase Warrant Per Unit</link:label>
    <link:label xlink:label="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of common share purchase warrant per unit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit" xlink:to="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsNumberOfCommonSharesPerUnit" xlink:label="dmac_UnitsNumberOfCommonSharesPerUnit" xlink:type="locator"/>
    <link:label xlink:label="dmac_UnitsNumberOfCommonSharesPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_UnitsNumberOfCommonSharesPerUnit</link:label>
    <link:label xlink:label="dmac_UnitsNumberOfCommonSharesPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Units, Number of Common Shares Per Unit</link:label>
    <link:label xlink:label="dmac_UnitsNumberOfCommonSharesPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of common shares per unit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_UnitsNumberOfCommonSharesPerUnit" xlink:to="dmac_UnitsNumberOfCommonSharesPerUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantLiabilitiesTextBlock" xlink:label="dmac_WarrantLiabilitiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_WarrantLiabilitiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liabilities [Text Block]</link:label>
    <link:label xlink:label="dmac_WarrantLiabilitiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A complete disclosure of warrant liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_WarrantLiabilitiesTextBlock" xlink:to="dmac_WarrantLiabilitiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued research and other professional fees</link:label>
    <link:label xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees and accrued research. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:to="dmac_AccruedResearchAndProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:label="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Warrants Issued In Connection With Private Placement [Member]</link:label>
    <link:label xlink:label="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to compensation warrants issued in connection with a private placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:to="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedInPrivatePlacementMember" xlink:label="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_WarrantsIssuedInPrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Private Placement [Member]</link:label>
    <link:label xlink:label="dmac_WarrantsIssuedInPrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to warrants issued in a private placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:to="dmac_WarrantsIssuedInPrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_IndemnificationAgreementsMember" xlink:label="dmac_IndemnificationAgreementsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_IndemnificationAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indemnification Agreements [Member]</link:label>
    <link:label xlink:label="dmac_IndemnificationAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to certain indemnification agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_IndemnificationAgreementsMember" xlink:to="dmac_IndemnificationAgreementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_TechnologyLicenseMember" xlink:label="dmac_TechnologyLicenseMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_TechnologyLicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology License [Member]</link:label>
    <link:label xlink:label="dmac_TechnologyLicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the technology license and associated costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_TechnologyLicenseMember" xlink:to="dmac_TechnologyLicenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchAndDevelopmentContractsMember" xlink:label="dmac_ResearchAndDevelopmentContractsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_ResearchAndDevelopmentContractsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Contracts [Member]</link:label>
    <link:label xlink:label="dmac_ResearchAndDevelopmentContractsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ResearchAndDevelopmentContractsMember" xlink:to="dmac_ResearchAndDevelopmentContractsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CompensationWarrantsMember" xlink:label="dmac_CompensationWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_CompensationWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Warrants [Member]</link:label>
    <link:label xlink:label="dmac_CompensationWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to compensation warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CompensationWarrantsMember" xlink:to="dmac_CompensationWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger" xlink:label="dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger" xlink:type="locator"/>
    <link:label xlink:label="dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger</link:label>
    <link:label xlink:label="dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Expiration, Stock Price Trigger</link:label>
    <link:label xlink:label="dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The expiration stock price trigger of warrants and rights outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger" xlink:to="dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfUnitsNet" xlink:label="dmac_ProceedsFromIssuanceOfUnitsNet" xlink:type="locator"/>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfUnitsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_ProceedsFromIssuanceOfUnitsNet</link:label>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfUnitsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Units, Net</link:label>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfUnitsNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the issuance of units, net of issuance costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ProceedsFromIssuanceOfUnitsNet" xlink:to="dmac_ProceedsFromIssuanceOfUnitsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_RightsExercisablePercentOfDiscountToMarketPrice" xlink:label="dmac_RightsExercisablePercentOfDiscountToMarketPrice" xlink:type="locator"/>
    <link:label xlink:label="dmac_RightsExercisablePercentOfDiscountToMarketPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_RightsExercisablePercentOfDiscountToMarketPrice</link:label>
    <link:label xlink:label="dmac_RightsExercisablePercentOfDiscountToMarketPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rights, Exercisable, Percent of Discount to Market Price</link:label>
    <link:label xlink:label="dmac_RightsExercisablePercentOfDiscountToMarketPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent of discount to market price of shares that are purchaseable by rights, discount is applied after threshold trigger is reached.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_RightsExercisablePercentOfDiscountToMarketPrice" xlink:to="dmac_RightsExercisablePercentOfDiscountToMarketPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual" xlink:label="dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual" xlink:type="locator"/>
    <link:label xlink:label="dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual</link:label>
    <link:label xlink:label="dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rights, Threshold Trigger to be Exercisable, Percent of Common Stock Outstanding Owned by Individual</link:label>
    <link:label xlink:label="dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage threshold trigger, past which, rights become exercisable. Measurement is the percent amount of the company's common shares outstanding that is owned by any specific individual.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual" xlink:to="dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_StockOptionsOutstandingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options Outstanding [Member]</link:label>
    <link:label xlink:label="dmac_StockOptionsOutstandingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to stock options outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_StockOptionsOutstandingMember" xlink:to="dmac_StockOptionsOutstandingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Reserved for Future Issuance [Table Text Block]</link:label>
    <link:label xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A tabular disclosure of common stock reserved for future issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="dmac_CommonStockReservedForFutureIssuanceTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:type="locator"/>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_ProceedsFromIssuanceOfCommonStockNet</link:label>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock, Net</link:label>
    <link:label xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the issuance of common stock, net of offering costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockNet-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_The2012DSUPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2012 DSU Plan [Member]</link:label>
    <link:label xlink:label="dmac_The2012DSUPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the 2012 DSU plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_The2012DSUPlanMember" xlink:to="dmac_The2012DSUPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DiamedicaStockOptionPlanMember" xlink:label="dmac_DiamedicaStockOptionPlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_DiamedicaStockOptionPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DiaMedica Stock Option Plan [Member]</link:label>
    <link:label xlink:label="dmac_DiamedicaStockOptionPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the DiaMedia stock option plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DiamedicaStockOptionPlanMember" xlink:to="dmac_DiamedicaStockOptionPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 1 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange1Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the first exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange1Member" xlink:to="dmac_ExercisePriceRange1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_NonemployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonemployee Stock Options [Member]</link:label>
    <link:label xlink:label="dmac_NonemployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the nonemployee stock options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NonemployeeStockOptionsMember" xlink:to="dmac_NonemployeeStockOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_The2012DSUPlanAndOptionPlanMember" xlink:label="dmac_The2012DSUPlanAndOptionPlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_The2012DSUPlanAndOptionPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2012 DSU Plan and Option Plan [Member]</link:label>
    <link:label xlink:label="dmac_The2012DSUPlanAndOptionPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to both the 2012 DSU plan and Option plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_The2012DSUPlanAndOptionPlanMember" xlink:to="dmac_The2012DSUPlanAndOptionPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_OptionPlanMember" xlink:label="dmac_OptionPlanMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_OptionPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Plan [Member]</link:label>
    <link:label xlink:label="dmac_OptionPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the Option Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_OptionPlanMember" xlink:to="dmac_OptionPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange5Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 5 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange5Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the fifth exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange5Member" xlink:to="dmac_ExercisePriceRange5Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange4Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 4 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange4Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the fourth exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange4Member" xlink:to="dmac_ExercisePriceRange4Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 3 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange3Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the third exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange3Member" xlink:to="dmac_ExercisePriceRange3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:label xlink:label="dmac_ExercisePriceRange2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 2 [Member]</link:label>
    <link:label xlink:label="dmac_ExercisePriceRange2Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the second exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ExercisePriceRange2Member" xlink:to="dmac_ExercisePriceRange2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount" xlink:type="locator"/>
    <link:label xlink:label="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount</link:label>
    <link:label xlink:label="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on revaluation of warrant liability</link:label>
    <link:label xlink:label="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to revaluation of warrant liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" xlink:type="locator"/>
    <link:label xlink:label="dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax recovery based on statutory rate</link:label>
    <link:label xlink:label="dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax recovery.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:label="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="locator"/>
    <link:label xlink:label="dmac_DeferredTaxAssetsPropertyPatentsAndOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents and other</link:label>
    <link:label xlink:label="dmac_DeferredTaxAssetsPropertyPatentsAndOther-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from patents and other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:to="dmac_DeferredTaxAssetsPropertyPatentsAndOther-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:label="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="locator"/>
    <link:label xlink:label="dmac_DeferredTaxAssetsPropertyShareIssueCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issue costs</link:label>
    <link:label xlink:label="dmac_DeferredTaxAssetsPropertyShareIssueCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share issue costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:to="dmac_DeferredTaxAssetsPropertyShareIssueCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017" xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017" xlink:type="locator"/>
    <link:label xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017</link:label>
    <link:label xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Grant, Recognized, Research Activities Performed 2017</link:label>
    <link:label xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of research grant recognized for research activities performed 2017.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017" xlink:to="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoncapitalIncomeTaxLossesNetMember" xlink:label="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_NoncapitalIncomeTaxLossesNetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-capital Income Tax Losses, Net [Member]</link:label>
    <link:label xlink:label="dmac_NoncapitalIncomeTaxLossesNetMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to non-capital income tax losses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:to="dmac_NoncapitalIncomeTaxLossesNetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016" xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016" xlink:type="locator"/>
    <link:label xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016</link:label>
    <link:label xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Grant, Recognized, Research Activities Performed 2016</link:label>
    <link:label xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of research grant recognized for research activities performed 2016.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016" xlink:to="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_TaxCreditsMember" xlink:label="dmac_TaxCreditsMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_TaxCreditsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credits [Member]</link:label>
    <link:label xlink:label="dmac_TaxCreditsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to tax credits.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_TaxCreditsMember" xlink:to="dmac_TaxCreditsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" xlink:type="locator"/>
    <link:label xlink:label="dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in unrecognized temporary differences</link:label>
    <link:label xlink:label="dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to change in unrecognized temporary differences.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018" xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018" xlink:type="locator"/>
    <link:label xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018</link:label>
    <link:label xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Grant, Recognized, Research Activities Performed 2018</link:label>
    <link:label xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of research grant recognized for research activities performed 2018.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018" xlink:to="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_PaymentForFindersFee" xlink:label="dmac_PaymentForFindersFee" xlink:type="locator"/>
    <link:label xlink:label="dmac_PaymentForFindersFee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_PaymentForFindersFee</link:label>
    <link:label xlink:label="dmac_PaymentForFindersFee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for Finders Fee</link:label>
    <link:label xlink:label="dmac_PaymentForFindersFee-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow for finders fees that were paid during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_PaymentForFindersFee" xlink:to="dmac_PaymentForFindersFee-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxesReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales-based taxes receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares, no par value; unlimited authorized; 11,956,874 and 6,370,661 shares issued and outstanding, as of December 31, 2018 and 2017, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares, authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares, issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockNoParValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash transactions:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_OwnershipDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax asset, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_OwnershipAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expenditures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentDisposals</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Disposals</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstanding</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts receivable</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total amounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating revenues:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsAndRightsThresholdConsecutiveTradingDays" xlink:label="dmac_WarrantsAndRightsThresholdConsecutiveTradingDays" xlink:type="locator"/>
    <link:label xlink:label="dmac_WarrantsAndRightsThresholdConsecutiveTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dmac_WarrantsAndRightsThresholdConsecutiveTradingDays</link:label>
    <link:label xlink:label="dmac_WarrantsAndRightsThresholdConsecutiveTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights, Threshold Consecutive Trading Days</link:label>
    <link:label xlink:label="dmac_WarrantsAndRightsThresholdConsecutiveTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold period of specified consecutive trading days within which common stock price to the volume-weighted average closing trading price of the common shares on any recognized Canadian stock exchange must exceed threshold percentage for specified number of trading days to trigger conversion feature.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_WarrantsAndRightsThresholdConsecutiveTradingDays" xlink:to="dmac_WarrantsAndRightsThresholdConsecutiveTradingDays-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherNonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-capital losses carried forward</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IPOMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other (income) expense:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesDeferredExpense</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accruals</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of common share purchase warrants</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common shares, net of offering costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OfficeEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OpenTaxYear</link:label>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligation</link:label>
    <link:label xlink:label="us-gaap_ContractualObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding&#8212;basic and diluted (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding &#8211; basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax credits, expiration years</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligationDueInNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Next Fiscal Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligationDueInSecondYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligationDueInSecondYear</link:label>
    <link:label xlink:label="us-gaap_ContractualObligationDueInSecondYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Due in Second Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_MinorityInterestOwnershipPercentageByParent</link:label>
    <link:label xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesNoncurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long term liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statutory income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Ending Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital lease obligation, non-current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Australian research and development incentive</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AustralianTaxationOfficeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Australian Taxation Office [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AustralianTaxationOfficeMember" xlink:to="us-gaap_AustralianTaxationOfficeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Per share exercise price, upper range (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockIssuanceMember" xlink:label="dmac_StockIssuanceMember" xlink:type="locator"/>
    <link:label xlink:label="dmac_StockIssuanceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance [Member]</link:label>
    <link:label xlink:label="dmac_StockIssuanceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to a stock issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dmac_StockIssuanceMember" xlink:to="dmac_StockIssuanceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Per share exercise price, lower range (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>dmac-20181231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 06:27PM UTC 2019-03-19--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities" xlink:href="dmac-20181231.xsd#statement-note-7-accounts-payable-and-accrued-liabilities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-5-deposit" xlink:href="dmac-20181231.xsd#statement-note-5-deposit" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-5-deposit" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable" xlink:href="dmac-20181231.xsd#statement-note-4-amounts-receivable" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-document-and-entity-information" xlink:href="dmac-20181231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="dmac-20181231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNoParValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" xlink:href="dmac-20181231.xsd#statement-consolidated-statements-of-shareholders-equity-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockAndWarrantsIssuance1Member" xlink:label="dmac_StockAndWarrantsIssuance1Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockIssuanceMember" xlink:label="dmac_StockIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dmac_StockAndWarrantsIssuance1Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dmac_StockIssuanceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-1-business" xlink:href="dmac-20181231.xsd#statement-note-1-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-1-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ReverseStockSplitMember" xlink:label="dmac_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="dmac_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties" xlink:href="dmac-20181231.xsd#statement-note-2-risks-and-uncertainties" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_RisksAndUncertaintiesTextBlock" xlink:label="dmac_RisksAndUncertaintiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dmac_RisksAndUncertaintiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:href="dmac-20181231.xsd#statement-note-3-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment" xlink:href="dmac-20181231.xsd#statement-note-6-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability" xlink:href="dmac-20181231.xsd#statement-note-8-warrant-liability" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:label="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantLiabilitiesTextBlock" xlink:label="dmac_WarrantLiabilitiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedInPrivatePlacementMember" xlink:label="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dmac_WarrantLiabilitiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies" xlink:href="dmac-20181231.xsd#statement-note-9-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_IndemnificationAgreementsMember" xlink:label="dmac_IndemnificationAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_OfficeSpaceMember" xlink:label="dmac_OfficeSpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchAndDevelopmentContractsMember" xlink:label="dmac_ResearchAndDevelopmentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_TechnologyLicenseMember" xlink:label="dmac_TechnologyLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="dmac_ResearchAndDevelopmentContractsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="dmac_TechnologyLicenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="dmac_IndemnificationAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="dmac_OfficeSpaceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity" xlink:href="dmac-20181231.xsd#statement-note-10-shareholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CompensationWarrantsMember" xlink:label="dmac_CompensationWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedInPrivatePlacementMember" xlink:label="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedWithIPOMember" xlink:label="dmac_WarrantsIssuedWithIPOMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dmac_WarrantsIssuedWithIPOMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dmac_CompensationWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party" xlink:href="dmac-20181231.xsd#statement-note-11-license-and-collaboration-agreement-with-related-party" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AhonPharmaMember" xlink:label="dmac_AhonPharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DiaMedicaMember" xlink:label="dmac_DiaMedicaMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_LicenseAgreementMember" xlink:label="dmac_LicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_SKGroupMember" xlink:label="dmac_SKGroupMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="dmac_LicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="dmac_AhonPharmaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dmac_SKGroupMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dmac_DiaMedicaMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_OptionPlanMember" xlink:label="dmac_OptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_The2012DSUPlanAndOptionPlanMember" xlink:label="dmac_The2012DSUPlanAndOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2012DSUPlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_OptionPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2012DSUPlanAndOptionPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_NonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan" xlink:href="dmac-20181231.xsd#statement-note-13-employee-benefit-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NotesToFinancialStatementsAbstract" xlink:label="dmac_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_AustralianTaxationOfficeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-significant-accounting-policies-policies" xlink:href="dmac-20181231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_FunctionalCurrencyPolicyTextBlock" xlink:label="dmac_FunctionalCurrencyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_GovernmentAssistancePolicyTextBlock" xlink:label="dmac_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_PatentCostsPolicyTextBlock" xlink:label="dmac_PatentCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-significant-accounting-policies-policies" xlink:label="dmac_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dmac_FunctionalCurrencyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dmac_PatentCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dmac_GovernmentAssistancePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:href="dmac-20181231.xsd#statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-tables" xlink:href="dmac-20181231.xsd#statement-note-4-amounts-receivable-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-4-amounts-receivable-tables" xlink:label="dmac_statement-statement-note-4-amounts-receivable-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-4-amounts-receivable-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-5-deposit-tables" xlink:href="dmac-20181231.xsd#statement-note-5-deposit-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-5-deposit-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-5-deposit-tables" xlink:label="dmac_statement-statement-note-5-deposit-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-5-deposit-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-tables" xlink:href="dmac-20181231.xsd#statement-note-6-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-6-property-and-equipment-tables" xlink:label="dmac_statement-statement-note-6-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-6-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-tables" xlink:href="dmac-20181231.xsd#statement-note-7-accounts-payable-and-accrued-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-tables" xlink:label="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-tables" xlink:href="dmac-20181231.xsd#statement-note-8-warrant-liability-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-8-warrant-liability-tables" xlink:label="dmac_statement-statement-note-8-warrant-liability-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-8-warrant-liability-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-tables" xlink:href="dmac-20181231.xsd#statement-note-9-commitments-and-contingencies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-9-commitments-and-contingencies-tables" xlink:label="dmac_statement-statement-note-9-commitments-and-contingencies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-9-commitments-and-contingencies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-tables" xlink:href="dmac-20181231.xsd#statement-note-10-shareholders-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-10-shareholders-equity-tables" xlink:label="dmac_statement-statement-note-10-shareholders-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-10-shareholders-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="dmac_CommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-tables" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-12-sharebased-compensation-tables" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-tables" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-14-income-taxes-tables" xlink:label="dmac_statement-statement-note-14-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-14-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-1-business-details-textual" xlink:href="dmac-20181231.xsd#statement-note-1-business-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-1-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ReverseStockSplitMember" xlink:label="dmac_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="dmac_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties-details-textual" xlink:href="dmac-20181231.xsd#statement-note-2-risks-and-uncertainties-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WorkingCapital" xlink:label="dmac_WorkingCapital-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-n2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WorkingCapital-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="dmac-20181231.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_PatentExpense" xlink:label="dmac_PatentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016" xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017" xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018" xlink:label="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_PatentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-details-textual" xlink:href="dmac-20181231.xsd#statement-note-6-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-details-textual" xlink:href="dmac-20181231.xsd#statement-note-8-warrant-liability-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod" xlink:label="dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:label="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsIssuedDuringPeriodUnitsNewIssues" xlink:label="dmac_UnitsIssuedDuringPeriodUnitsNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit" xlink:label="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsNumberOfCommonSharesPerUnit" xlink:label="dmac_UnitsNumberOfCommonSharesPerUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedInPrivatePlacementMember" xlink:label="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsIssuedDuringPeriodUnitsNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsNumberOfCommonSharesPerUnit-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-details-textual" xlink:href="dmac-20181231.xsd#statement-note-9-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_IndemnificationAgreementsMember" xlink:label="dmac_IndemnificationAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale" xlink:label="dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial" xlink:label="dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_OfficeSpaceMember" xlink:label="dmac_OfficeSpaceMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchAndDevelopmentContractsMember" xlink:label="dmac_ResearchAndDevelopmentContractsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_TechnologyLicenseMember" xlink:label="dmac_TechnologyLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="dmac_ResearchAndDevelopmentContractsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="dmac_TechnologyLicenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="dmac_IndemnificationAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="dmac_OfficeSpaceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-details-textual" xlink:href="dmac-20181231.xsd#statement-note-10-shareholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="dmac_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants" xlink:label="dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CompensationWarrantsMember" xlink:label="dmac_CompensationWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_PaymentForFindersFee" xlink:label="dmac_PaymentForFindersFee-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfCommonStockNet" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockNet-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfUnits" xlink:label="dmac_ProceedsFromIssuanceOfUnits-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfUnitsNet" xlink:label="dmac_ProceedsFromIssuanceOfUnitsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_RightsExercisablePercentOfDiscountToMarketPrice" xlink:label="dmac_RightsExercisablePercentOfDiscountToMarketPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual" xlink:label="dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsIssuedDuringPeriodUnitsNewIssues" xlink:label="dmac_UnitsIssuedDuringPeriodUnitsNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsIssuedPricePerUnit" xlink:label="dmac_UnitsIssuedPricePerUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit" xlink:label="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_UnitsNumberOfCommonSharesPerUnit" xlink:label="dmac_UnitsNumberOfCommonSharesPerUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger" xlink:label="dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants" xlink:label="dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsAndRightsThresholdConsecutiveTradingDays" xlink:label="dmac_WarrantsAndRightsThresholdConsecutiveTradingDays-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedCashConsideration" xlink:label="dmac_WarrantsIssuedCashConsideration-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedInPrivatePlacementMember" xlink:label="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsIssuedWithIPOMember" xlink:label="dmac_WarrantsIssuedWithIPOMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dmac_WarrantsIssuedWithIPOMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dmac_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dmac_CompensationWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_RightsExercisablePercentOfDiscountToMarketPrice-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockNet-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WarrantsIssuedCashConsideration-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsIssuedDuringPeriodUnitsNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ProceedsFromIssuanceOfUnits-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsNumberOfCommonSharesPerUnit-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_PaymentForFindersFee-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_UnitsIssuedPricePerUnit-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ProceedsFromIssuanceOfUnitsNet-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WarrantsAndRightsThresholdConsecutiveTradingDays-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party-details-textual" xlink:href="dmac-20181231.xsd#statement-note-11-license-and-collaboration-agreement-with-related-party-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AhonPharmaMember" xlink:label="dmac_AhonPharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone" xlink:label="dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance" xlink:label="dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CollaborationAgreementPaymentOfLicenseFee" xlink:label="dmac_CollaborationAgreementPaymentOfLicenseFee-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones" xlink:label="dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DiaMedicaMember" xlink:label="dmac_DiaMedicaMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_LicenseAgreementMember" xlink:label="dmac_LicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_SKGroupMember" xlink:label="dmac_SKGroupMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="dmac_LicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="dmac_AhonPharmaMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dmac_SKGroupMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="dmac_DiaMedicaMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromRelatedParties-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_CollaborationAgreementPaymentOfLicenseFee-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-details-textual" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NonemployeeStockOptionsMember" xlink:label="dmac_NonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_OptionPlanMember" xlink:label="dmac_OptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions" xlink:label="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares" xlink:label="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_The2012DSUPlanAndOptionPlanMember" xlink:label="dmac_The2012DSUPlanAndOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_The2012DSUPlanMember" xlink:label="dmac_The2012DSUPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2012DSUPlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_OptionPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dmac_The2012DSUPlanAndOptionPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_NonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan-details-textual" xlink:href="dmac-20181231.xsd#statement-note-13-employee-benefit-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-details-textual" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoteToFinancialStatementDetailsTextual" xlink:label="dmac_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_AustralianTaxationOfficeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:href="dmac-20181231.xsd#statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:label="dmac_statement-statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-option-assumptions-details" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-stock-option-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-option-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-12-sharebased-compensation-stock-option-assumptions-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-option-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-stock-option-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-shareholders-equity" xlink:href="dmac-20181231.xsd#statement-consolidated-statements-of-shareholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised" xlink:label="dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:label="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-1" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-amounts-receivable-details" xlink:href="dmac-20181231.xsd#statement-note-4-amounts-receivable-amounts-receivable-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-amounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ResearchAndDevelopmentIncentiveReceivable" xlink:label="dmac_ResearchAndDevelopmentIncentiveReceivable" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-4-amounts-receivable-amounts-receivable-details" xlink:label="dmac_statement-statement-note-4-amounts-receivable-amounts-receivable-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-4-amounts-receivable-amounts-receivable-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_ResearchAndDevelopmentIncentiveReceivable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxesReceivable" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherReceivables-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-5-deposit-deposits-details" xlink:href="dmac-20181231.xsd#statement-note-5-deposit-deposits-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-5-deposit-deposits-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AdvancesToVendor" xlink:label="dmac_AdvancesToVendor" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-5-deposit-deposits-details" xlink:label="dmac_statement-statement-note-5-deposit-deposits-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-5-deposit-deposits-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AdvancesToVendor" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositsAssetsNoncurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-property-and-equipment-details" xlink:href="dmac-20181231.xsd#statement-note-6-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-6-property-and-equipment-property-and-equipment-details" xlink:label="dmac_statement-statement-note-6-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-6-property-and-equipment-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:href="dmac-20181231.xsd#statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AccruedClinicalStudyCostsCurrent" xlink:label="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:label="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:label="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:label="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableTradeCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedClinicalStudyCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedResearchAndProfessionalFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_AccruedTaxesAndOtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-rollforward-of-fair-value-details" xlink:href="dmac-20181231.xsd#statement-note-8-warrant-liability-rollforward-of-fair-value-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-rollforward-of-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_WarrantsAndRightsExercisesInPeriod" xlink:label="dmac_WarrantsAndRightsExercisesInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-8-warrant-liability-rollforward-of-fair-value-details" xlink:label="dmac_statement-statement-note-8-warrant-liability-rollforward-of-fair-value-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-8-warrant-liability-rollforward-of-fair-value-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_WarrantsAndRightsExercisesInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-shares-reserved-details" xlink:href="dmac-20181231.xsd#statement-note-10-shareholders-equity-shares-reserved-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-shares-reserved-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DiamedicaStockOptionPlanMember" xlink:label="dmac_DiamedicaStockOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_StockOptionsOutstandingMember" xlink:label="dmac_StockOptionsOutstandingMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" xlink:label="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-10-shareholders-equity-shares-reserved-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="dmac_StockOptionsOutstandingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="dmac_DiamedicaStockOptionPlanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-sharebased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-unvested-shares-details" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-unvested-shares-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-unvested-shares-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-12-sharebased-compensation-unvested-shares-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-unvested-shares-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-unvested-shares-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-net-operating-losses-details" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes-net-operating-losses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-net-operating-losses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_NoncapitalIncomeTaxLossesNetMember" xlink:label="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_TaxCreditsMember" xlink:label="dmac_TaxCreditsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-14-income-taxes-net-operating-losses-details" xlink:label="dmac_statement-statement-note-14-income-taxes-net-operating-losses-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-14-income-taxes-net-operating-losses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="dmac_NoncapitalIncomeTaxLossesNetMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="dmac_TaxCreditsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="dmac-20181231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_IncomeFromGovernmentalAssistance" xlink:label="dmac_IncomeFromGovernmentalAssistance-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-n10" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="dmac_IncomeFromGovernmentalAssistance-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-n10" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-cash-flows" xlink:href="dmac-20181231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise" xlink:label="dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dmac_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_Cash-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_Cash-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:href="dmac-20181231.xsd#statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange1Member" xlink:label="dmac_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange2Member" xlink:label="dmac_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange3Member" xlink:label="dmac_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange4Member" xlink:label="dmac_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_ExercisePriceRange5Member" xlink:label="dmac_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:label="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-12-sharebased-compensation-stock-options-outstanding-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange3Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange4Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="dmac_ExercisePriceRange5Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:href="dmac-20181231.xsd#statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-1" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:href="dmac-20181231.xsd#statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_CommonStockPurchaseWarrantsMember" xlink:label="dmac_CommonStockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredShareUnitsMember" xlink:label="dmac_DeferredShareUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:label="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:label="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_EmployeeAndNonemployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_CommonStockPurchaseWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dmac_DeferredShareUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount" xlink:label="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:label="dmac_statement-statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n10" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n10" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets" xlink:href="dmac-20181231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dmac-20181231.xsd#statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:label="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:label="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="locator"/>
    <link:loc xlink:href="dmac-20181231.xsd#dmac_statement-statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="dmac_statement-statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dmac_statement-statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_DeferredTaxAssetsPropertyShareIssueCosts" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dmac_DeferredTaxAssetsPropertyPatentsAndOther" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>chart07.jpg
<TEXT>
begin 644 chart07.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[@ A061O8F4 9$     ! P 0 P(#!@
M             /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$!
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\( $0@ N0)P P$1  (1 0,1 ?_$ 1\  0 !! ,! 0$
M       (!08'"0$$"@(#"P$!  (# 0$! 0            4& 0,$ @<("1
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M&^2Y1=^CW?FC9A;MT?.7=\YR/S;<@<^R-<GR\G[Y?U9OR=]@K^.#'G;60
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MJP^A_CX"(MA^/YRB[UDCBLP &V#YU^R9)5W[      (.$XP
M      63OUXOZM.;.'HK7CT      //G]N_F#OG^,_TGN7GEP       !!PG
M&                   #%'7IU86R'W34B>       @]<OS?.&F_I
M  ""F=>7+#\BRC%W>C;XVA;HW(L?;\3RM!R)'V_H>^6U>J$R7&W/%\G1[XX[
M*PL?MK64(R\8UDJ9='+-U'QU8YD*AEJ*OV.9"H5W3(UK1)XNE*/EV(^A6)W5
M7N^.FZ^:<P]*T#,L3]"LCLKAB]^.RX:EOGF8(J_VMTPG0]\M^<-JQ%+_ #[*
M$7=Z-OC;<WQF2XZWXHE:'D./MO1]\]J=4%DJ-NF,9.CWKQV7[QFQNVL91C+S
MC22IET<LW4?'5CB0J.<H3Z;5]7>        !J\F?G&RF+O%:U=X
M     &#N_GS9P]'ZX          "QNVL_ICU>O'9         ->W3"3KU2_8
M\[0             !R>*W[=0?0-\]LNTNIS(  Y/+#]7IVRJLRVW.G38
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M7IOOGRS:Q3/H=<QPT_9'79QVZQY"@W5QW#J^N6C[X2K:Y'957=F1(^W
M ")\MQZ];'%]++8+7Y*84+W0$]9T+_5X+:)5;!F7AZZ3[\4#9XUS6:$TH7BJ
M^OWXU]+,&3!D<,<LF#(X8Y9, SPQRR8!GACED&#/#'+(,&3!D&#)@R.&/IG2
MS>*KFW@Z]GU5G_PSCEDP9%6\>=DD#Q#Y    .3D  $<I/EU_6&,DG39[Q/\
MZ)^?^R3XK]-_, '2]>>[Y]                    8LZ^;6G:(/(W-N_3&?
MC.+LT[/K&=A5<FJOYQLD@.+$?7LP9T;/D   &8.?QG'DU   1%F>'%,7V^/'
M[_1?7O\ &OI'YY                        #[+,W:M0ERK6ZNCVJJ^,;%
MH+C_ !RT>R&Z%/G&0O3M8<953"V"L94[#<[JQ,+DU@  #6H8XDN60\=U
M     ?)]    'X'['(   !UC]C[      ."9F%P$)9/?&\L3&.NS<.6;BW2J
M,_GE*;F\2*Y-0 A[,<4-)GAR=S;=G]7EM"QOI    -7YLI*N   "%9K$/0>
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MBU=SS@NISA.$E)95606DTW=#FX%4:Y.7H=P3B6<5-Z)6/:1M<JLZOC^>_P#
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M!TP'VH.F ^U"TP'VH6F ^U!TP'VH.F ^U"TP'VH.F ^U"TP!?ZH6F)#[4'3
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M=#=<,%W+[+=@Y2Y'7?@ROA2QM:].\^:U;N:Q.>T9H7B5UW%ME>Y#H1;^F'>
ML"[<43]Q(04)N9MG?;2&PW8V/M.\4PDW3.0S/+"#QW=%R46JQP/C3 >/[BS#
M9. ;V?7=VHM';TM#M5]M[;35O="ZKGHM1K:EYIW97.9+1@I5"9I7@(C)Z$Q)
MW5=B=J)6I=R=V43.3D8:44FJ4[?@\EHSLK==XIVF=JW31=;:3RDC&2+Z:H8P
M5OY'1N&5NN]4[47M:Y:+J9/,KH,GLQ-4PT+;>0DKED[IOI*U7ELW!1<\>IEM
M%N\;85P!B6[[8O\ 2NB2N>_TK7D;=G:;CBT\LH*.KEGZ+9C;6OM*ZGMR9"2M
MJ3@YWK,1FQU=VGV<XG,5D79CFU;V3NM>X<CHV[*Q\U3(P4;E-"2D;JNBBU&M
MJ7DG=E<[DM&!EIZMU<V/<1,'D7BSXVW^O-U[%V1_AS,KOPUV;:L77U@;;R&R
MA?XUT_JMW&L1XWW=VLP!@'%6L&*>)D)R M^Z(^_\;8YRQ:DGV]+UP EVKMM=
MM,Y]UGB9#B9CFJ!&9 S,QQ,AQ',8(S(&9F.)D.(XF",R!F9CB?LXF8(S(&9F
M.8_9Q,P1F0,S,<U7LXF8(S(&9F.:H$9D#,S!&9#B9CFJ!&9 S,QQ,O859D,B
M/Y+M#7KH9W5,#[Z2*B#E N(YC!&9 S,QQ,A;YGY@]G/2.>@<] YZ!ST#GH'/
M0.>@<] *HC]_9+5_&FSMKWCW$+[T0B-<:J/JMD71#<K8ONP+5%6K[C:+BF3S
M\)S=A?'FQ.)L*]CG0?$]N)]LQGC^JFSN[EBT*;S;/XT3LSNKZ&79)ZX=T;3K
M:O,XM_\ GXOBZ+CCDZYJ34KZO(CJ\B.KR(ZO(CJ\B.KR(ZO(CJ\B,5.W#IU[
M^R&ANHFW+O4>V8^VKZPIW+\Q8C[IZT)+I*](EQTB7'2)<=(EQTB7'2)<=(EQ
MTB7'2)<=(EQTB7'2)<=(EQTB7'2)<=(EQTB7'2)<=(EQTB7'2)<=(EQTB7'2
M)<=(EQTB7'2)<=(EQTB7'2)<=(EQTB7'2)<=(EQTB7'2)<=(EQTB7'2)<=(E
MQTB7'2)<=(EQTB7'2)<=(EQTB7'2)<=(EQTB7%$7-)U7_B6U\KP6EG8[L'3G
M9;I$N(&*E:)X+((N*.XYDO87%\GC3NC7+<]3OND7)(6LGW/9VWIG$6[M];![
M"2>X.5,7;F*=V6.4QO\ Y.;@MJX8CN?WO<T+I[DJ/S/BGX$6EM=@K.163?-.
M<?4!NJ/4!NJ/4!NJ/4!NJ/4!NJ/4!NJ/4!NJ/4!NJ/4!NJ/4!NJ/4!NJ/4!N
MJ/4!NJ/4!NJ/4!NJ/4!NJ/4!NJ/4!NJ#V W4(O4%ND=/J W5'J W5'J W5'J
M W5'J W5'J W5'J W5'J W5'J W5"FQ.YB2WJ!W3.KU ;JCU ;JCU ;JCU ;
MJCU ;JCU ;JCU ;JCU ;JCU ;JBC8S<FNE+83=!=+U ;JCU ;JCU ;JCU ;J
MCU ;JCU ;JCU ;JCU ;JCU ;JCU ;JCU ;JCU ;JCU ;J@]@-U2*U)&=E[9%
M]V_ 35SYJMC6"Q\55YNTWN*[[GR=I6A>^O\ =.H629-[9^*W,JSP5K\Q<OL9
M88EJ(3"^%[>:X,B(FWV?N;H6\K<=D1D[N98R^&\V[19+N(:VWK-RNZGP>Z!A
MK'>:L?V_!QML0/P.XSC:/RMHQM4[VWF,L?!WNF<)7AM3KOC=&P]\/@5&5--W
M3&+<FXT[6'44=4OD+I_GFV&([@SYK.RT4V,QA;45I%G:%V\PAAR<Q;F^_>U3
ME"6P&MVZK]+*6!=%<TY8@=8,0N<#8)Q%_P"KW7C-I(M&3)G&LPA"0K65^#P(
MS_$;I_GGO5J5J&,1?^K_ ()=/\\^!B+_ -7L_]H " $" @8_ /N'28Y$#1M<
MQ @BH(+J"".((U&#_P $M-?_ &D^;#V?\.LO>5)!7DJ,U7<5!*[2P7/:"33A
MB&XAZ):&&10RGDIF"*@TVUTP?^!VG[E/FQ]16G[E/9Q]1VE/\%/FQ3^!6E?\
M%/9Q<Q)T:T+PTWCDIE5=P_)SJN>7JUPDB]#M=C $?J5&1[05J/4:'!DDZ-9J
M@XF) .S4BFN6)$7H=KN0T/ZA1G0'*JYY'45'#4''U):?ND^;#)9=.LI' K00
MJ#2M-P#(*K7+<*BO''U%:?N4]G$TIZ1;<I&(+>[C;4,$-&V4:CD+EQK30XSZ
M':?N4^;#^\]+LU*[:CDJ3XR0F2J35B" !F:'A@RVG2K*1 :&D25!'!@5!4YC
M(@''U':?ND^; '\"M*_X*?-@2P='LWC)(!$2:J2#^3P((^3'U':?N4^;!GN.
MC6BP@@5Y*'S,%&B\20,4/0[0?_:3YL/LZ%:^%B#^H49C75<QV$9'@3@37?2;
M-(RP4'DJ:L=  JDDFAT'#$:6W2[)R\?,6D*$%-VVM=OYV1!S!X8I_ K2O^"G
MLXFN)NBV@AC4LQY*&@ J3DM<AAVBZ19L%-#^J3(@ D'PY9$'U$$8CN(.C6;0
M.H*L(DH0=#Y<1FZZ59KN)H.2K$TS-%5"Q &II0<3A2O1+0@BH_5)H?\ TX6]
MBZ-:M;%201 M2 2#0;:DY'("IX8!_@=I3_!3V<(C=%LP[5H#$E305-!3.@S/
M8,9]#M!_]E/FP(K6PL7D*[@.2JEE&I7<@W <2M1CZBM/W*>S@_\  [3]RGLX
MMX'Z+:"67=M')3/:-S9[:9#/'N Z5:&[RJH@!I45%2$VBHS%2,?4=I^Y3YL?
M45I^Y3V<%FZ):!0*_LDT'_IPYM>DV;[31AR54@D5%0R@BHS&5",Q@06UA8M,
M:T')4%J:[=R -2F>TFGJQGT.T_<I\V*_P.TI_@I\V #T.TI_A)\V+E5%%$C4
M'RG'*M8'DDI6B@DT'&@Q]5S_ *#?-CZKG_0;YL?5<_Z#?-CZKG_0;YL?5<_Z
M#?-CZKG_ $&^;'U7/^@WS8^JY_T&^;'U7/\ H-\V/JN?]!OFQR;F%HY: T8$
M&AT-#]WZ-_\ ZHO_ .1<-Z\=1GN97Y(NWEBBHNTMRE19"WF.>ZBD@5%2#B*.
MWM797LH5E4L6_6!U#D+O6K+'NHJLH8 +6E!B(722[8H;K8"]/&T@,%0KD5"5
MV@E@FA.)&A283K:VQ3]8Q_WA6_7-FU"Q4 ,3X6&0XXZC-!;O"TD4P-#12>:A
MCVN9&)9HP^U]J",MMH*8C,/2;K^'<EPD0;:Z3EA21OUE:%<E?<=A!.WQ5Q--
M<!I8FB0>!@/UXMPG..8WH&#+3+:Q$E&X1W4JR^^)+:;:N2 BQQK/ENH03O#U
MS;7/(XZC'>K-)<LGB4@!)7$RN&5^:=S! 0GAC !VFAI1WFLYY.DF=B(E;Q4,
M,0C)&\$JC!PR[LF(8@ZX6@H*#Y,1"2:5NI"!8E4%4Y2F5&D52M*DJN;%B:"@
MUQ*EO;2[Q/%R)0YY<<"[=Z,"]:Y2;@58R;P:Y9);06K*A68LNZH+&[C=-6I7
ME*2.P5KF<Y[B\EEW[I=QVCER*SUC\?,).Q:;0(TVY@^F^Y4#R3K?6TVU:;C"
MJJ*K4@':584KKZ\/>RV[Q037%N&CW@.8HEDW/(4:@WEPNT,3M J> 6V@AD1H
MI;MA*6'+VR))R,RQ)"EE!!'@(]6+E(H)8HUM(=P=]_ZPN^YLG<58"M:@N/%2
MF$Z='9SQR)<LSFBD21&9V*I212Q(925)2H!%>!LH!+,UG/03%CM:-8Y#(H"A
MVIO0\K)F.T#<<L71N#*UT6&X;0(Y#[PCA@_,;=M0': B;5JISH,=2YD$G)9]
MPDDRD<EG)4@.RLJ C:X"54A2N5<77/64P[;LI1R!O9U,!R89@ E."^C'2E*2
MM<)+"TG+V\P;4(<KN\)-3GVU.(]MNX40E2 RB1HS="1D9@:<YXJEV! +$BH)
MPI:RG/1?>&;W<-^L"&-0I(WUV<T,W+WY;@U,J!X+JSGG<V;)$%DSCD+O02'<
M 6Y9C7>=P.UEXY]6=5_5[84]!D2(AZ=M 44GM%.&*F*07D5M:"(!R KH3S:
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MC^7+=>H%Q9%J.5\P!RW"H-=NM.-*<<".VN>==E$,C ^ #EHL:J-:[5WL:_E
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MN'WA066-3N#*,ZB09>(9J*=E2,5^XVEO**Q/(JL-*@FA%?5B^@A%(DE=0-:
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MQ'I(II@3"^MX\R*.^ULN-*:'A@VYFC>E/$IJN?I]''"=$ZGU.U-Y%]$E$@+
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M&ZM3C3&F-,:8TQIC3&F-,+Z_N!7IG4'B0MNH*$5I2M"",P #VX>=Z;V<L:
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MD_R\OJ'W%?7_ .!5]0^XKZ_L_P#_V@ ( 0,"!C\ ^X7C*Q#")R"-0=ISP/\
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MJ1YN&FFF+VX6Y5Q-&5"K6OB"@EJ@ ;:5 J233UXM[6-U<NSIN J0C*NUCX5
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M)T*;H0"\M[B>X28G:-^Y8XV44>H6AS%"<\1R]6M+-/BKD,6CC=VMA-XMBAV
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M,9*2PK64,>69W"U5;,4)<)<M7;>872!YQC(;%*W!-KQ*B))TFK80LO(S*#1
MZP+OH7#F2,VQDIC<C\ $R[1"P/*]/3;-NH!5/"O@7Z0!P7J\"UM./);#^4N1
M'[PNP9WD)+&;.3?V[&>3:XQ)Q]--3DM4G%N)%&L;?QL(BQ61<14B'B#@B.PZ
MN%'S#=^.J&"+E)XT<9MQ)R)7OT>K=(RN+RH$R#ARQ8[J\].U[,N,F$Q(A%+M
M7+=PN:2% Z#QJJNF4T] 9.HC-G2.(7-; 4!CV^5*53S5=LDVV_Y/E>.]N>1\
M757E64>3./[9%",\K(I&B)!B=H()"5'4'%$O^).0U:R'R;X5R& L=T[%+LUG
MQ/#TA& ;\D;;E=W)X[A56-9G81BO%RA9"1EFUB7.1\)4D&H'+@NI3%'QA;,8
M,5,*L\S4=U9)@,M0V0*SF?YQ9DR16\;QV'VI+-\[*VBLD>3-?18RM6?>;2-$
MET4D4^:.+K-RSX_W-SEZEX@DZ#)5*H-(S%5AJM#S9(S4]B@S1CARN2-=FW..
MI8PLH04$S-F@F:IO4G291#&ERIEYJMB>+UPRUTH^-5FDYB+#+EK=G*\+2<17
M%/'6,)>?I#NN@20;QLG'NI"M H$<H_>"3K+SFRQ^V2F9]JG,FR_-J-Q%A]C>
MP<CC*?SQC_*=JN>5IRV56EP<%9*[5*8X9P4:S4D) \Q)=YWK9!)112N2LAD#
MB;FZ38\G;1=N/G?U20Q7C_"_%][C6^0;7'>0K#&XA(YH5A--2]>6K,8ZC+22
MN6.!-(N3'16/XC/#"KV3'^<;7+Y.RK*WJQ9XFCXZ?YYQ[9L-52&Q_%11*;QZ
ML;3(J5 O83C5N2.^8JSB53:3PI$(Y,+7D+1Z'FG%+W'5^J_#QIQMX_UVB.8?
M*./$\>2D/(YBC\C325$BTV,^UFT7;J24=SLL%E=K _0-TE* <8_FW,<47^7^
M/:F5+ ^A\I1.07>?HZ96S_\ M)J5=QH1"+<XPEJQ:X8A1>MY(52J)KN$CF)U
M  34%CL:DWKTQBS+&7<9W^RIN*!'X[Y-<@;Q2K.YQE)WAWC+)3^JM\'8?@7-
M,A)<T#)1#:7<.ETNZ*Z!X3&9,1XTQ%,#8>8>3[1FO#.,:.A?&N2L9RT-A*LP
MU9KMILV-Z]9)6N7V09VF3CV;!E%E0FW)UR-$$@;EU$\8L=6& 4Q[QO03PDOE
M%]&*-$K9<'5KDK%D_(=R6C&3V<D$(FQV \2<.ATNW808)H$'L*;CW1*=,8>>
MVC&E2RI V>N\9RVU/CI!Q]AMK6:J<C5/GNS:2[C)]SZGKVW.$3K,E3E8%**:
MJ:J).96?(+/U&R4UY387E<*T[%F,H2^2-B30R/5L90$_<<S*V2K5*KPK'%'S
M6=R;".0>23^1G&[0J'<I@=P7!?&JCW"G9;4R9;^0O'B?R9"P1+3<*1QTR/CB
M@#AC-ME5B\-8H@Z"OBS)M7-97<'')/#5AHWD&ZK]0KE45.3]6B;)C?$U80FG
M\9@N+H[1B.7,KP6/X#'>/,:47*5.?8UD6LSCRU1%3<6-M:HRS0TG!33V04>(
MO0=$()?\H/\ YZQ9_P#QQ1__ -LQFDS%$2F"ZQ6P@(@(;P5F =A#M#<!UL+H
MI1[/:G=$(;M]CVIU"F[?R=G;KWU7X0W].O?5?A#?TZ,8#K"4@ )S 8X@0##T
M@)A =B@)AV#?\NO?5?A#?TZ]]5^$-_3KWU7X0W].O?5?A#?TZ>-FLHT=N8Y8
MC>2;-)%NZ<QKE1,%DVTDW;KJ+1[E1$P'*FL4AQ(/4 ;=NO?5?A#?TZ@S&$3"
M,[,[B(B(CL1D ;B/;V 'XW]X6(  ";E)4!,(  "8?[J_'H-Q_E'8-OP9/Q!/
M/Y&+@\J8]N>.9F3AS-BRT?%7:NR-;D'T89XW=-"R#5I)'.B*J2B8*%#J*8-P
M$1'D1R;W$=QV<XJ -Q]G8/V=#MKZQ')SXSBKZ.=?6(Y.?&L5?1SKZQ')SXSB
MKZ.=?6(Y.?&<5?1SKZQ')SXUBKZ.=?6(Y.?&L5?1SKZQ')SXSBKZ.=?6(Y.?
M&<5?1SKZQ')SXUBKZ.=?6(Y.?&L5?1SKZQ')SXSBKZ.=?6(Y.?&<5?1SKZQ'
M)SXUBKZ.=?6(Y.?&<5?1SKZQ')SXUBKZ.=#MR)Y.@!A QB@[Q6!3&* E*82_
MLZZ1,!1$ ';?8=M?6(Y.?&<5?1SI!RVY'<HFSELLBY:N6S_%R#ELY;J%6;N6
MRZ..R+-W#=8A3IJ$$#D.4# (" #I&>R1S$YHY#G&S).-;3-[NM(M\JUCDE#J
MIQ[5_8*1(.FS(JRAC]T0Q2"<PF$!,(CKZQ')SXUBKZ.=?6(Y.?&L5?1SKZQ'
M)SXUBKZ.=?6(Y.?&L5?1SKZQ')SXSBKZ.=?6(Y.?&L5?1SKZQ')SXSBKZ.=?
M6(Y.?&L5?1SKZQ')SXUBKZ.="8>1/)TQAZ0$3.\5F'8I0(0-QQT(])"%  #V
M  -@[-?6(Y.?&<5?1SKZQ')SXUBKZ.=?6(Y.?&L5?1SJ37J?+#F!55YN&?UR
M9<5FSX^@'$O794"%E*_)KQ-$:+/H23*D4'#54QD%@* '*(!H"EY#\FRE*  4
MH.<4@4  -@  #'.P  >QKZQ')SXUBKZ.=?6(Y.?&L5?1SKZQ')SXUBKZ.=?6
M(Y.?&L5?1SKZQ')SXUBKZ.=?6(Y.?&L5?1SKZQ')SXUBKZ.=?6(Y.?&L5?1S
MJ.LM3Y3\MZK9(=<SF'L5;G\<0<]$N3HJMC.8N7C* VD(]R9NN<G>(J$/T'$-
M]A'1C&Y%<GCG.8RASG>8L.HHHH83J***'QT)U%%#F$QC&$3&,(B(B(Z^L1R<
M^-8J^CG7UB.3GQK%7T<ZE#UOE5RZKAYR%?UJ;4@+%CJ&5F:W+%3+*UZ45CJ$
MV4?P<H5$@.6BHF07*4 .4P!MH #D/R;  [  '.*0  #V   QSL !K<.1')L!
M#M#_ %G%0]H?RA^SKM#5=J[)9=PSK<%$0+1PZ$@N5VT/'MXY!9P*1$TA752;
M@8_24I>H1V  [-$_]ZQ/_H5FUQCRD; #S*)TF>?GN6',%%R4@O8DZ1A-P^PY
M!V$_G%K!$>%N31)&!(\%)%61$A#"8!$-4^L2$EEF@,;CR?PO!+Y0M&"HI>WU
M#!=^P_<Y_)!)>.F\=T:N.B4&^P[-CYT-%(-F;U8J0+.D#)G5FZ-#N;?9<T/<
M;\SK(VP18L-5F%H\-*8EE8:(PH_Q?<&C%O*9282=8>^=7)_&K-74P<K7J 5/
M#EX/9$R%DC-RU$9\CLH5BVJ5'$4U%2BE1F<<Q 4@<Z5*6Q917#IDM=EY"$--
M%A&T0PCU!<IG*[0!V.7Y''3O)08;Q9Q0B,DP-,QSC2I6:4RGF:3N%JK+^J0%
MOM,+,E2D:[ *-)E=@W2=KG39IB"!RG,FK 1(S>3J?+1[SF@JXOP8'BG%BMT#
MCG&=2N?'!.3C+=1*\U8O+G:W[R);.@AHUQ*%*=,K8K@@=&&(RX/KGC]Y>\J\
M-J+"XL)AN#3QC?JGDS&;2PYHDY_)LDQ<SE6R2ADDKF,/"HN$%XR/3.84 (3Q
M!<CJ<HUGT"JW80Q35F:QQ*TV4QKDEQ8[$SFX>J2CVAUBJVNA-(!!FLT*B_LI
MTU4BK*OCINN[*S^;[K.M>6RCE3F9=\@7NI<;ZQDO+DWEVNVV29<;ZK;H(*RH
M^)C?,8 H]<S;MN<B":X-VKMBS!+66IGD/*2-,JM2KN&8JNXD9T6#8U&1N=QP
MU4K'E";A\@&04GIYC3,A ^8HMV[E9L@NLLDJH?NT@+!_^>S/^BR_&_O"O^*.
MH?\ *QQ[_P +$_\ >L3_ .A6;4KD?)UB+6*;$NXB/=R7@I&477E)Z2;Q$#$1
M\5$-GDE)RLO*NDT&R"*1CG4-^0 $0R#3+DXR/2X_&6(Z+F:T7VTXYN\77&=>
MR!+MXJ(CG39:#\]Q<LW<.VW>@[12(JLH=!'O%F[@J;E+&2%0J.6LM&8I2<ZW
MQ5<*L]F;/<&LG=*U0[K=9:M-F%1N=X\*K)M:\^<LGCSO2K^'$ZA!-5LK7RP(
M4NU2%8H#^[TFN1]ONY*Y:LH2$RTH^-8:1CH9=>UWJ>80QWI(9L52209;KKI)
M(['&FY\?9#;*XBOLI68FFW"&BK!.I3<S;WKF,K\:TB(6,>SI9)W*,EFAT1;
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M_P#!-^D,#-ZP_P P1E?<2U!B+DBY5K5@G(I1*1)6)0[-XP<,D[0V;*1Z;L%
M!DLY(N8IRIB0TC,9&QVWQ5BB-O>1X?$55F&[XV0Y24>9@R?;\H6:S/EU&[9.
M$:6BU%@(UJ5HDN56"=K*F,"R0%_'YHS?+-1\98+]=8.J'6*4=HQ&RR(RLJW'
M<P"1VX*#9,W88O=+A^B?^*?O$S,BHG>!R;JPM".#&(@=R'%3CZ*!5SD 3E1,
MKL!A !$"[[:9$E:KAQ*(,];E?KLYFRF>D8"L0'2C=-0YTO$%;]0D >H.K;?<
M--#XPC*G*3)GQ2O4;<\D6;%..\.N8RC8T:'>J.A= F78QBE AC#VB  ,@&4H
M6A13,J!1C#4]_+O%U'/>$ Y7820F("7="8=R[" @'L[CL]2H-<Q<_K)>X\ Y
MLDM/MI93=JW,X%RDR$K<@E>&5*4"@/ZLI1W$3" =_-,:ZE?/-LB;P#!R]&MF
ME2"[\U)"Y5!5\FS7*5$5Q#K,F)C@43; (QR<_5\0(U\T@U)*.8Z8L@R1(L72
M17BS1%8RJ'C",A.9,ANHHJ !1'81,#$V+XNH2DD9RH$BG;WDDT:IM0(7NS-3
M1HE4,L8XCOU;@  '9V[A*!E.&HL4D1-J,.:G2$L\465,=<'A'Q)(!*1-,A4Q
M(8@[B)C (=@",BE2JSBE[62+%"*=3\O8$)95#NDQ,=XDT$K<BG?"8-BAML =
MHZ.Y4CZY^T,(-PHG&E=O2U<UB*@H+5L=YTJOTXQ1R! .8 ,H4HCMOL C')6R
MLXE:ULSM(LHYAI>Q*RJ;(5"@LHS2<G.W%P5'<2E,!BB8  =@'J"-'%L32Y1P
M8[GSJ6X/91FFD0/#^$!EYM$HF$_4J)Q,([=)0 !ZA$LD.4HFF1;DIVWFHM/>
MR;Q)5,?$>*!X,D)C%,3I2$@E$-^HP"'M0$9%*J5C$KJME=JEBW,S+V)*548@
MJ8$%'B38Y&X.#(@4QBEZ2@81 -P#J$CA%A7/VA#!M5%(X[IZ:L$L)D$A>-TW
M>R3]2,2<B<$S"!%#E -^D1':.2NM9Q2RK)U3!*NH"7L*\LDAW*HE,S2=B9N=
M7OP(&Q@VZ1'M =M188LA:+*HG3=#+GN,A+,E$52G0!F1D2- "J)J)BH)S&-N
M E* !VB(/3Y0BZC%R97) CTJ@\D7C11IT#UF<GDA,H58%-MNG8! 1[.S<9%.
M!JV(%J^61=DBW,C,60))2**[5*R7=I(F20\8HR AU"%Z2E4$2@(@ &$5X5C7
MEKWYMCC P?N7I:X$J<6H2B8.4@3?*,D"F6%$1Z#*"4@&$NXB#-*_5S%T?63
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M60B@'*"B1P*HBJDH@L@J4JJ"Z"Q1(L@N@J!T5T%R&$IR'*)#E$0$! =)W/\
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M1/&2].^*7+- HJ+Y+ID<DM0\KI$ 1&N9[QNF0(6[Q$@.Q5'P(A(I=AQ%<2E
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M,CD(,A"UT'L6YZTDU0.T="[3[XA04Z1'I#8X"'Y-%GPC)9(AHY22\T+- ).
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M!=3^(/O\I/\ \(FLXX3JDG#PMERACZ3J4'+V$7H0<=(/7+)9)S*C'(N7X,R
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,/Q*__<R/^E"?A__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>chart06.jpg
<TEXT>
begin 644 chart06.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[@ A061O8F4 9$     ! P 0 P(#!@
M             /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$!
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\( $0@!-0)P P$1  (1 0,1 ?_$ 2$  0 ! P4! 0
M       (!@<) P0%"@L" 0$!  $% 0$!              0! @,%!@<("1
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MX4-3)?_:  P# 0$"$0,1    [_
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MX              8:.WT-2X,FO1%G:Q*JQUXF^EJI>"9>DV&6;D-U4..X
M                                         ;)3>J@         4-EM
MP=]]RF.'H])P5[(]S>\SN<!U5?8;@          !L".Q)@           %@\
ML*_F*: *;5VI5R@      BEM8?GF_0ODE[?.?IB0_$^XW UNWBWT?"6&]/\
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MJSR?OJGPZ-F25STN!N\N,<!&GUW9A]:SY1]QD'"O
M  '4P];XSHN>X\" ,I_,;;U(_EKUL        >:M]+>08G.IYO@<JF;I.K6W
MA,$RN\<?U9_ECW"8FJD         ;$AV32            .IAZWQG1<]QX$
M93^8VWJ1_+7K8        X>Y!W=0?/0^D/#\;6ZOU;K>/Q2-2/?W&_+.M[G7
MB_HH         Z_YV           ?((M$I0=3+UOC.BY[CP( RG\QMO4C^6O
M6P      !Q-S%YU6CZ]'I7!=<+TKAHWY=EL+LFKDQ;:R_C<,BM[(G9K\\ZKL
MT^7=]DEYC<UEC        8"#/N         66I?A*LDC1-8W"D/?7^"Z,ON/
M  #*?S&V]2/Y:];      &UJZFGKWGG50]7X&.$W!15L_87W;B_%K7X?VM/E
M7;6YN/QY]Y92L:P[C8,W9!\X[+NQ^(>D5YAN       P6F=(         L?2
M_!-9) &[(R>O\#T9O<>  &4_F-MZD?RUZV      .J%ZYY_TE/8^ HBLS=9,
M>O?AU+\?U6T?-U?FMWY1\4NT+;]KCR\=BD;V/D[2'G_1=]7P;T@      #%P
M91P   ;0W1^@   %CZ7X)K)( W9&3U_@>C-[CP  RG\QMO4C^6O6P     *'
MRT\JGZR^?87RMAR.>+JW8E:#XNK\UN  'Y2NULRT_#V%R<>'U5_E[V6;&FE@
M     #$V99 4R83#.R "*1*DU  6A+O  L?2_!-9) &[(R>O\#T9O<>  &4_
MF-MZD?RUZV     !A5[CF?.%^B/(:+S2M_EC?I\W5^*W    ?-+N%CRM")+[
MW'C?;]KCRGL@     !U\3L'    CJ2*  (WDD  6/I?@FLD@#=D9/7^!Z,WN
M/  #*?S&V]2/Y:];      ZBOLGFW2=];XW2DX]?+9\UK^*@#\/T 'XIIW.,
MQ2> @[+L]\!N_0)\!]+      &%TS'G)@ $?Z7TXK9XO""\%;+AJ"-Y)  %C
MZ7X)K)( W9&3U_@>C-[CP  RG\QMO4C^6O6P     .AU] >0]6KT'3[B5@U;
M[    /Q3XNI\W5_#9XL]-P-EF1YJ;Z>?S-ZV      .L&=FHY(  P<62H^TN
M &5V[!.R[$(WDD  6/I?@FLD@#=D9/7^!Z,WN/  #*?S&V]2/Y:];      \
MXOZ6\3P)]=&W\B/J5L5  #\4^+J?-U?P"C;69:<A[*;6JN]:+Y2]HU
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M4?:7 #(#.@^6S]B>'Z=M0!ZI_P M>N9(^8VMCZ7X)K)( W9&3U_@>C-[CP
MRG\QMO4C^6O6P ! 'H-=%K:0[QQ,UJ9>+B[K9\\_LH!=!KK?R,5P,&2<^AV%
MCIT>+^TB\'?;SEE;E1LU+9K)8:F7;N1C_2-FRBS\Y_9<W96 N_UUSHV:F\EE
M;X;\A'.[.%NZ@6:F8:BQW6GF8+GQLTIM3,F?I9P  '7I.PL  #!Q9*C[2X 9
M 9T'RV?L3P_3MJ /5/\ EKUS)'S&UL?2_!-9) &[(R>O\#T9O<>  &4_F-MZ
MD?RUZV  *9RV47FLXR^W874MY(QWQ@R.)OMH3/CYS'=Q=].-NINZ+E1<M&9[
M/HXZZEY86?B;[:2S6:"E\(,B,VSB:RM%9L=U8N;7I6L,-]EIN"ML&3CKK><L
MOXN^VVLG%,W2S@  .ON=@@  &#BR5'VEP R SH/EL_8GA^G;4 >J?\M>N9(^
M8VMCZ7X)K)( W9&3U_@>C-[CP  RG\QMO4C^6O6P  !B[ZG4V2FQ[)SL%CIT
M;+[Q^[N%'RXK.KT][(.>SLS#,#43;,3<'%76V0G8+[0)'"Y+94ZJ9Q=U()[W
M72!U\FWTC'S]E:8R6W>AYXP[2'*'5S/PKC!?';91IQZ'89%.=V8   '6*.SJ
M  #!Q9*C[2X 9 9T'RV?L3P_3MJ /5/^6O7,D?,;6Q]+\$UDD ;LC)Z_P/1F
M]QX  93^8VWJ1_+7K8  '#WVQBVD60&ND<Q;=N:5Y2RO$WV_JO%W6\[9=M*T
MCIL8TB]=)H7/946.[F[+K+3,%Z8>?04Y&VO'74Y&VO'W4H;/CT*KAQ\G)6W6
MFEX* SXY,:V7JT       #!Q9*C[2X 9 9T'RV?L3P_3MJ /5/\ EKUS)'S&
MUL?2_!-9) &[(R>O\#T9O<>  &4_F-MZD?RUZV  !UL/2N6N/&RW@AYK"3X]
M_H$F4NJEPEW<"96GG0@W<"T$W!(O62HM;:)(C6R9,ZN7"C>:^ZD3-;*5CI#/
MBR[<ANX.[S7T-GQVYDXI#ZZ3++4380;R!04C%SN.Z8>FG1+VT.G,UE4X;\['
M"=!NJ5      &#BR5'VEP R SH/EL_8GA^G;4 >J?\M>N9(^8VMCZ7X)K)(
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MY,<   &V(8E''('$ESB8
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M^RM/A7I;7(=U3A XB4.BX: /*8..E0U6" +TIU4?3L+T ^C;:3V_96GPKTM
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ML,FLJ*;L3G_]!I =2/$"M%RN6OFZLO9]D%[WZF_D6$4VEYA.?FO_ %Q_%,W
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M8""0]ZJL&E:1B0=O_MZ<4&U@\'_-WW9GT[[.25_:AU'(*ST7D'8S(NCGM W
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M>>>S&Z!V_8L"@(&#H<D/X7V,?:ONO_IJV<DK^U#I;F7!IRTUN<L;XU;>^Z9
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M1W6S;=L;N^ZL 6MCUJ]2MTX'NZ@>#>7,SF!C?[>O=.IW.VW(-+"Q@EKNS5A
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MC&YONNM%UH*.3(+#*5/JB/+R$91&'V MM_":=13. I@D\)"DP3$ \3AKSN+
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M.\_<+]?T>^?<_P Z_ )56I:QB  .)), ?&<6DFJ$LT3U$@N%U,%.J&*"-49
MD"9(Q2AM.FLDKZB3)(]9.<X-BV,+#,F3.?'/CGSPZJY"MQ /'V^/Y-=;E6\0
M8/ZL$!R 3)SXQPQ8Z:A5D&(F,Y@'EG!@'C!QDQX1\7AA=;DP($DF!X#P&-AL
M[P%J6G4L'WDL8V M!@YG(91A4+DH. DP/8,4;NTDTV%E4DS)KTR.,B-0C]6
MH+O:V0&9)\!XGV8,.02(.?+P]GJQNZZK&8=(L\GBE?FXGD.,##!'(D08,2/
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MZSNE\QI8,@IFDLM2A "_]-3J8$Q/+%&Z1]L.]-LF +"M5ZBWD200*Q9T?=+
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M2*!.H',ASX>'P72IW#+NO^GFH0""'.YZA /+[/.1[..-Y&[LUVIL]7O>9JU
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M#!G,<1[1^5G=@% DDY #UX-I8=,"9Y1$S\F*[J7#5,)!\0>!Q?6U@#5@%ID
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M8J[K7N3L:T"+MJ48:DJ9D-]EA *LUBJ5&4+ T$$%FWE5>RLN[:]8T+J5 :P
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M\<N8_5CA@Z5 GCC<WUF7+P9Y%0%,?)\>"P42<65)&M0"1'^:8^6#@F%5!GR
M'KP)4<<4LZ@'7"Y?.;+EX^.!J4&,*2HD</5[,<,"5!C!RPQ"B3Q]?MP"X 0D
M+P\3 'RG%5; #6T 1Q(!/[!C5I&KQYXF,\65A070B<N$B1CH ^?5IX&-4%B
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M\PY;A\YRB^5SC_;Y"H1S:/R1K#3JN@R[HL>%,^3$I.$0D07(<S,[=<%  4A
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M,=114QM3M#^1YT0M[S#ZLS@[9<IAZQ<->@ GN3\)&,R7Y&1A8YQWN6@PJA7
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MR,3W#VE!$#JH?\\I>FL+'W*JOIA\:5(RB6=AB',F\/!*BC-D:L$7AW3@T.L
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MNYW3Z3=$M??OJB?+[G%W-B]D.U4EH^RO953W @S'VQ9XS:-O3W244*'BZC+
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M)U5"@D4Q,IIDAA4 &0Y'];/I_-(VWMM:I!D[/ENF&F'$>C'YX*R-E9R4 B^
MKY-7PJ^=Y9&Z2Q/,53H\"AQ:D9WF$?D+I&G6"8S^]X1*,S'C;=H\CBB>L0&P
MO'N;ZEDQ8B?;).81,Y5XY1VJZ*GYQW13O^,T6ZSO->2LQAM"K4O#YNNO4,O"
M=KSBNR%KSJN.XXI1KE6L\3%.84IT *U13=" =F_JYZ$IO#?.^+;'8LQX[U?"
M^)K72L^LS$FP9;;8Y2X;F>;A'@4&G3;BH+OXUFX*Z(_D6BB@NO =7]TKO'RI
M\,JSR-I48>FP\AQ^K&A0&'.*U#Q[)\X<6S,+>\5CHF&ME3L I+-"$=,Q<$66
M#S>QC$4XF6W;\0B^2%FX^\VK!>:WBFIZM0+SKM1X93T&BQ@,EMNRSY6M0OTI
M6;(V)(KMRJG0$ 2\OXJ?DH\_IF*S"EH<C=PYL7'1JO[POK>.5V7B4MHM-O!\
M0D+A$.G*-$@M#"(<&=,UBHE6=))%>]DO"9/1IG+\8AN&=8TWG+PXUW/>.E6T
M+/;'_JY5C$J[/P.F[O'>[7*N:GM4_+2+632A(T53N!:% Y!/V#KBA3)G#B6.
M&P&0Y*4O:J9GMUPNQS6Y6K4BM$H3F)#(\@AGZ+)VRZ,%%$)$D^=&Q5Y0@FC@
M22\!4JYQS=8:^Y92$'C^=T2?PS6M1K4'8[K$L%X!&;KTCK#-LWJR5PIT4FH>
M/DT ;MUGT:B9)5$3$5+%4*;I]J@LKJGUA'$O:\$X_:UN]3UO1,-PK+9N1DM4
M0E-,1D!A)6)76<-SQ$(V=.'+5ND<H%.J<QE>(.;/:-B>C;XP^LVUW5;MR=S3
M<*3J>H:GG"#^X3+XUXH=:>25TSN%SY--)G)$L960,7[(B+1,YE7AB\%Y^+Q>
MG5/5:C0/K$JGROLL1>JR:7L*&TUZ\1>!0LY)(RRB%RB2JRS0J*3?S$(@3F.H
M"9@.;KB5?;_A>?\ O/*?JR+/BMQL#B6I$G,1/)UO+'9T55)=L^<N'\I#5(WL
MK690\YLT;F,D"Y0 H#PRLNV<-Z?S J5"XETW!G&736M9Y'%XP:Q&:E+6JPZC
M&L+6]=4ZR-YR$?)*+/X<[B6251\DGQ2)^-+D!=,3I-*9)S'.VO7BRT.P8E5Z
M=>JELN<6EAD#V.@JK'MM4MRDY:'K1>7>7&1?.FTB?S$6S1),YAXXQ+W#<]K"
M,M]7AR$PCE0Z5L-7DV5FVBYO0D<W0NK9G)22US1BI9%JY1>-B.V[ 6J8$.0$
M$"]<*(3DQB%#XYX9AG&'FIA7+.?D=+RU*&5>ZO4:O6878E)2,FB-E5KJ^C@>
M>TJG%PP7:$,X.0 2$U^Y9;!)QEMGEJS1.&^'7:,]J6C;/QZXL(.ZJUOT"[>E
M!=Q':K=3NGZBH")%S,$U"B(&[C]8A*PV=PL_2N2&[?5PVJB%<7BMQI[)2,&;
M.6.RK/T%Y5F\@C0S=R)4TUA2</"&$6P*&  '7KEEV 4:KRL9]9IQ^VSCW+P5
MIK$,XIO&NL/(J0TI6IIEFDB5)H\>$54=112-W;\Z9/W%7R&_:&NV6<?JG429
M;];=O^R7'FZ&BPJ5Q;YQ2+O.M9S"&=&(=.Z!\L!D4P\HA5(55(X*JB50RQB\
M<VY.-E!OFS5/E$_V'EQQ^7T.O1Z?)S,H2\Z0ZSZER=X=/'%'E24Z"L3%]'PT
MBHG$"L9;S0!P)O,KNX8/F%0H?)2D\M^1FFX3QI#2H!2N83QJY/9NZSNQY G>
MO;6E366K<R5K8P9,%C1:2Y#@V#S3&#K */3J?:-<PBH<,:AQ[4:9A9<%K]PS
M79TKDO=])U&+_P!8"->1U:+HEG?*22]AK!DK&@L0$?2B4A3\EVS+C75-[LVC
M[OQWU'*>95NUZD1=VIF4YPC2XZ;RLM:FEVLXC-MTX-S[2" (13M%PLN4QUR-
M$1R?.<<3?IV"#Y58+HD[,PUEA:G8*I2J=/OG-EMU:EITX,RV*NMG)7+,A2+*
MBL0!(DJ)? . Z!C^0V#G=1:_JFNZ=RIQ3>-?A#WSD/H6A4=E4:'J4]9[\2+H
M%@=Y.9NL#.,=(MF[=!R<S9,53JFZX8%K&*P]TVW(S6T(].\7C(=0XHY!F^A[
MH_OCK&+C5-+ ^AJR^953R%(JSTP@N3KB5DB<46Z1^N>UY>\=*7 YOO-BB-#R
MC?:Q*TTCA*,?1U?3MF4.ZJW,G<H=>3MB;B8<*BD5@NX;BH8QCJ)",!LG'/C/
M(\;I9;<*BXW#D]!\CZH]QGD=QLARBVGX72^.()JS\OHDW#G!D0GL:12&3%11
MT83)N$-*X\DXGY_"T]U]:S0N02]^K]YH<3%ZCP\7M5Q=*U%%DR>1]L@RY;5I
M3R$XM?RE>\D<C$!,10X\DJ?D'&+.KA [.OQSCN(_* -,@*8?@'2\?1@T):JP
M-+>&3N</&QJD<NO'(U,IDWYG/_:/C>(@63DG-U*-U#)G/-*\7N(S22ME,0)"
MM[OD-0I-;YGP+%U+)1\G?LXG89P<8&4*9XFF<5(]%-<PK]1%SWJLZ!$W#/J9
ML56LNMP]QP-_EN_J:!>D; RE9A.LQ+7D'=YEZ93WHF[N*@K1#AL9N0W@5(F%
M_P"45MF-0H^0-<%Q2$H\_E>QNZ&I;K_1+O(SLM5+U6ZY()S%@JA62B9E4'R)
M6*Y3"4IC"8P%PNES>$5Q#)<.^M"V3EJYVQCK=)4;6K,]3&<=Q/NC._,1LK!S
M#)R()O4EO"L"WED115)YJJ? ^TUW/ZOD.W4]7ZPJ%Y+:Y7;G7G5ABXK:JW>8
M;CM)OW$9***W=C R$VR=(LV8*C%G(8XE(H)S#JO&%3ZOO*\XY-TICCLDUV4^
MG9K:E.5]ZHFCDG;=96UA24+9*W(66IJ2/A7L1V_A/,JLBE(B!O#RDM5"X_UC
M,*5JF<?5T.*]QJ6TJF1$);:YQX&9>;%Q9DYVINU(NOQ9DGR#1)X)$8AZ=L0"
MJ>68QDQ=/.-5/Q/#=!^LLXI[VIPO;Z13Y:OY#A664.R5+:+.Z=UM^G3U9;3G
MTLFNYA(-90YT \'81 "EYAYG;*G'9[G=YYD[M?<$JU8GH^0AX/#KJW@$:D2!
M8QCIR2HMB^R+BG&G\I5J(=Q(7Q>F#X"/N--:M&.5>UZ3'U'FG5]JI,,A'9[=
MI^UV:-M<_DT@S-=I/08>4FR 9JD!$UOB@*OA3%=7*HIQQMI6/6_#LCYDU/<>
M2<1L-<LTESUF=RHML@,^C'\>U6"T@T^44PUDWKFW%(,<HEV;^$Q"]9BPGN->
M<'2;_53:'D^CMEK15UDY;G Y7>J4*:ERHS2J4Q-PP/.[&=_=V4:($\I9/V=#
MPZMQD><5ZER)Y"P7U6W"[&I.:M^K5.&'CYJBE3<5EQK323G'2S2WJU*1CS+&
M=1BRLB4R"14/&BY7'KC[>9?-JE-,N/G(3A[-I\@ZS/XU67^@8[F6?5ZD:G/W
M24>QJG(.ZZ#(&C5R.8]U(LX,\:!2),W*PE/UJJ-+S.MQ')>Y<YI[8]!BVMHI
M3N<W#C/$:O,6ZM962<LBTUG*4<[]J:S",%-D+#KO6P^WI HH8H\1IT.+L_R*
MR6C:QRIN&B\,]VUK ZVA59_=8Z(CZ3?HA'/&C3$6-2J4@R=/48..17<097RG
ML:8J',5/*L-VNNQM4T.J3^IO)2 B)^/L\='L+)J-NLD"DUFXM=RT>)#!RC<0
M'QBH4!\*G8X& /NK6N&WRR"'TG&:9\L+;-SXM8FF]F#!_-6R(:3+IR7RW5&@
M&/MLJNZ(V9HHJ!Y:J@E4 EG9\>=QH&L/:8+4UFCZI+^T2,4V?G53822L>Y2:
MO%H9^=$P(/DB*,UA#L10W7)2#E>)TC9./?$_5\BRK8]MA-DK3:S1+S9(^"=5
MJ7A,BE*VVD[,B@ZFP160:R0J !0/X@#Q^#>;ER2G*9A$)EW+_;N,=,<KR4[,
MJ7B-R%"#?FM2D>WAE9-B[4BICVF03*B=K'I% RBH (CUEKG0N0^85Y+;8^.F
M,G UA1DUKY!RXM"QMA@&\,21<.:X[,^2 LB)2LNY^PJ@(#VTG&ZSL6>63>\[
MJMUG'64H3P>^%Y:E5A>SRU:]H22.R6GHN/*FM(1[=5608MC^:L@0@=^L[?RF
MHY+4=VG<B/KF@8]'W5!TXHL"S4=#-.EY"3*S3.U@F2)5WX&/YS!(WB<%3('B
MZUHO#;:L6VC3\[J\A*H5]Q:)%M"-WGE.20\G8!C(US8%*8[?MQ3&1CVSENH(
M>%-03"'7'W>+?'PD5:-9RRIWF>C:T1Z2 8RD]&I/';:')(NGS\L>DJ<02\Y9
M13P_MC"/P9NXU/-,_J]NLJCA:QVFNTVNPECL"SM<'3I6;G(V-;2<JHY<AYBA
MEU5!.?XP]Q]/PI.MVJ#A[+79IHJPF("P1C*9A99BL'99E)Q4B@Y8OVBH>@R:
MJ9R&^^'4?!P$7'0<)$LT(^*AXABVC8N,8-4RHM6,?'LDD6C)FV2*!4TDR%(0
MH    ?9=L*E6H"KL9"5D)U^RKL-'0C1[-RRWM,K,.V\8V;(N963<?NCAP<#+
M+'^,<PCZ?NB3N#.M5]I;9M@QBIFTMH:.0L<O&1AE#1L;)S:38DF_81YE3B@B
MJJ=-(3#X0#N/W?RUN<1H]!@,6YG<58C!]!*ZBK ?4Z':J2PE"4VP4_V,4JW-
MUV0DW2(S#9ZL@JX:>:DF8H^ XLN3G)2Y88M:Z-Q4J7$#/*CQTJ]HK=7E*-6K
M"TL2]YOZ]I.F[=6IXZCDDFK!LF+!@W,8J9OBE#KE)RRY T[.-@D=2U?,=*Q!
MI)HV)\OFJU%H[*NNU9R"?KH5"4EU)B/1<LU3-G@MP3\13D,/A"_UZG<A,W;4
M/5^7/,+>]#SU\\URJPEFJ_(J!KT7GHSTYG,I6[?,6/+'D4Y<+0_MS>!EC."E
M<&43*8@\;=/QS0N-MTN-'XDT3B-L4-LU;OLC74J[2KF\M*5SQ^8KP-9YE*/4
M'YT%V#XB#5<Z8*''N?LG>;#*6'.+[F3K6>0^VY=;)R_;XPTZC6[<ZC9(<C1S
MF\;/!B<JZC)2>\E],*MU',C%@8IT 5\'EX_D'(+9L-B<YX]<5^16!9G-X+2K
M7&7^PS_)&"<P$[8=)=65=I&RD54FKD3HH-?*]ZK>-1<B)G"O:F;_ ,E+EA#Q
M]CG$N(X<YG4N/M4L\!"VBD1\S'RKN\:<O;#^:>PNB1222,6Q(,:W\U0Y! 0
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M=!-3I80*4H"J<0 .PE IC"8 *(>@2]O4(?>Z#\@^GK\GJ^P8ABE,4Q3 8H@
ME$!#L("'J$.G=6E9-W)1SN#4KKE-TJJN9W%E(8C)%P90P@JHQ(;PIG-W,!
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MF(#Z?N20<1C(DE)(,7:T?'*.2,B/WR2"AVC([Q0BB;0CI<I2"J8I@3 WB$!
M.F]5Y-RN#YDZG9FL4BKE@].;.9!;4[,Q+-16:R43-&:O2VB:KBQ)%LBB!R%:
M@4PJ* X2'[JXG?3'=OF8T^#PS^DUY\SK/]QKPMG@X>QPSKP^U1,]&,I>,<^
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M$>6;JLU875DO+BQ4>A8_(GFZS$1@2JD-YCB#8L%EWKMB8C9+[C[B/8 ]8CZ
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MU3F,/X1,;N(^O]?K]7KZ#U_@_)]CT?9_5ZOA_J^_T?\ $/\ 6Z3[>C]T ?\
M?]7K]77)'CU(R9U5ZM9JCL=8C5?4C&7:+7IUK!H/WD$)FD,EU"AW[*R F'MX
M_3]ND]*SSB'3+E0]$W+(IJQ2T[7.1FTSVCZ$0<_?N;DI&P6W5_)LNK=<CTY!
M)J[FX)U#1<K74EW(@5XV3+]HSO\ ]0W';_SBI_PJ;_Z;]+_\SLF^#=OWK&_P
MU'?!2_&;\PW7$/Z6;=\QV/P>&?TFO/F=9_MW%S(T#]D8ZM:EI\F0%/6ZDWU5
MI==4.EXNP"1JWF (80]1C@ ^OI41]/8X_P!?[_?U]!UZ.O3]G];K]CKT?D$/
M7_P_"[?[_1NX_J[ '1!_]H!^]]XW;\G49316*2/UO'M,IKA,PE[*R$"E!:-%
M"41#]LFA3WP!V$!^.(??^WDKCS4.1] LUEU"5S^C0D=Q[XJDQGWBU?$\$4O&
M7#5Y;9[N2(@U$Y"1%E,1\H9B<7)&C4IB)A%$L*T:YGR1S(LVXAVSEG$.)8K9
M,)%:+:/7+UXUCU78',BFJLLHFF(%,<X@)A^#(UJ>DY!O*1BQD'2:; %" H7T
M#X#>>4PE[AZ!$ [^L/1V'K_XU)_^&A_WGJGQ\#*/%G,/K^/6]\"[0C<I(2G:
M-7;'.+$,=SV461BHY4R:8>E0X 4/7WZ_^-2?_AH?]YZ_^-2?_AH?]YZ>2E2<
MN'3-BN1LN=PW! 044!02@4 44 ?[D;UB A^#L(?9IO\ Z;]+_P#,[)O@W;]Z
MQO\ #4=\%+\9OS#=<0_I9MWS'8_!X9_2:\^9UG^W*5T1-[/0\"RJ"2 1#P@X
MFIS1K8[\(>ON9*8;]_Q!TJ(>GXX]?L?\/P?R_A_Y?A>C[(_B$.B&'U@(?U^N
M'4H@X% '&TP]97$![ HWO4#8J*HW-V$/0L:RE+^/M]OE3R==Y.GL3*P0C4(>
ML\)L@M$M<6U<W)WM<1;8;DI!V8U39WNP2RI&CVXR;Z+F C_*(]1261*)8I]*
MQ2L%)O(YDZD819VT?K0[YPV35=Q:KY@HJQ>*L%SF2,JB<R2@D\1!$H@/PKS_
M (S-^:'P;1_CQO\ X)U]FF_^F_2__,[)O@W;]ZQO\-1WP4OQF_,-UQ#^EFW?
M,=C\'AG])KSYG6?[=R7D&!RG8UFPUG-&YRJ"H4ZV<T:NU^;[>@ (*-K"11,7
MT@!TQ_7Z4-^$P]_R]?L!]I]'P1_5][H!_!_9ZPO57!?&TS78<OOD@0#"03Q=
M3O$%-S $,'J/[I9K]OU^W22Z"A%D5DR*HJIF Z:J2A0.FHF<HB4Y#D$! 0]
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M:&_(/0_%-^0>O"!3=_Q#]_KQ%14$/5Z"B ?K!W'UCZ>A\:9P[?>$H@(#Z?6
M]>@IOR?K]$]!P^.7[P_A_8ZVK#W[DAWV3:DPN4,W.L K)U77(/SQ(F@/8Q$"
M76GS2HB'</&Y_"/;[<YL:%HC-%JJ]ORVJT:,L^G\_,EELNFZ]()P-YBX#/\
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MWH_6_I,?>ZL5P@^#_)5*,F7AG#4DA8>*C-V"?[4!6;*<EO,1,8 [^$?2'?\
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MRU#E[&'X9K+<L^K%IRYQSWC]]?,IR3@Y!B]S^*X1+Y PF7U?<J*"_6;:F5%
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A,J":WD1[A6,NDQ93I@JX4!!NZCUA-\8Z!@*7_=S_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>chart05.jpg
<TEXT>
begin 644 chart05.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[@ A061O8F4 9$     ! P 0 P(#!@
M             /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$!
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\( $0@!DP*@ P$1  (1 0,1 ?_$ 44  0 !! ,! 0$
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M4RB5(7/2FZD8<$7%%3IH5&6/?E5:G'[    ,I+;*[#;'9
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MZ!+C!G)N7L#?!W?[$TJ>$'9&E:E:7L0C*]E/:E:'?E3CCZOP926V5V&V.R
M                0=7QNK_(:P/&SWG6M,F^8ST$<^V6V*TEHU:=_4*MYT)[
MBISVQ5I_*,#7]M/^/N?/QT'6[;JR_P!%/PODJ-KN+ZU*3K4:<9ZG@,@>E[I$
MEYPK0%PGXKA".3M[V2[8[!FYFO0%K4\+'-OK&,=AQ_&2SXV,Y-R]@;X.[_8G
M G9+2"LE2D&UFJ<DUIUY)&M*E@W,DN653-_7KK*2VRNPVQV0
M     "#J^-U?Y#6!XV>\ZUIDWS&9H86_O"E4N6E'M0C;E26\*-6-[FWE6UKQ
MW<4J5-# [/X[@B_H)_/.ADYT;=:U?W0 Q#TWS/H?X9\<P/M/^'W"?G5>94ZD
M;;@41FMN/K/>-W3ZX_18]Q+8ES)49(]69VI5W4)KTH3?)E);978;8[(
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M7=<RDB8>]@ZOC=5V9U6D7E(  #JT:?;KU?R$   *_CZW9I3#XEAUZ4F.^O\
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MVS                     PUVO@@  NBWRF46N=G $$V.[8>]_X9LXX=OH
M  $'5\;J_P AK    @GG>H35ONU=RO5   &Q.QV')ZVS       \]^\9C'2]
MK  5J6'I_P">8+Z         !Y'_ $A\7IWQ'1*]1R-2DNNO&G"N5T*8+':-
MP'G'[70W:;1S MZCEJWZ8\8;+^';\   !!U?&ZO\AK    A#GNI2_O&SU"ZK
M   #8G8[#D];9@      >0'IVQ89Y*O.5G2ZT8UV27'F^K71+#W-<DU;L21
M        &H/IOA_FA4[DM?\ $/U'H3VTE66R;+^?^N@!"%EN>LWU/YXW,^:.
MI=B28   0=7QNK_(:P   ( YKIDD;5G;WV#+   #8G8[#D];9@     42\H6
M]?VWD]W/<L,\E7R(L:-?DA2YHXV7]:Z)8>X#F&GVAEK*4=:RH          &
MJ_O?/,7-VP/X56A/P3P_#I59.S)-U9X=J2/5GE_4>65]PCP30%6DFWM^4>OP
MA7QOGI] <IUN^F>?"\\;<VU>T..+FEC6K:K2+BE4Z%2E7%/K3RU*C4JE"?H5
M9:!=T1N!\:]6W%<RWO)ZVS     %NY"VM3)VDFZYE//SNV8QWO*H %9A#TY\
M^P=/N*4;[%BY4U?,<TL0         -!?K'C^ _3M3^8LXN9;5)>$OX(VG$6M
M?V]5MZM*N*7=I34.ZI7587'TCR2Q@C:<1962M;CI3^L?P-Z(A"MCO,WZJXQI
MR]H<F&0>HYG*_1-@BG.X^DUZ?>ISTFXI]NG-1;FE?>*N^&:''-#&K<\'&F:L
M1Z#OG7W7=MQOHN3UMF    !;&2M*!?4)&U_)     =>>6*]GQ$F:YE:A0J
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MFN8S1B]\X(TY$LMFQ=V#D=PR5O0%Y=^]<0V>U 6'2S&U39O-=F9>QZ=:2_\
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M@  !O'\(=FV*Z[LO%MU'JU9*E;U.A6DH5W0N>QN+3OZ&S3BN\C&"9D_*
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M)N*="NJ-D9.UF/7<G;EY0LO)6UA96S ]%_S:[[N9Y7OV35OEP!:]_;W187
M\LES+Z;;>:[H         !QGCHZEL= C$ #(VSI>JWG&    PNZAJD,['BP
M     .[)-L2X;T;'F:&E_J_+,8.NZ>       ,\^ ;MM,U/;<GK;,   #\/&
M;=R^GJWFRYD         #C/#!U[:+8FCE=CJ'&A2IIL:K^ME18T?9%RW7
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M68CGO[$A&[KW9.&%&5,MT/N3W0&Q.QV')ZVS    \CMU+BI,_3UKVTV6L@
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MF&S\,O:OB(AM-AJ$9>&,E1C+#-ELTFW6 CRVS=7GH:]]<[-_:(]H?F7
M     &JW4/&?C<XY\2<D+SK54FOLL\KV;'#'\KX5*\:FP56>]P-POFZDPQX%
MP396WY<4$8 >K;J_U\W?[W]!@  *3%XDKN7J@[9-$JSHK4B[)43J0?97"Q8I
M5@H!\EI1;5J<?1+;Q \N/+/>O@%X%]<_R,OH^Z7XARYRW/<+,)U"6KS7*/2O
MJ!+7[R&$N$Z?J%T[TD/[1'M#\RX          U6ZAXS\BW(/CAMUVCV[VXW%
MVW&4@#'<YNNOEX>LM(G"\Z)5:EQ5ZE_$=CIERU\E59KVGTZ.'F+X3A-BO/0'
MJVZO]?-W^]_08  "DQ>)*[EZH)<@F&"W(+Y*9%$454);ECQH1Q%<)7X1MV,+
M$,_I8^B6WB!A'@NJZKM4] C[2]N:ET9:X   ]%O2/%(          U6ZAXS\
M;G'/B3E+D>QY'9#JD06NC<$LM2FNH<L]&EZ\W:VJ&-K]6_K4]_6YLG]S2Q;;
M:AW5S<E3*4:&.Y4^][H'OW>!OGT%   ZAI+K0XP  ?)]    &6,K8E3B
M              -5NH>,_&YQSXDRQ7WB;[SH-)ELKCJY;A4;9HXJ1;C9X-L=
M R.R'4K2DP7?C<VU3Q7!+(37/5RD7VNI2O>;?O*WWWCN^WSZ"
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M;9ANMYID;&\*V<H-+'==1I\MM>U;8+=DQ,E5MPK]:^A2ST"[JV;I4EEA-A^
M(RCU;=7^OF[_ 'OZ#                               #5;J'C/QN<<^
M)(        ]6W5_KYN_WOZ#                    #_]H " $"  $% /9B
M_:^S4AB5T]0/.?<3W1I#KKJZD:54R9RFFD,2N4P1I2K '#I[N9ZRDF<J#I+F
M:IR!&JE.4Y3YDUV?\*7[70UV25<"7Y6I\>5J?'E:GQY6I\>5J?'E:GQY6I\>
M5R?'E:GQY6I\>5J?'E:GQ*UJ?.==/1KY+>4T1/3D]?2 ZDU<#! 2CR454-H$
MD:CQ]-$64 ^AHA8!<2"Z:.OH1J=3G3>_'E4D$2,+J>8.%7(BUBF:Z1#7,FNS
M_A2_:Z+<?;>E-//(ZA+KM6ZRSR=J@!0\%%PI]+E6#H2_2[E)1(,U:,+*?HI^
M(7MN2>4"286VU:D;:M2-M6I&VK4C;5J1MJU(VU:D;:M2-M6I&VK4C;5J00<J
M"J&8ET=:BGA4R$0IA3D@3K%DA3J*U(5<JA&_,*O0:[/^%+]KHMQ]MZ2;3=)9
M,FU0@S]# .T(3E13"TGN$BL'ZZF^>3D1NHG@9'13\2FX4%,.R=;6JG)R-RJ5
M*ZAU0X+AMQMF4]1(*I5__:^F54IQU!CHUABAS$#%"@0(8*=88@56A@?=$!B5
M!"4K*C14,LBBTGE91$-R/F9!35U"<25#E(LOZE!KL_X4OVNBW'VW#C=2DE+%
M3H. K=:VO$T=1<*ZC4S>1P2I-=RH:52CQ.=>8=JE0A&77,NLS<#B&(A2%I#I
M^)R6^:KG59V98,XJLJPISG9!C3AP60HF=9ENT=F0_P#[7T3_ +D?&$'F**-X
M&H"4BCB4"TJX )XG!XKW6K0P/NB"X1&A,!#($C\@DVL.5:8#11X308ZL@;*5
MS1@1U>E-!+0:[/\ A2_:Z+<?;<'4!.4!0FX4". M1+"+2:J7W>;:1YF 6HDE
MS!=M)96D%FH(=)1L)92@%N)H!**?BN&YG6T%Y+5""TG\A_4UUMCJ#,=09CJ#
M,=W,QW<S'=S,=V,ZN[FH[N9CJ#,=09A@@CTN:-4 $S!@.:0I2G4EJ% <TE1D
M+6EJ%,C!4P4KT&NS_A2_:Z+<?;?(>E!NLF4-D$^H2OIN5/*R+/+D4_$?*ECU
M$Y*=F7 4-E3Y73*<Y3Z54=.J4=9..LCISCIU1TYQUDXZ<XZ<XZ543JJGI*J%
M10*I:#%''6RY8_6I!=TI<4J!SIJ9L;0:[/\ A2_:Z&R]PV^F^:0$>:0$>:0$
M>:0$>:8,>:@,H\TP8\TP8\T@(\T@(\T@(\T@(E=,"4ZZNG6IIA!93TQ04[0+
MP8@8P?(:LR\E:D(H)-/-T# IH2(8$)A$.[?_ ,,S.8Q.1LA)%'&/&B5;;YPU
MV?LR.T@%)!":S@&F?8+H(G]EG#T)LEV4R*ME8&!5F<JDEA%;IA;+[%#@EZ&F
MX.YNIH*+:.<@OVO+.G2J<4N^[$!<1;.KZ,GMD,0,8/EKR$FN5+;"ZI6T6M"V
MK@H:=YF),>9B3.)W*2)QYEI,>9:1'F6D:_,M(CS+2(\RTB/,Q)U^9B3"(]2"
MZHZ9HYV0E4NC.<IRT?W+2:[/V9!=Q5,;P[R*"MA;?!11!'N70.9)/^@J(-<&
MD=*D[09([=<@C>+4W KK!4%Y-D@+[T#6BW(+]KRQ@03 +G0A6TOV_:DW<Y)4
MTTT\PZVLFN])0'BL,FBV"ZJN-I/_ .U]- =8E- -8@09&=809:5= 98.H/2P
M/NC03'I*FP!$\LIT+"?2'4KDIS\<!ZM0%#'/:#79^QTRUS<S'02Q0*W(PRPU
M6,!,^"R10X/,0N5==;%'I2SS"I&44MM5CNY#:;85D>3012K6<"84*%5AJ!UK
MQ^W:@2H+VO5#)FIC!*8 X?4CP7[7F+Y-WKB5LFILLV^:N*UTQR-RRE4JV&__
M +7TE1"X81$4((P >#F;F*&, *H !T^[2P/NB"A#OI6:61$!H32QFHX6"F>K
M2!*Z"B0:.%J4([56=2!R 4&NS]C 3U Q0=<SX/4E7$]2I@HYWP3H4%%0#;U3
MG?58_B;OG087'H:F4..0LY ' ZTX(LMO0K):FJ*=%;B>E=%*R[ 5<JKNXL&4
M6G:4J-$5TX9@OVI8D=.U> K\> K\> K\> K\> K\> K\> K\&&RKF@9H2_.?
M@*_'@*_'@*_'@*_'@*_'@*_'@*_ X Y871532)27*E2@;P3SJH@;$NN-B77&
MQ+KC8EUQL2ZXV)=<;$NN-B77&Q+KC8EUQL2ZX9[87DM>@L>,E :E$6H'QDU*
MHJ/63,343$Z0CU<RHRX8F<J/BU%8-=G[':"JJ3)Z=<=.N.G7'3KCIUQTZXZ=
M<=.N.G7'3KCIUQTZXZ=<=.N.G7!BNON\_>7[7%VJJES=:)'6B1UHD=:)'6B1
MUHD=:)'6B1UHD=:)'6B1UHD=:)'6B1UHD=:)%\9SG=7VLUV?L=H/LJ%=24PE
MBES2(D9N*<ZRSDZ^2:KT*I)%7C9U)&<9DW!5?$K5A7@$$7H<%<QC"G4,DUK2
MOTBRN=,)TY:IF/EY^\OVN+_W-"B:6"*V(]J"]-+O!ZEOO8BXE(NX%0\]1GO,
MZ9F]S))(./>I-E7< OU22L5'ZYNQ?K.&UI4+HP:VO*+1)*1NI5B^'Y4-?'_'
M6@^RHI+@T&A6XCBQ)'(=Y%0TH8$JGE28=: E"4T("2'3-!2M=2*GS"I2R-!@
M9+ J3NX%)E1T8J*+!CY>?O+]KB_]S092$XV)4VDNHQL2V90GHQ!+%';Z09%*
MLUNDJJ&FW@Z06J@@%!FNCF00"14L9+M%)I3Q&@BBBS1$SI I(8*G%\/RH:^/
M^.8-QF^VFYYRM&/.5HQYRM&/.5HQYRM&/.5HQYRM&"=QTE03/.5HQYRM&/.5
MHQYRM&/.5HQYRM&/.5HP+>-I5A3]Y?M;,/\ 0K>K&\I;R-Y2WD;REO(WE+>1
MO*6\C>4MY&\I;R%+*>UJ.2IR6MW53O*6\C>4MY&\I;R-Y2WD;REO(WE+>1O*
M6\BY#C3W<]C7Q_Q6Q:_&Q:_&Q:_&Q:_&Q:_&Q:_!IJ+),OR"IZ@T8M_/7:;F
M2_:\Q=B6NWY2>LIS!KX^>3D1.,$=G4F-G4F-G4F-G4F-G4F*F\E2I]F430P!
M@=3JF,74A^J!53/4%!Q# ;A^AG#:F"-X@NSCOZ]'?UZ$"L40W;K_ +6OYDOV
MO,75E.=OB.ON',&OCYY'^EP:-R*P(.+,:DR+69BKX*:*Z_9?,$")O\O.)/LG
M*=+[)TQMV3URN 7E)2>P1\AR"Q$,J/:FX;8;]N1*ZA!.8+]KS%UD)16VHU4H
MRBM_F#7Q\X1(F% =3FG%PD?Z7 I*D<8,L; G26%I-15\">H#II@RFEU$'V>W
MMOFTXVUY0LJ/*%E1.U; E(*U##' !M.Q# /E"RHG:5C4B>4+*BJTK&HK\H65
M'E"RHE:-D3JIM*QJJO*)DSCRA94"VC9= ,_>7[6Q3+;;W7/(.U4>0=JH.V:L
MVGFYV*M%*J5B+25546,M")4+9:SH8TK&V@Z!FREH"E=-C+0U2E8BTLXE8^T,
MYAV8LV(?(V2L\I%?(.U4>0=JHNDA);9?QKX^;3DTPICGU$N5 A/74\L1VC2X
MVC2XVC2XVC2XVC2XJ<:9.F"IL<D/67*KX5=%8=?LMH/LJ)>^356J3$JG$45F
MTB.!(3YI:Z% J8O"0"07)4"%'".(DIJO*KN#NK &"52(2>EJHY=&+B%$F#'R
M\_>7[7%_[FT.A 4E@T+:'O)EEV\J:9XO;\F6IV %%!362(G"!,E2IAN,FA%/
MSMMK#&9HB> ALFN1%O),T-(T7P_*AKX^:3DT90$4%,$,#FPQ! 1*!2C@",EA
MB@WLEH/LK3KT"KHP)V3A'$J <A@6FAU=. '0;,@@"TF .08^7G[R_:XO_<W)
M7Z%D-?([94T%*GT"3/*SI*$N_P!P1X2)*- ?)OA^5#7Q\REI0BA6I*@8@?.^
MZ"Z@64P#Z<93AN3U(L=2+'4BQU(L=2+'4BQ,(64N6R+FIK60//!%CSP18\\$
M6//!%CSP18G>MOU3\ZT"/-I,&("W<;HQZB]#=#E*]Z)*7G@BQYX(L>>"+'G@
MBP+>U%K"@OVMM+C#6V4MZ10C>D4(WI%"-Z10C>D4(WI%"-Z10@QE<,4H-Y*3
M/RWI%"-Z10C>D4(WI%"-Z10C>D4(WI%"'JYQ'FZ#7Q\PF)<SDEA< JHY"$A(
MYE'V;0HV;0HV;0HV;0HV;0HK;B%(/D!C@BUD%4.8"FE")]7(IG/HZYQKG&N<
M:YQKG"G.?AO/I-4YX]\R7[7F+LRELZ)\?,&OCY:6E4CAJ:I4>FY*JJ _&%"/
M&%"/&%""JF='';?T&!#XE"D ,=.B%E,04&7]R%[(ZH&RHWC"A'C"A'C"A""+
M6,>A-5:R<E)*H##TT_#"D/.BF<Z30A.JJNB%/Z;SZ+_=@.9+]KS%VOM>OXN8
M-?'"JR3:2.(S'"7%FSW'2=":R\+6>05=,+E&]2$34U050KA5)#G.2V_H,5HA
M02@,F. +2F#2+2_J0O9<@B3&+GM"<I&$T8VG%CP6BGX8E13(2D &FJ@.@.4*
M?TWGVLX6&!87F2_:\Q>0@O&D9, .E4[F#%-50M=%8<S3\43HA=[*@8B2_P ^
MDS)O\^1#/KRFIHAM36C('+2GF13TW;Y.C;Y.C;Y.C;Y.C;Y.BM^IU5',%#A@
MB/65++U%5-5%4G.H2EM0HQM0HP:%=1)#VH48VH48'<1XP#R[8M5MJS3V#9<;
M!LN-@V7&P;+C8-EQL&RXV#9<;!LR-@V7&P;+C8-EQL&RXV#9<;!LN-@V7 S$
M9E($_>7[7'UL-YT+_E);&/*2V,>4EL8\I+8QY26QCRDMC'E);&/*2V,X\I+8
MQY26QCRDMC'E);&/*2V,>4EL8\I+8QY26QBY:<02+@-VJFE>"5&O6&'0R0B4
MEA#\** L, 4XJ- Z71UE+!8BRK)JNKZ)2UT^R!"B "$P0'3"D2K3CVAT?@KF
MK0?96F:\>I<%;I*A)IYPB!F3SH*EQIKO5& W(7$K$6:*D.2XHAN!-7U-42:*
MZ10]!CY>?O+]KB_]S:7PY51!,@NP,6D^_P  = 5GK0701WN0" '>)8(9$70E
ML59>JV 7).Q15'&AGQU GINH#,S=<>QRA57Y%J$>1:A'D6H1Y%J$&L=I4,T2
MCJQ--$O^GLH(XY>HR:,&Z]#PN^47+1<U:#[*TU(1.LZ8;"68+^"%03)-KD9)
M8*,4!,%6^G$ZQ$@O-)DB%Q#8C=+4%::::*=!CY>?O+]KB_\ <VE7;Q99,5L]
M$F4K8"'44I:8)Q2K9"#6$=:B0?-$DLH0.4LT&H*EGH0<(R=6F$]-W?R>8III
MKY RHI#D.0'+53/^I^RTIQ"=/AQ"/#B$>'$(\.(1X<0A0($J"'+:MSSK51_/
M%3CSQ4X\\5.//%3CSQ4X\\5.//%3CSQ4X\\5.//%3CSQ4X\\5.//%3CSQ4X\
M\5.!+WJ8@8@E = )DN&';:Y!NWIW>A<4;T+BC>A<4;T+BC>A<4;T+BC>A<4;
MT+BC>A<4;T+BC>A<4;T+BC>A<4;T+BC>A<4;T+BAT+XSI<1KX^9IEJD)+57[
M+3\,&CE0!B4S4C10P*-7"G]-Y\1F="W=:R<HK\:.QXT=CQH['C1V/&CL>-'8
M\:.PH*QL8C/5LH1/..DCX@YX\0<\>(.>/$'/'B#GCQ!SQX@YX(FET<SS)KX^
M8E_<X%E_V]EI^&*B1>N=!>FBH$M0#5"G]-Y8E4Z:.]"1WD2)C#2GW@6<3,BR
MGWH2 !*A)#_KP"%UU?<)QW"<=PG'<)QW"<=PG X'43/@UF"0:>.*B*BL&U&]
MYR(L2O&C53JN^E45><*1$[QHTI^<B+#6<Y5UDKI"C ,,M/I%::)52ZN43IHI
MCH4QT:(ZN4=7*)RU3-?'S <M=<"R_K2C-)'/)>Q"%&Q"%&Q"%&Q"%&Q"%%;)
M0Z0^;DZPJ92=84XVK#C:L.-JPXVK#@TY0S!;EC=E$O?.<NG5/7.OXH*^X?\
M7@EV\"=G[J)3HZ(=,Z:(/_$G@ &3KI*$29VY_P!F0W/KVND4U4.?*.-2_I0B
MSOV_=66NWY">L@'\,#?U/5/554'5IK^(U\?,!2_[0)+71I;?T&#BA03&,J8A
M<>:I72=@7LCJRGD!MID>-ID>-ID>-ID>-ID>-ID>-ID>-ID>-ID>-ID>%%P)
M9@@D_3(= 05-C>:&[*FGI3G15'0JB0=4="J)TSE!7W#_ *\$NWJJE3$IRG*5
M-$I52HB4I2E!_P")J%Z!5>LQ6;/W/^S"*<,?G65.%1!O$ZA B:H+.98U.8@
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M-6@+M9>Y5^3N)].TH"644 JT>NB9=NB!J1)"J$4 T$Q4(&B"UT'T^LA020B
M@HZ.5*)J@7#+#Z6Y7U;:3GP7 "V_+QM^7C;\O&WY> ;ESJ6Z:NE3IG[_ &6L
M,,200(0%.A$98R>\^:>GUS3(^-2 &K&PA._BUA#JQB9L0\,($*HFAI4'1)'.
M_B4@TJ0M0LYSJGH"[67N5?D[B?3M))2%)!TK1^0TG$H2&FL5@%:5Y0IK 5SI
M8(<V,8!FN"2KFLGZX/&:30^EL?;R/.<P.104*AF.1/V>0 .KJ 8Z@&.H!CJ
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MGL<@IO\ ]<LR4A47+),9NW/9%8RP[0"Q:E_)C:= KV(.@L>?)(VYVU<-Q,_
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M4M4M' D_6S_@'&4_1WV+@2?K9_%?_]H " $" @8_ /R8=P_D[LD;%5%6(!(
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M2K&O25B[-*!KHE%0",YYACIKCB=EP_B;F!N)1RQJ"X @*DNM#0!59M)78:5
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M^+_J^+VL7T=M)*Y3B<+2B1@= #*%:$"M(RW1>M",JBAKBZ*PW,=RPN=P9WU
MS$G08J@!:C5H'(2O+3'#;M8+N2\,LBF&6M3\GTWBS+@T) ?:&%<\6HUS:7BU
M!9C66,:B-#FIYJJ<M0-2 >S!_=YO>7L-(WHYU6S$EB#+OBX1545U((U(>H'2
MVU.P&>(VID-S(8QJ1E5(X6W=23I7>N5(J=HSH<L0K-Z*L$FXHX($AE9U,Y:A
MJD:#6I5@% TE:DUQ*)+.W=MU<2,*U.HR%8(E(.6F@8Z<RI(K3$!>"V.\FB#[
M-"HL(:8J*T76S:0>1EZ.>/DTMXKMK<T&H*%U3@ DL<Y(X@2:])@U:'!C2"W>
M$O.2QS^3CC"(%SR:212ZGQLQ3;BW@L8T8'25D!740$&H-1F<EF->F$TTTJNW
ML+\;]!_T,.X>R?[U+_L]B^FND9GN(%B;.@"HVI&7+HNK9AOS8N+STRZ8S4WJ
M&3Y.6B;OY1 H#57;SG/$]BTES)P]TTB)Y6:-!4,-V-JE2!I:I*\F+V":6XED
MN%5'DDE+2:$8,J*Q'14$5H!GRUQ/<*K":2[CN&HP^<BJ5%*9+4DLO*36HQZ2
M9YV"R2.J-+6.-Y:ZF5* !LS2M:86,([Q^A^C:7((,.HMF*#.I/2[PJ,6L<MJ
M9X8(FC192'50SER0*#I$GQN;+!B59)(C:FV*NVH&(N7T[!F": \@ YL<*L(]
MYZ/93B6.K9Z@6/2-,QTCE0<F?8&+#C<,"S]3=3)-&J](.S&I=CF&Y86%$K56
M%37%KQ3AEP);&9:JP_.K#X+*<F4Y@^QO%CC9FWL62@L?''( 3C['/]')YN/L
M<_T<GFX^QS_1R>;C['/]')YN/L<_T<GFX']DG^CD\W%#:7!';CD/OKBIM;@G
MGT2D^X:5'N8)]$G)/*8Y"3W25J<?8Y_HY/-Q]CG^CD\W$#/;RJGH\V;(RC8O
M*0!V9I8(2T<=-1R %:TK4C,T-!M)R&> #9L"5)S*@  @'42:*02 58AJD"E3
MB.9K-]VY4+L).OQ* $MTO@FE#L&>#!Z(V\":]JD::Z2VH'30-D<\CMIAR]FP
MTR:*&E2]0***U;,C-01F,\+'<1%6(J,P01F*@@D',$9'(@@Y]E?C?H/^AAW#
MV3_>I?\ 9]CP=;"@O/WC#H)!*AJ-I+4^"#2O)CJ?<SB2$P3W0NBZLSB=HP'9
M]();4Q!4@4TT V'%[?7:L_5H\0A9J!OG# NXD<4JT2FM13)J%N;''&0R%9+.
M)R68L-32-4*3D ,J*,@/8C%_97L"RVDI=71A4,I)J#^@[0<QGBHWEQU!OI.Z
MT3>\)4'<$T8_I#*WO;*=9;.5 R.IJ&4["/TC:#4',>PJ#GCQCCQL>/\ GQX_
MY\>-BFK/%-6>/'_/CQL>-CQCBA.79BC2($K=),:G)MV.BI',"2:]O9B=G@D:
M&1&7=LZ;OIDEBZK&H(#48$ /502U<2O8P%H]:AF+UUI$AC01T4:%SU@G4=5.
M04+V$%L4M="H*M5M D,DFHT )D:E:    4.!<^AEI?2#(-3 A 05(CZ%5)4@
M-4LI*@Z<;P%MVJA5#%>B!R#2JJ!6IHJ@9]E?C?H/^AAW#V3P]^&-,=ZSZ@X7
MQJ94TG93;7'J-_I1YF/4;_2CS,>HW^E'F8]1O]*/,QZC?Z4>9C/@KC_S5\S%
M?W(_TH\S'J-_I1YF/4;_ $H\S'J-_I1YF/4;_2CS,>HW^E'F8!_<;_2CS,2/
M3QF)[YKBZX7Q.W$MC,M&4_F(.T,IS5AF#@<!XU(\W4J[<M#-2N[)VM3D9?\
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M3("%>$G7IHH)1Q2@)J,ZD[!PN]]!E62.XMY)HP8A%)Z.*+I81;VIVC6[!*D
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M_I1MTHV]U2/=!Q:V,J5X;#\K.?\ PU/B5YY&H@[6H\F%5%"H   ,@ ,@ .0
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MXQ8"5)&1=U:O+.Q2I^&X@ B@C8TFG-6-,C_$2Z2>MQPV658&**2 EK#(NH
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MS'S-Y]&GUF/F;SZ-/K,?,WGT:?68XKQFRX3Q"7A=CHW\HCCTQ;PZ4U5E!Z3
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M[^3_ #X8:WS!^#VN[V$N+:0K*/SCE!&P@\H.1Q)<686+BJBK1[ XY64\X_\
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M7#RP/%'9K*4 92S/H;2QKJ 6I!"Y$Y5/-B]GEO8@(Q)T%C)9 C%03TJ-D*D
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M!K#R6\_'X&L/);S\=;N%\+M$@X=!>%8XTJ%1=*'2M232I/+BVZ2K<&&81$D
M"8Q2"',Y [PKI/(U#CAZ<1CMII62TAE,BN7CB2S*RZ"*:66:@U %@P%.C6O!
MHQ=6,O$U1PKNK+&6:",QFZ14V+-O%Z9D.JA>D9ICAXOX^'RM:Q3(8HT*-(_I
MT4A%0!JC>W+[LL: @Y @8XI;-?6LMG# 8E9E8-,QBED$Z,4+!A,T<6A=!"H"
MS:20>(W]U;V,W$&M80$4[CY,6BI1 (FI<)< E])5BH0:BA.)+"?B4<=QHN5*
M[Q]YJ=H7C @TF)U<I1I6(:-:E2"%!O;_ (;Q!!P-8+U9K?,!24;Y=20-Z+J8
MQ,K-\JLM(R-"1GLL>:GY*DT+E95-01D0<&.0;KB: $N%JKKD#4#8>;FV#HT5
M;FS>O0;(\XVJ?=%.S_"[_$>(_KCVN#^]2_[/L'L#*GH@O%ATF)@ A@$FKTBN
MC>ZSI6(BK T'/BVXM-8SI92BH+&)6T9=/29 S5KDB@N0"=-*5M!:6<SV?I4D
M;N A63=12LZ1U;4&#H K%0K$,H..'-%(?0V=-9TUU[V!Y8HH^4RDA.B!M95Y
M322V-G<2W;3:%B"Q@HP@69E+:PIHIS8G)ZJ*BA*O;QSS"8VZQQA44AIHY'45
M+#;H.O4:(1E45.)>,VT3$Z#I1LB)->[T-0G9)DU"10$@[,?NR:XC:%;J.!AN
M65:- LC.)ZZ YD-$A-2P(&W/%UQ6$1!;:(ZU*FLDJ=-P!6L<8C&E":EV.L=!
M>E'*GB.H8=PBH_,>S<_LW_5.#@=PXZV?X='_ %X]AP^'ATX0/9W<Q_LKW1=X
M-UNXR(V!BC;6=Y*<D%#48XCHX;+)Z)% TLB/"("\\4<JI%+)(@9=,E=XVE H
MJ34J#?<0X!8W,UXO#Y[@Z1$PM]TTD0:6LFF0;Z-Z+"9-:(SCHTKQ"6S1UXW'
M'<* RJ0DEM;K.\SBM-P5>-D/PMX@H,Z0<6 N3PKT2YF73&A%S'!N:S1$L'"Z
MI"(<@)A5LE"$D7-O=6TUO).)H&2)F8169NU.I78*&C&I"A+%QNY HJ<7-N+&
MXMKF-(9-$P0$Q7"EHI!H=Q1@K J2'1E(8#+'#[VSF2*"ZCXA-&!:273%+5D2
M!'","@EZ3RS9+&& RTU,G5RU-NLVZM;@R#IQK;O!').(C4"XD:1PD6FBQQ'>
MR C2&F-VJB]@N9H)-.2EX7*ZE!K0.FEZ5-"Q%<O8=<+82*ADXF$U,:*NH1KJ
M8\BBM6/( 3C_ # ZL99?;AYF/Q_U8^_#S,?C_JQ]^'F8_'_5C[\/,Q^/^K'W
MX>9B/CT'73AW[PCWF]8RJ;)PK'2([F@TN%R964C5D",21EE)5B*@U!H:5!&T
M'D/*/8-^3:X)F1^=20?S8$ES*7D I4[=I.9Y<R<SGV>K_5R".(=8Y6,5U1%&
MB.#31UHH"M== L5H3HD!V^UP?WJ7_9]A)>/-.0TRS&/7\D944(KZ *DJ%! +
M$:AJI7%M;.TPBCMC!T7H6B)#:6-#\( U72>0DC+"7T)F:2*9ITB,E(MZZLK$
M+I-->HUJ2H)+ "IK:V7$(0[K+)*P5CI#RAEHI/2TQ(P2,Y%="L*4 Q%=ZY7N
M5?7J9JDL81 2V0K6,"O.W2VXMGA$FJ%HF6K5SA5T2N6?1D:O.:'DQ<<(A9DA
M<.02:E69S)J[=)#4#F%,&^N9I6D:6.9XP](#-&JJLFBE<M(*@L14 D5&&@L)
M&BE:V]'+$DZHB<]8^&Z N(F-"NH@DKEA(T%$4  <P H/S=FY_9O^J<' [AQU
ML_PZ/^O'L+6ZDOKRWN(HI8@UO+NBT<VC>(QTL:-H7-=+#D88GLH4EA@::WE7
M0]-V]I&D<!CU!A1$C4%7#AC4D$[)+*.XO8H9(98I2DY5IHII'F=)6TDL!)([
M(1I90Q6I4D8ZRWO$X0D%Y9QV:K'(2Q@1=+2L=("2S (I"@Z4B0,2=DMMIG6T
M9)T6,2$)$EQNS*L0IT%+1*ZJ#I1B^D -07EY<++OY]>NCT'3MC:-04R^1) Y
MGZ7:Q-?6X;?R000FIJ-%N&$67/1SJ/PLME,6\+\4NXA;M=+"UO)NG%O=.'>"
M0E6K0C2&32= 6A#5PGH\#Q-');O$4<JT)MHA#&(FH2JM$-W*IU"52P<&N'BF
MF$EW+/+-*P%%,DSEVT@U(500B@FNE17/V'7G^_M^HF%TJ!ER>QM.%S7\K<-@
M+&.(L=VA<ZF*I72"Q-2:5//[%<$?DR_V*+8/@CFQ]BB\D8^Q1>2,?8HO)&/L
M47DC'V*+R1B]=+2,.(S0A14'M>T)P>#A,,T8D9]3,X-6IE1<LJ8_#]MY<GAQ
M^'[;RY/#C\/VWER>''X?MO+D\./P_;>7)X<?A^V\N3PX_#]MY<GAQ^'[;RY/
M#C\/VWER>''X?MO+D\./P_;>7)X<?A^V\N3PX_#]MY<GAQ^'[;RY/#C\/VWE
MR>'$D9X!; ,I'CR<HISX>61@J 5).P#GP;QYE%J$+%N333;ER8XAQ;AG#8+P
M7ELL=)&=0%#B0,I3,D[*'DQ^$+#Z:;P8_"%A]--X,?A"P^FF\&/PA8?33>#'
MX0L/IIO!C\(6'TTW@Q^$+#Z:;P8_"%A]--X,?A"P^FF\&/PA8?33>#'X0L/I
MIO!C\(6'TTW@Q^$+#Z:;P8_"%A]--X,?A"P^FF\&/PA8?33>#'&.L=S;)#/>
MS&1D0DJI( HI;,C+ESPO<]J P?R9>X/>'8B52NZ4 R5VZ6.D4[8S8]H8GC-U
M6-(PU-"YU+95VTRV[<(KD4-O&^SX3$U]S+9V+_\ 9'\@@Z^_O'Q^*&SW&C92
M+>;S>:O<TZ>W7DPZ#@=RP!(J*4-#M':.W'J&Y_-CU#<_FQZAN?S8]0W/YL>H
M;G\V/4-S^;'J&Y_-B\B?@MPBM&P+&E!4;3VAB?F]!_V1BR6'@431") K;X"H
MTBAIR5&=.3'X>B^F&/P]%],,?AZ+Z88_#T7TPQ^'HOIAC\/1?3#'X>B^F&$C
MO.#QQ6Y!JRR!B,LNCRU.7M2]SVD=@'\F7N#WAV)VDC#-)M) ) I2@/( -G;S
MP6UL6,80D\PKGW<\\*RDU$:IGS+6GNYY]B__ &1]H9AM QL&-@P 4&?\N? H
MHSP05%<;!ABU,L6/_N=_^%.-&JF6/G1WL?.CO8^='>Q\Z.]CYT=['SH[V%&J
MM<7<$5-X\; 5V5(IA^& J+EK;=YGHAJ ;>;+FQ'?7D+2K L2,J$ DFBU!/)7
M\V/4UUY:>#  X+=$G_63P8T/P*[#TV%DK[V%/[DNL]G23/\ -@@\%NJ_&3P8
M]377EIX,7%]:6LD4<<N@AR"2=(:HIR4...S6\SQS*(J,I*L/E4K0@@BNPXM&
M.TQ(>^HQ4G&W%6:@QXV!T]N-N-N",+W/:1V%/L+&[G$N^D2IHP K4C(:>UC9
M/Y8\W&R?RQYN-D_ECS<;)_+'FXV3^6/-Q(P$U0I/CCD'Q?;!6R.0_I<P[F*B
MR-/C?S8^Q'ROYL?8CY7\V/L1\K^;'V(^5_-BXMQ9D%T(KJV5]SVA^YV!W<#8
M.G7N]LX#*<O>[6&IS]A^[BQ_]SO_ ,*<#N'L/W#B0 "NE3D<MO+S'!W@JY;,
M'GYN:G-R4SPH)J?Y>]V(NX<6UO<3%(7< D#4<^0 <IV#FQ806.@+'$49002I
M4UZ?+J(:M3MQQ#]K#^N.QPC^\1_K#'"I+HW.X5+M6WH&_*[DLQ4G(H :)7(/
MKY\N$M&5%DS1K 5 *;EG Z.H$A]HD/CA]537%Z/_ !7_ %CV.)_WS_[M,=8^
MU&A[TJ8L#SP1_J+CW>Q$=0&9VYC9B.@RTFO;%>3N^]E@(" ,L_> _EEV6PO<
M]I/<[!]APO\ 9_[1[%I$T982-TC_ $%J%UGM:V5?=)Y,72^BAK>'=ZVUT;Y3
M9I2G2IS:@3R8DMC;J8EG$50XUZF4-JW=*Z17,@Y4)[$OQ&]XXW%S*5DI7Q2<
MCW!VL?:&\AO!C[0WD-X,?:&\AO!C[0WD-X,?:&\AO!C[0WD-X,?:&\AO!C[0
MWD-X,?:&\AO!C[0WD-X,7D$4[&1XV Z+#,CGIBP_8K[P['\,95B02MQ'B%6"
M@,0'% 6I4@<E3E[6_<Q3/9@T%1@T&SL#+&>'[N+'_P!SO_PIP.X<"N*@U!&*
M "F*L!B@  [$7<.([B8?V>V1I6YJ(*C\],3W4AZ<C,Q]VIQQ#]K#^N,2[IT5
M4 )+,%&9"C,\Y/ARPVJ)U=)"E17)U.8!&501R'$LL^^,J"C%M55!Y"3F :\N
MVN$CC@F)16<"AR"YLP[E,R.7$;- Y,E2IH>ESD<_N85I86522 2" 2,B/<Y>
M;'$_[Y_]VF.M.6R!3_O$QPPD;;:+^K7'NXTTY<5U"F#TAEBFH;*X'2&>*@Y8
M;"]SVECV&':]APO]G_M'L7LMS.X$B!%",5 0"O2'*2Y+<V0Q+=S/'^\M,11Z
M'HO&M#6OP7.T<Q/*!B:<K H>=)-X-6]4*J@HIH!1M)%2::2:BO8E^(WO'%2H
M)QX@[V/$'>QX@[V/$'>QX@[V/$'>QX@[V/$'>QX@[V/$'>Q>QPQ5E:)@ !F2
M1BRBD4K(L2@@\A &78ZFR<.AEWSRR>BQ&8DQ7#$&],AI5TC(H@-/G$S()]K9
M1M(P:$;,#,8---#W<5&FF*]&ONX"U%,,"=N+'_W._P#PIP"304.%&\%*\_:P
M:RK6G(>U39S85BZ@#D![=<L*=2<G+MH:YX(UIW\SG7/#'6M#VQ_+W,1T(.1Q
MQ282KZ7<R+$!4:@@Z3$C: =E<#N'%[9</MGFNFDB(514D*]2:=H8N7AZN7)F
M<*!5 1DZL00=H(%.3NXMU@ZKW:QH^:E5-5#,P.NFH."V1SS )KLQ<VL/5Z]H
MS,0S(K,P=55@Y(.P#HE3R\FW%RD/5^_>!WFU-6IZ:E1NS_1V&AVB@RI7&\BZ
MM7PE:I-=B-NWC&ZRZ(Z=3VE51LKBR@/5R\:YC%"[+R4H% &1 Y&/2Y"3CB%M
MQ2RD@G:ZU .*$KH45':J",72<,>4WT'R@C1B!.GPXF4&CU%&4$'I**;<<*X;
M=W+S7J1@R,S%CK;,J"22%3)%&P!<L9G!.K,^"E/=P"KBH[6W TL*U'N"M?=Q
M\Y_UUK[^"2]20?SX UUP3A>Y[3W>R>S86MQ=,LZ)1AH8T-2=H%#C[:WT;^#'
MVUOHW\&/MK?1OX,?;6^C?P8^VM]&_@Q(HO6J5(\1^4=SVIY;<+H5J&IIG2N-
MD?E#&R/RAC9'Y0QLC\H8C@:13"A)52_14M340-@+4%2-M!78,;(_*&-D?E#&
MR/RAC9'Y0QLC\H8>WF WBTK0UVBOMMC_ .YW_P"%/9E@M"@=%U'4:"E0.8\^
M/'@\L^;CQH/+/FX\>#RSYN/'@\L^;CQX/+/FX\>#RSYN(8;PH7="PTFN5:<P
M]@!BZNHVDTPW*P.NGI!W?0II7Q"VQJ[ 3R4Q/,UI=/#%</"[)'J570A:$ZA0
M,6 0_"YA@BZLKR/3"LLE8OF49BH:6C=#,=O+'$#(\E;>5(B I)=Y%#HL0%2Y
M((Y!3.NS#WTL,MO$FK4)EW;*%S+$5/1IF#7/#:+>Z#&%I8PT14SH@JQAJ1K(
M&=#I)&8&);B(RR6\<,,C,JU4"<Z8UK4=/E9=JC,\F)[:>*X2..?<M*8SN1(:
M44R FE:C,BF>+JR@M+GY%W1I"E(M:4JH>N9-104SQ'PZ42F=C&"0M54RDB,,
M:UZ1!&0-/A4P)(9%>,UH5((-#0YC+(Y'M^P7N>TJ.RWY'<_M?]D=DP*^F/Q*
MTK1Z:JU(I_JT/*<6,AFU:W&JH&PUR%*4V<Q.$$1H I9L@:+4"IKM&VH7I8$X
M%'< +RYL>B:<N72IS8MVWY52CZA0 !D(!VBH!J2>U3#L[%DU=$D $K09T')6
MM.<4[-S_ -G]4>VV/_N=_P#A3V;[]A_M+V+F=EJ#>: =3DZ=8'BY* .0C;RY
M8X>)"IED",PT4&ES3(UK5-IR[M 1A'25)%ED,:46A5B1H+BIVJ'8CD %<ZX@
M($=9&>E1I'1?2J5)VL.E7;_1!'8L/V!_6/L <69@GB2_6[+2YG1) ;@S*":5
MWD>U<MI9:T-<<9LEDBWUSQ'?J:F@3>(]&-,FHIR (K3/%[Q".5 WH\0A#%M)
MEC<L1,@Z+Q,*"AU$', $5Q>\3CE@CO\ TZ*YB4EF2J0B)T>@! /2TL*T%#3D
MQ>V'%UBCFGC=#NBS*JL* @L%)(VG(#DQP^>ZDLS<6$+K!H+@2RL@C5Y:CH*J
MYE%#5/+3'$>$VMQ$]K<;F74Q*L)U<--L4_)N!5!\$Y4 ..,V#26R<'O+T3,]
M6:;0-!T!*! 3H\8L: XXC?2VML89I96$@DDWH5Z%4W=!'3+,UJ.2N+R^MIX1
M<LRM!<,S[RU"K0QI&%*NC&K&K"NK/8,6EG-$B21K2B,7!SJ6U%5)+DEB*9$T
MJ=OL%[GM ]@13/')C9^;%*9XI3&S&S&S&S&S&S&S&S&S H.7V-S^U_V1V=RT
M1I522!T06/1)[9(VT./'3=H:;113S=H_GQ\INRR9YT-*]W9B*)&2N;*!3DR)
M'?/Y\:PT9U5SJ,ZT!';KE7!]'"A"?@TIEW.S<_\ 9_5'MMM=CK.OH:WIO0=U
MTC.R&W]#TZ\G$E:R5II&K33LS7"VPE+IIH213,&N0/-CU4GEGS<>JT\L^;CU
M6GEGS<1RMPE"Z5I\HU!7(FE*5IE6E0*TVX]5IY9\W'JI/+/FXMYWMA$4C*T!
M)KF37,#V*VG#KPH39F1$$&^,LNO2J&F:*PR+5 '/A>'I.%D-Q!&(3$N[H\:O
M-6>M5=.D43,M3+%QUCCN81PV.],/HQCZ1191$29:ZA,3T@H&FF5.7%YPN]XB
M;.X<R;A/1U='C4C3+'*3\HX&;HU*5.66#>W'&HO3;FY-O"7CC1(BDC*TC&M&
M&A:D-D#LQU=LN&W$<-U=P2222E0^DPD(ZQH2%+,YJ*U 7.F+7A27"S2WB(D,
MN[5=W*C?+LRY@C==-5-0&%-F+WBD=^D7#H9YHQ#NE9F$.I=4DA-5=F&H!0 !
M04QU2X@\P]*N[B!)6TBC*Y(8 ;%K09C9BY2YD07#WE+>30*-$MR(I8B-F\1<
MZ[2K:MHP0-E?8+W/:![#5RG]/@QIIG3 &=<L FM,>Y^GW\&E=.!ET< =O&>S
M&>VF#MV?GP,L#L#N^QN?VO\ LC&S&S!GU4EHNDTV4)KW00:=K;B,HR[Q3D2&
M(( *](%CG0Y4H!B=DHS,U14'*KJ6J"=-,N8&G<PY+KJ;56BY=(J1I%=@*BH-
M:@G!ED*ECJJ O1Z2A<A6NP9\]>3 C9JT.7:'(!7.@[=3C9C9BY_[/ZH]LS&$
MZKF\;]R+=&X$?)O2@C+>2-FRM3M.!44K[2.X?8CB.@^F;K=:JGQ"VJE*TVYU
MI7%YOK:IGECD<ZF!WD5!&ZD&JE:"FFG;VX_>1L1Z7KU[6T&0;)#'707_ -8K
M6N>&XC!;'TPEJ,SNVG6:MH5F*IJY=(&+CC=EPN*::Q8O''*6:/5<2 2EEKF3
MJ)%:Z>2@Q CV ",^_&EF4I)(H+F-E(9 :YJI [6.&LL)U6@81$LQ*ZAI:I))
M8D<K5/+MP_$EM"MVQ)8J[JK,1I+,@8(S4.TJ3R[<1+;VSA$D1U!ED95:,DH5
M#,0*$G(  \H.(K.2S#6Z7!G45:JREBY8-6HJQJ16A&5*8)]@O<]H'L=N-N".
M7%,;?85Y,>Y7! [([OL2L,[HI-: D"ON8^V2^4?#C[9+Y1\./MDOE'PXL^"<
M$W\_$IVHJ!CW2220%514LQ(  J3AK^WXG;75TJZC!%-)K-!4A"ZJCMS ,*_!
MKAXI;F99%)!!9@01D00<P0<B#LQ]LE\H^''VR7RCX<?;)?*/AQ]LE\H^'!>5
MRSGE)J>^?:>&\-DN8X8YYT1I'8(B*S ,[,Q "J*DD\@QPKB"\2LY>&V"7UJT
M2GT-FBAMWEX?G4-(2ZF-I@")'95VD PQV=M%.]SZ,SP>G,#:QO8[^4PTZ=PR
MW :.16+-$JT8+74+.;B_%8;B5;/AT<IEOMT;:W]$K/-#3YZ:&4",6W3T9*8S
MJU#J>LE\'%P8S+.;N--4ABE:2WN(BYDMDWJQ1K*(E" EFD;4"(7XQ):O/9\&
ML8DMH;Z)4C4&X-P8[AY46::!M"JK.^35*2BAQPM+RWB>4KPG>.;YD+&\+I=E
ME!HAM0%D8*0$8T>B&F/3[#B=M)UC2>,J8[@.\D<DDZ.DD!<E6B5(R65$7I5!
M<&H]D"S #MFGOX^>3RAX<?/)Y0\./GD\H>''SR>4/#CYY/*'AQ\\GE#PX^>3
MRAX<?/)Y0\.+I^%W@,,; SQ#2=[%49C:P:-PK=$BJUK7'"8>.<16;BNY4R$E
M!I)%1& M!2-:)LJ2"3CYY/*'AQ\\GE#PX^>3RAX<?/)Y0\./GD\H>''SR>4/
M#CYY/*'AQ\\GE#PX4JP(IR$'WO:![ Y;<;,ZXH/Y?R[6"?Y=W%*<F":4YL$<
MF#S8.6TXI2F/<Q2E1V1W?:>L=P\8,T?#P%/,'F0-3N@4/:RQ?2]8.M\L:7,D
MR;N5F,4[DL(XP2VB%D;28B0!EH!&H ]9I^ \0CN+66X9V,:T1)&/316J1)1J
MU=0%+$@5 J?;N$6_ ;Z>3BMS( $N!&D<D2VJW,]S&\;,5BM]0CD$BAR2N@&M
M,3\-?K1Z/%=<7@LIK2WG"/.D\.\61)2"@UQL**ZBL>O> :=!M;JP6VF,^X*0
MK,AG"7,KQ0NZ9!5,B%6:M <_%SQ-.>)\,'"T@67TKTE?1BAG]&.F2F;)-T'6
ME=A&H$$W[W;VT*6EZMO/JDSBK*D.]( HT0>1>DK%J,#IIGCBD7"^-6]SQBTX
MG>0$&1426.TMTG;=*1J,Z@N9(]1"Z: DYE;SB;0;AY]TA1]6\^1CGWD>0U1:
M)H^G_2;32H/LY =F]C_6QLPA="H854FH##G7G';&6.3')@[,L<F*<N/1/1G]
M+K3=TZ=:5 ISD9]S%.7!V98AU0L-X 4R\<$T!7G!.0YSA?2K5XJD@:A2I&T=
MT5%>:N.3&0QLQLQLQLQ>4'_?G]5?:!V #R]D]C9@XJ-F 3C;A1V*<N*=S&78
M'=]@&FE5%)I5B *^[C[;#Y:^''VV'RU\./ML/EKX<?;8?+7PXXKQ%;."]])@
M$6DSB+31P]:@/792E!SXN;GTN%3)(S4UKEJ)-*UY*X^VP^6OAQ]MA\M?#C[;
M#Y:^''VV'RU\./ML/EKX<?;8?+7P^U75RG$DWDTL<C Q1,NJ.#T;)2I4+)!\
MG,H%)5 U@D BYELIK>,27L5V%%O"$CGA&E'B712/HDHP2@920P-3A/1^)[N1
M8;>)65$#*MK,T\-#IVK(Q).U@=+57+''C?6T$MU/:Q0VZB" 6T 2Y%PY-MN]
MTV\;4Q.G49#J)R&+SAUUQ0213LY=FCC,IWDZW# 2:=87?('"@A0<@*98].>\
MA%R9YYB5AB4&6Y@%M.Y"J 6DB'2-/&)?QC7'5WA]G%,G".%V*6\(E97D:A+.
M[E55:L2%4 =&-$6II[.3]JGOX(W3^DU\;4-&GFT4KJI\+52O)BS$AA>YAX>J
M*KKJ"R[[45H12NBIYJ8CAMX+8JL\Y0!*!H=P6#.*=("2I%<QL IB>2-+2;B?
MHL0!6.D3RZVUF-2!0B,BIR!(%:TPDD4-O+")H=VBQD2)%II.)RPHQ.;+F<P"
M*8FBI#)%%$BQR.*+(=1:4L=#]*A5%)6M 0I!SQ"ED(4O!+XB59BI8FKNRAET
MB@TZBK94 Y(KYKNV=A=QNCHC!TC$163?,1TJMDNWDI2F-+B(KN!5 A%SZ1O*
MN^\I3=E-F=*94KA&E-LT8G<QE(V58XMU2-;D4Z9$E"1TCSFF.J]R;FW=+:&-
M96C2D2L&8N50CH@ U6@RVC$:W,T O%:\,9=*Q1O(X,+R(!0JR@G8<\V%3BX>
M2WB98S&Z@)19G*%)54$91AJ2!305%0,:.&E391QJJL!36<RSGG))I7M>QO/V
MY_57V@>QVXKV^P<\'/%, X':[ P<\;>P.[[#A]1_^+'ZCX "C'"K>6\!6=9!
M(0GS4L<6],9J<R 5SRVGFQZ28_[:\L2I&"I)$BN]6Z54Z*AAK Z)KL&+B62V
M001*K%]<>@AZZ=+:M+UH::2=AQ<VEO#',8D0ED9:5==045(J]*T4=(@:@*$$
MP_V9 'B$E3)& $:FDL2PTZB0%#4+'("H.);E[&B)JJ"4U=!@C]"NHZ6(!H#M
M&.'6W$+?="XD"!NBP!U ,#I)Z2ZA520148CMIIPUX2Q*Z::4U$1DFIS<#5I'
MB@BIJ<N&W\5RORUQH9=-61-2IO-O24,P#;*5'/E+?B)6L5E*:@5J""5&I02R
MU*FE1CQ1^3R?M4]_L"!I"D01W=AF0D:EFH#D6.0%<JG%LT)C#2Q;P4DHZQD5
MU.%&H ^+E74V0J,>CNL,<ID9%#OIWC*NMMV*'4 N=<L0I-I$),!8ALPEPVE"
MN7C9&H.SMXOKB$QFSAE926:C!5?1K8::4KF:$FF=,7MG921S"!E4M73TF74$
MI0T>F>>0!4ELZ"P@NW6)KI3NP#J8-I+)K%*!6TE3I8E21@&F?\J^U7G[<_JK
M[0.P*;.R 1E7_JP*4I3';PN66!W#C;E7%>Y@X;/V([OL.'_WL?J/B&=45BC!
MJ,*@T-:$<H/*.;#//(DK;TR+J6NAF5T(7,4!5R*=H<V$ LD$J+'(S;HZG5$,
M:M)R%#&^DF@!!&=34W2+#"J20[H *:)'G54&HC,L35@S:C4$'$Z/%"4D5 PT
ML*M&NA9.BP.O3D?@F@JN)+QK2.2R,<4#!D)C.[ ,>K/QQIKM%<\J5&)3&@DF
M$4Y8A"6"R,))'-,AI*@@THHY,6O$)HXQ<Q.'R#49J@ZF!8C,@5TZ1VAAX;KA
MRW,XCFT$!@R:SK)RKJ6/IE%/BU.=!3'#?1613:F0KEM$E-8?/I T&65.[0X?
MADL<0@:E2%HQTLSC.M,BQY*D;23G^42?M4]_L)>FT=K8HR-56"LDBE6 >FD$
M\ASS Q'<+(FI+<09KT3$-BN*BI'*P(SS%,'TVU9KI6:2-#&@5-X@4%68F2-2
M,R!74-A%3B*$O"= BZ6[&L[EM489JU(4\G-EV\36LCQ;J164D( VEGUD!JY#
M7F,N[7%Q<.D1AG=0Q,70:1%H&J&'RH6E<Z$ 57+%K'#:"6.VU.BQH11RI02R
M&IK0$D@:0QSVUPT,BE95-""*$'EJ.0\X]A)(D;&- "QH:*": D\@)R!Y3C;[
M&\_;G]5?:!['W.QMQE[ ]@<V!C;V!W?8</\ [V/U'[ Q/!%&AF;AD<2OH<NT
MB[KY,BNG352*Z<Z#//'%8X[:WBW-HLK&2(/NI9IHV*%0"?DE(C %=.=1D1CB
M8M;2)97GD(#HU2I*[LQD Z M&.@LHSH=6.+VQ2-(7N"8*1'=K2.15D=*=+-J
M9U()#4(6F(TM)AZ1Z+-&6$11F#P !6HH!.\U#5G2M2V-Y:6EN8Q:RZ 8F)#E
M4$:R KI8A@QUU;,FK4(&)&2WA1%>73IB9:J]K05H,_ER:5\7:*+CAT?"F5KJ
M,D,PC,9*:4IJZ(4L&UYBO=/Y3)^U3W\:=W)Z7J\;4-WIYM--6KMUIVL6O#VN
M]$WH*QO5B4H)=4D6D9+,R?-OGS8E%G':*1#*(F:K1:B%W8G0**$=*E=1K6IV
M8WUQ=6U%EMR6(.EHDB*R(G1.0?X)ISXX8)#;_N__ +Y2K;_>5:A)I\QXN0RT
MTRQ?T2UC9H@%8'>5<!J[M-"KTC0$KI*L*XMDXANMZ)9F97J<C#2.O(09* ';
M7%REKZ.LLT5F64)EO%?Y< <F[6C4K13TA4XXU*]S!)-,TSH2*2!ZC<Z3I)8,
M 374H'BT)SQI:WLO1O2@*Z#\P81J:O/O<@U*C8!RXC18+5[E;2(C4FIC,)2'
M#'E(BZ1&SESV8XLB36S*YF,0(HRF@W(0Z265C7X2J/%(-<3R7,D)@>VM5TH"
MKU1QOT( '2"UTC.BU P[R"S>4"YT;M2(M&G^S)("!66ON[:G/$=_920BW=8T
M*)E241ZI2%V*H.1_ULA["\_;G]5?:![ =W!':Q7L ?RI@8-<4KEBO\LL4[ P
M-E1@X'=]A#:<1,@B236-#:34 C,T.5"<>/=?2#S<>/=?2#S< B2[K^U'FX<[
MZ[JVWY7;RY]''CW7T@\W'CW7T@\W'CW7T@\W'CW7T@\W'CW7T@\W'CW7T@\W
M'CW7T@\W'CW7T@\W\GD_:I[_ &!:RS[N(1N[&H!(05(6H(KSDY**FAQ+<PSZ
M6W4#IO)$"$3,RYN!LR&C*I)V4(HM8(P[2M&%,BARZFC +R@>,2#0)TC@M&(6
MAW9?>"0&/2&TFC ;0V1&G+;LQ'<VX&X]'21V=U &LL!IH#D=)H&SYSF,3W-J
MBM'&I9AJH]%%31:9T'.17DKB-5BC9V95HL@)4NNM=8H-(*YU.RF.$L)5DEN(
MV8Z&#IJ#Z (V %0>WG7&Z"PM)K9*+(&(D5=9B:@RD*YJOPLP#7#(J WPN!$0
M'70M8]X0YI4,HS8^*NS,XX9%9S123SV^\/R@*5+E0(V"G4#SD=TC%B\TRUFF
MEC,:LH=3$"3FP*D@CI#X(IF:X&B!6J(R"&%&WU=V%-,S0$L,M(!)Q%8F!/2W
MB:13JZ)C0T8ZJ5Z)R(TUJ10'%E)!<0///.\2H'&V,$DAJ9[*D4&D4)VXEN$@
M1X4U9JX;5IIJ*4%&"DT)J,P0*TQ<QND(:%0TGRF2 F@!.G:3LRIRZL79_P#'
M_P!E?:?%QXN/%QXN/%QXN/%QXN/%QXN/%QXN/%QXN/%QXN/%Q2G^AY/VJ>_V
M!<0BCF-U!8&A5QI8C97+802 <);&*!X%CB32Z:AIA):,G,=($UKRFF+2X:<>
MD0S22JVD5U2^/7D*D=$+E1<JX@EAC@3=*1&H2BQZCJ8J VUCFVHD'(4RQ&\>
MZWJQ;L,4S"]+_6 ).HUJ"-E *8]#@W>YZ=-2U8;P:7H:C:.<&G)EEB1B5CN"
M\;,"A!K&FA 03XI0T8?"K4$8LU9(XUMU(C$:Z HU:LA4YAA48WMO;1F0REB8
MX=LS)IWAH36;173S9L%P\J&)9&FWC43QGT;MM0K3I+DXRJ<\CB*.&*V6)$5%
M01T151]:4&K+2W;H>4'$<@$1=)WF4E:E7D!#TS\5@=G<SQPVTMY/LTFJ(*M6
M+=*BG^F &8!:;#A;I+=&ND! 4(Y H:L::M0*G:0U ,B*8A>-8Y;D3O*GR>I@
M[J5?2%(Z)7:*'96N!P]2C6JEM.H$E=1JP!! H3R$&F8RQ',@A$B1Z$Z!Z"FM
M0*L:UKL8L-E *8NP/_CG]5?^@,G[5/?Q3=R>E:O&JN[T\VFFK5VZTQ8^D""6
M>'ARJJOF!+OJE:5'2T5)'-VL)!;VUJ4$\VE5!H\(@+*SYDL!)6A%*4H!EBXE
M6"REXD+6+HH"86F+MK,(J*D)0MG0FE>7".L%M+;B:$1JH)EW1%)S<UY0266N
M=0-.6)X&$$RQ1($=R%25BQ,I+$$:@I502*@ Z37$7H"PI>"7Q5.N1D)/29Z
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M"_(G\&+>9NM/"RJ2(QZ$^Q6!/)VL >T-%,M4/\JCF.%BN27M#DK\J\P;P_\
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M6T$V\U<[Z=.FGNUK[F+.ZE_C3P"&66)':-M[JC+*&*-EXR$Z6[8./\\>KO\
MO?!C_/'J[_O?!C_/'J[_ +WP8_SQZN_[WP8_SQZN_P"]\&/\\>KO^]\&/\\>
MKO\ O?!CJGQ&U_C#P*[N8.(0.L,>\WDI612(TJ*:GI1:Y5..'&G2_P"<#_7R
M8ZV7'%?XS<2M^*/Q.Y::)>%NZQ2F9S)&K_#"-50WP@*\N/\ /+BG_I,F/\\N
M*?\ I,F/\\N*?^DR8_SRXI_Z3)C_ #RXI_Z3)C_/+BG_ *3)C_/+BG_I,F+N
M\ZG?Q2ON*=8%9!';2</>!'4L Y,IR70M6 ^$13VJ7X_Z!_H$=S]'8<LM2W/W
M*98)J2=('>Q4?T0.]V)OBGVBUM9&(C=P"1M]RN/GYN^OFX)-Q-0"NU?-Q))'
MQ"0H@!)J!0'8:%:T[>S$H:]D!0 M4J-(.RII05YMN$ECNI3&PJ#5<P>7Q<?/
MS=]?-Q:K;R.P=6)U4Y"!E0#%Q_A0_K<&X,>KI 4K3;C[&WE#P8^QMY0\&/L3
M>4/!C[&WE#P8^QMY0\&/L;>4/!B8B$IH(Y:UK7P8ZK<<XD7%A:7\,LFD:FT1
MR*S:5J*F@R%17$'\162>3J_%UA],HJC?-#O68 (6 UD$9%@.WCB?5KJWQ**Q
MEXO=7]W%)<HS!(U+SZ76,UUE#3(D!N4C'^9'!/H+GPX>23^)? UC45),%R
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MVBOG2YX3>/PRSXB+V>UACN+I(VNY+>%;B8VHHQE1(7C<M11TU45:JC@8XW-
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MF!U>.7H21D$-B\COUX!=6%_UA>&6>;?R20\._<-OIDAD+:D OU94<ZF64$*
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M7(,V_P#G&92KKT2G+A>O"\)X8./+"Z*VFZ*(\DF\DE6-KME!<T#14]'9 JF
M@#%I<VUAPT\0M^$#AT4K0OJ2 /<N:H)A#(SFZD+++%)%58RL8*9DG:>SUW_Q
M]O\ A;?_ * \3_Q:P_KQ^1]=_P#'V_X6W_T7_]H " $! 08_ /W-,_74/M:_
M[GBH^3FH>-D)YTJQ@(^1E6#!_//D$1<KL8-D[<(NIAZ@V 5#I-B*J$3#B$ +
MTZF7"EJJZ;>N/T8JR+GL4,1"MRKD40;1=B6,]!."DG(N4^6W=BBLIS"<)1XB
M[N(\F7L3GD&?A$'D>7)5(,_9C#E4/, \9!.BY:^""(G,[YA"]6*0PJ<(%'9*
M2E)>*C(U=5B@A)24DR81ZZ\HLDWBD$7SM=%JJO*.%TTVQ"G$SA10I4P,8P *
MCU*U5=5DC.A55WB5BAE&B%J%R1D%67<D>BBC9Q>J%1".,8'@K& G+XA -2,<
MUR?C5S(PRR#:9CVU^J2[^'=.I!.):M9=FE,'<QCEU+JD:))KE3.HZ,5$H"H(
M%U&-9>9AXAU-OPB81K+2C",=3<L*9U@BH9N^<(+2LH**9C]7;E46X"B/#L&I
M]FE::PH\J:15K:S3L,.=W4T3(G<E6M+4KT5ZXB9LF90#O2H%%,HFWX0$=1T=
M"W*H34C,Q(S\-'0]H@960F8 %#(C/1#%A(.'4I!@L0Q!>($4; <HEX]P$-/;
M&6\TDU<C9 T1)6,MNKIJ_'2Y7";,\1(3@20Q;*5*\6(B+954BX*G*3AXC  J
MUE_E'&C"S(/DXM>LOL@5%G8T918A5$8Q:"<3"<JE)+)G Q$#(@J8H@(%$!#5
M>>R%\H\>RMRJ:-1>O[C6V32V+*\/*3J[IU)I(6(ZO&'"#,RW%N&W=U/-G-DK
MK9S5&B,A:VSB=B4'-6CG"2CAO(V9NJ\(M7X]PW1.HFN\*BD<A#&*80 1!)PW
M527;KI)KMW""A%D%T%B%517063,9-9!9(P&(<HB4Q1 0$0'SI]^3DI]^0O\
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MTQ>HD<,GS9=F\;G !(NU=)'0<)& >@0424$/[^K#47(&$L2^.5@N8!_G<0X
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M80UEC(60G!3Q] R1?*\D+!H@BL>'@)!FPB6A$RBBBJ\<N'()@<YB@)CAQFV
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M72_W37J][ZZ7^Z:ADU'KLY#O4R'(=RL8AR&W*8IBF.(&*8!V$!Z!#1/]$O\
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MG)I5:PL&4NCBZ)B)R_79R^?K(^"JQ&QL@L9B15(7TB=N!011YH"1M3T[92%
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M%$]VY#Q)KVXHGNW(>)-1T@M+4<R31RFL<$YE^8_"7?Z4HPQ -MOW-PT4![H
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M#^SI<;;<4KG1H)^Z&RM.B3 3;T!,)>@=O.IGZZA]K7\YN_\ V20Q_P!X"S;
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M/2;% 2LV2:39'@:MB%[TH;B&X](CJ2_#/]";>>"Y=B*KA3B*R8I"7K#Q4-@
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MJG232V+N5R<S8$._XC/&-,LMH1-.NK40F4KBVMKQ*1D\IT+)+VKI.DX9J4E
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MA.('1C]R&(1-N0!,F15-(XD "")$2B)2"(F445\]$I@ Q3 (&*( (" AL("
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M#PG,.VVIBJ,LA4Q)M/D=(R\F9G9%I9ZS>N&SIVT.*RAXDO65&B93N : \,D
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M$.X7,&Q" (F,/<#3Y>J=H^_5=Q),SQLDO7H(D*N^CSFXCL7BL=8VZB[43]/
M81 !Z>[H #-$X !T?B3%^.]>6F=^!,7X[UY:9WX$Q?CO7EIG?@3%^.]>6F=^
M!,7X[UY:9WX$Q?CO7EIG?@3%^.]5;&[:97L"%80?H$F'+)*/7>]>E'LF)E&:
M*SA) 4C/.   YMP+OZ.VI+\,_P!";><IQ<8EX0L+T2)M&2916Y K<?*7<ID.
MF8W%RS"1/B*)P*8QC$2(HH2"F<G6Z$B;+>; UJ\ YG'Z+<KZQ2J:AFE=@S+
MF#F3=I-S!WA2B<I.$A2)E*0/F+[6*S?9B+A(N4!%BQ;K<*+=(4$E 3(4 V
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MUUY3['Z]7^ZZ\I]C]>K_ '77E/L?KU?[KKRGV/UZO]UUY3['Z]7^ZZXOTFV
M3  @!Q=JB<I3" F*4XJ<12F$H"( .PB ;]P->4^Q^O5_NNO*?8_7J_W77E/L
M?KU?[KKRGV/UZO\ ==>4^Q^O5_NNO*?8_7J_W77E/L?KU?[KJ+9N,G60R+AV
MFFH /EM]AWZ0W4,4=A#?80$H]P0$-PT41Z1$H"(_1VU,_74/M:^L>26/K;,5
M"0E;I)1\D[AE445GK%&OJNDFJXK(KE,DFX*!P   >+7EKO/KUCXOUY:[SZ]8
M^+]>6N\^O6/B_7EKO/KUCXOUY:[SZ]8^+]>6N\^O6/B_7EKO/KUCXOUL.:;P
M8-P'8SM@8-P$#%'88\0W*8 $/G"&^O+7>?7K'V!KRUWGUZQ\7Z\M=Y]>L?%^
MO+7>?7K'Q?KRUWGUZQ\7Z\M=Y]>L?%^O+7>?7K'Q?KRUWGUZQ\7ZQ19;-*.Y
MNP352;OI>7?F(=[(O#/GR9G+DZ9$R&5,FF4-P*'0&K/NBX<Q*-TI;FV-FJ2J
MZSBCM;-6'%U2%! IE5FPUA)T+@@ /&V!0NP[[:N#FFN;K6V#22R[=JLQKC^$
M1B;'9Y?-K26JYY5JMSO"D?)4@ZY@:J&30.U6.!P!0$^'(SLT'E*!H[R3@U92
M%AI6/D;$WC8^_3[:P)XKF)*64+UJ4IIHYP ,TF"16XJ$;@9X3C&W&JCW+D&C
M>IZES#6TV679R[*!A$\"6FOHN3MGCEV,59X;(C5B61213!11,Y.^43.?5%FT
MJO>82QV*TM;5)1D7+QCN*I<>TM50KKN@R\6TE648YCG-+CY"8,[=&>IF7>'3
M12%<I#%IM3@YC)E<I["YW51Q*OD#7E16P.\O/YDKV854M49SL?36.72!&QW)
M'#=)PJZ,9$CDJ>[6UQ5+EI>'&2Q9)-Y,:_!)UT6,%$7.)L[Q[D 9)M:85[!L
MIL3MHINDJWDW(IIJD,DHJ)*U5+G47ZN4G5HP3(4S(Y"HK.'R#*78$-0W[9!=
MQ[UU<4TYK+-'35#_ ,K=18J.RJ"X=.B!YG9EHHNEDTKXIE--Z@0VR)QCJLS5
MB3.2]/$!GYC%3_[8_1_<J[)\W2=-'*9D7#=8@'353,'24Q1_P@/= >D.G0O&
MQS3-;>F= 2-76#KC-T5!9R"B0E ZZI>(FRAB$,"H"'&!5=U58V;0Y8=;0^KI
MI'XR(NT3&1=(E-N(B4BY#<(CTB78?1\WMK"(;![P,'=/^E4*_P /^';SM?\
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MZ:D/30Z&,IY>=F+(]CK?.-A?NG)Y*'1G$7!$DFA52O6B8D<%(&^BE$1,)2@
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M-LES%!.UZ\T42XNCOR"&I)*OJR!IB&-X31BF3A9-.PLB\)9"&=-4SE2>BHD
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M"H3</WP]\G1K_P!Y^Y,+\8]?^\_<F%^,>O\ WG[DPOQCU_[S]R87XQZMD]2
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MA#903<0"/FXN_P!IN?YZ3WGLO"?H:=%FUL:$PRX2&QJ P;55I/M[L.4 ?C!
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MR8R0K%/U<>A/A#3:.<4M)NR<3SN_,O!<O-1#R!LME;-59IU69*,?M7U?9O\
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MY9!LVG7W47A1>=5**;%QN@<PJ .S>"96_'EJ?DR76,06-.NRLN8]*O=P3.M
MQ=E1E8.,5%F[316'K+/K:)11.41 >'>*GI]:*8GL$M-L(*%%=0U@E8FOO'$6
M\N2;'D #:HNI5LHU8N5SIG?*)J&13,F0Q_-NWZL)C\Y*?\RVE+WCBC7.29M
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MYUM+PIHX:V0EQL5&""GQ%PMX/LJDU5'YBLQXC=60%41 #%W^:MOY:T;Z'_\
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M;7!S!LZ6_/V:)^UO(*P(+3[2B]IBVHUJHNH9LYCSMUI]$ 5,Y1. D:"!1-S
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M):%'63CG:A5@AWZ+5 5X\YTP,-ES9+8IQIDG#+W''9[[)E_C[_BN0LN$YY?
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MY4H'X@:]4=HOY4H'X@:361=]HY)5(Y5$E4\J0::B:A# 8BB9R4$#$.0P ("
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M% IFFS<-M6VA."8CR*EC#&V/H6DWFX/"P%)S)8)FU2UERY,O[#)14K'%L$3
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AM@\W*'ZWU_S/K7_(&V_EK1OZR6_<>4/UOK_F?6O[E__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>chart04.jpg
<TEXT>
begin 644 chart04.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[@ A061O8F4 9$     ! P 0 P(#!@
M             /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$!
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\( $0@ \ $; P$1  (1 0,1 ?_$ 18  0 " @,! 0$!
M       ("04&!PH+! ,! @$!  $$ P$               0! P<( @4&"1
M  ,& @8'" ,  P      ! 4& ! ! P<( @DQ%#46-C<P0#(7&#@:(!$2$S05
M.0I0(1E@(C,1  $$ @ "! 8-"08#!@<   4" P0& 0< "! 1$A,4%39VE@D@
M(;34=;46MG?G.'BH,#$BLA<WE[?70$$CF+C8,M,84%%QL=;90Y,D9*>(:1(
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MX06*ZPY6Z;742P/8+U S5H$&759PD#<%*;?I5JG7QEOQP[,VEF<[_-4<O@
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M+U=2%BX!W'L0^SG/QJ   *5BZD   I\./#8B1Q8L   80IG,6;$3,)L@
M                  '_V@ ( 0(  04 FV[R9$2VWX$<R8T23^$,.H.5%D?#
M@WAP;PX-X<&\.#";>@P.5+H:23C3PX-.M\"!I_AP81;Z#!X@]"B87*QT-),$
M)-O081,+Z!%QL%\.#>'!O#@WAP;PX-X<&\.#>'!O#@WAP;PX-X<&\.#>'!E;
M0_==.NJ$GS!4I\I"+P.,*$<L"\EEIA?S) P@J'$<H)I^GR^<154QA5$1U'D
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MH?BIP41-!S]ZC_YDE5GH>8'-,4<(I0F8I4!#(8! B5.>BQ@90FH,27*4[*9
MH3.&XC!1G)K@D#Q08N-S<P/A 95'H0YDFHZ0%%'AF-P#3XS,\1D8C3<PZ=#\
M5.U<.VKAVU<.VKAVU<.VKAVU<.VKAVU<.VKAVU<.VKAVU<.VKAVU<.VKAVU<
M.VKAVU<.VKAVU<.VKAVU<.VKAVU<.VKAVU<.VKAVU<.VKAVU<.VKAVU<.V&3
M)PQ_GXQ:.*$,,)N"+1F8(-#%AQ?P!U40K)#-.* (IP&+"'QM"7*Q-AEX<'\
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MY>'%\,?FQ;YL6C-C&!]3>2>&W=$';NB#L1HJ42%VYLIMS93;FRFA#W0_X?\
M_]H " $!  $% "+]DA5J@.L/V.5U3U40S]*]8AZ9_84JXM2OU.S>IV;U.S>I
MV;U.S)_]DQ3JR>J\_>NZ#1/J=F!_LAK Q2WJ=F2O[%E1EU),_P!@NLI*H,'[
M U:9DH9^QTN"XS6W[':WIHIO4[-ZG9O4[-ZG9O4[-ZG9O4[-ZG9O4[-ZG9O4
M[-ZG9O4[-ZG9K.L^SQ9W*NRSKHJ2VGU!'+?+X(Z6J&[RQA<59J==!8X9$TRX
MW+@-Y-L@"U*M%2D-<%E=$Y!3NMF6<?EJ*KQEG%)I2];TMG \-^MN)@I4;<SE
MR)!;V\UOM*0!,E:^Y:H)=9:-V]";;4*55?MM3!X'N^M]5UTM<S!$ 4#5^[^Q
M>8H5PK+$"^FH:X:T$U62YN:RCC!5U;K380J$'T63K^2IV7K9H37M+\UL<3-4
M0ZVRHQ9T=*'*5NC2Z&HA9@5&=YAAEV5 6.)899-8T:LDE8>F3!.IG*IK:I"L
M+:>HTQ>==38;4&UM/VYY;M ;AZ0&5I=(C"[&H&6 2KTT'Y?\@M+5!DUW*(XV
ME97"^-<:E(A264?3Y.OY*G4[J_4BD\H=F#7;&2J'YA%W1B=TJOJ7"7J>35WJ
MLGZG4VO*N+I'3C#?#=!O*57?7 $97AO_ +ML")&7$UB'UMJO=17FN!8D+L:]
M4]3AQ<Y6X\K+3*]2Y"D 7Q<7!X4\;7PW)'!I)O9N)@,52H4"W4_3Y.OY*G;A
M(9MPD,VX2&;<)#-N$AFW"0S;A(9MPD,VX2&;<)#-N$AFW"0S;A(9MPD,VX2&
M;<)#-N$AFW"0S;A(9MPD,VX2&;<)#-N$AFW"0S;A(9MPD,VX2&;<)#-N$AFW
M"0S;A(9MPD,VX2&8&D$D7">DK+5I/T.I\5CHF98X@J!5$;=1UR@I1C!W NO9
M\JST[YV?8H74"IRV6GLU.N/5"'7-**L"%H@2^HZ/,,8Y<)(OD%2B3Y]TU$N?
M3KV?*L].^=GV+=.8?LW;WV6M4BN'L4K%2*YFA:A(*#J6874_IH<SD\CD\ENB
MK12.X!:+*B:26J'ITZB7/IU[/E6>G?.S[%NG,/V<Q$GR[#.\K*>25"RJU"30
ME" )*/2Y>C2*;.DR(2I\B?'I*)<^G7L^59Z=\[/L6Z<P_9S@LD/,>NNS'\BR
MRVO%I.72)I,9"))334Z+"@^H-%1F2"IN)1BC]HW6])%[F1P_IZA49&E"OO\
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M97!B(CKO6VG'U0U%=BW*5T3C)*F6U@F]:%MT*DN672*$/AP',+3F"-YJ&G]
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MA-DY)XU49CS9X()("$C9)=8UZ+8FG?U)-E9D4N=7";D%TAP4I>NM%B3*6@Z
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M.,S,<D1/%C^.<>79,@B,5S&''/\ U"4X\O+,<7)ACQYMJB!3(PJ,,9*)QC*
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M#]UGEM_FUS6>QYS_ +TT3_2[RR^RV/KK8.N]WF[A6Y-?:,E*G-I;5?E+(U$
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MS$A1?,WL6HLC]>AM<<LT^A4$H8-U"DV#G0V!8Y^Q:_?S!\7X4Q+.LS(XA#R
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C*2=;01LI>1-LQNK-"83DV7#B8%*603F/+>RI<:%_V?\ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image02.jpg
<TEXT>
begin 644 image02.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[@ A061O8F4 9$     ! P 0 P(#!@
M             /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$!
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\( $0@!( )I P$1  (1 0,1 ?_$ 0X  0 ! P4! 0
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MO.IJ*E3:(ZT[/'M&1P;M%U4";:ICL+>7E.YK(W7;^[3FY?C67+-O/=6%N
M   T&&:)\4L'82KBSG+Y@]DAOYUW\4OM?YMLZJGZ%MUJ9 5V^2 ;.'-@Z+,Q
M]J<K(W0ZS'NBS;DW^/C3A=GT^5DW_E8N=.VTW,S*:@      TF$#IS/D/FAT
M6T\S='V.8[=&2MYR_P!<W1Z7#L.@)#FX"AL@W0;)J03I-)O(TIW#4   4!4
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MMS,#J8D/<ISEN.>D%;V4@L?+D8 >69@4Y)R#L3NBS3%AD@Y!BT]#3T$
M*$:S/R?-S5^@><V%Z7YOZ?T7R+T?N%_XN-]%GH'RM,/(XOU%V'F^:;^LP 2*
M!I(/GGF9+,PEL$>ST/(5EL%NE_&1RT2^3MR:A(    %LF%S/Z-$NAHGI(O\
ME1J/3+JO:/-FTXN?T48LJ=E#)X!#R[-HX]FZZ[EDI[8[(MD[ TG))IG*-X
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M5\6-=[5D?)P/K"[/XUY>9R^5K<R#A>YK-M'E]K_5?++7^K_4#T/RKV,0
M     -LL/794 +761\NU>I.3Q/Q,\;]_>;W+>Q]59N^^/?\ RI]8?6?(,!=?
MTN4<;*G%G<K<N3:UTSII;%R-JQ%LUUXLN1L';G*.C.0:S0=@6:749U-P   '
M$(QEO0TRM"NO?IKS-59[.Q;P77F=;D7KUHP=5#>A)DNDTG 12:N9$:C44-8
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MK7(Q!I[ZW+&TY=>!,'-Y..-CI<,:W<YUV&FMFQ;S+7HH>WNY]L-EY?=EBUJ
M          !:=%7F-SF]R[D6K9R:,,:'T3J,/:9GOT0SCI;UKUN?-EY;>]S-
M@7S/N,@=AYYZX]EX]=-VQJ@           -JF;<HK@CK>LP1>W6?Z>8N[:8&
M+L+;\?+IL;4Y]\Y=O'-C-SY<Y:5>9I\G5N4           !2I4Q_@9$(\;?U
MQ<C&V#TT7=!Z9V5./W#6XIM=-//K_ L#8/J.=-IY'/3=:7)U_$U0K(
M     "APB/#8V;&KVYO\/%V$!,3T.9E?#7UM-7>]-G+9>JWN@
M &F%N8E^#/.]K";6]C(S'Y'#6O[^T;MS(=%O!%6_](MWY%,OK^#NW+M;L2
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M[5.FFYJR8Y1J!@4\>2%A+@ZTS >V9W0        !Y#D2SG'J,>91]!A4
M"  202   $;CS])#G<D[C=    !U9Y$E23YD\DT5.A((G.-!U!)$D*:@
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M5B^XX'<IJ^163>4%%XI$PR;)%&II)N#04>B@^HB2JR5*3:IJ5G]YHW!JAX(
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ME',?"1A4I5(XF<"H#KJ,+(YBZ;.=S$-U>SI_/E/(QJJUP?EE2QAY@%#P1 $
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MESGJ;E1Y7"_,/:H.P"81 3B&O,^?44=>9MH3_+S/S%4UU@(@I\NO7F%*(J%
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MF7HENX(NC[5 W*\I[%U;%,)5[_(Z?38^E5ZFX9/29!CC&OL:2OQM@7K&T8
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M8ZP_'1V(\<UF8O5MRI2+G$7: $=&$P:Y)\BJSA6,X6\LD;HP*.Y>DNM@]_I
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M83GOQRL6:Z;W0>)]XK%PYZ5<F:$NZ#Q92BWG+VOV+B*Y[K?'"AMZ9W0\</\
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MUJOY4=L6X4'7\4011!@F(/SFJ$SEODU6ORZKS>R;956Z,Z'I_<@Y\/2F'O\
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MTNQ'UXL$\)U0B."<(1(HKL)VXRW1(J 6=3N",=QD9:!_L=",(N/9"26B%,1
M<=",828D*7\XU/2@?4)?K42 YXOHCZ=B#,>'XJYS&U!MOW*>%=L@S%*_@I1C
M;:1?3\%*[8N$AZ)[EXLZ$+U9*($XU6ZV?W+3VB4D7#A>KBGP#I7I7RT]$97I
M."4UH>)T?4C5'\M&KZ]#<%&UF1)+-TU"E.R=>"+QU3C1>GCQ:6G0MTB2$_%#
MH705M=>:B>6I3^Q%NE3D'$MNOQ4P_B=$M0HR=,:@+:R D5+%MQ;&(KT>]2O8
M<@<@ARS'@_\ M4]]]PY1A<BZ]2(J:IA%JLHS$R_:HP)?3K1D#14]G+(G@$;8
MBQ"A*4N* M%R $/68(>*BD\_$=%;M ?^,2[G@3K[ON5GT30:D&BB' 7F\*-[
M'#D="-B\&(1/$I@?9R2IM]:*3Z.4QH@P#HU9$D@K:#1"QC3$8FE2H7O6\XZ>
M!H?O1N1RR;IX-WU1V5"(/E3RCP1?B4034*>Z5&1C[.:J0/041$-5%O>@+M1P
M1],M5 Q-5'5@?KVJ_BRA_P"0(T/6.M7KMPDG=JHC?1T!N<D*=N^7!0N60U4!
MV)_9R41&M%)XT=$A>&=$?$66R4"8'4U49C>)/7BADPR-DQVA#&_,QV1HY*,9
M3B?>ZF\@R),A\$7E1E(DU4B"I \0C[.*JBT1"+ZA,S! ([HA9>10AOK595B&
MN_[U'<*+Q2X*<B:*,1H"%$,F/L_N4[<N*):A*.Y/*1_! [E*U)A/IU/<IW92
M.PZ!D(8TO"33H0] '=Q91A&,NC0H';)QU%;6DO$2C$FJB[ZHR/4B?9W.B)19
M  53(G@$R:)#E2L[_%+@A=D/%*J:(8)X/M4R:=JD^CIXE M3VED22BS+2@0R
MR7B_>H724) :AT/!0\4-\8N>I%XQKU!'=&+]BV@M-N'2M\&+U91,8EG"MPX@
M51]G8%5-/DC6@6]Z!2MPBY/U]RF+\F?ZT6ZW+=$*W".CU^NBB":-\AB15'TN
M*,KSBJZ4W#VERC%D3!$2DP;WHV)'3N0Q7XH1D2RKH@(R>16NB&JW$UX*H!HI
M/!.R(.GL]=$2 5MD:IR:J<B:*8GHZ$;) 4_5K0]:-QB8;D(B3 !5X*/2@+A<
M(3LL"H@Z([?:6)6X-0(QVN%T-T(!UNU+\4(QB&"E2C)B:$T40Z&X([>"(JR!
M]I<(]*,N+H!T8$HS.GVJ/J7&;K36)@EC]BD"!QKQ3F18H2 HA&)JN+)R_M9:
M2U<*1"9D"R((JJ])4J\%2M5$'5'4JKU3@T0?VDU^3J"U8)@73O0KU(28A&-V
M3AE,1DH!Z \$#N>B/B&J<ZI@*HE/[7HNI:*E$X%57550HRT6GMK\41P*=SJB
M[L$8H[D?$B162E 1(JMQ=G0#=J?A^P1Q1#:IR@^GM]$Q1&A1,M5(NG&B<\54
MU31B%0?)73]@.C*14HQ9@2.Q'V)DWL,"10K+RKI:(J_4%#F%F0E'I["R&0-%
MKJNGV"L?8=%Y5DW=S$1)'V++MSD2U5)!UHM%HM%HM%HM%HM/F^5>5!D7D%Y@
MO,%Y@O,%Y@O,%Y@O,.]>8=Z\P[UY@O,%YAWKS#O7F"?<%;D]'6;>M3:1BP4H
M7[KR$CJ>M"R"%M,X@]!+(QC.)Z@=%Y@O,%YQWKS!<.]4">08+@O,%Y@O,%Y@
M@-P=/.X(CK+(;9 ]B#$+S!>8+S!>8+S!4^>%,#5J)[<AM<MHO-'_ *5I'NBM
M(]T5=Q+DXB,A_NA7,BU(2$GX@ZK2/_2OX?\ I7\/=%<.Z*_A[HK^'NBOX>Z*
MX=T5_#W17\/=%?P]T5_#W17\/=%?P]T5_#W15-O=%:0_Z42UO_I5\9L6S6II
MJKHY2/\ Q>%!HG$:=L5I\8K3XQ3L.^*T^,5Y1WQ6GQBM!_TK3XQ5!\8KR_&*
MH!WQ1\/QBM!WQ6GQBBP#]L4+<-?^5#DO."1 ?\*EB\EGX):AXMW%2NGS:_PJ
M]C?JNU(W8"C,.%-%<R^2N<.\7 )!^W1/LU_X42W_ .*\OQBCX?C%$6!XO^56
M_P ^!Z9D'\NG%&]B3_\ ==FE/,U=5=_*V?Y E2L='58U[8K0=\5Y?C% B([X
MIY1:(T\J.+^JL>7Y9J$$=%-.E3GR@GT)%PYCH]-5$1CXN/E58U[8KR_&*\OQ
MBAX1WQ4/2I;X^50_^56P9MU?<C] PD.Y1\7P6OP3O\$)QDQ4H7"[)OD\WP7F
M^"\WP7F^"\WP7F^"\WP7F'<O-\%J.Y>;X+4=R\WP3"0?L7F"H1W(;PQ0%&[
MZ;:O+\%Y O(O(O(O(O(O(O(%Y%Y O(O[M>1/L0NP VHSF/&B8UEUH^K$;5<R
M#C"5R8U1A&T/#P3B*\H7D"\@1%F(W)[T0Y0E*X]KH3"S_)"\B;91>1.(!T#?
M@/46V[B@R'$]" P(@6_P0\(WKR+R!>0+R)Y0 "\$''[$T^9I\_1:+1:?)I\M
M/GU6GTU3_P"E/__:  @! P(&/P#YWI6XUZ5##Q,:5[(D6$8Q))[ '*C<Y?\
MI6[&,@"-YVFO4Q*E/*_2MR40"?"7H/<%/$YK@W,>^-8SB0?B*H2VDVS^P=BZ
MU&S8L2N73H '4;V#RJY&T6;=3[:HW<KD4Y =!?[@I6<_$G9D.$@1]J(@7DC"
M6O[!Q/T]R>T^3=D 3PB.,CV='$^]8O,N<8\,GG<X@R,@"7UXZ#J%%'\CCPMT
M_LC\$87\>$QHQB%E8IY;;L<X$283B ")=(++)_3_ #?')Q-Q].;4E$'7HW#^
M(#M'5^P''!6>78ULSG.0% X ?S'J"M7^<XPOYAB"Y''[D8XN'"%@= "$)3A.
MUQ!B%<E^7C&_M)! 8OP*NX63&1M.=LF82'XCCTH2B?V %G?_ &!^HL>/JW")
M0E.C0&E3I2I[4<W&S;$L6 :37(D Z#B5AW<O*LSMW',8[XA^(XU97,K-YM8M
MVQH=\?Q4<C)YO8E8N4B3.(?WNI?J/D>/&7-<0&Y&42"3Q-1J"'!ZD1[>RC&&
MH*S/U;FV03M<&0JT=&?O5S&N8QM .(F0($MFK$ACHK/-L2Z")7?3,:N9;MK-
MVKF5R[;(G;VN*U) +#I->"EDVK1%X4$>+]BR.9\KM@\TQ@9D,T@U6/:%<>EU
MV([/V &Z58L8>//\^<5I&V^[;U-U+-L?HNSE_P"D_E)?F1'U&WD#8P/\0JY%
M='X+]"X7,[^;;Q,+U+;G>UPFW21KP'3Q67F9-S(ERK$S+L3;N2N_S#*9XER2
M9$&(+C0!ER/GW/\ EU\\J,YPM8DKDP^X_P L])DP<1.CD+F>/^I;$H9,L>X8
M1F7-N)W$0<Z[8T6=;!'AOW!W3/T5/D?@FX_,I7Y*)N*;Z,[N)"Q<+$(%R[CG
MWDA6\#F&)&S;PC,[P?%,R<!J!@Q<EU:,(B5LWHS$3H^YY2[2-%SVYZ/\S;;]
M.(.IC&O825G969BF7.][P@^G"AZ&U7,LKF$C++R+<Y2!T%#0=0&BS9VZ-?N
MCJW%OH=?F-\^B;C\FOT+'0K#_3F3;A++QH;)Q)!TH:'L65<Y;RRS_,/B&V+?
M8B?]*M[O^$:]5$1_I5HQU8Q!!(THRQI\PQK>P'PQVA@W4S+G%R4HV[0L2C;
M:+DAF5V[/SRD2>TE_FNIX>=S2>/>C:G,-%W$0YU'PU/!6L_]//F8IO;'I#;'
M<QF1)CX=2/@N>WLO*E 8#;O*Y>(E5P5;YY9YC=%F=V5L"-LR+Q)B#( $QBXK
M(M$<5^H+6+E;8X/%O.2';J8-[RK_ #7F&==L2C?-DQC#<TQ(Q.^A84\Q8#BK
M^)@\SC.Q8DU^3CP#;N!ZWI3K=?DL?,>PT]AZ1'4^_AU+DN9AY1E;RA,W?_U;
M03[W(^*Y/D<VYE*UCYF1.U$B+UC,QZ"P+5>@7,.1<FYI+(R+%GU)R(V_PB3
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M+QCAW9 2K3HW?B5:N0O0ENB"&(.H0$8^$E1)%64Y7YQCM!-2!IVH\GY?=_\
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MZ1D P'AE4#W=*QL.]CB5F1\P--.I7+V/?WX]BNUV%?M5K,Q\W\M?D2\10/\
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M@?7O1MXG._3O2# %Q5F  X/Q5G/PVO8<IB-P [G$S0MU'CP#K,,(QC?C&$A
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M!Y>65%5L'AK/(MQ;R,HC+3#N40]XIBHJ*SQ!)SR'5$VZAB\W?KCWA^#\'[T
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M,-).VC5!!L)S]$QC)D#X^.K.I98IA7XJ*Q[#V6/AGLHF*1GDN]5*19Y+E3Y
M,9$I2], ,(#\(Z:^-AE&"0V)U69>2:.TG<7&R"$0$RV5!P<$E?=T@@'(!SD*
M<BGQZJ\(A6?=K:Q,_>+1[.R)&'BFAW1T4TX4XI"A)+BW(!SIB<AR@<.7?1N
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M85F:ZQS*V6@OQ W(5TT,=JGS 8Z8ETW=PBY6$XM%M9A>O.7;5XY/$. #HS$
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M=@AL/?\ =V^;0S$G,7-BXZ!6P(P5KEH5CT_R3>$9+$2%7<?;U^LN3_VBV/\
M2=?K+D_]HMC_ $K7ZRY/_:+8_P!*U^LN3_VBV/\ 2M?K+D_]HMC_ $K7ZRY/
M_:+8_P!*U^LN3_VBV/\ 2M?K+D_]HMC_ $K7ZRY/_:+8_P!*U^LN3_VBV/\
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M=15.=]_M7 =;IE*FW44Y1WU>L6NQ$1QE>9.)A@W#8U1G0+/US8H\029M7ID
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MZIN#I:\V&*O-X9U0[8TE3)]&N5J9O;0KNIU&\V;P8Q--NDZB;_+QKQ1)<-P
MP;Z\S<Y@26D;59/+A6;;)R%BN-/ML1AV1E*7,%@;!%H75JP41E'$3+<R2Z:
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MT8A#U@_U)TA#?LUX&7QUG>O074]2SJ5EA(())$.'6<+,&<@+L"H /,<I0.8
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M_P#J@\S+9;&-]4G&Q\199<OX:;Q\[?<Z%CQX>R1!322+5D5<[7P;LAB"@(%
MQTQYM1\0T<QR$1!,'D)!HQ^>G;9G%1+HA47+&(3(LD9DP?ID #I  $!,.4"Z
M8WKSR9HIU*Q16Q:6"[5VH2[^U66=@8,A55:VXG9(I&<'!K(( F?I]4W3$2IE
M 1#5=R>I$+5NAU6OM:3Y?L?.D3)FK%*9HIQQKG-QQ]E6MAM;-N0C4HASMH\"
M@;8RAM"!0V^'[HAOMOHLM:J?7)^1/7YBG*NIF(:R+D]1L0%)8JX*R@"H$1.%
M(7Q"/YM38.8.&DUEL8TE8Z#>J-DCJP;(3IHT-0RE$1#ZO@WJ9AV9$_L#>SIY
M]O<&8ZOK&:O"%J>0LK68IQ[ZR#/"WBEK$Y%R0H!*/FI2E74./*LF3U]]@#2L
M:;%,,#=RI5TG<>CCPB9%V6, 4DJ;-'3%($OLY3%FAO=JP>JBNG]7L.VGCUSB
M%HV4?0]OGY*8E**@W=KO[DZ;1-I@Y@'! 6"PWI)0AEP-_K6^W-PTHW1PC#7J
MG3#"EXQF1:4IJI$'J[-474!71,X2!5=K1"G%0C=+8S4!^KXZQ[-16':DE0*1
MD0)S$\/%4-L+V!R,JX<(I6NK1A$NO&3"O*HJNY.8IE */4W'4?2K%BW&UG-7
M[LI=*VPF*(Q=,4[Y,G&9E[/%KJMSI&DE'1.=^<0]98H<X&VT^?*XXCI9:0NL
M39W,Z%%3*WE;I6FR#5C= <@CSKJ5=HJDD#TP 9N!BE(.W9&Q+%6=.^EI\(%@
M1S$KM_&*F\6F60;&5$"&C3JL%2E4'83\H[;ZF("<]\%E(MK&.T64?'*O5I8L
M@^0C44XT$A4ZHE=.TRF >40YM,J]%-919H[@9&<<V1=HLWA6(1C=)V\CEU%"
M<POTVZG,H0/8$.7MTSCXIA,B+A5!$7$PD:((5-SX,S-=%)4#G6;OFCTBJ)@X
M'*/K;::UF(9RB?BRS[4DB\33*DG-UI9L61A5DTSJ "@,W::Z9P]0Y![=PT'?
MV\?E']Z4?/#;%+P11_M%E>Y)$>'$="JL)VZ"*B8MFP''ID%,X'07_P#SH*?/
MJ6MV(DFLHWG'8.K=B*4=$B(2Q20#RN['2)(_^6JUG6 1$Z9@!J[4]OE-QT\;
MP<HNSLD48B-BHEF0"%NM8>$ 2*(2D(Z.5PJ100^K<H=1!4-A*8=]<A0^M 2<
MI0+L(<>.Z@AP >_AJ9\SWDTRJE@C,4S+?::>K<EXEM59JT\IP5GZ]+QFTA5Y
MI^J;ZXP%515-N(E#?3CW;&+3ZWCT)$+!7<Z1[9-Y,,'KB192Q2O%6BB/2D'*
MJZ8J)B8IE3<.(ZEJUES)4!BBD7N<1GLE+V'):MU4G) %$>K+.X.(2-[YD$T4
MBE*FLJ5'F(3;;;?5)P7'VE5"*A2+.$WKHAGETR3<)0_6F'\=6F!'$F]?R#W@
MB@B0Y4R<A1'8!'2;C(,6K3\5-5F[R'Q"=TB:P6MPDH"S.9RPX0,9N2($"%.$
M*B?<I]NN83!R@W?LRE:*MTBI-R-S 1NBU;"46[%-,! I&I2AL4NW .'=HJ1B
M>&?D+]:W.<./?U"[\1W]';KO_HB'X_N?]P?ATTFZAYALM88#&53N4F\J6-'8
M),<C^)BE%DXRP) '6<E-X;IID(!A'J"&L?\ F3F\U9ZQW&URV7:*<>6&3;+0
MU"E.@NXCPE)*'D$FSSF=J&\5U3$V4/[.C"H3D]<1  X=O=\7\%YOH'?\/=I_
M-ODUW16K<#HQS,HJ2#\^_K$:(% 5E@*'$=347)2,RE9J\P++Q*<1+.V1/LM)
M+<D66.CT5FRJ<JW5YB/DW!.8H 'Y(AK*D519!6]XL";(X?8:>K)DEG$S($(H
M[E<-2@E2:C8G3U4X/HM7ZDRI>81((\PJGJLWUI6-(D$[3)4A(BZU%PJ3UH^Q
M5AR<K]HX(8! J@$%(X<2F,''4'F2ZL9U[@ZS8TAJUBZVIM5S5"H2T6=0]BJ[
M]YL=E%3,R\/UP,KT^N00 !'EX8OB,EP=DLF6(?*R.3,ASZ$+XF%L](Z;J,7P
MH@Z06%RV!9D*;H'/3\.5R.Y3#MK(E2PA0:C60M>0*)9,>E>446UXQACXL L2
MZ4)[;SG ]C>QUC0( .R_ZI!41[AUYP9DQ)(N$I(] 8PZRZ3I.!?Y08%D0G!@
M.H -U7+2(.D1T9'<!,)0..X:(YN4Z1DY?%!&%@(Y%61MD^Z#;D8P->9$5D7[
MIRKZ@ ! )WB(!N.H*4R; J5S&;RR0\5"X?96))E:EYJ2=$1AK1D:7;J Q=EC
M'!RJC!H*\J.P"H<XAR@6,@W4LDPI$C)0=GDWBIY$ECF8H2I&C8Z1Z92N8YJ4
M2F.L   &-TR[[#HPEY2.&_U2Z9>'24[5>7<..P>C?7,'W ].MN)1WV[]^/=P
M#0@ "<>8"G NYQ)V\1#AWZ&(E04%J9TR?@= W3=H/(Y<CEDL@K_9B5=/L]'#
M0(F)+3STZ,M'+O)624<*&BIH51=,"&X=&/+UA I"_FS#ZNACW[.P+)BF8YEG
M<ZZ<R1W9'C=XW?.G*BAP>/VJJ! 1.?FZ:1>73SPZ,\V3?O(J6.T;33AM'MY^
M#*5-A/,V:)P19R:A4R]4Y"\JNWK%T,"WCWBC-6RN+BX%T^4767L3PIDGCHR^
MW*F4W4-LF4  ##S;;ZF&*,9)QK>9?H21C1<FJ@X8NVJ(H XBW9 %=DH[2/RK
M !OK.8=1$(TBY-@QAW9E4$6DF[1.X243;IKM9!85!5<QT@#5,7!#>V8FHX'4
M,X3]UO8I\R%H^42()X1ZN_BP>B @8YF+QTH9,H"&X#L(CJ<NR\&]>V"9,B==
M5:4<%:@L1RU>IN&+43B#9;Q3!-4Y/8]4/2.G5B90[U%Z[C7D2Y9KRCIQ#^$D
MD4D) B,=U/"HO9 B12J*$+OPU+-)@TG<0D)%5=!2;>*$7AXOI((,8*,51.94
M&<2W:ID2$QM_4'3>5K+-X18B$FB5)Y("N1LZE54!D'Z29B[F7<-VB20GWWY"
M!P[=%^#A\?P_O*SEP?D103%54_#U$P[_ )PT+@QN5DB<09MB_F^EO^>W_P#7
M[_N;$$/^[N#MW[AVWXZ9/[%'\TO%' 8RU13I:*M<2J4/4!C8&2B4@")-@V34
M,HD'>4= C6<G1%QC6J1^A#9/A.K(@*? J?VO@C-U%PV_]1$QR?E".IJI6:"6
MIF4JFDU7L]*=JBY14BWHBFPME7DB@5":JTF4!$BI=U$3@*:H%$ WBU5F#Z?L
M=G?^XZ/3H0H+3=NFQ)U>@VY0,FQC6"0"JZ=J?5H(@([[[ *8R]RJN.T5R<SV
M.QW'>^["Q3YS"H@,W._Y03MP]151)$_$-P !T>P-BOI2WN1*=2]VA^M8K68/
M;,$=)R(&"(;KA_8-2I)AOZ=&/R"',(AL(B)@*.XF,;<?6,8>(B/?]QJZ;G,F
MLU6ZR1P-MN?O*X'AVAI-XD(%.3ZEXGMQ(Y#T=^V_W-M=4#?D=/?;@5/OX?E:
M#;I\@<" "9$@-OW\I"E 1'XM#L(".X ?8 $=Q#AS@ [E'X]M (B42B.VX<>/
M$-@]([AK81 #"&_*(@!N7T\O;MH!Y@$!#<!#B A\ AP'^!*OESI DWW,;J*%
M(!CB @0O,8P%W,L(:R&I(V5W&3--?",JSC#-3!C]FB'4(FDLJ00F5Y5IL<$P
M*<I3'Y1-OPTGYGI>"6>G80,Q#VFGM \1;HK&DF8KTMZD7J( >5LK!5$JZB!0
M^K:B*9.S6)$GZC2;7:UF]9!FWY91)"1:OK?-B:)5(N@Z1>H2BZ9 Z9 ^M3*4
M>&FUKA?M]1(A_/PE<R#)2DK)PV5&"0R!0@K?CVP/-E)VNOE3\BJ2BJIDP P=
M/E$-.J-9IG'_ )A,;3[)D0U3SK4X^10?,!2YB+NYA@B5)PY53.!A54;@*0CO
MOJV%E?+Y.85RE6W)5;OCZD7N6C6*2+C<&,_5OKA:2E-E>3G;KH$(0I]R'*4P
M<6%LL6%[1D2PS4HSAJ=4;)D.7>K6.9541!,%>9ZU;1L&PY@\<Z5'H();B;<1
M HVKRB8 B\<8/=4D\2A5DO+Q"Q-EH-=ILVB59U<)RVKF,P8S350BC=5D=$7C
ME<H'*/*.^E&S,[RQW-"MQY)N?E'[BU7.<F9-<R("G*K]<T21TT1.KT$Q2(D!
M]BAPUDZUJV%NW;3->4C5("3(D_B74^1\1C5W\,0J?693;=TLB0[E-4#CR#PW
M#3-S.R*J\W%1@N;D_=+<B+2ROD2+3K9LRXI-HY<5 Y '=3B!^W50R8^GY9E"
M567F8V$B6(FC*I:&;E(S>/:HI"(+RA@*H)U72I!YQ3'E -M)3<,L55H5\_C'
M0 /!.0CUS-WB "/<18INW[GR#M_%I"'F#3B,];(.<"ON(A@J_39OD6YDR.W!
MB%,5N*"QBF()@VU5\6WJ:G[+E)\65=.I]2)4)&NV:)U7#?K/BD322%!KL3;;
M?GT7\LO#?B'R:[/O^+LUV!\W[OB4 []OA^,-=GTCK<"EWW[1+^/8>_6WS_O'
MH^/LT2 2$?K4O$.>78 %/?ZI(=A[]A^;0= AE!_+31[2_$B/'2DU=+#7Z=#H
M\RRDE9Y=I"MB) GU#"95ZNAS_5AW .C1<?D&9S!9DA534C,6Q0S* &0$0Z2T
M\Y\/%]$1#;U#&T^:>7[RM5]D3K*(L9C)D\N\%N7L\6O&PY$$ 5$.(@98VB,(
M7(E:I:R@D(G$8FQ8WL3L@KC]4 ^)0D11[>*@CJ@9@:27F*NLQ1909&/:6.J1
M36L3D2],092J2#--JS<?9V;2$06 =S)B(&( "&^IS.EDF[[Y>EY)@C"5VG,Z
M",C0:56F8$YX6,E7L?((JJ2;HHG<NPY%%0Y0,  &VDO]Q:;B?.=>3/RK*MHE
M:M3:B0%^O<GDXI42(/1'M 4-AX::PV:J[<O+_-.%BH!)2[8UFIR;GE %17EX
MY/QC)OU1Y>=9$O 0TVM6-+G6[]7'R:3AO+527:RB0HK["CSHHJBLW ._J%)M
MI0NP_4F #FY Y!5]'5X\0W^?6X=OX.[Z=M)('$/#22Q$5O017\VE\''6X<?^
MK8-A^8=!\8;_ (=5\<4O[E&'BEZ1.MUX!Z=*+>/H&P.Y9_7Y1N.R2K&Q1S<&
M;L1[$5@'N#3D]F-/1IKG:+1=Q2G;=8(:-Q>65CX5*!AH-2N*)^\SU@J2@I(*
M?4K+<_-WCJ^R31"UE0?GOY&5J:3D\^L%HCX8(^.)$S,.Y7+ P"TO%>(=Q3IL
MGU#JE NX&T]N6%H?*3BH%MS>B4:FV1[+%F6T'?8-I%6FVR+:?45D$FU2MH%?
M)+JB8Q$RJ\GJGUY@JK9)K+3"V$A$(:CY"9,;C-NQK["#CQDGR)RO@@)1*6D$
MS!T6Q$W1TSG*!N;80A2S=9DZHK%NI"&;-GZTNJG.LD505;V2+;V-=S.QK"2$
M1$K5P8RB)MR@82@'[CXNW6WP;_O@_P#Z=N.GU&95Y6P T;>)735DTHF/<2BB
M2HLVK9<QBG>+ME@W43)S;:BK1565)Q[>J;4AF7$PI.+.@?Q#5X5\[K]\B2-2
M)2\1-],1 RAO$)&#F*.HK&&:''^PE>LM<0FY9]7)H#U_-:3T"(GBJAD!R0@5
MZ-:%*!'C$W(Z$#<I> ;Z1M3=SCIJ28EXUZG032;^V765EV^QF4M1U8IT\L2D
MHV O4%NH4[8QM]Q* [ZD'S/R^_:FMW&-6K<'%YLRK%UQ@64*V4,XLT;2X\DG
M+1$NFF!%^HITQ;=,! I1T&/9SR_1/F-B:<$B1];L*W=J+B'C(TXMHN,EU9=)
MO&R$RJW*)4R-U1%ST^8Y $=2MRI,U,8M\R^%HA>:C,=W2$<UF]G9(EZS^G6"
M#>F0)::).(I&*NX2,JF@(]9+E, #J-SMYK996[9HR=%Q*]2KZ;^3;8HQ!%.P
M+)0V/:C4&[M DTW!CL>2?.>HL\4$1$0*4 U9;#6R?_UJNI9F2KM.F_+;*3=<
M;G7A#G9#+W=JJ[.SLJ,@Z#BU53$4$.;80WU:<3Y*QHQKV7\+WRL%G<@492*C
MV&3*O[V2BHZ?KS24Z2_OZ?AW8]94141:G$3!ZW8;%%DQME>J@H]969^]FG3V
MYVM"DU:7;V)]/5J+5;IQ4N^=J?4J%36,H0I^8"CPU(7&LQ$CC7"UW0AQ>3#N
M1;REGEYBH*&%@4:PL(##IO#=,LH58H+F1+R@7OU*6"PHV1M(TU\I#J,U9LIX
MAG88X$BI.L>G0.#D'$TFH7HM%4S$ IA+PXZ90CUXFF-AEK))K,7*H)+1\R_D
MS++1CE#\VG()F4 %-]MQ'AKU>.W#;F[-N&W#??0_)M\_X]3$0[;,Q4E(E]&H
MOEV2+I=D+U%1 %2B<HB'0%3GX"'9J-IJK]C8'S%V^7-.ECD6[A5)XN*@(]@K
M); ;^?MK_P (?P,?O[AT^EY%R1G'13!W)R3I;;I-6#!$SA=;Y$2B.I1U1X&Y
MY=?E5<D:G8(DK=?ZJ:JA! 9.6V650*8H>P4W;PTX88KB:?A**41504E8MB-E
MMA4EP$$C^/E/\JT$ _+(B/'T:<O<N91O^3)$QA$I[):'[E% !/O_ )&%27(Q
M('';U"%#;2)(B$<$BA632<!T? -@:[@'6>2.P(MPW[>03''?41BJ7PI(^8VT
MQ+RNQUGC7-O/3:3&STZLD+6$A8F.05E[ \;(K@=518_3'CL&FDUY:O*)C-_*
M#(1D>[KU>@'2JM=CW+4I_>\BN@D>1EDVZH@FH0GK[\=1F1KGC&L4A=)IXJY0
MRK>0,E4! YDF9II<72(L6T@0H'3((%. &#?26%;SY;VM\B%UH1K*3[=Z=2)7
M&P=,I30-<?-WQYQLB9?=50H\A U(/76$9K#=I>))K.K9B:7C4GA".2 NS=R5
M1.8&AB#U?K1Z)3</:T^FZ7.ER/ @CS)2;.'5AKI&D2-N 66"$RS28:;>KSMS
M#OZ.&E+9B&^W''\RDLFJ]D*Z^<MXYP1NH'^1F:VX,HQ3 .0-T3)B10..HRK>
M;7&*-O:D,DW/EO%*98Z51)P+XR;I3E3PKU</[46B@&'VN33>2POE&MVQTND"
MXUQ=Z6%MC8G#<KJ D11>E.W]!2CQ[]"F!3D=$V7* !R*$$!Y^._$%>&F#L3;
MG!%)%;???JH\/CXZVWV'VOF#;7EKP'DF(GV*/F<>345"9-;K-2U6CST:=HSB
M&UK%4Q3M$+%(/$VJ3C<$B*F ##QU?<CY9F6^"8.CYTO/E_37N<B1RXL%EH<E
MX!]+PS>+*X74CGA5!7$W3'PZ&YU1*''5Q<2.8:@T2H%7HURN[PC\SME!UC(Y
M@;8^L+IVD04%(VT*J@#90@B0XB'9JYXS/GJAM;[C:#D+#>H!Z^5;*U.OPK1!
M_+R,X[<HI-&J:+-V0PB*GK%.  !A$-8]=XWSS2+0WR=8K%5,<J1T@L<)^T5!
MBI*V6M(HJE0.A*L(@AEP17 AS)>N3<NJ3876<:@TA,D2LM%4F>73D_<T\ZAI
MP:U(((2AFQFC-NTL)#-.LJ9-,ZOL[ZD< L,P4]UF*)(X-*T@CPYG<:=I'!,R
M+=W($2-$I/6$/LX50,N"B:0\Q@U99RK^8K&L]"TZTP%'LKV+FC.0A[5;I@:_
M6HIP@5$%%"STT'0;."\R2RG I]8MQ? E/D"PY!SI(8 GU*PX;D:XOO$?6%;<
MLVN0K'YNK[K*4>1+F'F.'=K*3IAFZF"AA=DZE<G@Z-(1Z]4AHUT,>_FWK=XV
M;KNX-![]2+MN51,%/5WX:M/F0IV2H:V82J$58IN8N\*@[58),ZJT.YFTFG6(
MW7>N$"I;)\I=C&,!0[=2MLRGY7\E^6K""] =95HN<LF6"K*U";HK?E52<7%*
M/>B[H,P]C52/D6COG,+<Y?6YAVU4K;0<VTBV5Z]WY+%]2E(E\H8)7(JR"CE&
MG%9'(1\VFW+1$RR)5R$(HAZP#L.H>Q7/S$8_K<#.V:W5&&E'KAQX>2LE >^[
M+M#(&30.87=9?F CWALGZ0#CK+-9J]*4O7^U<9Y<9H;0-J@X"IW&,\Q]C)!P
M#NNRSLZZ*@1*2A5A PCXK?II^MQT_P#+W!YTHC[-L6^E8N1QZ1X<DTREX-J1
MY-1*P*$(T]YL&I^H9/J"?I\>40XZF\98@S;2\C7VMHR;N;K%7>JOG3%G$R01
M<F[(N9%)HY;MI#Z@52G%/J (!N(:#T]_\OP_N7[Y- 7"S-FZ=(M2* 07*S=(
MZJ3?J=A#N#  <?3J#3L;Y.A0Q!MMZDW<G)M32=9EVZ:)W<6NZ7*#-LV%!4BQ
MQ$QSE(&Q>W1Z-6*?8,F4:["PODM;U$Y*G0DJ>!;&B6D'9D"B9X7&;IR/BSN6
MR( \$.D4!YAV>O/,Q9,=S=3+XY8^(QB$EWQ'H<RL8;'S)\HJ<S!PZ<)H"F?I
M%33'J".X"&FGFPO[#'L;EK,R95<65./,T.ECRK6 P+0%.K3951TY>V249"F9
M^^ @$(4!(42@&LF9FHE0IV2,BU^?=4[)\A(6!^5E0Y%B!!G'S6&C7 LE):-9
MN %4@F3.N5("CWZK3-N=H,:P8S]N>+1K=JT6GF<R[5EF+M44C=)4KQ)8@)"8
M1Y ^(=6HC^::63.SZ1EE<79"Q_$696XXK4BD%%GN.;,W9(">6I,H@AX8SY(3
MMCKK<>7;6$\E5&GWE!''])J[8EJK<FB96EY@J"A8>RUBQU1X":\]$V1FFHU6
MZ9%!9<Y3\-]9\MV-LANXQ[]L+?;8^H-#-&]FQS!M#ED'L(L@<J<C%3JD@V66
M056 2G$P)[B4=1]4R=3+M(57-T71X)%:;@%07KU1;,O>2=ED+$NBF89^Q6@A
M52D:+BG')F+S"/9I]0+7@_)/F.CX9DQ+ YPBYJ/5N$?#-7Q%/!3E.GWO7]YQ
M3!($0=QX[/T"!S% W#5EAL&,WH7&_2@6.^P"R#NG76D3T.U19(W)*B/UV!WR
M9G;4$7@-1 IB'%0>8=26599K-P]A-<Y)W7XMU,+D8C+1RI8EXFJQ35Y%&:JJ
M!SI+'$RI1'U1  #2-I8,P.@R>QTY/NXU5<DFPD8]8IUI%PHH=0)=!TJ'34 "
M\Y  3".H.Y1)S&:2S43G2,GTSLWA1%)ZW5 =A^K<)B/RZ'EVW[N/S_'IO$/Y
MV&83#TG/%QSR29-Y&2X<O,QC7"Y'CC8X"3@ \=2[QM;*JZ:P7"=6;3T<NE!E
M#?F"86*X%)D(&*8!ZG)L(;=VD73*4BGK9TS"3:.6S]NL@>+_ /\ 9E516,5:
M.#_U0]7X=-HU6Q01'[Y@I*1\>:5C_&R4<B',M),F_B.NXCT"]JA2B' 1YM&?
M_;>FF9(K T4<DLL3X4C@1V!OX@' E\7N&W2[?@TFJD<AR*D*HDH0_434*8O,
M4Q3!P,42CN A_ .'H#\(:S+,)+@F]=UM:"9*B(>JXFCIQ^V__P"-8=&!XH1'
MJ$1233< ":CE;;<R39@3=9981] <=$<Q%:=04()SC]H+$48]NHF(_6*ILE1!
MVJCMV )=$F;Y--IE^V%%1:1D7:,%! JMS #-1=P8IUC"I^:3 =U-,IW&>-_M
M<9:59PD3%0[1V>,A6RH&$DO)MHE-5TZ0,IRE >40$Q@$VJWYELI8*AJ7G64!
M07!W)W3@WAVI/#1\R+%4.1JX61Y1#G)U$]M-JAD.R9+Q7#4>JO9DETK<@+BM
MS*TBUWCS3-0;E&2LJ[F0.#9FBW.7;F,)AX:R7C#&B]?R[2J@[KBGFF/*UML)
MW,9D1^@UJ%(]P)<]A63+&NT1>*HF,Y074/ZY>4-4FNIPC)S8F%0BK9=Z55%)
MG.<M4YFU@W3BABH=PTD+I6\?P_LK*"?F8&,(*$$.4=/?,K!9NG9^&FI:4!]
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MNGK(L7$X]KU9S1:#MJC05*K.1-P?1 OE4XR,>9'CXY,JM-CH=(YWBB8CR*[
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M= 1V4.0IA -="6R^RC9JP'")JD?4FSR:N\K.#LJ@P@:T9@=U(RGJANAT]@(
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MNBF5P].  +QT4 !9<R7#BN.OO]/\)[=M_HTNT<I^LHFJ":Q?SC958-@71WW
M%BCQ] Z>H2GF+O[JK/%%BA'M:E5XR09MG*:J16[><;LSKJHCS F D*51/?FW
MWUC5I$-')8R:#(U.FRJ+JOWP3Q+;(RT5(3,@O]8LL^ 50445]LY@WUDAB@1-
M4+=7"3+!/F^I7D19^XY1NEL'*DJ\:E2,/Y0F*.H1FD0B3=C#1[!-%$O1*@1J
MU(4J(I 'M )1W'OU+XV/[OA<<6"+E$KW,J2?7F9Z.&.<BSI<5'I$ZL2C-N2
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MZV[?O]'\/X (?]VAVW'F]HPFV$/B$.(<!UTYR%CY(!-U>HL@4JQ5 #8IA7*
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M,SA>=>E,^D96'S#'D,)_KG=@.NG83E P\5CJG3,H<.\0UN'X]=@?,/X]=_\
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M%YN0P@)1Y3#OR&VX<..@,&Q3F)L COLH&^^^XCQ[>W0&#E$IORMA HCV=H[
M(:]CZ?Y-=@??MKL#Z?ZVO9^@?XQ'78'S#_6UV!\6P_CVUV!]/];7=]/X]=WT
M_CUW?3^/78'T:[/P_CUV?0/X]=@?3_6UV!\V@Y1X?%KB'M;?'Q_!K?EX[[;[
M=NW9V\.&A'8/EX\/DU(.)"NQ+US-()-)1=TP174D&C)3JLVSQ0R8BLDW5XI@
M?@0>S12$2*5, 3(!0+L!0('*4 ] %#LUZH;_ "AKV0^<?QZ[ ^+[^&N[Z?QZ
MWV+W[[\.'Q]VMU.0P%V/ZW83T?'^/1_4#<X )N( <Y2\"\Y@ #& O=N([:
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ME"CJ@_8R.QI;;W:7R$:UQK,24XVN&1I%L+89"*QLQBFK@2 UYU#'=O!(V;%
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?YC(VA^V _B)R0C6",4S=O3&$>9P@Q;$2W[1(7[O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>chart03.jpg
<TEXT>
begin 644 chart03.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[@ A061O8F4 9$     ! P 0 P(#!@
M             /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$!
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\( $0@ Y@)P P$1  (1 0,1 ?_$ 1P  0  !@,! 0
M       !! 4&!P@" PD*"P$!  $% 0$!              0! @,%!@<("1
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M:B;6L=V,YN#'TW!E'7R,$;:'+EY1\MZ1<WH#R6Y
M                                             HBL 3Q/*
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MU:%58EK2=5L8R=6E'HY*]"F9:5]Q;0   &*2XP<B!$@<2 (@$#D1(@@0!R!
M$"  ($2)$$F765,   '37'U5LZKK(T=%V*9MS3-N;LI>       .D[@
M                                 #\[[Z,\RQGGQ@
M     #UYY'<_8EXUW'(                _'\^PO%,(2L(    X5<Z.U7B5
M"VM,NM   E;GU5>5=?Y2]7I\@1[[1S6US'?FV#(T\W,"_(^6\<-V08^6>I7S
M_P!_K=[M%L<3R\.6H>;#TW!Y+=9I@%7V%>1=I]LWA_>\@6QFUWACZ!\C^+G<
M?+M-NPU&W/3;L BK/6Y>Y=,6WT+)$BK4K<W!20NQ%!]U7S_^N(&-)6'QG[;1
M6_DMRK"SYCB9L/R\.#MA&]&^:VOH#SNR_'\^PO%,(2L(   ]..9VWM'Q6_\
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MN>DWQZQCDX$V/'Y#C;K:[4>AZ-[_ ,GNS#L=-=WYB!^@)\Z_L:
M                    /C@]L_,?2G>>82M<>Q&M[6ULNOK%DFMV2K9RP:#D
MAWU'V\K7'C.5H;BQS<=2=+2[XX_0$^=?V-     M?+98TC'F&%G
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MVPC/Y3)\7?V/GU.+Y>@T]W7F@ 'Z GSK^QH    'YN/TGY=JMMH?U9^5]?
M B0I0  1.*X  #MHB  "9I7MI4  =ZDQ0  -H-5+]P^$Z$  >)_>_*&!-AR
M A6D:5    'T5^9?;P    %OY+>JJY<5P
M         P%5K55@PRP8[-TJ-GZ  !B4R$5@    &+#O,F    '$UP,K%]@
ME#0ZK)1I_5F(NNC2FK:$]&K0             QP:XU4PKA6C.]%]@  LXK!6
M0    6*3Y=8    ,:%T%Q@ MXTAJS&6P6V=!/E--\:
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MZZ Z05Y',+788,ER8$W0W*409VM<NE24D^9R%]VMMK3^O/MG.4HJJX_;1O\
MZK?W'(MRQ*<[[B&6HK7+6IM/('S3MJW .J NY]7:7BQ=UO1]!2>J,DN=E "E
M0K;-Q 1SS+8C@.-1UW/=*D3?3>,N5Z/7Z_BG'BJCQ51.<Y_;P$=)+"^R-X(
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M2,QPQLQ$/.KUG=J#6$H%-?GQL6R[E=,FW[=N>XO</'1I"D H>2AJ79F%!D:
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MW..!;QE 8Q1K&&().I@OE.:YL<SEW,;%L]W=J;+;B##10&!4 *689L5 H">
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MRJ5ZK5K48V3;'L442V\<K/J(+MH8A!G0!VI4\2>%,;#=R;8+3<&N9%Y8U=9
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M^8OBQ[E#YB^+'N4/F+XL*C6L =N *I4TXT%,Z=-, R6T"@D 55!F> X<3T#
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M4R"*(H'4E5(JSDZ-9R&@TS.###"8HY(HY>74GEF1 S)4Y]5B0*YTI7/Y+#_
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M%:UKBQ]F=]!;K)&.N^8 HQ1EH.E25J,ZXW&&"[G$[WZ"I0,!$X\L=6A[A -
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MNH@T EB1$8,GVG+(+1^23QQVFGDWJ6UWN/=[.SEM:QJFV[<Z#EW,<CHRGVH
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M+I SNNT.Z]IO:+0;1?3W]JMQ;RW<,L0)C:TL1"CVIA:D;1S-(K5#M6F/ZF;
M.T]W=[4>S"W\8]IBNY5</1X7FBMX5TR(=-Q BGED$+(#4#^F.R[%VTE7LW<;
M/+*;QKN"U!O(PJBT:ZD@>-$M. MRHDD4:6<E:G:MG[9]N1M5O_Z4]J62U$;0
M[E>/J1E5FC82H4"D0QA2=1*TR([!94_Z!?[S?J0\,\:O"PH58 @CN$'(CO'
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M'<D\D\EZ2D9GE'320T%>I7(5X8N+N78[M+:&AD<P2!4J 078K1:J006(R(/
MC$<O^07@C=U56Y$E&:0515.BA9P1I J6!%*UPUQ+8R) )"FHH57F)FT=2 -:
M_O+74O2!C?[U=PC&V;;917$DP@N6!:=0R0(G*$AD%?M&IRT7[0L4SPF^1[QM
M=I9/>^R1BZF,1DN- <(AT,F:MD2P%:X[6;]=6T,<6RW!@NHBU9@5$;,R  J\
M:K(K:@V:]8"F.Q\=R;-9][B+PAY1'RU54D(G>0*L9"NI"@L2>J 6H,=H=HDW
M';[?_+;R.UDGFD:.%[J<Z888CH+%Y3D"551Q8@8GNYA:0WJ>UF.TDDI<S+8M
MINWA0*5*PM4&KJ7H= -, @Y'\].RV#E2[$<.!8TZ<>X/]'CQ[@_T>/'N#_1X
M\>X/]'CQ[@_T>/'N#_1X\>X/]'CQ[@_T>/'N#_1X\>X/]'CQ[@_T>/'N#_1X
M\>X/]'CQ[@_T>/'N#_1X\>X/]'CQ[@_T>/'N#_1X\>X/]'CQ[@_T>/'N#_1X
M\>X/]'CQ[@_T>/'N#_1X\>X/]'CQ[@_T>/'N#_1X\>X/]'CQ[@_T>/'N#_1X
M\>X/]'CQ[@_T>/'N#_5\>/<'^CQX]P?Z/'CW!_H\>/<'^CQX]P?Z/'CW!_H\
M>/<'^CQX]P?Z/'CW!_H\>.;N<12W4^2:5<]^AR7N])X8"J % R'Y7;+_ !X_
M^1%\EGO=VEPU@(9HI5A8+(4FB:/4M2%)1B'4,:54'(@8M-D0[C+MT79_<+!A
M(RTEGNI2\-Q*FLJVE:<QC5PQ.BHS/9G<EL+F.VM[JUFN+98H=*FVMF@!@GYF
MIJZNJICB 0L&)-,;PF[VVXW/:&\CW!)9699EE6ZCT05,LE8Q" %9$3KT!U$*
M%Q'L6P;C=W':2^V;:+>*L\0V^WDB$<HF5B_4G$@"MJTA#UF<#(6NR[08A:VZ
MR3W'*<21-N-X1)=E77JN$;3&&%1DP!ICMG9V4=[$=RVW;+:/KA0CV059V<*_
MDRJ-(TU++DX RQ'V6[56.Y2F+>#?+[*8563[%8A$[2&J T)+(M0.&>+ZZWK9
MI'AOMWFFNH4*F-K&6R%I[."2I:1="/J(4$K6H/#LH9;25;NQW&ZGDKI*F.:X
MCDACCSK]E%&L9U "H%,L=L.T[R[C'M=_>QW"VT<=LXE,9U*LQGUB%PP&F:&K
MHK. :T..T5Q<S7<N]7KWS1VY2W]DMVOB=;I.P-T JL285*H\@#,:9851P I^
MH';+_'C_ .1%\N_R3;Q%8V>VV#W<LDB/(.6CJK +'UBW6J.-:4RK4;I?W/:R
MV&WQ>Q\A^3+6Z]OB+VP5.,3NPT,),DS<MI%"-MA[8V;7<&XQ6%Y]C,JVMU.C
M/"@9J"='<<HR)ITN0=)7$2WFZ1VQ6P%W<(8F>2W22=K>!"@9=;S%&DXH$C6I
MJ2 8;.;M991WTU]=VENBQR2)/+:1B6JR(=*QR1FH9J:31:,:TWB--T6W>SA$
MG+6,SW$U6*E8(%96DT4U2%22JT(5B:8C[53[UR+9&@:>-[>17C@GFY(ECJVJ
M;2:%@(U4UHCL5(QOMCV;O;3;MAVN2"S+<N9F:ZE37]NSR4-%(:6X2D85E58F
M96..WR3PV[7.W01C6Q<E':[6 O 48(Q->,@92AJH!SQN%_%VC@OC9[G[#<(D
M4D9BF:+G)0ODX*>5IR5LJMG^H7;+_'C_ .1%B&UM('EN9&"HB LS,>"JHJ23
MT "N'CD4K(I(((H00:$$=!!R(Z#CM+/;VY>\O=M>VC;J%8W9T?6Z2*RR)12K
M(0=5<\L;E#NF[/+'=SPRRC2B@O NB$KI4<M8E-$1-*CN5Q9P;GO;R)!,DRT6
M-&::, 1S2LBJTTJ  *\A9@,;UVG6_DN+Z6W1;MFACEA:%2%C$\31M"(U8#06
M4 /F#4FNWSVNZ<N2UNI[F+3'$ DUPNB9U4)I =3ITTT*/)48GN=CNDAN9*=<
MQ12.K"H#1-(C&)QJ(#1E6S^;$O9K==PE6U$4<3QR1(LI2)Q-$LCM&)FT-1DU
MMD#ED<]YW [FLEQN$BO<"6&&6.21!I23E21M&LB#)750P'3C=8-ON^7%>*J3
M@!3K"2"51F#II( W5IW.&6-SMMRW(RP7EZ+N8:4&NX5.6),E%"$ZNE:+TTKA
M[6]M9(;I:5212C"H!%58 BH((RS!!_//(YZB@D_,!4XAN8O5NH(_;^DNV7^/
M'_R(L=B;BXF6.!-RA+,Q"JH#9EF-  .Z33&P;E=V=I;75Q)O*M )V:.XGMY1
M[&9N9,A!F#.U.;"DQ 565<79N.SML=>^[?:F&>XT\B*X@_ZMTY-S(.4C]9-4
ML@B8A7;JTQM\L&V64=Y'-O$$-LUVXBO)+1E%A[3*TE4YP+G4K1I*0%! ICM=
MN8V2PGWJWV[;F]D6ZD>"WO9WE6ZC@=)2TR1KH=D#R!&HI:E<?U)VO9]AV]MO
MAV&S8CVB5A?2RO;R/&Q$M:1-JJD)#>7J(K0=J87&VMV?>[$48]H^UM@UDLP:
M.5KF,"+GL42D=PY<%&TJ"<7=Y:;38W*P]F6NVO/:F-VNXB0+)&]NL@"1P@C2
M6B J11FU8[?7^RV5ANV]1WT::;J^8""S]BC;VF!FG4W$G.U+4O)HTA AX8[4
M_P"=VMK[2D0Y-S=2#V>"B.S<R);B"8M)0!)8UE"/163//L9N6Y]G]K?;+;LE
M<OI6X:-WOH&J+9P)1("?+!9=;M(P!8 *'W8[;80V4NS2W#W2W3>UP;KS#R["
M*V:4DPJ*( T3%D^T:2O';+Z^O;2:&XW&.._F-P%>+181FTMXPL@7V6>0!9K@
M=99/LRT8SQ:6^R[;[(?9$,\89&CYVI@7B"7%UH1U"G0TS,#GD&'YV5%/7E(0
M?,<V^@'PXDM6/6B;+^%LQ]-?TEVR_P >/_D18((RP>J,\4"BE*<,'JC/$D6R
M[/<7<D0!80QLY0,=*DA0=(9L@>%<;D4[-WE+%B)Z0O\ 8$#4PD%*J0IU'N*=
M7#/&W7N[6;VUC=[=-=PN(9)M2Q+JY;K&I,3.O6U-U40AW(!QM>R+87B]G[X)
M%"J6RI[4!5XXC*D8DG&19$=V! J 0,0;-#V:N([YK=YU$T;1#E1^4X++TM1%
M %6<A>)Q'NNX;'<P[>9- EDC94U@D%06'&JL/G4CH."=(KC7I&KN]./)'@Q1
M0 .]^=BM5/5B7/\ B;/^RGAQ&A/4E!0_/Q7Z13]OY_CCCCCCCCCCCCCCB,>4
M,>4,>4,>4,>4,>4,>4,>4/#CRAX<>4/#CRAX<>4/#CRAX<9N/#CUB^$8]8OA
M&/6+X1CUB^$8]8OA&/6+X1B@<$_/^7VR_P >/_D1?D_U,BWR[F2"YV^W14@E
M6&YD_P"I!98&8$%U7K$4-5J#0&HW#?9^R<_^823$*ZR1,S6PLUM(XY7E1F#K
MIYCM#HYI.EV*J =BMIMLO'W*SV&]VQF$J&%TN=7+F"L-0="U'!-"HHO1CLU?
M#:;A'MI[*2YA46W)E]BC,:F*3EBXU'(JLCZ4!9<P13LJU]MUW.EB=U68B8"2
M2/<F)41LU:- #^_5215:8VKLS%M]W+?V;(L5S<M"9(;=-7V"M"BM*C$U^VKR
MS7234'_09YW4\F4Z@W1P (KT$=SN82./4L(S9Q^Z.\>Z>@?MQ\3GQ\3GQ\3G
MQ\3GQ\3GQ\3GQGN<]/V8^(S^$8^(S^$8^(S^$8^(S^$8^(S^$8^(S^$8^(S^
M$8]_G\(\6/?Y_"/%CW^?PCQ8]_G\(\6/?Y_"/%CW^?PCQ8]_G\(\6,[V>OSC
MQ8]\G\(\6/?)_"/%CWR?PCQ8]\G\(\6/?)_"/%CWR?PCQ8SNIC^T>+'O,WA'
MBQ[S-X1XL>\S>$>+'O,WA'BQ[S-X1XL>\S>$>+&=S-X1XL>\3>$>CCWB;PCT
M<>\3>$>CCWB;PCT<>\3>$>CCWB;PCT<1W<4TAD6N1(IF*=P?E[YVFMNT]M!!
M=R*PC:%V9=,:)0L' -2M<ATX_&5G]Q)_,Q^,K/[B3^9C\96?W$G\S'XRL_N)
M/YF/QE9_<2?S,?C*S^XD_F8_&5G]Q)_,Q^,K/[B3^9C\96?W$G\S'XRL_N)/
MYF/QE9_<2?S,?C*S^XD_F8_&5G]Q)_,Q^,K/[B3^9C\96?W$G\S\X5= R]PB
MHQIC0*O< H/H_P#8L__:  @! 0$&/P#[J<"'(<4S;% *8IA(</:4X ([3?P#
MX_9>5YO,Q2\_'-6[Z0@T9%FK,,6+L1*U>/(PBQGK9JY, @FH<A2'$/ 1^QJ8
M0*'LU$0 -1]@:C^_UH!RB/[P& 1_T /W 3&$"@ :B(B   ?OB(^ !T!MQ=IM
M-HZAH;=_%T'V#NU\/W^EWTF^9QS)JD*SEX^<HM&K=$H@!E5W#@Z:2*11$ $Q
MA  UZ*<A@,0P 8IBB!BF*8-2F*8-0$! ? >M1\ #Q$1Z"2K\Q%3L<99=N#^'
MD&DFR%PU4,BY0!TR670%9NL42'+NW$, @( /[M<@\6<9+Z7&F=KO0G,)CJVC
M,N*X=O+*OV"SR';V-H4SNO.[1#(N8M%^EH=FJ\*J!B[-P<[,>8,P5E'@E^U6
MP9PW5M6=D\QYER;DZIY.Q+ /X=:\Y]PO-*6*>@0RBXE7*3B(7*V28MC/C(I.
M'"*:ID?V1N!HBF<:<X<@>=&',@3;"TW2R91CHU"!J>-J#9<<W*_65=563=VH
M(J<>25M*@U7)(.$BHL#IF4%3KFIE3#N%^*LAA/\ 9L3L1CWDFPR#9\E1N1LN
MY!@HYC^MQ7#)X@IX2J5>#DQ<FASS*3I=\U*D8.XL<S=/D9R*Q%26M@RIS X?
M_L^:AQSJ.11=PU#86O/"=,F(QSEVXMG,?&5*"K4&JJ==15VW!TY3*FFH4@G4
M)F+CYC;%6)\D73B#3</!FZ(;XPY,V>3Y"97OL-%S]NJ."%\7UVY0N(:]78M\
MJ9A(79PIY]1#0H&#=LIU2SE4[L3'EZ9T+*GQ5:VNWXTMT1)*1"<S%QLS)5&4
M@9]D\BRRYT7;052E[Q1 Y=Q TN_[4;%=!D<G\IZ5S!O?&6N-\DY4RG*4UWC6
MPY B*<2'/54;<U@#33>)6%)L_51,J18_=4%3:!>L><5K?B_C76>4<IA^^<D,
MA.8VM<ELX8OB*.%HD8G$F(:G%8<K$KD"4R#8$XXS:9L+MNVKS%P8BA $IRDZ
MQ)EG&=+PI2L@O>+!N1F8.*V4L<\F;]GB#>0-AL4):6#U+&]=C*SAS&#@E>%2
M*LUQ<LO- X(86Y4BF4Z_9TGQ!;\8T[CIR-X95_D8VPO:)G(!XSXDS\6Q>Y7<
MWE"OH),I_+<$LJ];U)<@>DE22:G<E3.9QK3N04=QZXI3F()C]H!:."A*ZI<<
MD0.1;=8W4DJSI-@9KG++UVF0S$Q ;OG*PRBSEP&\K1NCX]?M(6G*'#N&)_D'
MPBRY@S%=10PI)7Q#$]^D>1J4JYI;F54LQ9&X-(^IQ\89V_.DFFY>D,#=)%%;
M\(/*B_SF$L:VW(&!+GQM:8_R2RQ5R4Q%@W,=>S?94:[::]'P&<HJF9 B[GCF
M6$S-5P"BK)T!@<$3 A-%/VI7%^UU[C/B_D9QOXALN3V+LCXNF\C2U9@<<3\0
M#NWQ+A]/MR2+_+51@'AS04@1DUBUIML!ET/*&*8*!$\N;=6+9/\ (# 3N(A;
MK5Y6Y/+7)XWR%C]".A[!DJ9LBA'RV6!=R3MP^7CC^3 01%$V\##UQIX54.^3
ML;G#]G%3>=_(CD)Z1)3"T\F?B=>"PN*H*0,BZ2=&</F=F>MT"JJ"(BW()""(
M (?M=OVD$S3X#-N',=<2N$7'NC8ZMT_;V>/I^?O#K$^4LPMW'Q+G:[)-9"GW
M"60VJ-7*"Y7 BF<>V90I\W\>N*&&^+):GQ<_9YX@Y:C(Y4E\G-SQU?2Q]"6*
MQ46%8P<D[6LCYW'J'90_F7$>FV!N"CMVJ8X%'A-A#AWASC_'9:S[PH9<V\S+
M9]LMZ2H=;J2\R^IX8^H[NG(EFUI>9M<0NDD_<HN"-6SE!11(0(N/7!3B)Q:Q
MWBJ9Y*\R^0_--_#V'-<Y8B8;QC4L3W1[-7&1EE*<"-AM\J9)T8C)NQ.3>" F
M-_*IAU0FV:<3X9J+_$_[29#]GQS:GJW)6F8H\.-E8*J4S+F*)=[)LW,/!'?Q
M3]%^A,$>'1.5OKV^\)4Z=BZ'PYBZOY=RYSIP[C3%4)+(6SRS_A'EBFW;)*6=
MGC(EB%^^L$?2J,NL"Z1DH\QW">Y OL-^Z]QPAE E@-2KNA&)2BU4LDM4+*R<
M0LU'6&(DH.R0;AK*1$E&S,2W7352/[4]I@,43%'.B#B$R=F&Q\CL8R6%\KY$
MSUEFXY3R+-XIE6P-G=%8VJ;?$=P<(8")'_%"I+"HW0$5![*>WBO/5U;,%DF^
M&;S*:^!)._96L-K<5>/R[#Q<!9*VX(Z!%L_JT9#PZ"$4P%,J$<0#=L-3F$;K
MF*[US)\0^RO(UV7S?0*!F"]T3$N=I2JKI.(5_EO'M?E&L/:';91 @F.7RYEC
M@*BFY4QSFSM.Y!QP_D?_ ,A\28UPM>85C8'D578RG8@=1+W'!Z/#L2HMZ=.5
M1S!M#-733:8A4M@%V'4*>&R+'7KE-C[(26/J/C"^WG%O)3)&/;5G"H8YC48:
MHMLW3-;D&;J_RL;#-DV@R2HHR*R*9047,8-W2+=+?VVZ2:*?<4464V)$ A.X
MLL8ZJI]I?$QC"8P^(B(]2_#HU=O(X2G,TGS[(1@WZ:]?/D12Q-;0+M.Q /GD
MHSU1FF/E@]SL 0UW")NJ+E^V2>7\7YIQW7I&FUO,O'[+%JPYDLM(EG)GLA2Y
M.QU=PF:7K3AXHHJ#=PF<4CJJ"F8G</JPLEV5SWZF; <-QLNBL)R#R=#J9>QA
M7&YT:\SS&];S9I7(LK%+F*X!R_<'%TNDD9T5<$R%#AW;V2.4ZA;>#M8KE$PG
M9Z/E*S5F;7H%85BE6=$OSUDMNN=6>C$@1ZW7 AG:+APBH<4EU"&KV%DJW=PH
ME8Y7!S/B&GQ]FO/HYQ*_-(%DU)'7O+5X%SB'IP_@=/O[O==<PW-[Q_+6HG.9
MWCV2STTE+9-^5=S.*F2K3'\[3/*.&KBDS=955!RW<L5"*@X(4PB)0$HWKCED
MB]\H<S8_R#:<<VN8=9CY&9 R':8YSBE^>1I456)R<>*FK,&P<*#WD&:21G@
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M\FNR"14U<&14]T(B!1#_ -@FH^ !XB(_>Z$I[!"%,7P$II5@4P#[=! 5P$/
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M5[/X'N ^W[MGN=?9X=&_\IO_  'I^0D@^(0AT2$(5XX*4A"M4"E*4H* !2E
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MB::I]1=/Y."G&:P2$C$BY]+(0JTFFV,F.J0* ,4[D[-ENOYA7L/&L<5X7B:
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M*IV +*E)W@#MB80 !U^Q%EMMA80BDV[!E$H.164<OW&](ABMVS9)=P9-(ZY
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MLGVA,*8Z@'49YRL0+;OMGIY?L6YVZ].=)&2!@W9;ZHU]41=E,<5%3>6% 2@
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MB7.'Q4,"4BB<R@%9:F(<" /F"[A O]F8+3UDS81^-KK7T$"&$LMI\5?ZQ,H
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ME[0G X@4<?5QQ#-7H7R-RG(^L24\E 0\ 3&="?7E927=JL'_ &8^039"BHX
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M!M!:&0.FF<; 76P /H*8GVF/X.=Q1T1$-!$@?$BYEWSRT()C-H'1-!(BQRV
M^E@$0@5Q1 I#AJY$3EU1 -1!L4:5<4O,3+Z),91M! 5JBS!Z))MSLGSB$,_\
MH4$#$ ZXBNGO2)J?8Q U)N2 /9&2CSF7;00%CTX_SO;DWW;GU!)'2?E"^6,F
M"JIN^GO33U/LC=U*N+7U!U(ME/,MH(OIA& NNV[DNU/K;&LGY8/+"EWCF[I-
MY4]3;8H#TJY-/4AD05%TV@BA$^0,8J8RO9GUQ3"3VZMNSWM0$-_;\=(G?1[H
MR]3:/G2OG&T"7T@[,R)4V<MV+"OVW;_NB* (]\@@0V\Q/#6,,>C75GZC$N9-
M4KMK %-%*MQ:@6(D^S85P)+.O,CVBHBLB/9/N5+H7<S.:C75N+N#4F3D7:P
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M"]HA=J*8% "E#W(:> =.G:$9'HNGH&!XY29-DW#L#CJ<'2Q$P47 P^W>(Z]
M1G&L&A 2,@!6S-N@4$#G,H=$"I)D#M&4.)A+[!$1'V])QQX6)-'I*BNDQ-&L
MS,TUA,)Q63:BB*!%1.(CN H#J.O34SB/9+F8ZBR%9H@J+,3$!,PM1.F86^I
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MIZ03H\!8(X<JJ0.+IR<!MDBY,,'OC1^6)2GPR3!Q'NF5/>IG*;NND%'8IF%
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MR"AU$&XE,5)0Q@+TUS;)Y#^+T0Q<TA[=(*;H%@C).#I=VN7Q-0M-=,Y?E?W
ML<[$JBI$F+9!0#B1!=4Z9PZR56\0V&C8HQCAB3HN'W,B>O6Y\]D,EV.*--@>
M]/9JP DL#:.63=2MA:F28I-UTDTF:BB2H]<H6TDPJ3V7Q17*ZW++/G<V[5@Y
M5[E2+H[F8IJT$_:14FHJ=<P"9\1PV59FW)E X@8+59F>6JQD<V/\QDPC?XJ'
MK-BKKBMVQ[6?C;$*(N9LZC:;:NXKP6%N(D;K>X ZF@C_ (A9X_Y_ ?W(J_3"
M&A(U_,S$JZ28Q<3%-%Y"3DGJYMJ#-@Q:D5<NW2QO B:93&,/L#I=JY15;.6R
MRK9RV73,DNW<MU#(KMUTC@51)=!4@D.0P 8I@$!#4.LQ2,5%KOI[(V(I7'%?
MD"%B7+.NRLA-P\JG,R\3-LI".GHDJ,8=%9FHD8JQ5=# )=0ZM["YWE]-M+U8
MJI:K(@9E%LDUYJC1ZD53E(T(]DU]!8UN.5%)JU9=ALF70=@F#7J CKGD>1DV
MU<L,/;V1VL9!0KU_;Z\BBV@K;9I&$C(]];+-$-VY$V[V14<KIE#0!\>LB9E2
MLLK:[)-U>,C<K2;^FP-IJ3RFL%V;*%;7.K/H-]4$8)B_11!J9=J0B;L=Q#=P
MYMU7D82Z>ENJ7=;GD.K>1@*XU:PEOR%'*1-NE&3!"*38II2D:J9$K7M^5;D'
M\"F0>I*5QO-1\#+RO:$TLXK%9GY:.=H@[3;25<?S\3)NZU,(@_5*1RP,@MH?
M34= T>X>NUKFVL*E!UVK3->L54AXVT+PM:ETK558RPRSZ#;6YXG#2)RN&8.E
MS"1-00+[A0V[(%J4NC26E,IR49-7UO9*?3;1 3\]"M"L8:P'K,_!2, QG8EF
M7MMW;=NDLF7P >KM&5>>-&,<@M(Z,NB"31@N68:P\^VM,>W.*[9467E9UJFO
M^ [0CMV#[@1+U<HBX6Y:8C<@9":95N#52/BFI)B_LH;XO-+"<[1F@=JHC#CV
M 11%-N(>(DW>/3B&L<-*U^9:%0.[B)N/=1<FU*Z;INVIG#%ZDBY1*Y:K$53$
MQ0WIG*8-0$!^[6Z^V5T5E7*36)ZVS[PYBE(UAJY%NIB3<&,<0* (LF9S>(Z>
M'6+,\4,R_P 4<KTF!NT*B[V>=8H33)-PM%R )"*9)&(=BHU<%#^*NB8/O?NE
MGC_G\!_<BK]<<Y65D&<5&1V7J>[D).0=(,6#!HD^U6<O'CHZ;9JW3+_&.H8I
M0#VCUBZWSU?H=.F;3*\P64E2V=ZD'L#?KKC^TMAQ"YN)IVXQ#ALYN*3]VZ$H
M2<0SF#I%12523$-)PTGBBHJE>\F./^,G53O%_,P3I5;O=,$V4Y>#)3\DV)F>
MK1,P;S307$H_)&N#E3<+#VNV-5>1U/QS&6"+G>7%(J>/7N599M6,OV/%;Z,0
MP<.2++)6,CJ+^-Z"CI872+B.9R9R%23,4@E#K/%Q#&V,;'D6K8JX\29\2L,G
MS<I2Z'F>[RUDC,EURF2T/9%I*UPT!'D8O7+4CI\1FX $A6 F[7E_3*!C+%SJ
MK0?&3$3Y5N?(-D>(9LL]DF*%/R\"_7;V,RQ&M;?&6WLH=5)QXN 6,4# 4F:V
M3HF('N*WUY;UNNH&OP!9\;MI/"L?<&\C!V20R3!,FM;-=WBC5D9*/L#Y9RD9
MNJ"*1#&";L$#1L<6TE>X;OLJ/,NADE\ME-GR 1L;6/L=<F,?L;$@A"P%216(
M1L9:-(D4YB""J@JZ!R@L^.JYC+.618G(L'#>G9-S4_13I.'S89A))3(U+D7]
MTCG5\G_C@9=N911Z_%D9L1 K<P>XZS3^L2&I@3#&$9FJ61\FS:"5"HI6\/+2
M,GZ_56%[I5M4?SHH)),91BA*ILW0%34;>ZT/Q\MUQQ=A5]3JGP9R1+F91E\?
M5V6E<UT5\5RWQY-M6EI1GFJZF\7:2RS;SCI=^L4JBI2)ID6O/Q0Q=!5V:X_6
MC($GDICD^2#*5*Y0GGE_B_@JMXX?619V[IK-,R31%)>-7.X9:N5'>X!$:C9;
M-8:18(^T97@X+/%Q=7I%A+U@8K!E?/B>A5Q%G.(1Q\:7FP-2HR\^4>^@^U:'
M5:%U.$%%8[J T54U%AW5WKK1_"O*Z2W*/9)-22JR$+?\FEAHF4BTFZAF2\PX
M625 Q]"E4*'W7(%8BWY&EOY%3<5A2$(!SE<^A2H+3E^<IE3,4PH'J,,X8*&'
MW)32!/OB'5UX]S,CYBQ\;\@./2&R[GNN QWDX[ZRPXIIG'N BTMS:;3'34J9
M#IAX:@'[I9X_Y_ ?W(J_0E.4#%,&ABF #%, ^T! =0$!Z,!DDA Y2E. IE$#
ME)_$*8!#W12?> ?9T!012 H$,F  F0 !,XZG( :: 0P^T/8/1@%)(0,4I# *
M91 Q"?Q"& 0T$I/O![ Z<LL=T&T7=W$)M57K6I5][-KQ:,FZ!BR6=)1Z"IF:
M#UX/:(<VTAC^ C[>K<HAB'()R8Y<NT+SLJ$KNICQHT"0?(SJ7E@5CW+:.4!R
MJ7:)BMS J/X,0,-4L5ZK[^FUN\8GMV5J=+DJ-@MP/8VL,SR:<'+,Z\P56K3Z
M9:%!T"S@?+-&9R.%S%(8.J;CI&MY!:XLR,G$5NILH;';*)_6:BT.M+0%:4L\
M5 -+!>&B1DCN&35T[735*F)TP.4NH1^/X[#]JB+(\J<S>6#2VP#^MH'J\(0Q
MGDHW5?LM1!=Z!&B!"EWK/54TM ,<!Z:7>SXVN$#4W$HI"L[+/UQ['11YE)=V
MV5C$7;Q(@"[3=1ZZ0@7W(J(*% 1$@Z"H*20G,8IC'%,@G$Q/XAA-IJ)B?>'[
MW7=[2?=TT[NPO<T]FF_3=II_#T  BD  4Q #MD\"''4Y \/ IQ]H>P>MB29$
MR:B.U,I2%U'VCM* !J/W7'O'&#DO,U_CK02.[ V0<E4;DR-D[R,_)I+))B)/
M,,*>QA2AJ(F3.LJ7P\0ZIM&D7JJ%2Y(5R9P]+(>!F_QC< G8Z&].3V^8^,D(
M1@F8/XI9(_WA'[A[0_TAU[0_TAU[0_TAU[0_TAU[0_TAU[0_TAU[0_TAU_+H
M^^D_WNOY='WTG^]U_+H^^D_WNOY='WTG^]U_+H^^D_WNOY='WTG^]U_+H^^D
M_P![HQ%)2.(<@B4Y#O6Q3%,'M Q15 2B'\/7];QG]/:_SO7];QG]/:_SO7];
MQG]/:_SO7];QG]/:_P [U_6\9_3VO\[U_6\9_3VO\[UL6L$(B?0#;%95@F;:
M/L-M.N Z#^_U_:6 _/$=^4]?VE@/SQ'?E/7]I8#\\1WY3U_:6 _/$=^4]?VE
M@/SQ'?E/7]I8#\\1WY3T47%LK2 &$0**T[%I 80\1 N]T740#K^VE3_2.'_+
M.O[:5/\ 2.'_ "SK^VE3_2.'_+.O[:5/](X?\LZ_MI4_TCA_RSK^VE3_ $CA
M_P LZ38QEGKTB]6 XI,V,U&NW2H)E$Z@IMV[E14X$( B.@#H :C]OGC_ )_
M?W(J_P!KS#8Y(G)Z-CK;BFB0K&*I5JCJCD.Q&)D5HO),Z-(R:3A!269,#"NJ
MF*9RG; <IMI3"8+5DR2P99"VJ7GW*,?)1UCK,C(2./$L2L\6P=>M4I9(E\^0
MEV'D0D';B),T&255%-=0R292&QI#R5,OCVX4/C-F;C0]>(VB+4J,K$9(3?&K
M]K:Q;MN,DUEX5=[L=D.H8JC8@$2]@:8>LH4>T1KFGV7#4]D6GQB6.4JI8S8<
MKCJ!BW-;GRP"%Z([<"H11LB^=BW9)'62#>0Y=,(JV6J7JPML<+<IF-O<HV]N
M2<GZ[R/D'CIHC /WQ'/E9&F)N@$ =B9!18NY,": (4C#S&J7B<LM$>Q#&K9'
MR._J#B>J5#A@?B%&C']3C(V0LT9)+NRK?\7%46)]_9,83 8/\ RUF:Q0$Q(8
MHY"S3.\4"_)-'"\&J[5@XMC.4YY($*=NRGZ[),5"%:J&*H=@*"Q $AO<UNF5
M96X47&M957G,GYJ@6*Y$\?1C-HLLR2C9)06[)2VSC\$FS!H"H+&[AUQ+V453
M%_[@O*C_ #ECOAOK_N"\J/\ 9COAOK_N"\J/]F.^&^O^X+RH_P!F.^&^O^X+
MRH_V8[X;Z_[@O*C_ &8[X;Z[;WG[RH=-3?RS?2*+W #Q*&JTJX3#:?0?$AO9
M_GZ^O+RH]\K?^KKZ\O*CWRM_ZNOKR\J/?*W_ *NOKR\J/?*W_JZ^O+RH]\K?
M^KKZ\O*CWRM_ZNM#<Y.5!B#X'+W*T&X@^!BZB4P!N+X>("'\'7AS#Y5?TND?
M '7UQ.57]+I'P!U]<3E5_2Z1\ =?7$Y5?TND? '7UQ.57]+I'P!U]<3E5_2Z
M1\ =?7$Y5?TND? '0"MRPY5*JCXJ*^HT .X<?:;0U14,'^<P_P"7KZUG*K\Y
M8^^1_7UK.57YRQ]\C^OK6<JOSEC[Y']?6LY5?G+'WR/Z^M9RJ_.6/OD?U]:S
ME5^<L??(_K\<Y,<IWBVX=%AFJ EHGX;2;0I1_P"*.OCK]_KZQO*;\_4'Y$=?
M6-Y3?GZ@_(CKZQO*;\_4'Y$=?6-Y3?GZ@_(CKZQO*;\_4'Y$=?6-Y3?GZ@_(
MCHWGL_\ *1\70.V4UDH27;-K[HP"%$4W;@\.OGMY1?I50O\ I_U\]O*+]*J%
M_P!/^OGMY1?I50O^G_7SV\HOTJH7_3_KY[>47Z54+_I_U\]O*+]*J%_T_P"J
M5R.QOE'/%DM]&0L:$9#W2P51[7'06:MRM8>"_;151B7JO892ZATP*N4 5*4P
M@.FGV^0<OL,MUVO-+I(Q[Y"'>5^3=N6)64%%0XIJN$71$E3'-&B?4 #P-I][
MKY]:I^B\Q^6]?/K5/T7F/RWKY]:I^B\Q^6]?/K5/T7F/RWH!'.E3$0]@C5I?
M4/\ )^.>'7SZU3]%YC\MZ^?6J?HO,?EO7SZU3]%YC\MZ^?6J?HO,?EO7SZU3
M]%YC\MZ^?6J?HO,?EO7SZU3]%YC\MZ^?6J?HO,?EO7SZU3]%YC\MZ^?6J?HO
M,?EOW1S7;G6J_;J^]V^<@K/#1T]#N]@B)/,QDJV=LE]@CX;B#ITE7J-4ZU2X
M!!119&#J<%%UV'166T[JJ49#M6;)-17:&XP$ 3:>/^)=WRA#P3:SV*)^+<#4
M:^^>'CHR6NU]ML#0*6TF)!)-59C"'M5G9B]6(4RB;0%#$ 3  =8C_7!D^@9E
MJ&;K#+XS=IP.,38[D\:92/CRXWZJ/:P=O:)X+3CZ24I+R/=H20!)-C*-W .5
M"]Y(,4*9*;5&"Y!2-_XD.+4K&0SH*G>L$\F;W7&$%DFEQ;IWWV8KPLH]AGZ1
M5EQBK#&K%-JFHW ^9(K(>5:]0[U0"9=>,>)DMBTD3).:)6GDRSQKDNI9/DYT
MCW)4-/Q3:/E)!_%I+1S=5\=@HBU61WFG<EUWES!RF16V+:/D:89)\7C04/0)
M9[4)2R3M3;A8):/;7)C(/R>5(]0<'[";+N%$W? >L?9$R_DB,R)/Y.I5(R"V
M&)H4=0658;VJI1$PYKJ#5A,3(RR+1\\4V.ECD5,30!+X?;U>'BA20E;6^DT4
MI!>#F;*2-CX6-4DI)TE7X#;)RSP2]M-)(ITTP$XG.;0FTT/+-9%G+MY&-9O$
MI2/3.BQD"+H$4\VU14574017$VXJ9CF,0!VB(B _<[S45&E;:I1-9@YRJKE5
MDG9UAF']BCRJ6 =C4"!W80I^RV 1*0V@JF$?<V9.66BI9O!6%2'B[3!-'+"(
MLB*4>Q</5F;1T[D!#TF4<+,5%$UU455&YA*("!@#[B<4RE.H!#"0AC;"F. #
MM*8X%.)"F-X".@Z?O=3TG*-:W'3<9E(M 778(3,['QT>LI'@$FSATO*SMJD6
MR3W_ .F;E2.J8#' A4R&#J#LDDBT;O9%-YWB,>Z5N?RDB\8I. ;.#'=QZCI%
ML551HL(KM#G%%7\(0WVKWTORGJ?E'/IWG^]Y'SW9/Y3SOE]7'E/,;>YL]WLU
MV^.G7(.K9[N>.+M4<(4*D7>PY.QE4YNL,*I;[6ZL"#_"$G O+1<U9^YH-(Q@
M^C$VJY)%PC+-D%FH++MQ5R#8<JTZ,H-HK&;,CT-&HQRJKE>#KU?=L%ZVPGWA
MW+E%W:VT/)))RAT!(V!\54B90*4-4)(UTQ>')!3.BF*C8S!*<!,6P<I%L0II
M%9>8,N$P./2E?"877:\WJ< V:)=9@O>!'V%*KC_$N1<A8TI],R)5;39+#FF<
MQ++NJU=GLM<86X5]GC"%D[=$OHV),C&3*Y4T >+@8BA6X9(EV<$PA*7'X4XX
MY9HS)<BZEA;*YFI-PLLY#V9V5QY)Z>%?P"3=(S=) ! #B.[<73%DXWO/'^BS
MMDX>8^Y!,\?72IVF8E\WY-N%HM,"&)L:##WF-F8Y]**P;1HQ*@RF7?G)%,12
M4*&T:UB:0L&..-K"1K>+K+4*KE>B6"U3N>75CCB2V3JA3+XTN=0J,-9,>K%-
M$^GMTI24,Y_'3H&:&2*;_#+ABB_-';NIW:(4B90(Y\M&2K(Y5D7D=,0LHV$'
M$7.P4JU0>L71/=MW;=-0 $2Z=5:S9OY%7_.I\:L+$VQ7&S58HU-CJS,V6M/Z
M<\OEC0I\0P+><A-*Q*.FC1\Y!%HU*\<J)-"+*]PO$VNJ66W1\MQ'?8U"JVZ,
M4C6LQ>*MCM:O/5*)?42LA8R=6LTM5(U^X23324;/V22[8Z1@-OA;_EC.]IR3
M'4,V3#XJK*E)H%5/3E,HUF6I4P:6LE>B$):W$BZI-+M&:2GE43&!-=R1PNDF
MH5?#]FSY9LH4!EC"+Q338V7HM"K,C4X&(@1K#-V$Q6(MDZG9$(4B29C.P,03
MI;]NXQNL>XRBWSR3C,>4FK4B.D9 $2OW[&JPC&#:O'I6Y$VY7;E!B4Z@$*4F
M\PZ  ?;Q+H)26@)F"<.EXB=@U6B<BR+(-#L9%L!7[.08KMGS4^AR*(GT.0AR
M[3D*(15=AD3-XN&9(,&21U#K* B@0"@=9901.LNJ;4QSCXF.(B/M^YVMTN]F
M6+JWU-I3I)S&/P:+MXMFM,+HJQQ^RH+5\)YQ<#*>Z 2[0T\/'TP)^8G&J8()
M,2RR<*B6,:MD0029,482(AVZ34A"AH42&$-/ =/#[F\3;OYN+?N+JOD!G,,'
M;?U")LKAGZ<HNP!TS<LQ9J,#'1.@LDJ0Z:IP'Q$!!.&CE7KHGFY&1=OI)P#J
M1DI27?N).4D7RY2)$.Y>OG1SF A")EUVE*4H  ?:6> A;"]J4Q.5Z:B(FUQJ
M"#J1K,G)1KEDPL+!JZ_%G+V%=+$<I)J?@SG3 #> CTSPKF^YU?-&)8=6O3\+
M6XO&;O$LV&1Z_))RI,G6"YU7(C^>LMQD9(@O7+I8R:ZTB<71E!4 NF48^A.I
MITVR?E"P9*>EFIFP3!XL9@C9%G!-EI^=G%UT8I% 2^:$Q'#L3[EMQBE$$>.(
M7F7&.1R4ID@MK](8!)"Y/R%6Y A%#' OY0&Y9%;TSN@?>+<.[IO]SUDYCA?D
MI.8@QAF>T6&ZWJDHX\KUOG8*U7<"_K FL27F4E&2]#<7!SW'RB;MA-(,Y5RN
M[;$2,H*?2;CC1F=[@*+D<.T/!UK@UJ'#9,9R-2Q<QF8G'TW7E9V6B7%:O->B
M+$];"^5-(M'A3I&<,U#H@8SBM/7,N]HX<8Z%QDAH)P#8TW7HG'<W8IVO9 B+
M>4I9)G?F;^=(X1>))IG;OFB;@@@?P"J4')_)4EJQ?$JXLEK'%AAJLQN09FU8
EQ?Q$Q\9*_D=O8CC39"U34,FY=+(QCAXS%5<C-PB50O:_QA__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>chart02.jpg
<TEXT>
begin 644 chart02.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[@ A061O8F4 9$     ! P 0 P(#!@
M             /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$!
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\( $0@!& '@ P$1  (1 0,1 ?_$ 2,  0 !! ,! 0$
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MI&!C5"47_]H # ,! 0(1 Q$   #W\             $';:S=JM=(/4I\CQ
M          'H/RGH3L'ML//J              !!VVLW:K72#U*?(\0
M      !Z#\IZ$[![;#SZ@              0=MK-VJUT@]2GR/$ AEUO[4:+
MM$RE0$K7KA3=O\T>'%#E+&NXGZCA.1@HF3:5Z*MUW"9E?7<455WTN(]!RUVW
M9*(1ZCA-Q(H&6P /0?E/0G8/;8>?4              "#MM9NU6ND'J4^1X@
M$,\V4=$*G[J;5W?2NFZYND.BJP6MC.<]+IP/6\S1+7R=R=KRZ;AS=O0HMS--
M[ZE95\JE8]%R]9N9.6W14O6<-6/-Q8U4;)8 ]!^4]"=@]MAY]0
M    (.VUF[5:Z0>I3Y'B !*&MXO_ #PYU+W4W@X]E6S%)H.5KN0"Z\ V^E+@
MZ7KG* E+AI*7JW7\9BD)>K3>N7"<&K9SA&2BY-  'H/RGH3L'ML//J
M        !!VVLW:K72#U*?(\0 )7UW%&1N[]<ZZFJ'^7CWW,G+9PA8VW8RJW
MSJS6TQ18=V_E^T%/O&2%8QO>JHV757?2JB[I"(U RUB!L#;P  >@_*>A.P>V
MP\^H              $';:S=JM=(/4I\CQ            'H/RGH3L'ML//J
M           (R$A3M@ "$=MYLU:NDGJ)^(       4[US?&B  *D[)/^@#T
MY2T,V VUOG^           $:R2@          !J1M#/6?8NGWB !D&NG VTD
MW9\O7]QX@            "-9)0           U"V@GKGMW+UD #VW;'?%KU?
MYU^4@             $:R2@          /R<>W3]: ^O'HN$T *K[:?MA-Z?
M*=?ZJV              !&LDH          "E>BJ:?\ T"]=W\1X@#T-96T!
MV">UOG]         L"<1(,    C624          !:>1NO47:$>MOCY=('U'
M9";>>=+-1D?2L        ##,5\96P 474Y6%F2K9 '1G>  Y(,@>([P
M   CW2<@:EK1#UC<?+I FA<&(=JCO#Y8_P!G+I            M_5Y/'YERS
MP   .3C')_@Z^P       (DT'+&J*T9]5?\ ,> 'LPV#^//K]V ^0H
M      M_5Y/'YERSP   .3C')_@Z^P       ((VQG75@Z1>HSY& [CET;6S
M>7RM2IKF*P           !;^KR>/S+EG@   <G&.3_!U]@       8Z+.V0U
M=.EOIP SM9+T?V*>W'G?        PW%WR&A+TB&?R6M)/F9$J M_5Y/'YERS
MP   .3C')_@Z^P       ,7%C[3:QG33TM ;$;;'SY9Y\I:&        8U"U
M1^TO\05)!%MS\YEM+@%OZO)X_,N6>   !R<8Y/\ !U]@       8A<?[>:TS
M3STB"4%8QQM<MY_*GW?9)         8A2W1.8QXF6LOX 6_J\GC\RY9X   '
M)QCD_P '7V       !A-QONOKA-1/12/7AGGY,>SW8KXS          1M+Y'
MX@5: 6_J\GC\RY9X   ')QCD_P '7V       !@@Q=OAKL=3?0A^IQVI&[WE
MOFW<N$0            !;^KR>/S+EG@   <G&.3_  =?8       'GRQ-]!]
M>_JK]^<S>0=/MDEN%YP              +?U>3Q^9<L\   #DXQR?X.OL
M    #S?X?^CG@2U<^\FP'VG^"/HFRY\[0             +?U>3Q^9<L\
M#DXQR?X.OL #K"R)($    'F%PM]-_&%KM]EML/O5Y2JPF*.          !'
MDHDEX "W]7D\?F7+/    Y.,<G^#K[@IE:T.#E  6!@O]$ ):8^N2OJ1.  >
M5K!OU1A1;N9_;YLI\1P          !8 ZXD@ "W]7D\?F7+/    Y.,<G^#K
M[UX?UYTRIF8Z@   /:3\X=G<C.'+U  \F&!OK1F\R7I!D3N[78
M    6_J\GC\RY9X   ')QCD_P=?>O#^O.F5,S'4   ![2?G#L[D9PY>H &$W
M&V[6;+).DH             %(G7E&U.6AGDFUP   .3C&?6);P\57TNU:Z/O
MX    >I31G/MO-?=PK24^\0$%%=TA6O5/@"9%QX6EG<&(/I79_0
M
M
M      !_);6+^(.V*9BKV"DCC/UG8E$Q7L@^@
MZ4\D/;"\\%"DRH1DU!C-Y0HB*ZD%*GXSU6=<>8
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MH\YDJA9!H),*C"IC,-#7[W&N-[C7&]QKC>XUQ-,XY=&]QKC>XUQO<:XWN-<
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M%D!IS84L-E2(9P#8"HK-=F2LO&%2PYOK6#,X-(,W=OQ%1AR),10G3-#XS_\
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MS&T5-$5>:,QC280NO\8ZV<YMD#EGRQ666">IN2)&L;RI$/)@IS=8I$^-=&Y
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M9R-"0,Q 5F8:B=@.)N,8^<:WCAN*MCI))G9HQ'43#5%'*DBK)%O%[M'D549
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M/JS3&.(#KN,7KB2\U!EN]PJY:F9S^5+-(TDC?A9B<NIR=/5/P?2AZ#*U[CU
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MV1]CEFHZ]OVD?TO[CAE=V[,(6FX#*V'C^_4M3<DA#9=)[J:SM6Q;X,6(JN_
MCU$6?4@G**2B2JF73<AQMT:/C=FG:[5\Y6?M(UDK-6*X,5I.H0C]FZDDGM6D
M[8P0.K&(RZ; \@0.J *>;L>9B\/OTBQ)NRG&,@,HCTE\YW]!LL\<90PBD53R
MLC;FC5LHHL@@BH5$A#"<Q0 >S+%W7&O1U-.E*1.:-#U6.:1LPXG:9671&-AF
M:_(1$D^AY[U)(*%;.FS-PN[0=&*B=(%3 0=0<-.,FF.R8W*/H+1"MF$>X7AI
MV*KS6V2\#'M4I$[FU3L-6GJ3YZSB"/W+-NH!UB$ >U\S->WRE-/3\&UO8V3J
M'K86I_-R&:P:,JRJZ,7ZQC5 &>77!'Q4S**$'IW4SB(!VQW"M'ONR6WD59L!
MN^X[OC6%YI5K3.<>1;U$ULSVFV-[9+S!H2MD5C3$<V5L!&RD.AW )XP+IK!"
M7S4L]UR@<8K%G^KVB'VB"BX=%G(2]#J4U+PQ6J<\FZ76K<K/Q8,3/@:>BJJF
M\%)<%3%Z&VR)XT:9)96&:(;"2[,HUFXB'.;.&SEZ%J8>&_,[D6B+%HHX6102
M4=-VP JJD1,Q3&:<C&6$7I3%'Q6[AI?U&;-M&+13J91KJ-E!FZ>HS!:<,XN1
MJ::,V")(L/=,X#S]MTC[EB]PK;KC.RITCO!)5%BU3S-GH1FA*,M8'!GWHX_G
M:+Y(8\K<ZYG13]X@" "(:1RTY(<FKC@--H^Z5[#&X5/%5M?\>7LU20L\?,R+
M-A;ZY*(L4@%8BI$4E3 "0=!$QP+VV)A.WBY;30H_AH',/CYK_'VEQ<O3[S1)
M602CZ]9-2C[798F6SNHD<E52DC-ADWC3JFH0JI3%*?*WMMX_7Z'4VV<AZSE\
M*9HQ>6RU6&PQY9:"A4J5'OW=OBY*8C#@X;(OF+4ZJ/VY0$ $>U9P^:X]7:/T
MVY5Z9ME7@5U(#T"9K=;,JG99AI:R3)Z?Z'65D3)R0G?E&/5Z)N 3.8I1N.&Q
MO':^FT[/H6)LET@7I(>)85RO6#POS=G)&V2LLRIQ(FQBL!8YP60,D_,!BMQ4
M,0X%T2Y43CWH=HK653MFJUVE(J.;+$8V6EHN'-NK\0W,\(\MTU6FK519\UAT
MWZS9$OB'*4@@8?8F_4)I_P!^U3^ .<']U?<_V=6#L/V1]AYOK]M4X]YPMR_V
M%]KN6U^KM<&Y'K9?8...)Z8@>,D+!I6;RT?(/;B5%"PMEGD2P19,"@)B"Z$R
MX N2SWCC_(Z9E6JZU?\  -'TG.9##>.T?5&%JP)Y%6"LS!^1-9,3<-&5@;7
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M'[(^RP7D-<(6<L=9R:]M;7,P=:] ]>R31NP?M1;QGK1TRCQ<BH[*/159,HE
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M'L&B74/%<O':Y$TR_P#>.8 [8;QXB4VH+9S18UE97;,I 1E[S*BK/7V;(8H
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M:?'.IYER;N#N7=T'B5DP76%HM;MMF)2XYO+V*>DY*(BX/UDV:G[ZPG$L]^\
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MJQ:MMB8F<8S>AN73!2KWQP=)"8TFW34:H*K.JN&Y@=1DBBJ  <1*!^A@ P"
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-0!Z&*/G*(=/^BG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>graph01.jpg
<TEXT>
begin 644 graph01.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[@ A061O8F4 9$     ! P 0 P(#!@
M             /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$!
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\( $0@!&0&P P$1  (1 0,1 ?_$ 0<  0 " @,! 0$
M       &" <)! 4* P(! 0$  00# 0               00%!@<" P@)$
M!00! 0<"!0,$ P     $!08'"  ! @,)$1 @,$!001<A.#$3%!8*$A488'"
M&9 W*!$  04!   $ P,)!@,$!0T ! $" P4&!P 1$@@A$Q0Q(A40('6UU1:7
M. DP0%!!(Q=1,D(S)"66<9,U-]=@<&%20],TE-25-M8Y$@ " 0($ P,'!P4,
M!PD!   ! @,1!  A$@4Q0091(A-087&!D3('$*&QT4(C%"!2@C,(,$#PP>%B
MDJ+2)#0U<$-CD],5-F" D'+"<X/#11?_V@ , P$! A$#$0   /?P
M                      ?,^@                        -9YA0W-E>Y
M6$@                         !YB<UQCN;AR] F"9# N_A92W=_Z
M                   -)^&^B]0UNV9KEW-YGMOLSR'=/']H^EK7>3Y?I.T
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MMLVK;(ZVH5SCU[:GS^T%MJ             !K))X7Z-1AP3<"5[E82
MPE;,ST2:L]Q[@]^?._I^4Y%ZK#Y&]KZVC7;7^AS7F?;.\;N&2J?F
M    -<IGXLX0\_1+BO<K"0      TW:Y]?9YNN#7GS;SY52Z=MP;5:]=F4Z3
MQ].>Z-,PNEJK94[4,8N&SC'*_D0           UV%DRP  *]RL)       >9
M?2GTD]-&Z_FWABLYU$NO=.>GA.8U[@RYZZM;9-G:$<UN=:KAU;D,2N<WZ>>S
M+&Z\         #5\9(+\@ KW*PD      !IFUQ["M9?M6WMRG1XCO9-1+KW=
MCPZ^P[,'B-7AE+KQ:<C4.>U<K[UJKR;A?ZQ5@D_5/I'U[?:#RQ#+A0D\A9.%
MJ8 4.Y,0'#(L;5.*8@U\'(+_ ( *]RL)       #S\ZE][]IV4>_+:WA0# U
M=SQUW\^LY3-.O'NRY8]5"^:PG5->;8V/:'*CLD737R/JKJ^2K*6'(J2XQT=X
M3 EL(C+H",G2%PX2D&I8L<7;-:!D@O.5[E82        \ZFG_H+Z*]P?/H "
M+]DT3OE1G&BX3+IXII,!73 LD4W5C6LQV]>-[IHXY5[EF$K^2LY4.7*S$+*P
MUW<G..J.27XXIJ"BYD M08,,A$Q*]RL)        :I,#]25LLNQM]VUO"H '
MRE%>R8;W<N'SFM-?V3;JCDPN%:.C71+!DLWPX9'9=Y".2L_#.<*?RQ!+KCA&
MTSBF(*"'Y+^@ KW*PD       !@JU9QH0U1[N@%+??5!O7Y>_N8    B/;,K
MZHZD@1RSK"3$7) ?LGIB@E!UIUQ/#M@:]3K#8Z "O<K"0        &FC7'L&
MDF-;EW?;-\76TO\ JH            :TSXFS( %>Y6$@        /C'/@<.[
MS#:1^E_I@W5\W)=46H           #749 +JFOPEY=0KW*PD         !B*
MWY7YI-*_2#=UL[Q;?[+-#           "D!#38B5<.867*]RL)
M#\I\BWG[ZP^DS<OSIL_?-9@          5))V9[ !7N5A(          # ]K
MS?RU:*^GM^\LT182[X#EJX8EL@S/SMVG.F X)SCKCJSCG8''.P(89#/J0\EY
M_0   "O<K"0           '1]=97RT9[A.V9IK'PCTOV_;0RCNMOH$VUX+I[
M*L4I/#ED.E8"&)990A7V652MAGF%_(3,    KW*PD               *:RK
M+*9'S@E&B0D<,E0V)P    %*CM"X)7N5A(               =(<X_AP#GD2
M)0?(^!WX    *8$[+*%?Y?$              &7H2@
M                   &J4VGG+ -3!98NB :5"]I;X T5FRTM. :0"^I<H T
M;&Q\M4#I#0R;D#.(          (L2D &/SO"2 &)#()W0!C<G)SP#JS@DB ,
M=$T.Q ,6F4#]                  QX?TEAU!+0
M    :="M!W)D(O&7D
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MB3\,PYR>4R;5Q7Z'-IYY!,(3P@?M62,9:G8?UTD5+UF%'*50<@E(#[A.Y.F
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M6(G[43,A]@.G^KA;W;-ZNA %8&)R&0U%!6FGAQ%0?5BXW&8"3;X5J2LP4@9
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M&Q$:QC&-1&L8QJ>2(GP1/!.D2GK?W@,K@*@JY^C@6R(JZHTJRK*^8Q6?/D$
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MAS)+8'K&>YR"R(QRM>OI7RSL<]W5QOUI/T>7:IL#ET!/X67=_*J/2]WUZ_A
M$Q/G'ZD^1&Y_GZ4\_%1%J]3G<U)H+&.HHH[^ZKJA]S:R^E(JVK;8$CJ>=(KT
M1L47J>JJGP^*>*FE.N:H*YOOKOP.I+L!!K.Z_"QT+L_PD":9A5C^'"N26?Y+
M'_)C7U/\D^/BTT#^H<]90T=NV@N;IVRSS:JIO'JK64]C8+8H*%9O5%\H)'MD
M5$543R3Q"2--$0.1%'/!/!(R6&>&5B2130RQJYDD4C'(YKFJJ*B^:?DT-H_8
MYE:_),?)J2X[NNF@SD<<I,$C[M\)#_PMC)@IFJLWH1'0R)_T.\D<U4<UR(K7
M(J*BHJ>:*BI\%14_LO</^A>*?J37_P!Y^1HL]1WT/EZ?DW52!:1>GS\_3\LX
M>=GEY_Y>7A3-7[7>!7ACG>MQAO)\2I;W?\7E1TL<[_/S^/FY?/\ S\$YJW]K
MO,L[',CE@NN?4S.?Z6OF=Z?*<.[RKJPIRM5B+\N;YT#O+[T:^#-C_38]Z&QR
M(S)I#DX_U*P>E#9N0E24$G/!!.QETY_FK42PH(E7U*JD-7X^(X'\@]M)CX6-
MA<9.5S]LQ;HT1BDRH-U(0=))U;ZU1D43/-?@QJ?!,M%LN.^V\?(2Z.DCU) )
M>)^L@SC[,5EW.-\KJ9,WSXJU97,]$<C_ %(GI:Y?)%\97HG*\1!JH9^-="Y8
M3<-U6=H2L+>ZK3XRXI=9/6:%J-T-36-HI991QW+.YT:-1CO5XB!K]MJ<%-93
MXK#ZMA?;+W961 .CS.ARO?\ N&;MBV$+6WI<AU9;YBI\X4$L:Z25L82D.C\<
MMSF^Z ?2],@]R3^B;'79'5H\[ 8FGPN[YQG2^>&VM>1$M@54R59Y@:0Q^9EG
M8>F1'>4OB2O@X9BDJM/[8Z'V^69."V]!1XW(6F-T_6?D:&MS=W%!>S933U>P
M"/A%C=.:$^6>"999&?.DZMQ/5X?,]L.W7#\0+77.AO:)="_?U.$!QB<NTI]F
M +46F!YG8AM-S!C8F10@.>/(.I+$G*]JC+"EN,A;9[EF_P"::.ZSY=%I+3DV
MNO.=TM=3[0$B8>PS]@R*7+$BQD2BSP-E.A9)'Z97M\15(P^7[)8:/AO7N$V>
MFU%]:5A.<N>CZFIN:_M)T6J,U1I9TD ?S[@*LGCD88&,RN9$/Z6#^U3H"<?!
MNK7F,F\H=_M#=EEI+\?(V..UV%JH89BH83;5NC)LA;LP:#Y;(O4L;UDEB;XV
M]\-[4<51]0UM[D<I55]=MN2%9;D_),[5;6BK9^3@$U\=47LL]G-,8.A-K$+]
M4;=2.5J5XK G<RJN>F:OGN+P?&N1XRFQX/7KNHGHK:DZEBTVX=J3FC(0-&8O
M% K2K0]ZRME?,J0_+D=',RDSB ]3W"9:N+J.?BQ[#6%TI+#DZPW'%ZJWM;,'
M'Z/F5#5V=!+H2[!2]&VWKH88WOB\V2]PSN>Y%/TO!]&X+B\>W64FGST%M)JL
MKB.@5E^ZUQUD^&[MS];I](TA9H'2-<XR1[U;Z'>>#S5Z8MC=Y[&9>CN;!7>M
M3K6IHP0+ Q7_ /6I)8[W^?\ GZO[+W#_ *%XI^I-?_@!>-SW1=3S0*B]O72^
MG@FX]M(EK?:BFN<_6B-F=HJ2^KB:[."2*LD"0^I[K)CE5/2Q4YO;6^IL.Q9:
MW]N_MRZ5T"+;S5E?JF7_ &OIK<;9RXF+*9*IJY'UJVL<D0I?H8D R1>I7R?-
M9W+J.?Q-#DKC(YZ@N<S.*>+OK;(@Z&\-J='+N,!3'D7S;_E%(!-:F02QBQ'O
MAD@;"WY$OJ$@PO=LQ[EA;.OVNO.W_1-=B ,_4/PN5H-$1S&EON6Y6NJC-ST.
M&Y4FG"G8^0.&.5?3,QL<2NN/]I\N#CFD[2TE"L]!H1=V#E^=]BP/)-(#8524
M+JR#8%3=%'-'A2=1XOH)X9'*LK'QW5Q-1<J@L)LR'I,LP#4Z._KA;)MST&N,
MYSLYP*>%M/NK*NY_.>"R20<=('3)(OJ'8I6OZFF.P.>H@KP//8.@T-YJC=3K
M;<?DM1V&_KRVUE!!34Q$=+9/!%64E&/(@=*Y?C&,_?R7<7)71R]-V[<;)I[F
MRR5=CL+E^/XSJ-5CMG810%J7O-K#H9(::1L<41"#ESHV9L#8'83<)GA^?YB3
MW+9?DM=D?Q,LW5::KOLW9)JF;JL,K0@:F?.,LHC((1)IIHIZJ5\CO0[Y:?V4
MG*IN>[$G%UO6L1[>]'V>(J@9E:/NW1\A6;C'X1:&2Q34V !E-H*L<BVA'406
MSM!QE1W^M)#V;V_5^-;11\>F*KIM->[7.AZ#6VE;!F9;8G.\OE2/7$XT&33,
M@_'6_, <3'\M5:Z2+U^/</\ H7BGZDU_^ 5%_85 )EU0CVPE/9SP,>97B7L0
MT-R(/,J>IHMG&%"D\:^;)%A8JIYL:J-:M>$K6PCC-:HL"HT<.5)A(&I\OR2$
M69$?&W_E8Y/-J(O@R8"O!!EL27&V$H8@XTAYCT1'EF/AC8XHEZ)Y+(]7.7_C
MXBKH,Y10U\-@VVA BJ*^,.*U9+\]MG$*P=(([!L_WTF1J2(_X^?GX<KJX%5>
MLZO51!U5RDD1EDJY5C^\I!4+)7^?_/(Q'+YJB+X#QV7Q]#59D"9I U0P&(D=
MI3)WDL+F>:A,Y1D<[U<V:5[Y6K]CO@GAHY-16$#M*B.;!. ++"TV!C8X3&Q2
M1.8A4,;4:V3R];41$1?$J$T=.0D\X),R3U@4R3$U;6LK")4D@=\R>N:QJ0/7
MS="B)Z%3R\4UJ;25I-CG;,RZHRY18G35EO8UQ=2;:"+Z42,\FL.F@?-Y>M8Y
M7)Y^3E_L[SI?[\=,S7[PZVDZI98O/6]''CG]RR&&9SS"]HB!M,]:&QZ_'Y\4
M*0<;ZA:<FQJP2R@YY1D5]/VO6])Z/TO1X[/:;-\WK=D3EV4W/@]W%F&;PBGC
MS.7SIMJ=IWY$/U264QJ!QH^,=(FO7\FGWV&[%?8"?85>8K[ZG'R.+TH,\N4B
MLQZXT:?059)PLD@UFYLC$D6-5:CD1%\_/^9O0?PLY=^Q/'\S>@_A9R[]B>/Y
MF]!_"SEW[$\?S-Z#^%G+OV)X_F;T'\+.7?L3Q_,WH/X6<N_8GC^9O0?PLY=^
MQ/'\S>@_A9R[]B>/YF]!_"SEW[$\?S-Z#^%G+OV)X_F;T'\+.7?L3Q_,WH/X
M6<N_8GC^9O0?PLY=^Q/'\S>@_A9R[]B>/YF]!_"SEW[$\?S-Z#^%G+OV)X_F
M;T'\+.7?L3Q_,WH/X6<N_8GC^9O0?PLY=^Q/'\S>@_A9R[]B>/YF]!_"SEW[
M$\?S-Z#^%G+OV)X_F;T'\+.7?L3Q_,WH/X6<N_8GC^9O0?PLY=^Q/'\S>@_A
M9R[]B>/YF]!_"SEW[$\?S-Z#^%G+OV)X_F;T'\+.7?L3Q_,WH/X6<N_8G@>N
MU&N)W%Q%,4^;0ETU/0SDQ33OD'@=6T0XM=$@D+DC1S6(YZ-\W>:JO_R-TE-@
M-_DN=UO+?;!9>XZLI=)F:V]G]P>R Z/#D6<:@*M9(BJ^O>'# ._\#5MTMCH0
M7M>D;$A)"+G%E!G*$&(F!G5JSARS0LDD%F5GW%E'>Y6.\OAYI\/S.S!T&IYE
M98NE]D6]Z_S?GLF;G(U%/O\ (=$YGF;'H.YM_P ;6QN<Y4U.U-+6K"$$@:!6
M/DE(<]SG0^XGGVQW]9V@#B?4,[D<MVVGI<Y1"[FOTW*\+T.SJ+ /'N_=.308
M6YU4U>1+7LAB= @Z2QM);/Y_E[32\U]PG,]ED<?<9W"],+*QV0'S_M8T73NQ
M<EPV%BJB8+R;1]&V6#Y_K;2\VK;=R4E7++6?-4-)7BR=1&W.BKMX7ROOO4./
M4?4:JJKZ8/J&;Q1=:H&K>!2MCST=J$39STMBZM9&!)95)#HHXD58F?EI^24/
MN&P-CS_ME]GZFGZS58WGMKG>-M*[+8XG0!Y1:^VOY!K;*AB"9HY_1&MB.U=I
M'+7Q21#% MH]GN#*J\O1=?U+$)M*$".KH.DU/..F:S!472Z6N@(*%"!W=/G8
M;+Y8\CQ$EG?].JCK%^9N\;B<_=8C'8WF?5J.EDWW!^H%@[3HU&3R8B3M[-^Z
MB%Q4'%.6T6O/7Y<1_P#XP4*0\F<8>,;YW?L9M-O7=<@XIV=>=YGM%33T5&-T
M.H,YW@]V3%8@95&95='BKC8$TQTM;' +(HD:K%'.D[?S-YS#6=>HZVWZ5VG"
M5?/]7GP^0[GD_"^!;+OEUS +1RV%31!Z 'J98 ]?7H'M)SJMUR<]\#I6B3B>
M'Z/<659I[?/]-[)S43H5'7C5-%U6@Y=U+5X'/].IZT*<FN$'V5301$RM$D<"
MI:S.%7Z98D3\F@U%E&;-79NDM;\^&M$E/L90J<">Q*C !@19C39(!W)%$S[T
MCU1J?%?&$PUUM<W[8;OJ?[Z]OFZ$>%S+H^)YUQ>PY9=[[@O+@M)%9GY8GH-W
M79PJPUL5VT>VBC!.2N8P5XA,/#NM;&@9E]5TGE6$VVBH(8B(1JRXTF;K[8\<
M.$Q\A<(*D%.= R5SI60N:CU5R*J_W;.V6LQ^6T]AD+5M[DS]#GZFZ,S%VQJ,
M;<9XJR$)FI;1K6HB$#.CE1$3[WP3\UG2+#FV".Z''634L>\,R&?*V3*8D.:O
M(J&:>>O?=MJR 29(7CI/\E\3W-5JHJIX%S.&RN;QF;!?/(%G\G1UF=I!)"IG
MD%/&JJ<4,"!Y)$CI)%9&BO>Y7+YJJK^9I-6#Q3DH>IV0MX#K]*+SC'#W^K"T
M[V2:4/27$-,RQO1=#)&UQT94DK"W-194>J)XK<SDZ&FS&<IAFAU%!GJP*EI:
ML1KG.:+75== ,"$.USU5&1L:WS55\OC^9MV$<LYS.SICF.Z.V;$YJ1N_=%_V
M3MHCZQR:A8U7S;]=\_TJOFGQ\ 4U+7 4]/5!C5]7558@]?6UM>'$R 0$ $2.
M$4,,6"-K(XHVM8QC41J(B?F,DM:>KLY(P[&NC?85XAKV5]O%%!; L<3#(YH=
MI#"QA$2?<G:QJ/1R(G@'+8?,9[&YFK;*VMSN5I:W/T5>V>:0F= JFI&$ %28
MB5\C_1&WU/<KE\U55_,V57#R_G<-;T4B0SH-?%BLW&#NBY?4LI.P$;6H/I2)
M%>Y7/-;,Y5<JJOFJ^*^CH*NNI*2H#'KJFGJ 1JVJK*\2-L(H-?7A10B!!C0L
M1D<4;&L8U$1$1$_,L,G)R#E[\M;Z!-9:YI^ RCJ"SU*2I.FEL*=:E:\V_29J
M.^LDC<1ZD\_7X:QC6L8QJ-:UJ(UK6M3R:UK4\D:UJ)Y(B?9_@O1.5YW:Y^XZ
M/R6#(%=*Q81\<F@Q8N^JR[K%E7U?\)@Q=-5@3S!R*BLF;!(B+YL<B4_3>1;7
M/]#Y]H9KF"BV&6/CLZ"XDS]Y99JX6ML(?] R(&]IR1G21JZ-SX7>E5;Y*MAH
M-);UE!15(SS+2YN3AJRKKA(O+YA)QYDL(HL#//XO>YK4_P"/C<9G/7HEI?<V
MO*W-;FM'2?Y^;O;?,4>TK:P]9(HXE(+RVE -;\MST^24SS5%\T3_ !+W#]HY
MYOJOB)/8]/S#F6QV(O\ XI=]-]H1G'<3E>PXH&&MEB*R73<]KJ DC&71/S$J
M""C)4C?$6Y/%'SOG>3FS5+1C@4OMBNL'VY</BO9D74^ZKIW0-#IM%SVJM:\7
MI=9N^27]$C(X!;DA\=<^E*''@F>0[9T4%/<ZP_J_+?>R%V+-Z'OND)K-UK;C
MW.9?J7M&J(HK;5S4M&E)@@; 0&4%H0=1&1]$6OR%\FZKL/*LQNN8Z+4=[XK8
M"UV=[Y)2ZND]MH'LYH>0]+R+))-'?8-^U"VP3H!RRH;*9YHHQ[)Y&01/:1A>
MRYM,[8TVZT,>.DLM#^\&YTF%<)3_ (7J>GJ'M.@YFKZ#;V;3%-'I;6:LD8R(
,AD0\L\T$?_S$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[@ A061O8F4 9$     ! P 0 P(#!@
M             /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$!
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\( $0@!, )P P$1  (1 0,1 ?_$ 2T  0 !! (# 0
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M5;?:KGG02S>\5^C#?/S:[CMK<0<OL       %I+L  #""F)     !"1-H
M     !\:7'_W=Z"+?MB_T.2_4)V!\<-Q-Y<;\"+T]0-KG>W2YP]]I+%:[I6U
ML%MM4ZAIYO'.@]?/4V5D-7;O65+QBDKN.&;[S?.";Y?*JG[==I\C?3'T!\K\
MUK+                          !\6O*7W<^4S NG.PK*M._8%]$OS]7WW
MRZ14U6ET?GO4_P <_5/2/0W;=)*C\01^\Z"ZU4CVN$B!:B]:.VC*Y;\QW?.G
MQC&Y=>>^8(^.;[RU$G>'-M+?5OTE\A-A[[K(
M ?F5\:?HRTDPK=/;UN?BKZ0^YOB;TJVJ2B1U+\^@B^^]:O.'T2ZKN4_IY[^R
M,?FQQ]%70I676$\?RJLH:J\VRY5%=;>Y3)N9(NH[[1P^TLN*NCBI_7M.CV+R
MG7?UC=)_(3=;+="@                        ?EX<1?I.B["-O;&Y9JKZ
MX/IK^<#V0>IZ//3WSY5.'OM]TYZVZ:W%QK:6328_:5%<+?[5493^>L<RQUL.
MZ^<Z=V":[PZFNW'[![03[C<:>W2)E%/BEZ[XO]8/2/R*[#\YYF
M              'YJW!7Z9M>\;VE04TWMVZC^9G>EV1\C_,4JIN&/]4NB.ZO
MG;P/>$9<Q?3'.YF3318[]5VZKK(_*&GF>*63R2I-K0V/)*'MER[F:/Z*XT,F
M?E.2T6.6NHYJF70T%1P>3)!NUA^KWI3Y&]E6?\K@
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M]?/3?T2Q;W9=-(DR9>M=[A7#6-WI9_%['S5OGTH]!?-CO7V]\^
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MNO,"O5I[3LJYICFRWJAE3;?-J,OR"C^]3L[\]N?U>/
M  #\R#CO])^D%CV'@<ZDRSVSQ=<)D-166OIXK5,AV5VZQG7V0Q'8K+D,N?9Z
MB7Z4<WU2)DVEY#^LH[M)N&=P7&\TON>W2'N[XSX\UGW?M_3';&\<KL-ZVLQ"
MZ[G<T_*O23JGK#%K9U-$]5!6YAJ[L@H]981;[Y15TW<;/]2?;QUK\&O=X
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MP!3%,'_ $QDN'C23UOEYQ<71A#[D_"K', *& ?E$0,L/ 5.'/F$."X4XFN(
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M;'-Q-DIQ-D4@*?$V35>K*$3<I+.%B]< 0* @(\+V @/$EA*:N6M_!KP-AC[
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M51ZY-22;Z01=(R#19L=$! X#T'.R")T@YXF#@=E&*6%8 /\ >('_ )0\B@#
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MT]G=:E*QKJ&D_IF)"N'.($F0'>E2*3ARF\2)&4XH!%%") 8#$31!5\4Q2IG
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M1Y]A,HK%.RDRF3 V;\,U_-]4R#C2[8JG?X\_CQ4@*I!%(E!Q'J$30(":0CT
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M%E350UKV^E-=9'8[8)]L!.W_ -B3*"Q\KL!;;/;\99Z5JJ)XV&LL6\CU6H@
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M3,-K)-2,74MM#Y5CYCF.,<$0L2H]0H/0*87;[Q=4T8^Z;[5/U*\P.0/+AG3
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M:,&A /YCGA9DC+1<* @LI[&4>(#L-/9C;0]VMAO-JX5;EHV<>2Q^\CD12K,
M?''0U5ZBH5CC>-CV;=[[<KN_\H3W%P$C4"$L5$,25*K5C77(['+,8W3J?XA[
MZT>UW=]//#969K<3I)*S(TMP04A1@1X8P\E,M2G!Z:Z7Z?MMJV8J1HC%'DY:
MIY3665JYZI&)KW8_ ;G&WDJ:5(\2'\Z<^[B,":)PT3<",QC)?7^C%2V>*$9X
MIBAX8/BYX&H^O$(ED_U.:BN.6>0;T@_-7 (.7R?OTD$C),E_,0P-"")6H01P
M([<0G>-UN+ED%%,CEJ#NK^YYFFC#GPIZ,;F=[_#MN:6P-GYNG3KU4F9-?A\X
M)0(?>"Z].9QL<VR-!^W1 XNFATT(U#RM93(R*-0)S.D@$FF+J[Z?Z:N[VVB-
M'>)?"&I735B%9Z9Z5JW=F,?=O-;[E!)0A@T<D;J:$<F5E/&M#C\9NMW)<W/Z
M\C%R0.1)Y8)DD>,FM0 "!Z,QEW98TPWX]#(5R]IS_*N%:2\;4>(5*T^<?/AB
MI9LOM^'/MHM33UXH#[!E\^ %;+\L\73$YHRGT @BOMH/7@O]KMP=,K <\ZU]
M-<CC?MTMIU&XRQ_AX#I4GS9P4!!I6J(7?NTXL+:TODN=E\I=5O<CS8AD*E"W
MCA/?&RBN94XV3JZWB-O;7SN$C8@FD;Z#(K  M$S A"P!(!RYXE28$L&-:<?R
M[ <,^WR%X>)1AD1WCD>P@X4F)XK@CW6'A/\ !;@WMK@Y98H:TQ0#+!P .&!G
M0<, ,?9C:;EZZW@6M>X4^>GR?OX _P"VS?YQL;9LUG3\9=W$<*:N :1P@+=P
MK4]V/V9.UY+NY72;OSBK"3AK6$?=! W!"&.G(M7/'4F[;W:PWFYV6Y262!U#
MQQ^4 6E"-52\E:*S Z57+,DXZ>ZEV:RBL]ZEN7B<0J(A-&$U"0HE 'C;PZU
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MAJ/0RD9JZG-6&8/=EB:]M$:[Z9<?=SHOCAU<$O$0?=L!FLP'E2#CY;^''PL
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M5D(!':*$?13UXKII45& UP2+./Q2'@=(^R/WSGPKZ:\ <,$4*@R"C@J\E7N
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M?L6ZI_U4G\W']37?^2?^;BTMI=KN(XY)%4LT;@!2?$22,J"N(X8EI&B@ =@
MH![/E*Y:V,:6T*AI))&"1H#D-3'F>0%2>S$]NCI.(P"7A/F1T(K4,!P[:TH:
MC!<0N4I6M#2G"M>RO/$T\-["PCLFN6 +5558+H/A UYUR)6GVL-8L/-E$22$
MQAB KJ'%<JB@.?*N%*0N0>% 37EEZ\%BAT@T)H: ]GI[L;?*Z M<H71%J7T
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M&!45Q6F+G:MZVV*ZV^4$,DBU&>51S5NQE((Q?=2?#M7NMH4%WM:5FB XZ/\
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M/'&0X8R.7=C(XS&9PUEOMIHW"-3Y-R@'FQ'LK]M.U#Z5H>,FT;_:DV[5:&=
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M@_3Q'$4P_4?3T<DW15Q*0,B6MG;,1R']0\(V/'AQ^4OA-E__ %K;?]TBPL8
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M>8 >5>%.X\\6FX;3+%#U-;>%7;W982:F-Z9U4^*,\C53D<#JB]W!/Q[*-2(
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MYDG*CRS/;1W#EFFA@FC1B[:0FHXV?IOI_:8K/8K"WCM[>"(!(XH8E"1QHH%
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M0M?%SIB[3>[!H+EV8C,$,&8FH(R-13 J<%CPIB-/,6._B),+G(5.9C8_J/\
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MED3PPV[WUQY>VZ13]:0D>ZHYD\ .9J3D,!I$,.UJ?NX1PIR:0CWF/'L7@.W
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M$>G#68VM!OGK4PD695T'$^N10,93$T:DLW\N_P#?P'1PC(J\S@D,8"^U&,F
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M<X$ '_R/%W8''#;E:KOZ:]?CZ 3D7KEY.TMI.6)^TL-O6O1V\3*4Z1M#HCV
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M?O:\Q$US5RT158R%M[AFP=V:>CH>E&;(L)U1M&,%W[M))LJ)$4CK* !2B8(
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M!+VPZV#KJS22K]U;_>M+)1RX5<">?BT@!V!57!CJG7>1!Q\AR/F* #TH00$
M QL!@ S\W7ID<CGOG'WY$.L8[X]0QVQVSW]>A] #[@]1_P"(,]=AP..WIWZ
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MJIP[8Q^$!^7/Q]>@.'SAV#P5#W!#( ("4PYQ@0Z^7PP41 < 4,#ZB';UZP!
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M\J-U R!TA <YST/_ +.<&Q]BR'_*;K_W2\-_JJMQ_P!OK_W'(F_8=#_I=?\
MR[+&_P!4S<?]KK_Y7FS?< M_^EU_\H6 W[/IO^ET/_P5938^PK;[,_WNO_D6
MU&[X^4C8?]KH?^[ZX&_8DV_Z77_TXNIO]5%L/^UT/_=E>C8_NMVP_P"UT/\
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M@R9P*<!^'6#E$#>0@/V  8[@(?'/7B'D'? _$,_$ Z[A\W?T] #[0^_'7_*
M_?\ ^?H<]LCDWV@ ^GQ[]"7(&'X" >N/^7QZR ADP]N^/V?'U >HA"5D%4Z+
M=5VM=N+-14PM46ZRHIL)L$O,"%<PKI;W//\ _ ,J7OD,)JI'*HDJ0JB:A! Q
M3IG*!B'*(=A*8HY ?L_S?RD52*4I_P#Q!;?5*<AO;.4P;!GSD.53(&(<A@R
MAW >^>OKIN2DY55)($6YY%ZZDEB^(_*DFY>+JG*B.,B4!\>A,<03,3YR*%P)
M_3_J\?+Y#^\>A: L0$#  E @8, '$0$%S (9,;X%[_?ULR3JIH5+=+ZOPY-9
MNIAQ'-C-6@22G\W-:V]DS!'MK:I&BD+<QA*K['OE1'S]: A='D7-;7CH>62O
MLO&N6;]3Z=5^DI5XJ<E(_P F<I8HMG[WO*%.H=-)1-(YA,7Q*O(4RH2E@BV;
MGZ([TJK)DS,^!,JHQK%U).V:4C(%3. BW;BHJ7R#(!D,N6TC'R4-*1+LZ#EN
MJFJQD8Z09JB11-1,11=M'C54F!R!3D,'2CA:6.Y?+J =0TD]57=KG   HG7=
M*'65.F  '<PB =NB*.B@)R*$,40)D $H^0" !@IBB(9$?]/1ERID,8 ')@3
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MPE^ /(I\W.UD8YRLT?-E1 3(N4!$IR (!@Q! 0,4P=C%$!#L(="!BB( /;.
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M,%F8\:QW<TW+K:ISD[9)P'EQJ,A"-(>!1D)]IAN^-^7MGA73=9,XJ)@DH?\
M4'VM<^%=L8<;/T_MS;,XYV/<;#<=1=O-I[X@KM3Z3K#7=1HB\ SFHTMV<6LC
MN7E7!U(^NM3)")G9S'(3CZQUNTG^/&S]4?K%?ITZ;VA)Z7VY/7+5.V-8;V<6
MV6)&U'::%2UJZNE9?%BW$79(EQ%D3;2##P.*R1TS"QX_0NE!8ZKMVT]YZ;HF
MU"[/9N[DTLNBXR<?N[KMO6:E0916KM1[!<5YTVA9A6Q/7")R%4?M6B1A,3E=
M#RG%E.\7#C]Q2?\ +NC0_%S<QN04#M>D15\CM=3E0:W NKZ0Q2L]6FIALZD7
M\(C8X((LKAPW=KF;BF?C/MU_KCC_ &#:O+3;6Q=?:OK]*Y6%G]&5BO:NI]?N
M-QL^XMQ%U C:=<6.#"Q-XQ>M+U)64_,%$S%RV4*MUM;]0SC&ZV)Q?V9+P%7;
MQ(/1;C==86N/Y!UC5US9MGZ\8#29C%13>?1OTVJ8/XQPFN5-(ZG@3]+7AGO.
M\RU(Y2Z<WCR3U'SUUK5QCB1G)BCUSBV\VAQUWY!QZC BLA2-Q1$8$JT%I],5
MO.E>-SIIE*B3K8/Z_<=^HC<J=;JYL2Q7*K<'&D!0%^)T7J*J;S)J(NC;?"+P
M9;?)7V9C4A7_ #DT@20,JNF4I054*Y3U))\?+I;M7<K>7EKT!3]%ZZH40G)[
MAV'-7IY7;9L#4^N)>3AYB$U_;CZ]_,R%M$LU&.A#I HJ*9SIF#07!O8DE9MS
M[JLF^>:TAR,I>]0E2<G^!_&/4\7#/-"P&^;+%5"I5C9=SN%BL#!HTLY&A(RP
MM)1,S!9?Z<YP9:#I'+#FEHZCJ_IO3>Y-7T#AOJQ+<EDO7*!CMFTU^D1]HI*.
MNKZZ5I\^R0(VD5U_H&9?813,[;"?R-JWA[OO<?(#B1:N.GZ9^O.9G,2#X7:T
MJUCYI;_VU<[*G66VO]8UQW SS2OFKD8_9O)EC"M#"66,[:F+[8(@V_0PI.E>
M5W)[;6A-R2WZEU-W5+\DJG5:-MC;LSHBNJ/:VPV_7H2*1:IR&KYET+1JX;_2
M*N :@=R3W/,O0S-.LU?MD05VZ8&E:U,QT[&@^9*>T]9"^BW+IJ#MHK\JJ?EY
MIF[& !_HY=-GCU95DAR/W01!J'\)%,";&LA2^21 #W3@4/Q&\L]-ETR@)@(H
M7 9P >0%   .X]NW0"H % /$3&P(#W$/0 ^(CZ=>2_F5$#"83F*'?("(%+D1
MP./ZNE$6A2J'4* B3(B4 #/_ %JAA 5,YR/H4/AT1!RZ2(F!OXXB<A0P(Y*@
MF7(83^T?ZND_%5#N7(@ @8?E#OY#GN.?0.A$5TD$0[B;L F[#^(>PX^X/7HR
M,84XIB80!T?)2=AQY))8 QQQZ"/0N#*+BN(?,<QS8SW[ 4/AGX8ZCI>-550>
MPSYL_CW9 (=0CELJ!R *)_\ K$U@R0Y,X43,8HA@1Z37"OQ\ W(*QPC6*:X)
MD7=*>XX4%=VJLLMD<%(43 1-, *4/41-],FNFGGQ*5("@/WAD1[Y_J#H$A,B
MH@ Y2;K@H#E'N/<K@!$#E$!]! 0#[>A%RQ$Q#8 Y@[ER'J "("7(9Z.9V04S
MJ&$WF4GC@OK[9LB)_(H]@QVQTHV(O[B'D*9!.4 ,GY%'P _D'X3@/8?Z^LID
M$0(<#>9,% ,?$!] $/Z^LRWNG:I"F0'14Q4$A3* F45RE^8  3!DQ<X]1#I-
MU&..RI@$2"/\,P"&1, AZ"/[NDY!-!9(%B )O)-0J9P'_M$3F "J)C]I1$.E
M4E $OX3 ?R# "4P&*8PB( 'S!CMWSU%VNVBPA4&BT?)1E<DW[II:K*@1=)10
MK2+C<R\*R<-RF#ZQP+3Y392$PX'JI6*L2HR6O;'!-',,HX,#MQ$*>U](ZA9!
MTH<[M&1CG)3MEA5.?W#$SGN'4%8V$@Q;V"51)'S=>]XA9)TT10_]G3_T1?XJ
M9$R%%!0YP)[A?;$/+ ]>/;R*&<!W^(X$ #XA\>CACM@WP$![? >^.W41#$()
MSRK^*C$^P^CZ110./8?0J8B/[NBLFX 5NR239($+V*5%HD5!(H!Z !2$  Z,
M(_:(AC_U_'H0,/;.!#OZ]OOZ[_'[A[8Z2 @B4R8E$ILC^(![#WP("&.W[.H2
M$<.Q<RVM))S4'8&_$G&F(24@0P/?VTH]W[)?A_![?=_3LCBWOEC.R6IMK-()
ME;F59GG59FUT*Y:8.XQ@,IMD4[ED))NO-C'\0$%$P,0?E,/5]V%2Z[LR_;>V
M+KE_J&<W9O;;]]W5MF/UA)-A:N:/5+=?)>56J$ 8@@(I1R;<3B4H',8I0*'#
M^^5V@V1>W\&M/WG1V@)V:N$E*O8:AWYK9&DFA/BN0$[%*Q*5PE!C'2Q0.P.^
M5,F'EXB6)_3&-"7X.*D&=FHQA@V!,$NJ?T&US[H;@I=RE"4,0EW.*@A@ ^E_
M@?@#JIV'<]TWY8M>0T%6ZS8M%4[D'?JMQRV[$TRPN[!"-=NZLK$LUKU[,SEG
M!BK&5,F9RDF1%?W$TR%+5MO[?E=XVVN5*0U].QW&A;=MX9<1W-GU4@FCK^SR
MG'E@_;T5_*ULS=%1,AD@9KJH$,N@KCO3M<[R"^1J>N-G5C<FM;MJV\S.M]D:
M\V74$9)K!VVGW&",#Z(E&K.7<I <"FP57R+XJ%(<LUN>XP.W7?\ .]SH6S-N
MZA9;LV!&: WKM#6:3).H;)W/J!E*I5:]W%FI'(KN'"Y")2#D@K.TUE#J&-QA
MW9L1A8'%YXAWFS[$TRO#V!W$1<?9+=6?Y1F5)Z+;E%">9GA?D315P5,XB8/4
M0&V<KJ'8M_:PMNQKTVVCM76FM=Z7JGZ'VOLMM$_DPWK8&IXQ\2!F9]\S*07I
MB"@@_62(HY26.'EUR,E[5(;JY#V/DUHV4XL[+OV]=[W#:MT9Z(<R*TFYU55;
M2[>H/Z]$L9PR;LBODK))NFJ)C.!]H ZT?4G]KY41EDT'K"T:,J>YZSR6V+6=
MY6'0]OE7<K+:/V%L>%>,Y*Z:L0^L,V8Q3I,4XUF4J+4R10'-=W)INEJ5BS:Z
MXH0/".#J3"SO9"C0.AX.VK7]A7'=2>K/$U[ \L#Q5PZDGAU7KT%U#+&.90QA
M?V#0-JY!0E(^CM;"H:!L&];S:>/&KVMTL"-EGD];:JEWJ\/7@/*)F%MYG<?0
MIKK$;>T590#<P6VQ:7;9H_-W8.J-K;@?IWB88RL-L;2<9^4:YN.K)-I[3W7,
M[!L3'3%9B<#+IJJ)J>21S)BYY;$V=S @]W32VF'-YL%3Y0[%J$=M%QH>NURK
M417:$%6G$7&WC,3640D"/2'3?*.')SE 7"OEHRL5N$V?5I7C9R,OG*#2VQJY
MLZ<BMG4C9&T)U:P[!CV-N0)[[JA6]\H0LA!N$U6+I%%,BA3  ^4WSH;L+$&_
MK!H6,XWR4F>Q/3U<^L(BY*7QDS2JPA^7I3!;"J8XO _BBD/AZ=;!W5O:H/+?
M;-S\6W?"RWPDM;Y)C4Y_3;Z\?XE!%Q]?:N&GT=Q:6U$CQK+-%4W[8R)!2,42
M 8-V\0KO=N2.\-.[XKL34K2VWQONZ;0L==KE=;E1J\5KV>G5A5I2=;712<M5
M6B8.#.VZ2RRBITR"'&CBQ&,=AZZB^)\S)6_C=L+6^V+%1]^Z[L\FI)+7"U0>
MR(MRG.2,A<%)QR:;^I2<MGYE@%9(1*F)=8V^4O')939FH= ;&XY4K<2?(*^)
M[?94W:<\C9K58G&Q?JS61QL(9I JK26]XJC0@ B0@(E*F'(+2]<AKM>X7E?(
M7"5Y)VS;5\GKUL3<TA>:N>EV%Q;[:Y69N"_45A4[1,C%-FFB4YCD*"ISG-L*
MII..1-MC]E<3'/"&:<; W_=[F]B.-AK5&6V(UW3332R[6FQE6>PZ"$62.101
M:M0.7VS'554/?UMD4.T6UKLOA_KOA!:(J2O$X6-4TEJ>S1ESU\I'I-%&R\=?
M*S:H9H_;S::@.BN$"F_O -]WCJR:WI<=L[0UQ3=77Z^;QW9==R6*S5JA.!5K
M O9&Y/'JZ+Z-;%2:IB@*3=-HW3332)@PFYA:"GZ!-VS5_.;=-TY!;[@;+;YQ
M\L]VG=W4!)/;%3I1%PTDJ4I"3%78/HH&*J8L';8BB8YR T#5U^V+RCW-%:PY
M+ZGY74NP;GY"W78EPAMGZ2;':Z[9M9R9.8&])B2*&.K%)))I/%S"LN91814'
M;%JILAOB&U]NM;;[[8'&=MO6_)\79.8WQ!2U>VK-M=-)R)(6/?6AG.NE?!)0
MK1F[5]]JBBJ1,Q'DKK>_<O(*X?\ AV:\5ZQL(O*79BUZUMI2)OT'L6L5'5T\
M=Z!M?LZC-5YNA'IQJ:#<C$RR*J2OU"QE*_KV%;[PKMRK._;CRBBN2-=W;<8;
MDXGOC84.TKE[V KMIDLD\4=6ZMQ[9@_8_3!%KMFZ8"V\B^74CP0VU)[8ONE9
MN$@8.PS-FVC9IG;5C)7K=&WAG)3NSY%=S8Y*77L,4DHLN<_S)![10*GXE#C;
MS>LM'D4N1_%BO2M3UG>86>>Q)GU;DX67@DH:\,&_^[6]I#,[#(&8?4AYME'J
MPE,(&\0E-H.J#LTE2GMH$W78.,K3<^P&O$J?VT1TG(?SW+Z 1EBTUW)GDDBK
MG;> 1IS!X"V%(13&FTG=D9;63C65XB-EZGV!K"[6#6.T=4; @T5VL=;->WFJ
M.V4M 2B3)RH@8 %1!1,^#)B)2"6H<D=>6SE4PWQ#RI)38^TI7E1N&Q6GDBFV
M>,'T5!\DEIVQ/V6TZQ!+1;<K&.61;M&Z*14@(*10(##GBHRLO_B"C= NN-+:
M1)9GY*I_A:[NG\_+,5:F'_LY68&QX4!X/\4$P GH'5!W!LE':FM][:QB7E<I
MF_>.^V+AH[<D74I!9PY>U!:ZTIZT=2=:6=.U5"MG2:WL'65%$R?NJ^?&NPZ4
MH%OD+EPICN3,OH&+N&V;5(QMEN/)Z!=,=J*;3E9G\Z7LW\\.3%(HX<)J)L 4
M,=)' > [SD]_:>U[IW<N\=PI[/O<)IFTU=YI!1VC1ZQ3(>,T_KRG5&I1.L*3
M4JY66<8F@Z*_F9APW5DY%XJX<B5/KE\0 \CCR2W64.V!#_O(L@B ?:&1Z%XH
M  1(OME <!D2CDPB(_:(X#'V=)II)^"AS%$0.41#Q^(%[=L /;X_'HX&4(!$
MP,)A\_;(0"AW,? YP/PQZ_;T=C'I>RWQCZ@0$5EAR "ICN"11#T_M?LZ\U"^
MXH(Y,<P".1[^0]^V<]^E%A(1--,F<J 7.,#GQ[>HA\.WKT8HB/@!\^V4IC 7
M(_(4WCGQ''J'0BJ)2"0/(^4S9* !CU$HC_4'1TT$U! 0^4YB@FE@<X* CE0<
M_LZ!=Z[(F'HFF4H@4HCG()@ "(F^_HS=D($#L)G!P\,=^X$\OF$WW]$*V64,
M/E@H")C%'T#/<<F#/QZ*(J![R9B% Q@$XF,?U*0,B0H 7UZ0BF<<#IX\4]LB
M)1,*1A F164R4PMRI%#)S>@!Z]?ETM BFLB9DLHJS41=MO8>E*9 Z+E QDU?
M=((]@]# )1[AT1P@8YFYA'(&+XF2$/E$HE$ ,'CCN!ND*2TBU&^PV S#M!Q%
M%=/9FV1)2GDA5C8P53(3$C6VJ2OU4:4$G2[$GO-#'5341.9M:+]5FZ;]DJ=F
ME!$?V%T[:G(9$CPR;=!N1@/N?]FN)52'*)3% 0QU&!(H-+*PB9QJ1^V5(NS:
M3C./=IJ*(*E.'U+9&7:E IP !,0#CC..\=<:_#RT4VD09 XKRYHM9A$(/D#&
M9IM6Z*2L<K&%(0J:12$3 I1 !* ]NFLLA3ZZC8)%\[8U620@2@LV?)E(@68(
MU!P$*J[9O7! 2,LW,4J@&.&!( ]3#K<NS(IU,HJ'>/ZM0IAG>+]8'"RN#"_E
MP6/!P)'"H@4RKEPHJ4P_*F/8.I2LZ(UPXU)I>TSAYZ(M>UG!*\Q@FBY 0,6J
MO["T<6&5%X@FFHNX9QBGN+D\TC)YZ-+[SY$35AG9 P.I='7M?!,SAV; K"O:
M[JO(R3TPF$0]SZ,@C]@>G2?YC2KO='!"@!U[7L6=,1<P .3'9P 0;4 ,/]D
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M))HMUDUT7"S-8JGD!QZBKO4=,ZD?U*_\-*M%:NE5&UP<!8/U5'=?U#9;=QL
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MO7'9,/Z^F%UV+8I>$:65$CV#A:^DS"14B0.<&\A)OGZ3E)%-^)?-)%-(QA3
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M!Z6\V8E7*V)0W#JI@)J26-,I]&<Q14$WEA3R /TVP.<">?ZC&L"D 3^'F?\
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MD$B&\<" "(!^X/+'_JZ>&.J(&21.)SIY(1)),!-[28=C&,J8  <=AR'0**"
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M0"G#'S9,(% 0[]L#T=F_$7,0])X'; 8?X2I0 4EDN^2*D'OGIV#T7+DB"_\
MN92&%N)VAL"F<XX-E02#@1^ AU]3 .$G!>YRQ4@<".3F*41^G2<  $,*F/E\
M@#(]'?.VXLC/72CD6P^)DF2X8(Y:JD]0-[A<C]YLAU[*0E3.<2G$@8R10"X4
M !'N B'</MQU^5/1P<A?,BV!P9(3>/D(E[ /Q$.M2,XQVV4FM2I26I[='HJ
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M"2DX^/6F'Y8N)1?/6S164DSMG+PD=')N%$SOGYFC-94$4@,H*:1S8\2F$/\
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M=502_A( C@.F\ALJ4A-8*SIY.(K<1=6\NE(V$S<4FSMW[3"/>$BX)-XN5O\
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M?<BBV+['B90#&(!A 0 0'L(#W ?VAT B "(#D,AZ#@0R'V#@1#]_]&<!D $
M'X@ XR&?L' ?U=&#Q+@_XPP&#?*!?F_O?* !W^']"5 _(K<+Q6HKW +,6L2P
MT,C9"9;PHP2ES!#\C3MJBK@'!(P5?JSLRF7 OME$?Z=E:E:16P+'>=3LM'2=
MPAZE1INS*MXKD#8[+6:3*LB1"3E=Y%QCFI/W,VX @(P\>B+E<P) (AU^SOT
MX#(>@_$,^N/LZ_9Z?=T:*M#>P0\.UH-PV/-[ =P,DCK&K5RCJQ)9PMKV 9$M
M<KLN+26%VV:.5TUW+)F[73 4VRHEI.IM4U!]%4)'5K"[4:8J5/?(:=0IZT@U
M8Q4-$7%FV"LDL#Y)^5ZC&E5^K68F,Z\1)DW5)K:T%;Y->\R4O&-)6!J\O-5V
MNJ0\$^GU7=VGF#=6.J,:^18"V:.'ITDW3]1)NF(JJ%*,)=Z!9(6WTVQ,_KJ_
M9:Z^;R<),,054;@ZC7[0ZC9TV]U$Q0.0PE$2C@>LX[AD 'XX'&0S]^.AP !D
M<C@,9' !D?M' !T(@  )AR80#&1P!<C]HX  _8'0C@,B  (X[B 9$ $?7 "(
M_P!?]'8 #N(]NW<1R(_M$1ZS\?3/[<9_KQUCX?\ FZSCN&0 ?C@<9#/WXZS@
M,B  (_$0#. S]@9'^OH1   1[B/V]L=_M[!_0     !@ #L  'H !\ #H"@4
M * >(%   H% , 4 ]   ^']!<E ? <ER ?*/B)<E^P?$PAV^ ]"(  "8<B(!
MW$< &1^T<!C_ ".6ZG83!R%W0<0.8 $SI38MA19IE#.0$%#E/G[ Z^F<9\@,
M"B:H]_=(<?(IP'XB(^OW].71R$ % $^0,(G[%[$ 1Q\XX^'IGIR"AA*N]4(W
M0[ < (4P**DQ_<!,F!_UNFBP!XH/0,)#%]2*I"!%T!$/B0X@(?\ ,,'3=J"@
M)=_<.J @)OD+CL #D.X]NE'8AE-80! 1/@R782ID. @(8. 8,/VCWZ(DP6<L
M7Z:K%\BX16,D[9%3%-XV^G72$IDEDW!0,!RB!OE 0ZB4+/-@Z:QSM1ZDBQBX
MF'0._>@DB]EGZ<.R8DDYETBF!5'2X*+"7(>6!'+I5---5O) #EQ].(%4*H41
M1,?O_P!J7P <?'/6OG]RLMN&<VTK)C5%*JTC%HF!9M9U>LLUIQJ]*9]//E9A
MLH==JT4;"@V IO<,<X$"4L6V;1-1(-[W+ZU@X^DQ3">?2$Q6VT<K+R[E61?L
M&A8QO^<-B(-B"9T[.H8 ]L">1I"-A[%3;A6(.1/(13R._)YN9HLA-(HKMG:;
M*4:+3E(=6%N4@G^F.9$KD/$Q_> !$74DD4''O%<$DFZIF\@T= I[J3E%P4WN
M LFJ7R\@$1\@STHP4-6VI+#(,5+=9XZ$90LK8')%03;R=J7:$*606064%4YR
M%33,J(JG(*G?K8=!?UNY.F=#;M@M$Y//6AXZT@B^:,$W+1!"+;*ULS]X[*ZC
M2HNG N&11!03"/EU*O81HT/%OW3@Q6L>L)PC&AU1.BG[*IA7 C<F._<1Z3-A
M%9;PP=1Q\^!$!#)2A\@8_?U$'GFR,Q!IR4>K,QJ1#(+O(I-VB>29MED\*)K.
M&8'(0P8$IA 0$/7H\%0&98NIL$%H.+@4&/Y14(RN.%R*H1J-9*)1DU#&034<
MJ//(%ER@<P*&^;I))ZE"+H"B"PK)P;%LZ]T%?,3)N&R:!2'*8 _"4.@)YB8A
M0%940\C")CB(%%0<8(4QL8SZX[=*S!&CDT0S=,XQ_+$;J*,6$D\(L>/:N7!0
M%-%9\BW4%,IA#S\!QTF/D!P,4#^10  ,(@ Y ._;H[5))PY54<F]MNDF99RH
MLJ8/$J*"(*'.!\X H (C]G1)F>C6U%C')A4:.)P@I3;\! !*,; ,\21LE'\:
MXMR%^)NIN*3LMH*G$R;MD15"?F&'OF;*>)E#MFLB4J0"(!\O<.W7NELME<JM
M'C=XV^IL4VY*1PW,19(/!=\H02 HD X$.H6U()I+(3L6TE .8I5#@=R@!G"0
MF-DP&2<^9!^.0Z%' ^IL$Q@!* ]P_=Z=)MY9L=8B)?;;NFQB@[22QV35*?!%
MR$QV[@8 ^WKW?.0<>(!E$4$D $0'\!E3G, !\<@ ^O1,$*@V1 P(M$P'VB9]
M1,8>ZBIOB8>X_<'2:GAXD X !,^H>61^SMCK2<D*X(H*W6*AG1A4%,H-[")X
M _8"F\N\D 8]!+GT_IWEQBU]MR2T1<=L04!%0>V8A&67D::XAKK6;4L\;(P4
MW7)53Z]G J,S@B]0'P<F\A,7R(;2W&'8NXI/?MRU='VEI-;:F$9AO(VY2PWF
MSVULLX1GYVRRJ?Y8RGDV1 5>K?(V#Q\2>)"\ W54JT_96U,YY:[N-O<0<6[D
MD:O4F.H=XQ;RS3ZC5-0L7!-)*7:(*.5?%(BSE,HCDY0'@+*;;I/)1RZVIM3G
ME%<STK+?-SM65MU>VL.[+?H.F;H9*61%LPUM&6%A7EJJR,5JW$A6Z*?FDY6(
MMH+5O.K7O-?:%2J_Z?.Z(=KJFJ-N05SL2-BKO-_8%/TC+7&IZYDBW9S?U]4Q
MC!C4;-*%%)N!@66>HK*-U^G]DNO^,DIRLU%^D'H]CIZ3EKS/MJ<SYKB^Y'L)
MB:^L)+-];6KD17JM*1#!Q*R)';9)VY3=+ *:A5.KN3@31N7>A82L\4$+U<%]
MZ-]YT0]LYTZGVEK'9V@89=AMZ20G;CL9TC4[/"[!EXH7$-*P\ZDV=.7ACM@2
MTIR0V;4-K534G*7?>X=L\@])W_4^_MPJZ6HS'6-;U]PPUWMC1.@-@T3:C:OP
M<36)"7G$XI0[!G=IY)S)M5?;(JA^GI*3:V^N:]WK-"TG3$Z3M'1/)S5R-.JT
MAN:Z2A.0U(V4,Q)476FS]84>98M[O [*>/9:>KM:CT3.$'CD4W?)E+4$3O)U
M$S7Z7]RJE2>ZN6N3<@;C?\A*RLR;5%Q7EB(MMJH5,%W#55L 22;,AC%'V@$.
MN:FJZ))\A-4<;;CK'@[LUI.1-0Y!<CZ;:MX,MP;D:;@B+/6*5,/=G6&H[1J%
M7K++:"%<D&#T\8Y2?+*$464.M!72=XJ\D]65C;?Z8NR]):MTQI>J[LVG$5WD
M+3-U;<D(!BA$K-W5IU1+[=HMGB9ZLJVU.*=1\<H,8\=(.(XR0.I0E$W:UMDG
MJ7] *'F9I".N"-BEWNM-R3;OD1'2DN022LDM38&054MZ:ZAQ0:.#B^#P4-G7
MO(F,KG(13=CS]9;=T58;!)6'94HE'\*[GL+=$2>"-5GTFM68[CJ[KQHN29?[
MD#!!X=N]14*<2&ZT7?:_2MD<@'KU;3M.-K>PZYWS$TS0$)^;7=>>Y&Z5WS5C
MMM"-2QB<LF:^UJSIK2$NVC62#-P0ZB35;DE.VFW;RB.7K'A=SC@=\TBN<=.4
ME?L&[-PVZIS;/7;Y3?5MVA:=&7B9K%Q%J^UHMK^,8N312IFK9-HV!1N3>&O*
M9.<HM/:5VY^G]Q[L6S]CU6"WGR DGO)2M;_086*3FJQ#2\C=[!:;OK]T:.V"
MU@7$?+R-4566,H@9!)PDPUJ?C'>-8:]L/Z;?ZEFL6.K*X?<=<U19]D.]T:C<
M:+MD7#;%D(Z[T)QN1&-=SU:K]F%&;B8M=PT,'TY5/<UQ2N.$+OW2U9@?TIJX
M\U9_,S';VO6%2YFZEY(UO8L76;3%7UQ'RS"P2UTJ:K60;/,_75ARNDD*D:J4
M#<7.1.W-<[WI4#RUW[R0L^V-,65:]P0:,X[M>%]\TYI?66U()A(M8ZGNY:98
M#-+9*@H:RV(#%,#E-(4^)K_CY0]PZSW#LR+VA^F1M;5=P0V- (UODQN*;_,=
M)[_BZ_?GH1<K7M2V*$?.G5@@1<L7=?DU%$%3)-U/;U[JZ%D)B7B==TJLTJ/E
M[%(NYBP2[6LPS.'2E9V6?K.'LG-216GONG"JAU%EU#',(B(C_P $Y6QZ1BD%
MOR.W \<X$!,95/8-C3:IB(?_ (9!,<0^T0^SIJ8XD^J3*<&JI<@118OS U$1
M[@"Q?E[^AL#TDW[!W#Y3>8G,.<"   Y' _L#INDD!0:,"_3("0# =P<PY7<F
M\A[F.H/B X#Y2AU(B<O@I".V\F(AZ%9KB+5R?R$V1$IC$$WP "YZ23%0?9,!
M1 ^?[9A_AC_J /[N_2Z1C%46)D!\BX$!24#S*'?.3 &/W]1CP2F31>,$"B<I
M1%1(R0BFFKXYR=+Q'Q$._P"'MT#-TE[:BA"*)*Y\DEFZ@^1%T#>BB9P#L(?'
ML.!#HBARB(E('<.X_.<QCB/[<]NIB194RUVRDP4@K*-56]<&5AHB8720(_72
ML;AHZ/5"MT (HZ-'@550H@*@E[&Z-<0D*%KZE7BX&EJY1-I-)+845+7^ 4:H
MS5IB7:,:=_4(I15=%FL],J0J@_PQ*H"64]AL6E;L,19[@]!K:SS,^VL$3%E8
M20/SP=679QS$A(H))NF*:KCR7*W2(F'81,,V*MOH]<WG=:C V+743/).5W,#
M!O -89-%:7=Q+VO5VU62J>VLU*85%R-A,F(I'6\>B/FWT*ZCJ*C"6*0AH\(Z
M E;&5D1.<DHMFF@@BBRD'>3?*FD4Y_)0"% X!TUJC^T2TK"Q1$D8UH^?KN4&
M:"1!3;H$]Y0P>#5(1(GD1]LGREP';I%RW?MVKDHB(E/[H>YZ9+Y@04S=OM[#
MT*HR46W.J!?)'"I2&5'T,0$B& GN?9C&>FR5FBSQ:B[9NLKYX449'=(D72:O
MQ /%D[%$X&\!R'? #Y ( #H/G25$2G)D1]THB B?[Q*/I^WIKNZ(=6#9DK%M
MWL/<8!Z_!LTH-I9I?5+1DG6(?V7#QFX1,FX9O%E5DG+8P")2F Y07)#PT?&M
M@?0!/".8-VB2BBBN2E,+<B8X\RCD?F''327E4"3;S<VX=A/I\CAN*R 1M3BX
MNLQ$<(>'FD1L9NLLF)1_AG4 Q1 P#U[*Y%G=>75.E%2I@,<R!A^8D=)F*4 2
M<D+V(H;!5BAV^8!#IG/03H\;+1[DSEH]*!3_ ,< \3D52,'@NW53_AJ)F^4Y
M!$/7OTPCW#I.'N**GN3U8E'PF3DD&9?<,^HS]ZIY23%90H%4C3F%\S,8?'WD
MOG#928E2$&URL2)?E$#91DG"?MB8X@)O$Q<8P&.@4$3)&\R$6(I\H8 1 H (
M@&,#GN'8>I*GG<%.[K*@R4<F8_D=6&D3"*Q29'(E9OQ'/P %0Z.(#XB!Q ?+
MXA\<=_MZ$1$! !]0'[,?N[=%$V1 <>/V>G?MGKMGQ$?B 9']XCZ]$%3N7S.4
M@ /B( 40P.<AY8ZHLX<3I%A;; 2IEBF]OQ)'2C5X)_<R $\?8SD<=)+$P)%D
MR*E$! P"50H' 0,'8P" ^H>O]$C:+E8X*I5F(237EK%9I>/@8*+1572;)+2,
MO*N&D>R24<KD3*950H"<Y2AW$ Z86BEV2 M]9E2*J1=BJ\Q'3\%))H+JM5U&
M$O$N7<>\(BZ0.F<4U# 50ABCW 0ZUI)?X7[!W':=O[=KVEM?T#6JM,:V"9N%
MB@+59VXK2-_M=,J\;%M8>G/5%5G#X@@8"%*4PFZDKD_E'.E9>L;$L^H+[KK>
M3RM42\47:5-E86&GZ9+H&L$C 2KDCRS19FCN*?R#"00E6:C==3ZA,!MVP(:U
MZSE>05$UD.MKXK&7R)?7"F:R;64UN-#VVLM9Q4:Y&(V-87)G#QHBH4YO$5/'
MY>I61=;XTRVCX&>A*K./E]H4A%G#6BRM_JZY6Y5RI.%0CIZ?:_Q63-8Q'#I/
MYDB&#OU5Z7;-C42KW&[K_2TNIV*WU^$LMO<BJ5 &]7@I*0;2D^N*YP)X-$EC
M>8@&,CUO;6U,VO39:X\:IQ. W/$%GHM%6ENQJD!<G3M^*KLN8:)B;(W3>O@_
MW1H^*NU54*X;KIIMMM.]U:E:ZK>NBL6>S'&QZ<CKYV].Y59$9MKFI,EKB[HS
MQ Z0)D<B<52&+CR 0Z:V&=M5;A:^]*B9E.2TY&1T.[*X:*OVYFLF\=(LG!5V
M*!UB"0X^21#'#)0$>DMO*[9UFEJ9=$CA':"E\JQ-=K-U'HQJ:Z5U-*A6E$5)
M$!;E,#D2BN'@ ^7;I,[.UUIV16M-KFD9M.Q:Y5*>\!06=K3,DZ,!ZTZ!(WMO
M@RU4\1\3C@>H" '8-("=M:;96K0HVN!"6LJ3R*>SK-2 CA?_ %DRFZ@XUP\3
M%N10#M&ZBQ<ID,8+#9*/M/7-RKM16>M[9/52[UFQ0M8<1K8SR10L,I$2;QC"
MK,&A!56*Y42,DF F, %#/4E>*EM?6MII4-&FF9>WUR]5>;J\5#D(\4/*R5@C
M)1U$L8TB<>X,*ZJQ4@!!0?+Y#8C]CK;?U<EKR78R$I%7Q78%33IDG&1'N?FL
MC'V@\L$&]8QGM&^H637,FCXCYB7 ]0-WM.T==5JEVI6*;UBWV"[5J&J]C7G$
M!=0B,#/R,FVBIA68;![C4K=507!/F3 P=^HK7TG?*.SV38XI],5374A<:W%W
M:U,8]!TLX=0%<D9)O+23-(&:GN.$D3HI F83F "F$-4L[O8J/K39>W*XSGJS
MJ6<V=KV8MLBHNU^I>,:R>O6&0CKXG'>)@.[A5'K0X$$Q%!+W_HU]O2TUU>>V
M-JF*G(O7+^2GK"Y@:<I9&SN/FY^$IAY3^3FUR?0[]Q'C-BQ-*IQSA5J1P5!5
M1,W_  3E^LY %C..26Z/ #  G$YMCV0PCZ9\2%P'2C+YSH@HD^0 H!Y =,X
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MS8P!D2)*F$%4A'\22A?L'HP8!,OD(?>(%]<_9T0<Y\1R/;(8'OC/Q[]*>8E
M3".,  B'8,!D?B =-!*4QOXI5?D !,8$_G,!0_O"!< 'Q'K7,48JA#1M%J3
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M9,1(HBNB<! <_P"GHP_A @8$,9 .X]PP("(=)IJ> @N4CA$Q1R55(_;S[X,
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M"'< \P[]>TY(>+]H1!4CWR.("7U!-,H"HIYB&"X[#]O1!1CD7*I0,4ZL@ B
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M 42Y,FF;N.0]1^/15%#%.IW,/AZ@(AD2CY=O0/F']V>C)>?R@&3%+W''J!0
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M;M*3BY2,U==WK)_'O;M..63Z-D&4*J@[9N4%2J)*$.<AR& 0R ]&=Q?&;?\
M,MTLG,@GJ#8!'B&?'YE&I:[ARD4 [BEDWVE#IJ@3B7R:,)E$A<*$T5M'N<%
M-\P_RM@Q" /22!N*G)/!"@ %/H[9Q1 V!#U/6  0[9]>W1/=XN\A6YP,4144
MT[L%/R#&0SY5X!R.?W=+N5^+W((RIVPI(J(::OZI2&.< $PF3KQU#'$I?L#
M=+$)Q:Y!K%52.F)7&DME*IE$X^OB%;+Y%.7[^P]^C(?^%ODFV,F >*A=,[.*
MF.>YL>=9$@"'H/7^[\;>1"Y! #>VXTGL<3!Z9P8E:R C\.W7^\<6^0") $P%
M4<:BV"0Q@$/F,"9JX"G?[P#OZ=6 C/B_O>0/88UDP]TVI]B$69G:OBOO=\2U
MH_N)K>'@),%QV'(]1\@KQ4W]' QK\5 BF34VQUA=_E0+E*Z4$E93\3*$7 H$
M[^(%#OU]6'&'D8"X"0PB73^QUQ$/B4GNULP$[]^W</AT5N3BQR(*B0N !/2F
MR1^\3"4*UG/]?VYZ$Z7%?D.. 'Q4<Z;V(B43? 1]ZNE,.!].P]%D77&;?2JZ
M8Y1(.HMBG IO(/(<A6R@&"?AQVSUD.+N_%.V,#J+8A1\O4 \OY;'(F+VZ41?
M<9M_MFYC%*F@GJ+88>780 551KA"$+_IQ]G7N+<;]W>^8O8"ZDOG\+/<2D'^
M7\@!NV1["(^H]"U;<:M]*E$<@='3^P3$#M_>+7A ! >B'<<<MZH>UXC\VI;^
M50V2B8?E-7P#R PY_;T/_P#SYNLZRB?D< U7?%3DSW*EDD (" !@!^_KR/QU
MWH/D(B(CJ:_  Y#_ /I_M@.P=#CCIO+L."@74U^$V SD<!7_ +^W3@ XU[_4
MR4Q2@GIS8IQ].PAXUT0'!A[8ZCXEGQ9Y"HOW<@2+$'NG-B1C$JHG$H/5I!]7
M$&S=H ?.94QL 41_9TG'--1;'DK?,HD6M,XE0[48RRH"*B<6Q$8D12C61C?*
M 8]P_P PY[=&..F]J&,83#@*#;A+D?O&([X#K :5VGGU[:_MN '[?_= >G7C
M_@KM00$! 0_P_MOH/_\ !^L%TEM(,X__ ,>VP _>(0_PZ ?\%=I@/H _X?6W
ML'?X?DX!^_H/^Y3:AAR)LAKZW#W]?4(?XCU4ZW*:LV%!,K!8H>%=2TK4+)$L
MXEC)/D6LC+N7[N,10:)1$>=5T)C&+GV?$!\C!U#UZ%:D8P\%%Q\-$LT^R;2,
MBF:+"/;)A@/$B+-N0H!]W^<J"QV$A>[EL';,R^@=5:<U#39#8>V=B2$4V3>3
M)JU48TZ*BD="MEDSNW2ZJ#='W"%\Q.8I1IE]E(VV:6<WF0E8>)UYOR'0U9LY
M*9AY=W"NHIU3YM^9T=XJY9BHW!N=<%VZB:A!$IPZ2A7-OJ[>97E$X-&)7GXE
M*36FEFY7B,0DP4=E=*2BK0X*E;@053)B!@+X]^JC1;;J+;L,YO?,BM<,ZA,/
MF523A[%:;15'EJ9[&BE$+4Y=+:Z028J-E%%$DI$%P  :B7(@QW6P74UG7)38
MFP-:1K#9DO6H*2D)_7MODZ;( R%*9<L719)_%F4;)D5,N*9R^1"FR4';6;N-
M5AW+ 4 ?-Y6PQ$>NR%TU7?-@=HNWB*C<7#)LHLGY@'FDF8X9*41!I&-YJ(7D
MG\8$VQCT9)FJ^>PPG(D$NT:$6,NXC!44*7Z@A12\C 'ED0ZWU68J97CXWCC<
M(C7FR=@6(K*OZY1OTC!LK#)4^%M,F_0;RDS4F,JS)+ !")-'+M-#S.H!RD0*
MYN]0;F<A#BV*O989(7 6(#&KXH H]**H3I2"+/QS]4 #[?ECJ;F#W"K$B:R\
M<1]DE#6")+'5]^T,4CIC-O1=@VBGC8YR@HDN9,Y!$ $ SUI76+^)L-R<[TUO
MR V=4K/2UZ_)U=&!X\T$FPK,D[D%9AN9=S.Q9O9CC-B+)'7#^*=,OS=:SKD!
M%72DV[;7':N<G*- W:,CVR5BUO-S2U=E20DU%2DI&2=AI,T#=*99$.51J1\V
M5)[B2OF7:NIM@U#D"X2T4&ME=U;2J.I'UKU'JIGMIJR<T61N]KBI51[#L)H[
M\J":@L3>;DATR <Q>N3U*CF4K52<5[[!T2ZV>UN81A6YE:?J,?<6<[!ODY-8
M484L=(D*8[PK8X'[^/B(#T6XKVNM(5$Z!')+2M.Q:=<.V54]I-P6<.Z+&&04
M5'Q*<%?$3=@'/1[;+ST,A#J,SNHMRK+QC9&=4%DL_9LH5TZ=H-)!Y)((C].1
M,XBKG)<AWZJ_ZA\Y5-G1&DK!'Q<L_BF=>CK#=ZQ$RM\/KTLM-1,1,JLAC6$P
M!5G2K=RM[+0WN8'Q, 1G&)N^F)"^O=%+\CI*<9L6QJ#5M5A.A7(^9M-J7?H)
M1"\W)9^C2%(P*)%%0QBEP(L+;(7BGL:K*G03B[,\LT*UK\DHZ,8K5-A,KO21
MSP[DQ!!,$U#"<0'&<=%J)+1736L[#\T)6"S<::PGC! #!(EA0<C)&8"4P#[P
M)>W@?7J5WI+@[V/6(38%&UO),=;R5=FI-G8KS<8>EMD7)G$NT8-SQ,A-)J.T
M5%BKD2*.""80*/\ GGC'SMXMZ\JF^[!I.D[&U->]#6>ZQVN92>IVPO!?^::!
M<YY-:NQ=DB%_<*X3= 47*'MIDR J>-;>*\1M=TU:9X\VN%81D3LW04_L/5>W
MD]DK2<(PMNVKS6'K]2F2--8M'J"%(_+G83A_:<R2;<AS]?J(:NHG'^E7'< [
MSX5QCGEE8]G14-9>+$]2]7:ZL5UMD+#N"#8+ XGS0;M KF"5,X=J^17!#)E1
MZ_G<*C"N*^3]::D<RC2:MTK)'+K04'J1U4).WF9@_%<LP>:6_P#=7B#XPF$2
MI^ >?6M>/(:'UY;F8N^=+V;<H6;1"]SIEMW/L"2L6JY MRV7#6]O!Z\F8@6Z
MTF%720LH.T4R?4LA*!PWGNK]0BAZZ5IBG!;BGJ-CLV[W>MS"=0M%/XYO-6\D
MY]U)/)-1I!N68'%N6>>  ';^XJ@OX*JB.PN3NS)J.O"5$JM=X%<9K_&_4+Q=
MPXZ<:YJ:;&V1 O'8'5>1VS[,\2.*Y#>"HP^0R YZY%\:Z[IN_P!^Y!:-_4GW
MCR!AS,;%JVOUB48;B2F=@:0VG=:QOE@MKS=.K;-&V T/)L4532$<NP5\0#VS
M$-RBLURT=I>3W%:>$W#S6^D'5/G*S7J;4=[:R<1@;10UI&O'S(:%%0[!H9!@
MY73;(F;Y1;*>TJ<G7-%GQLX]ZK?Z<W1-\!7T#K9Q):NE@EV>K:Y-(\C+/2:M
MM/\ -M=1.WDK&X;+LY.SM7#-\N*CHQ'*H8'CJWLU$B&4+JM]^JHB:.=[*H,D
MO5*WREU9%P>DH9F6M-X6"72E+/\ 5$=)QC%BSCS&.L+9LDH"8?I6Z7GZLM%7
M'@QP<W"MR1EV"A).NP;_ '(VJ='U[KS^:XX5Z_-34C)U1_*@U;.%Q3;,Q7[%
M,0QN6^T-9Z16L[+=*/&131>WAY+PFN:-J^T:@AXH)RT[4TNK^<FV\R92K4/H
M6$A$/4TA0,9(O\<1#DE9'>O:EMR%L?/SCOR9FM/2%]@:C"<MM4ZVTZA4+Y37
MZHNW,/5 D[L<)%K&SY4V*@MP*H02E2$]#N<IQIH-[U)%\WMT<BGWZ8*FV:JG
M3*SJ[8^OH^ITFO1UJE03U/(3U!M3)>>-$D,2%*H\,#;YS*E'BD:[\;=<<GZ/
M3&/+IDZXCS6Z8:*H_&R2WY9PF=5/86Q6=$T-<HW6<&(QZZC%-5VP$QCQY51*
MDIU2N#7(N&81%ED='[$U5?8UE*1\\TB5;C,7(S-ZRE8=9PP<N8YK--G:2B"A
MO:7(&!\B];F<;3&JN.4D_<N(U";TMA<ZH\C]E<5^'E?BX:/I9[%*DFZ4RE-H
MSBSB<=M)@AX]Z]8(!()E*H8A-0DU=QWV9*[8@]Y;\VQ5J/N79/#NTZ3U6ZVL
M%)AY:O;)TQ&P#+5<EK*Z,8U[),T:H@>5K+@%B) "CHI2<H;)K+7]:U#&[\TW
MNBOW+=E_LNLKDM$[<L^IF]%HEGXHV2J-@W]JZE2,BG[3^#G53-(J*)XM@%4$
MRAMVCL=/V>B[9L9N%58>TV;V-QM;:JNH:#VM%6JV;#J;75$3 *-Y1A#1RP!*
MV592?F&SP4U0573R;_/<U+1$#"Q4I9'*#VQ24;%L6,A/O&K<&C5W-/&J"3B4
M<MFI02347,H<B8>(" =OZ9&"GXJ.G(279N(Z6AYABVDXJ3CW:9D73&1CWJ2[
M1ZS<HG$BB2A#$.41 0$.F$) Q<="0T6V291D1$,6T;%QS- H$0:,&#-)%HT;
0(D#!$TR%(4.P!_\ H%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>chart01.jpg
<TEXT>
begin 644 chart01.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[@ A061O8F4 9$     ! P 0 P(#!@
M             /_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$!
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\( $0@ TP)P P$1  (1 0,1 ?_$ 2P  0 ! P4! 0
M       &!0<) 0(#" H$"P$!  $% 0$!              0! @,%!P8("1
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M^,;]F<.'HAYYZ;*)Y?;1?+;U:VD.U$O%WTT&RPX^RT.%CVFB
M                     ])/./3_ *%/SUTK\RKZ:Y4-QQF\U-]&RKC-P
M   .*MM+S8P   !Q5MI&3#H    "@YX^M0   %.NL^*[&   !]EM]Y=3N@
M ,V_B=[['N-^X           %$SX+4;75@   "E9,-I]EI]    #:I8W>Z J
M   !!)<"'28@   $KBR\RO)NS@               "B9\%J-KJP   !2LF&T
M^RT^@   !M4L;O= 5    @DN!#I,0   "5Q9>97DW9P               !"
MY,>Q&YU(    IF3%:O8Z?0 %.V<;;=0 ;5+*[O1@"I8+Y9KLX $$EP(=)B
M  2N++S*\F[.                /+7U3R/@B[USP37!?),=]I)>$5_'=]-$
M^CY+,3< N[$SVNE8?AK3<J.X'0?.94>Y^ Y*@JOMY;;;K:QZ7AM-O]<*I@O]
M"GQ=U/O+R/TH @DN!#I,0   "5Q9>97DW9P               !Y:^J>2\$/
M>.=CN'J)W8;6R>T.LE4"^E@MA&N1&RV0G8+[0)'!6E7MNB>2RLV789?9Z(5R
M5BS1?1_,KI;R !WRY9ZV ;6)RVNH_0/.@=W^5^A]%_Q#UD 027 ATF(   !*
MXLO,KR;LX                P@^Z\_Y6>K>, &U0:A71357Y[K*!GC[2]$+
M/9J;@T,C7N?/=D/1ZL ;2&S(8 D</+F#^9?>UR'E $$EP(=)B    2N++S*\
MF[.                *)GP6HVNK    %*R8;3[+3Z    &U2QN]T!4   ""
M2X$.DQ    )7%EYE>3=G                %$SX+4;75@   "E9,-I]EI]
M   #:I8W>Z J   !!)<"'28@   $KBR\RO)NS@               "D9L-L=
MIJP   !2LF*TNRTV@   !L4L;OM H VU?/4 !!)<"'28@   $KBR\RO)NS@
M              #S\]6YI^<I]:?,@%SX.QM?.UVIH5[#GKV++!)</:7*@SK9
M3H10   #A !<.-(]Y'SKVC([Y?? ""2X$.DQ    )7%EYE>3=GM=,B8N/8^3
MN7$EW*B2>EGH-)>"#-A,B/D)\OZ/M'IML           !YY^L\R_-L^N/E\<
M2_TM\;[%TTWNLN''NL_/@S.-+D6'/\M\6*Y;[^ZZ19Z?$M+.A8KO=\^
M R0^6]'^AK\S=QU5 @DN!#I,0   "5Q9>97DW9\4/4O TNZR]FFVEOIT.L8L
MLY@RK3[2!/X,O(?X/UP           &&KHGA/$']'\" VKM%=*5UK35392[?
M6W@JI&3!]UM]W=?L;+[+4@  :%!D8 !/(V?V=<)ZSV#ULX 027 ATF(   !*
MXLO,KR;L_0CW7DH/,C?19=]-*W7U6PMU/B4[)9PUID#\+ZV08,H
M  HF?!:C:ZL    4K)AM/LM/H    ;5+&[W0%0   ()+@0Z3$    E<67F5Y
M-V<                43/@M1M=6    *5DPVGV6GT    -JEC=[H"H   $$
MEP(=)B    2N++S*\F[.                *)GP6HVNK    %*R8;3[+3Z
M   &U2QN]T!4   ""2X$.DQ    )7%EYE>3=G                %$SX+4;
M75@   "E9,-I]EI]    #:I8W>Z J   !!)<"'28@   $KBR\RO)NS@
M          "B9\%J-KJP   !2LF&T^RT^@   !M4L;O= 5    @DN!#I,0
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MHNJRYW&GJT<Y;BU0+BU0+BU0+BU0+BU0+BU0+BU0+BU.+GU +G5 +G5 +G5
M$M%/1I[>WI6Q+\BSZK%!X\7+9?*C:&0'(2Z%:"5B2A&)"<52K,2631301,70
MS&4FN(Q3%)RMP1_H4]Q9*.XLHZH:K%9]5B@\?V$I[BR4=Q91U0U6*SZK%!X_
ML)3W%DH[BRCJAJL5GU6*#Q_82GN+)1W%E'5#58K/JL4'C^PE/<62CN+*.J&J
MQ6?58H/']A*>XLE'<64=4-5BL^JQ0>/L_P#_V@ ( 0$  04 _P ^65&,.N7?
MJ!OU WZ@;]0-^H&_4#?J!OU WZ@;]0'M0I@T16KM/&KAQJX<:N'&KAQJX<:N
M'&KAQJX<:N!BU=NX.KKH\U=1YJZCS5U'FKJ/-74>:NH\U=1YJZCS5U%7O#Q(
MH\[>QYV]CSM['G;V/.WL>=O8\[>QYV]CSM[%#/#R97'8667_ .Y+)\^SQUV)
MG=V58^(L:#_.K/7%;3%3MI:&B*X=%$K(^3SRTM5,]/IJ/K!8I7T!B U0A353
M3,$*<J.*F>2<N>URR_\ W(2G4*(EHU9L)$BHPJ22<R8Q*J*$$RF82)U!D"TR
MDZ2)1L"C"S"IGS[/'78F=W95CXCX3IE)<D2#H1B49*7PBK0:2<3-%,HEC-+-
M)-0?YU9IHP@JQEZAL(Z/J9_<?*ZKQ-Q2HQVICJII;%O'BMNKK&;#JN\-<7<<
M9ZJZM$N)"9-7^#6*V!M55=5ADAU76N67_P"Y,WTBL:BQAZM</>MG"%8U8E4U
M4^9UF1=1N)ZS"]QQAZ,NF/J_ZBJKQ/Q<>L?^K7J$Q&H.CZHZ=\6<P# 'KHQ(
M?<SO)LZD* Q Z>WS[/'6(:\*,4NO3$_KPPDZ]NM6J>F>C\RE_=\U9ZZ@>IW!
M23*U78J5)@1E=8I8B8R=(@,[OX=8%4U%0W24YXP=?E =&+GUWXT8?=5/2AU/
M=6.+?3O6?4EB.LPKZX<1,3<'LK7I3Q&KRL>IT5CX@(X0BKZ6,/\ J*Q!Q.P"
MQ7ZH'##CIOZMJU7=9\<1B,/<!LO];3"GIOP<Q+KY9@WT;.2YYZ0J#_.LP=R6
MLW02SM75MTT=$]28T8BU+T3ON%U*5=EV8OM.+'2-F+4O6J:H<+G=[K=LS)TF
M(M)8;U,W8G=9ZO%1+A]U"]5+QA+3M7TAA6)2BI!,G3S2[LO1%,FFGB7)&,"2
MH2[DG>1**C+;99?_ +D5L[.X+#&1C.=(8281RJ7)N;GIO-P@P?/:2J*HD@+Z
M.HUV->Z%H2IG:%(4?*RLV'N'E-NSY]GCK^%'X=4#AZJ1=-W3ZVT4GZ=<!$N&
M-+]#O1M1*S!7ITP$Z;T5 8<T!A338,[OX5'3E/UC3S]A-A=5- 5S@#@9B<\8
MF8!8&XT.2OHRZ15V'J[!7!]SPL8*#HFE7P5CX@0C&$4;2TMQ$:7I>*.:FJ:F
M;D- T UHF6FZ:II*525(D%)4B1 EH/\ .E21*O2SL#$9 ^E:85+SJ5I=09*U
MMDB]7ASAZX)3J4I=2D08?4"U&F4[3YLZ&G:?;#Q^Y^"8_<_!,?N?@F/W/P3'
M[GX)C]S\$Q^Y^"8_<_!,?N?@F/W/P3'[GX)C]S\$Q^Y^"8_<_!,?N?@F/W/P
M3'[GX)C]S\$Q^Y^"8_<_!,?N?@F/W/P3'[GX)CHMS*>F7 SJ;]R1EG#W)&6<
M/<D99P]R1EG#W)&6</<D99P]R1EG#W)&6</<D99P]R1EG!T_I!RTE3='^B++
MBC'W$.7$/<0Y<0]Q#EQ#W$.7$/<0Y<0]Q#EQ#W$.7$/<0Y<0]Q#EQ"?^B'+B
MC)Z_&7N/7XR]QZ_&7N/7XR]QZ_&7N/7XR]QZ_&7N/7XR]QZ_&7N/7XR]Q4>?
M)T!.)WKI]!@]=/H,'KI]!@]=/H,'KI]!@]=/H,'KI]!@]=/H,'KI]!@I7/BZ
M!&JJ?<Z99@]SIEF#W.F68/<Z99@]SIEF#W.F68/<Z99@]SIEF#W.F68.B;.6
MZ.>OS%[X])V77U8=;E,U%E>]==']3,V7OU<R=8M)9877'7O5'@ME]]5'4#BA
M2F6/UMU;C[C]T_XO]+N+'_ _Y9__ */_ !RP<!,3>J/*1Z<79LP$Q=;,=\.G
M7!BIJ[J%B_J/Z5I,4<8L4\;\9EW4WU?9\6*6&.('6;_P/^6?_P"CX]OIFV#V
M^F;8)?Y]\W&0%?SXYM2<>WUS;A[??-QVB_Y^\W0F9/\ S[YN*,2?SXYM1<GM
M],VP>WTS;![?3-L'M],VP>WTS;![?3-L'M],VP>WTS;![?3-L'M],VP>WTS;
M![?3-L'M],VP>WTS; ?_ #]YM*8GT$LUP>@EFN#T$LUP>@EFN#T$LUP>@EFN
M#T$LUP>@EFN#T$LUP>@EFN _(8S5TQ/H:YH@]#7-$'H:YH@]#7-$'H:YH@]#
M7-$'H:YH@]#7-$'H:YH@]#7-$$<C;-#A#T6LRL>BUF5CT6LRL>BUF5CT6LRL
M>BUF5CT6LRL>BUF5CT6LRL>BUF5A;DW9CS?-Z/V8H/1^S%!Z/V8H/1^S%!Z/
MV8H/1^S%!Z/V8H/1^S%!Z/V8H&_)PS'71?[?3-L'M],VP>WTS;![?3-L'M],
MVP>WTS;![?3-L'M],VP>WTS;!D'95O77T6]:_P#HJ+[-9/GV>.NQ,[NRK'Q%
MC0?YUV%47V:R?/L\==B9W=E6/B+&@_SKL*O:DINFF#FCA6.:.%8YHX5CFCA6
M.:.%8YHX5CFCA6.:.%8YHX5CFCA6'O%#"R9HCB5ACIYE88CF5AB.96&(YE88
MB;&'!^6/./!X<X\'ASCP>'./!X3XQ8/1+YKX5#FOA4.:^%0YKX5!IKZ@G]=\
MM8^(L:#_ #KL+^KW_P#.BK3$:8C#S#C$+%RK:MP(QJH J)D(1WLHIFF:EK1U
MJZCJIH)WI#IYQWK^@)3I)Q$R2,&K +%]\IAT;%3([?\ \HS;$@V)!TW]2BO#
MD\A7(J(WA@WA@B:9"";IYQ#<XH^FW$]SJ0C!6N%%!_!D?'BFG?H\ZQ&CJ!:/
MDK'Q%C0?YUV%_5[_ .*?AT,5=AY1&.3+UIHI>G]!3O1<@<Z5FZ5U]3H:^PA:
M.O+'JJ\-*CP:HUNHRN\NU3B!TO536U!5]AK6SW2V)?31-AI4=?\ 3@0EQI8\
M+WCIJ^%-4T^U@^X-8<J<*Z ^&C3$W%+ NDG9'BY0+#B71^.C;2^!7QZ+>F&N
M,:*VC\E8^(L:#_.NPL]OH'QWS!NFOVS^9&/;/YD8]L]F1CVSV9&/;.9D.GVS
MN9# >V=S(H0]L[F10C'^9W,AC'VSN9$%?\TN8^E3Q_G)S$M,W\X^8A/+6V2C
MG!8CT5[<K,2'MRLQ,=-.0KB[A;1/H\8MCT>,6QZ/&+8]'C%L39/.+<LOI58I
M#TJL4QZ56*8]*K%,4EE6U.74=,TS3U%T]\E8^(L:#_.NPJB^S63Y]GCKL3.[
MLJQ\18T'^==A5%]FLGS[/'78F=W95CXBQH/\Z["?BS#6CRYP'ES@/+G >7.
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MU >@YFH".0[FH0AZ(>9J/1#S-1Z(>9J/1#S-1AAD.Y@]8U]TO]+^#_1_@_\
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M;MHQ%B.7 8 1A@-#7 4UG)\K!V66>5V1/U%+$JO^Z+#\GR&Y.FKAC??HZ==
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MI/G57,L 0I)Q$$V!M\Y! WJUFM9IH7S-I5;"1IO<1]K;5_PQBWOGT4LB.2C
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M]F1M(K:,S-'V:L?TG",68+KPBV(Z"0+UFMI;2S3S9^9RSNQN6)^@#4 +!0
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M,K8&E4$ F%':-&8V(:6,8=)MM-<GM&"<9>+.%\)E4L<DT7M$:K)&A<CM5="
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MU<O4KXIZN7J5\4]7+U*FER^::;, <E CJ6.X,3* !WR=0U G14F?S\N*5M
MYJ+N*HW .$G2;G\%]_N6<^R?ZI^3*;<+Q-)%E%RW8L&:!H1EQE61HR_[V(6D
M*E26)92IM;9NTHMD9%?884CRL:B=$RRH[2?LS'F%D8O([-+VKR"0FS"UA68R
MDV4R;9N2#,0>T=F1,L&:E>::)<+B(*SR/8F(NBLRJP%K9_)YIH6R<^TDSV#
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M!BT3087>.QTM&P# C4R@:ZVMD]C[7C.:78N4BBE$JQ8F1VU.6 5L.DBX(O\
M/6UXLQGX9MJ)L,1SR(PM+*)0<*L+"1U302+W_)HC79NV85^Z,W8(B"=$1$Y
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M)>PBS.:[+MRS B,DJ"K$6.+2&%M(.H_RJ3_N8?K?*E^^*@R"3.R#-+(S-(,
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M[G+O=S.]0[E'O'Z>Y9'[9/K#\1R;W]/<Y=[N9WJ'<H]X_3W+(_;)]8=T_]H
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M:MU-Y))Z4%0#> !T[F<O8AQYDR7?U ^/WLK=JS'S\BZHQYUM:!J*SQZF=<T
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M(7>>L2=ARK(AS0F*C_(C_8Z_KI>I4GX7UKWY9_4/AZ_ZHH[^ZC)GFS\YE55
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M(ZB:@]GG=@=M3+.W2ZRAS1[%P[$JBT9 HJ!SK:&:J /-E,.TYQ,?87>W0\P
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MO>'40K><FU5>II/$U9QM5VTZ,\[9)^C.TCE)2*:L6RSH0 @K*&,"13"<"'$
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MDS?*SDJ*:SJJK6UV6-R:P?PQTQ=-91FL+CGRD.434NK6VG63$,W;(J"L<?\
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I^Y2_2$NIR7L8WIR:'[(_;ZDI^+4](;J<?['7]=+U*D_"^M>_+/JG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6828566624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 14, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DiaMedica Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001401040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">dmac<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,956,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6828313712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 16,823<span></span>
</td>
<td class="nump">$ 1,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Amounts receivable</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">17,972<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposit</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">18,339<span></span>
</td>
<td class="nump">1,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,291<span></span>
</td>
<td class="nump">919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligation</a></td>
<td class="nump">5<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligation, non-current</a></td>
<td class="nump">18<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">18<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value; unlimited authorized; 11,956,874 and 6,370,661 shares issued and outstanding, as of December 31, 2018 and 2017, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">62,993<span></span>
</td>
<td class="nump">41,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(45,968)<span></span>
</td>
<td class="num">(40,234)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">17,025<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 18,339<span></span>
</td>
<td class="nump">$ 1,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815681328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br> $ / shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common shares, authorized</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued (in shares)</a></td>
<td class="nump">11,956,874<span></span>
</td>
<td class="nump">6,370,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="nump">11,956,874<span></span>
</td>
<td class="nump">6,370,661<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6828392272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Operating revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License revenues</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,522<span></span>
</td>
<td class="nump">3,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,739<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,261<span></span>
</td>
<td class="nump">4,519<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,761)<span></span>
</td>
<td class="num">(4,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_IncomeFromGovernmentalAssistance', window );">Governmental assistance &#8211; research incentives</a></td>
<td class="num">(1,214)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense</a></td>
<td class="nump">68<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">39<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="num">(1,107)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income tax expense</a></td>
<td class="num">(5,654)<span></span>
</td>
<td class="num">(4,260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">80<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (5,734)<span></span>
</td>
<td class="num">$ (4,260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding &#8211; basic and diluted (in shares)</a></td>
<td class="nump">7,743,520<span></span>
</td>
<td class="nump">5,935,790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_IncomeFromGovernmentalAssistance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income generated from governmental assistance including, but not limited to, research incentives and grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_IncomeFromGovernmentalAssistance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6829183584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="nump">5,526,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,085<span></span>
</td>
<td class="num">$ (35,974)<span></span>
</td>
<td class="nump">$ 1,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants', window );">Issuance of common shares and warrants, net of offering costs (in shares)</a></td>
<td class="nump">707,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants', window );">Issuance of common shares and warrants, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,917<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants', window );">Exercise of common share purchase warrants (in shares)</a></td>
<td class="nump">134,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised', window );">Exercise of common share purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock option (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,260)<span></span>
</td>
<td class="num">(4,260)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">6,370,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,033<span></span>
</td>
<td class="num">(40,234)<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants', window );">Issuance of common shares and warrants, net of offering costs (in shares)</a></td>
<td class="nump">1,322,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants', window );">Issuance of common shares and warrants, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,840<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants', window );">Exercise of common share purchase warrants (in shares)</a></td>
<td class="nump">146,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised', window );">Exercise of common share purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">731<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock option (in shares)</a></td>
<td class="nump">16,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,734)<span></span>
</td>
<td class="num">(5,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, net of offering costs of $1,674 (in shares)</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, net of offering costs of $1,674</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,726<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,726<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">11,956,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,993<span></span>
</td>
<td class="num">$ (45,968)<span></span>
</td>
<td class="nump">$ 17,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the exercise of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common stock shares and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_StockAndWarrantsIssuedDuringPeriodSharesCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock and warrants for issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period due to the exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243414&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418191&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815941600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dmac_StockAndWarrantsIssuance1Member', window );">Stock and Warrants Issuance 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dmac_StockIssuanceMember', window );">Stock Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 1,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dmac_StockAndWarrantsIssuance1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dmac_StockAndWarrantsIssuance1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dmac_StockIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dmac_StockIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815707296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,734,000)<span></span>
</td>
<td class="num">$ (4,260,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">620,000<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Amounts receivable</a></td>
<td class="num">(700,000)<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(308,000)<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(271,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">372,000<span></span>
</td>
<td class="nump">248,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,696,000)<span></span>
</td>
<td class="num">(3,900,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="num">(22,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="num">(22,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares, net of offering costs</a></td>
<td class="nump">14,726,000<span></span>
</td>
<td class="nump">2,917,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common shares and warrants, net offering costs</a></td>
<td class="nump">5,840,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of common share purchase warrants</a></td>
<td class="nump">607,000<span></span>
</td>
<td class="nump">615,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">21,216,000<span></span>
</td>
<td class="nump">3,539,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash</a></td>
<td class="nump">15,470,000<span></span>
</td>
<td class="num">(383,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at beginning of year</a></td>
<td class="nump">1,353,000<span></span>
</td>
<td class="nump">1,736,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at end of year</a></td>
<td class="nump">16,823,000<span></span>
</td>
<td class="nump">1,353,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise', window );">Reclassification of warrant liability upon warrant exercise</a></td>
<td class="nump">123,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Assets acquired under capital lease</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification of warrant liability upon warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_RelcassificationOfWarrantLiabilityUponWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819710544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Business</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">DiaMedica Therapeutics Inc. and its wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. (collectively &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;DiaMedica&#x201d; and the &#x201c;Company&#x201d;), exist for the primary purpose of advancing the clinical and commercial development of a proprietary recombinant <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">KLK1</div> protein for the treatment of kidney and neurological diseases with our primary focus on chronic kidney disease and acute ischemic stroke. Our parent company is governed under the Canada Business Corporations Act and, commencing on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 4, 2018, </div>our common shares are publicly traded on The Nasdaq Capital Market under the symbol &#x201c;DMAC.&#x201d; The Company&#x2019;s shares were previously traded on the TSX Venture Exchange in Canada and on the OTCQB in the United States.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 15, 2018, </div>we implemented a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div> consolidation of our common shares. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> fractional shares were issued in connection with the share consolidation. Instead, the Company rounded to the nearest whole number the number of shares shareholders would be entitled to receive in connection with the consolidation. The share consolidation was approved by our shareholders as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 6, 2018 </div>and was implemented to increase the market price per common share to a level that qualified for listing on The Nasdaq Capital Market. Proportional adjustments were also made to common shares reserved for issuance under the Company&#x2019;s equity-based compensation plans and outstanding stock options, deferred share units and warrants. All references to share and per share amounts included in these consolidated financial statements have been retroactively restated to reflect the share consolidation.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813171248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_RisksAndUncertaintiesTextBlock', window );">Risks and Uncertainties [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Risks and Uncertainties</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">DiaMedica is subject to many risks and uncertainties. We are in the clinical stage of development of our initial product candidate, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199,</div> for the treatment of chronic kidney disease and acute ischemic stroke. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> completed the development of any product candidate and, accordingly, has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> begun to commercialize any product candidate or generate any revenues from the sale of any product candidate. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199</div> requires significant additional clinical testing and investment prior to seeking marketing approval and is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expected to be commercially available for several years, if at all. The Company&#x2019;s future success is dependent upon the success of its development efforts, its ability to demonstrate clinical progress for its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199</div> product candidate in the United States or other markets, its ability to obtain required governmental approvals of its product candidate and ultimately its ability to license or market and sell its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199</div> product candidate, and its ability to obtain additional financing to fund these efforts.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>we have incurred losses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$46.0</div> million since our inception in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2000.</div> For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>we incurred a net loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.7</div>&nbsp;million and negative cash flows from operating activities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.7</div>&nbsp;million. We expect to continue to incur operating losses until such time as any future product sales, royalty payments, licensing fees, and/or milestone payments are sufficient to generate revenue to fund our continuing operations. Further, we expect our operating losses to increase in the near term as we continue the research, development and clinical trials of, and to seek regulatory approval for, our product candidate. In addition, we expect our operating expenses to increase in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> compared to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> as a result of our recently obtained Nasdaq-listed U.S. public reporting company status. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>DiaMedica had cash of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16.8</div> million, working capital of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16.7</div> million and shareholders&#x2019; equity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$17.0</div> million. Our principal sources of cash have included net proceeds from the issuance of equity securities, including most recently an initial public offering of our common shares in the United States in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2018. </div>See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div> titled &#x201c;Shareholders&#x2019; Equity&#x201d; for additional information. Although the Company has previously been successful in obtaining financing through equity securities offerings, there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that we will be able to do so in the future. This is particularly true if our clinical data is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> positive or economic and market conditions deteriorate.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Despite our recent initial public offering in the United States, we expect that we will need substantial additional capital to further our research and development activities, complete the required clinical trials, regulatory activities and otherwise develop our product candidate, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199,</div> or any future product candidates, to a point where they <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be commercially sold. We expect our current cash, which includes the net proceeds of our recent initial public offering, to be sufficient to allow us to complete our currently ongoing Phase II Remedy trial in patients with AIS, our Phase Ib trial in patients with CKD and a planned Phase II study in patients with CKD caused by rare diseases and to otherwise fund our planned operations through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div> However, the amount and timing of our future funding requirements will depend on many factors, including the timing and results of ongoing development efforts, the potential expansion of current development programs, potential new development programs and related general and administrative support. We <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>require significant additional funds earlier than we currently expect and there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that we will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> need or seek additional funding prior to such time.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_RisksAndUncertaintiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A complete disclosure of the risks and uncertainties the company may face.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_RisksAndUncertaintiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819715616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Summary of Significant Accounting Policies </div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of consolidation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying consolidated financial statements include the assets, liabilities and expenses of DiaMedica Therapeutics Inc., and our wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. All significant intercompany transactions and balances have been eliminated in consolidation.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Functional currency</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The United States dollar is our functional currency as it represents the economic effects of the underlying transactions, events and conditions and various other factors including the currency of historical and future expenditures and the currency in which funds from financing activities are mostly generated by the Company. A change in the functional currency occurs only when there is a material change in the underlying transactions, events and condition. A change in functional currency could result in material differences in the amounts recorded in the consolidated statement of loss and comprehensive loss for foreign exchange gains and losses. All amounts in the accompanying consolidated financial statements are in U.S. dollars unless otherwise indicated.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of credit risk</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand and savings accounts at commercial banks. At times, such deposits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be in excess of insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any losses on its deposits of cash.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Fair value of financial instruments </div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Carrying amounts of certain of the Company&#x2019;s financial instruments, including amounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. Certain of the Company&#x2019;s common share purchase warrants are required to be reported at fair value. The fair value of common share purchase warrants is disclosed in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> titled &#x201c;Warrant Liability.&#x201d;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Fair value measurements</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Fair value is defined as the exit price, or amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The hierarchy is broken down into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> levels defined as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: top;"> <td style="width: 27pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1&#x2014;Unadjusted</div> quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: top;"> <td style="width: 27pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2&#x2014;Quoted</div> prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> active or model-derived valuations for which all significant inputs are observable, either directly or indirectly.</div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: top;"> <td style="width: 27pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3&#x2014;Prices</div> or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable.</div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our cash is comprised of bank deposits in demand and savings accounts. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Common share warrant liability</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The common share warrants that were issued in connection with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016 </div>private placements of common shares were classified as a liability in the consolidated balance sheets, as the common share warrants had an exercise price stated in Canadian dollars, which is different than our functional currency, and thus these warrants qualified as derivative instruments. The fair value of these common share warrants was re-measured at each financial reporting period and immediately before exercise, with any changes in fair value being recognized as a component of other income (expense) in our consolidated statements of operations. These warrants were exercised in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018, </div>see Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div> titled &#x201c;Warrant Liability.&#x201d;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Long-lived assets</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Property and equipment are stated at purchased cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years for office equipment and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> years for computer equipment. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheets and the resulting gain or loss is reflected in the consolidated statements of operations. Repairs and maintenance are expensed as incurred.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Long-lived assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset or related group of assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. If the expected future undiscounted cash flows are less than the carrying amount of the asset, an impairment loss is recognized at that time. Measurement of impairment <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be based upon appraisal, market value of similar assets or discounted cash flows.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue recognition</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We followed ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> &#x201c;Revenue from Contracts with Customers&#x201d; in accounting for our License and Collaboration agreement with Ahon Pharmaceutical Co Ltd. Accordingly, the Company recognizes revenue upon transfer of control of the product to our customer in an amount that reflects the consideration we expect to receive in exchange.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We intend to enter into arrangements for the research and development (R&amp;D) and/or manufacture of products and product candidates. Such arrangements <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>require us to deliver various rights, services and/or goods, including (i) intellectual property rights or licenses, (ii) R&amp;D services or (iii) manufacturing services. The underlying terms of these arrangements generally would provide for consideration to DiaMedica in the form of nonrefundable, up-front license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In arrangements involving more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> available.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> occur. We intend to utilize the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and development costs</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Research and development costs include expenses incurred in the conduct of human clinical trials, for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party service providers performing various testing and accumulating data related to non-clinical studies&#x37e; sponsored research agreements&#x37e; developing the manufacturing process necessary to produce sufficient amounts of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199</div> compound for use in our non-clinical studies and human clinical trials&#x37e; consulting resources with specialized expertise related to execution of our development plan for our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199</div> product candidate&#x37e; and personnel costs, including salaries, benefits and share-based compensation.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (&#x201c;CROs&#x201d;). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual work performed at each clinical trial site and by each CRO.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patent costs</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Costs associated with prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, resulting in probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in research and development costs and were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$156,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$160,000</div> for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Share-based compensation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The cost of employee and non-employee services received in exchange for awards of equity instruments is measured and recognized based on the estimated grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The fair value of share-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our share price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon Canadian Government bond rates appropriate for the expected term of each award. Expected volatility rates are based on the on historical volatility equal to the expected life of the option. The assumed dividend yield is zero, as we do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect to declare any dividends in the foreseeable future. The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income taxes</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,</div> &#x201c;Income Taxes&#x201d; for additional information. The Company&#x2019;s policy is to classify interest and penalties related to income taxes as income tax expense in the Consolidated Statements of Operations and Comprehensive Loss.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Government assistance</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Government assistance relating to research and development performed by DiaMedica Australia Pty Ltd. is recorded as a component of Other (income) expense. Government assistance was initially recognized when reasonable assurance existed that the Company complied with the conditions attached to the incentive program and that the incentive payments would be received. In subsequent periods, the government assistance was recognized when the related expenditures were incurred. During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$621,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$593,000</div> for research activities performed in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively. During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$244,000</div> for research activities performed in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net loss per share</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table summarizes our calculation of net loss per common share for the periods (in thousands, except share and per share data):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,734</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,260</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding&#x2014;basic and diluted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,743,520</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,935,790</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted net loss per share</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.74</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.72</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap">)</td> </tr>  </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following outstanding potential common shares were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the diluted net loss per share calculations as their effects were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> dilutive:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">639,359</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">480,035</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under common share purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">807,563</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">216,213</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under deferred unit plan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,183</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,183</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,468,105</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">717,431</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recently adopted accounting pronouncements</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued a new accounting standard that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard and clarifying standards require an entity to recognize revenue when control of promised goods or services is transferred to the customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted this new standard as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018, </div>but the adoption as of this date had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impact on our financial statements, as we had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> revenue until the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> We followed ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> &#x201c;Revenue from Contracts with Customers&#x201d; in accounting for our License and Collaboration agreement with Ahon Pharmaceutical Co Ltd. (Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div>).</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recently issued accounting pronouncements</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> <div style="display: inline; font-style: italic;">Leases</div>. The guidance in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> supersedes the lease recognition requirements in the Accounting Standards Codification Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840,</div> Leases. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. The new standard requires the immediate recognition of all excess tax benefits and deficiencies in the income statement and requires classification of excess tax benefits as an operating activity as opposed to a financing activity in the statements of cash flows. This standard became effective for us on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The FASB has subsequently issued the following amendments to ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> which have the same effective date and transition date of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019, </div>and which we collectively refer to as the new leasing standards:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: top;"> <td style="width: 18pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01,</div> <div style="display: inline; font-style: italic;">Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>): Land Easement Practical Expedient for Transition to Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div></div>, which permits an entity to elect an optional transition practical expedient to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> evaluate under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> land easements that existed or expired prior to adoption of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> and that were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> previously accounted for as leases under the prior standard, ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840,</div> Leases.</div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: top;"> <td style="width: 18pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,</div> <div style="display: inline; font-style: italic;">Codification Improvements to Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842,</div> Leases</div>, which amends certain narrow aspects of the guidance issued in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02.</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: top;"> <td style="width: 18pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> <div style="display: inline; font-style: italic;">Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>): Targeted Improvements</div>, which allows for a transition approach to initially apply ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption as well as an additional practical expedient for lessors to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> separate non-lease components from the associated lease component.</div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: top;"> <td style="width: 18pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,</div> <div style="display: inline; font-style: italic;">Narrow-Scope Improvements for Lessors</div>, which contains certain narrow scope improvements to the guidance issued in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02.</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We adopted the new leasing standards on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019, </div>using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019; </div>and, consequently, financial information will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be updated and the disclosures required under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be provided for dates and periods prior to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019. </div>We have reviewed our existing lease contracts and the impact of the new leasing standards on our consolidated results of operations, financial position and disclosures. Upon adoption of the new leasing standards, we expect to recognize a lease liability and related right-of-use asset on our consolidated balance sheet of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$200,000.</div> The impact of adoption of the new leasing standards will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on our consolidated statements of operations.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">07,</div> &#x201c;<div style="display: inline; font-style: italic;">Improvements to Nonemployee Share-Based Payment Accounting</div>," to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. This ASU is effective for public entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018, </div>with early adoption permitted. Prior to the adoption of this ASU, stock-based compensation awarded to non-employees was subject to revaluation over its vesting terms. Subsequent to the adoption of this ASU, non-employee share-based payment awards are measured on the date of grant, similar to share-based payment awards granted to employees. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect that the adoption of this ASU will impact our financial position or our consolidated statements of operations.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811562752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Amounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Amounts Receivable</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Amounts receivable consisted of the following (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development incentives</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">622</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales-based taxes receivable</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">134</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total amounts receivable</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">780</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5162-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5066-111524<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813081504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Deposit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Other Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Deposit</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Deposit consisted of the following (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Advances to vendor</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">271</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">271</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total deposit</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">271</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">271</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have advanced funds to a vendor engaged to support the performance of the REMEDY Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> clinical trial. The funds advanced will be held, interest free, by this vendor until the completion of the trial and applied to final trial invoices or refunded. This deposit is classified as non-current as the trial is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expected to be completed during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811573440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Property and Equipment</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Property and equipment consisted of the following (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Furniture and equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">49</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">71</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">120</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(24</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(26</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">37</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Depreciation expense for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4,000,</div> respectively. During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we disposed of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$17,000</div> of equipment, which was fully depreciated.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811553472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Accounts Payable and Accrued Liabilities</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accounts payable and accrued liabilities consisted of the following (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Trade and other payables</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">483</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">513</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">417</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">355</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical study costs</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">292</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued research and other professional fees</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">65</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued taxes and other liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total accrued liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,291</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">919</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6633039440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_WarrantLiabilitiesTextBlock', window );">Warrant Liabilities [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Warrant Liability</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the Company completed, in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> tranches, a non-brokered private placement of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">234,375</div> units with each unit consisting of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> half of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share purchase warrant. The Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">117,188</div> warrants. Each warrant entitled the holder to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.00</div> Canadian dollars at any time prior to expiry on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 18 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> for Tranche <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> and Tranche <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,</div> respectively.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As the warrant exercise price was stated in Canadian dollars and the Company&#x2019;s functional currency is the U.S. dollar, the warrants were deemed to be derivative instruments, with their estimated fair value classified as a liability on the Company&#x2019;s consolidated balance sheet. The initial estimated fair value of the warrants was recorded as a warrant liability with subsequent changes in the estimated fair value recognized in the consolidated statements of operations and comprehensive loss. The Company allocated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$281,000</div> of the net proceeds to the warrant liability and the balance of the proceeds to the common shares. The initial fair value of the warrants was determined using a Black-Scholes pricing model with the following assumptions: expected volatilities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">191.8</div> &#x2013; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">225.0%,</div> risk-free interest rates of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.43</div> &#x2013; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.49%,</div> and expected life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> years.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In connection with the offering, the Company issued an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,915</div> compensation warrants. Each compensation warrant entitled the holder to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.00</div> Canadian dollars for a period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> years from the date of issuance. The Company estimated the value of these warrants at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$24,000,</div> which was included in the issuance costs. The initial fair value of the warrants was determined using a Black-Scholes valuation model with the following assumptions: expected volatilities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">191.8</div> &#x2013; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">225.0%,</div> risk-free interest rates of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.43</div>&nbsp;&#x2013; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.49%,</div> and expected life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> years.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">121,256</div> common shares were issued on the exercise of warrants for gross proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$483,000</div> and the remaining <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,346</div> warrants expired.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The fair value of the Company&#x2019;s common share purchase warrant liability was calculated using a Black-Scholes valuation model and is classified as Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> in the fair value hierarchy. The fair values at the time of exercise of the warrants were estimated using the following valuation assumptions: expected volatilities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16.7%,</div> risk-free interest rates of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.8%,</div> and expected life of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.01</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.03</div> years.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following is a rollforward of the fair value of the warrants (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Warrant Liability</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Ending balance December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercises</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(123</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Ending balance December 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_WarrantLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A complete disclosure of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_WarrantLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813084816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Commitments and Contingencies</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Clinical trials and product development</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In the normal course of business, the Company incurs obligations to make future payments as it executes its business plan. These contracts relate to preclinical, clinical and development activities, including the clinical research organization conducting our Phase II clinical trial for acute ischemic stroke. These commitments are subject to significant change and the ultimate amounts due <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be materially different as these obligations are affected by, among other factors, the number and pace of patients enrolled, the number of clinical study sites, amount of time to complete study enrollments and the time required to finalize the analysis and reporting of study results. Clinical research agreements are generally cancelable upon <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div> days&#x2019; notice, with the Company&#x2019;s obligation then limited to costs incurred up to that date. Cancelation terms for product development contracts vary and are generally dependent upon timelines for sourcing research materials and reserving laboratory time. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the Company estimates that its outstanding commitments including research and development contracts are approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.9</div> million over the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months and approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$600,000</div> in the following <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 11, 2017, </div>the Company announced the initiation of REMEDY, a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div>-patient Phase II clinical trial evaluating <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199</div> in patients with acute ischemic stroke. The study drug (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199</div> or placebo) will be administered as an intravenous infusion within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24</div> hours of stroke symptom onset, followed by subcutaneous (under the skin) injections later that day and once every <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> days for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div> days. The study is designed to measure safety and tolerability along with multiple tests designed to investigate <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199&#x2019;s</div> therapeutic potential including plasma-based biomarkers and standard functional stroke measures assessed at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90</div> days post-stroke (Modified Rankin Scale, National Institutes of Health Stroke Scale, Barthel Index, and C-reactive protein, a measure of inflammation).</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 14, 2019, </div>the Company announced the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> enrollment in its Phase Ib dose ranging study in patients with moderate or severe CKD caused by Type I or Type II diabetes. The results from this Phase Ib study will assist us in the design of upcoming Phase II studies in patients suffering from rare diseases and CKD. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199</div> drug levels from this Phase Ib study will be used to determine the optimal dose levels for testing in the Phase II studies.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Additional clinical trials will be subsequently required if the results of the Phase II are positive. However, at this time, we are unable to reasonably estimate the total costs of future trials. Such costs are contingent on and subject to change depending on the results of current and future clinical trials as well as developments in the regulatory requirements. Clinical trial costs are expensed as incurred.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Technology license</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company has entered into a license agreement with Catalent Pharma Solutions, LLC (&#x201c;Catalent&#x201d;) whereby we have licensed certain gene expression technology and we contract with Catalent for the manufacture of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199.</div> Under the terms of this license, certain milestone and royalty payments <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>become due under this agreement and are dependent upon, among other factors, clinical trials, regulatory approvals and ultimately the successful development of a new drug, the outcome and timing of which is uncertain. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> milestones remain which include <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$185,000</div> due upon the initiation of dosing in our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> Phase III trial and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$185,000</div> upon our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> regulatory approval for commercial sale. Following the launch of our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> product, we will also incur a royalty of less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1%</div> on net sales. The royalty term is indefinite but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be canceled by us on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90</div> days&#x2019; prior written notice. The license <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be terminated by Catalent unless we fail to make required milestone and royalty payments. There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> amounts due or payable under this agreement during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Indemnification of directors and officers</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company, as permitted under laws of the Canada and in accordance with the Company&#x2019;s by-laws and indemnification agreements, will indemnify and advance expenses to its directors and officers to the fullest extent permitted by law and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>choose to indemnify other employees or agents from time to time. The Company has secured insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to the Company. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> pending litigation or proceeding involving any director or officer of the Company as to which indemnification is required or permitted, and we are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> aware of any threatened litigation or proceeding that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>result in a claim for indemnification. Insofar as indemnification for liabilities arising under the United States Securities Act of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1933,</div> as amended (the &#x201c;Securities Act&#x201d;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be permitted to directors, officers and controlling persons of the Company, the Company has been advised that, in the opinion of the United States Securities and Exchange Commission (the &#x201c;SEC&#x201d;), such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recorded any liabilities for these obligations as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Future minimum lease payments</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company leases certain office space under a non-cancelable operating lease. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 3, 2017, </div>the Company amended the lease agreement to extend its lease term by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">42</div> months, for an expiration date of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 31, 2022, </div>and increase its leased space. Rent is expensed on a straight-line basis.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Future minimum lease payments under this operating lease are as follows (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">64</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">66</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">68</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">244</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6631710240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;" cellspacing="0pt" cellpadding="0pt">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Shareholders&#x2019; Equity</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Authorized capital stock</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company has authorized share capital of an unlimited number of common voting shares and the shares do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a stated par value.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> vote per share at the Company's annual general meeting and any extraordinary general meeting.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Shareholders rights plan</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company adopted a shareholder rights plan agreement (the &#x201c;Rights Plan&#x201d;). The Rights Plan is designed to provide adequate time for the Board of Directors and the shareholders to assess an unsolicited takeover bid for the Company, to provide the Board of Directors with sufficient time to explore and develop alternatives for maximizing shareholder value if a takeover bid is made, and to provide shareholders with an equal opportunity to participate in a takeover bid and receive full and fair value for their common shares. The Rights Plan was renewed at the Company&#x2019;s annual meeting of shareholders in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2017 </div>and is set to expire at the close of the Company&#x2019;s annual meeting of shareholders in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The rights issued under the Rights Plan will initially attach to and trade with the common shares and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> separate certificates will be issued unless an event triggering these rights occurs. The rights will become exercisable only when a person, including any related person or entity, acquires or attempts to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20%</div> or more of the outstanding common shares without complying with the &#x201c;Permitted Bid&#x201d; provisions of the Rights Plan or without approval of the Board of Directors. Should such an acquisition occur or be announced, each right would, upon exercise, entitle a rights holder, other than the acquiring person and related persons, to purchase common shares at a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> discount to the market price at the time.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Under the Plan, a Permitted Bid is a bid made to all holders of the common shares and which is open for acceptance for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div> days. If at the end of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div> days at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> of the outstanding common shares, other than those owned by the offeror and certain related parties have been tendered, the offeror <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>take up and pay for the common shares but must extend the bid for a further <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> days to allow other shareholders to tender.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The issuance of common shares upon the exercise of the rights is subject to receipt of certain regulatory approvals.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Public offering during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div></div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 11, 2018, </div>the Company issued and sold an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,100,000</div> common shares in an initial public offering at a price to the public of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.00</div> per share. As a result of the offering, the Company received gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16.4</div> million, which resulted in net proceeds to the Company of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$14.7</div> million, after deducting underwriting discounts and commissions and offering expenses. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">None</div> of the expenses associated with the initial public offering were paid to directors, officers, persons owning <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> percent or more of any class of equity securities, or to their associates, or to our affiliates. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 11, 2018, </div>as additional underwriting compensation and in exchange for cash consideration of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$50,</div> the Company granted the underwriter a warrant to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">205,000</div> common shares (equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.0%</div> of the common shares sold in the initial public offering) at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.80</div> per share (equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">120%</div> of the initial public offering price per common share in the initial public offering), subject to customary anti-dilution provisions. The warrant is exercisable for a term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years. The warrant includes a cashless exercise provision entitling the underwriter to surrender a portion of the underlying common shares that has a value equal to the aggregate exercise price in lieu of paying cash upon exercise.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Private placements during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div></div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 29, 2018, </div>the Company completed, in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> tranches, a brokered and non-brokered private placement of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,322,965</div> units at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.90</div> per unit for aggregate gross proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.3</div>&nbsp;million. Each unit consisted of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> half of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share purchase warrant. The Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">661,482</div> warrants. Each warrant entitles the holder to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7.00</div> at any time prior to expiry on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 19, 2020 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 29, 2020 </div>for Tranche <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> and Tranche <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,</div> respectively. The warrants are subject to early expiry under certain conditions. The warrant expiry date can be accelerated at the option of the Company, in the event that the volume- weighted average trading price of the Company&#x2019;s common shares exceeds <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12.00</div> per common share for any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div> consecutive trading days. In connection with this offering, the Company paid aggregate finder&#x2019;s fees of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$384,000</div> and issued an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80,510</div> compensation warrants. Each compensation warrant entitles the holder to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.90</div> for a period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> years from the closing of this offering, subject to acceleration on the same terms as the common share purchase warrants.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">128,594</div> common shares were issued on the exercise of warrants for gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$607,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,954</div> common shares were issued on the exercise of options for gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$43,000.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Private placements during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div></div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 18, 2017, </div>the Company completed a non-brokered private placement of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">181,220</div> units at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.20</div> per unit for aggregate gross proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$944,000,</div> or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$934,000</div> net of issuance costs. Each unit consisted of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> half of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share purchase warrant. Each whole warrant entitles the holder to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7.00</div> at any time prior to expiry on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 19, 2019. </div>Warrants are subject to early expiry, at the option of the Company, if on any date the volume-weighted average closing trading price of the common shares on any recognized stock exchange equals or exceeds <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12.00</div> for a period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div> consecutive trading days.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 17, 2017, </div>the Company completed a non-brokered private placement of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">526,316</div> units at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.80</div> per unit for aggregate gross proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,000,000,</div> or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,983,000</div> net of issuance costs. Each unit consisted of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> half of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share purchase warrant. Each whole warrant entitles the holder to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.60</div> at any time prior to expiry on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 17, 2019. </div>The warrants were subject to early expiry, at the option of the Company, if on any date the volume-weighted average closing trading price of the common shares on any recognized Canadian stock exchange equaled or exceeded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.00</div> for a period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> consecutive trading days, which occurred in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2017. </div>The Company exercised its call option and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">131,578</div> shares were issued for the warrants exercised and the remaining warrants were cancelled.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">134,079</div> common shares were issued on the exercise of warrants for gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$615,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,000</div> common shares were issued on the exercise of options for gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,000.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Shares reserved</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options outstanding</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">639,359</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred share units outstanding</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,183</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shares available for grant under the Option Plan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">123,376</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under common share purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">807,563</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,591,479</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813081504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - License and Collaboration Agreement With Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">License and Collaboration Agreement with Related Party</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 27, 2018, </div>the Company entered into a license and collaboration agreement (the &#x201c;License Agreement&#x201d;) with Ahon Pharmaceutical Co Ltd. (&#x201c;Ahon Pharma&#x201d;), which grants Ahon Pharma exclusive rights to develop and commercialize <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199</div> for acute ischemic stroke in mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Under the terms of the agreement, the Company is entitled to receive a non-refundable upfront payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$500,000</div> due upon signing the License Agreement and an additional non-refundable payment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.5</div> million upon regulatory clearance to initiate a clinical trial in China. The Company also has the potential to receive up to an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$27.5</div> million in development and sales related milestones and up to approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> royalties on net sales of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199</div> in the licensed territories. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territories will be the sole responsibility of Ahon Pharma. The License Agreement <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be terminated at any time by Ahon Pharma by providing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">120</div> days written notice.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company received the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$500,000</div> upfront license fee and recorded it as revenue during the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018. </div>The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.5</div>&nbsp;million payment and the up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$27.5</div> million in additional development and sales related milestones were determined to be at-risk substantive performance milestones and were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recordable as revenue as they were determined to be fully constrained using the most likely amount method. Revenue will be recognized for these milestones when it is probable that a significant reversal of the cumulative revenue recognized will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> occur. Under the terms of the License Agreement, the Company is obligated to pay, and Ahon Pharma <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>withhold, approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of any license fee as income tax due in China. The Company will record this withholding as income tax at the time it records the related license fee revenue. Accordingly, with respect to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$500,000</div> license fee, the Company recorded this withholding as income tax at the time it recorded this license fee revenue.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Ahon Pharma is a subsidiary of Shanghai Fosun Pharmaceutical (Group) co. Ltd. (&#x201c;Fosun Pharma&#x201d;) which, through its partnership with SK Group, a South Korea based company, is an investor in DiaMedica, holding approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.4%</div> of our common shares as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018. </div>This investment was made in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811754368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Share-Based Compensation</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Deferred share unit plan</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The DiaMedica Therapeutics Inc. Amended and Restated Deferred Share Unit Plan (&#x201c;DSU Plan&#x201d;) promotes greater alignment of long-term interests between non-executive directors and executive officers of the Company and its shareholders through the issuance of deferred share units (&#x201c;DSUs&#x201d;). Since the value of DSUs increases or decreases with the market price of the common shares, DSUs reflect a philosophy of aligning the interests of directors and executive officers by tying compensation to share price performance. For the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> DSUs or common shares underlying DSUs issued. The Company has reserved for issuance up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div> common shares under the DSU Plan and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,183</div> DSUs were outstanding at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock option plan</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The DiaMedica Therapeutics Inc. Stock Option Plan Amended and Restated <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 6, 2018 (</div>the &#x201c;Option Plan&#x201d;) allows the Board of Directors from time to time, in its sole discretion, and in accordance with the requirements of the Nasdaq Stock Market, to grant the Company&#x2019;s directors, officers, employees and certain consultants (as such terms are used in the Option Plan) non-transferable options to purchase common shares. The shareholders approved the adoption of the Option Plan on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 22, 2011, </div>which was then amended and restated on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 23, 2015, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 21, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 6, 2018. </div>The number of common shares reserved for issuance under the Option Plan at any time is equal to the lesser of: <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">783,918</div> (subject to adjustment) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of the issued common shares at the relevant time and the aggregate number of common shares reserved for issuance under any other compensation or incentive mechanism or plan (including deferred share unit plans or employee stock option plans, if any), shall <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> exceed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of our issued shares at the relevant time. In addition, the maximum number of common shares that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be issued under the Option Plan upon the exercise of incentive stock options within the meaning of Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">422</div> of the United States Internal Revenue Code of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1986,</div> as amended (the &#x201c;Code&#x201d;) is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">283,918</div> shares (subject to adjustment).</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>options to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">639,359</div> common shares were outstanding. Options granted vest at various rates and have terms of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> years. As the TSX Venture Exchange was the principal trading market for the Company&#x2019;s common shares, all options previously granted under the Option Plan have been priced in Canadian dollars.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The aggregate number of common shares reserved for issuance under the Option Plan and the DSU Plan as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">783,918.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Share-based compensation expense for each of the periods presented is as follows (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">170</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">450</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total share-based compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">620</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">409</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We recognize share-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A summary of option activity is as follows (in thousands except share and per share amounts):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Underlying</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average Exercise</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price Per Share</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(CAD$)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Intrinsic Value</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(CAD$)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at December 31, 2016</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">427,850</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.68</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">187</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">127,635</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Expired/cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(72,450</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeited</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">480,035</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.45</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">674</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">196,800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.08</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16,954</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Expired/cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeited</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(20,522</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.99</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at December 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">639,359</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.87</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div>  <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A summary of the status of our unvested shares during the year ended and as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>is as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares Under</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Option</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average Grant Date Fair Value Per Share</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(CAD$)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">216,793</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.69</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">196,800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Vested</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(150,739</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.48</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(20,522</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.27</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">242,332</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.45</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Information about stock options outstanding, vested and expected to vest as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>is as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11011100000%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding, Vested and Expected to Vest</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 110111%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options Vested and Exercisable</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="3" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 163%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Per Share Exercise</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Price</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Life (Years)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(CAD$)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercisable</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Life (Years)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$2.00</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.60</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$2.80</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.20</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$3.40</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.20</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">130,405</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">91,239</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$5.40</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.20</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">98,063</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.39</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,563</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$10.40</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$34.00</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">235,491</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.86</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">79,825</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">639,359</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.87</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">397,027</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The cumulative grant date fair value of employee options vested during the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$508,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$213,000,</div> respectively. Total proceeds received for options exercised during the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$43,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7,000,</div> respectively.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> total compensation expense related to unvested employee stock options <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> yet recognized was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$551,000,</div> respectively, which is expected to be allocated to expenses over a weighted-average period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.01</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.97</div> years, respectively.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The aggregate intrinsic value of stock options exercised during the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$104,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,000,</div> respectively.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by the Company for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017:</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 53%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 53%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Common share fair value</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.84</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.20</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.40</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;2.1</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.2%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.1%</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected option life</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;4.8</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.5</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;123.5</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">135.7%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;84.7</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">156.8%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Nonemployee share-based compensation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We account for stock options granted to nonemployees in accordance with FASB ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">505.</div> In connection with stock options granted to nonemployees, we recorded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$205,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$308,000</div> for nonemployee share-based compensation during the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">These amounts were based upon the fair values of the vested portion of the grants. Amounts expensed during the remaining vesting period will be determined based on the fair value at the time of vesting.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813122720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Compensation and Employee Benefit Plans [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Employee Benefit Plan</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We maintain an employee <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401</div>(k) retirement savings plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x201c;401</div>(k) Plan&#x201d;). The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401</div>(k) Plan provides eligible employees with an opportunity to make tax-deferred contributions into a long-term investment and savings program. All employees over the age of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>elect to participate in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401</div>(k) Plan beginning on their hire date. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401</div>(k) Plan allows eligible employees to contribute a portion of their annual compensation, subject only to maximum limits required by law. We contribute an amount equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4%</div> of each employees&#x2019; compensation under the safe harbor provisions provided by the Internal Revenue Service rules governing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401</div>(k) plans. Employee and employer safe harbor contributions vest immediately.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have recorded contribution expenses of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$45,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$33,000</div> for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809693024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; min-width: 700px;">  <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.</div></div></td> <td style="width: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Income Taxes</div></div> </td> </tr>  </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company has incurred net operating losses since inception. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> reflected the benefit of net operating loss carryforwards in the accompanying financial statements and has established a full valuation allowance against its deferred tax assets.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as operating losses and tax credit carryforwards.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The significant components of our deferred tax assets and liabilities are as follows (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets (liabilities):</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Non-capital losses carried forward</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,280</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,233</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Research and development expenditures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">887</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">887</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Share issue costs</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">529</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">117</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Patents and other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">293</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">319</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Accruals</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Property and equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Total deferred tax asset, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,886</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,552</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,886</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,552</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax asset</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that the deferred tax assets arising from the above-mentioned future tax benefits are currently <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> likely to be realized and, accordingly, we have provided a full valuation allowance.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The reconciliation of the Canadian statutory income tax rate applied to the net loss for the year to the income tax expense is as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended December 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Statutory income tax rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax recovery based on statutory rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,119</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,160</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Share-based compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gain on revaluation of warrant liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(450</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Australian research and development incentive</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">103</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">314</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">172</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in unrecognized temporary differences</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,131</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">534</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Net operating losses and tax credit carryforwards as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>are as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Amount</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(In thousands)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Expiration Years</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-capital income tax losses, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,002</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Beginning 2026</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development expense carry forwards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,284</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Indefinitely</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tax credits</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">525</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Beginning 2020</div> </td> </tr>  </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company is subject to taxation in the Canada, the United States and Australia. Tax returns, since the inception of DiaMedica Therapeutics Inc. are subject to examinations by Canadian tax authorities and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>change upon examination. Tax returns of DiaMedica USA, Inc., since its inception in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012</div> and thereafter, are subject to examination by the U.S. federal and state tax authorities. Tax returns of DiaMedica Therapeutics Australia Pty Ltd., since its inception in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and thereafter, are subject to examination by the Australian tax authorities.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6828626032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of consolidation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying consolidated financial statements include the assets, liabilities and expenses of DiaMedica Therapeutics Inc., and our wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. All significant intercompany transactions and balances have been eliminated in consolidation.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_FunctionalCurrencyPolicyTextBlock', window );">Functional Currency [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Functional currency</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The United States dollar is our functional currency as it represents the economic effects of the underlying transactions, events and conditions and various other factors including the currency of historical and future expenditures and the currency in which funds from financing activities are mostly generated by the Company. A change in the functional currency occurs only when there is a material change in the underlying transactions, events and condition. A change in functional currency could result in material differences in the amounts recorded in the consolidated statement of loss and comprehensive loss for foreign exchange gains and losses. All amounts in the accompanying consolidated financial statements are in U.S. dollars unless otherwise indicated.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of credit risk</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand and savings accounts at commercial banks. At times, such deposits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be in excess of insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any losses on its deposits of cash.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Fair value of financial instruments </div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Carrying amounts of certain of the Company&#x2019;s financial instruments, including amounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. Certain of the Company&#x2019;s common share purchase warrants are required to be reported at fair value. The fair value of common share purchase warrants is disclosed in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> titled &#x201c;Warrant Liability.&#x201d;</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Fair value measurements</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Fair value is defined as the exit price, or amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The hierarchy is broken down into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> levels defined as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 27pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1&#x2014;Unadjusted</div> quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 27pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2&#x2014;Quoted</div> prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> active or model-derived valuations for which all significant inputs are observable, either directly or indirectly.</div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 27pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3&#x2014;Prices</div> or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable.</div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our cash is comprised of bank deposits in demand and savings accounts. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Common share warrant liability</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The common share warrants that were issued in connection with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016 </div>private placements of common shares were classified as a liability in the consolidated balance sheets, as the common share warrants had an exercise price stated in Canadian dollars, which is different than our functional currency, and thus these warrants qualified as derivative instruments. The fair value of these common share warrants was re-measured at each financial reporting period and immediately before exercise, with any changes in fair value being recognized as a component of other income (expense) in our consolidated statements of operations. These warrants were exercised in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2018, </div>see Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div> titled &#x201c;Warrant Liability.&#x201d;</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Long-lived assets</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Property and equipment are stated at purchased cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years for office equipment and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> years for computer equipment. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheets and the resulting gain or loss is reflected in the consolidated statements of operations. Repairs and maintenance are expensed as incurred.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Long-lived assets are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the asset or related group of assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. If the expected future undiscounted cash flows are less than the carrying amount of the asset, an impairment loss is recognized at that time. Measurement of impairment <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be based upon appraisal, market value of similar assets or discounted cash flows.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Revenue recognition</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We followed ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> &#x201c;Revenue from Contracts with Customers&#x201d; in accounting for our License and Collaboration agreement with Ahon Pharmaceutical Co Ltd. Accordingly, the Company recognizes revenue upon transfer of control of the product to our customer in an amount that reflects the consideration we expect to receive in exchange.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We intend to enter into arrangements for the research and development (R&amp;D) and/or manufacture of products and product candidates. Such arrangements <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>require us to deliver various rights, services and/or goods, including (i) intellectual property rights or licenses, (ii) R&amp;D services or (iii) manufacturing services. The underlying terms of these arrangements generally would provide for consideration to DiaMedica in the form of nonrefundable, up-front license fees, development and commercial-performance milestone payments, cost sharing, royalty payments and/or profit sharing.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In arrangements involving more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> performance obligation, each required performance obligation is evaluated to determine whether it qualifies as a distinct performance obligation based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the arrangement is then allocated to each separate distinct performance obligation based on its respective relative stand-alone selling price. The estimated selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis or using an adjusted market assessment approach if selling price on a stand-alone basis is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> available.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The consideration allocated to each distinct performance obligation is recognized as revenue when control of the related goods or services is transferred. Consideration associated with at-risk substantive performance milestones is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> occur. We intend to utilize the sales and usage-based royalty exception in arrangements that resulted from the license of intellectual property, recognizing revenues generated from royalties or profit sharing as the underlying sales occur.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and development costs</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Research and development costs include expenses incurred in the conduct of human clinical trials, for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party service providers performing various testing and accumulating data related to non-clinical studies&#x37e; sponsored research agreements&#x37e; developing the manufacturing process necessary to produce sufficient amounts of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199</div> compound for use in our non-clinical studies and human clinical trials&#x37e; consulting resources with specialized expertise related to execution of our development plan for our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">DM199</div> product candidate&#x37e; and personnel costs, including salaries, benefits and share-based compensation.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (&#x201c;CROs&#x201d;). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual work performed at each clinical trial site and by each CRO.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_PatentCostsPolicyTextBlock', window );">Patent Costs [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patent costs</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Costs associated with prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, resulting in probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in research and development costs and were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$156,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$160,000</div> for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Compensation Related Costs, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Share-based compensation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The cost of employee and non-employee services received in exchange for awards of equity instruments is measured and recognized based on the estimated grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The fair value of share-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our share price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon Canadian Government bond rates appropriate for the expected term of each award. Expected volatility rates are based on the on historical volatility equal to the expected life of the option. The assumed dividend yield is zero, as we do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect to declare any dividends in the foreseeable future. The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income taxes</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,</div> &#x201c;Income Taxes&#x201d; for additional information. The Company&#x2019;s policy is to classify interest and penalties related to income taxes as income tax expense in the Consolidated Statements of Operations and Comprehensive Loss.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_GovernmentAssistancePolicyTextBlock', window );">Government Assistance [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Government assistance</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Government assistance relating to research and development performed by DiaMedica Australia Pty Ltd. is recorded as a component of Other (income) expense. Government assistance was initially recognized when reasonable assurance existed that the Company complied with the conditions attached to the incentive program and that the incentive payments would be received. In subsequent periods, the government assistance was recognized when the related expenditures were incurred. During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$621,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$593,000</div> for research activities performed in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively. During <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> we recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$244,000</div> for research activities performed in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net loss per share</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table summarizes our calculation of net loss per common share for the periods (in thousands, except share and per share data):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,734</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,260</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding&#x2014;basic and diluted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,743,520</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,935,790</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted net loss per share</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.74</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.72</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following outstanding potential common shares were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the diluted net loss per share calculations as their effects were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> dilutive:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">639,359</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">480,035</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under common share purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">807,563</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">216,213</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under deferred unit plan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,183</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,183</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td></tr></table></div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recently adopted accounting pronouncements</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued a new accounting standard that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. The FASB subsequently issued additional, clarifying standards to address issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard and clarifying standards require an entity to recognize revenue when control of promised goods or services is transferred to the customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We adopted this new standard as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018, </div>but the adoption as of this date had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impact on our financial statements, as we had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> revenue until the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> We followed ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> &#x201c;Revenue from Contracts with Customers&#x201d; in accounting for our License and Collaboration agreement with Ahon Pharmaceutical Co Ltd. (Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div>).</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recently issued accounting pronouncements</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> <div style="display: inline; font-style: italic;">Leases</div>. The guidance in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> supersedes the lease recognition requirements in the Accounting Standards Codification Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840,</div> Leases. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. The new standard requires the immediate recognition of all excess tax benefits and deficiencies in the income statement and requires classification of excess tax benefits as an operating activity as opposed to a financing activity in the statements of cash flows. This standard became effective for us on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The FASB has subsequently issued the following amendments to ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> which have the same effective date and transition date of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019, </div>and which we collectively refer to as the new leasing standards:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 18pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01,</div> <div style="display: inline; font-style: italic;">Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>): Land Easement Practical Expedient for Transition to Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div></div>, which permits an entity to elect an optional transition practical expedient to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> evaluate under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> land easements that existed or expired prior to adoption of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> and that were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> previously accounted for as leases under the prior standard, ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840,</div> Leases.</div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 18pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,</div> <div style="display: inline; font-style: italic;">Codification Improvements to Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842,</div> Leases</div>, which amends certain narrow aspects of the guidance issued in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02.</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 18pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> <div style="display: inline; font-style: italic;">Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>): Targeted Improvements</div>, which allows for a transition approach to initially apply ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption as well as an additional practical expedient for lessors to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> separate non-lease components from the associated lease component.</div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 18pt;">&nbsp;</td> <td style="width: 18pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x25cf;</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,</div> <div style="display: inline; font-style: italic;">Narrow-Scope Improvements for Lessors</div>, which contains certain narrow scope improvements to the guidance issued in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02.</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We adopted the new leasing standards on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019, </div>using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019; </div>and, consequently, financial information will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be updated and the disclosures required under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be provided for dates and periods prior to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019. </div>We have reviewed our existing lease contracts and the impact of the new leasing standards on our consolidated results of operations, financial position and disclosures. Upon adoption of the new leasing standards, we expect to recognize a lease liability and related right-of-use asset on our consolidated balance sheet of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$200,000.</div> The impact of adoption of the new leasing standards will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on our consolidated statements of operations.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">07,</div> &#x201c;<div style="display: inline; font-style: italic;">Improvements to Nonemployee Share-Based Payment Accounting</div>," to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. This ASU is effective for public entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018, </div>with early adoption permitted. Prior to the adoption of this ASU, stock-based compensation awarded to non-employees was subject to revaluation over its vesting terms. Subsequent to the adoption of this ASU, non-employee share-based payment awards are measured on the date of grant, similar to share-based payment awards granted to employees. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect that the adoption of this ASU will impact our financial position or our consolidated statements of operations.</div></div></div></div></div></div></div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_FunctionalCurrencyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for functional currency in use by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_FunctionalCurrencyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819826416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,734</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,260</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding&#x2014;basic and diluted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,743,520</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,935,790</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted net loss per share</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.74</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.72</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">639,359</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">480,035</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under common share purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">807,563</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">216,213</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under deferred unit plan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,183</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,183</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,468,105</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">717,431</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6629946528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Amounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development incentives</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">622</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales-based taxes receivable</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">134</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total amounts receivable</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">780</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819659792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Deposit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Advances to vendor</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">271</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">271</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total deposit</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">271</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">271</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819763600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Furniture and equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">49</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">71</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">120</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(24</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">37</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819708656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Trade and other payables</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">483</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">513</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">417</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">355</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical study costs</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">292</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued research and other professional fees</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">65</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued taxes and other liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total accrued liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,291</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">919</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813349696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Warrant Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Warrant Liability</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Ending balance December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercises</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(123</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Ending balance December 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6658774560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">64</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">68</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">244</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813349696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_CommonStockReservedForFutureIssuanceTableTextBlock', window );">Common Stock Reserved for Future Issuance [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options outstanding</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">639,359</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred share units outstanding</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,183</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shares available for grant under the Option Plan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">123,376</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under common share purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">807,563</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,591,479</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_CommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A tabular disclosure of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_CommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6604938032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">170</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">450</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total share-based compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">620</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">409</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Underlying</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average Exercise</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price Per Share</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(CAD$)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Intrinsic Value</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(CAD$)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at December 31, 2016</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">427,850</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.68</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">187</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">127,635</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Expired/cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(72,450</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeited</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">480,035</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.45</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">674</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">196,800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.08</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16,954</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Expired/cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeited</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(20,522</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.99</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at December 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">639,359</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.87</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Nonvested Share Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares Under</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Option</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average Grant Date Fair Value Per Share</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(CAD$)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">216,793</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.69</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">196,800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Vested</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(150,739</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.48</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(20,522</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.27</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">242,332</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.45</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11011100000%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding, Vested and Expected to Vest</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 110111%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options Vested and Exercisable</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="3" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 163%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Per Share Exercise</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Price</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Life (Years)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(CAD$)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercisable</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Life (Years)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$2.00</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.60</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$2.80</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.20</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$3.40</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.20</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">130,405</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">91,239</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$5.40</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.20</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">98,063</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.39</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,563</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$10.40</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$34.00</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">235,491</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.86</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">79,825</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 3%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">639,359</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.87</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">397,027</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 53%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="3" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 53%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Common share fair value</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.84</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.20</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.40</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;2.1</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.2%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.1%</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0%</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected option life</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;4.8</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.5</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;123.5</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">135.7%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;84.7</div></td> <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2013;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">156.8%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813074784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets (liabilities):</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Non-capital losses carried forward</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,280</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,233</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Research and development expenditures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">887</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">887</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Share issue costs</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">529</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">117</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Patents and other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">293</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">319</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Accruals</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Property and equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Total deferred tax asset, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,886</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,552</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,886</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,552</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax asset</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year Ended December 31,</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Statutory income tax rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax recovery based on statutory rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,119</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,160</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Share-based compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">243</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gain on revaluation of warrant liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(450</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Australian research and development incentive</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">103</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">314</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">172</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in unrecognized temporary differences</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,131</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">534</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of Operating Loss Carryforwards [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Amount</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(In thousands)</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Expiration Years</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-capital income tax losses, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,002</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Beginning 2026</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development expense carry forwards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,284</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Indefinitely</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tax credits</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">525</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&nbsp;</td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 14%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Beginning 2020</div> </td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819764976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Business (Details Textual)<br></strong></div></th>
<th class="th"><div>Nov. 15, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=dmac_ReverseStockSplitMember', window );">Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=dmac_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=dmac_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6659833952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Risks and Uncertainties (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Ending Balance</a></td>
<td class="num">$ (45,968)<span></span>
</td>
<td class="num">$ (40,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent, Total</a></td>
<td class="num">(5,734)<span></span>
</td>
<td class="num">(4,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities, Total</a></td>
<td class="num">(5,696)<span></span>
</td>
<td class="num">(3,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, Ending Balance</a></td>
<td class="nump">16,823<span></span>
</td>
<td class="nump">1,353<span></span>
</td>
<td class="nump">$ 1,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_WorkingCapital', window );">Working Capital</a></td>
<td class="nump">16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' Equity Attributable to Parent, Ending Balance</a></td>
<td class="nump">$ 17,025<span></span>
</td>
<td class="nump">$ 799<span></span>
</td>
<td class="nump">$ 1,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815579776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018', window );">Research Grant, Recognized, Research Activities Performed 2018</a></td>
<td class="nump">$ 621,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017', window );">Research Grant, Recognized, Research Activities Performed 2017</a></td>
<td class="nump">593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016', window );">Research Grant, Recognized, Research Activities Performed 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_PatentExpense', window );">Patent Expense</a></td>
<td class="nump">$ 156,000<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_PatentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense associated with gaining and maintaining certain patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_PatentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research grant recognized for research activities performed 2016.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ResearchGrantRecognizedResearchActivitiesPerformed2016</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research grant recognized for research activities performed 2017.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ResearchGrantRecognizedResearchActivitiesPerformed2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research grant recognized for research activities performed 2018.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ResearchGrantRecognizedResearchActivitiesPerformed2018</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6706311568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,734)<span></span>
</td>
<td class="num">$ (4,260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding&#8212;basic and diluted (in shares)</a></td>
<td class="nump">7,743,520<span></span>
</td>
<td class="nump">5,935,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815822928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">1,468,105<span></span>
</td>
<td class="nump">717,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_EmployeeAndNonemployeeStockOptionsMember', window );">Employee and Non-employee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">639,359<span></span>
</td>
<td class="nump">480,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_CommonStockPurchaseWarrantsMember', window );">Common Stock Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">807,563<span></span>
</td>
<td class="nump">216,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember', window );">Deferred Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">21,183<span></span>
</td>
<td class="nump">21,183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_EmployeeAndNonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_EmployeeAndNonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_CommonStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_CommonStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_DeferredShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6649918208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Amounts Receivable - Amounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_ResearchAndDevelopmentIncentiveReceivable', window );">Research and development incentives</a></td>
<td class="nump">$ 622<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Sales-based taxes receivable</a></td>
<td class="nump">134<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total amounts receivable</a></td>
<td class="nump">$ 780<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ResearchAndDevelopmentIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development incentives receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ResearchAndDevelopmentIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811697184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Deposit - Deposits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_AdvancesToVendor', window );">Advances to vendor</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Total deposit</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_AdvancesToVendor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of advances to vendor held as an asset by the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_AdvancesToVendor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811563584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Property and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation, Total</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, Plant and Equipment, Disposals</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6657624384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Property and Equipment - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6660322080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Accounts Payable and Accrued Liabilities - Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade and other payables</a></td>
<td class="nump">$ 483<span></span>
</td>
<td class="nump">$ 513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_AccruedClinicalStudyCostsCurrent', window );">Accrued clinical study costs</a></td>
<td class="nump">292<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_AccruedResearchAndProfessionalFeesCurrent', window );">Accrued research and other professional fees</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_AccruedTaxesAndOtherLiabilitiesCurrent', window );">Accrued taxes and other liabilities</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 1,291<span></span>
</td>
<td class="nump">$ 919<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_AccruedClinicalStudyCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued clinical study costs classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_AccruedClinicalStudyCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_AccruedResearchAndProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees and accrued research. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_AccruedResearchAndProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_AccruedTaxesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued taxes and other liabilities classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_AccruedTaxesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6831495408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Warrant Liability (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 29, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 18, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 17, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 607,000<span></span>
</td>
<td class="nump">$ 615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants', window );">Stock Issued During Period, Shares, Exercise of Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,594<span></span>
</td>
<td class="nump">134,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedInPrivatePlacementMember', window );">Warrants Issued in Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | (per share)</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants', window );">Stock Issued During Period, Shares, Exercise of Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedInPrivatePlacementMember', window );">Warrants Issued in Private Placement [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedInPrivatePlacementMember', window );">Warrants Issued in Private Placement [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedInPrivatePlacementMember', window );">Warrants Issued in Private Placement [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedInPrivatePlacementMember', window );">Warrants Issued in Private Placement [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedInPrivatePlacementMember', window );">Warrants Issued in Private Placement [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember', window );">Compensation Warrants Issued In Connection With Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants', window );">Stock Issued During Period, Shares, Exercise of Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod', window );">Class of Warrant or Right, Warrants Expired During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember', window );">Compensation Warrants Issued In Connection With Private Placement [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember', window );">Compensation Warrants Issued In Connection With Private Placement [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember', window );">Compensation Warrants Issued In Connection With Private Placement [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember', window );">Compensation Warrants Issued In Connection With Private Placement [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember', window );">Compensation Warrants Issued In Connection With Private Placement [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember', window );">Compensation Warrants Issued In Connection With Private Placement [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember', window );">Compensation Warrants Issued In Connection With Private Placement [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember', window );">Compensation Warrants Issued In Connection With Private Placement [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember', window );">Compensation Warrants Issued In Connection With Private Placement [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_UnitsIssuedDuringPeriodUnitsNewIssues', window );">Units Issued During Period, Units, New Issues</a></td>
<td class="nump">1,322,965<span></span>
</td>
<td class="nump">181,220<span></span>
</td>
<td class="nump">526,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_UnitsNumberOfCommonSharesPerUnit', window );">Units, Number of Common Shares Per Unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit', window );">Units, Number of Common Share Purchase Warrant Per Unit</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights expired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ClassOfWarrantOrRightWarrantsExpiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period due to the exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_UnitsIssuedDuringPeriodUnitsNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_UnitsIssuedDuringPeriodUnitsNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common share purchase warrant per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_UnitsNumberOfCommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common shares per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_UnitsNumberOfCommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedInPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedInPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsIssuedInConnectionWithPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811683872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Warrant Liability - Rollforward of Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value</a></td>
<td class="nump">39<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_WarrantsAndRightsExercisesInPeriod', window );">Exercises</a></td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_WarrantsAndRightsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant exercises during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_WarrantsAndRightsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6831540128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>May 03, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=dmac_OfficeSpaceMember', window );">Office Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 180 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dmac_ResearchAndDevelopmentContractsMember', window );">Research and Development Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Contractual Obligation, Due in Next Fiscal Year</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">Contractual Obligation, Due in Second Year</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dmac_TechnologyLicenseMember', window );">Technology License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial', window );">Milestone Payment, Due Upon Initiation of Phase III Trial</a></td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale', window );">Milestone Payment, Due Upon First Regulatory Approval for Commercial Sale</a></td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=dmac_IndemnificationAgreementsMember', window );">Indemnification Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment due upon first regulatory approval for commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_MilestonePaymentDueUponFirstRegulatoryApprovalForCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment due upon initiation of Phase III trial</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_MilestonePaymentDueUponInitiationOfPhaseIIITrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=dmac_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=dmac_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=dmac_ResearchAndDevelopmentContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=dmac_ResearchAndDevelopmentContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=dmac_TechnologyLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=dmac_TechnologyLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=dmac_IndemnificationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=dmac_IndemnificationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819666704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Commitments and Contingencies - Future Minimum Lease Payment (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2019</a></td>
<td class="nump">$ 64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6830468640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Shareholders' Equity (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 11, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 29, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 18, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 17, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual', window );">Rights, Threshold Trigger to be Exercisable, Percent of Common Stock Outstanding Owned by Individual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_RightsExercisablePercentOfDiscountToMarketPrice', window );">Rights, Exercisable, Percent of Discount to Market Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,726,000<span></span>
</td>
<td class="nump">$ 2,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants', window );">Stock Issued During Period, Shares, Exercise of Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,594<span></span>
</td>
<td class="nump">134,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 607,000<span></span>
</td>
<td class="nump">$ 615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,954<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedWithIPOMember', window );">Warrants Issued With IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_WarrantsIssuedCashConsideration', window );">Warrants Issued, Cash Consideration | $</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants', window );">Warrants and Rights Outstanding, Percent of Outstanding Common Stock Outstanding Called by Warrants</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants', window );">Class of Warrants or Rights, Percent of IPO Price Per Share of Exercise Price of Warrants</a></td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedInPrivatePlacementMember', window );">Warrants Issued in Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger', window );">Warrants and Rights Outstanding, Expiration, Stock Price Trigger | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants', window );">Stock Issued During Period, Shares, Exercise of Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_WarrantsAndRightsThresholdConsecutiveTradingDays', window );">Warrants and Rights, Threshold Consecutive Trading Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsMember', window );">Compensation Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class of Warrant or Right, Issued During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="nump">$ 16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_ProceedsFromIssuanceOfCommonStockNet', window );">Proceeds from Issuance of Common Stock, Net | $</a></td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_UnitsIssuedDuringPeriodUnitsNewIssues', window );">Units Issued During Period, Units, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,322,965<span></span>
</td>
<td class="nump">181,220<span></span>
</td>
<td class="nump">526,316<span></span>
</td>
<td class="nump">234,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_ProceedsFromIssuanceOfUnits', window );">Proceeds From Issuance of Units | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="nump">$ 944,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_UnitsNumberOfCommonSharesPerUnit', window );">Units, Number of Common Shares Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit', window );">Units, Number of Common Share Purchase Warrant Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_PaymentForFindersFee', window );">Payment for Finders Fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_UnitsIssuedPricePerUnit', window );">Units Issued, Price Per Unit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="nump">$ 3.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_ProceedsFromIssuanceOfUnitsNet', window );">Proceeds From Issuance of Units, Net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 934,000<span></span>
</td>
<td class="nump">$ 1,983,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent amount of exercise price of warrants measured against the IPO price per share of stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ClassOfWarrantsOrRightsPercentOfIPOPricePerShareOfExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_PaymentForFindersFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for finders fees that were paid during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_PaymentForFindersFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ProceedsFromIssuanceOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the issuance of units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ProceedsFromIssuanceOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_ProceedsFromIssuanceOfUnitsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of units, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_ProceedsFromIssuanceOfUnitsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_RightsExercisablePercentOfDiscountToMarketPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of discount to market price of shares that are purchaseable by rights, discount is applied after threshold trigger is reached.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_RightsExercisablePercentOfDiscountToMarketPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage threshold trigger, past which, rights become exercisable. Measurement is the percent amount of the company's common shares outstanding that is owned by any specific individual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period due to the exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_UnitsIssuedDuringPeriodUnitsNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_UnitsIssuedDuringPeriodUnitsNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_UnitsIssuedPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per unit price of units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_UnitsIssuedPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common share purchase warrant per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_UnitsNumberOfCommonSharePurchaseWarrantPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_UnitsNumberOfCommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common shares per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_UnitsNumberOfCommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiration stock price trigger of warrants and rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_WarrantsAndRightsOutstandingExpirationStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of outstanding common stock outstanding called by warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_WarrantsAndRightsOutstandingPercentOfOutstandingCommonStockOutstandingCalledByWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_WarrantsAndRightsThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to the volume-weighted average closing trading price of the common shares on any recognized Canadian stock exchange must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_WarrantsAndRightsThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_WarrantsIssuedCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash consideration given for warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_WarrantsIssuedCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedWithIPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedWithIPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedInPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dmac_WarrantsIssuedInPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dmac_CompensationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6646712960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Shareholders' Equity - Shares Reserved (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,591,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=dmac_StockOptionsOutstandingMember', window );">Stock Options Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">639,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=dmac_DeferredShareUnitsMember', window );">Deferred Share Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">21,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=dmac_DiamedicaStockOptionPlanMember', window );">DiaMedica Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">123,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">807,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=dmac_StockOptionsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=dmac_StockOptionsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=dmac_DeferredShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=dmac_DeferredShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=dmac_DiamedicaStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=dmac_DiamedicaStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6818676752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - License and Collaboration Agreement With Related Party (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=dmac_SKGroupMember', window );">SK Group [Member] | DiaMedica [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling Interest, Ownership Percentage by Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=dmac_LicenseAgreementMember', window );">License Agreement [Member] | Ahon Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from Related Parties</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance', window );">Collaboration Agreement, Non-refundable Payment Payable Upon Regulatory Clearance</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone', window );">Collaboration Agreement, Additional Payment Upon Development and Sales Milestone</a></td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones', window );">Collaboration Agreement, Percent of Royalties Upon Development and Sales Milestones</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_CollaborationAgreementPaymentOfLicenseFee', window );">Collaboration Agreement, Payment of License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional payment receivable upon development and sales milestone in collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_CollaborationAgreementAdditionalPaymentUponDevelopmentAndSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-refundable payment receivable payable upon regulatory clearance in a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_CollaborationAgreementNonrefundablePaymentPayableUponRegulatoryClearance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_CollaborationAgreementPaymentOfLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment received from license fees in a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_CollaborationAgreementPaymentOfLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of royalties upon development and sales milestones in a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_CollaborationAgreementPercentOfRoyaltiesUponDevelopmentAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873854&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dmac_SKGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dmac_SKGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=dmac_DiaMedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=dmac_DiaMedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=dmac_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=dmac_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dmac_AhonPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dmac_AhonPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815578048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">1,591,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="nump">$ 508,000<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years 3 days<span></span>
</td>
<td class="text">1 year 354 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="nump">$ 104,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense, Total</a></td>
<td class="nump">620,000<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dmac_NonemployeeStockOptionsMember', window );">Nonemployee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense, Total</a></td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="nump">$ 308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2012DSUPlanMember', window );">The 2012 DSU Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">21,183<span></span>
</td>
<td class="nump">21,183<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_OptionPlanMember', window );">Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Options</a></td>
<td class="nump">783,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares</a></td>
<td class="nump">283,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="nump">639,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dmac_The2012DSUPlanAndOptionPlanMember', window );">The 2012 DSU Plan and Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">783,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of options that can be issued under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest number of shares that can be issued under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share instruments newly issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dmac_NonemployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dmac_NonemployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_The2012DSUPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_The2012DSUPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_OptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_OptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dmac_The2012DSUPlanAndOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dmac_The2012DSUPlanAndOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811662768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 620<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6816002944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation - Stock Option Activity (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">196,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(16,954)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance (in shares)</a></td>
<td class="nump">480,035<span></span>
</td>
<td class="nump">427,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, weighted average exercise price (in CAD per share)</a></td>
<td class="nump">$ 6.45<span></span>
</td>
<td class="nump">$ 7.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance, aggregate intrinsic value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 674<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">196,800<span></span>
</td>
<td class="nump">127,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in CAD per share)</a></td>
<td class="nump">$ 11.08<span></span>
</td>
<td class="nump">$ 6.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(16,954)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in CAD per share)</a></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired/cancelled (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(72,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired / cancelled, weighted average exercise price (in CAD per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 13.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(20,522)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, weighted average exercise price (in CAD per share)</a></td>
<td class="nump">$ 8.99<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance (in shares)</a></td>
<td class="nump">639,359<span></span>
</td>
<td class="nump">480,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balances, weighted average exercise price (in CAD per share)</a></td>
<td class="nump">$ 7.87<span></span>
</td>
<td class="nump">$ 6.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6828344928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation - Unvested Shares (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested (in shares) | shares</a></td>
<td class="nump">216,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant-date fair value (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 3.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">196,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant-date fair value (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 9.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares) | shares</a></td>
<td class="num">(150,739)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant-date fair value (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 4.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeitures (in shares) | shares</a></td>
<td class="num">(20,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeitures, weighted average grant-date fair value (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 7.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested (in shares) | shares</a></td>
<td class="nump">242,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, weighted average grant-date fair value (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 7.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6826673280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation - Stock Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares) | shares</a></td>
<td class="nump">639,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">7 years 292 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in CAD per share)</a></td>
<td class="nump">$ 7.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares) | shares</a></td>
<td class="nump">397,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">7 years 36 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange1Member', window );">Exercise Price Range 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Per share exercise price, lower range (in CAD per share)</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Per share exercise price, upper range (in CAD per share)</a></td>
<td class="nump">$ 2.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares) | shares</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">6 years 292 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in CAD per share)</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares) | shares</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">6 years 292 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange2Member', window );">Exercise Price Range 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Per share exercise price, lower range (in CAD per share)</a></td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Per share exercise price, upper range (in CAD per share)</a></td>
<td class="nump">$ 3.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares) | shares</a></td>
<td class="nump">125,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">6 years 328 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in CAD per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares) | shares</a></td>
<td class="nump">125,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">6 years 328 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange3Member', window );">Exercise Price Range 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Per share exercise price, lower range (in CAD per share)</a></td>
<td class="nump">$ 3.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Per share exercise price, upper range (in CAD per share)</a></td>
<td class="nump">$ 5.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares) | shares</a></td>
<td class="nump">130,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in CAD per share)</a></td>
<td class="nump">$ 5.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares) | shares</a></td>
<td class="nump">91,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange4Member', window );">Exercise Price Range 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Per share exercise price, lower range (in CAD per share)</a></td>
<td class="nump">$ 5.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Per share exercise price, upper range (in CAD per share)</a></td>
<td class="nump">$ 10.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares) | shares</a></td>
<td class="nump">98,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">8 years 182 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in CAD per share)</a></td>
<td class="nump">$ 6.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares) | shares</a></td>
<td class="nump">50,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">8 years 182 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange5Member', window );">Exercise Price Range 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Per share exercise price, lower range (in CAD per share)</a></td>
<td class="nump">$ 10.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Per share exercise price, upper range (in CAD per share)</a></td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding, shares (in shares) | shares</a></td>
<td class="nump">235,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life (Year)</a></td>
<td class="text">8 years 73 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding, weighted average exercise price (in CAD per share)</a></td>
<td class="nump">$ 13.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, shares (in shares) | shares</a></td>
<td class="nump">79,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable, weighted average remaining contractual life (Year)</a></td>
<td class="text">5 years 328 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=dmac_ExercisePriceRange5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819073104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Share-based Compensation - Stock Option Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 182 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Common share fair value (in dollars per share)</a></td>
<td class="nump">$ 8.84<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (Year)</a></td>
<td class="text">4 years 292 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">123.50%<span></span>
</td>
<td class="nump">84.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Common share fair value (in dollars per share)</a></td>
<td class="nump">$ 9.33<span></span>
</td>
<td class="nump">$ 8.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">135.70%<span></span>
</td>
<td class="nump">156.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819806208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Employee Benefit Plan (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6828361648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxes (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2012 2013 2014 2015 2016 2017 2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member] | Australian Taxation Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2016 2017 2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2012 2013 2014 2015 2016 2017 2018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813134000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 14 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Non-capital losses carried forward</a></td>
<td class="nump">$ 9,280<span></span>
</td>
<td class="nump">$ 7,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenditures</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_DeferredTaxAssetsPropertyShareIssueCosts', window );">Share issue costs</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_DeferredTaxAssetsPropertyPatentsAndOther', window );">Patents and other</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense', window );">Accruals</a></td>
<td class="num">(97)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax asset, net</a></td>
<td class="nump">10,886<span></span>
</td>
<td class="nump">8,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(10,886)<span></span>
</td>
<td class="num">(8,552)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_DeferredTaxAssetsPropertyPatentsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from patents and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_DeferredTaxAssetsPropertyPatentsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_DeferredTaxAssetsPropertyShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_DeferredTaxAssetsPropertyShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6818902448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxes - Reconciliation of Income Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount', window );">Income tax recovery based on statutory rate</a></td>
<td class="num">$ (1,119)<span></span>
</td>
<td class="num">$ (1,160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount', window );">Gain on revaluation of warrant liability</a></td>
<td class="num">(450)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Australian research and development incentive</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount', window );">Change in unrecognized temporary differences</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (80)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to change in unrecognized temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax recovery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to revaluation of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dmac_EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dmac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6654383680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxes - Net Operating Losses (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=dmac_NoncapitalIncomeTaxLossesNetMember', window );">Non-capital Income Tax Losses, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 32,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Tax credits, expiration years</a></td>
<td class="text">Jan.  01,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 3,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=dmac_TaxCreditsMember', window );">Tax Credits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Tax credits, expiration years</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=dmac_NoncapitalIncomeTaxLossesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=dmac_NoncapitalIncomeTaxLossesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=dmac_TaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=dmac_TaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MKC_\+L+6:[,S_]CX+-BU\.LNNB]02P,$%     @ 08=S3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M02DMC<[XUB@\F<E\7)3RH.VK,.]M/Y[V"ZV:8?2.QOE__1]02P,$%     @
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M8#P@<??V ^RX:4*W_3%P.-_E8#C9*.2S:@$T>N&L5WG0:CUL,%95"YRJ.S%
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MRA$G(T<(3$D"GXXRMA,#WXX"9,5E\0=3!3.7P/>C=.P3) :D!("4-B E!Z1
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M P  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;&U3VVZ<,!#]%<L?$+-
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M?3C>X=G.8S8;W@S+#V+K-Z[^ E!+ P04    " !!AW-.<PT:'[8!  #2 P
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MO/=G,XW99#CLYQ_$EF]<_@-02P,$%     @ 08=S3C00E^&V 0  T@,  !D
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MG\TT9I/AL)]_$%N^<?D74$L#!!0    ( $&'<TZOKQ=\M@$  -(#   9
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MF7D[@=!#CC?XW?',F]8%!RFRCC7P ]S/[FR\16:5BDM0EFN%#-0YOML<3VG
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M965T,C N>&UL;5/;;MP@$/T5Q <$K]?)KE:VI6RJJI5::96J[3-KCVT48%S
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M;7-EVK*_;_0=+=KA+D7&"UWV#U!+ P04    " !!AW-. 3;.L,$!   W!
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MNW \^+.9QFPR'/;S#V++-R[^ E!+ P04    " !!AW-.CQGQ<;<!  #2 P
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M#L]V'K/9\&98?A!;OW'Y%U!+ P04    " !!AW-.A>3]MND!  !F!0  &0
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M4"NS/>J]F%M_/B@^+%,-K:.U^ M02P,$%     @ 08=S3JY[68W2 0  G 0
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M]R[?=C:"'>>'S):_J?D/4$L#!!0    ( $&'<TZ5R!HK8 (  %X'   9
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;'U576^;,!3]*XCW%3!@2$202J)I
MDS:IZM3MV4F<@&HPLYW0_?OY@U)BG.8AV)=SSCW7QM?%0-DKKS$6WEM+.K[Q
M:R'Z=1#P0XU;Q!]HCSOYYD19BX2<LG/ >X;149-:$H PA$&+FLXO"QU[8F5!
M+X(T'7YB'K^T+6+_*DSHL/$C_SWPW)QKH0)!6?3HC']A\=(_,3D+)I5CT^*.
M-[3S&#YM_,=HO<L57@-^-WC@L[&G*ME3^JHFWX\;/U2&,,$'H120?%SQ%A.B
MA*2-OZ.F/Z54Q/GX7?VKKEW6LD<<;RGYTQQ%O?%SWSOB$[H0\4R';WBL)_6]
ML?@?^(J)A"LG,L>!$J[_O<.%"]J.*M)*B][,L^GT<S!O,CC2W 0P$L!$B#XG
MQ",A_B DGQ*2D9!8A,"4HM=FAP0J"T8'CYG=[9'ZB*)U(E?_H()ZL?4[N3Q<
M1J\E@&D17)70B*D,!LPPT80(I/J4 KA25&!!![<)MDM$O+J%[!PB$+I=Q,Y"
M8RV0W AD5J$&DVE,IS%?DG0%<\NN"Q:".'';29QV$H<=*T]E,.D\3YK-TA@W
M#E0"8.@VDSK-I XSU@94J<,,7$'+C ,5K\([9J#3#%R:R4++#%RDB6 .8LN,
M Q6G%F@'%YL99?&=+RMS&LX<AB/+<.8PG-U;E]R9)G>DL0Y2E3N*"8%UGK=+
M5+:RSYM#2?XLO\&LR[28G74'Y]Z!7CJA#NLL.ET2CT!U*2M>1>NMZ?4?,N;F
M^8G8N>FXMZ="]D#=J4Z4"BP]A@]R/6MYV4T3@D]"#3,Y9J;EFXF@_7B;!=.5
M6OX'4$L#!!0    ( $&'<T[9B=.KA@(   P)   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;)56VXZ;,!#]%<0'++:Y)B)(N:AJI5:*MFK[[! G00N8
MVDZR_?O:AK $ADI]B>WAS#DS0X9Q>N?B35X84\Y[5=9RY5Z4:I:>)_,+JZA\
MX0VK]9,3%Q55^BC.GFP$HT?K5)4>02CR*EK4;I9:VUYD*;^JLJC97CCR6E54
M_-FPDM]7+G8?AM?B?%'&X&5I0\_L.U,_FKW0)Z]G.185JV7!:T>PT\I=X^4.
M1\;!(GX6["X'>\>D<N#\S1R^'%<N,A&QDN7*4%"]W-B6E:5ATG'\[DC=7M,X
M#O</]D\V>9W,@4JVY>6OXJ@N*S=QG2,[T6NI7OG],^L2"EVGR_XKN[%2PTTD
M6B/GI;2_3GZ5BE<=BPZEHN_M6M1VO7?\#S?8@70.I'=HBS/KX'<._H=#\$^'
MH',(1@Y>FXJMS8XJFJ6"WQW1OMZ&FG\17@:Z^KDQVF+;9[H\4EMO&8G]U+L9
MH@ZS:3%D@,$]PM/LO02!)#9DXDZ>!;93A+]XANP DCB H_#!1'U+$#P1A*-$
M6TQL,;7%1 0CA&"= -0) )UHI--BPH%.N/!G=4)0)P1TXE%=PTD^) AF=2)0
M)P)T$I@@!@EB@&#\=N-IH C-!IJ .LE4)T$CG>2_=!:@S@+0F>D'C.">0P %
M&3<=FL2*PV@8:_N.(5PTGQ.>^0Q@("1_A@)L\S4F $4PS@H"A3,Z<"-CH).3
M:(8"[E$,-.DT5 @4S^C /8J!)DUFF@?#[8>!_IN&"H$6(QUO,!(J)LYVW$HG
MY]=:F2_KP-J/]#4Q(V5DW^#EMAW,'S3M/>$;%>>BELZ!*SVP[%@Y<:Z8CA&]
MZ%I<]-6D/Y3LI,PVUGO1SN?VH'C3W3V\_@*4_0502P,$%     @ 08=S3NS]
M=U4+ @  0@4  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL?51=CYLP
M$/PKB/?&8" D$4&Z4%6MU$K15=<^.V0#Z&Q,;2=<_WW]03A*:%^PO9[9G3'V
M9CT7K[(&4-X;HZW<^[52W0XA6=; B%SQ#EJ]<^&"$:67HD*R$T#.EL0HPD&P
M1HPTK9]G-G84><:OBC8M'(4GKXP1\?L E/=[/_3O@>>FJI4)H#SK2 7?0;UT
M1Z%7:,QR;ABTLN&M)^"R]Y_"79$8O 7\:*"7D[EGG)PX?S6++^>]'QA!0*%4
M)@/1PPT*H-0DTC)^#3G]L:0A3N?W[)^L=^WE1"04G/YLSJK>^QO?.\.%7*EZ
MYOUG&/PDOC>8_PHWH!INE.@:):?2?KWR*A5G0Q8MA9$W-S:M'?LA_YVV3, #
M 8^$</U?0C00HG=";,T[9=;J1Z)(G@G>>\+]K(Z8.Q'N(GV8I0G:L[-[VJW4
MT5N.MT&&;B;1@#DX#)Y@PA&!=/:Q!%XJ<< /=/QW@>(1$6V7*T2+)B++CZ<"
M@VAFPF%2BVDMYD.21O%,R0(JQNM@64R\*"9^$(.WX4R,PR23,FD:1PF>G7SQ
MB$NV49)N_R$H6124/ C:I#,]#K*9V@Y6Z?QPEE%XI@5-KAX#4=E7*KV27UME
M?O(D.C:")VRN[BQ^T W"O>?W-*Z[?".B:EKIG;C2#\->WPOG"K3(8*55UKJA
MC0L*%V6FJ9X+]ZS=0O%NZ%AH;)OY'U!+ P04    " !!AW-.<!\8)S "  "6
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R-5=N.FS 4_!7$!RP7
M<XT(TB:KJI5:*=JJ[;-#3@):@ZGMA.W?UQ?"IN#MYB78AYDY,Q".BX&R%UX#
M".>U)1U?N[40_<KS>%5#B_D#[:&3=XZ4M5C(+3MYO&> #YK4$B_T_<1K<=.Y
M9:%K.U86]"Q(T\&..?S<MIC]V0"AP]H-W&OAN3G50A6\LNCQ";Z#^-'OF-QY
MD\JA::'C#>T<!L>U^QBLMKG":\#/!@9^LW94DCVE+VKSY;!V?64("%1"*6!Y
MN< 6"%%"TL;O4=.=6BKB[?JJ_DEGEUGVF,.6DE_-0=1K-W.= QSQF8AG.GR&
M,4_L.F/XKW !(N'*B>Q14<+UKU.=N:#MJ"*MM/C57)M.7X=1_TJS$\*1$$Z$
M(/DO 8T$]$:(='CC3$=]P@*7!:.#P\S+ZK'Z3P0K)!]FI8KZV>E[,BV7U4L9
MYF'A7930B-D83'B#"2:$)]6G%J&MQ29<T&<-MDL$RNT=D#4$TOSHGQ!H%L)@
M8HWI3(@HR0(_GGE9XM(@C= [B2.KG\CB)[(+Q%:!^(Y \<)H@G(4Y[,\2UB4
M^3Z*[782JYW$8N<=@=0JD-Z1)UT8S?PT3F:P[1(6!DD8(+N=S&HGL]A)[ *Y
M52"_(T]N,1ID\S@?H8P9[^9S;H&=].3C3D7/G5 ?SDUU&JZ/H1H'L_I&#ETS
M(]]DS,3^AMFIZ;BSIT(.&ST2CI0*D";]!^FOEH?$M"%P%&J9RC4SH])L!.W'
M4\";CJ+R+U!+ P04    " !!AW-.G\J'[.(!   E!0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q]E.^.G" 4Q5_%\ "+HN[\B9KLNFG:I$TFV[3]
MS.AU- MB@1FW;U] Q[AJ^T7@>L[Q=Q5)>B'?5 V@O7?.6I6B6NONB+$J:N!4
M/8@.6G.G$I)3;9;R@E4G@9;.Q!DFOO^(.6U:E"6N=I)9(JZ:-2V<I*>NG%/Y
MYQF8Z%,4H'OAM;G4VA9PEG3T M]!_^A.TJSPE%(V'%K5B-:34*7H*3CFL=4[
MP<\&>C6;>[:3LQ!O=O&E3)%O@8!!H6T"-<,-<F#,!AF,WV,FFAYIC?/Y/?V3
MZ]WT<J8*<L%^-:6N4[1'7@D5O3+]*OK/,/83(V]L_BO<@!FY)3'/* 13[NH5
M5Z4%'U,,"J?OP]BT;NS'_+MMVT!& YD,0?1?0S@:PH4!#V2NU1>J:99(T7MR
M^%@=M7LB.(;F91:VZ-Z=NV>Z5:9ZR\AAE^";#1HUSX.&S#4?%?E:$1XF"38
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M(QQ\SL/O@& ^4O;&&P#AO7>DYP>_$6+8(\0O#728/]$!>OFFIJS#0H;LBOC
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M&WN>%" 8:#V,ZCV@T3( /:.H[R4<@H11,$ E(["4@#<.>.,4;W;"O,\;!V$
M:IQ 38)^RM$-!X6:/82,J-,:O(B!O<L!:IQ"3=BAQ- )P0&-G*!16A6]&-&
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ML->,25 5>K>J2ZT:?\N&0"WU\DZM^30$IHUDPSS?T#)D\S]02P,$%     @
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M!I4RTT3/Q=B*QD#Q?NJR9&[U^5]02P,$%     @ 08=S3I4.YG8D P  !0T
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MPR071]4.(SVNN\:\FRA9]9>.8+CYK/\!4$L#!!0    ( $&'<TY&>2QL"@(
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MJCD?&\FXD*R;>B2:&W7Q#U!+ P04    " !!AW-.:.3]2"L#  "##   &0
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M971S+W-H965T-34N>&ULC5;;CILP$/T5Q < YA)(1)!"JJJ56BG:JNVS0YR
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MMWLUM>QD&-G/TX@L(S'_"U!+ P04    " !!AW-.HY*#'$P"  #A!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q]E=N.FS 0AE\%<=\%# 2("%)#
M5;52*T5;;7OM)$Y :S"UG63[]K4-08D]R0T^\,_,-[8U4UX8?Q<-(=+[Z&@O
M5GXCY; , K%K2(?%"QM(K_X<&.^P5$M^#,3 "=X;HXX&* P708?;WJ]*L[?A
M5<E.DK8]V7!/G+H.\W]K0MEEY4?^=>.U/392;P15.> C^47DV[#A:A7,7O9M
M1WK1LM[CY+#R/T?+.@JU@5'\;LE%W,P]G<J6L7>]^+Y?^:$F(I3LI':!U7 F
M-:%4>U(<?R>G_AQ3&][.K]Z_FN15,ELL2,WHGW8OFY6?^]Z>'/")RE=V^4:F
MA%+?F[+_0<Z$*KDF43%VC KS]78G(5DW>5$H'?X8Q[8WXV7R?S6##=!D@&:#
M*'EJ$$\&L640C&0FU2]8XJKD[.+Q\;8&K!]%M(S58>[TICD[\T]E*]3NN4KC
MJ S.VM&D68\:=*-!]XK:5<3%+ D4P$R!0 ID[),["BO&>M1D1M,;38'RT )Q
M11F*8Q@E!E%B "6V4$9->A,ESS.+Y+GF#B0!01( )+% $B=(B@H+Q-5$T0.0
M% 1) 9#4 DF=(*BP3JUV-7'TX)4L0) % +*P0!9.D$^%?36 'P1S9"!'!G!8
M,=:9RV&AUH D@3%R$",','(+(W<O/\QSF\15Y>FC(RE E@)@L1[BNG#SA6
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M(J=;6[R7*P*I8M4N OH@_3*I0'FD[4^S-6)TKCLPI+HC ?\BT^L;8M2P*PF
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MP6*']0-1$4L-]CDJ[+!%L]4:6C,250JE&'^T(8E:HYE9!XB$ A,./$$T(O\
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MR4TN2%=,:JE--H:"S@_[5SCVH$%,47]T+#*!H+V'^0,PRQQQ!#@L;,"M+)6
MU%H34=?5&O'W5BH^C0@""A'P6-C&]E)Q39+Q6BK/,M!Y6M)LB,,IFP&>S&SD
MIT9D1C&VK'-65TDT]S&47DH&TG59K)?D]N/I:+4'?Y]S[@Z9$M<Y9Q7_ M0"
MZCE0V%P<7YR(47<4X9=H\.8DZB2:ODP=A"?72M!J/V70+7-X_M_)8OG]J^?X
MY 6T!EQ>(S]3[G/E4V%6T7*P5.B>P%[=,7$5IWG]NS2_+3*D#1 O)4$,\ %V
M%5?]41E*Z5RE2H'8S HR.6AI"6J(*<:X8&A '^*"%-0QB8V(00I@O[(BH5*@
M>#,Q/[$L,KT?9AN*8DY;C!*!B!ZZT4I#B0;/27U:554@,J,4)*ME=43JLO&0
M@>AWY[=(@3Q6L,QJR_Q2(@& [B6Q=#9':CP3FY=58I:@" Y'+.L(\RO-#IUW
M!:;@![:= ^A;'FLGD-%\X0O4>%WSEO !O0IK6'/;A<?XEY;SFN,44!>HJKS>
M@)<T U<UKW>MGR-^\.P4)-4,.\2_O9,BXE?;Q#RMT36:-<I&A)8ZN4WBNO]:
M (F!V@B:T[I22&"3S$@+(5P#^K%+*\KK)%=2N!*'.K!P_J'2405$-)70 /R
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M_T-)8A2WREIA>6=M"S<#[5X1!%I?K,=2<K@_5TUY!0W=&4 :S%1,%KM ^@$
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M,BAG?-$BY1<>?N+R!\\=0CAVKNOV]H2];)OL+T7YF71'QN^=MC2TG"U@>4C
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M\U)Q][U#[;M+1K<^1X!1;^&*NDB)G\ULF.76Z>\.3SO%I9FB$V2_+H%O^2*
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M4$L! A0#%     @ 08=S3A\CSP/     $P(   L              ( !
M %]R96QS+RYR96QS4$L! A0#%     @ 08=S3B?HAPZ"    L0   !
M         ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !!AW-.
MR<6"^^\    K @  $0              @ &9 0  9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !!AW-.F5R<(Q &  "<)P  $P              @ &W
M @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $&'<TYBX5N0S0(
M )0+   8              "  ?@(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " !!AW-.V9T>SU0#  #J#@  &               @ '[
M"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 08=S3F5M
M.T / @  PP4  !@              ( !A0\  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( $&'<T[U]OM,#@,   L,   8
M  "  <H1  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !!
MAW-.R+$1?N,#   >$@  &               @ $.%0  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ 08=S3L!)O.[X 0  2@4  !@
M         ( !)QD  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( $&'<T[R:&0FV0,  /,1   8              "  54;  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !!AW-.E;I!:+4!  #2 P
M&               @ %D'P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ 08=S3E$83\&V 0  T@,  !@              ( !3R$  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( $&'<TYS#1H?M@$
M -(#   9              "  3LC  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ 08=S3C00E^&V 0  T@,  !D              ( !
M*"4  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !!AW-.
MKZ\7?+8!  #2 P  &0              @ $5)P  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( $&'<TYCT19WM@$  -(#   9
M      "  0(I  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ 08=S3OB1HZNW 0  T@,  !D              ( ![RH  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !!AW-._8G* ;4!  #2 P
M&0              @ '=+   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( $&'<TZ6?OW5M@$  -(#   9              "  <DN  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ 08=S3DPKB)>V
M 0  T@,  !D              ( !MC   'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " !!AW-.CS&&1K8!  #2 P  &0
M@ &C,@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $&'
M<TXY!>M8M@$  -(#   9              "  9 T  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ 08=S3LM<P/VW 0  T@,  !D
M         ( !?38  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " !!AW-.AXP^+;8!  #2 P  &0              @ %K.   >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( $&'<TXVA^0H@P(  -P)
M   9              "  5@Z  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ 08=S3@$VSK#! 0  -P0  !D              ( !$CT
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !!AW-.3W*Q
MXK<!  #2 P  &0              @ $*/P  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( $&'<TZG0I\CL@$  -(#   9
M  "  ?A   !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M08=S3BH[EQFX 0  T@,  !D              ( !X4(  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " !!AW-..3NTA+8!  #2 P  &0
M            @ '01   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( $&'<TZ/&?%QMP$  -(#   9              "  ;U&  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 08=S3GOJ7M2X 0
MT@,  !D              ( !JT@  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " !!AW-.E_?VT+8!  #2 P  &0              @ &:
M2@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( $&'<TZ%
MY/VVZ0$  &8%   9              "  8=,  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ 08=S3JY[68W2 0  G 0  !D
M     ( !ITX  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $&'<TYP'Q@G, (  )8&   9              "
M 19:  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 08=S
M3I_*A^SB 0  )04  !D              ( !?5P  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " !!AW-._5XJ2[8!   8!   &0
M        @ &67@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( $&'<TX)6G*AX0$  (L$   9              "  8-@  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 08=S3IQ !?(+ @  +08
M !D              ( !FV(  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " !!AW-.*=.6PQ "   W!@  &0              @ '=9
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( $&'<T[C,9G4
MQ00  !L:   9              "  21G  !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ 08=S3AD]UA0# @  < 4  !D
M ( !(&P  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !!
MAW-."=6#&#@"  !Z!P  &0              @ %:;@  >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( $&'<TZLV7\)SP$  *@$   9
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M970U,"YX;6Q02P$"% ,4    " !!AW-.1GDL; H"  "T!0  &0
M    @ &)?P  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M $&'<TYHY/U(*P,  (,,   9              "  <J!  !X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ 08=S3A? %U!5 @  3 <  !D
M             ( !+(4  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " !!AW-.(@6F!@($  #(%   &0              @ &XAP  >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( $&'<TYHD"BX@ (
M #P)   9              "  ?&+  !X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ 08=S3@Z*2=CA 0  B@0  !D              ( !
MJ(X  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !!AW-.
MW\K.@N !   >!0  &0              @ ' D   >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( $&'<TZCDH,<3 (  .$'   9
M      "  =>2  !X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ 08=S3O$%DJYI @  Z <  !D              ( !6I4  'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !!AW-.KS;M]P8"  #Q!0
M&0              @ 'ZEP  >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    ( $&'<TZI]T(\*#<  !49 0 4              "  3>:  !X
M;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( $&'<T[@A2V^8@(  " -
M   -              "  9'1  !X;"]S='EL97,N>&UL4$L! A0#%     @
M08=S3N4'/^_/!   ;R@   \              ( !'M0  'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( $&'<TZ4&.1R% (  %DD   :              "
M 1K9  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $&'
M<TYDQYS1Y0$  .(C   3              "  6;;  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !% $4 U1(  'S=      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>259</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-shareholders-equity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Shareholders' Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-shareholders-equity-parentheticals</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 1 - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-1-business</Role>
      <ShortName>Note 1 - Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 2 - Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties</Role>
      <ShortName>Note 2 - Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 3 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 4 - Amounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable</Role>
      <ShortName>Note 4 - Amounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 5 - Deposit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-5-deposit</Role>
      <ShortName>Note 5 - Deposit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 6 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment</Role>
      <ShortName>Note 6 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 7 - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities</Role>
      <ShortName>Note 7 - Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 8 - Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability</Role>
      <ShortName>Note 8 - Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 9 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies</Role>
      <ShortName>Note 9 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 10 - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity</Role>
      <ShortName>Note 10 - Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 11 - License and Collaboration Agreement With Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party</Role>
      <ShortName>Note 11 - License and Collaboration Agreement With Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 12 - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation</Role>
      <ShortName>Note 12 - Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 13 - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan</Role>
      <ShortName>Note 13 - Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 14 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-14-income-taxes</Role>
      <ShortName>Note 14 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 4 - Amounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-tables</Role>
      <ShortName>Note 4 - Amounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 5 - Deposit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-5-deposit-tables</Role>
      <ShortName>Note 5 - Deposit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-5-deposit</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 6 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-tables</Role>
      <ShortName>Note 6 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 7 - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-tables</Role>
      <ShortName>Note 7 - Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 8 - Warrant Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-tables</Role>
      <ShortName>Note 8 - Warrant Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 9 - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-tables</Role>
      <ShortName>Note 9 - Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 10 - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-tables</Role>
      <ShortName>Note 10 - Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 12 - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-tables</Role>
      <ShortName>Note 12 - Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 14 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-tables</Role>
      <ShortName>Note 14 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-14-income-taxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 1 - Business (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-1-business-details-textual</Role>
      <ShortName>Note 1 - Business (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-1-business</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties-details-textual</Role>
      <ShortName>Note 2 - Risks and Uncertainties (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-2-risks-and-uncertainties</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-net-loss-per-common-share-details</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-3-summary-of-significant-accounting-policies-antidilutive-securities-details</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 4 - Amounts Receivable - Amounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-4-amounts-receivable-amounts-receivable-details</Role>
      <ShortName>Note 4 - Amounts Receivable - Amounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 5 - Deposit - Deposits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-5-deposit-deposits-details</Role>
      <ShortName>Note 5 - Deposit - Deposits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 6 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-details-textual</Role>
      <ShortName>Note 6 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-tables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 6 - Property and Equipment - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-6-property-and-equipment-property-and-equipment-details</Role>
      <ShortName>Note 6 - Property and Equipment - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 7 - Accounts Payable and Accrued Liabilities - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-7-accounts-payable-and-accrued-liabilities-accounts-payable-and-accrued-liabilities-details</Role>
      <ShortName>Note 7 - Accounts Payable and Accrued Liabilities - Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 8 - Warrant Liability (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-details-textual</Role>
      <ShortName>Note 8 - Warrant Liability (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-tables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 8 - Warrant Liability - Rollforward of Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-8-warrant-liability-rollforward-of-fair-value-details</Role>
      <ShortName>Note 8 - Warrant Liability - Rollforward of Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 9 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-tables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 9 - Commitments and Contingencies - Future Minimum Lease Payment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-9-commitments-and-contingencies-future-minimum-lease-payment-details</Role>
      <ShortName>Note 9 - Commitments and Contingencies - Future Minimum Lease Payment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 10 - Shareholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-details-textual</Role>
      <ShortName>Note 10 - Shareholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-tables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 10 - Shareholders' Equity - Shares Reserved (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-10-shareholders-equity-shares-reserved-details</Role>
      <ShortName>Note 10 - Shareholders' Equity - Shares Reserved (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 11 - License and Collaboration Agreement With Related Party (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party-details-textual</Role>
      <ShortName>Note 11 - License and Collaboration Agreement With Related Party (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-11-license-and-collaboration-agreement-with-related-party</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 12 - Share-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-details-textual</Role>
      <ShortName>Note 12 - Share-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-tables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-sharebased-compensation-expense-details</Role>
      <ShortName>Note 12 - Share-based Compensation - Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 12 - Share-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-option-activity-details</Role>
      <ShortName>Note 12 - Share-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 12 - Share-based Compensation - Unvested Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-unvested-shares-details</Role>
      <ShortName>Note 12 - Share-based Compensation - Unvested Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note 12 - Share-based Compensation - Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-options-outstanding-details</Role>
      <ShortName>Note 12 - Share-based Compensation - Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note 12 - Share-based Compensation - Stock Option Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-12-sharebased-compensation-stock-option-assumptions-details</Role>
      <ShortName>Note 12 - Share-based Compensation - Stock Option Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note 13 - Employee Benefit Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan-details-textual</Role>
      <ShortName>Note 13 - Employee Benefit Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-13-employee-benefit-plan</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Note 14 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-details-textual</Role>
      <ShortName>Note 14 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-tables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Note 14 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 14 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Note 14 - Income Taxes - Reconciliation of Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-reconciliation-of-income-tax-rate-details</Role>
      <ShortName>Note 14 - Income Taxes - Reconciliation of Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="dmac-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Note 14 - Income Taxes - Net Operating Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diamedica.com/20181231/role/statement-note-14-income-taxes-net-operating-losses-details</Role>
      <ShortName>Note 14 - Income Taxes - Net Operating Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dmac-20181231.xml</File>
    <File>dmac-20181231.xsd</File>
    <File>dmac-20181231_cal.xml</File>
    <File>dmac-20181231_def.xml</File>
    <File>dmac-20181231_lab.xml</File>
    <File>dmac-20181231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>91
<FILENAME>0001437749-19-005272-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-19-005272-xbrl.zip
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M0[U?R*-NI]M?Q:(5 R[DE2_O]>$Z PB\&E]>7P'5!H<O:'_K:API'?HZN;-
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MH_U03?$H9>%0R<.S>%U<P=3>A.H%$EZ$Z@UX79B!H>N#G:C^/!YCXM<#OW3
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MZ A06VH10B".H%\O+)_ZTMZZWYCWBP>$J+W1RE[TM3(5'%D8VEXTCNW(6!K
M[03"]HEKF[>>=7_/O5OW$\][6LHW377XNWITN/EI?@E_/%AFN.*P9N4P.X7#
M;&>&^<+$9ICA_\**T9_Q'AY,_3,.:7Q=[XSZW;V=T0BD7?G,/+3;/9521SN[
M2RBZ"]"^0.H"^*\D7EN# !&XLY<G/@\I0I+?Z;\$VG#N"\O;_M]VRV[UKMPJ
MT(/1WKBUM/V?$;@TS@)MX^]IRHI/)LI!QZT0*YXGO:1 :2L^HT)7GD'E@2TL
MH"V\XK.J)#74\C'[\=_<H$.@*:9@>C&[PS2[F]H?/*J-H+Q,V<T12R?N.9X#
MI8]OX$\L_9%IH7@"98;P#@/-)=9>-$HX1KCXIH]&V7.$Z% E\#@+(D*-B>?"
M4+1?ENGPN0:4<(3O0@XP(PRPO@;[B<,5?N"YOW@36[C&&:L3YI<P%L<-,@.A
M/%DN4FCY(N>1K"6.BT-"K(7QT'S:\\:!2+_C]Z&#TF;$:3P@N 5$(W:C+)FB
M*SPL6PJYK+;"L?N8RE0TZ&998K9P6O5G:&'VKP_+CK8,\+ V;MR2+)V ^_')
ML.4\<-&<#$]744Y=6-S\%_X^)2^;KDP=^>+B+7_Z\)S7"$02]AU/3:(]7P#=
M]&&N/""53C#%^32PP;8SZX>4X?]^ F=W]+L?'5#[H6%@O14,T.2838U<"6>N
MT#S1KS#IN.69%GX^AA?C637^(#=FD%"3@]..2?!!2G%1TCB7I65XPR%D95GD
MI7[-5E0"A:*448C"\@C=.U34D>B9J=QU%!8I-3'/<K6#AAD#6- ',[GP=%OD
MNR$9@@"ZW@=OO#J,:X@UD<N6U.)+*C3A9ZS<1&[#T*3H-#>VR<?M(IR1K!PB
MX:"1R3AXY&"F'I(:"EGH60YQ?^GVF]FL#&"UC<C!/A:72!?'X )-N*0,\58K
M*Z-?4HDB!\P369JV>,:8YH#"H"+><F:MUQQD@H-X,46SAXK"X?>,BH,,YD^T
ML>T^2J<"T:=$J56J#J :A),/+@RP<*# ,P=O"#\3MU.TRV42PA4V6LP);011
MK1<X2M+.1CH4?2A0%!XUEIK'Y5(-J??Q>3)]RS'?H0V(&^[%E56,S/88G!T+
M#3%0%/MMTF>+]2VN&DDZ/EG2#/:YJ7T)/;1R#2P*D>-T\X8E!NR1GR[MI8/B
M'W!OBF-\Y"GF4&V6V'MM9+P%JC2/?3',J\:)%G9$>E]P9Y2 GOA>8"@:1%>.
MOWF9&)OB4<2Y<@OC*"6U:K042#!/N'.'J'["VD,))R!C1BS-<Q K0=AN(.T[
M\TWVYZDM:@:I,'\6WL'K$4 "C+:HZQ?A&!;RAX@#4!'[E83:$V8*75..+M'[
MS6&>Z0*I=#V**@S1\;@\>@:YII0\2<3ZP]UW[OGIB$#CU+BZ+!('^=:^J5W1
M8H>E:LUPQP/$U!!&@28T<E!$5BL:NYD\,D_"5$L>G.--<E"8&.R1>6FDD$D0
M*"19 \Q)]E"$R+N(LT%Z<RPU:0:8/"]X*$6S) L!%T$SLPAN.->^NT$9:;Q9
MF0^LP$9_*!8I0_2'R!,UT2,]^<H4VT6IT,%R\+B.2:04.YBXX?TD4[Z,.RHS
ML'>(/0.S=\>Y$X6KXQ ?()4:6=0D$)EX]*0EN8@G6Q0D"ZB7,D+^!1T=E6U3
M:348M4=8%QC\4ZB/X3482U>+@6O0M\ @WZ(('LQ+8!E@1#W@")["XTX 26YD
M>L%RLL-L9LQ<WR(G$"8ZSHH7>?H4Y::*STV.2#?8E)/7-D9\-CD%YP3QKOY!
M-K&Y#_:+IWR&0E69IQ73WEE&KAV.L$3A'9[MTM/2.W?29)(K2ZZJ?'U!%4,2
M033B+5OID,I]F@7_LY%Q.%,04N@WQ^A#\A7Y/NB!MM9152Y'%C%5J,%<\/5F
MK@5\>21E!N.9EV&9IFR>,4>+VY8^6(-T:$7*B1"4 C+P#8GS)4V\+^.-E)G/
MN*Y%8MB06Z;9, DH<!^UT)<[XD)$4A2@(^S<NRC&5 *J75YJ/_B4FW,A,E3@
M S9)X%M@S='9Y8T(3^3U=T47GO_]0IQR:,!R!SWM^ U^$)KS_#L,%OH"8<3#
MH$\>E_A1U)1(:1SL14]/(KW8Y)41<K07-DS^RWW$G>E&"J1,$&]-4WZ5%&0<
M!'XK%ZR$$4$](7:F87+$L9G$F$N[<G32)!Z*SQ=ACA 6.:.Y>]=XV\S%F@5+
MU%4Q",'A->AN2JG,@+X([!.X,;D)TSWRKI%TB+(N$:"+HP1F ID6[9"C.?3#
M&096M"@.L$ ELXO.3P3>'FA<VZ)^7N D/_+4>I'+6 +V5<MK*M_'(7M&QS'\
MUR(792V?/&V*=HD*<SGBC*E5&4VIU"?RM>] .YCH('/'%Z4_F"1[3TOITSRY
M1):XG#TRS_S&GJQI./T>8D!Q-;Z2/64+R_6QD=MW-N64"2VNQJ_6YT /EKNQ
MBTCJY.-@V!GI0SGD%Q[)'G@D^]Z]/(N&[4(6M??!(C&0-(<6RGZH)X I$&NN
M":])W/+\(J%_Q>5I(@@\C\"P!.Y#ZL%KV=7-R3B,):HUZ'7Z$;MV&M4>V9-3
MC_AR[.FU]$+VZ)UV>]3OE<^??S ;FTSL27K.8I5[S2SSTCD7,<0RJQ8 8U9@
MK(_2#31V&E^%^/2#B^W>S\S#_1$_8E":)=O71^Q]5*MFL+!4LA8SN+4B>*:D
M]UJ%>?79DM)CX=-Z2>^UB@HI2I/TK:JP6H6Z:H\S6&01HO*K3++^RH&VXX'"
MQ_;P7^<V>.]QB=>51R4"D:V+79OL($#<78AR"8#Y#XB5MR]_U9=+,F+3V-;;
MO8SG\*S![X^#FU?1C/1B!TEO#WNC;E6'F6/1B@5E43BV+\_,%-\M>DIZ;S"L
M#Y]6#G.50]AM#4;U&>9+AA'#NK)EO^&#/BAF2[???EGE027.RP^1E<^/]$L.
M!_J)0:&/+XN2,!@6LZ#=Z78&40"U$?6[CW;?F!"]#>/%DH:[9\@!?5@\W*'>
M;K?*'NU>$0C:H\+1]MK]CM[??;14F@J7XU?ESV9!#\#3&?=.%\;;S)O;-/7/
M&]]^$20*\ %RQM=I#K<<7[0?*'4T/N<Z] P\H9*Z.F_8UM[4;K&L)B73VQ'^
M@B/>B^JM](CW OA2')I48L1[6,'%,><>1^R7NW)7V-0U(_1?8DQ[69L''M->
M5E_Q05-)8]K#^EJQV;']F!8PAW;!D>COK?&IPI%0.!+/3]]5.!)%4Z9P)':4
M7JD]M1BR32%(/#OY]K*4DH(O_,X+P0YC24$_6U>SU#0,P1 :Y90Z!(_95"]L
MK&I,J#X.KH/Y0I0(3.Z="7\!$R"-N,EI"2F/G6ZC,^AE: P)'I22.#DS)O1W
M&M&]%,)<)]/\+U.[4A+6^B()$V:/*S#XF0REM$>AI+(8(Q9MEI1 HZX/&OHP
M6T,C*?*;VF<4'/FGAIFF5%R#*U'4TV 283R00TM3@&G-!(]75NWN H#_.7,8
M1!%.W$0828+)I#K<..F2/\TL#U.\2]6G"[#^0$H)6JG76&6MRJ@VQ7JN6Z&L
MRUA,V7Q@4&_EO;N]8?^$5^S"G(DZCEB?1:"]0FE@ET]J"DYM2I;7LFP&7X!B
ML]PXW1)O2W45;Z1?+SN%FAPK.V2="&A4=!\L*B[U R^41?E1:U3+TQ _:"I:
MF3/X\P&39S3#%DC%46M7._)W-0F@DTMTIC'Z';,I==V?<"YM4534DOM*4+'9
MP;#%_K(1FQ-B:!BIUJNBI7M<PIK[GE2CR)7-Y$6115)NDM]3/FMDL1"'6KJ7
MTH-RN-P<53(Q4U@D._,L<R\2P&BFY,V+-V:J@[,3N6;ZJ-YQ2O7W(2% ,.T3
MN+&_3F\,L/;8&A/6B2A8-KF=].L=NUC01#> US(5^>[O$]BH!Q<;&=LEPFKH
M(WVA%#Z1_$XI=J@-SL%O"QK9\G^=CCV.\P&,YECT+9">RF!)J]GM')(C\/[1
M D-0H&,AL:UQ27Y;.T,$094I QG'^$:<TI@L\%0YXW*( B:2W=][B*U3T@3J
MK<9(S\:Z1BI)<S%\R?NM!K%,)0(8@D.0+=(/MCH32 U3RE@$K9$UYXG_@->F
M[9R?LG3EL+9-#:<7VEY32?&CZ/<7]\/+0(50#[R7-=IXJY!]9;;K;[93-D+9
M;V6_%P$R*%6N['WZ!?RK$O1$6V^T>_U"\RE#:^F@R! XCO9!2&,-BO;MWD.<
MPC2P \&^/47 J"58B^ZPD]N(5."&3"5\T/X)Z38ZW2Q;8T[1KB4WU4H3%*"%
M7K;,!=LL*W;]T[LC8,T-9B-N4K"Q-9>@T-D-H*^( U&"N&0#R@@,*N'*Q.(>
M@N3,A4>3_$)>F,3*$/AHJ<6YO$>6.':"*5GO)6%)9?R8?G-0*2\"W*IJV.Y6
MLY79(S\MY96=(_(8C@K0ZS:SD"U"!H4_P2HC2D2D#%9$0&](Z;BA#_+LOWU?
M@TE-TG:R27-+[\N0^XP\FN4LO+5Y<HM9<B?:'>[G>_AQDW0YP8K?\Q+<=AW-
M(GOR.%U*3I0FV1//NXZ,7$N-X2*?G0\G[9.(LO1*1! Q[NT^Z452BTM.BJV8
MTC3Y&AVG:-[]W9M60\-_WJ;F<*^J0(Y[[QF*.Z2&K4P3JY:<14EK&ZU2[0[\
M2HA]0L<\!>ETO?<D >U6MZ&U.Q#3M7N]MZ6L94TJI6'OMPWD[B67Q7IE_ED@
M9D5G;HO0SX,-I4..4/_MY9?XQIIPCS0LJQD1UZXGIOU;UB7Q<)V61N#^O<]A
M=TF75&!R@,1'C\T^G(C_EJ%6>CW2*"6JE:JIDG/*=L P.7%HE?IX%@W'KC4Z
M(Z4U#N2,5$UK1,@5_N%5Q3-#GQ((VR*FJ86:V6I >]=&;_1VIX+Z*%\<\Y34
M6^71'"(X&E90976JHK+6KGF@5#/=$#<)EQ=]E2.KK0:R?^V5',9UMZLN/9 6
MZQ1IL?6N5EZQX@I0[Q6UY<L5Z(C^35AW,9:6?^D(4)[=D"2'[4(D2; ["9#D
M>CI6$7T5!MC= SG]&4^RZ<"0ROP)D.865L<]]XJ1'/8)^]<J (W-P=31VT7<
MV&R ^V!1! RQ3Q:U!S5GD<"9V">+.L.-6=0OA4.P*'%[_VJ<^BZ%OI?^EMDV
M-S_-<R$&$TA[?7/T381CO;R^6H^JDH/Q- L]CE@XK=X&;'K^(%=Q\78"\X19
MR>>N@[W!L"+HUF/XF LVWPRC;J_+<1F+1G"MK1?Q;,V07I@;2QAH>UUY13*D
M%]JN[;DAR#MG_@1OL4Q9Z)1G>\52V>NJ*5#')Q][K66+74!Z>I"B/Z5$#R_L
M:)%Q(GIIBOJM NT'D]!'W/6$J,RK! VA?WK/V.S]F6%@:R#_FLW1AX+9@F\\
MH#WE(IU'7:(VH;&31:4J0O@&FS72B<1G4/*"0UB+;S\8%OIJ(WU4W@@N+-^P
M71\6V;/1D'K#_:(A+>$-Y6 2Q<D?AT=,VB2]0Z$A[3]:'2@TI,W.A\K/R*@0
M*YXGO9%FU:1JI210J5RUE';=./M%@20M(0Q$+)ZE6,PDB^V$Q1$.#T^2'.,T
MR-KG-"9)@TOYA(OYAH=-?U0YC2JG\9AR&M,',!NG,QXI+Q;/GVJ:TEDY:M2B
MKYB@9TY=U:K/IN36=-77-'=*B]VKZB5RX^ZJ<,>I77GDH%<@K:J:Z0B53S,H
M:4.F.UR7^[1P5'^XV3JP#%6!!B7'17+<TX] CE7>WHO8PFC/+XV,I>R@JD3(
M,W\Y_G3MU$8U1:<*-!R[^'9ZO?J+;TVCP<I:/1 N9!R0%)IS ;FGK)]2'SGJ
MHSUJUU]]5%-TJD##L8OO?VY>^E #.5;!WXN:08_[','9TGNBGCOFOB_Z&(RY
MVAQ5>B57K_2/P*FNIN14@89CE][N$4BO"@E?U!8&[(G[*4-HYR=#5J2&6<$N
M5""EI(2]JW7045704]45SLH2IE;-7GW3(UTT*OK=@,5I U_H!8AYT(=Q9I"+
M-8<Y2?H5-/T*OJ1: ]F_/M,;[9%>1YU6&5&M+&%J#96TAD;Z.CS%NJZ@[9%_
M=BRS7EFK33FV.Q3(#PH+Y+O#SJKJ\O2+=Z!P??W[H+#^O:?O2.$/;G#K :_]
MSH,=F-@M0!,Z^3@8MG))S'OS+C2N9V.W$#]B%Q+#J6B=<\%G'KR9TMK@L\WQ
M PKXU 5O^7_H^VL/>P4'\VN;.0'\]OG/T)I-G\GR?B'X1+N[.)P7(;*LH:^?
MR?ZH<.C],H8.&E/TW;YFEGGI;(4@DAE)M],J&DF_/1HM+.[\USZ3MK5<[N*/
M!8I1;W6>1=N_0S^@OMFW;L$=!& D47%D?\ISS)7)Q=N)D#;6CV58R.?VJ+TP
MDN<3N<_A+@.+_.LFO/,MTV+>_(;9_&I,#R.$'?'),=-@./AL?1EE)\NH7C&D
M3:\].E)&10]<RQR]T,KI8%[VQ9VH7_P- JE]8CXWSU,IU)^?\"/?B ]GV.#H
M=C[C-/;OKL.G,]N=<RY@PT03LW5 3(-6J]!C:K=Z62YL1/O+C'=9'[S8> O]
MKTYK>+#QYLSOI6.X4Q@</ TE[RL^%ZT<COZ'S+P K7"!G?I<,FSRZ6LD'UA0
MZ#OI@U:5IGR/+"C4C/W#<6!+(?@;=[C';'1[S*GE6'Z J&@/?&,>%#I>W5YM
MQ&!7)NB%OD2G.ZJ0)*P:0J%KUV]7:1Y7#:%=*(JM%Y@%)P"'P2:(Q!MNA!YM
M37Q^$AW4OWCN%!\1!O2$J_%GYF&S7/^:>_02""K"A=!F,YO\61HH$,YGFJO^
M(..W+V"P=D:=WBC%FI<89BF<6VO=7X1S[4+.0031ZO3JR+FU,I="CKV6C8*C
MN&$#EG4*639LP06=.K)LK;#MQK)N(<O:>K^MUY)E:Z7L@H^YYTDE_!.&OPFG
M>BLXI0]KR:BULO4L1O6/CU&K'9HE#@P*.:!W^T.]54O=O=HC6N+!,D!VQ(.!
M/NAV]/VRP/=Y(8KZJLVYSJ@PJ@#1[2PX<_26S=Z\?ENP5>C*Z\-6>\,7/__8
MI#,J],/UP6B01T#^,<1J.M;RH3,J=*;U[JB['1G@?1D[<*1PHZ%#D-J+A"1O
MVY:6#;A2&/$O[?NLI.53Z%L.]_T+[AN>-9,'#Q"(6/[5^!I+8ARQT)Z-*]T=
M*%QIA2N]#[2SW=*(%*[T9J4Q"E=Z:^F-E&J1A"G<Z+6XT1<6^\9-4(K:+2QD
M-N/@#AJ^=ND832I+@=!#>YRXMCT_=1\=#K(8G:-9^,[D]I\W9XWDMN3[LQ#W
M5FV+:=?!7/L:F$WMC0'/XP;ZG?9<R!#5"AN_/_)&\J?Y>^:WT"_^S0V]XA]C
M6C)7()4(?YV^$OU=YLS3U[UM:!PBL@#FP*/K9QXX"MY<FX7>S/4YHF@S\X$Y
M: 7I@ACE =]@N-,I-@N#/\WDN(%NPJ)7>!@/\&D>AROO+(?!C_O7R7__^O=,
M9B>2$G#L#RT'&7B<!1&EORS3X7,:CL-#S[7=>QH?$,:9#[+X: 43#:8@YLW8
M-4)?PQXQ$\\%9D2/D'=(;/(PX)KE&Q,^A2M 2-Q?O*E=X6.8]-9H-N :[=X%
MTXW2%X)+(4@\9PXSF1:I .W<A?D0_5U\[<P(\"4-P7\Q-T#._CF;M*+LBDZ4
M66149))!^T::B,HT^!>(TAV\"I9"@+E:)E(*BU'[SGR3_:E%V1O?F/>+!RD.
M^/,IJ,*LJ'\[.V]FQ!P?M"36H]_]Z/V/' GP^(/EAGZ&!'S%[<U_:_^ N0CA
M(@@,XS[BDOE4MR:NO+H]_W^?-$O\@3L6\! Z>O&;&ZNVX]:TG\=CH?/*$,/O
ML&!(#/5>GAP^PBQ.9S:=B\%$L1)(RBB<4U TI_M_9[N5F6QL?8#E0:0D4+,M
M+<=F"8SX[F:(&GO,$'DAF25I44H(+BB@VN%TB5"TM/3QRNQXFF!\_8 S4'I!
MLN8U*L7!0E.7OG8XOB(@DPY_A20C](/X"$R15-!_L%$8]X D-[1-[8YK("]6
M8(OG>90:R8MH7*#N-I]L[9&!$IR! 7J I][-:4XR[X;?@:HRUTQ?+)G,BD%5
MAZ2FEPWPP'(,CTP:CG@J-/0,.Q9J,YZ5+;R:@0\-3@!<S +MSQ"H'%OP'+2Z
M-O@8TDH5ZOZFALF)F*I(XL*2]"(A,\SV72#"I'=ES0QN,'@/\EV63#1*6],\
M$\'_#*U@?GJ'IZ49R$8->._(LN6DSR#,#6Y;N.*DK0$.C]C$EN/'711QSZ,\
M)FEJ9[8-I,%E8*.!2B!;7(M7(0/E7U/1V@2835N3TLSX:5'"H:'[1*Z6'YWY
M^]J$@83><>[ >\#%8)'7B:N !9$@C]$=+5Q9ZW/:M]_=R>X.R7G^BJ)T!<[
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ME(^SJ39-$0!&"(0[F".,2(#H(G^&UO-->Z&:*!3234AYX7%L(+R%NJ+[HN/
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M_(&4%_(S;BMQ?X_-3(+GS1A.CS@+RH1:+IT-(=8WA&53CL=,EC_%KV<43PL
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M;198#UR[]Y@3:"8+N#9FEJ<],#ODFCO6^'1FNW,.GV5#UP?N8PMP,_2P9U\
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M*_%P+ 1+-;ZAD4_9DS4E6&TD JY'>MP[X/X#'5[(!V$>W-1REB\-G>6+[^;
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MM*(S+)*KFWKXRKY-*6<L[8(M*8#&@H;(K'%M^8'9!4Y!QJ(FV3\_%G$9Y)"
MMJEK<OL4EBE%<[&7*<;U.+&,"011=L9U3+GMB3/?T#@XJYB_94%L&$!H1]%5
M])=2;$JQ*<6V^T+NI!7;-6F@#(M<+Q4I!MR8.-:?(8\#:^JCEPFVJ2V@BSW
M-PT.246FMS..96V7%%1>45LV?X+Q)'8)]"S:6<$>@<XOB.IFKF\%9"A,/D5>
M4R]$]D"]!V7W>6SW3#MB^Y>XY:;BC0QRE.C>YWESW%*)&EKCU@/^ARQ"LK=A
M.>#^AK1!VY#81NF[Q*:BL";10+49FY/.)4X8AH?](E,&%:Z<S3SWR9JBPRU
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MUKI#W<JP4]J\=(5B89O#% !UN,/L-F2UM)ONBKCE0(?A\[UQC<5+D5_*WE?
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M[WHT5@/_:T#MB/A?(Q*$R4E2(!X%]@^>#QSMWB!5^DLQBG/ULY^-.>-CM:(
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M5)RV36*E:R/?U9$T?&RCT%1'A2JN;DH]L>JH4!T5BND5TU\RTZN&"M5046#
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M@EQ*KF"0]G8>_V=_T >XA3KSR]4<^(<^_G!V0:[/@@7?\.HLV]J["F?.C+.
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MKI;PYC[;.HBH<NI4?;:*6^K49]LP;FFROZCZ;%6;H&H3/%J?;2TE66WHM+:
M*0:J2Y]M4QDH;1,D;;;IPVY1A+]KL]GW@$TCYY,]W6IE_%8M,5^F4]MDN8:8
M/[X:[@-__S?;M>?17#;*)#T(P][@U:^WO7]N<<P$[!J?TW@N.^<(SJEWFG+0
MTAZG])$F<*3^2T[TE5%\YM: +WWS#3<P:.UL<("EH\,C+QU=6>M9L/HS[ADY
M_6)2DC(;7 ^U=+2")(NNMHYNE\RHOO:Y1JC8CWP_@6["213H!M]XCF. %<=G
M5%P_^(RV=VM/=CC3A-S52/"6T>,*YM56TOP<D"]N%1,^[M@BY#T3W1$?\='*
MS/C H2.HKPUWJ5$O ]RL[8:>9FA.BB+,#$48,46\QN\3+O_C&1YNQF04$TWR
MIO7S&TY!US-XQNW, #!-%I$: 1BT3Z'5UEZG'Y;Z8.8Q<B;$ ZV>3S]/8\^F
M$P7V(^/^3@"*2;/8(W.\A3C(?(Y+S &9_V857,"[W_1)IK!:PU$OA@GVD0:&
MRHS-;1-^WO?^A'^[0*[PT\2",]LU@, ,^\EP6]K_\]P'[7_QO^[:U^VO;3K+
M;X9I1/*%[V A\!DR<(GS0.ZTC:^JI:6OVL8A,Z$=.G#=@"&?F0QQ9@#L[I4/
M!I=KD:42+:8^G S<DR7==S4C00:=SLI,$"M":."B V CG(Z"QUFA-L*+ 10*
MQA62*E!6[D35GJ3?'F1. 8+$00ZBD_CL 7.,GK_43(<90,PFP]L ?R?$\29P
M'29 0OP1^D"R2"%$&&WM6^HR#2?PM)D1$$H67H@WBU])[C5:X+^R>*G@]-U1
MR?'A'((IXTL+# >$JR^4"WR0!:'GPDOXIH!_L? ]\)'@$\ZR OCUSM\RT/O>
MTG!"&V""([@L%#!70DFK<H165#,II2UD>WB"YP-\;>W:<=(8;J5HK<7!;J%J
M_).%P$JMG&34T)-ZM.FDQ$]!X/%Y._"A &3JFI\&"0\_?<_H X&',1\6+'#3
M]KWMV.$2L962UYR05]FX LTX-Y8937C/)2=P%Q[40*I<DF.GW2\S*@;^"73X
M:%O5S&C*E59IEK$$+,-7@,_A@Z ^69W'(!T'G!*3^E6A'5J109<6R4+P6L0&
M)]*84G=+.V[*N"T'L&& %NP\H'$4N8_,!>5J\:%C<@K="8?0M3-\^:T:#.8T
M=4+,4F=)PP%1B$CB.NG$6C2ES[=6J$]@Y,.GN;#C]A_(/B.\\NW@3RV([H,0
MS&HT&Q;,GR(D:)?D-#(]Y/B'!_F65<%$NV3(I4B7FS[+DI/QJ7$FZ*#0-^AU
M<! $I<]!GP&#_(D&A3'W(L#=G(4S#SR1K^+A4J'A3X/E^6_XOIC6&&2P\C0#
M>0PL!:8UJ(=[@C&<H1[A)NL4[#AX/,+LP]U( UT4FI''(GXQ]4OTX]6CV3/-
MR"_U*5;4]8IOX=V#;"2Z@RL QN$61EJ)GD#!H^\Y\QRK=7)#$O"(B,H(9K2J
MP 0#5!O/Y.P4V_I$$)P+ .EVH,E3(45G'P*D1U>')HP=BB]Q)T%*A30$@OK
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MCNB])NQS:B3IU &&<R=?I09KX#+630U^P9*"T^L[M?3M,I>^-7Q#XJF)L[:
M*:XYZARJ)BSN/ED<^-Q]V[U6)G[S0AP2+?J>Z^3JJG5OIQ=G)U[W-FJF0*L-
MH=86,,5!RB*H;F'B"VH*-Q4GWAI+_#P\Y9J/%?ED&[0<P6;!M_VK$X^\LTY5
M)ZKJ1%6H5(="I:UK=,X4%ZHZ43']Q3&]JDY4U8FJ.K$P[?3-QT'TR;BZ!;>O
M54FB*N5:Z^?VQ[T&.+IUH*$ZP*#HN(R.!_H9T+'*UAQ$%XJ(4F;JL]*#JH2K
M2/T5V-.-$QOU))TZP'#NY-L;#)I/O@WU!FNK]=*;)9:K>UZ4]E/B0Q8+3E0_
MFB+?QI(O@:CJ[Y7S5Z0&,T-7XSE_4Q8$?%,X#MQ4:E')E0*Y,CP#H[J>E%,'
M&,Z=>OMG0+W*)3RH+N3MV(DB=)):N].K0-5S<YD]-XWH_:XO<=86,,4U1[5-
MSY1IE/=[Y$8U80K46_6K/IMZ'>3X\DQO=2=Z$V5:;4BUMH I'JJ(AR;ZY$PY
MZ&7-:MOWF)5VJ[FA;=E.A-,][Y@9^?3=]\^XKXI9?#?L?!&%5&+T92H7Y]XR
M_PZWS^_7P]95/6RJA^U _E[<SC)4[2RUZ.#X)S-\[3T0OK4BLB^LER75V+,U
M*NK+:SOYKTI2K9%4JO&N'ORI.DP5H5\*H:NF2M5469 _?3]?.-Z2\;Y*UW.O
MF'PA"-&K\VB]70T"J76(]S0GHU-5JJ8W:?4&30C--))\Z@##N9-P?]QI=7JJ
MH.@RTHN;%>*--Y][+JU39;@#-X@HI,B78INI-[5%Y)LS(\#5T+CY5;6@* E3
M*&'&G5%K,#R#WNUZDD\=8#AW$N[JPU97C1]05;?;*$F+\57T\$\[U( 4:S"9
M0-427F8M85=OZ8T8_U-? JTM8(IS%.=<8"GNJ=FNML5X.U6L-5$@G+R.M3\<
MM_1.$V)E]:72V@*FV.?("TOT4:M?4 AT'LRS9QGK@8I/RXI;WPE7])OQ?!T$
M+,25#@?9PM ;J I65<%ZZ'(95<%:CW*9O;8PU)?$5.&FJF<[+P95A9N*T"^%
MT%7AIBK<+$C!2=<&)]]H!CDWVNM4Z_N;GTY$'R>3>5O_<%JDH<@YO$"K/PXN
M[X<O]]:;G.VHX^"1B03NL^=>F<8"XX&:XX$,#C33\'T;I/+4\Y\,W]I2!M>I
MEDGM=*FPL&K2ZC9B#6\=J*@.,"A*+DUOM+J])I0+G*>G4G]=^34]K-IBC\SQ
M%G/PJS7VO&"N98>17X=Y7740,LU)L59503]6*XP4^2KR;;QB5$[DJF*D2@:J
MH6=JDY&2(J529-!5?=:*?!M+OOHYK*%4WN&1E."M$8(OF%K@H)2@DB)%72F3
M,X@QU9-TZ@##N9-OKQ%CC)4G>!HE2".<#4<Y@$IX% F/UY/&6-!OFD$Q=8#A
MW*F60%0;;)4#N,$!]+T%8'%)'B#[*[(I.7AZ3:C&'USF^(/7S=Y"=AH%K)CE
M0IFEV7LN5YA%>;@O;5$H,:SXHCYKI76AI;FL!LJ^#J*J.3*HJL11IS4>-T$;
M-Y)ZZ@##N5/PN#48=)M/P,KW/9+O^P_#B6C"B68XCO=DN"8[O2Y4MOR%VO*-
MT;?*^U4<4PN.:8I^5QYPU4WZGUE8X.W64+G79@JAVJBM\G);R:[:4&QM 5.L
MI%CI4*RTWWC/G<9OELWPS _]?&L$M@D/>H=S0_'9^\[P[.IJAJ>:X7D@+T[-
M\*S9Y#2UA5YMH5>2:IVD4C,>Z\&?:IBI(O1+(70US%0-,RV)D^( O=-'1NL9
MN:E]1*:J5,N@->HUH=CPPKM@% 674G"_U1TV9N*CR@L>1]_]3N3"+,T U!D/
M3&[2]:(P" T7+9)T4/D>0YY\<!X/>IY>3ZIBA\LL=ABU1OU>:]!M@@BK+XW6
M%C#%/$<=X=6:],""G9PK\S34,ZZ;=? VK^ZQ.X;\8VW!?&XKU- "4(4/]3I(
M!<Y,ISUJ@C=>3JHUJ116K%.O@U3#.HVL&2YGG?UJA'8J[RFM$9I.F8E+A#^Z
MIC=GWXSGKT;(OC+3<TW;L:FYY@7+?H>J4$@5"JE"H?/,2B:%0IK:^ZMX5540
MU)A75:F,(O1+(715*J-*90J"@W>A$4:AYR^!A-#7H;9"'[R=TT<$ZQ#!:$YJ
MHJ) 0W?4;D*Z@6#]6S-(I@XP*+*M,=FJ*IF#J+J/*07'3 _PMP1D!>"H>RZ
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M*\.!*P ,>(O# \]_F7[8DC\LP.\-\3Q'^<&M;OZ)%-1/VKWG6#M\C=Z$UT)
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M[/3 4Q?FIRPYIK3C-,+$WB.KR%I?S1E5DZIBF79*;<FP!0.C2-YTBEHT=6V
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M'IG??"H_XFG*Q(8#$?#B'Z)_\N?#BTL5_\U3:)8&TH$*07>87XZ)1^0++9%
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M[HT4NVG1CVR<DO?(R$ALGX!U<1D5WR_E. ;8R5Q"& \^XZL$Z:'7,WCM=F8
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M@L8OLXGZM*3PQG1"X,__!U!+ P04    " !!AW-.YVGXDT4+  ";FP  %0
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MFAGU2_/#\&TPX0QYMYSE(4;X?T9SCU%VV6Z,.CZEP0&\%4F;#+3B[) E2@>
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MW4(R89SPV3'%%CBHDYL&^2F7FS;F=_>4+9P.8"+<ZA9>G@*?N6&M:*XA4->
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M$13"?T/XKUBLYX('%G4R;+6YW LAJ>(?=0PJL(L#XNH"35^7XMA6DZ-LY("
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M]BMC]HL0$CGN=Q=U=Z.H4706$"26@B(]!=T!9P%;>1$'$9A Y-C*CL #0H
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M(S&3!Q@<K?W8O<%=4W$U6]>_5M19,N[<'\$;B_ -7<695,W;6*:Y#I?KP1T
M/DW%BI:GD'KM*YHX>/GZ$VZG0DV#OJ6+PCY__XW1<JFFH+%!YTP&SHJ=+ ;Q
MK_W#03SZIXS\8'R>+AN.!N7OGDEK/%8U+9"2-WR2W9<TITP<\N=Y08087VP)
M7.\3\3TY7ET+C3M79;Q;C. ?YDTMIEY+*56;&*EN."JBAV>L79IVXGTUB5R
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M6@S:MOY)/Z.,I/<YA')=4_^$GU<;E."#25G,JRH_FNQ2?6,,Q&NS-]J:CQ;
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M)V3N'(X9N<O9/E+;,N#$')EY&7:JCLQF;"ZB>==)?Q)[W9+RM-C\W[:>6?M
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MA;RJ]>HN2^\K0:^%3V"=T(!I_1S@?D- >KY9]A75^Y?.>B6,+A9I407 R:N
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MW++,2&/-Z9$N-A3%GL0/T$FJ0F9B^@ X?LPR@FZ7<^W <UQM*@>%"=WHAA'
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MH=?+(8"$Z+ <@9+:4)K.DD<&HKPCO^(\(8/VH6P,1$X.YW(M% T\9O\\<HB
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M(P%'8'8%'53I3X!$-=3O5WF"UWFZ3&.N"<X>"LS9?23(1?$3B$:?F-HU.QV
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M0JT$U0I!-=*M(Z###BK:AQX\H^UQ5ROO QY\FE?[PG+%/#ISZ*)Y% 6;=>9
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MR2_LML%.[H<\_4>OWRH[]7GKV1M<T!U=XX3.\<.0V)K-9-+@1 ^BGYJ!(-3
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M" 0T 4OF9Y<D([1$P"+YQ261@,P=L&@^N20: &H&%LQGIP0CP>?@NIM3ZJP
MBX%+Q"UU%NQX@ O($>56 M'"Y>&(ABO#6^$"<42YY;M"X:)P1*T%N*SA,G%$
MH06%<\"EXHA."PS(@<O%$856$/9E-OPOPAG!:1*S@I/!79BR HP!F2-4E?%C
M[,Y100=)%8H5JH]I*"A0ES"?S+5'5D<>K_:9'CL*[16>AOGW,"WW_=N@ME9)
MKW7Q25G,<9[\C>)O69HL$KI(Y9Q(NPZ L0K! //RLO4 R.='=*ET\:E;:D1?
MS[9)2U-<0QN2Y$&5KCXG;1CI)9"ILIZ8YL,9S"^,PPMD\*E7>MF9 +7.N:4!
M%0A0.QQ[($-+^31IG&,/:&@I$H!?P#@ZL?TS"?",FNV4SCE.Z220 /U5L@2_
M3@ +W<_8P##:T0J#-3A55ZK%,LGBW\.<!8Q5FXCA*4=?T.+N=3BO0I<.2L)4
M7]H,+R&HN9F%IPSB_RU)44WF+9[$<:4,4[4X3.*+["1<)@4KW[ FN X+8&2?
M8%+P#+LNAK1@*84INI[5%SK=$=>SRKE-+0)*?"-0IM[1&^.JQG@EU?79<E8=
M+7!K7-[7&7.\)V++.Y+0ZR%?[2SQ!F@6W-YI1 &PW X$4E P*6$KQAF!2-G%
M.CJ+,W:FFGA$&I0SIB5$)+J*B#/KQD-72F9W=_JY6;.\JH%Z%-SMA58"B[B^
M[FBR="OOZ]['OT?6811LY9!X@]C[K:A&Q)9I4O!!!$E3\];")N+Y%)$H3Y;5
MP9G%QR%)R/5LNK.C9*5*]0<:>:U91]BP63*W-KQ8Y##.Z#(1XC;"MA:A@3VZ
MB,CBAO3QJ)./E !' _CJO;YZKP\A:;,JA$<Q5KI^G).-W$"77V3.H1:R!0-7
M]YT338_A6$,'_CRFI5<)NZWU: '2>A_D"?F35#6CRRQ">4%O O8&K2+")1W'
M). %),;C7Q[_VL&_V)*AV_7;[H+AX44*/4:.J#C"ADU@R$,28]4#/"3A(0D/
M20S5C!JM)>G-J$8S2EFILF O?0A(N5B$^:J*/D_NLV1&^[%'=Z*(/8^:9/?!
M$J=)I&Y"Z0QMTJK2I\\;6@=I:#4JHB0O=I10^E_[$J1_^N-+^)0LRD5C! +W
M=T.D)9F8M*;?S9!V$V;WJ&'%-?YFD"2NK!I^M5+\8%E2O9E!X4NVYAO)!;8>
MN97L"!LVC?V+C%ZDZ%FS8Y]FRAH_D +08S!L"(-:0'W,LW(]HWH*@FUO85OS
MI$]SO*1:\&J:4CV+*L5;PHY7K":?8%$I]!P06XPTX1)3Z&F>K1NJ<E.39$[I
M.D4/*,4596=/2Y21YDM0HZ<%)/!9U9]L-?WI6M&7!52J=?;8K)N9?.BODJWG
M!]GQ*VQKG73)D2MI/0CRQ<G$LO8>V/? O@?V#Q/8;P81L,20'SO7*C8:UK*$
M7)&0BL&!6RCTKLA+IBU@Y7O9&<E(_6;*QJTK+D7-309 -5R1$'_Q"%#PL3,O
MO)L%#HFQ!RR+^>;[B,;.=\OC .3#<$5&\ML$C+^/_9C05&:5P4FPG,922%)8
M0T@*^;BR;/0UUE:+9*!O*9D,=!OH&TH^T*UEOI".<\1"S-O/P7*M:%09-6BC
M-FP( \:WR88Q&<L&H\7'K>V1=<!Q:SXP9^2!.5QCJ8%>#F<Z0WB7MD\W\EY)
M[Y7T7LFQ6V%#-\^]%:9GA>G?ZA9LL4_!8UV6.4B3\"Y)Z9)6-,,$(YBTP*1D
M>./+F/'%' (H(]7T[E;]1JPF+\XR5)5Q_CTIYM,\>:#32+=*A+C!U)V.Z9AM
MR2%Q+:'+]5:059X -.^.J.VTP2=?K:?/*?,Y98[EE*4A(=>S]3:XSF^2^WDA
M"!V6MA\("\+P84"/D<-7CK!A$X7[@D)&$[L$+K)E6;F1HP+%MRAO/O_4.]IG
MBEYW$?J.4ZK\,+U6B2]A7_NLL?(,YSE"%UF!J%%0W-!K78D_^0#VF90D>LB:
M#X,!X5DM[V #H >HE[#&%O!K_X*?VYZ$_E*T_#-WWAGBG2'>&>)3M%KM!;D-
MC35L55>D(]59L;IRZ(ILAO'0X="%! J&[O)!U:'[6U56#<1<<48PTI4"A#M=
M$0CH9M+VFQQ.H@X,=W%EU;2YL0$@HOM).C[AT[FSXM 3/MN<"5#@W96#H8VL
M9,XE5]837#/I-IS')__YY#_G+&25*O?@ "X+(::? ]IDD105S%ZEQT6XRDQ$
MF495>^!H)D-/E4CR8:A[9/47AGI!Y;RH$V*KG7]/M95JCOB!AL NAQ%$6I?Y
M^;JD%R]?8MQ&'1#07"F"J@<5IX)I5.K8 :&W*)IG.,7WJTLJ#%YU7DA3"X%Y
MSV<7%=?)[LD%SV34&V3D<6^.L&$S?.^2&DIHPG27>[2ITB<(5Y U'P8#PO@<
M>0?S3%P7<Y3O;F'^#(B:VB=<*'EQ8Q\-Y?.J?2B1#R7RH41]K@KA]8'5SFI7
M9")5:K"Z]N"*;.1HH%PA&;MS#KIW="U?5YP/(/F S&]77%8@B2A!7J[L)?FY
M C,U79$'Y Z"P'VNG"4F''$#/SR\(T[1$=<%%FK!/7?T8T#F5 9SG-+)(%7M
M2N4B,.)!3#KC()1X']P>669+P:@5>3E$S]L0*Z6 2&4!.Q?3:RA]C<T'4IO"
ME]<8NV/+$3:LOC[-V<O<WWV:OT_S]XZM_HFE\[[6<,\J!9>I)_!P#>7^OI+!
M@.Q2[W[T[D?O?O0Y_9WO&9^W[O/6^UTU''O!&5GX5/5N4M4%P) S+B9K]1X&
M+IB!E#<8N'NN7:JER^O'^VZ][U;[!44]8,2&V_8H2.L(IG7&84H%B_/JBT&X
M">()'NE%&N0HI7WC@(I+W;/;]CM&G;_=$.O]PWMD]><?GLQQ-IV'^2+D^PQY
M;3KX_&E"QV1KB_]U3I,./KZ.0-Q&W/%I$+<\#)_XUW_]EN-RR1=28X/6P#7H
M"8GKQXQ>&/-DR7G9HO%WPZ0UGCF"%B/WFCK"ADWG[TU]0T[9!2ET1O(;VB5Z
M!Y(4>(X /0;#!G@:!N0.YI!%CE>[OZA/D&" X3 )]\EJC.!=^SYGU3N-O=/8
M.XW[*@[9K+AC@.(\=NY;7+X8KADZ+B6(6+S?7%4/=\4Y"EPT8 3(%;EH+Q6I
M1>"*A/0.90"8ZGV HU\C,IU- I6Z[P*5 +)CGW^AVBKW:(#9'VTI9>\"%[K
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M(=Y"0W9EX2A!N"V5Z0/"&K6U1!M(3G!7$GHH$!+$J B3E&H7E+@R3%71'.E
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MCZS#BLKOQO]^BNAZCNI"R7OT-S499)#9:4*6F(2I<HS9MJ--MGQTSUC=9#Y
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M5(&+QQ$UO6VZ^K/ S!6C.PK2NLCV^BW"- WO\-J-$&[J3 >/23$/<I32OG%
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MKGA74EC@XI&;7JXL&9T-Y'9RJ-I5I *1N)('!=]' /#%E</%Y\=YAY>.LT:
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MP)?^=MQ@$7L50]4":O]+$*XCEX)EN*HCBZG&3_](I18'Z?H%]P01>$,]9-\
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M86,M,C Q.#$R,S$N>&UL4$L! A0#%     @ 08=S3FM"FZM!%   _@$! !$
M             ( !%.\  &1M86,M,C Q.#$R,S$N>'-D4$L! A0#%     @
M08=S3N=I^)-%"P  FYL  !4              ( !A ,! &1M86,M,C Q.#$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( $&'<TYW1Q<'ZT$  -[J!0 5
M      "  ?P. 0!D;6%C+3(P,3@Q,C,Q7V1E9BYX;6Q02P$"% ,4    " !!
MAW-.['K'&?%;   A.@4 %0              @ $:40$ 9&UA8RTR,#$X,3(S
M,5]L86(N>&UL4$L! A0#%     @ 08=S3O/"$M]J10  L&H& !4
M     ( !/JT! &1M86,M,C Q.#$R,S%?<')E+GAM;%!+!08     !@ & (H!
(  #;\@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
